HK40057217B - Diagnostic and therapeutic methods for the treatment of breast cancer - Google Patents

Description

Diagnostic and treatment methods for breast cancer

Cross-references to related applications

This application claims priority to U.S. Provisional Application No. 62/719,545, filed August 17, 2018, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

Refer to the "Sequence List"

The sequence list is in file format _{048893-517001WO_SEQUENCE_LISTING_ST25.TXT} , created on August 13, 2019, 560,154 bytes, machine format IBM-PC, MS-W _INDOWS operating system, and its full text is incorporated herein by reference for all purposes.

Technical Field

This article provides, in particular, diagnostic and treatment methods for breast cancer. For example, it provides methods for predicting treatment response, monitoring treatment response, selecting treatment, treatment methods, and diagnostic kits.

Background Technology

Cancer remains one of the deadliest threats to human health. In the United States, cancer afflicts nearly 1.3 million new patients each year, making it the second leading cause of death after heart disease, accounting for about a quarter of all deaths. Solid tumors are the primary cause of these deaths. Despite significant advances in the medical treatment of some cancers, the overall 5-year survival rate for all cancers has improved by only about 10% in the past 20 years.

The estrogen receptor (“ER”) is a ligand-activated transcriptional regulatory protein that mediates the induction of a variety of biological effects through its interaction with endogenous estrogen. Estrogen and the estrogen receptor are associated with cancers such as breast cancer, lung cancer, ovarian cancer, colon cancer, prostate cancer, endometrial cancer, uterine cancer, and other diseases or conditions. However, estrogen receptor degradation as measured by immunohistochemistry (IHC) is insufficient as a predictor of ER pathway activity or a pharmacodynamic (PD) biomarker for endocrine therapy; ER protein levels are not always correlated with ER pathway status. For example, activators of ER signaling, such as the ER ligand estradiol (E2), promote ER degradation. Furthermore, the progesterone receptor (PR) is a recognized ER target gene and is often used as a readout measure of ER pathway activity; however, PR is not always present in ER+ breast tumors, and even when present, PR inhibition may not fully capture ER pathway status.

Therefore, there is an unmet need for biomarkers (e.g., transcriptional signatures) that comprehensively reflect ER pathway activity and can be used for diagnosis and treatment.

Summary of the Invention

This article provides, in particular, diagnostic methods, treatment methods, kits for informing individuals with breast cancer about treatment, and kits for predicting an individual's response to breast cancer treatment.

In one aspect, a method is provided for identifying individuals with breast cancer who may benefit from treatments including endocrine therapy, the method comprising determining an estrogen receptor (ER) pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatments including endocrine therapy.

In one aspect, a method for selecting a therapy for an individual with breast cancer is provided, the method comprising determining an ER pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

In one aspect, a method for treating an individual with breast cancer is provided, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified as an individual more likely to benefit from treatment including the endocrine therapy described herein.

In one aspect, a method is provided for treating an individual with breast cancer who is identified as having an ER pathway activity score that meets or exceeds a reference ER pathway activity score, the method comprising administering an effective amount of endocrine therapy to the individual.

In one aspect, a method for treating an individual with breast cancer is provided, the method comprising: (a) determining an ER pathway activity score from a sample from the individual, wherein the ER pathway activity score from the sample is determined to be at or above a reference ER pathway activity score; and (b) administering an effective amount of endocrine therapy to the individual.

In one aspect, a method is provided for monitoring the response of an individual with breast cancer to treatment with endocrine therapy, the method comprising: (a) determining a first ER pathway activity score from a sample from the individual at a first time point; (b) determining a second ER pathway activity score from a sample from the individual at a second time point after administration of endocrine therapy, following step (a); and (c) comparing the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score predicts that the individual may respond to endocrine therapy.

On one hand, a method is provided for identifying individuals with breast cancer who may benefit from treatment, including endocrine therapy, the method comprising determining an estradiol (E2) induction score from a sample from the individual, wherein an E2 induction score from the sample that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from treatment, including endocrine therapy.

In one aspect, a method for selecting a therapy for an individual with breast cancer is provided, the method comprising determining an E2-inducing score from a sample from the individual, wherein an E2-inducing score from the sample that reaches or exceeds a reference E2-inducing score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

In one aspect, a method for treating an individual with breast cancer is provided, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified as an individual more likely to benefit from treatment including the endocrine therapy described herein.

In one aspect, a method is provided for treating an individual with breast cancer who is identified as having an E2 induction score that reaches or exceeds a reference E2 induction score, the method comprising administering an effective amount of endocrine therapy to the individual.

In one aspect, a method for treating an individual with breast cancer is provided, the method comprising: (a) determining an E2-inducing score from a sample from the individual, wherein the E2-inducing score from the sample is determined to be at or above a reference E2-inducing score; and (b) administering an effective amount of endocrine therapy to the individual.

In one aspect, a method is provided for monitoring the response of an individual with breast cancer to treatment with endocrine therapy, the method comprising: (a) determining a first E2-induced score from a sample from the individual at a first time point; (b) determining a second E2-induced score from a sample from the individual at a second time point after the administration of endocrine therapy, following step (a); and (c) comparing the first E2-induced score with the second E2-induced score, wherein a decrease in the second E2-induced score relative to the first E2-induced score predicts that the individual may respond to treatment with endocrine therapy.

In one aspect, a method is provided for detecting estrogen receptor (ER) pathway activity in subjects with breast cancer, the method comprising detecting the expression levels of at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 5; or at least five genes listed in Table 3 and at least five genes listed in Table 6.

In one aspect, a method is provided, comprising: detecting first expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 by one or more processors; detecting second expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 by one or more processors; and detecting estrogen receptor (ER) pathway activity in a subject with cancer based at least on the first expression level and/or the second expression level.

In one aspect, a kit is provided comprising a plurality of nucleic acids, wherein the plurality of nucleic acids are at least 5 nucleotides in length and have at least 95% identity with a 5-nucleotide sequential sequence within at least five genes listed in Table 1 and at least five genes listed in Table 4, at least five genes listed in Table 2 and at least five genes listed in Table 4, or at least five genes listed in Table 3 and at least five genes listed in Table 6, or a sequence complementary to the 5-nucleotide sequential sequence has 95% identity.

Attached Figure Description

This application contains at least one color drawing. Upon request and payment of the necessary fees, the Patent Office will provide a copy of this patent or patent application with color drawings.

Figure 1A is an overview of estradiol (E2)-induced genes shown in red (columns) in seven breast cancer cell lines (rows). E2 induction was defined as a ≥2-fold change in E2 expression after treatment compared to DMSO treatment (p ≤ 0.05).

Figure 1B is an overview of the E2 repressor genes shown in blue (columns) in seven breast cancer cell lines (rows). E2 repression is defined as a change in E2 expression ≤ 1/2 fold after treatment compared to DMSO treatment (p ≤ 0.05).

Figure 1C is a heatmap showing z-score expression of 23 E2-inducing genes and 18 E2-repressing genes in 989 breast tumors from the Cancer Genome Atlas (TGCA), annotated with estrogen receptor (ER) immunohistochemical (IHC) status and PAM50 subtype.

Figure 1D is a graph showing the overlapping reference density curves of E2 induction scores (defined as the mean z-score expression of the 23 E2-inducing genes shown in Figure 1C) for 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data.

Figure 1E is a graph showing the overlapping reference density curves of E2 suppression scores (defined as the mean z-score expression of the 18 E2 suppressor genes shown in Figure 1C) for 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data.

Figure 1F is a graph showing the overlapping reference density curves of ER pathway activity scores (defined as the difference between E2 induction scores and E2 inhibition scores) for 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data.

Figure 2A is a graph illustrating the in vivo efficacy of treatment with compound A (selective estrogen receptor degrader (SERD)) at specified compound A concentrations in a mouse model of hormone receptor (HR)-positive breast cancer derived from HCI-013 patients, assessed by changes in tumor volume over time.

Figure 2B is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-013 tumors after treatment with compound A. Treatment regimens are annotated above.

Figure 2C is a set of bar charts showing the E2 induction score, E2 inhibition score, and ER pathway activity score as a mean log _10- fold change relative to the agent-treated animals in HCI-013 tumors after compound A exposure. The bars show the mean relative scores and standard errors, n=4. One-sided t-test: *, p<0.05; **, p<0.01; ***, p<0.001; comparisons in black (1 mg/kg vs. 0.1 mg/kg); comparisons in red (10 mg/kg vs. 1 mg/kg).

Figure 2D is a graph illustrating the in vivo efficacy of treatment with mediators or compounds B (SERD), C (SERD/hybrid SERM), or F (SERD) at specified concentrations in an HCI-013PDX mouse model of HR-positive breast cancer, assessed by changes in tumor volume over time.

Figure 2E is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-013 tumors after treatment with the specified therapies. Treatment regimens are annotated above.

Figure 2F is a set of bar charts showing the E2 induction score, E2 inhibition score, and ER pathway activity score as a mean log _10- fold change relative to the vector treatment in HCI-013 tumors after exposure to the specified compounds. The bars show the mean relative scores and standard errors, n=4. One-sided t-tests: *, p<0.1; **, p<0.05; ***, p<0.01; ****, p<0.001; comparisons of compound E with the vector, compound C with compound E, compound D with compound C, and compound B with compound D.

Figure 2G is a graph illustrating the in vivo efficacy of treatment with mediators, compound B, compound C, or compound F at specified endocrine therapy concentrations in an HCI-011PDX mouse model of HR-positive breast cancer, assessed by changes in tumor volume over time.

Figure 2H is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-011 tumors after treatment with the specified therapies. Treatment regimens are annotated above.

Figure 2I is a set of bar charts showing the E2 induction score, E2 inhibition score, and ER pathway activity score as a mean log _10- fold change relative to the vector treatment in HCI-011 tumors exposed to the specified compounds. The bars show the mean relative scores and standard errors, n=4. One-sided t-test: *, p<0.1; **, p<0.05; ***, p<0.01; ****, p<0.001; comparisons of compound E with the vector, compound C with compound E, compound B with compound C, and compound A with compound B.

Figure 3A is a heatmap showing the relative changes in z-score expression of 21 indicated E2-inducing genes and 17 indicated E2-repressing genes from a collection of 139 hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast tumors.

Figures 3B-3D are a series of reference density curves for E2 induction score (Figure 3B), E2 inhibition score (Figure 3C), and ER pathway activity score (Figure 3D) in a set of 139 HR+/HER2- breast tumors. Expression data from six patients before and after treatment with compound B are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity score for each patient.

Figure 3E is a scatter plot comparing the pre-treatment ER pathway activity score with the pre-treatment ESR1 expression level in six patients treated with compound B.

Figure 3F is a scatter plot comparing the treatment-induced differences in ER pathway activity from before to after treatment with the pre-treatment ER pathway activity level in six patients treated with compound B.

Figure 3G is a scatter plot comparing the treatment-induced differences in E2-induced scores from before to after treatment with the pre-treatment E2-induced scores of six patients treated with compound B.

Figures 3H-3J are a series of reference density curves for E2 induction score (Figure 3H), E2 inhibition score (Figure 3I), and ER pathway activity score (Figure 3J) in a set of 139 HR+/HER2- breast tumors. Expression data from seven patients before and after treatment with compound A are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity score for each patient.

Figure 3K is a scatter plot comparing the pre-treatment ER pathway activity score with the pre-treatment ESR1 expression level in seven patients treated with compound A.

Figure 3L is a scatter plot comparing the treatment-induced differences in ER pathway activity from before to after treatment in seven patients treated with compound A with the pre-treatment ER pathway activity level.

Figure 3M is a scatter plot comparing the treatment-induced differences in E2-induced scores from before to after treatment with the pre-treatment E2-induced scores of seven patients treated with compound A.

Figures 4A-4C are a series of bar charts showing the E2 induction score, E2 inhibition score, and ER pathway inhibition as a mean log ₁₀ -fold change, based on the complete 41 gene signatures (Figure 4A), 19 gene signatures (Figure 4B), or 14 gene signatures (Figure 4C) in HCI-013PDX breast tumors after exposure to compound A, relative to the vector-treated animals. The bars show the mean relative scores and standard errors, n=4. One-sided t-tests: *, p<0.05; **, p<0.01; ***, p<0.001; comparisons in black (1 mg/kg vs. 0.1 mg/kg); comparisons in red (10 mg/kg vs. 1 mg/kg).

Figures 4D-4F are a series of reference density curves based on ER pathway activity scores for 41 gene signatures (Figure 4D), 19 gene signatures (Figure 4E), or 14 gene signatures (Figure 4F) across a set of 139 HR+/HER2- breast tumors. Expression data from six patients before and after treatment are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity scores for each patient.

Figure 4G-4I is a series of reference density curves for E2-induced scores based on 41 gene signatures (Figure 4G), 19 gene signatures (Figure 4H), or 14 gene signatures (Figure 4I) across a set of 139 HR+/HER2- breast tumors. Expression data from six patients before and after treatment are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of change in E2-induced scores for each patient.

Figure 4J is a table showing the characteristics of 41 genes (23 E2-inducing genes and 18 E2-repressing genes).

Figure 4K is a table showing the characteristics of 19 genes (11 E2-inducing genes and 8 E2-repressing genes).

Figure 4L is a table showing the characteristics of 14 genes (8 E2-inducing genes and 6 E2-repressing genes).

Figure 5 is a scatter plot of ER pathway activity scores in 60 tissue samples, where expression data were prepared using RIBO-ZERO or RNA. Formalin-fixed and paraffin-embedded (FFPE) samples are shown as triangles; fresh frozen samples are shown as circles. Breast tumors are shown in pink; other tissues are shown in black.

Figure 6 is a graph of the E2 induction score of ER+/HER2- breast cancer cell lines.

Figure 7 is a comparison of the effects of E2 induction score and fulvestrant on cell growth rate.

Detailed Implementation

I. General Technology

Those skilled in the art will readily understand and generally use conventional methods to employ the techniques and procedures described or referenced herein, such as, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd Edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (edited by F.M. Ausubel et al., (2003)); Methods in Enzymology series (Academic Press, Inc.): PCR 2: A Practical Approach (edited by M.J. MacPherson, B.D. Hames and G.R. Taylor (1995)), Harlow and Lane (edited by Harlow and Lane (1988) Antibodies, A Laboratory Manual and Animal Cell Culture (edited by R.I. Freshney (1987)); Oligonucleotide Synthesis (edited by M.J. Gait, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (edited by J.E. Cellis, 1998) Academic Press; Animal Cell Culture (R.I. Freshney), editor, 1987); Introduction to Cell and Tissue Culture (J.P. Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, and D.G. Newell, editors, 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D.M. Weir and C.C. Blackwell, editors); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Calos, editors, 1987); PCR: The Polymerase Chain Reaction (Mullis et al., editors, 1994); Current Protocols in Immunology (J.E. Coligan et al., editors, 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical The widely used approaches described in *The Approach* (D. Catty, ed., IRL Press, 1988–1989); *Monoclonal Antibodies: A Practical Approach* (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); *Using Antibodies: A Laboratory Manual* (E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press, 1999); *The Antibodies* (M. Zanetti and J.D. Capra, eds., Harwood Academic Publishers, 1995); and *Cancer: Principles and Practice of Oncology* (V.T. DeVita et al., eds., J.B. Lippincott Company, 1993) are as follows.

II. Definition

It should be understood that the aspects and embodiments described herein include those referred to as “comprising,” “consisting of,” and “substantially consisting of.” Unless otherwise indicated, the singular forms “a/an” and “the” used herein include the plural of the referred to items.

As used herein, the term "about" refers to a common range of error for a corresponding value that is readily known to those skilled in the art. References to "about" values or parameters herein include (and describe) embodiments relating to that value or parameter itself. For example, a description referring to "about X" includes a description of "X".

As used herein, “administration” means the method of giving a dose of a compound (e.g., the endocrine therapy or composition described herein (e.g., a pharmaceutical composition, such as a pharmaceutical composition comprising an endocrine therapy (e.g., a selective estrogen receptor modulator (SERM) (e.g., a selective estrogen receptor degrader (SERD)), a gonadotropin-releasing hormone (GnRH) agonist, and/or an aromatase inhibitor (AI))) to a subject. The compounds and/or compositions used in the methods described herein may be administered via, for example, orally, intramuscularly, or intravenously (e.g., by intravenous infusion). Note: Administration methods include subcutaneous, intradermal, percutaneous, intra-arterial, intraperitoneal, intralesional, intracranial, intra-articular, intraprostatic, intrapleural, intratracheal, intranasal, intravitreal, intravaginal, intrarectal, local, intratumoral, intraperitoneal, subconjunctival, intracystic, mucosal, intraperitoneal, intraumbilical, intraocular, local, by inhalation, by injection, by infusion, by continuous infusion, by local perfusion to directly immerse target cells, by catheter, by irrigation, as a cream or lipid composition. The method of administration can vary depending on various factors (e.g., the compound or composition to be administered and the severity of the condition, disease, or symptom to be treated).

The term "anticancer therapy" refers to any therapy that can be used to treat cancer (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and/or metastatic or locally advanced breast cancer). Examples of anticancer therapeutic agents include, but are not limited to, endocrine therapies described herein, growth inhibitors, cytotoxic agents, agents used in radiotherapy, anti-angiogenic agents, apoptotic agents, anti-microtubule agents and other agents used to treat cancer (e.g., anti-CD20 antibodies), platelet-derived growth factor inhibitors (e.g., GLEEVEC ^™ (imatinib mesylate)), COX-2 inhibitors (e.g., celecoxib), interferons, cytokines, antagonists (e.g., neutralizing antibodies), other biologically active and organic chemical agents, etc. Combinations of these are also included herein. Anticancer therapies as used herein may also be referred to as "non-endocrine therapies," which in turn refers to any anticancer therapy that does not include endocrine therapies as defined herein.

The term "endocrine therapy" refers to a therapy or treatment that modulates (e.g., regulates, reduces, blocks, or inhibits) the expression, level, or amount of one or more hormones found to cause or otherwise contribute to the progression of breast cancer as described herein. Endocrine therapies described herein include non-hormonal and hormonal therapies such as, for example, selective estrogen receptor modulators (SERMs) described herein and understood in the art, selective estrogen receptor degraders (SERDs) described herein and understood in the art, gonadotropin-releasing hormone (GnRH) agonists described herein and understood in the art, selective estrogen receptor covalent antagonists (SERCAs) described herein and understood in the art, selective local human estrogen receptor agonists (ShERPA) described herein and understood in the art; aromatase inhibitors (AIs) as described herein, or combinations thereof. In one embodiment, an endocrine therapy comprises one or more compounds from Section IV-A of this document.

Other exemplary endocrine therapies used in the methods described herein include, but are not limited to: anti-estrogens, such as tamoxifen (including tamoxifen), raloxifene, droloxifene, 4-hydroxytamoxifen, trivoxifene, nacroxifen, LY117018, onanasone, toremifene citrate, nafoxitin, clomiphene, diacetylcholine, bardoxifene, bromhexene, cyclofennig, lasoxifene, omexifen, arcobifen, ilextron (RAD1901), oflomiphene, etacstil, opemifene, fulvestrant, EM800, brilanestrant (GDC-0810), LX-039, AZ9496, GDC-0927 (SRN-0927); GDC-9545 G1T48 (G1 Therapeutics), H3B 6545 (H3 Biomedicine), SAR439859 (Sanofi), aromatase inhibitors that inhibit aromatase, which regulate the production of estrogen in the adrenal glands, such as, for example, 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, formestan, fastrozole, vorcicloazole, letrozole, and anastrozole; antiandrogens such as flutamide, niglutethimide, bicalutamide, leuprorelin, and goserelin; and trisatabine (a 1,3-dioxolane cytosine analog); antisense oligonucleotides, particularly those that inhibit gene expression in signaling pathways involved in abnormal cell proliferation, and combinations of two or more of the above.

Examples of chemotherapeutic agents (and applicable non-endocrine therapies) include, but are not limited to, targets of mammalian rapamycin (mTOR) inhibitors such as sirolimus (also known as rapamycin), tamsurolimus (also known as CCI-779 or), everolimus (also known as RAD001 or), deforolimus (also known as AP-23573, MK-8669 or 42-(dimethylphosphono)rapamycin), OSI-027, AZD8055 and INK12. 8; Phosphatidylinositol 3-kinase (PI3K) inhibitors such as ederalipse (also known as GS-1101 or CAL-101), BKM120, and pelifoxine (also known as KRX-0401); Dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitors such as XL765, GDC-0980, BEZ235 (also known as NVP-BEZ235), BGT226, GSK2126458, PF-04691502, and PF-05 212384 (also known as PKI-587); and cyclin-dependent protein kinase (CDK) 4/6 inhibitors such as pomarcilin, palbociclib, ribociclib, trilacizil (G1T28); anthracyclines such as daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pentorubicin; taxanes, including paclitaxel and docetaxel; podophyllotoxin; gemcitabine; 5-fluorouracil (5-FU); cyclophosphamide; platinum analogs such as cisplatin and carboplatin; vinorelbine; capecitabine Ixaspirone; and eribulin; ribozymes such as VEGF expression inhibitors (e.g., ribozymes) and HER2 expression inhibitors; vaccines such as gene therapy vaccines, e.g., vaccines, vaccines, and vaccines; rIL-2; topoisomerase 1 inhibitors; rmRH; vinorelbine and esperamicins (see U.S. Patent No. 4,675,187), any compound described in Sections IV-A below, and pharmaceutical salts, acids, or derivatives of any of the above; and combinations of two or more of the above.

Other exemplary chemotherapeutic agents (and non-endocrine therapies) include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, inprossurfan, and piperossurfan; aziridines such as benzotiprine, carbaquinone, metotipa, and urotepa; ethyleneimine and methylmelamine derivatives, including tratamidoamine, triethylphosphamide, triethylthiophosphamide, and tris(hydroxymethyl)melamine; polyacetogenin (especially bratacin and bratacinone); δ-9-tetrahydrocannabinol (drocannabinol); β-lapaquinone; laparol; colchicine; betulin; camptothecin (including synthetic analogs topotecan, CPT-11 (irinotecan), acetylcamptothecin, scopolamine, and 9-aminocamptothecin); lichenin; and callystatin. CC-1065 (including its synthetic analogues, adapalene, biceracilin, and bisacodyl); podophyllotoxin; podophyllic acid; teniposide; noduloside (especially noduloside 1 and noduloside 8); dolastatin; pyroxine (including synthetic analogues, KW-2189, and CB1-TM1); eleutheroside; hydatidin; styraxol; spongistatin; nitrogen mustards such as chlorambucil, naphthylambucil, chlorphosphamide, estradiol, ifosfamide, nitrogen mustard, nitrogen mustard oxide hydrochloride, melphalan, embezzin, benzyl mustard cholesterol, prednimustine, trolophosphamide, uramustine; nitrosoureas such as carmustine, chloramphenicol, formustine, lomustine, nimustine, and ramustine; antibiotics such as enediyne antibiotics (e.g., chachiin, especially chachiin gamma). ₁ ^I and chachiin ωI1 (see, e.g., Nicolaou et al., Angew. Chem Intl. Ed. Engl., 33: 183-186 (1994)); CDP323, oral α-4 integrin inhibitors; danexycin, including danexycin A; esperamycin; and new carcinogen chromophores and associated chromogen ethynylene antibiotic chromophores), akanamycin, actinomycin, atrazomycin, diazoserine, bleomycin, actinomycin C, carabixin, erythromycin, carcinogen, chromomycin, actinomycin D, daunorubicin, detoxin, 6-diazo-5-oxo-leucine, doxorubicin (including morpholino-dxorubicin, cyanomorpholino-dxorubicin, 2-pyrrolino-dxorubicin, doxorubicin hydrochloride liposome injection, liposomal doxorubicin TLC) D-99, PEGylated liposome doxorubicin and deoxydoxorubicin), epirubicin, isorubicin, idarubicin, mesorcinol, mitomycin such as mitomycin C, mycophenolic acid, nogamycin, olivomycin, pepromycin, pofibromycin, puromycin, triamcinolone acetonide, rodorubicin, streptozotocin, streptozotocin, tuberculin, ubenimex, fenestrated statin, zorubicin; antimetabolites such as methotrexate, gemcitabine, tegafur, capecitabine, epothilone, and 5-fluorouracil (5-FU); folic acid analogs such as folate, methotrexate, pteroxate, trimethoprim; purine analogs such as fludarabine, 6-mercaptopurine, thioimidine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmoflurane, vidarabine, dimethoprim ... Deoxyuridine, deoxyfluorouridine, enoxabin, and fluorouridine; androgens, such as capprotestone, drotalbutone propionate, cyclothrostanol, meandrostan, and testrolide; antiadrenergics, such as aminoglutethimide, mitotane, and trilosterone; folic acid supplements, such as folinic acid; glucuronolactone; aldehyde phosphoramide glycosides; aminolevulinic acid; enturacil; acridine; amustine; bisulfite; edarax; dexamethasone Famin; Colchicine; Diacinone; Elonixyl; Hydroxypicarbazole Acetate; Epothilone; Etogluconol; Gallium Nitrate; Hydroxyurea; Lentinan; Clonidamine; Maytansine compounds, such as Maytansine and Ansericin; Mitoguanidine; Mitoantrone; Moperadol; Diaminonitroacin; Pentostatin; Methamidomus Acid; Pirarubicin; Loxoantrone; 2-Ethylhydrazine; Methamidohydrazine; Polysaccharide Complexes (JHS) Natural Products (Eugene, Oreg.); Razosen; Rhizomycin; Cizonan; Germ-spiroamine; Alternaria solanilic acid; Triaminoquinone; 2,2',2'-Trichlorotriethylamine; Trichothecene toxins (especially T-2 toxin, Verrucosporin A, Bacitracin A, and Serpentin); Urethane; Vinpocetine; Dacarbazine; Mannitol mustard; Dibromomannitol; Dibromoeutherol; Piperobromide; Gasetucin; Cytarabine (“Ara-C”); Triaminethione; Taxanes, such as paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), albumin-engineered nanoparticle formulations of paclitaxel (ABRAXANE ^™ ), and docetaxel (Rhome-Poulene). Rorer, Antony, France); chlorambucil; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin, oxaloplatin (e.g., and carboplatin); vinca, to prevent tubulin polymerization and microtubule formation, including vincristine, vinblastine, vinorelbine, and vinorelbine-etoposide (VP-16); isophosphoramide; mitoxantrone; folate; norxetine; idatraxa; donomycin; aminopterin; iban phosphate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); visual pigments such as retinoic acid, including bexarotine; diphosphates such as chlorophosphate (e.g., or), etiolated phosphate, NE-58095, zoledronic acid/zoledronic acid, alen phosphate, pamiphosphate, teluphosphate, or risecine; and trisatabine (a 1,3-dioxolane cytosine analog); antisense oligonucleotides, particularly those that inhibit gene expression in signaling pathways involved in abnormal cell proliferation and reduce cell proliferation, such as PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R) (e.g., erlotinib (TARCEVA ^™)) . ); and VEGF-A; vaccines, such as vaccines and gene therapy vaccines, such as vaccines, vaccines and vaccines; topoisomerase 1 inhibitors (e.g., ); rmRH (e.g., ); BAY439006 (sorafenib; Bayer); SU-11248 (sunitinib, Pfizer); pelifoxin, COX-2 inhibitors (e.g., celecoxib or etoricoxib), proteasome inhibitors (e.g., PS341); bortezomib CCI-779; tepifrazil (R11577); sorafenib, ABT510; Bcl-2 inhibitors such as oligosine sodium; pisafenone; EGFR inhibitors; tyrosine kinase inhibitors; serine-threonine kinase inhibitors such as rapamycin (sirolimus); farnesyltransferase inhibitors such as lonafamib (SCH 6636, SARASAR ^™) ); and any of the above-mentioned pharmaceutical salts, acids or derivatives; and combinations of two or more of the above, such as CHOP (an abbreviation for combination therapy of cyclophosphamide, doxorubicin, vincristine and prednisolone) and FOLFOX (an abbreviation for a treatment regimen of oxaliplatin (ELOXATIN ^™ ) combined with 5-FU and leucovorin), and any of the above-mentioned pharmaceutical salts, acids or derivatives; and combinations of two or more of the above.

As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., radioisotopes of At ²¹¹ , I ¹³¹ , I ¹²⁵ , Y ⁹⁰ , Re ¹⁸⁶ , Re ¹⁸⁸ , Sm ¹⁵³ , Bi ²¹² , P ³² , Pb ²¹² , and Lu); chemotherapeutic agents or drugs (e.g., methotrexate, doxorubicin, vinblastine alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents); growth inhibitors; enzymes and fragments thereof such as lysozymes; antibiotics; toxins such as small molecule toxins or enzyme-active toxins of bacterial, fungal, plant, or animal origin, including fragments and/or variants thereof; and various antitumor or anticancer drugs disclosed below. Cytotoxic agents can be non-endocrine agents.

"Article" means any article (e.g., packaging or container) or kit that contains at least one reagent, such as a medicine for treating a disease or condition (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), and/or a probe for specifically detecting the biomarkers described herein. In some embodiments, the article or kit is marketed, distributed, or sold as a unit for performing the methods described herein.

As used herein, the term "biomarker" refers to an indicator (e.g., a predictive, prognostic, and/or pharmacodynamic indicator) that can be detected in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue sample). Biomarkers can be used as indicators of specific subtypes of diseases or conditions (e.g., breast cancer, HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), characterized by certain molecular, pathological, histological, and/or clinical features. In some embodiments, a biomarker is a gene or a group of genes. Biomarkers include, but are not limited to, polynucleotides (e.g., DNA and/or RNA), polynucleotide copy number alterations (e.g., DNA copy number), peptides, peptide and polynucleotide modifications (e.g., post-translational modifications), carbohydrates, and/or glycolipid-based molecular markers. An exemplary collection of biomarkers is listed in Tables 1-6.

The terms “biomarker signature,” “signature,” “biomarker expression signature,” or “expression signature” are used interchangeably herein and refer to a combination of biomarkers expressed as indicators (e.g., predictive, prognostic, and/or pharmacodynamic indicators) (e.g., a combination of 41 gene signatures (e.g., combinations of genes listed in Tables 3 and 6), 19 gene signatures (e.g., combinations of genes listed in Tables 2 and 5), or 14 gene signatures (e.g., combinations of genes listed in Tables 1 and 4)). A biomarker signature can be used as an indicator of a specific subtype of a disease or condition (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), characterized by certain molecular, pathological, histological, and/or clinical features. In some embodiments, a biomarker signature is a “gene signature.” The term “gene signature” is used interchangeably with “gene expression signature” and refers to a combination of polynucleotides expressed as indicators (e.g., predictive, diagnostic, and/or prognostic indicators). In some embodiments, the biomarker characteristic is a “protein characteristic.” The terms “protein characteristic” and “protein expression characteristic” are used interchangeably and refer to a combination of peptides that are expressed as indicators (e.g., predictive, prognostic, and/or pharmacodynamic indicators).

Unless otherwise specified, the term "AGR3" refers to any naturally occurring member of the end-gradient 3 protein disulfide isomerase family from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed AGR3, as well as any form of AGR3 produced through cellular processing. The term also covers naturally occurring variants of AGR3, such as splice variants or allelic variants. AGR3 is also referred to in the art in the form of protein disulfide isomerase family A member 18, breast cancer membrane protein 11, BCMP11, PDIA18, HAG-3, HAG3, AG-3, AG3, and pre-gradient protein 3 homologs. An exemplary nucleic acid sequence of human AGR3 is shown in the following NCBI reference sequence: NM_176813.4 or in SEQ ID NO:1. An exemplary amino acid sequence of a protein encoded by human AGR3 is shown in UniProt accession number Q8TD06 or SEQ ID NO:2.

Unless otherwise specified, the term "AMZ1" refers to any naturally occurring lysozyme family metallopeptidase 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed AMZ1, as well as any form of AMZ1 produced through cellular processing. The term also covers naturally occurring variants of AMZ1, such as splice variants or allelic variants. AMZ1 is also known in the art as archaea metalloproteinase-like protein 1, archaea-1, metalloproteinase-like protein, and KIAA1950. An exemplary nucleic acid sequence of human AMZ1 is shown in the following NCBI reference sequence: NM_133463.3 or in SEQ ID NO:3. An exemplary amino acid sequence of a protein encoded by human AMZ1 is shown in UniProt accession number Q400G9 or SEQ ID NO:4.

Unless otherwise specified, the term “AREG” refers to any naturally occurring bimodal protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed AREG, as well as any form of AREG produced through cellular processing. The term also covers naturally occurring variants of AREG, such as splice variants or allelic variants. AREG is also known in the art as colorectal cell-derived growth factor, schwannoma-derived growth factor, bimodal protein B, AREGB, CRDGF, and SDGF. An exemplary nucleic acid sequence of human AREG is shown in the following NCBI reference sequence: NM_001657.3 or in SEQ ID NO:5. An exemplary amino acid sequence of a protein encoded by human AREG is shown in UniProt accession number P15514 or in SEQ ID NO:6.

Unless otherwise specified, the term “C5AR2” refers to any naturally occurring complement component 5a receptor 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed C5AR2, as well as any form of C5AR2 produced through cellular processing. The term also covers naturally occurring variants of C5AR2, such as splice variants or allelic variants. C5AR2 is also referred to in the art as complement component 5a receptor 2, G protein-coupled receptor 77, GPR77, C5L2, C5a anaphylatoxin chemokine receptor C5L2, and GPF77. An exemplary nucleic acid sequence of human C5AR2 is shown in the following NCBI reference sequence: NM_001271749.1 or in SEQ ID NO:7. An exemplary amino acid sequence of a protein encoded by human C5AR2 is shown in UniProt accession number Q9P296 or in SEQ ID NO:8.

Unless otherwise specified, the term "CELSR2" refers to any naturally occurring cadherin EGF LAG heptacortex G-type receptor 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed CELSR2, as well as any form of CELSR2 produced through cellular processing. The term also covers naturally occurring variants of CELSR2, such as splice variants or allelic variants. CELSR2 is also referred to in the art in the form of multiepidermal growth factor-like domain protein 3, multiepidermal growth factor-like domain protein 3, adhesion G protein-coupled receptor C2, epidermal growth factor-like protein 2, multi-EGF-like domain protein 3, cadherin family member 10, flamingo homolog 3, EGF-like protein 2, CDHF10, EGFL2, MEGF3, flamingo, KIAA0279, and ADGRC2. The exemplary nucleic acid sequence of human CELSR2 is shown in the following NCBI reference sequence: NM_001408.2 or in SEQ ID NO:9. The amino acid sequence of an exemplary protein encoded by human CELSR2 is shown in UniProt accession number Q9HCU4 or in SEQ ID NO:10.

Unless otherwise specified, the term "CT62" refers to any naturally occurring cancer/testis antigen 62 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed CT62, as well as any form of CT62 produced through cellular processing. The term also covers naturally occurring variants of CT62, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human CT62 is shown in the following NCBI reference sequence: XM_006720429 or in SEQ ID NO:11. An exemplary amino acid sequence of a protein encoded by human CT62 is shown in UniProt accession number P0C5K7 or in SEQ ID NO:12.

Unless otherwise specified, the term "FKBP4" refers to any naturally occurring FK506-binding protein 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FKBP4, as well as any form of FKBP4 produced through cellular processing. The term also covers naturally occurring variants of FKBP4, such as splice variants or allelic variants. FKBP4 is also known in the art as gyroisomerase, FKBP51, FKBP52, FKBP59, HBI, peptidylprolyl cis-trans isomerase FKBP4, T-cell FK506-binding protein (59kD), HSP-binding immunoaffinity, immunoaffinity FKBP52, peptidylprolyl isomerase FKBP4, PPIASE, Hsp56, P52, and P59. The nucleotide sequence of an exemplary human FKBP4 is shown in the following NCBI reference sequence: NM_002014.3 or in SEQ ID NO:13. The amino acid sequence of an exemplary protein encoded by human FKBP4 is shown in UniProt accession number Q02790 or in SEQ ID NO:14.

Unless otherwise specified, the term "FMN1" refers to any naturally occurring FMN1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FMN1, as well as any form of FMN1 produced through cellular processing. The term also covers naturally occurring variants of FMN1, such as splice variants or allelic variants. FMN1 is also referred to in the art as limb malformation protein homolog, FMN, and LD. An exemplary human FMN1 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001277313.1 or in SEQ ID NO:15. An exemplary protein encoded by human FMN1 has an amino acid sequence shown in UniProt accession number Q68DA7 or in SEQ ID NO:16.

Unless otherwise specified, the term “GREB1” refers to any naturally occurring breast cancer estrogen growth regulator protein 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed GREB1, as well as any form of GREB1 produced through cellular processing. The term also covers naturally occurring variants of GREB1, such as splice variants or allelic variants. GREB1 is also referred to in the art as breast cancer 1 gene regulator protein and KIAA0575. An exemplary nucleic acid sequence of human GREB1 is shown in the following NCBI reference sequence: NM_014668.3 or in SEQ ID NO:17. An exemplary amino acid sequence of a protein encoded by human GREB1 is shown in UniProt accession number Q4ZG55 or SEQ ID NO:18.

Unless otherwise specified, the term "IGFBP4" refers to any naturally occurring insulin-like growth factor binding protein 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IGFBP4, as well as any form of IGFBP4 produced through cellular processing. The term also covers naturally occurring variants of IGFBP4, such as splice variants or allelic variants. IGFBP4 is also referred to in the art as IGF-binding protein 4, IBP-4, HT29-IGFBP, and BP-4. An exemplary nucleic acid sequence of human IGFBP4 is shown in the following NCBI reference sequence: NM_001552.2 or in SEQ ID NO:19. An exemplary amino acid sequence of a protein encoded by human IGFBP4 is shown in UniProt accession number P22692 or in SEQ ID NO:20.

Unless otherwise specified, the term "NOS1AP" refers to any naturally occurring nitric oxide synthase 1 adaptor protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed NOS1AP, as well as any form of NOS1AP produced through cellular processing. The term also covers naturally occurring variants of NOS1AP, such as splice variants or allelic variants. NOS1AP is also referred to in the art as the C-terminal PDZ ligand of the neuronal nitric oxide synthase protein, nitric oxide synthase 1 (neuronal) adaptor protein, CAPON, ligand of neuronal nitric oxide synthase having a C-terminal PDZ domain, 6330408P19Rik, and KIAA0464. An exemplary nucleic acid sequence of human NOS1AP is shown in the following NCBI reference sequence: NM_014697.2 or in SEQ ID NO:21. The amino acid sequence of an exemplary protein encoded by human NOS1AP is shown in UniProt accession number O75052 or SEQ ID NO:22.

Unless otherwise specified, the term “NXPH3” refers to any naturally occurring extraneurotrophic protein 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed NXPH3, as well as any form of NXPH3 produced through cellular processing. The term also covers naturally occurring variants of NXPH3, such as splice variants or allelic variants. NXPH3 is also known in the art as NPH3 and KIAA1159. An exemplary nucleic acid sequence of human NXPH3 is shown in the following NCBI reference sequence: NM_007225.2 or in SEQ ID NO:23. An exemplary amino acid sequence of a protein encoded by human NXPH3 is shown in UniProt accession number O95157 or SEQ ID NO:24.

Unless otherwise specified, the term "OLFM1" refers to any naturally occurring olfactory mediator 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed OLFM1, as well as any form of OLFM1 produced through cellular processing. The term also covers naturally occurring variants of OLFM1, such as splice variants or allelic variants. OLFM1 is also referred to in the art as neuronal olfactory mediator-associated ER localizer, Noelin, NOE1, neuroblastoma protein, Pancortin 1, Pancortin, NOELIN1, NOEL1, OlfA, and AMY. An exemplary nucleic acid sequence of human OLFM1 is shown in the following NCBI reference sequence: NM_014279.4 or in SEQ ID NO:25. An exemplary amino acid sequence of a protein encoded by human OLFM1 is shown in UniProt accession number Q99784 or in SEQ ID NO:26.

Unless otherwise specified, the term “PGR” refers to any natural progesterone receptor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed PGR, as well as any form of PGR produced through cellular processing. The term also covers naturally occurring variants of PGR, such as splice variants or allelic variants. PGR is also referred to in the art in the form of nuclear receptor subfamily 3 group C member 3, NR3C3, and PR. An exemplary nucleic acid sequence of human PGR is shown in the following NCBI reference sequence: NM_000926.4 or in SEQ ID NO:27. An exemplary amino acid sequence of a protein encoded by human PGR is shown in UniProt accession number P06401 or in SEQ ID NO:28.

Unless otherwise specified, the term "PPM1J" refers to any naturally occurring Mg2+/Mn2+ dependent protein phosphatase 1J from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed PPM1J, as well as any form of PPM1J produced through cellular processing. The term also covers naturally occurring variants of PPM1J, such as splice variants or allelic variants. PPM1J is also referred to in the art as protein phosphatase 1J (containing the PP2C domain), protein phosphatase 2Cζ, EC 3.1.3.16, PP2C-ζ, protein phosphatase 2a, catalytic subunit, ζ isotype, protein phosphatase 1J, PP2Cζ, and PP2CZ. An exemplary human PPM1J nucleic acid sequence is shown in the following NCBI reference sequence: NM_005167.5 or in SEQ ID NO:29. The amino acid sequence of an exemplary protein encoded by human PPMIJ is shown in UniProt accession number Q5JR12 or SEQ ID NO:30.

Unless otherwise specified, the term “RAPGEFL1” refers to any naturally occurring Rap-type guanine nucleotide exchange factor-like 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed RAPGEFL1, as well as any form of RAPGEFL1 produced through cellular processing. The term also covers naturally occurring variants of RAPGEFL1, such as splice variants or allelic variants. RAPGEFL1 is also referred to in the art as Link guanine nucleotide exchange factor II, Rap-type guanine nucleotide exchange factor (GEF)-like 1, and Link GEFII. An exemplary nucleic acid sequence of human RAPGEFL1 is shown in the following NCBI reference sequence: NM_001303533.1 or in SEQ ID NO:31. An exemplary amino acid sequence of a protein encoded by human RAPGEFL1 is shown in UniProt accession number Q9UHV5 or in SEQ ID NO:32.

Unless otherwise specified, the term "RBM24" refers to any naturally occurring RNA-binding motif protein 24 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed RBM24, as well as any form of RBM24 produced through cellular processing. The term also covers naturally occurring variants of RBM24, such as splice variants or allelic variants. RBM24 is also referred to in the art as containing an RNA-binding region (RNP1, RRM) containing 6, RNPC6, RNA-binding protein 24, and DJ259A10.1. An exemplary nucleic acid sequence of human RBM24 is shown in the following NCBI reference sequence: NM_001143942.1 or in SEQ ID NO:33. An exemplary amino acid sequence of a protein encoded by human RBM24 is shown in UniProt accession number Q9BX46 or in SEQ ID NO:34.

Unless otherwise specified, the term “RERG” refers to any naturally occurring RAS-like estrogen-regulated growth inhibitory factor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed RERG, as well as any form of RERG produced through cellular processing. The term also covers naturally occurring variants of RERG, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human RERG is shown in the following NCBI reference sequence: NM_032918.2 or in SEQ ID NO:35. An exemplary amino acid sequence of a protein encoded by human RERG is shown in UniProt accession number Q96A58 or in SEQ ID NO:36.

Unless otherwise specified, the term “RET” refers to any naturally occurring Ret proto-oncogene from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed RET, as well as any form of RET produced through cellular processing. The term also covers naturally occurring variants of RET, such as splice variants or allele variants. RET is also referred to in the art in terms of cadherin-associated family member 16, rearranged during transfection, RET receptor tyrosine kinase, cadherin family member 12, proto-oncogene C-Ret, EC 2.7.10.1, CDHF12, CDHR16, PTC, multiple endocrine adenomas and medullary thyroid carcinoma 1, EC 2.7.10, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, and MTC1. The nucleotide sequence of an exemplary human RET is shown in the following NCBI reference sequence: NM_020975.5 or in SEQ ID NO:37. The amino acid sequence of an exemplary protein encoded by human RET is shown in UniProt accession number P07949 or in SEQ ID NO:38.

Unless otherwise specified, the term "SGK3" refers to any naturally occurring serum/glucocorticoid-regulated kinase family member 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed SGK3, as well as any form of SGK3 produced through cellular processing. The term also covers naturally occurring variants of SGK3, such as splice variants or allelic variants. SGK3 is also referred to in the art as cytokine-independent survival kinase, EC 2.7.11.1, SGKL, CISK, EC 2.7.11, serine/threonine protein kinase Sgk3, and SGK2. An exemplary human SGK3 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001033578.2 or in SEQ ID NO:39. An exemplary protein encoded by human SGK3 amino acid sequence is shown in UniProt accession number Q96BR1 or SEQ ID NO:40.

Unless otherwise specified, the term "SLC9A3R1" refers to any naturally occurring SLC9A3 regulatory factor 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed SLC9A3R1, as well as any form of SLC9A3R1 produced through cellular processing. The term also covers naturally occurring variants of SLC9A3R1, such as splice variants or allelic variants. SLC9A3R1 is also referred to in the art as solute carrier family 9, subfamily A (NHE3, cation proton reverse transporter 3), member 3 regulatory factor 1, regulatory cofactor of the Na(+)/H(+) exchange pump, NHERF-1, EBP50, NHERF, EZ protein/root protein/membrane spike protein binding phosphoprotein 50, sodium-hydrogen exchange pump regulatory factor 1, and NPHLOP2. The exemplary nucleic acid sequence of human SLC9A3R1 is shown in the following NCBI reference sequence: NM_004252.4 or in SEQ ID NO:41. The amino acid sequence of an exemplary protein encoded by human SLC9A3R1 is shown in UniProt accession number O14745 or in SEQ ID NO:42.

Unless otherwise specified, the term "TFF1" refers to any naturally occurring trefoil factor 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TFF1, as well as any form of TFF1 produced through cellular processing. The term also covers naturally occurring variants of TFF1, such as splice variants or allelic variants. TFF1 is also known in the art as breast cancer estrogen-inducing protein, polypeptide P1.A, protein PS2, HP1.A, PNR-2, BCEI, PS2, gastrointestinal trefoil protein PS2, D21S21, and HPS2. An exemplary nucleic acid sequence of human TFF1 is shown in the following NCBI reference sequence: NM_003225.2 or in SEQ ID NO:43. An exemplary amino acid sequence of a protein encoded by human TFF1 is shown in UniProt accession number P04155 or SEQ ID NO:44.

Unless otherwise specified, the term "ZNF703" refers to any naturally occurring zinc finger protein 703 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed ZNF703, as well as any form of ZNF703 produced through cellular processing. The term also covers naturally occurring variants of ZNF703, such as splice variants or allelic variants. ZNF703 is also referred to in the art in the form of zinc finger elbow-associated proline domain protein 1, ZEPPO1, ZPO1, ZNF503L, and NLZ1. An exemplary human ZNF703 nucleic acid sequence is shown in the following NCBI reference sequence: NM_025069.2 or in SEQ ID NO:45. An exemplary protein encoded by human ZNF703 has an amino acid sequence shown in UniProt accession number Q9H7S9 or in SEQ ID NO:46.

Unless otherwise specified, the term “BAMBI” refers to any naturally occurring BMP and activin membrane-binding repressor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed BAMBI, as well as any form of BAMBI produced through cellular processing. The term also covers naturally occurring variants of BAMBI, such as splice variants or allelic variants. BAMBI is also referred to in the art as a homolog of the presumed transmembrane protein NMA, the nontransferable gene A protein NMA, and BMP with the activin membrane-binding repressor. An exemplary nucleic acid sequence of human BAMBI is shown in the following NCBI reference sequence: NM_012342.2 or in SEQ ID NO:47. An exemplary amino acid sequence of a protein encoded by human BAMBI is shown in UniProt accession number Q13145 or in SEQ ID NO:48.

Unless otherwise specified, the term “BCAS1” refers to any naturally occurring breast cancer amplification sequence 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed BCAS1, as well as any form of BCAS1 produced through cellular processing. The term also covers naturally occurring variants of BCAS1, such as splice variants or allelic variants. BCAS1 is also referred to in the art as breast cancer amplification and overexpression, novel breast cancer amplification 1, AIBC1, and NABC1. An exemplary nucleic acid sequence of human BCAS1 is shown in the following NCBI reference sequence: NM_003657.3 or in SEQ ID NO:49. An exemplary amino acid sequence of a protein encoded by human BCAS1 is shown in UniProt accession number O75363 or in SEQ ID NO:50.

Unless otherwise specified, the term “CCNG2” refers to any naturally occurring cyclin G2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed CCNG2, as well as any form of CCNG2 produced through cellular processing. The term also covers naturally occurring variants of CCNG2, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human CCNG2 is shown in the following NCBI reference sequence: XM_011532399.2 or in SEQ ID NO:51. An exemplary amino acid sequence of a protein encoded by human CCNG2 is shown in UniProt accession number Q16589 or in SEQ ID NO:52.

Unless otherwise specified, the term “DDIT4” refers to any naturally occurring DNA damage-inducing transcript 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed DDIT4, as well as any form of DDIT4 produced through cellular processing. The term also covers naturally occurring variants of DDIT4, such as splice variants or allelic variants. DDIT4 is also referred to in the art in the form of developmental and DNA damage response regulator 1, HIF-1 response protein RTP801, REDD1, RTP801, and Dig2. An exemplary human DDIT4 nucleic acid sequence is shown in the following NCBI reference sequence: NM_019058.3 or in SEQ ID NO:53. An exemplary protein encoded by human DDIT4 amino acid sequence is shown in UniProt accession number Q9NX09 or in SEQ ID NO:54.

Unless otherwise specified, the term "EGLN3" refers to any naturally occurring Egl-9 family hypoxia-inducible factor 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed EGLN3, as well as any form of EGLN3 produced through cellular processing. The term also covers naturally occurring variants of EGLN3, such as splice variants or allelic variants. EGLN3 is also referred to in the art as prolyl hydroxylase domain-containing protein 3, hypoxia-inducible factor prolyl hydroxylase 3, HIF prolyl hydroxylase 3, HPH-1, HPH-3, PHD3, Egl nine-like protein 3 isoform, Egl nine homolog 3, EC 1.14.11.29, EC 1.14.11, HIFP4H3, and HIFPH3. The nucleotide sequence of an exemplary human EGLN3 is shown in the following NCBI reference sequence: NM_022073.3 or in SEQ ID NO:55. The amino acid sequence of an exemplary protein encoded by human EGLN3 is shown in UniProt accession number Q9H6Z9 or SEQ ID NO:56.

Unless otherwise specified, the term "FAM171B" refers to any naturally occurring sequence-similar member of family 171B from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FAM171B, as well as any form of FAM171B produced through cellular processing. The term also covers naturally occurring variants of FAM171B, such as splice variants or allelic variants. FAM171B is also known in the art as KIAA1946 and protein FAM171B. An exemplary nucleic acid sequence of human FAM171B is shown in the following NCBI reference sequence: NM_177454.3 or in SEQ ID NO:57. An exemplary amino acid sequence of a protein encoded by human FAM171B is shown in UniProt accession number Q6P995 or in SEQ ID NO:58.

Unless otherwise specified, the term “GRM4” refers to any naturally occurring metabolized glutamate receptor 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed GRM4, as well as any form of GRM4 produced through cellular processing. The term also covers naturally occurring variants of GRM4, such as splice variants or allelic variants. GRM4 is also known in the art as GPRC1D, MGLUR4, and MGlu4. An exemplary nucleic acid sequence of human GRM4 is shown in the following NCBI reference sequence: NM_000841.4 or in SEQ ID NO:59. An exemplary amino acid sequence of a protein encoded by human GRM4 is shown in UniProt accession number Q14833 or in SEQ ID NO:60.

Unless otherwise specified, the term "IL1R1" refers to any naturally occurring interleukin-1 receptor type 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IL1R1, as well as any form of IL1R1 produced through cellular processing. The term also covers naturally occurring variants of IL1R1, such as splice variants or allelic variants. IL1R1 is also referred to in the art as CD121 antigen-like family member A, interleukin-1 receptor α, IL-1R-α, IL1RA, IL1R, P80, CD12la antigen, D2S1473, CD121A, and IL1RT1. An exemplary nucleic acid sequence of human IL1R1 is shown in the following NCBI reference sequence: NM_001288706.1 or in SEQ ID NO:61. The amino acid sequence of an exemplary protein encoded by human IL1R1 is shown in UniProt accession number P14778 or SEQ ID NO:62.

Unless otherwise specified, the term "LIPH" refers to any naturally occurring lipase H from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed LIPH, as well as any form of LIPH produced through cellular processing. The term also covers naturally occurring variants of LIPH, such as splice variants or allelic variants. LIPH is also referred to in the art as membrane-associated phosphatidic acid selective phospholipase A1-α, PD lipase-associated protein, phospholipase A1 member B, MPA-PLA1α, LPDLR, membrane-bound phosphatidic acid selective phospholipase A1, lipase member H, EC 3.1.1.3, C 3.1, ARWH2, HYPT7, LAH2, and AH. An exemplary human LIPH nucleic acid sequence is shown in the following NCBI reference sequence: XM_006713529.4 or in SEQ ID NO:63. The amino acid sequence of an exemplary protein encoded by human LIPH is shown in UniProt accession number Q8WWY8 or SEQ ID NO:64.

Unless otherwise specified, the term "NBEA" refers to any naturally occurring protein kinase-anchored protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed NBEA, as well as any form of NBEA produced through cellular processing. The term also covers naturally occurring variants of NBEA, such as splice variants or allelic variants. NBEA is also known in the art as lysosomal transport regulator 2, BCL8B, LYST2, protein BCL8B, EC 1.14.14.5, EC 6.1.1.11, and KIAA1544. An exemplary nucleic acid sequence of human NBEA is shown in the following NCBI reference sequence: NM_015678.4 or in SEQ ID NO:65. An exemplary amino acid sequence of a protein encoded by human NBEA is shown in UniProt accession number Q8NFP9 or SEQ ID NO:66.

Unless otherwise specified, the term “PNPLA7” refers to any naturally occurring PNPLA7 containing the potato glycoprotein-like phospholipase domain 7 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed PNPLA7, as well as any form of PNPLA7 produced through cellular processing. The term also covers naturally occurring variants of PNPLA7, such as splice variants or allelic variants. PNPLA7 is also known in the art as C9orf111, PNPLA7 containing the potato glycoprotein-like phospholipase domain, chromosome 9 open reading frame 111, EC 3.1.1.5, NTE-R1, and NTEL1. An exemplary human PNPLA7 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001098537.2 or in SEQ ID NO:67. The amino acid sequence of an exemplary protein encoded by human PNPLA7 is shown in UniProt accession number Q6ZV29 or SEQ ID NO:68.

Unless otherwise specified, the term “PSCA” refers to any naturally occurring prostate stem cell antigen from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed PSCA, as well as any form of PSCA produced through cellular processing. The term also covers naturally occurring variants of PSCA, such as splice variants or allele variants. PSCA is also known in the art as PRO232. An exemplary nucleic acid sequence of human PSCA is shown in the following NCBI reference sequence: NM_005672.4 or in SEQ ID NO:69. An exemplary amino acid sequence of a protein encoded by human PSCA is shown in UniProt accession number O43653 or in SEQ ID NO:70.

Unless otherwise specified, the term "SEMA3E" refers to any naturally occurring semacin 3E from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed SEMA3E, as well as any form of SEMA3E produced through cellular processing. The term also covers naturally occurring variants of SEMA3E, such as splice variants or allelic variants. SEMA3E is also referred to in the art as the Sema domain, immunoglobulin domain (Ig), basic short domain, secreted (semacin) 3E, SEMAH, semacin-3E, M-Sema H, KIAA0331, M-SemaK, and Coll-5. An exemplary human SEMA3E nucleic acid sequence is shown in the following NCBI reference sequence: NM_012431.2 or in SEQ ID NO:71. The amino acid sequence of an exemplary protein encoded by human SEMA3E is shown in UniProt accession number O15041 or SEQ ID NO:72.

Unless otherwise specified, the term "SSPO" refers to any naturally occurring SCO-vertebral protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed SSPO, as well as any form of SSPO produced through cellular processing. The term also covers naturally occurring variants of SSPO, such as splice variants or allelic variants. SSPO is also known in the art as SCO protein, platelet-reactive protein domain-containing septal vertebral protein, EC 3.4.24.82, EC 3.4.21.9, and KIAA2036. An exemplary human SSPO nucleic acid sequence is shown in the following NCBI reference sequence: BN000852.1 or in SEQ ID NO:73. An exemplary protein encoded by human SSPO is shown in UniProt accession number A2VEC9 or SEQ ID NO:74.

Unless otherwise specified, the term “STON1” refers to any naturally occurring lithin 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed STON1, as well as any form of STON1 produced through cellular processing. The term also covers naturally occurring variants of STON1, such as splice variants or allelic variants. STON1 is also known in the art as stone B-like factor, SALF, SBLF, STN1, stone B homolog 1, and STNB1. An exemplary nucleic acid sequence of human STON1 is shown in the following NCBI reference sequence: NM_001198595.1 or in SEQ ID NO:75. An exemplary amino acid sequence of a protein encoded by human STON1 is shown in UniProt accession number Q9Y6Q2 or in SEQ ID NO:76.

Unless otherwise specified, the term “TGFB3” refers to any naturally occurring transforming growth factor β3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed TGFB3, as well as any form of TGFB3 produced through cellular processing. The term also covers naturally occurring variants of TGFB3, such as splice variants or allelic variants. TGFB3 is also referred to in the art as precursor transforming growth factor β-3, arrhythmogenic right ventricular dysplasia 1, TGF-β-3, ARVD1, LDS5, RNHF, and ARVD. An exemplary nucleic acid sequence of human TGFB3 is shown in the following NCBI reference sequence: NM_003239.4 or in SEQ ID NO:77. An exemplary amino acid sequence of a protein encoded by human TGFB3 is shown in UniProt accession number Pl0600 or SEQ ID NO:78.

Unless otherwise specified, the term "TP53INP1" refers to any naturally occurring tumor protein P53-inducible nucleoprotein 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TP53INP1, as well as any form of TP53INP1 produced through cellular processing. The term also covers naturally occurring variants of TP53INP1, such as splice variants or allelic variants. TP53INP1 is also referred to in the art as P53-dependent damage-inducible nucleoprotein 1, stress-inducible protein, P53DINP1, SIP, P53-inducible P53DINP1, TP53DINP1, TP53INP1A, TP53INP1B, and Teap. An exemplary human TGFB3 nucleic acid sequence is shown in the following NCBI reference sequence: NM_033285.3 or in SEQ ID NO:79. The amino acid sequence of an exemplary protein encoded by human TP53INP1 is shown in UniProt accession number Q96A56 or SEQ ID NO:80.

Unless otherwise specified, the term "TP53INP2" refers to any naturally occurring tumor protein P53-inducible nucleoprotein 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TP53INP2, as well as any form of TP53INP2 produced through cellular processing. The term also covers naturally occurring variants of TP53INP2, such as splice variants or allelic variants. TP53INP2 is also referred to in the art as P53-inducible protein U, C20orf110, PIG-U, PINH, DOR, chromosome 20 open reading frame 110, diabetes and obesity regulatory gene, and DJ1181N3.1. An exemplary human TP53INP2 nucleic acid sequence is shown in the following NCBI reference sequence: NM_021202.2 or in SEQ ID NO:81. The amino acid sequence of an exemplary protein encoded by human TP53INP2 is shown in UniProt accession number Q8IXH6 or SEQ ID NO:82.

Unless otherwise specified, the term “GUSB” refers to any naturally occurring glucuronidase β from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed GUSB, as well as any form of GUSB produced through cellular processing. The term also covers naturally occurring variants of GUSB, such as splice variants or allelic variants. GUSB is also referred to in the art as EC 3.2.1.31, β-G1, β-D-glucuronidase, MPS7, and BG. An exemplary human GUSB nucleic acid sequence is shown in the following NCBI reference sequence: NM_000181.3 or in SEQ ID NO:83. An exemplary protein encoded by human GUSB has an amino acid sequence shown in UniProt accession number P08236 or in SEQ ID NO:84.

Unless otherwise specified, the term "PPIA" refers to any naturally occurring peptidyl proline isomerase A from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed PPIA, as well as any form of PPIA produced through cellular processing. The term also covers naturally occurring variants of PPIA, such as splice variants or allelic variants. PPIA is also known in the art as cyclosporine A-binding protein, cyclophilin A, gyroisomerase A, EC 5.2.1.8, peptidyl prolyl isomerase A, CYPA, epididymal secretory sperm-binding protein Li 69p, peptidyl prolyl cis-trans isomerase A, T-cell cyclophilin, HEL-S-69p, and CYPH. An exemplary human PPIA nucleic acid sequence is shown in the following NCBI reference sequence: NM_021130.4 or in SEQ ID NO:85. The amino acid sequence of an exemplary protein encoded by human PPIA is shown in UniProt accession number P62937 or SEQ ID NO:86.

Unless otherwise specified, the term “UBC” refers to any naturally occurring ubiquitin C from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed UBC, as well as any form of UBC produced through cellular processing. The term also covers naturally occurring variants of UBC, such as splice variants or allelic variants. UBC is also known in the art as polyubiquitin-C and HMG20. An exemplary nucleic acid sequence of human UBC is shown in the following NCBI reference sequence: NM_021009.6 or in SEQ ID NO:87. An exemplary amino acid sequence of a protein encoded by human UBC is shown in UniProt accession number P0CG48 or SEQ ID NO:88.

Unless otherwise specified, the term "SDHA" refers to the flavoprotein subunit A of the succinate dehydrogenase complex from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed SDHA, as well as any form of SDHA produced through cellular processing. The term also covers naturally occurring variants of SDHA, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human SDHA is shown in the following NCBI reference sequence: NM_001330758 or in SEQ ID NO:89. An exemplary amino acid sequence of a protein encoded by human SDHA is shown in UniProt accession number P31040 or in SEQ ID NO:90.

The terms “cancer” and “cancerous” refer to or describe a physiological condition in mammals typically characterized by uncontrolled cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include, but are not limited to, breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer); lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma; bladder cancer (e.g., urothelial bladder cancer (UBC), muscle-invasive bladder cancer (MIBC), and BCG-refractory non-muscle-invasive bladder cancer (NMIBC)); and kidney or renal cancer (e.g., renal cell carcinoma (RCC)). Urinary tract cancer; prostate cancer, such as castration-resistant prostate cancer (CRPC); peritoneal cancer; hepatocellular carcinoma; gastric cancer, including gastrointestinal cancer and gastrointestinal stromal cancer; pancreatic cancer; glioblastoma; cervical cancer; ovarian cancer; liver cancer; hepatocellular carcinoma; colon cancer; rectal cancer; colorectal cancer; endometrial or uterine cancer; salivary gland cancer; prostate cancer; vulvar cancer; thyroid cancer; primary liver cancer; anal cancer; penile cancer; melanoma, including superficial diffuse melanoma, malignant lentigines melanoma, and peripheral macular melanoma. Malignant melanoma, including nodular malignant melanoma; multiple myeloma and B-cell lymphoma (including low-grade/follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate/follicular NHL; intermediate diffuse NHL; high-grade immunoblastic NHL; high-grade lymphocytic NHL; high-grade small non-lytic cell NHL; giant mass NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's macroglobulinemia). ulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); acute myeloid leukemia (AML); hairy cell leukemia; chronic myeloid leukemia (CML); post-transplant lymphoproliferative disorder (PTLD); and myelodysplastic syndrome (MDS), as well as abnormal angiogenesis associated with maculopapular hamartomatosis, edema (such as that associated with brain tumors), Meigs' syndrome, brain cancer, head and neck cancer, and related metastases.

As used herein, the term "breast cancer" refers to breast cancer that has been histologically or cytologically confirmed. In some embodiments, breast cancer is epithelial carcinoma. In some embodiments, breast cancer is adenocarcinoma. In some embodiments, breast cancer is sarcoma. In some embodiments, breast cancer is HR+ breast cancer. In some embodiments, HR+ breast cancer is ER+ breast cancer. In some embodiments, ER+ breast cancer is luminal type A breast cancer. In some embodiments, ER+ breast cancer is luminal type B breast cancer. In some embodiments, breast cancer is metastatic or locally advanced breast cancer.

The term "locally advanced breast cancer" refers to cancer that starts in the breast and spreads to nearby tissues or lymph nodes, but has not spread to other parts of the body.

The term "metastatic breast cancer" refers to cancer that has spread from the breast to other parts of the body, such as bone, liver, lungs, or brain. Metastatic breast cancer can also be called stage IV breast cancer.

As understood in the art, the term "ductal carcinoma in situ breast cancer" or (DCIS cancer) refers to breast cancer characterized by an intraductal, non-avoided, and pre-invasive primary tumor.

The terms "cellular proliferative disorder" and "proliferative disease" refer to conditions associated with some degree of abnormal cell proliferation. In one embodiment, a cellular proliferative disorder is breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). In another embodiment, a cellular proliferative disorder is a tumor.

As used herein, the term "simultaneous" refers to the administration of two or more therapeutic agents, wherein at least some of the administration overlaps in time. Therefore, simultaneous administration includes a dosing regimen in which administration of one or more other agents is continued after the administration of one or more agents has been discontinued.

As used herein, “delayed progression” of a condition or disease means the postponement, impediment, mitigation, slowing, stabilization, and/or delay of the development of a disease or condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). Such delay can vary in length depending on medical history and/or the subject to be treated. It will be apparent to those skilled in the art that adequate or significant delay can effectively encompass prevention, as the subject will not develop the disease.

The terms “determination,” “determining,” “detection,” and “detecting,” and their grammatical variations, include any means of determination or detection, including direct and indirect determination or detection.

“Symptom” or “disease” means any condition that can benefit from treatment, including but not limited to chronic and acute symptoms or diseases, which include those pathological conditions that make mammals susceptible to said symptoms (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS and/or metastatic or locally advanced breast cancer).

As used herein, the term “diagnosis” refers to the identification or classification of a molecular or pathological state, disease, or symptom (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). For example, “diagnosis” can refer to the identification of a specific type of breast cancer. “Diagnosis” can also refer to the classification of a specific subtype of breast cancer, e.g., by histopathological criteria or molecular characteristics (e.g., a subtype characterized by a combination of biomarkers expressed (e.g., a specific gene or a protein encoded by said gene)).

An “effective amount” of a compound (e.g., an endocrine therapy described herein) or a combination thereof (e.g., a pharmaceutical composition) is at least the minimum amount required to achieve a desired therapeutic or preventative outcome, such as measurable overall survival (OS) or progression-free survival (PFS) for a specific disease or condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The effective amount described herein can vary depending on factors such as an individual’s disease state, age, sex, and weight, and the ability of the antibody to elicit the expected response in a subject. An effective amount is also the amount at which the beneficial effects of treatment outweigh any toxic or adverse effects of treatment. For preventative use, beneficial or anticipated outcomes include elimination or reduction of risk, lessening of severity, or delay of disease onset, including biochemical, histological, and/or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes that occur during disease development. An effective amount may be administered once or multiple times. For the purposes provided herein, an effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to provide direct or indirect prevention or treatment. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved when combined with another drug, compound, or pharmaceutical composition. Therefore, an "effective amount" may be considered when administering one or more therapeutic agents, and an effective amount of a single agent may be considered if the desired outcome can be obtained or achieved when combined with one or more other agents. For example, an effective amount of endocrine therapy as described herein for cancer treatment may reduce the number of cancer cells; reduce the size of the primary tumor; inhibit (i.e., to some extent slow down and preferably stop) the infiltration of cancer cells into surrounding organs; inhibit (i.e., to some extent slow down and preferably stop) tumor metastasis; inhibit tumor growth to some extent; and/or alleviate one or more symptoms associated with the disease to some extent. To some extent, a drug may stop the growth of and/or kill existing cancer cells; it may inhibit cell growth and/or be cytotoxic. For cancer therapies, efficacy in vivo can be measured, for example, by assessing survival time, time to progression of disease (TTP), response rate (RR), duration of response, and/or quality of life.

The terms “expression level,” “amount,” or “level,” or interchangeably herein, refer to the detectable level in a biological sample. “Expression” generally refers to the process by which information (e.g., genetically encoded and/or epigenetically inherited) is converted into structures present and functioning within the cell. Therefore, as used herein, “expression” can refer to transcription into a polynucleotide, translation into a polypeptide, or even polynucleotide and/or polypeptide modification (e.g., post-translational modification of a polypeptide). Fragments of transcribed polynucleotides, translated polypeptides, or polynucleotide and/or polypeptide modifications (e.g., post-translational modifications of a polypeptide) should also be considered expressed, regardless of whether they originate from transcripts generated by alternative splicing or degradation of transcripts, or from post-translational processing of polypeptides (e.g., by proteolysis). “Expressed genes” include those polynucleotides transcribed into mRNA and then translated into polypeptides, as well as those transcribed into RNA but not translated into polypeptides (e.g., transfer RNA and ribosomal RNA). Expression levels can be measured using methods known to those skilled in the art and disclosed herein. The expression levels or amounts of biomarkers can be used to identify/characterize subjects with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer) who may respond to or benefit from specific therapies (e.g., therapies that include endocrine therapy, such as SERMs (e.g., SERDs), GnRH agonists, and/or AIs). In subjects with breast cancer described herein, the expression levels or amounts of the biomarkers provided herein can also be used to determine and/or track the benefit of endocrine therapy administered over a period of time.

Expression levels can be measured using assays and techniques suitable for measuring RNA levels. For example, RNA-Seq kits can be used to measure expression levels and are applicable to the kits described herein. Exemplary techniques that can be used to measure expression levels herein include, but are not limited to, RNA protocols or schemes, RT-qPCR, qPCR, multiplex qPCR (e.g., fluidigm), nanostring technology, microarray analysis, SAGE, or MassARRAY.

As used herein, the term “E2 induction score” refers to a numerical value reflecting the aggregated expression level of a predetermined genome, the induction of which reflects estrogen receptor (ER) pathway activity. For example, an E2 induction score may reflect at least five, six, seven, or eight genes listed in Table 1 (i.e., AMZ1, C5AR2, CELSR2, FKBP4, GREB1, OLFM1, SLC9A3R1, and TFF1), at least five, six, seven, eight, nine, ten, or eleven genes listed in Table 2 (i.e., AMZ1, AREG, C5AR2, CELSR2, FKBP4, FMN1, GREB1, OLFM1, RBM24, SLC9A3R1, and TFF1), or at least five, six, seven, eight, nine, or ten genes listed in Table 3. The aggregated expression levels of 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 genes (i.e., AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703) were induced, reflecting estrogen receptor (ER) pathway activity. The aggregated expression level of a predetermined genome can be determined, for example, as the mean z-score expression of the predetermined genome detected in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) obtained from an individual (e.g., an individual with cancer, such as breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). However, it should be understood that aggregated expression levels can be determined using methods known in the art, such as, for example, the average gene expression plotted over a reference population space, or, for example, as the average gene expression relative to untreated or drug-treated tumors, which optionally express as a fold change.

As used herein, the “E2 suppression score” refers to a numerical value reflecting the aggregated expression level of a predetermined genome, the suppression of which reflects estrogen receptor (ER) pathway activity. For example, the E2 suppression score may reflect at least three, four, five, or six genes listed in Table 4 (i.e., BCAS1, CCNG2, IL1R1, PNPLA7, SEMA3E, and STON1), at least four, five, six, seven, or eight genes listed in Table 5 (i.e., BCAS1, CCNG2, IL1R1, NBEA, PNPLA7, SEMA3E, STON1, and TP53INP1), or at least four, five, six, seven, or eight genes listed in Table 6. Aggregated expression levels of 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 genes (i.e., BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2) were calculated, with suppression reflecting estrogen receptor (ER) pathway activity. E2-induced scores for aggregated expression levels of predetermined genomes in HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer can be calculated as described above.

As used herein, the terms “estrogen receptor pathway activity score,” “ER pathway activity score,” and “comprehensive ER pathway activity score” refer to numerical values that reflect the mathematical difference between the E2 induction score and the E2 inhibition score. The ER pathway activity score can be used as a predictive, prognostic, and/or pharmacodynamic biomarker (e.g., to identify individuals with breast cancer who may benefit from treatments including endocrine therapy, or to monitor the response of individuals with breast cancer to treatments including endocrine therapy).

The terms “reference estrogen receptor pathway activity score” and “reference ER pathway activity score” refer to an ER pathway activity score that is compared with another ER pathway activity score for, for example, to make predictive, prognostic, and/or therapeutic determinations. For example, the reference ER pathway activity score could be the ER pathway activity score in a reference sample, the ER pathway activity score in a reference population (e.g., a patient population with HR+ breast cancer), and/or a predetermined value. In some cases, the reference ER pathway activity score is a critical value that clearly distinguishes breast cancer individuals with ER pathway activity from those with low or no ER pathway activity (e.g., a reference ER pathway activity score of -1.0 or higher (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). In other cases, the reference ER pathway activity score is a critical value that clearly distinguishes breast cancer individuals who are likely to respond to therapies, including the endocrine therapies described herein, from those who are unlikely to respond to therapies, including endocrine therapies (e.g., a reference ER pathway activity score of -1.0 or higher (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, ...). -0.4, -0.3, -0.2, or higher). Those skilled in the art will understand that the reference ER pathway activity score may vary depending on the type of breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), the method used to measure the ER pathway activity score, the specific gene signature examined (e.g., the gene combinations listed in Tables 1-6), and/or the statistical method used to generate the ER pathway activity score. For example, the activity score described herein can be calculated by calculating the z-score of a reference population and recalibrating the expression of each gene in all samples to a mean of 0 and a standard deviation of 1 using the following formula. Expression data for a given patient can then be overlaid onto the z-score reference space described herein.

The Z-score can be described by the following formula: z = (x - μ) / σ, where z is the recalibrated score, x is the measured gene expression level, μ is the mean gene expression calculated based on the reference population, and σ is the standard deviation of gene expression calculated based on the reference population.

In some embodiments, a reference estrogen receptor pathway activity score is calculated with reference to a standard control as defined herein.

The term "reference E2-inducible activity score" refers to an E2-inducible activity score that is compared with another E2-inducible activity score for, for example, to make predictive, prognostic, and/or therapeutic determinations. For example, the reference E2-inducible activity score could be the reference E2-inducible activity score in a reference sample, the reference E2-inducible activity score in a reference population (e.g., a patient population with HR+ breast cancer), and/or a predetermined value. In some cases, the reference E2 induction activity score is a critical value that clearly distinguishes breast cancer individuals with E2 induction activity from those with low or no E2 induction activity (e.g., a reference E2 induction activity score of -2.0 or higher (e.g., -2.0, -1.9, -1.8, -1.7, -1.6, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). In other cases, the reference E2 induction activity score is a critical value that clearly distinguishes breast cancer individuals who are likely to respond to therapies, including the endocrine therapies described herein, from those who are unlikely to respond to therapies, including endocrine therapies (e.g., a reference E2 induction activity score of -2.0 or higher (e.g., -2.0, -1.9, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). -1.8, -1.7, -1.6, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). Those skilled in the art will understand that the reference E2-inducible activity score may vary depending on the type of breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), the method used to measure the E2-inducible activity score, the specific genetic characteristics examined (e.g., gene combinations listed herein and, for example, in Tables 1-6), and/or the statistical methods used to generate the E2-inducible activity score. As described herein, the E2-inducible activity score can be calculated using the estrogen receptor pathway activity score. In some embodiments, the E2-inducible activity score is calculated with reference to a standard control as defined herein.

The ability to discriminate (e.g., by calculating an activity score as defined herein) is relative to the identification/characterization/quantification of gene expression as described herein, rather than by a form of measurement used to determine gene expression levels.

As used herein, a “reference gene” refers to a gene or group of genes (e.g., one, two, three, or more genes) used for comparison purposes, such as housekeeping genes. A “housekeeping gene” herein refers to a gene or group of genes (e.g., one, two, three, or more genes) that encode proteins whose activity is essential for maintaining cellular function and is generally similarly present in all cell types. Exemplary housekeeping genes include SDHA, GUSB, PPIA, and UBC.

As used herein, the terms “individual,” “patient,” and “subject” are used interchangeably and refer to any single animal, more preferably a mammal (including non-human animals such as dogs, cats, horses, rabbits, zoo animals, cattle, pigs, sheep, and non-human primates). In some embodiments, the individual, patient, or subject is a human.

"Isolated" nucleic acids refer to nucleic acid molecules that have been isolated from components of their natural environment. Isolated nucleic acids include nucleic acid molecules that are contained in cells that normally contain said nucleic acid molecules, but which are located outside chromosomes or at chromosomal locations different from their natural chromosomal locations.

When used herein, the term “label” refers to a detectable compound or composition. Labels are typically conjugated or fused directly or indirectly to reagents, such as polynucleotide probes or antibodies, and facilitate the detection of the conjugated or fused reagent. The label itself may be detectable (e.g., radioisotope labeling or fluorescent labeling), or, in the case of enzyme labeling, may catalyze a chemical change in the substrate compound or composition to produce a detectable product.

As used herein, the term "modulator" refers to an agent that interacts directly or indirectly with a target. Interactions include, but are not limited to, interactions between agonists, partial agonists, inverse agonists, antagonists, degraders, or combinations thereof. In some embodiments, the modulator is an antagonist. In some embodiments, the modulator is a degrader.

As used herein, the term "degrading agent" refers to an agent that binds to a nuclear hormone receptor and subsequently reduces the homeostatic protein level of said receptor. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 65%. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 85%.

The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and their polymers in single-stranded or double-stranded form, as well as their complement. The term "polynucleotide" refers to a linear sequence of nucleotides. The term "nucleotide" generally refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms thereof. Examples of polynucleotides considered herein include single-stranded and double-stranded DNA, single-stranded and double-stranded RNA (including siRNA), and hybrid molecules having mixtures of single-stranded and double-stranded DNA and RNA. Nucleic acid as used herein also refers to nucleic acids having the same basic chemical structure as naturally occurring nucleic acids. Such analogs have modified sugars and/or modified ring substituents, but retain the same basic chemical structure as naturally occurring nucleic acids. Nucleic acid mimics are compounds having a structure different from the general chemical structure of nucleic acids but functioning in a manner similar to naturally occurring nucleic acids. Examples of such analogs include, but are not limited to, thiophosphates, aminophosphates, methylphosphates, chiral methylphosphates, 2-O-methylribonucleotides, and peptide-nucleic acids (PNAs). The term "oligonucleotide" refers to relatively short polynucleotides (e.g., less than about 250 nucleotides in length), including but not limited to single-stranded deoxyribonucleotides, single-stranded or double-stranded ribonucleotides, RNA:DNA hybrids, and double-stranded DNA. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are typically synthesized by chemical methods, such as using commercially available automated oligonucleotide synthesizers. However, oligonucleotides can be prepared by a variety of other methods, including in vitro recombinant DNA-mediated techniques and through expression of DNA in cells and organisms.

The term "packaging insert" is used to refer to the instruction leaflet typically included in the commercial packaging of a therapeutic product, which contains information concerning the indications, usage, dosage, administration, combination therapy, contraindications, and/or warnings related to the use of such therapeutic products.

The term "pharmaceutical formulation" refers to a formulation in which the bioactive ingredient contained therein is in a form in which the activity is effective and which does not contain any additional components that would have unacceptable toxicity to a subject to whom the formulation will be administered.

"Pharmaceutical carriers" refer to components in a pharmaceutical preparation that are non-toxic to the test subject, excluding the active ingredient. Pharmaceutical carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

Unless otherwise specified, as used herein, the term "protein" means any naturally occurring protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed proteins, as well as any form of protein produced through cellular processing. The term also covers naturally occurring protein variants, such as splice variants or allele variants.

The "sequence identity percentage (%)" relative to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acid or amino acid residues in the candidate sequence that are identical to those in the reference polynucleotide or polypeptide sequence after aligning the candidate sequence with the reference polynucleotide or polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum sequence identity percentage, without considering any conserved substitutions as part of sequence identity. Alignment used to determine the nucleic acid or amino acid sequence identity percentage can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the full length of the sequences being compared. However, for the purposes of this document, the sequence comparison computer program ALIGN-2 is used to generate the sequence identity % value. The ALIGN-2 sequence comparison computer program was written by Genentech, and the source code has been submitted with the user documentation to the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registry No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, California, USA), or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged.

When comparing nucleic acid or amino acid sequences using ALIGN-2, the percentage of sequence similarity between a given nucleic acid or amino acid sequence A and a given nucleic acid or amino acid sequence B (which can be alternatively expressed as a given nucleic acid or amino acid sequence A having or containing a certain percentage of sequence similarity with a given nucleic acid or amino acid sequence B) is calculated as follows:

100 multiplied by the fraction X/Y,

Where X is the number of nucleic acid or amino acid residues that are scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B, and Y is the total number of nucleic acid or amino acid residues in B. It should be understood that if the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the sequence identity percentage of A to B will not be equal to the sequence identity percentage of B to A. Unless otherwise specifically stated, all sequence identity percentage values used herein were obtained using the ALIGN-2 computer program as described in the preceding paragraph.

"Correlate" or "correlating" means comparing the performance and/or results of a first analysis or protocol with the performance and/or results of a second analysis or protocol in any way. For example, the results of the first analysis or protocol may be used when performing the second protocol, and/or the results of the first analysis or protocol may be used when performing the second protocol. Regarding examples of peptide analyses or protocols, the results of peptide expression analyses or protocols may be used to determine whether a specific treatment regimen should be performed. Regarding examples of polynucleotide analyses or protocols, the results of polynucleotide expression analyses or protocols may be used to determine whether a specific treatment regimen should be performed.

The terms “polynucleotide” or “nucleic acid” used interchangeably in this document refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerases or by a synthetic reaction.

Polynucleotides can contain modified nucleotides, such as methylated nucleotides and their analogues. If present, the nucleotide structure can be modified before or after polymer assembly. The sequence of the nucleotide can be interrupted by non-nucleotide components. Polynucleotides can be further modified post-synthesized, for example, by conjugation with tags. Other types of modification include, for example, “termination,” with similar internucleotide modifications, such as those with uncharged bonds (e.g., methyl phosphate, triphosphate, amino phosphate, carbamate) and those with charged bonds (e.g., thiophosphate, dithiophosphate, etc.), those containing side groups, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those containing intercalating agents (e.g., acridine, psoralen, etc.), those containing chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.), those containing alkylating agents, those with modified bonds (e.g., α-anomeric nucleic acids, etc.), and the substitution of one or more naturally occurring nucleotides with unmodified forms of polynucleotides. Furthermore, any hydroxyl groups typically present in the sugar can be substituted (e.g., phosphate ester groups, phosphate groups), protected by standard protecting groups, or activated to prepare additional linkages with other nucleotides, or can be conjugated to a solid or semi-solid support. The OH groups at the 5' and 3' ends can be phosphorylated or partially substituted by amine or organic end-capping groups of 1-20 carbon atoms. Other hydroxyl groups can also be derived as standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro-, or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars (such as arabinose, xylose, or lythose, pyranose, furanose, heptacaphesose), acyclic analogs, and non-base nucleoside analogs such as methylriboside. One or more phosphodiester bonds can be substituted with alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which the phosphate ester is replaced by P(O)S (“thioester”), P(S)S (“dithioester”), (O)NR2 (“amic acid ester”), P(O)R, P(O)OR’, CO, or CH2 (“methylal”), wherein each R or R’ is independently H or a substituted or unsubstituted alkyl group (1-20C). Optionally, an ether (-O-) bond, aryl, alkenyl, cycloalkyl, cycloalkenyl, or aryl substituted group may be included. Not all links in a polynucleotide need to be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

As used herein, “polymerase chain reaction” or “PCR” generally refers to a procedure for amplifying trace amounts of specific nucleic acid, RNA, and/or DNA fragments, as described in U.S. Patent No. 4,683,195, granted July 28, 1987. Typically, sequence information is required from the ends or regions outside the target region so that oligonucleotide primers can be designed; these primers are identical or similar in sequence to the opposite strand of the template to be amplified. The 5' nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences and specific DNA sequences from total genomic DNA, as well as cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, etc. See also Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). As used in this article, PCR is considered one type of nucleic acid polymerase reaction method for amplifying nucleic acid test samples, but not the only example. Other examples include using known nucleic acids (DNA or RNA) as primers and utilizing nucleic acid polymerases to amplify or generate specific nucleic acid fragments, or amplifying or generating specific nucleic acid fragments complementary to specific nucleic acids.

As used herein, the terms “reverse transcriptase polymerase chain reaction” or “RT-PCR” refer to the replication and amplification of an RNA sequence. In this method, for example, as described in U.S. Patent No. 5,322,770, the reverse transcription is coupled to PCR, the entire text of which is incorporated herein by reference. In RT-PCR, an RNA template is converted to cDNA due to the reverse transcriptase activity of an enzyme, which is then amplified using the polymerase activity of the same or different enzymes. Thermostable and thermolabile reverse transcriptases and polymerases can be used. “Reverse transcriptase” (RT) can include reverse transcriptases derived from retroviruses, other viruses, and DNA polymerases that exhibit reverse transcriptase activity.

As used herein, the terms “reverse transcriptase quantitative polymerase chain reaction” or “RT-qPCR” refer to a form of PCR in which the nucleic acid to be amplified is RNA that is first reverse transcribed into cDNA, and the amount of PCR product is measured at each step of the PCR reaction.

"Quantitative real-time polymerase chain reaction" or "qRT-PCR" refers to a form of PCR in which the amount of PCR product is measured at each step of the PCR reaction. This technique has been described in various publications, including Cronin et al., Am. J. Pathol. 164(l):35-42 (2004); and Ma et al., Cancer Cell 5:607-616 (2004).

The term "multiplex PCR" refers to a single PCR reaction using one or more primer sets on nucleic acids obtained from a single source (e.g., an individual) with the aim of amplifying two or more DNA sequences in a single reaction.

The term “RNA-seq,” also known as “whole transcriptome shotgun sequencing (WTSS),” refers to the use of high-throughput sequencing technology to sequence and/or quantify cDNA to obtain information about the RNA content of a sample. Publications describing RNA-seq include: Wang et al., “RNA-Seq: a revolutionary tool for transcriptomics,” Nature Reviews Genetics 10(1):57-63 (January 2009); Ryan et al., BioTechniques 45(1):81-94 (2008); and Maher et al., “Transcriptome sequencing to detect gene fusions in cancer,” Nature 458(7234):97-101 (January 2009). Exemplary RNA-seq protocols include those using RNA sequencing or RNA sequencing.

"Response to a treatment," "responsiveness to treatment," or "benefit from treatment" can be assessed using any endpoint that indicates benefit to an individual, including but not limited to (1) inhibiting disease progression (e.g., progression of breast cancer) to some extent, including slowing and completely stopping it; (2) reducing tumor size; (3) inhibiting (i.e., reducing, slowing, or completely stopping) cancer cell infiltration into adjacent organs and/or tissues; (4) inhibiting (i.e., reducing, slowing, or completely stopping) metastasis; (5) alleviating one or more symptoms associated with the disease or condition (e.g., cancer) to some extent; (6) increasing or prolonging survival, including recurrence-free survival (RFS), disease-free survival (DFS), overall survival (OS HR < 1), and progression-free survival (PFS HR < 1); and/or (9) reducing mortality at a given time point following treatment (e.g., treatment with endocrine therapy, SERM (e.g., SERD), GnRH agonists, and/or AIs). The response to treatment can also refer to a pharmacodynamic response or a pathway response (e.g., the ER pathway), and can be assessed using methods known in the art.

As used herein, “progression-free survival” or “PFS” refers to the length of time during and after treatment during which the disease to be treated (e.g., breast cancer, e.g., HR+ breast cancer, e.g., ER+ breast cancer, e.g., luminal A or luminal B breast cancer, e.g., advanced or metastatic breast cancer) does not progress or worsen. Progression-free survival may include the amount of time an individual experiences a complete or partial response, as well as the amount of time an individual experiences stable disease.

As used in this article, “overall survival” or “OS” refers to the percentage of a group of subjects who are likely to survive after a specific time period (e.g., 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years or more from the start of diagnosis or treatment).

As used in this article, “recurrence-free survival” or “RFS” refers to the length of time a patient survives in the same local or localized area without any signs, symptoms or recurrence of tumor after the initial treatment.

As used in this article, “disease-free survival” or “DFS” refers to the length of time a patient has remained free of any signs, symptoms, or recurrence of tumors in any region after initial treatment, including the development of distant metastases.

As used in this article, "complete response" or "CR" refers to the disappearance of all signs of cancer in response to treatment. This does not necessarily mean that the cancer has been cured.

As used in this article, "partial response" or "PR" refers to a response to treatment of a reduction in the size of one or more tumors or lesions or a reduction in the degree of cancer in the body.

As used herein, “hazard ratio” or “HR” is a statistical definition of the incidence of an event. For the purposes of this article, the hazard ratio is defined as the probability of an event (e.g., PFS or OS) in the experimental (e.g., treatment) group/arm divided by the probability of an event in the control group/arm at any given time point. An HR of 1 indicates that the relative risk of the endpoint (e.g., death) is equal in the treatment and control groups; a value greater than 1 indicates a greater risk in the treatment group relative to the control group; and a value less than 1 indicates a greater risk in the control group relative to the treatment group. The hazard ratio in a progression-free survival analysis (i.e., PFS HR) summarizes the difference between two progression-free survival curves, representing the reduced risk of death in the treatment group compared to the control group during the follow-up period. The hazard ratio in an overall survival analysis (i.e., OS HR) summarizes the difference between two overall survival curves, representing the reduced risk of death in the treatment group compared to the control group during the follow-up period.

"Extended survival" refers to an increase in overall survival or progression-free survival relative to untreated individuals (i.e., individuals not receiving drug treatment) or individuals not expressing a specified level of biomarker and/or individuals receiving an approved anticancer therapy. Objective response refers to a measurable response, including complete response (CR) or partial response (PR).

"Reduction or inhibition" refers to the ability to cause an overall reduction of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more. Reduction or inhibition can refer to the symptoms of the treated condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and/or metastatic or locally advanced breast cancer), the presence or size of metastases, or the size of the primary tumor. When tumor pathways are involved, reduction or inhibition refers to a decrease in the expression or activity of any component of that pathway (e.g., decreased ER expression, decreased ER activity, or ER degradation).

As used herein, “reference sample,” “reference cell,” “reference tissue,” “control sample,” “control cell,” or “control tissue” refers to a sample, cell, tissue, standard, or level used for comparative purposes. In one embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from the same subject or individual. In another embodiment, the reference sample is obtained from one or more individuals who are not the subject or individual. In any of the foregoing embodiments, one or more individuals from whom the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained have breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). In some embodiments, one or more individuals from whom the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained have breast cancer and have previously been treated with anticancer therapies (e.g., one or more doses of endocrine therapy, e.g., SERM (e.g., SERD), GnRH agonists, and/or AI). In other embodiments, one or more individuals who obtained the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue had breast cancer and were treatment-naïve. In any of the foregoing embodiments, the subject/individual and one or more individuals who were not subjects or individuals had the same breast cancer.

As used herein, a “standard control” for the expression level of one or more genes refers to the expression level measured in a control subject (e.g., in a sample from a control subject) or a population of control subjects. In embodiments, a control subject is a healthy control subject relative to a test subject, wherein the healthy control subject does not have breast cancer. In embodiments, a control subject is a test subject prior to treatment of the test subject, wherein both the test subject and the control subject have breast cancer. For example, in embodiments, the test subject has been treated with an anticancer agent for breast cancer, while the control subject is the test subject prior to treatment. In embodiments, a population of control subjects is a diverse collection of healthy and diseased subjects, wherein the expression level of the test subject is compared to the expression level of the control subject population (e.g., the mean expression level of the control subject population). In embodiments, a population of control subjects is a collection of healthy subjects without breast cancer, wherein the expression level of the test subject is compared to the expression level of the control subject population (e.g., the mean expression level of the control subject population). In this embodiment, the control group is a collection of subjects who have already received treatment for breast cancer, wherein the expression levels of the subjects being tested are compared with the expression levels of the control group (e.g., the average expression levels of the control group).

As used herein, the term "sample" means a composition obtained from or derived from a subject and/or individual intended for the purpose of the study, which contains, for example, cells and/or other molecular entities to be characterized and/or identified based on physical, biochemical, chemical, and/or physiological characteristics. For example, the phrase "disease sample" and variations thereof refer to any sample obtained from a subject intended for the purpose of the study, which is expected or known to contain cells and/or molecular entities to be characterized. Samples include, but are not limited to, tissue extracts such as homogenized tissue, tumor tissue, cell extracts, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, follicular fluid, semen, amniotic fluid, breast milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysis products, and tissue culture media, and combinations thereof.

A “tissue sample” or “cell sample” refers to a collection of similar cells obtained from the tissue of a subject or individual. The source of the tissue or cell sample can be solid tissue from FFPE, FF, fresh, frozen, and/or preserved organs, tissue samples, biopsies, and/or aspirates; blood or any blood component, such as plasma; body fluids, such as cerebrospinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; or cells from any time during the subject’s pregnancy or development. The tissue sample can also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from tissue/organ of a disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The tissue sample may contain compounds that are naturally occurring and do not mix with the tissue, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc.

For the purposes of this article, a “slice” of a tissue sample refers to a single portion or piece of a tissue sample, such as a thin slice of tissue or cells cut from a tissue sample. It should be understood that multiple slices of a tissue sample can be obtained and analyzed, provided that the same slice of the tissue sample can be analyzed at the morphological and molecular levels, or that analysis can be performed on peptides and polynucleotides.

As used herein, “treatment” (and its grammatical variations, such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of a subject being treated, and may be for prevention or in the course of clinicopathology. Desired therapeutic effects include, but are not limited to, preventing the occurrence or recurrence of disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), relieving symptoms, mitigating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing disease progression, improving or alleviating the condition, and mitigating or improving prognosis. In some embodiments, the treatments described herein are intended to delay disease development or slow the progression of disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). In some cases, treatment can increase overall survival (OS) (e.g., by about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more). In some cases, treatment can increase overall survival (OS), for example, by about 5% to about 500%, for example, about 10% to about 450%, for example, about 20% to about 400%, for example, about 25% to about 350%, for example, about 30% to about 400%, for example, about 35% to about 350%, for example, about 40% to about 300%, for example, about 45% to about 250%, for example, about 50% to about 200%, for example, about 55% to about 150%, for example, about 60% to about 100%, for example, about 65% to about 100%, for example, about 70% to about 100%, for example, about 75% to about 100%, for example, about 80% to about 100%, for example, about 85% to about 100%, for example, about 90% to about 100%, for example, about 95% to about 100%, for example, about 98% to about 100%. In some cases, treatment can increase progression-free survival (PFS) (for example, by about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more). In some cases, treatment can increase PFS, for example, by about 5% to about 500%, for example, about 10% to about 450%, for example, about 20% to about 400%, for example, about 25% to about 350%, for example, about 30% to about 400%, for example, about 35% to about 350%, for example, about 40% to about 300%, for example, about 45% to about 250%, for example, about 50% to about 200%, for example, about 55% to about 150%, for example, about 60% to about 100%, for example, about 65% to about 100%, for example, about 70% to about 100%, for example, about 75% to about 100%, for example, about 80% to about 100%, for example, about 85% to about 100%, for example, about 90% to about 100%, for example, about 95% to about 100%, for example, about 98% to about 100%.

As used herein, the term “tumor” refers to all proliferative cell growth and proliferation (whether malignant or benign), as well as all precancerous and cancerous cells and tissues. The terms “cancer,” “cancerous,” “proliferative disorder,” “proliferative lesion,” and “tumor” are not mutually exclusive in this text.

III. Methods

This document provides methods and assays for identifying individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and/or metastatic or locally advanced breast cancer, ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and/or metastatic or locally advanced breast cancer, who may benefit from treatment including the endocrine therapies described herein; selecting therapies for individuals with breast cancer; treating individuals with breast cancer based on the diagnostic methods provided herein; and monitoring the efficacy of endocrine therapy. In one embodiment, the endocrine therapy is a compound described herein. In another embodiment, the endocrine therapy is a SERM, SERD, AI, or a combination thereof.

The methods and assays described herein are based on the finding that estradiol (E2) induction scores or estrogen receptor (ER) pathway activity scores determined from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) can be used to predict the therapeutic efficacy of the endocrine therapies described herein. Any method may further include administration of endocrine therapy (e.g., as described in Section IV-A below) to the individual.

Therefore, this article also provides methods and assays for determining E2 induction scores and/or ER pathway activity scores from samples from individuals. Any method provided herein may include administration of anticancer therapies other than endocrine therapy (e.g., as described in Section IV-A below) to the individual. Any method may further include administration of an effective amount of other therapeutic agents described herein to the individual.

A. Diagnostic methods and measurements

Predictive diagnostic methods and assays

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and/or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapies described herein. The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score that meets or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including the endocrine therapies described herein.

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer), DCIS, and/or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapy described herein. The method includes determining an E2 induction score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an E2 induction score that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from treatment including the endocrine therapy described herein.

In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score that meets or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including the endocrine therapies described herein.

In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method includes determining an E2 induction score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2 induction score that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from a treatment including the endocrine therapy described herein.

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and/or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapies described herein. The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein.

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer who may benefit from treatments including the endocrine therapies described herein. The method involves determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2-inducible score lower than a reference E2-inducible score identifies the individual as unlikely to benefit from treatments including the endocrine therapies described herein.

In specific circumstances, the methods and assays provided herein can be used to select therapy for individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method involves determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score below a reference ER pathway activity score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein. For example, the method relates to selecting an anticancer therapy for an individual in addition to endocrine therapy.

In specific circumstances, the methods and assays provided herein can be used to select therapy for individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method involves determining an E2-inducible score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an E2-inducible score below a reference E2-inducible score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein. For example, the method involves selecting an anticancer therapy for an individual in addition to endocrine therapy.

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and/or metastatic or locally advanced breast cancer) who may benefit from treatment including anticancer therapies other than endocrine therapy), wherein the method comprises determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including anticancer therapies other than endocrine therapy).

In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer who may benefit from treatment including anticancer therapies other than endocrine therapy. The method involves determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2-inducible score lower than a reference E2-inducible score identifies the individual as potentially benefiting from treatment including anticancer therapies other than endocrine therapy.

In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method involves determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as someone who may benefit from treatment including anticancer therapies other than endocrine therapy.

In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). The method involves determining an E2 induction score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2 induction score lower than a reference E2 induction score identifies the individual as someone who may benefit from treatment including anticancer therapies other than endocrine therapy.

In any of the foregoing circumstances, the reference ER pathway activity score can be the ER pathway activity score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapy described herein. In some cases, the reference population is a group of individuals who have not received prior endocrine therapy described herein. In some cases, the reference population is a group of individuals who are not currently receiving anticancer treatment (including the endocrine therapy described herein). In some cases, the reference ER pathway activity score can be a pre-assigned reference ER pathway activity score. In some cases, the reference ER pathway activity score can be at or above -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference ER pathway activity score can be at or above -0.9. In some cases, the reference ER pathway activity score can reach or exceed -0.8. In some cases, the reference ER pathway activity score can reach or exceed -0.7. In some cases, the reference ER pathway activity score can reach or exceed -0.6. In some cases, the reference ER pathway activity score can reach or exceed -0.5. In some cases, the reference ER pathway activity score can reach or exceed -0.4. In some cases, the reference ER pathway activity score can reach or exceed -0.3. In some cases, the reference ER pathway activity score can reach or exceed -0.2. In some cases, the reference ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2).

In any of the foregoing circumstances, the ER pathway activity score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) can reach or exceed -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the ER pathway activity score can reach or exceed -0.9. In some cases, the ER pathway activity score can reach or exceed -0.8. In some cases, the ER pathway activity score can reach or exceed -0.7. In some cases, the ER pathway activity score can reach or exceed -0.6. In some cases, the ER pathway activity score can reach or exceed -0.5. In some cases, the ER pathway activity score can reach or exceed -0.4. In some cases, the ER pathway activity score can reach or exceed -0.3. In some cases, the ER pathway activity score can reach or exceed -0.2. In some cases, the ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2). In some cases, the ER activity score from the sample can be less than -1.0.

In any of the foregoing circumstances, the reference E2-inducible score can be the E2-inducible score in a reference population of individuals with hormone receptor (HR)+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and/or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapies described herein. In some cases, the reference E2-inducible score can be a pre-assigned reference E2-inducible score. In some cases, the reference E2-inducible score can be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference E2-inducible score can be at or above -1.0. In some cases, the reference E2-inducible score can be at or above -0.9. In some cases, the reference E2-inducible score can be at or above -0.8. In some cases, the reference E2-induced score can reach or exceed -0.7. In some cases, the reference E2-induced score can reach or exceed -0.6. In some cases, the reference E2-induced score can reach or exceed -0.5. In some cases, the reference E2-induced score can reach or exceed -0.4. In some cases, the reference E2-induced score can reach or exceed -0.3. In some cases, the reference E2-induced score can reach or exceed -0.2. In some cases, the reference E2-induced score can reach or exceed -0.1. In some cases, the reference E2 induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1).

In any of the foregoing circumstances, the E2 induction score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) may be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, or higher). For example, in some cases, the E2 induction score may be at or above -1.0. In some cases, the E2 induction score may be at or above -0.9. In some cases, the E2 induction score may be at or above -0.8. In some cases, the E2 induction score may be at or above -0.7. In some cases, the E2 induction score may be at or above -0.6. In some cases, the E2 induction score may be at or above -0.5. In some cases, the E2 induction score may be at or above -0.4. In some cases, the E2-induced score can reach or exceed -0.3. In some cases, the E2-induced score can reach or exceed -0.2. In some cases, the E2-induced score can reach or exceed -0.1. In some cases, the E2-induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1). In some cases, the E2-induced score from the sample can be less than -2.0.

In any of the predictive methods and assays described above, the methods and assays may further include administering endocrine therapy (e.g., as described in Section IV-A below) to the individual. In specific cases, the method further includes administering endocrine therapy to the individual when the ER pathway activity score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) reaches or exceeds a reference ER pathway activity score. In specific cases, the method further includes administering endocrine therapy to the individual when the E2 induction score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) reaches or exceeds a reference E2 induction score.

In any of the predictive methods and assays described above, the methods and assays may further include administering anticancer therapy other than endocrine therapy (e.g., as described in Section IV-A below) to the individual. In specific circumstances, when the ER pathway activity score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is lower than a reference ER pathway activity score, the method further includes administering anticancer therapy other than endocrine therapy to the individual. In specific circumstances, when the E2 induction score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is lower than a reference E2 induction score, the method further includes administering anticancer therapy other than endocrine therapy to the individual.

The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

In some of the aforementioned methods or assays involving the determination of ER pathway activity scores and/or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapies described herein. In other cases, the individual has not previously received endocrine therapy. In another embodiment, the individual has received one or more prior therapies prior to performing the methods and assays described herein, wherein such therapy may be an endocrine therapy or a non-endocrine therapy described herein.

In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some embodiments, the report includes output from a method that incorporates an assessment of ER pathway activity and/or E2 induction scores.

Pharmacodynamic diagnostic methods

This article also provides pharmacodynamic methods. In some cases, these methods may involve monitoring an individual's response to treatment with endocrine therapies as described herein.

In some cases, the method includes: (a) determining an ER pathway activity score from a sample from the individual at a first time point (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample); (b) determining a second ER pathway activity score from the sample from the individual at a second time point after step (a), following administration of endocrine therapy as described herein; and (c) comparing the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score (e.g., a decrease in the ER pathway activity score of approximately 0.1, 0.2, 0.3, or greater) predicts that the individual may respond to treatment with endocrine therapy (e.g., SERM (e.g., SERD), GnRH agonists, and/or AI). In some cases, a decrease in the ER pathway activity score is defined as an overall decrease in the ER pathway activity score of at least 0.1. In some cases, a decrease in the ER pathway activity score is defined as an overall decrease in the ER pathway activity score of at least 0.2. In some cases, a decrease in ER pathway activity score is defined as an overall decrease in ER pathway activity score of at least 0.3.

In some cases, if the second ER pathway activity score is lower than the first ER pathway activity score in a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue sample), the method further includes administering one or more additional doses of endocrine therapy. In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.1 in the ER pathway activity score (e.g., a reduction of 0.1, 0.2, 0.3, or greater). In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.2 in the ER pathway activity score. In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.3 in the ER pathway activity score.

In some of the aforementioned methods, the first ER pathway activity score is determined from a sample (e.g., a tissue sample, such as a tumor tissue sample, e.g., FFPE, FF, archived, fresh, or frozen tumor tissue sample) obtained from the individual prior to administration of the first dose of endocrine therapy as described herein. In other words, the sample may be a baseline sample. In other cases, the first ER pathway activity score is determined from a sample obtained from the individual at a previous time point, wherein the previous time point is after administration of the first dose of endocrine therapy as described herein. In other cases, the first ER pathway activity score is determined from a sample obtained from the individual at a previous time point, wherein the previous time point is after administration of the first dose of non-endocrine therapy as described herein. In other cases, the first ER pathway activity score is a predetermined ER pathway activity score.

In some cases, the method includes: (a) determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) at a first time point; (b) determining a second E2-inducible score from the sample from the individual at a second time point after step (a), following administration of the endocrine therapy as described herein; and (c) comparing the first E2-inducible score with the second E2-inducible score, wherein a decrease in the second E2-inducible score relative to the first E2-inducible score (e.g., a decrease in the E2-inducible score of at least 0.1, 0.2, 0.3, or greater) predicts that the individual may respond to treatment with the endocrine therapy as described herein. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.1. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.2. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.3.

In some cases, if the second E2-induced score is lower than the first E2-induced score in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), the method further includes administering one or more additional doses of the endocrine therapy described herein. In some cases, a lowered E2-induced score means an overall reduction of at least 0.1 in the E2-induced score (e.g., a reduction of 0.1, 0.2, 0.3, or greater). In some cases, a lowered E2-induced score means an overall reduction of at least 0.2 in the E2-induced score. In some cases, a lowered E2-induced score means an overall reduction of at least 0.3 in the E2-induced score.

In some of the aforementioned methods, the first E2-inducing score is an E2-inducing score determined from a sample obtained from an individual prior to the administration of the first dose of anticancer therapy (e.g., endocrine therapy as described herein, such as a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample). In other words, the sample may be a baseline sample. In other cases, the first E2-inducing score is an E2-inducing score determined from a sample obtained from an individual at a previous time point, wherein the previous time point is after the administration of the first dose of endocrine therapy as described herein. In still other cases, the first E2-inducing score is a predetermined E2-inducing score.

In some cases, the second ER pathway activity score of a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is reduced relative to the first ER pathway activity score, and the method or assay further involves administering an additional dose of the endocrine therapy described herein to the individual. In some cases, the second E2 induction score of a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is reduced relative to the first E2 induction score, and the method or assay further involves administering an additional dose of the endocrine therapy described herein to the individual.

The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

In some of the aforementioned methods or assays involving the determination of ER pathway activity scores and/or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy. In some cases of any of the methods and assays, the sample (e.g., tissue sample, such as tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) was obtained from the individual prior to the administration of the endocrine therapy described herein (e.g., minutes, hours, days, weeks, months, or years prior). In other words, the sample may be a baseline sample. In some cases of any of the aforementioned methods, the sample was obtained from the individual after the administration of endocrine therapy (e.g., minutes, hours, or days prior). In some cases, the sample from the individual was obtained within thirty hours after the administration of endocrine therapy. In some cases, multiple samples were obtained from the same individual at different time points (e.g., before and after the administration of endocrine therapy).

In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and/or E2 induction scores.

On the one hand, a method is provided for detecting estrogen receptor (ER) pathway activity in subjects with breast cancer. This method includes detecting the expression levels of at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 5; or at least five genes listed in Table 3 and at least five genes listed in Table 6.

A control used in the methods provided herein is valuable for determining the significance of the data. For example, if the value of a given parameter varies greatly in a control, the variation in the test sample will not be considered significant. In some examples of the disclosed methods, when assessing the expression level of any gene provided in Tables 1-6, that expression level is compared to the control expression level of that gene. A control expression level refers to the expression level of a gene from samples or subjects lacking breast cancer, at a selected stage of breast cancer or cancer, or without a specific variable such as a treatment agent. Alternatively, a control level includes the amount of a known gene. Such a known amount is associated with the average level of subjects lacking breast cancer, at a selected stage of breast cancer or cancer, or without a specific variable such as a treatment agent. A control level also includes the expression levels of genes from one or more of the selected samples or subjects described herein. For example, a control level includes an assessment of the expression levels of a gene in samples from subjects who do not have breast cancer, are at a selected stage of breast cancer or cancer, or have breast cancer but have not yet received treatment. Another exemplary control level includes an assessment of the expression levels of a gene in samples collected from multiple subjects who have never had breast cancer, are at a selected stage of cancer, or have cancer but have not yet received breast cancer treatment. In this embodiment, the threshold for elevated gene expression levels is higher than the median expression level of a control group, which is optionally a group of subjects with breast cancer.

In one embodiment, the method includes detecting the expression levels of at least five genes (e.g., 5, 6, 7, 8, etc.) listed in Table 1 and at least five genes listed in Table 4. In another embodiment, the method includes detecting the expression levels of at least five genes listed in Table 2 and at least five genes listed in Table 5. In yet another embodiment, the method includes detecting the expression levels of at least five genes listed in Table 3 and at least five genes listed in Table 6.

In the embodiments, the expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 1, all genes listed in Table 2, or all genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 1 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 1 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 2 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 2 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 3 are all higher than the standard control.

In this embodiment, the threshold for elevated gene expression levels (e.g., the expression of any of the genes listed in Tables 1-6) is higher than the median expression level of a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the first quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the third quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the fifth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the tenth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the twentieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the thirtieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In one embodiment, it is above the 40th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 45th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 50th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 60th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 70th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 80th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 90th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer.

In the embodiments, the expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 4, all genes listed in Table 5, or all genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 4 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 4 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 5 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 5 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 6 are all lower than the standard control.

In this embodiment, the threshold for reduced gene expression levels (e.g., the expression level of any of the genes listed in Tables 1-6) is below the median expression level of a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the first quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the third quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the fifth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the tenth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the twentieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the thirtieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In one embodiment, it is below the 40th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 45th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 50th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 60th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 70th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 80th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 90th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer.

In one embodiment, the subject was treated with endocrine therapy prior to the test. In another embodiment, the subject was treated with endocrine therapy after the test.

In one embodiment, the method includes detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4. In another embodiment, the method includes detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5. In another embodiment, the method includes detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4, but does not detect the expression levels of any other genes in the subject. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5, but does not detect the expression levels of any other genes in the subject. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6, but does not detect the expression levels of any other genes in the subject.

In one embodiment, the subject was treated with endocrine therapy, wherein the endocrine therapy was a selective estrogen receptor degrader.

In one embodiment, the method includes determining an estrogen receptor (ER) pathway activity score from a sample from a subject. In another embodiment, an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies an individual as potentially eligible for treatment including endocrine therapy. In yet another embodiment, the method includes comparing ER pathway activity scores from the sample that reach or exceed a reference ER pathway activity score to identify individuals as potentially eligible for treatment including endocrine therapy.

In one aspect, a method is provided, comprising detecting first expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 by one or more processors; detecting second expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 by one or more processors; and detecting estrogen receptor (ER) pathway activity in a subject with cancer, based at least on the first expression level and/or the second expression level. In one embodiment, the first expression level is increased relative to the second expression level. In another embodiment, the first expression level is decreased relative to the second expression level.

In this embodiment, the threshold for an elevated first gene expression level (e.g., the first expression level of any of the genes listed in Tables 1-6) is higher than that of a second expression level. In this embodiment, it is higher than the first quartile of the second gene expression level. In this embodiment, it is higher than the third quartile of the second gene expression level. In this embodiment, it is higher than the 5th percentile of the second gene expression level. In this embodiment, it is higher than the 10th percentile of the second gene expression level. In this embodiment, it is higher than the 20th percentile of the second gene expression level. In this embodiment, it is higher than the 30th percentile of the second gene expression level. In this embodiment, it is higher than the 40th percentile of the second gene expression level. In this embodiment, it is higher than the 45th percentile of the second gene expression level. In this embodiment, it is higher than the 50th percentile of the second gene expression level. In this embodiment, it is higher than the 60th percentile of the second gene expression level. In this embodiment, it is higher than the 70th percentile of the second gene expression level. In this embodiment, it is higher than the 80th percentile of the second gene expression level. In the example, it is above the 90th percentile of the expression level of the second gene.

In this embodiment, the threshold for reducing the expression level of a first gene (e.g., the first expression level of any of the genes listed in Tables 1-6) is lower than the threshold for the second expression level. In this embodiment, it is lower than the first quartile of the second gene expression level. In this embodiment, it is lower than the third quartile of the second gene expression level. In this embodiment, it is lower than the fifth percentile of the second gene expression level. In this embodiment, it is lower than the tenth percentile of the second gene expression level. In this embodiment, it is lower than the twentieth percentile of the second gene expression level. In this embodiment, it is lower than the thirtieth percentile of the second gene expression level. In this embodiment, it is lower than the fortyth percentile of the second gene expression level. In this embodiment, it is lower than the forty-fifth percentile of the second gene expression level. In this embodiment, it is lower than the fiftyth percentile of the second gene expression level. In this embodiment, it is lower than the sixtyth percentile of the second gene expression level. In this embodiment, it is lower than the seventyth percentile of the second gene expression level. In this embodiment, it is lower than the eightyth percentile of the second gene expression level. In the example, it is below the 90th percentile of the second gene expression level.

In the embodiments, the expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 are all lower than the standard control.

In one embodiment, the method includes treating the subject with endocrine therapy prior to the test. In another embodiment, the method includes treating the subject with endocrine therapy based at least on estrogen receptor (ER) pathway activity detected in the subject.

B. Treatment methods

This document also provides for the treatment of individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). Therefore, in some cases, the methods provided herein include administering the endocrine therapy described herein to the individual. In other cases, the methods provided herein include administering an anticancer agent other than endocrine therapy to the individual. Any anticancer agent described herein (e.g., in Section IV below) or known in the art may be used in conjunction with this method.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising (i) determining an ER pathway activity score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the ER pathway activity score is determined to be at or above a reference ER pathway activity score (e.g., a reference ER pathway activity score in a reference population, such as a reference ER pathway activity score at or above -1.0); and (ii) administering an effective amount of the endocrine therapy described herein to the individual.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as being more likely to benefit from treatment including endocrine therapy.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified as having an ER pathway activity score at or above a reference ER pathway activity score by any of the predictive diagnostic methods described in Section III-A above.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising (i) determining an E2-inducing score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the E2-inducing score is determined to be at or above a reference E2-inducing score (e.g., a reference E2-inducing score in a reference population, such as a reference E2-inducing score at or above -2.0); and (ii) administering an effective amount of the endocrine therapy described herein to the individual.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type breast cancer or luminal B-type breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified as having an E2 induction score that reaches or exceeds a reference E2 induction score by any of the predictive diagnostic methods described in Section III-A above.

This article also provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising (i) determining an ER pathway activity score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the ER pathway activity score is determined to be lower than a reference ER pathway activity score (e.g., a reference ER pathway activity score in a reference population, such as a reference ER pathway activity score below -1.0); and (ii) administering an effective amount of anticancer therapy to the individual, other than endocrine therapy.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as unlikely to benefit from treatment including endocrine therapy.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering anticancer therapy other than endocrine therapy to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as being more likely to benefit from treatment including anticancer therapy other than endocrine therapy.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual, wherein the individual has been identified as having an ER pathway activity score below the reference ER pathway activity score by any of the predictive diagnostic methods described in Section III-A above.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising (i) determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the E2-inducible score is determined to be lower than a reference E2-inducible score (e.g., a reference E2-inducible score in a reference population, such as a reference E2-inducible score lower than -2.0); and (ii) administering an effective amount of anticancer therapy, other than endocrine therapy, to the individual.

This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual, wherein the individual has been identified as having an E2 induction score below the reference E2 induction score by any of the predictive diagnostic methods described in Section III-A above.

In any of the foregoing circumstances, the reference ER pathway activity score can be the ER pathway activity score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer). In some cases, the reference population is a group of individuals who have not received treatment including endocrine therapy (including those described herein). In some cases, the reference ER pathway activity score can be a pre-assigned reference ER pathway activity score. In some cases, the reference ER pathway activity score can be at or above -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, and -0.2 or higher). For example, in some cases, the reference ER pathway activity score can be at or above -0.9. In some cases, the reference ER pathway activity score can be at or above -0.8. In some cases, the reference ER pathway activity score can be at or above -0.7. In some cases, the reference ER pathway activity score can be at or above -0.6. In some cases, the reference ER pathway activity score can reach or exceed -0.5. In some cases, the reference ER pathway activity score can reach or exceed -0.4. In some cases, the reference ER pathway activity score can reach or exceed -0.3. In some cases, the reference ER pathway activity score can reach or exceed -0.2. In some cases, the reference ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2).

In any of the foregoing circumstances, the ER pathway activity score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples) can reach or exceed -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the ER pathway activity score can reach or exceed -0.9. In some cases, the ER pathway activity score can reach or exceed -0.8. In some cases, the ER pathway activity score can reach or exceed -0.7. In some cases, the ER pathway activity score can reach or exceed -0.6. In some cases, the ER pathway activity score can reach or exceed -0.5. In some cases, the ER pathway activity score can reach or exceed -0.4. In some cases, the ER pathway activity score can reach or exceed -0.3. In some cases, the ER pathway activity score can reach or exceed -0.2. In other cases, the ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2). In some cases, the ER activity score from the sample can be less than -1.0.

In any of the foregoing circumstances, the reference E2-inducing score can be the E2-inducing score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapies described herein. In some cases, the reference E2-inducing score can be a pre-assigned reference E2-inducing score. In some cases, the reference E2-inducing score can be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference E2-inducing score can be at or above -1.0. In some cases, the reference E2-inducing score can be at or above -0.9. In some cases, the reference E2-inducing score can be at or above -0.8. In some cases, the reference E2-inducing score can be at or above -0.7. In some cases, the reference E2 induced score can reach or exceed -0.6. In some cases, the reference E2 induced score can reach or exceed -0.5. In some cases, the reference E2 induced score can reach or exceed -0.4. In some cases, the reference E2 induced score can reach or exceed -0.3. In some cases, the reference E2 induced score can reach or exceed -0.2. In some cases, the reference E2 induced score can reach or exceed -0.1. In some cases, the reference E2 induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1).

In any of the foregoing circumstances, the E2 induction score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples) may reach or exceed -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, or higher). In some cases, the E2 induction score may reach or exceed -1.0. In some cases, the E2 induction score may reach or exceed -0.9. In some cases, the E2 induction score may reach or exceed -0.8. For example, in some cases, the E2 induction score may reach or exceed -0.7. In some cases, the E2 induction score may reach or exceed -0.6. In some cases, the E2 induction score may reach or exceed -0.5. In some cases, the E2-induced score can reach or exceed -0.4. In some cases, the E2-induced score can reach or exceed -0.3. In some cases, the E2-induced score can reach or exceed -0.2. In some cases, the E2-induced score can reach or exceed -0.1. In some cases, the E2-induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1). In some cases, the E2-induced score from the sample can be less than -2.0.

The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

In some cases involving the determination of ER pathway activity scores and/or E2 induction scores using any of the foregoing methods or assays on samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy.

In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and/or E2 induction scores.

C. Exemplary methods for determining E2 induction, E2 inhibition, and ER pathway activity scores

The methods and assays provided herein may include determining E2 induction, E2 inhibition, and/or ER pathway activity scores based on the expression levels of predetermined genomes (e.g., biomarkers) in samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) from individuals (e.g., individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and/or metastatic or locally advanced breast cancer)). In some cases, the predetermined genome is any of the genomes listed in Tables 1-3. In some cases, the predetermined genome is the genomes listed in Tables 1 and 4 (e.g., 14 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 2 and 5 (e.g., 19 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 3 and 6 (e.g., 41 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 1 and 4 (e.g., 14 gene signatures) without including other genes. In some cases, the predetermined genome is the genome listed in Tables 2 and 5 (e.g., 19 gene features), excluding other genes. In other cases, the predetermined genome is the genome listed in Tables 3 and 6 (e.g., 41 gene features), excluding other genes.

In some embodiments, the ER pathway activity score is calculated using eight gene features by subtracting the E2 repression score, determined by the average z-score expression of the five E2-inducible genes listed in Table 3, from the E2-inducible score.

In some embodiments, the ER pathway activity score is calculated using nine gene features by subtracting the E2 repression score, determined by the average z-score expression of the five E2-inducing genes listed in Table 3, from the E2-inducing score; and by subtracting the E2 repression score, determined by the average z-score expression of the four E2-repressing genes listed in Table 6, from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using nine gene features by subtracting the average z-score expression of the three E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using nine gene features.

In some embodiments, the ER pathway activity score is calculated using 10 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the seven E2-inducing genes listed in Table 3 from the E2-inducing score from the average z-score expression of the three E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the six E2-inducing genes listed in Table 3 from the E2-repressing score determined by the average z-score expression of the four E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the six E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 10 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2-inducing genes listed in Table 6 from the E2-inducing score determined by the average z-score expression of the five E2-repressing genes listed in Table 3 from the E2-inducing score determined by the average z-score expression of the five E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the five E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the three E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the seven E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the six E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the nine E2-inducing genes listed in Table 3 from the E2-inducing score from the average z-score expression of the three E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2-repressing genes listed in Table 6 from the E2-inducing score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2-repressing genes listed in Table 6 from the E2-inducing score, determined by the average z-score expression of the seven E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 repression score, determined by the average z-score expression of the six E2 repression genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the six E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the three E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the ten E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the nine E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 repression score, determined by the average z-score expression of the seven E2-inducible genes listed in Table 3, from the E2 induction score.

In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 9 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 8 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2-suppressing genes listed in Table 4, from the E2-inducing score determined by the average z-score expression of the 8 E2-inducing genes listed in Table 1. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 7 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 4 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 5 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-inducible genes listed in Table 3, from the E2 induction score; and by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2-repressive genes listed in Table 6, from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the average z-score expression of the 7 E2-repressive genes listed in Table 6 from the E2 induction score; and by the E2 suppression score, determined by the average z-score expression of the 8 E2-inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3, from the E2-inducing score from the average z-score expression of the 6 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-inducing genes listed in Table 3, from the average z-score expression of the 7 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2-inducing genes listed in Table 6, from the average z-score expression of the 8 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 6 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 7 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 8 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 9 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 repression score determined by the average z-score expression of the nine E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the nine E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 5, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 2. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2-inducible genes listed in Table 3, from the E2 induction score; and by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-repressive genes listed in Table 6, from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 10 E2-repressive genes listed in Table 6 from the E2 induction score; and by the E2 suppression score.

In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2 repressor genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 20 E2-inducing genes listed in Table 3, from the E2-inducing score from the average z-score expression of the 3 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the average z-score expression of the 4 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3, from the average z-score expression of the 5 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 21 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 19 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 12 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 22 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 20 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 6 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 7 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 8 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 13 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 23 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 21 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 20 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducible genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 13 E2-inducible genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 27 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 4 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 28 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 5 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 29 gene features by subtracting the E2 repression score determined by the average z-score expression of the 6 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 30 gene features by subtracting the E2 repression score determined by the average z-score expression of the 7 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 31 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 32 gene features by subtracting the E2 repression score determined by the average z-score expression of the 9 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 33 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 34 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 35 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 36 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 13 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 37 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 14 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 38 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 15 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 39 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 16 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 40 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 17 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 41 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 18 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 4, from the E2-inducing score determined by the average z-score expression of the eight E2-inducing genes listed in Table 1. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 5, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 2. In some embodiments, the ER pathway activity score is calculated using 41 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 23 E2-inducing genes listed in Table 3. The ER pathway activity score can be used as a surrogate biomarker for ER pathway activity in an individual tumor.

In any method or assay provided herein for determining the expression level of a predetermined genome from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), it should be understood that the expression level of the predetermined genome can be normalized to, for example, a reference gene, such as a housekeeping gene. In some cases, the reference gene is SDHA, GUSB, PPIA, and/or UBC. In some cases, the expression level of more than one target gene (e.g., any of the predetermined genomes listed in Tables 1-6) can be determined by aggregation methods known to those skilled in the art and also disclosed herein, including, for example, by calculating the median or mean of all expression levels of the target gene. Prior to aggregation, the expression level of each target gene can be normalized using statistical methods known to those skilled in the art and disclosed herein. These methods include, for example, normalizing to the expression levels of one or more housekeeping genes, normalizing to the median or mean expression level of each gene in all reference populations, normalizing to the total library size, or normalizing to the median or mean expression level of all measured genes. In some cases, prior to aggregation of all multiple target genes, the normalized expression level of each target gene can be normalized using statistical methods known to those skilled in the art and disclosed herein. These methods include, for example, calculating a Z-score for the normalized expression level of each target gene, or scaling the normalized expression level of each gene to a corresponding scaling factor for those expression levels in the reference population.

Samples from individuals may be FFPE samples, FF samples, fresh samples, frozen samples, or archived samples. In some cases, the samples are FFPE samples. In other cases, the samples are FF samples. The expression level of the intended genome can be quantitatively determined based on any suitable criteria known in the art, including but not limited to measurements of mRNA, DNA, cDNA, and/or gene copy number levels in an individual.

Table 1: Eight E2-inducible genes among the 14 gene characteristics

E2-induced AMZ1 C5AR2 CELSR2 FKBP4 GREB1 OLFM1 SLC9A3R1 TFF1

Table 2: Eleven E2-induced genes among the 19 gene characteristics

E2-induced AMZ1 AREG C5AR2 CELSR2 FKBP4 FMN1 GREB1 OLFM1 RBM24 SLC9A3R1 TFF1

Table 3: Twenty-three E2-inducible genes among 41 gene characteristics

Table 4: Six E2 repressor genes among 14 gene characteristics

E2 inhibition BCAS1 CCNG2 IL1R1 PNPLA7 SEMA3E STON1

Table 5: Eight E2 repressor genes among the 19 gene characteristics

Table 6: Eighteen E2 repressor genes among 41 gene characteristics

E2 inhibition BAMBI BCAS1 CCNG2 DDIT4 EGLN3 FAM171B GRM4 IL1R1 LIPH NBEA PNPLA7 PSCA SEMA3E SSPO STON1 TGFB3 TP53INP1 TP53INP2

In some cases of any of the foregoing methods and assays, gene expression levels can be nucleic acid expression levels (e.g., RNA expression levels (e.g., mRNA expression levels) or DNA expression levels). Any suitable method for determining nucleic acid expression levels can be used, for example, as described in Section VII below. In some cases, RNA-seq (e.g., using an RNA protocol or protocol), RT-qPCR, qPCR, multiplex qPCR or RT-qPCR, microarray analysis, SAGE, MassARRAY techniques, or combinations thereof are used to determine nucleic acid expression levels.

Methods for assessing mRNA in cells are well-known and include, for example, RNA sequencing (RNA-seq), whole-genome sequencing (WGS), serial analysis of gene expression (SAGE), and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific to a predetermined genome (e.g., qRT-PCR)). Additionally, such methods may include one or more steps that allow one to determine the level of a target mRNA in a biological sample (e.g., by simultaneously examining the level of a comparative control mRNA sequence of a “housekeeping” gene such as a member of the actin family). Optionally, the sequence of the amplified target cDNA can be determined. Optional methods include protocols for examining or detecting mRNA (e.g., target mRNA) in tissue or cell samples using microarray technology. Using a nucleic acid microarray, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The probes are then hybridized to a nucleic acid array immobilized on a solid support. The array is configured so that the order and position of each component of the array are known. For example, genes whose expression is associated with increased or decreased clinical benefit from treatments including immunotherapy and inhibitory matrix antagonists can be selected and arranged on a solid support. Hybridization of a labeled probe with a specific array component indicates that the sample from which the probe was derived expresses the gene.

In some cases of any of the methods and assays, samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) are obtained from the individual prior to the administration of the endocrine therapy described herein (e.g., minutes, hours, days, weeks, months, or years prior). In other words, the sample may be a baseline sample. In some cases of any of the foregoing methods, the sample is obtained from the individual after the administration of endocrine therapy (e.g., minutes, hours, or days prior). In some cases, samples from the individual are obtained within thirty hours after the administration of endocrine therapy. In some cases, multiple samples are obtained from the same individual at different time points (e.g., before and after the administration of endocrine therapy).

In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

In some cases involving the determination of ER pathway activity scores and/or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy.

In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and/or E2 induction scores.

IV. Anticancer agents

This article provides methods for treating individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and/or metastatic or locally advanced breast cancer). Any of the foregoing methods can be based on the determination of E2 induction scores and/or ER pathway activity scores from samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) from the individual.

In some of the foregoing methods, the anticancer therapeutic agents used in the methods described herein can be administered via, for example, orally, intramuscularly, subcutaneously, intravenously, intradermally, percutaneously, intra-arterially, intraperitoneally, intralesionally, intracranially, intra-articularly, intraprostatically, intrapleurally, intratracheally, intrathecally, intranasally, intravaginally, intrarectally, locally, intratumorally, intraperitoneally, subconjunctivally, intracysticly, mucosally, intraperitoneally, intraumbilically, intraocularly, intraorbitally, intravitreally (e.g., via intravitreal injection), via eye drops, locally, transdermally, parenterally, via inhalation, via injection, via implantation, via infusion, via continuous infusion, via local perfusion to directly immerse target cells, via catheter, via irrigation, as a cream, or as a lipid composition. In some of the foregoing methods, the anticancer therapeutic agents used in the methods described herein can be administered orally. For example, in some cases, the endocrine therapy described herein can be administered orally or intramuscularly. In some cases, SERM can be administered orally or intramuscularly. In some cases, SERD can be administered orally or intramuscularly. In some cases of any of the foregoing methods, the anticancer therapeutic agents used in the methods described herein may be administered intramuscularly. For example, in some cases, the endocrine therapy described herein may be administered orally. In some cases, SERM may be administered orally. In some cases, SERD may be administered orally. The anticancer therapeutic agents used in the methods described herein may also be administered systemically or locally. The method of administration may vary depending on a variety of factors (e.g., the anticancer therapeutic agent to be administered and the severity of the condition, disease, or symptom to be treated (e.g., breast cancer)).

Anticancer agents, including endocrine agents (and any additional therapeutic agents) described herein, may be formulated, administered, and applied in accordance with good medical practice. Factors to be considered in this context include the specific disease being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the disease, the site of delivery, the method of administration, the timing of administration, and other factors known to the practicing physician. Anticancer agents are not mandatory, but may optionally be formulated and/or administered concurrently with one or more agents currently used for the prevention or treatment of the disease in question. The effective amount of such other agents depends on the amount of anticancer drug present in the formulation, the type of disease or treatment, and other factors discussed above. These are generally used at the same dosage and route of administration as described herein, or at approximately 1% to 99% of the dosage described herein, or at any dosage and via any route determined empirically/clinically to be appropriate.

For the prevention or treatment of breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer, the appropriate dose of the anticancer agent (e.g., endocrine therapy) described herein (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the severity and course of the disease, whether the anticancer agent is administered for prophylactic or therapeutic purposes, prior therapy, the individual's clinical history and response to the anticancer agent, and the attending physician's discretion. The anticancer agent is appropriately administered to the individual either once or in a series of treatments. For repeated administration over several days or longer, depending on the condition, treatment typically continues until the desired suppression of disease symptoms occurs. An initial higher loading dose may be administered, followed by one or more lower doses. However, other dosing regimens may be useful. Progression of the therapy can be easily monitored using routine techniques and assays. In some cases, the dose of endocrine therapy provided herein is from about 1 mg/kg to about 100 mg/kg. In another instance, the dosage of the endocrine therapy described herein is from about 100 mg/kg to about 1000 mg/kg. In yet another instance, the dosage of the endocrine therapy described herein is from about 1000 mg/kg to about 2000 mg/kg. Some of the endocrine therapies described herein may be administered according to a cyclical administration procedure known in the art—for example, continuous administration for 20, 21, 22, 23, 24, 25, 26, 27, or 28 days or more followed by a rest period of 1, 2, 3, 4, 5, 6, 7, or more days. In yet another instance, the endocrine therapy described herein is administered according to the package insert.

A. Endocrine therapy

In some of the aforementioned cases, endocrine therapy may be administered to an individual.

Exemplary endocrine therapies used in the methods described herein include compounds that modulate estrogen receptor activity. In some cases, the compounds described herein include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), aromatase inhibitors (AIs), or combinations thereof.

In some cases, endocrine therapy includes aromatase inhibitors. Aromatase inhibitors can be agents known in the art. For example, in one case, an aromatase inhibitor is letrozole, anastrozole, exemestane, or testrolide, or a pharmaceutical salt thereof, or a combination thereof.

In another case, endocrine therapy includes SERM.

Endocrine therapy may comprise a compound that is a tetrasubstituted olefin compound known to have antagonistic activity against ER. For example, endocrine therapy may be tamoxifen, including its derivatives such as hydroxytamoxifen. In one case, endocrine therapy includes nafoxidin. In another case, endocrine therapy includes clomiphene, toremifene, raloxifene, diacetylcholine, bardoxifene, bromhexetine, cyclofennig, lasoxifene, omexifen, acoboxifene, ilesetron, brilanestrant, oflomiphene, droloxifen, etexil, or opemifene, or pharmaceutical salts thereof, or combinations thereof. In yet another case, endocrine therapy includes G1T48 or pharmaceutical salts thereof.

In yet another case, endocrine therapy includes SERD.

In one case, endocrine therapy includes fulvestrant.

Or its medicinal salt.

On one hand, endocrine therapy includes compounds having formula (1):

in;

Z is -OH or -OR ¹⁰ ;

^R2 is a _C1-4 alkyl, _C1-4 fluoroalkyl, _C1-4 deuteralkyl, _C3-6 cycloalkyl, or _C1-4 alkylene-W;

W is hydroxyl, halogen, CN, _C1-4 alkyl, _C1-4 haloalkyl, _C1-4 alkoxy, _C1-4 haloalkoxy, or _C3-6 cycloalkyl;

^R3 is independently a halogen, a _C1-4 alkyl, or a _C1-4 fluoroalkyl;

^R4 is independently ^{a halogen, -CN, -OR9, -S(O)2R10 ,} _{C1-4 alkyl} , _C1-4 fluoroalkyl, or _C1-4 heteroalkyl;

^R5 is independently ^{a halogen, -CN, -OR9, -S(O)2R10 ,} _{C1-4 alkyl} , _C1-4 fluoroalkyl, or _C1-4 heteroalkyl;

^R6 is H, _C1-4 alkyl, or halogen;

^R7 is H, _C1-4 alkyl, or halogen;

R ⁹ is H, _C1-6 alkyl, _C1-6 fluoroalkyl, or _C3-6 cycloalkyl;

R ¹⁰ is a _C1-6 alkyl group;

m is 0, 1, or 2;

n is 0, 1, 2, 3, or 4; and

p is 0, 1, or 2.

In another case of the compound of formula (1), Z is -OH or -OR ¹⁰ ; R ² is _C1-4 alkyl, _C1-4 fluoroalkyl, _C1-4 deuteralkyl, _C3-6 cycloalkyl, or _C1-4 alkylene-W, wherein W is hydroxyl, halogen, CN, or _C1-4 alkyl; R ³ is independently halogen, _C1-4 alkyl, or _C1-4 fluoroalkyl; R ⁴ is independently halogen, -CN, -OR ⁹ , -S(O)2R ¹⁰ , _C1-4 alkyl, _C1-4 fluoroalkyl, or _C1-4 heteroalkyl; R ⁵ is independently halogen, -CN, -OR ⁹ , -S(O)2R10, _C1-4 alkyl, _C1-4 fluoroalkyl, or _C1-4 heteroalkyl; R ⁶ is H, _C1-4 alkyl, or halogen; R ⁷ is H, C _1-4 alkyl or halogen; ^R9 is H, _C1-6 alkyl, _C1-6 fluoroalkyl or _C3-6 cycloalkyl; ^R10 is _C1-6 alkyl; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; and p is 0, 1 or 2.

In another case of the compound of formula (1), Z is -OH. In another case of the compound of formula (1), Z is -OR ^10. In another case of the compound of formula (1), Z is -OH, -OCH ₃ , or -OCH ₂ CH ₃ .

In another case of the compound of formula (1), ^R6 is H, _-CH3 , F, or Cl. In another case of the compound of formula (1), ^R6 is H. In another case of the compound of formula (1), ^R7 is H, _-CH3 , F, or Cl. In another case of the compound of formula (1), ^R7 is H.

In another case of the compound of formula (1), ^R3 is independently a halogen, a _C1-4 alkyl, or a _C1-4 fluoroalkyl. In another case of the compound of formula (1), ^R3 is independently F, Cl, or _-CH3 . In another case of the compound of formula (1), ^R4 is independently a halogen, -CN, -OH, ^-OR9 , -S(O) _2R10 , a _C1-4 alkyl, a _C1-4 fluoroalkyl, or a _{C1-4 heteroalkyl} . In another case of the compound of formula (1), ^R4 _is independently ^a halogen, -CN, -OH, -S(O) _{2CH3 , -S} (O) _2CH2CH3 , _-CH3 , _-CH2CH3 , _-CF3 , _-CH2OH , _-OCF3 , _-OCH3 , or _{-OCH2CH3 .} In another case of the compound of formula (1), ^R4 is independently F, Cl, _-CN , -OH, _-CH3 , _-CH2CH3 ^, _-CF3 , _-CH2OH , _-OCF3 , _-OCH3 , or _-OCH2CH3 . In another case of the compound of formula (1), _R4 is independently F or Cl. In another case of the compound of formula (1), ^R5 is independently a halogen, a _C1-4 alkyl group, or a _C1-4 fluoroalkyl group. In another case of the compound of formula (1), ^R5 is independently F, Cl, or _-CH3 .

In another case of the compound of formula (1), m is 0 or 1. In another case of the compound of formula (1), m is 0. In another case of the compound of formula (1), m is 1. In another case of the compound of formula (1), n is 0, 1, or 2. In another case of the compound of formula (1), n is 0. In another case of the compound of formula (1), n is 1. In another case of the compound of formula (1), n is 2. In another case of the compound of formula (1), p is 0 or 1. In another case of the compound of formula (1), p is 0. In another case of the compound of formula (1), p is 1.

In another case of the compound of formula (1), Z is -OH; ^R6 is H, _-CH3 , F or Cl; ^R7 is H, _-CH3 , F or Cl; ^R3 is independently a halogen, _C1-4 alkyl or _C1-4 fluoroalkyl; ^R4 is independently a halogen, -CN, ^-OR9 , -S(O ^)2R10 _{, C1-4} alkyl, _C1-4 fluoroalkyl or _C1-4 heteroalkyl; ^R5 is independently a halogen, _C1-4 alkyl or _C1-4 fluoroalkyl; m is 0 or 1; n is 0, 1 or 2; and p is 0 or 1.

In another case of the compound of formula (1), ^R2 is a _C1-4 alkyl, _C1-4 fluoroalkyl, _C1-4 deuteralkyl, _C3-6 cycloalkyl, or _C1-4 alkylene-W; W is a hydroxyl, halogen, CN, _C1-4 alkoxy, or _C3-6 cycloalkyl. In another case of the compound of formula (1), ^R2 is a _C1-4 alkyl, _C1-4 fluoroalkyl, or _C1-4 deuteralkyl. In another case of the compound of formula (1), ^R2 is a _C1-4 alkyl. In another case of the compound of formula (1), ^R2 is _{-CH3 , -CH2CH3} , -CH2CH2CH3, -CH( _CH3 ) ₂ , _{-CH2CH2CH2CH3} , -CH2CH( _CH3 ) _{2 , -CH2F} , _-CHF2 , _-CF3 , _-CH2CF3 , _-CD3 , -CH2CD3 _{, -CD2CD3 , cyclopropyl , cyclobutyl} , _cyclopentyl , _cyclohexyl , _{-CH2 - W} or _{CH2CH2 - W} ; W is hydroxyl, F _, Cl, -CN, _{-OCH3 , -OCH2CH3} , _-OCH2CH2CH3 , -OCH( _{CH3 ) 2 ,} cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In another case of the compound of formula (1), W is hydroxyl, F, Cl, -CN, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In another case of the compound of formula (1), ^R2 is _-CH3 , _-CH2CH3 , _-CH2CH2CH3 , _-CH ( _{CH3 ) 2} , _{-CH2CH2CH2CH3} , _{-CH2CH ( CH3} ) _{2 , -CH2F} , _{-CHF2 , -CF3} , _-CH2CF3 , _-CD , _-CH2CD3 , _-CD2CD3 , _{-CH2 - W} , or _{-CH2CH2 - W} . In another case of _the compound of formula (1), ^R2 is _-CH3 , _-CH2CH3 , _-CH2F , _-CHF2 , _-CF3 , _-CH2CF3 , _-CD3 , _-CD2CD3 , _{-CH2CD3 or cyclopropyl .}

In another case of the compound of formula (1), Z is -OH; ^R6 is H; ^R7 is H; m is 0; n is 0, 1 or 2; and p is 0.

In another case of a compound of formula (1), the compound of formula (1) has the structure of formula (1a), or a medicinal salt thereof, or an N-oxide thereof:

Equation (1a).

On the other hand, endocrine therapy includes compounds listed in U.S. Patent No. 8,299,112, such as those in Table 1 therein, the entire contents of which are incorporated herein by reference for all purposes.

On the other hand, endocrine therapy includes compounds having the following formula: (E)3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-benzo[d][1,2] [3] Triazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(( (E)-1-(1H-indazol-5-yl)-2-(3-methoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-) 1-(E)-3-(4-((E)-2-(2-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(o-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(o-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2- -(m-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(p-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-methoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-( 1H-Indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; ((E)-3-(4-((E)-2-(2-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E) -3-(4-((E)-2-(2-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)but-1-en-1)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)but-1-en-1)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-(trifluoromethyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluorophenyl)-1-(1H-))phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluorophenyl)-1-(1H-))phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E))-2-(2,4-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; -2-(2-chloro-3-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)propylene) Acid; (E)-3-(4-((E)-2-(2,6-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,6-dichlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4,4,4-trideuterium-1-(1H-indazol-5-yl)trideuterium-1-(1H-indazol-5-yl)trideuterium-1-(1H-indazol-5-yl)trideuterium-1-(1H-indazol-5-yl)trideuterium-1-(1H-indazolium ... (E)-2-(5-fluoro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-3-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4- (E)-2-(2,3-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,5-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-5-fluorophenyl)-1-(1H-indazol-5-yl)but-1-) (E)-3-(4-((E)-2-(2-chloro-6-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-methyl-1H-indazol))phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(6-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(6-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1 -(3-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(3-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)prop- Acrylic acid; (E)-3-(4-((E)-2-(4-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-hydroxy-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-4-methoxy-2-phenylbutyric acid)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-4-methoxy-2-phenylbutyric acid)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-3-methoxy-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indole-5-yl))phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indole-5-yl))phenyl)acrylic acid; (E)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(6-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-4-methyl-2-phenylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-phenyl) [d][1,2,3]triazol-5-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopentyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid ；(E)-3-(4-((E)-2-cyclohexyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-3-cyclopropyl-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl) (E)-3-(4-((E)-2-(2-chlorophenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(6-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-benzi[d]imidazol-5-yl)-2- (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylhex-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-3-cyclopentyl-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)- 1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-fluoro-1H-indole-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-( (E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)-4-methylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-3,3-difluoro-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(7-fluoro-1H-indazol-5-yl) (E)-3-(4-((E)-4-fluoro-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-3 3,3-Trifluoro-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-methylphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-1-(4-fluoro-1H-indazol-5-yl) (E)-3-(4-((E)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-methylphenyl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3- (4-((E)-1-(4-chloro-1H-indazol-5-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-2-(2-chloro-4-fluorophenyl)-3,3-difluoro-1-(1H-indazol-5-yl)prop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-1-(4-fluoro-1H-) (E)-3-(4-((E)-4-chloro-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-2-(2-chloro-4-fluorophenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3 -(4-((E)-4-fluoro-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-fluoro-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-5-methoxy-2-phenylpentan-1-yl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-6-methoxy-2-phenylhex-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)-3-methylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-3-methylbut-1-en-1-yl)phenyl)acrylic acid; H-Indazol-5-yl)-2-(3-(trifluoromethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclobutyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E) (E)-3-(4-((E)-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(3-fluoro-1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(3-fluoro-1H-indazol-5-yl)butyric acid) -1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclobutyl-1-(3-fluoro-1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-( 1H-Indazol-5-yl)-2-(2-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-Indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-Indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)-2-methylpropane Acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-3-methylphenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-methylphenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-methylphenyl)acrylic acid; (Z)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)-2-fluoroacrylic acid; (Z)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)-2-chloroacrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenyl) (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-fluorophenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-(trifluoromethyl)phenyl)acrylic acid; (E)-3-(4-((Z)-1-(1 H-Indazol-5-yl)-2-phenylbut-1-en-1-yl)-3-methoxyphenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-Indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-methoxyphenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-Indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid ethyl Ester hydrochloride; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1- (1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; s(E)-3-(4-((E)-2-(4-chloro-2-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-2-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-(trifluoromethyl)phenyl)butyrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(4- (E)-3-(4-((E)-2-(4-chloro-2-(trifluoromethyl)phenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-4-fluoro-1-(1H-indazol-5-yl)but-1-en-1-yl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-4-fluoro-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropane) (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(4-fluoro-1H-indazole-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclopropyl-1-(4-fluoro-1H-indazole-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-2-(2,4-dichlorophenyl)-1-(1H-indazole-5-yl)) (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-methyl-5-(methylsulfonyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1- (1H-indazol-5-yl)-2-(4-methoxy-2-methylphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluoro-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-5-methoxyphenyl)-1-(1H-indazol-5-yl)but- 1-En-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluoro-4-(methylsulfonyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-3,3,4,4,4-pentadeuter-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(methylsulfonyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(7-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-3-methoxyphenyl)-1 -(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(7-fluoro-1H-indole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(7-fluoro-1H-indole-5-yl)but-1-en-1-yl)phenyl)acrylic acid ；(E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-3,3,4,4,4-pentadeuter-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2- (Cyano-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-cyano-4-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-cyanophenyl)-1-(1H-indazol-5-yl)but-1-ene) -1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(5 (E)-3-(4-((E)-2-(2-cyano-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)) (E)-3-(4-((E)-2-(2-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(1-(1H-indazol-5-yl)-2-phenylbut-1-ene) -1-yl)phenyl)propionic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(2-methoxyethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(3-methoxypropoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)- 1-(1H-indazol-5-yl)-2-(3-(2-methoxyethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(3-methoxypropoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-(cyclohexyloxy)phenyl)-1-(4-fluoro-1-yl)phenyl)acrylic acid; H-Indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-butoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(pentoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-( (E)-2-(3-(hexyloxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-butoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(pentoxy)phenyl)but-1-en- 1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-(hexyloxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-(2-hydroxyethoxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H- (E)-3-(4-((E)-2-(2-chlorophenyl)-1-(1-methyl-1H-indazol-5-yl)but-1-en-1-yl)phenyl)propene Acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1-methyl-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1-(difluoromethyl)-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; or a pharmaceutical salt thereof or its N-oxide or a combination thereof.

In one case, endocrine therapy includes brilanestrant (GDC-0810) having the following structure:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds listed in USPN 9,499,538 or 9,586,952, each of which is incorporated herein by reference in its entirety for all purposes.

On the other hand, endocrine therapy includes compounds listed in USPN 7,612,114 or 8,399,520, each of which is incorporated herein by reference in its entirety for all purposes. In one instance, endocrine therapy includes ilextron (RAD1901):

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds listed in International Patent Application No. WO2018077260, such as in Table 2 therein, the entire contents of which are incorporated herein by reference for all purposes. In one instance, endocrine therapy includes LX-039. In another instance, endocrine therapy includes compounds having the following structure:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds listed in International Patent Applications Nos. WO2017136688, WO2017162206, WO2017140669, WO2017216280, WO2017216279, WO2018091153, WO2018019793, and WO2018077630, each of which is incorporated herein by reference in its entirety for all purposes.

In another case, endocrine therapy includes AZ9496 having the following structure:

Or its medicinal salt.

In another aspect, endocrine therapy includes compounds listed in U.S. Patent Application No. 20150284357, the entire contents of which are incorporated herein by reference for all purposes. In another aspect, endocrine therapy includes compounds listed in USPN 9,475,791, the entire contents of which are incorporated herein by reference for all purposes. In yet another aspect, endocrine therapy includes compounds listed in International Patent Applications Nos. WO2018081168 or WO2018129387, each of which is incorporated herein by reference for all purposes. In one aspect, endocrine therapy includes compounds having the following formula:

Or stereoisomers or their medicinal salts.

On the other hand, endocrine therapy includes compounds listed in USPN 8,703,810, such as in the compound table provided therein, the full text of which is incorporated herein by reference for all purposes.

On one hand, endocrine therapy includes compounds having formula (2):

Equation (2)

Or its medicinal salt, wherein:

^R1 is H, F, _C1 - _C4 alkyl, or _C1 - _C4 fluoroalkyl;

^R3 is H, halogen, _C1 - _C4 alkyl, _C3 - _C6 cycloalkyl, or _C1 - _C4 fluoroalkyl;

^R4 is independently selected from H, halogen, -CN, -OH, ^-OR9 , ^-SR9 , -S(O) ^R10 , -S(O) _2R10 , -C(O) ^R10 , -C(O)OH, ^{-C(O)OR10 ,} -C(O) ^NHR10 , -C(O)N( ^R10 ) ₂ , substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkoxy, substituted or unsubstituted _C1 - _C6 alkoxy, and substituted or unsubstituted _C1 - _C6 heteroalkyl;

^R5 is independently selected from H, halogen, -CN, -OH, ^-OR9 , ^-SR9 , -S(O) ^R10 , -S(O ^)2R10 _, substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkoxy, substituted or unsubstituted _C1 - _C6 alkoxy, and substituted or unsubstituted _C1 - _C6 heteroalkyl;

^R6 is independently selected from H, halogen, -CN, -OH, ^-OR9 , ^-SR9 , -S(O) ^R10 , -S(O ^)2R10 _, substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkoxy, substituted or unsubstituted _C1 - _C6 alkoxy, and substituted or unsubstituted _C1 - _C6 heteroalkyl;

It is pyrrolidinyl or azahexacyclic butyl;

^R7 is H or _C1 - _C4 alkyl;

^R8 is independently selected from F, Cl, -CN, -OH, ^-OR9 , ^-SR9 , -S(O) ^R10 , -S(O ^)2R10 _, substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkoxy, substituted or unsubstituted _C1 - _C6 alkoxy, and substituted or unsubstituted _C1 - _C6 heteroalkyl;

Or one ^R8 together with ^R1 and the intermediary atom that connects ^R8 to ^R1 forms a 5-membered, 6-membered, or 7-membered ring;

^R9 is independently selected from H, -C(O) ^R10 , -C(O) ^OR10 , -C(O) ^NHR10 , substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 heteroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C3 - _C10 cycloalkyl, substituted or unsubstituted _C2 - _C10 heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, _-C1 - _C2 alkylene- (substituted or unsubstituted _C3 - _C10 cycloalkyl), _-C1 - _C2 alkylene- (substituted or unsubstituted _C2 - _C10 heterocycloalkyl), _-C1 - _C2 alkylene- (substituted or unsubstituted aryl), and _-C1 - _C2 alkylene- (substituted or unsubstituted heteroaryl); or

R ¹⁰ is independently selected from substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 heteroalkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, substituted or unsubstituted _C3 - _C10 cycloalkyl, substituted or unsubstituted _C2 - _C10 heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, _-C1 - _C2 alkylene- (substituted or unsubstituted _C3 - _C10 cycloalkyl), _-C1- C2 alkylene- (substituted or unsubstituted _C2 - _C10 heterocycloalkyl), _-C1 - _C2 alkylene- (substituted or unsubstituted _{aryl), and -C1-C2 alkylene- (} substituted or unsubstituted heteroaryl).

Y is -O-, -S-, or -NR ^11- ; R ¹¹ is H, -C(O)R ¹⁰ , substituted or unsubstituted _C1 - _C6 alkyl, substituted or unsubstituted _C1 - _C6 fluoroalkyl, or substituted or unsubstituted _C1 - _C6 heteroalkyl.

X is -O-, -S-, _-CH2- , -NH-, or -( _C1 - _C6 alkyl)-;

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, or 3;

p is 0, 1, 2, 3, or 4; and

t can be 1, 2, 3 or 4.

In one case, the compound of formula (2) is a compound in which ^R1 is H or _C1 - _C4 alkyl; ^R3 is _C1 - _C4 alkyl or _C1 - _C4 fluoroalkyl; ^R4 is independently selected from H, halogen, -CN, -OH, ^-OR9 , ^-SR9 , -S(=O) ^R10 , ^-S(=O)2R10 _{, C1} - _C4 alkyl, _C1 - _C4 fluoroalkyl, C1- _C4 fluoroalkoxy, _{C1 - C4} alkoxy and _C1 - _C4 heteroalkyl; ^R5 is independently selected from H, F, Cl, -OH, _-CH3 , _-CF3 , _-OCF3 and _-OCH3 ; ^R6 is independently selected from H, F, Cl, -OH, _-CH3 , _-CF3 , _-OCF3 and _-OCH3 ; R ⁷ is H; R ⁸ are each independently selected from H, F, Cl, -OH, _C1 - _C4 alkyl, _C1 - _C4 fluoroalkyl, _C1 - _C4 fluoroalkoxy, _C1 - _C4 alkoxy and _C1 - _C4 heteroalkyl; Y is -O- or -S-; X is -O-, -S-, _-CH2- , -NH- or -N( _CH3 )-; and p is 0, 1 or 2. On the other hand, endocrine therapy includes compounds having the following formula: 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (S)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (R)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((R)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((R)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((S)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3-hydroxyphenyl) -4-Methyl-2-(4-((S)-2-((S)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((R)-2-((S)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(4-((S)-2-(3,3-dimethylpyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 2-(4-(2-(3,3-dimethylpyrrolidin-1-yl)ethoxy) 3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((R)-2-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((S)-2-methylpyrrolidin-1-yl)propoxy)phenyl) -2H-Benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-Benzopyran-7-ol; 3-(4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-Benzopyran-7-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-phenyl-2H-Benzopyran-6-ol; 3-(4-fluorophenyl) -4-Methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (S)-3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (R)-3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxyphenyl)-4-methyl-2-(4 -((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-fluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(2-fluoro-4-((S)-2-((R)-3-methylpyrrolidin-1-yl) 3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(3-hydroxy-4-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R))-2-((R))-2H-benzopyran-6-ol 3-(4-hydroxy-3-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-fluoro-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-chlorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol 3-(2-fluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3,4-difluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3,5-difluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(2,4-difluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3,4-difluoro-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(2-chloro-4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(2,4-difluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-bromophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-(o-tolyl)-2H-benzopyran-6-ol Pyran-6-ol; 3-(4-fluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-ethynylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-(4-(methylsulfonyl)phenyl)-2H-benzopyran-6-ol ; 3-(2-fluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 5-fluoro-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-( 4-Fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(4-((S)-2-((R)-3-fluoropyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(4-hydroxyphenyl)-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-4-(trifluoromethyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-2-(4-( (S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-4-(trifluoromethyl)-2H-benzopyran-6-ol; 3-(3-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-3-(trifluoromethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; or pharmaceutical salts thereof or combinations thereof.

In one case, endocrine therapy includes GDC-0927 (SRN-0927) having the following structure:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds listed in USPN 9,980,947, such as in Table 1 therein, the entire text of which is incorporated herein by reference for all purposes.

On one hand, endocrine therapy includes compounds of formula (3):

Or stereoisomers, tautomers, or their medicinal salts, wherein:

^Y1 is CR ^b or N;

^Y2 is -( _CH2 )-, -( _CH2CH2 )- _, or NR ^a ;

^Y3 is NR ^a or C(R ^b ) ₂ ;

One of ^Y1 , ^Y2 , and ^Y3 is N or ^NRa ;

^Ra is H, _C1 - _C6 alkyl, _C2 - _C8 alkenyl, propargyl, _C3 - _C6 cycloalkyl, or _C3 - _C6 heterocyclic, optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, OH, _OCH3 , and _{SO2CH3 ;}

^Rb is H, -O ( _C1 - _C3 alkyl), _C1 - _C6 alkyl, _C2 - _C8 alkenyl, propargyl, -( _C1 - _C6 alkyldiyl)-( _C3 - _C6 cycloalkyl), _C3 - _C6 cycloalkyl, or _C3 - _C6 heterocyclic, optionally substituted by one or more groups independently selected from the group consisting of: F, Cl _, Br, _I , CN, _-CH2F , _-CHF2 , _-CF3 , _-CH2CF3 , _-CH2CHF2 , _-CH2CH2F , _OH , _OCH3 , and _{SO2CH3 ;}

^Rc is H, _C1 - _C6 alkyl, allyl or propyne, which is optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, OH, _OCH3 and _{SO2CH3 ;}

^Z1 is a CR ^a R ^b , C(O) or bond;

Cy is a _C6 - _C20 aryldiyl, _C3 - _C12 carbocyclic diyl, _C2 - _C20 heterocyclic diyl, or _C1 - _C20 heteroaryldiyl;

^Z2 is O, S, ^NRa , _C1 - _C6 alkyldiyl, _C1 - _C6 fluoroalkyldiyl, O-( _C1 - _C6 alkyldiyl), O-( _C1 - _C6 fluoroalkyldiyl), C(O) or bond;

R ¹ , R ² , R ³ and R ⁴ are independently H, F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F, -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirnebutane, 1-methylazirnebutane-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirnebutane-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholino;

^R5 is H, _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, -( _C1 - _C6 alkyldiyl)-( _C3 - _C9 cycloalkyl), -( _C1 -C6 alkyldiyl)-( _C3 - _C9 heterocyclic), C(O) ^Rb , C( _O ) ^NRa , _SO2Ra ^{or SO2NRa} , optionally substituted with one or _more of halogen, CN, ^ORa , N( ^Ra ) ₂ , _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, C(O) ^Rb , C( ^O ) ^NRa , _SO2Ra or ^SO2NRa _;

R ⁶ is F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F , -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholine; and

m is 0, 1, 2, 3 or 4;

The alkyl diel, fluoroalkyl diel, aryl diel, carbocyclic diel, heterocyclic diel, and heteroaryl diel are optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, -CN, _-CH3 , _-CH2CH3 , _-CH (CH3) _{2 , -CH2CH(CH3)2 , -CH2OH ,} -CH2OCH3, _-CH2CH2OH , -C( _CH3 ) _2OH , -CH( _{OH )} CH( _{CH3 ) 2} , -C _{( CH3} ) _{2CH2OH , -CH2CH2SO2CH3} , _-CH2OP ( _{O )} ( _{OH ) 2} , _-CH2F , _-CHF2 , _{-CF3 , -CH2CF3} , _-CH2CHF2 , _{-CH2CH 2} F, -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH, -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone, and morpholino.

In one case of the compound of formula (3), ^Y1 is ^CRb and ^Y3 is ^NRa . In another case of the compound of formula (3), ^Y1 is N and ^Y3 is C( ^Rb ) ₂ . In another case of the compound of formula (3), ^Y2 is -( _CH2 )-. In another case of the compound of formula (3), ^Y2 is -( _{CH2CH2 )} -.

In another case of the compound of formula (3), ^Rc is H. In another case of the compound of formula (3), Cy is a _C6 - _C20 aryldiyl group, the _C6 - _C20 aryldiyl group is a phenyldiyl group, and the phenyldiyl group is substituted with one or more F groups. In another case of the compound of formula (3), ^R1 and ^R2 are H. In another case of the compound of formula (3), ^R3 is H and ^R4 is _-CH3 . In another case of the compound of formula (3), ^R5 is a _C1 - _C6 fluoroalkyl group. In another case of the compound of formula (3), m is 0.

In another case, endocrine therapy includes compounds of formula (3) having formula (3a):

Or stereoisomers, tautomers, or their medicinal salts, wherein:

^Y1 is CR ^b or N;

^Y2 is -( _CH2 )-, -( _CH2CH2 )- _, or NR ^a ;

^Y3 is NR ^a or C(R ^b ) ₂ ;

One of ^Y1 , ^Y2 , and ^Y3 is N or ^NRa ;

^Ra is independently H, _C1 - _C6 alkyl, _C2 - _C8 alkenyl, propargyl, _C3 - _C6 cycloalkyl, and _C3 - _C6 heterocyclic, optionally substituted by one or more groups independently selected from: F, Cl, Br, I, CN, OH, _OCH3 , or _{SO2CH3 ;}

^Rb is independently H, -O ( _C1 - _C3 alkyl), _C1 - _C6 alkyl, _C2 - _C8 alkenyl, propargyl, -( _C1 - _C6 alkyldiyl)-( _C3 - _C6 cycloalkyl), _C3 - _C6 cycloalkyl, and _C3 - _C6 heterocyclic, optionally substituted by one or more groups independently selected from: F, Cl, Br, I, _CN , _-CH2F , _-CHF2 , _-CF3 , _-CH2CF3 , _-CH2CHF2 , _-CH2CH2F , OH, _{OCH3 , or SO2CH3 ;}

^Rc is independently H, _C1 - _C6 alkyl, allyl, propyne, which is optionally substituted by one or more groups independently selected from the following: F, Cl, Br, I, CN, OH, _{OCH3 or SO2CH3} ;

^Z1 is a CR ^a R ^b , C(O) or bond;

Cy is a _C6 - _C20 aryldiyl, _C3 - _C12 carbocyclic diyl, _C2 - _C20 heterocyclic diyl, or _C1 - _C20 heteroaryldiyl;

^Z2 is O;

R ¹ , R ² , R ³ and R ⁴ are each independently H, F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F, -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirnebutane, 1-methylazirnebutane-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirnebutane-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholino;

^R5 is H, _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, -( _C1 - _C6 alkyldiyl)-( _C3 - _C9 cycloalkyl), -( _C1 -C6 alkyldiyl)-( _C3 - _C9 heterocyclic), C(O) ^Rb , C( _O ) ^NRa , _SO2Ra ^{and SO2NRa} , optionally substituted with one or more of halogen, _CN , ^ORa , N( ^Ra ) ₂ , _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, C(O) ^Rb , C( ^O ) ^NRa , _SO2Ra or ^SO2NRa _;

R ⁶ is F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F , -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH ₂ CH ₂ F, -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ ,-N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ 、-NO ₂ 、＝O 、-OH 、-OCH ₃ 、-OCH ₂ CH ₃ 、-OCH ₂ CH ₂ OCH ₃ 、-OCH ₂ CH ₂ OH 、-OCH ₂ CH ₂ N(CH ₃ ) ₂ 、-OP(O)(OH) ₂ 、-S(O) ₂ N(CH ₃ ) ₂ 、-SCH ₃ 、-S(O) ₂ CH ₃ 、-S(O) ₃ H 、cyclopropyl 、cyclopropylamide 、cyclobutyl 、oxetane alkyl 、azacyclobutane alkyl 、1-methylazacyclobutane-3-yl)oxy 、N-methyl-N-oxetane-3-ylamino 、azacyclobutane-1-ylmethyl 、benzyloxyphenyl 、pyrrolidine-1-yl 、pyrrolidine-1-yl-methyl

Ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholino; and m is 0, 1, 2, 3 or 4;

The alkyl diel, fluoroalkyl diel, aryl diel, carbocyclic diel, heterocyclic diel, and heteroaryl diel are optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, -CN, _-CH3 , _-CH2CH3 , _-CH (CH3) _{2 , -CH2CH(CH3)2 , -CH2OH ,} -CH2OCH3, _-CH2CH2OH , -C( _CH3 ) _2OH , -CH( _{OH )} CH( _{CH3 ) 2} , -C _{( CH3} ) _{2CH2OH , -CH2CH2SO2CH3} , _-CH2OP ( _{O )} ( _{OH ) 2} , _-CH2F , _-CHF2 , _{-CF3 , -CH2CF3} , _-CH2CHF2 , _{-CH2CH 2} F, -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone, and morpholino.

In one case, the compound of formula (3a) includes that of formula (3b):

In another case, compounds of formula (3a) include those of formula (3c):

Where R ⁷ is F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F , -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholine; and

n is 0, 1, 2, 3 or 4.

In another case, the compounds of formula (3a) include those of formula (3d):

In yet another case, the compound of formula (3a) contains the compound of formula (3e):

^R8 is H or _-CH3 .

In another case of compounds of formula (3a)-(3e), ^Y1 is ^CRb and ^Y3 is ^NRa . In another case of compounds of formula (3a)-(3e), ^Y1 is N and ^Y3 is C( ^Rb ) ₂ . In another case of compounds of formula (3a)-(3e), ^Y2 is -( _CH2 )- or -( _CH2CH2 )-. In another case of compounds of formula (3a)-( _3e ), ^Rc is H. In another case of compounds of formula (3a)-(3e), Cy is phenyldiyl. In one case of compounds of formula (3a)-(3e), the phenyldiyl group is substituted with one or more F groups.

In another case of compounds of formula (3a)-(3e), ^R1 and ^R2 are H. In another case of compounds of formula (3a)-(3e), ^R3 is H, and ^R4 is _-CH3 . In another case of compounds of formula (3a)-(3e), ^R5 is a _C1 - _C6 fluoroalkyl group. In another case of compounds of formula (3a)-(3e), m is 0.

On the other hand, endocrine therapy includes compounds having the following formula:

(1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-(2-fluoro-2-methylpropyl) 1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)-2-methylprop-1-one; 1-((1R,3R)-1-(2,6-difluoro-4-yl)-2-methylprop-1-one; -(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-one;(1R,3R)-1-(4-(2-(3-(difluoromethyl)azacyclobutane-1-yl)ethoxy)-2,6-difluorophenyl)-2-(2-fluoro-2-methylprop-3-methyl-2,3,4 ,9-Tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(4-((1-(3-chloropropyl)azacyclobutane-3-yl)oxy)-2,6-difluorophenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-propylazacyclobutane-3-yl)oxy)benzene (1R,3R)-1-(2,6-difluoro-4-((S)-2-((R)-3-(fluoromethyl)pyrrolidine-1-yl)propoxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R, 3R)-1-(2,6-difluoro-4-(2-((R)-3-(fluoromethyl)pyrrolidine-1-yl)ethoxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-(6-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)pyridin-3-yl)-3 -Methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3R)-2-(2-fluoro-2-methylpropyl)-1-(3-fluoro-5-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)pyridin-2-yl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-2-(cyclobutylmethyl)-1-(2,6-difluoro- 4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2-((3-methyloxacyclobutane-3-yl)methyl)-2,3,4,9-tetrahydro-1H-pyrido[ [3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2-(oxacyclobutane-3-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3 -Methyl-2-(oxetane-3-yl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(pyrrolidone-1-yl)ethoxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-( Piperidin-1-yl)ethoxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1-(2-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-yl)phenoxy)ethyl)azacyclobutane-3-yl)methyl Alcohol; (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-(2-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-di Hydrogen-1H-pyrido[3,4-b]indol-2(9H)-yl) acetone; 1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-hydroxy-2-methylprop-1-one; (R)-3-((1R,3R)-1-(2,6-di) Fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-methylprop-1-ol; ((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-methylprop-1-ol Indole-2(9H)-yl)((1s,3S)-3-hydroxycyclobutyl) ketone; 1-(1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3,3-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)-2-methylprop-1-one; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl) Heterocyclic butane-1-yl)ethoxy)phenyl)-3-methyl-2-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclic butane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-2-methyl-prop-2-ol; (1 R,3R)-1-[4-[2-[3-(difluoromethyl)azacyclobutane-1-yl]ethoxy]-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole;(1R,3R)-1-[4-[1-(3-chloropropyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)- 3-Methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-propylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; ((1S,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)) (1R,3R)-1-[4-(azacyclobutane-3-yloxy)-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-yl)methanol; (1R,3R)-1-[4-(azacyclobutane-3-yloxy)-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-2-(2-fluoro-2- (1R,3R)-2-cyclobutyl-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-2-cyclobutyl-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole Indole; (1R,3S)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-(fluoromethyl)-2-(2-fluoro-2-methyl-propyl)-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-[(3-fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-[(3-fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl] Cyclobutane-3-yl)methyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; cyclohexyl((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl) ketone; 1-[(1R,3R)-1-[2,6-difluoro-4-[ 2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-dimethyl-prop-1-one; cyclopropyl((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol- 2(9H)-yl) methyl ketone; (1R,3R)-1-[2,6-difluoro-4-[2-(3-methylazetane-1-yl)ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-((R)-3-methylpyrrolidine-1-yl)ethoxy)phenyl)-2-(2-fluoro-2 (-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[(2S)-2-pyrrolidone-1-ylpropoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[3-[3-(fluoromethyl) [(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[(E)-3-[3-(fluoromethyl)azacyclobutane-1-yl]prop-1-enyl]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3, 4-b]indole; (1R,3R)-2-[(3,3-difluorocyclobutyl)methyl]-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2, 2-Dimethylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; cyclobutyl-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl] ketone; cyclopentyl-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-] (fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl] methyl ketone; (1R,3R)-1-[2,6-difluoro-4-[2-[(3S)-3-methylpyrrolidone-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol; (1R,3 R)-1-[2,6-difluoro-4-[(2R)-2-pyrrolidone-1-ylpropoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[(1-propylazacyclobutane-3-yl)methoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; Hydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-[(1-fluorocyclobutyl)methyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (S)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy] (2R)-3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-fluoro-2-methyl-prop-1-ol; -1-ol; (1R,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; 2-cyclopropyl-1-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1, 3,4,9-Tetrahydropyrido[3,4-b]indol-2-yl]acetone; 2-cyclobutyl-1-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]acetone; 1-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]acetone; Heterocyclic butane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoro-prop-1-one; (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)-3-methyl-azacyclic butane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4] [-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-methylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[4-(1-ethylazacyclobutane-3-yl)oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1, 3,4,9-Tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-pentylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-(cyclopropylmethyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2- (2-Fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-(cyclopentylmethyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1- (2-Fluoroethyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-prop-2-ynylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole Indole; (1R,3R)-1-[2,6-difluoro-4-(1-isopropylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-isobutylazacyclobutane-3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3, 4,9-Tetrahydropyrido[3,4-b]indole; 3-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-1-yl]phenoxy]azacyclobutane-1-carboxylic acid tert-butyl ester; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)- 3-Ethyl-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-ethyl-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[2, 6-Difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-[(1-methylcyclobutyl)methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole;(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-1,3,4,9 -Tetrahydropyrido[3,4-b]indole; (1S,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(2,2,2-trifluoroethyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-(3,3-dimethoxypropyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl] [1R,3R]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2-fluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; 1-[2,6-difluoro-4-[2-[3-(fluoromethyl)] [1S,3R]-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1S,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-(4-(2-(3-) (fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2-(methanesulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)-3- Hydroxy-2-methylprop-1-one; aziridine-3-yl-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)aziridine-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl] methyl ketone; ((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)aziridine-1-yl)ethoxy)phenyl) -3-Methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)(2-fluorocyclopropyl)methyl ketone; (1R,3R)-1-[2,6-difluoro-4-[(2S)-2-[(3R)-3-methylpyrrolidin-1-yl]propoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [(1R,3R)-1 -[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-phenyl-methyl ketone; (1R,3R)-2-(cyclopropylmethyl)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-phenyl-methyl ketone; [3,4-b]indole; (1R,3R)-1-[4-[1-(2-cyclopropylethyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (1R,3R)-1-[4-(1-allylazacyclobutane-3-yl)oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl] (1R,3R)-1-[4-[1-(cyclobutylmethyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-isopentylazacyclobutane- [3-yl)oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(2-methylbutyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3 R)-1-(2,6-difluoro-4-((1-(pentyl-2-yl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[4-(1-cyclobutylazacyclobutane-3-yl)oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1 ,3,4,9-Tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1-(oxetane-3-yl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-(1-cyclopropylazacyclobutane-3-yl)oxy-2,6-difluoro- [phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]thioalkyl-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro] -4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-isobutyl-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole;(1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2-((R)-2-phenylpropyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4] [-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2-((S)-2-phenylpropyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-(1-propylazacyclobutane-3-yl)oxy-phenyl]-2-isobutyl-3-methyl-1 3,4,9-Tetrahydropyrido[3,4-b]indole; (1R,3R)-2-(2-fluoro-2-methyl-propyl)-1-[4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxyphenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxyphenyl]-3-methyl -2-Methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-(3-fluorocyclobutyl)methyl ketone; (1R,3R)-1-[4-[(2S)-2-[3-(difluoromethyl)azacyclobutane-1-yl] [[propoxy]-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[2-[3-fluoro-3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole] Dolphin; 4-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indol-2-yl]-4-oxobutyronitrile; (1R,3R)-2-(cyclohexylmethyl)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl (1R,3R)-1-[2,6-difluoro-4-[1-[2-(oxetane-3-yl)ethyl]azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-(cyclohexylmethyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [1R,3R]-1-[2-chloro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R]-1-[2-chloro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R] )-1-[2-chloro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; 1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4]indole [(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(oxacyclobutane-3-yl)methyl ketone; [(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(oxacyclobutane-3-yl)methyl ketone; [(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(oxacyclobutane-3-yl)methyl ketone; [Cyclobutan-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(thiocyclobutan-3-yl) ketone; (R)-1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutan-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-3 -Fluoro-2-methylprop-1-one; (1R,3R)-2-(cyclopentylmethyl)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-[(4,4-difluorocyclohexyl)methyl]azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2- (2-Fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole; (S)-1-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyridino[3,4-b]indole-2-yl)-3-fluoro-2-methylprop-1-one; ((1R,3R) )-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)(oxetane-2-yl) methyl ketone; (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)(oxetane-2-yl) methyl ketone; Hydrogen-1H-pyrido[3,4-b]indole; 2-fluoro-1-[(1R,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-2-methyl-prop-1-one; 1-[(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy] [-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-fluoro-2-methyl-prop-1-one; 1-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-(dimethylamino)acetone; (1R,3R) -1-[2,6-difluoro-4-[1-[(1-fluorocyclopropyl)methyl]azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[ [3,4-b]indol-2-yl]-(1-fluorocyclobutyl) ketone; [(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(1-methylcyclopropyl) ketone; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(1-methylcyclopropyl) ketone; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-(1-methylcyclopropyl) ketone; [1-[1-(fluoromethyl)cyclopropyl]methyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [1-[[(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]methyl]cyclopropyl]methanol; 2-fluoro-1- [(1S,3R)-1-[2-fluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methyl-prop-1-one; 2-fluoro-1-[(1R,3R)-1-[2-fluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9- Tetrahydropyrido[3,4-b]indol-2-yl]-2-methyl-prop-1-one; (1S,3R)-1-[2-fluoro-4-[2-[3-(fluoromethyl)azacyclobutan-1-yl]ethoxy]phenyl]-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol; (1R,3R)-1-[2-fluoro-4-[2-[3-(fluoromethyl)azacyclobutan-1-yl]ethoxy]phenyl] 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-yl)-2-fluoro-2-methylprop-1-ol; 3-((1R,3R)-1-(2 ,6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; 2-fluoro-1-[(1S,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3 [,4-b]indol-2-yl]-2-methyl-prop-1-one; (1R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-1,3,4,9-tetrahydropyridino[3,4-b]indol; (1S)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2- (2-Fluoro-2-methyl-propyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; [(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-(1-fluorocyclopropyl)methyl ketone; (1R,3R)-6-chloro-1-(2,6-difluoro-4-((1 -(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-7-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro- 1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl) (1-(((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-yl)methyl)cyclopropyl)methyl) Alcohols; (1S,3S)-6-chloro-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-fluoro-2- (2-Fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-2-[(3-methyloxacyclobutane-3-yl)methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-2-[(3-methyloxacyclobutane-3-yl)methyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole; -Difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-5-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole;(1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-7-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl 2,3,4,9-Tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-5-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-[4- [2-[(3R)-3-(fluoromethyl)pyrrolidone-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole;(1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-5-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b] Indole; (1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-7-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-5-fluoro-2 -(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 2-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-N,N-dimethylacetamide; 3-((1R,3R)-1-( 2,6-Difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (1R,3R)-2-(2-fluoro-2-methyl-propyl)-1-[4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-2-methyl-phenyl]-3-methyl-1, 3,4,9-Tetrahydropyrido[3,4-b]indole; (1R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(2-fluoro-2-methyl-propyl)-3,3-dimethyl-4,9-dihydro-1H-pyrido[3,4-b]indole; (S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl (1R,3R)-2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-[4-[1-[(3,3-difluorocyclobutyl)methyl]azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R, 3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-8-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-8-fluoro-2-(2-fluoro-2) (-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-8-fluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (S)-1-((1R,3R)-1-( 2,6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)prop-2-ol; (R)-1-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido) [3,4-b]indol-2-yl)prop-2-ol; (1R,3R)-1-[4-[2-[3-(chloromethyl)azacyclobutane-1-yl]ethoxy]-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indol; (1R,3R)-1-[3-chloro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl] ]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[3-fluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (2R)-3-[(1R,3R)-1-[2,6] -Difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]propyl-1,2-diol;(1R,3R)-1-[2,6-difluoro-4-[1-[[(1S,2R)-2-fluorocyclopropyl]methyl]azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl- 1,3,4,9-Tetrahydropyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-((S)-3-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (S)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-) (fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1,2-diol; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-(3-fluoro-2,2-dimethyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridine [3,4-b]indole; (R)-2-fluoro-3-((1R,3R)-1-(2-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyridino[3,4-b]indole-2-yl)-2-methylprop-1-ol; (S)-2-fluoro-3-((1R,3R)-1-(2-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyridino[3,4-b]indole-2-yl)-2-methylprop-1-ol; Cyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; (R)-2-fluoro-3-((1R,3R)-1-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methyl Propan-1-ol; (S)-2-fluoro-3-((1R,3R)-1-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl 2-(2,2,2-trifluoroethyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; (2R)-3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-2-methylprop-1,2-diol; (1R,3R)-2-(2- (Fluoro-2-methylpropyl)-1-(3-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3R)-2-(2-fluoro-2-methylpropyl)-1-(3-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-2,3,4,9-tetrahydro -1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,3-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(((1S,2S)-2-fluorocyclopropyl)methyl) Azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 1-[(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]propyl-2-one; 3-[( 1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-dimethyl-prop-1-ol; (1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-ethylsulfonyl-3-methyl-1,3 ,4,9-Tetrahydropyrido[3,4-b]indole; 3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-2,2-difluoroprop-1-ol; 3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane]... [-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-dimethyl-prop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylpropane -1-ol; 1-((1S,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)prop-2-one; (S)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3- (Methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-N,N,2-trimethylpropionamide; (R)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-N,N,2-trimethylpropionamide; (S )-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropionic acid; (R)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3- Methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropionic acid; (1R,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-(fluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol; 3-((1R,3R)-1-(2,6) -Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy-phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol;(1R,3R)-2-(2,2-difluoroethyl)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9- Tetrahydropyrido[3,4-b]indole; (1R,3R)-2-(2,2-difluoroethyl)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1S,3R)-2-(2,2-difluoroethyl)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[1-(3,3-difluorocyclobutyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1] -[(E)-3-fluoroallyl]azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole;(1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-2-(2-(methanesulfonyl)propyl)-2,3,4,9-tetrahydro-1H- Pyrido[3,4-b]indole; (1R,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-vinylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-N,3-dimethyl-1,3,4,9-tetrahydropyrido[ 3,4-b]indole-2-sulfonamide; 3-[(1R,3R)-1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indole-2-yl]-2,2-dimethylpropionitrile; (1R,3R)-1-[4-[1-(3,3-difluoroallyl)azacyclobutane-3-yl]oxy-2,6-difluoro-phenyl] [S]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (S)-2-(((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-yl)methyl)-3,3,3-trifluoropropyl-1- Alcohols; (R)-2-(((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methyl)-3,3,3-trifluoroprop-1-ol; (1R,3R)-2-ethylsulfonyl-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy [1R,3R]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-N,N,3-trimethyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-sulfonamide; (1R,3R)-1-[4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxyphenyl]-3- Methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; 3-[3-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-1-yl]phenoxy]azacyclobutane-1-yl]cyclobutanol; (1R,3R)-1-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl]cyclobutanol]cyclobutanol; (1R,3R)-1-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-((R)-isopropylthionyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)- 3-(3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenoxy)azacyclobutane-1-yl)cyclobutanol; (1R,3R)-1-[2,6-difluoro-4-[1-(5-fluoropentyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3 -Methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[3,5-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,6-difluoro-4-[1-(4-fluorobutyl)azacyclobutane-3-yl]oxy-phenyl] -2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[3,5-difluoro-4-[1-(5-fluoropentyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1R,3R)-1-[2,5-difluoro-4-[1-(3-fluoropropane-2-methyl-propyl)azacyclobutane-3-yl]oxy-phenyl]-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; [3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethylamino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole; 3-[(1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethylamino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-yl]-2,2-difluoroprop-1-ol; (1S, 3R)-2-(2-fluoro-2-methylpropyl)-1-(5-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)pyrazin-2-yl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)-3-methylazacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3 4,9-Tetrahydro-1H-pyrido[3,4-b]indole; 2-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-yl]-5-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-benzyl nitrile; 4-((1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-yl] [-b]indol-1-yl)-1-(3-(3-(fluoromethyl)azacyclobutane-1-yl)propyl)pyridin-2(1H)-one; [4-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indol-1-yl]phenyl]-[1-(3-fluoropropyl)azacyclobutane-3-yl]methyl ketone; (R)-3-((1R,3R)-1-(2,6-difluoro-4-(2 -(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylpropionamide; (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)- 2-Methylpropionic acid; (S)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyridino[3,4-b]indol-2-yl)-2-methylpropionic acid; 3-[1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyridine] [3,4-b]indol-2-yl]-2-methyl-propionic acid; 3-[1-[2,6-difluoro-4-[1-(3-fluoropropyl)azacyclobutane-3-yl]oxy-phenyl]-3-methyl-1,3,4,9-tetrahydropyridino[3,4-b]indol-2-yl]-2-methyl-propionic acid; (1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-fluoro-3-methyl -2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoro-4-( (1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H- Pyrido[3,4-b]indole; 3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-yl)-2,2-difluoroprop-1-ol; 3-((1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy) (1R,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(3,3,3-trifluoropropyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1S,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(3,3,3-trifluoropropyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; (1S,3R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(3,3,3-trifluoropropyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; -Difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-2-(3,3,3-trifluoropropyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole -2-yl)-2,2-difluoroprop-1-ol; 3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoroprop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoroprop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3- 3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; 3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylpropane -1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyridino[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; 3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6- Fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-dimethylpropionic acid; (R)-2-(((1R, 3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methyl)-3,3,3-trifluoroprop-1-ol; (S)-2-(((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-3-methyl-1,3,4 ,9-Tetrahydro-2H-pyrido[3,4-b]indole-2-yl)methyl)-3,3,3-trifluoroprop-1-ol; (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-(2-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)pyrimidin-5-yl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; 3-[(1S,3R)-1-[2,6-difluoro-4-[2-[3- (fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-dimethyl-propionic acid; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-(2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol; (S) -(4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)(1-(3-fluoropropyl)azacyclobutane-3-yl)methanol;(R)-(4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)(1-( 3-Fluoropropyl)azacyclobutane-3-yl)methanol; (1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-2-(2,2-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1S,3S)-1-(2,6-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; -4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2,2-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-cis-(3-(fluoromethyl)cyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9- Tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-trans-(3-(fluoromethyl)cyclobutyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl) (S)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)-2-fluoroprop-1-ol; R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoroprop-1-ol;; (R)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H- Pyrido[3,4-b]indol-2(9H)-yl)-2-(fluoromethyl)prop-1-ol;; (S)-3-((1R,3R)-1-(2,6-difluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-(fluoromethyl)prop-1-ol;; (1R,3R)-1-(2,6-difluoro-4-( 1-(3-fluoropropyl)azacyclobutane-3-yloxy)phenyl)-2-((3-fluorooxocyclobutane-3-yl)methyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole;; (1R,3R)-1-(2,6-difluoro-4-(1-(3-fluoropropyl)azacyclobutane-3-yloxy)phenyl)-6,8-difluoro-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-((1-((1-(fluoromethyl)cyclopropyl)methyl)azacyclobutane-3-yl)oxy)phenyl)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; (1R,3R)-1-(2,6-difluoro-4-(1-(3-fluoropropyl)azacyclobutane-3-yl)phenyl) (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-(1-((1-(3-fluoropropyl)azacyclobutane-3-yl)methyl)-1H-pyrazol-4-yl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; or (1R,3R)-2-(2-fluoro-2-methylpropyl)-1-(1-((1-(3-fluoropropyl)azacyclobutane-3-yl)methyl)-1H-pyrazol-4-yl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole or a pharmaceutical salt thereof or a combination thereof.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having formula (4):

Or stereoisomers, tautomers, or their medicinal salts, wherein:

^Y2 is -( _CH2 );

Ra ^is independently selected from the group consisting of: H, _C1 - _C6 alkyl, _C2 - _C8 alkenyl, propargyl, _C3 - _C6 cycloalkyl and _C3 - _C6 heterocyclic groups, each optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, OH, _OCH3 and _{SO2CH3 ;}

^Rb is independently selected from the group consisting of: H, -O ( _C1 - _C3 alkyl), _C1 - _C6 alkyl, _C2 - _C8 alkenyl and propargyl, each optionally substituted by one or more groups independently selected from the group consisting of: F, Cl _, Br, _I , CN, _-CH2F , _-CHF2 , _-CF3 , _-CH2CF3 , _-CH2CHF2 , _-CH2CH2F , _OH , _OCH3 and _{SO2CH3 ;}

^Rc is H;

^R1 , ^R2 , ^R3 , and ^R4 are independently selected from the group consisting of the following: H, _-CH3 , _-CH2CH3 , -CH( _CH3 ) ₂ , _-CH2CH (CH3 _{) 2} , _-CH2OH , _-CH2OCH3 , -CH2CH2OH _{, -C(CH3)2OH , -CH ( OH} )CH( _CH3 ) ₂ , -C( _{CH3 ) 2CH2OH} , _{-CH2CH2SO2CH3} , -CH2OP _{( O ) (} OH _{)2 , -CH2F , -CHF2 , -CH2NH2 , -CH2NHSO2CH3} , _-CH2NHCH3 , _-CH2N ( _{CH3 ) 2} , _-CF3 , _-CH2 CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN and -CH ₂ CN;

^R5 is selected from the group consisting of: _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, -(C1- _C6 alkyldiyl)-( _C3 -C9 cycloalkyl), -( _C1 - _C6 alkyldiyl)-( _{C3 - C9 heterocyclic} ), C(O) ^NRa , _SO2Ra and ^{SO2NRa ,} each optionally substituted with one or more of a halogen, _CN , ^ORa , N( ^Ra ) ₂ , _C1 - _C9 alkyl, _C3 - _C9 cycloalkyl, _C3 - _C9 heterocyclic, _C6 - _C9 aryl, _C6 - _C9 heteroaryl, C(O) ^Rb , ^C (O) ^NRa , _SO2Ra and ^SO2NRa _;

^R6 is either F or Cl;

m is 0, 1, 2, 3 or 4;

Where R ⁷ is F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F , -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH _{2CHF 2} , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, oxetane, azirane, 1-methylazirane-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirane-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholine;

n is 0, 1, or 2; and

^R7 is a halogen on its own.

The variables ^R1 , ^R2 , ^R3 , ^R4 , ^R5 , ^Ra , ^Rb , ^Rc , m, n and ^Y2 are as defined herein for the compounds of equation (3).

In one case, the compound of formula (4) includes formula (4a):

In another case, the compounds of formula (4) include those of formula (4b):

In yet another case, the compounds of formula (4) include those of formula (4c):

In one case of compounds of formulas (4a)-(4c), ^R7 is F. In one case of compounds of formulas (4a)-(4c), ^R1 and ^R2 are H. In one case of compounds of formulas (4a)-(4c), ^R3 is H and ^R4 is _-CH3 . In one case of compounds of formulas (4a)-(4c), ^R5 is a _C1 - _C6 fluoroalkyl group. In one case of compounds of formulas (4a)-(4c), m is 0.

On the other hand, endocrine therapy includes compounds having the following formula:

N-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylpropane-1-ol; (S)-3-(( 1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (R)-2-fluoro-3-((1R,3R)-1-(2-fluoro-4-((-1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; (S)-2-fluoro- 3-((1R,3R)-1-(2-fluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; (R)-2-fluoro-3-((1R,3R)-1-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; (S)-2-fluoro-3-((1R,3R)-1-(2-fluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; R)-1-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; 3,5-difluoro-N-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethyl)-4-((1R,3R)-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)aniline; N-(3,5-difluoro-4-((1R,3R)-3-methyl-2-yl) (2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; 1-(3-fluoropropyl)-N-[4-[(1R,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]azacyclobutane-3-amine; N-[3,5-difluoro-4-[(1R,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]- 1-(3-fluoropropyl)azacyclobutane-3-amine; 1-(3-fluoropropyl)-N-[4-[(1S,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]azacyclobutane-3-amine; N-[3,5-difluoro-4-[(1S,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]-1-(3-fluoropropyl)azacyclobutane-3-amine; 3-((1R,3R)-1-(2,6-difluoro-4-((2-(3- (fluoromethyl)azacyclobutane-1-yl)ethyl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; 3,5-difluoro-N-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethyl]-4-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]aniline; 3-fluoro-N-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethyl]-4-[(1R, 3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]aniline; N-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethyl]-4-[(1R,3R)-2-(2-fluoro-2-methyl-propyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]aniline; N-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethyl]-4-[(1R,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]aniline; [3,4-b]indol-1-yl]aniline; 3,5-difluoro-N-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethyl]-4-[(1R,3R)-3-methyl-2-methylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]aniline; 2-fluoro-3-((1R,3R)-1-(2-fluoro-4-((2-(3-(fluoromethyl)azacyclobutane-1-yl)ethyl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; 2-fluoro -3-((1R,3R)-1-(4-((2-(3-(fluoromethyl)azacyclobutane-1-yl)ethyl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-methylprop-1-ol; 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azacyclobutane-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoro-prop-1-ol; (R)-3-((1R,3R)-1- (2,6-Difluoro-4-((2-(3-(fluoromethyl)azacyclobutane-1-yl)ethyl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (S)-3-((1R,3R)-1-(2,6-difluoro-4-((2-(3-(fluoromethyl)azacyclobutane-1-yl)ethyl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (2R)-3- [(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azacyclobutane-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methyl-propionic acid; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoroprop-1-ol; 3-((1S,3S)-1-(2, 6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoroprop-1-ol; (2S)-3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azacyclobutane-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-methyl-propionic acid; N-(3,5-difluoro-4-((1R,3R)-6-fluoro- 3-Methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3,5-difluoro-4-((1S,3S)-6-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane) Butane-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-dimethylpropionic acid; N-(3,5-difluoro-4-((1R,3R)-6-fluoro-3-methyl-2-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3,5-difluoro-4-((1S,3S)-6-fluoro-3-methyl-2-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; Pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(4-((1R,3R)-2-(2,2-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(4-((1S,3S)-2-(2,2-difluoroethyl)-6-fluoro-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluoro N-(3,5-difluoro-4-((1R,3R)-7-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azon ... (S)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; (R)-3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indole-2 (9H)-yl)-2-fluoro-2-methylprop-1-ol; (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; (S)-3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[ [3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; N-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)-N-methylazacyclobutane-3-amine; (R)-N-(4-(2-(2,2-difluoroethyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)-1-(3- (3-fluoropropyl)azacyclobutane-3-amine; (S)-N-(4-(2-(2,2-difluoroethyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorophenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3,5-difluoro-4-((1R,3R)-5-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3 ,5-Difluoro-4-((1S,3S)-5-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3,5-difluoro-4-((1S,3S)-8-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; N-(3,5-difluoro-4-((1R ,3R)-8-fluoro-3-methyl-2-(2,2,2-trifluoroethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)-1-(3-fluoropropyl)azacyclobutane-3-amine; (S)-3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; (R)-3-((1R,3R)-1- (2,6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; (S)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; (R)-3-( (1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-methylprop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; 3- ((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-5-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoropropane-1-ol; (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-(hydroxymethyl)propionitrile; (S (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluoro-2-(hydroxymethyl)propionitrile; (R)-3-(1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3,3-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; (S)-3-( 1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-3,3-dimethyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; 3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-8-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; 3-((1R,3R)-1-( 2,6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-8-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; 3-((1S,3S)-1-(2, 6-Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-7-fluoro-3-methyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluoroprop-1-ol; N-[4-[(1R,3R)-2-(2,2-difluoroethyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]-3,5-difluoro-phenyl]-1-(3-fluoropropyl)azacyclobutane-3-amine; (R)-3-((1R,3R)-1-(2,6-difluoro-4-((1-( 3-Fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (S)-3-((1S,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; (S)-3-((1R,3R)-1-(2,6- Difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol; or (R)-3-((1R,3S)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-fluoro-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluoro-2-methylprop-1-ol or a pharmaceutical salt thereof or a combination thereof.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having the following formula:

Or its medicinal salt.

On the other hand, endocrine therapy includes compounds having the following formula:

This includes its stereoisomers or its medicinal salts.

On the other hand, endocrine therapy includes compounds listed in U.S. Patent Application No. 20170129855, such as those in Table 1 therein, the entire contents of which are incorporated herein by reference for all purposes.

On one hand, endocrine therapy includes compounds of formula (5):

Or stereoisomers, tautomers, or their medicinal salts, wherein:

^Y1 is CR ^b or N;

^Y2 is -( _CH2 )-, -( _CH2CH2 )- _, or NR ^a ;

^Y3 is NR ^a or C(R ^b ) ₂ ;

One of ^Y1 , ^Y2 , and ^Y3 is N or ^NRa ;

^Ra and ^Rc are independently selected from H, _C1 - _C6 alkyl, _C1 - _C6 fluoroalkyl, allyl, propargyl, _C3 - _C6 cycloalkyl and _C3 - _C6 heterocyclic groups, which are optionally substituted by one or more groups independently selected from the following: F, Cl, Br, I, CN, OH, _{OCH3 and SO2CH3} ;

^Rb is independently selected from H, -O ( _C1 - _C3 alkyl), _C1 - _C6 alkyl, _C1 - _C6 fluoroalkyl, allyl, propargyl, _C3 - _C6 cycloalkyl and _C3 - _C6 heterocyclic, and is optionally substituted by one or more groups independently selected from: F, Cl, Br, I, CN, OH, _OCH3 and _{SO2CH3 ;}

At least _one of ^Ra and ^Rb is _-CH₂Cl , _{-CH₂F , -CHF₂ , -CF₃ ,} -CH₂CH₂F _{, -CH₂CHF₂ , -CH₂CF₃ , CH₂CH₂Cl , CH₂CH₂CH₂F , CH₂CH₂CHF₂ , CH₂CH₂CF₃ , or CH₂CH₂CH₂Cl ;}

^X1 , ^X2 , ^X3 and ^X4 are independently selected from CH, ^CR5 and N; wherein none, one or two of ^X1 , ^X2 , ^X3 and ^X4 are N;

Z is selected from O, S, S(O), S(O) ₂ , C(＝O), CH(OH), _C1 - _C6 alkyldiyl, CH(OH)-( _C1 - _C6 alkyldiyl), _C1 - _C6 fluoroalkyldiyl, ^NRc , ^NRc- ( _C1 - _C6 alkyldiyl), ^NRc- ( _C1 - _C6 fluoroalkyldiyl), O-( _C1 - _C6 alkyldiyl) and O-( _C1 - _C6 fluoroalkyldiyl);

R ¹ and R ² are independently selected from H, F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ Cl, -CH ₂ F, -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ ,-CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirane, 1-methylazirane-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirane-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone, and morpholino;

^R3 is selected from _C3 - _C20 cycloalkyl, _C2 - _C20 heterocyclic, _C6 - _C20 aryl, _C1 - _C20 heteroaryl, -( _C1 - _C6 alkyldiyl)-(C3- _C20 cycloalkyl), -( _C1 -C6 alkyldiyl)-( _C2 - _C20 heterocyclic), - _{(C1 - C6} alkyldiyl)-( _C6 - _{C20 aryl} ), and -( _C1 - _C6 alkyldiyl)-( _C1 - _C20 heteroaryl);

Or ^R3 forms a 3-6 membered spirocarbocyclic or heterocyclic group;

R ⁴ and R ⁵ are independently selected from F, Cl, Br, I, -CN, -CH ₃ , -CH ₂ CH ₃ , -CH(CH ₃ ) ₂ , -CH ₂ CH(CH ₃ ) ₂ , -CH ₂ OH, -CH ₂ OCH ₃ , -CH ₂ CH ₂ OH, -C(CH ₃ ) ₂ OH, -CH(OH)CH(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CH ₂ OH, -CH ₂ CH ₂ SO ₂ CH ₃ , -CH ₂ OP(O)(OH) ₂ , -CH ₂ F , -CHF ₂ , -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CF ₃ , -CH ₂ CF ₃ , -CH ₂ CHF ₂ , -CH(CH ₃ )CN, -C(CH ₃ ) ₂ CN, -CH ₂ CN, -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CONHCH ₂ CH ₃ , -CONHCH(CH ₃ ) ₂ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ , -N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone, and morpholine; and

m is selected from 0, 1, 2, 3, and 4;

The alkyl diel, fluoroalkyl diel, aryl, carbocyclic, heterocyclic, and heteroaryl groups are optionally substituted by one or more groups independently selected from the following: F, Cl, _Br , I, _-CN , _-CH3 , -CH2CH3, -CH( _CH3 ) ₂ , -CH2CH(CH3 _{) 2 , -CH2OH} , _-CH2OCH3 , -CH2CH2OH _, -C( _CH3 ) _2OH , -CH _{( OH} )CH(CH3) _{2 ,} -C( _CH3 ) _2CH2OH , -CH2CH2SO2CH3, _-CH2OP ( _O )(OH) _{2 , -CH2F} , _-CHF2 , _{-CF3 , -CH2CF3 , -CH2CHF2} , _-CH ( _CH3 ) _CN , -C ₍ CH ₃ ) ₂ CN, -CH ₂ CN, -CH ₂ NH ₂ , -CH ₂ NHSO ₂ CH ₃ , -CH ₂ NHCH ₃ , -CH ₂ N(CH ₃ ) ₂ , -CO ₂ H, -COCH ₃ , -CO ₂ CH ₃ , -CO ₂ C(CH ₃ ) ₃ , -COCH(OH)CH ₃ , -CONH ₂ , -CONHCH ₃ , -CON(CH ₃ ) ₂ , -C(CH ₃ ) ₂ CONH ₂ , -NH ₂ , -NHCH ₃ , -N(CH ₃ ) ₂ , -NHCOCH ₃ , -N(CH ₃ )COCH ₃ , -NHS(O) ₂ CH ₃ , -N(CH ₃ )C(CH ₃ ) ₂ CONH ₂ ,-N(CH ₃ )CH ₂ CH ₂ S(O) ₂ CH ₃ , -NO ₂ , =O, -OH, -OCH ₃ , -OCH ₂ CH ₃ , -OCH ₂ CH ₂ OCH ₃ , -OCH ₂ CH ₂ OH, -OCH ₂ CH ₂ N(CH ₃ ) ₂ , -OP(O)(OH) ₂ , -S(O) ₂ N(CH ₃ ) ₂ , -SCH ₃ , -S(O) ₂ CH ₃ , -S(O) ₃ H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone, and morpholino.

In one case of the compound of formula (5), ^Y1 is N and ^Y3 is C ₍ ^Rb ) ₂ . In one case of the compound of formula (5), ^Y2 is -( _CH2 )-. In one case of the compound of formula (5), ^Y2 is -( _CH2CH2 )-. In one case of the compound of formula (5), ^Y3 is ^NRa and ^Ra is _-CH2Cl , _-CH2F , _-CHF2 , _-CF3 , _{-CH2CH2F , -CH2CHF2} or _{-CH2CF3 .} In one case of the compound of formula (5), ^X1 , ^X2 , ^X3 and ^X4 are independently selected ^from CH and _CR5 . In one case of the compound of formula (5), one of ^X1 , ^X2 , ^X3 and ^X4 is N. In one case of a compound of formula (5), Z is O or O-( _C1 -C6 alkyldiyl). In one case of a compound of formula (5), ^R1 and ^R2 are H. In one case of a compound of formula (5), ^R3 is _C6 - _C20 aryl. In one case of a compound of formula (5), _C6 - _C20 aryl is phenyl. In one case of a compound of formula (5), the phenyl is substituted with one or more F. In one case of a compound of formula (5). In one case of a compound of formula (5), ^R4 is OH and m is 1. In one case of a compound of formula (5), ^R5 is F and n is 2. In one case of a compound of formula (5), ^R5 is H. In one case of a compound of formula (5), n is 0.

In one aspect, endocrine therapy includes compounds having the following formula: (1R,2S)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthyl-6-ol; (1S,2R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthyl-6-ol; (1S,2R)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(4-fluorophenyl)tetrahydronaphthyl-6-ol; (1R,2R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthyl-6-ol; (1R,2R)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthyl-6-ol; (1S,2S)-1-[2,6-difluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthyl-6-ol; Fluoro-4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-phenyl-tetrahydronaphthalene-6-ol; (1R,2S)-1-[4-[2-[3-(fluoromethyl)azacyclobutane-1-yl]ethoxy]phenyl]-2-(4-fluorophenyl)tetrahydronaphthalene-6-ol; (5R,6R)-5-(4-(2-(3-(fluoromethyl)azacyclobutane) (5S,6S)-6-(4,4-difluorocyclohexyl)-5-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6S)-5-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6S)-5-(4-(2- (3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydronaphthalene-2-ol; (5R,6R)-6-(4,4-difluorocyclohexyl)-5-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol; (5R (5R,6S)-5-(4-(2-(3-(fluoromethyl)pyrrolidin-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalene-2-ol; (5R,6S)-5-(4-(2-(3-(chloromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalene-2-ol; (5S,6R)-5-(4- (2-(3-(chloromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-(2-(3-(fluoromethyl)pyrrolidone-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-(2-(3-(fluoromethyl)pyrrolidone-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-(2-(3-(fluoromethyl)pyrrolidone-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-(2-(3-(difluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalene-2-ol; (5R,6S)-5-(4-(2-(3-(difluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalene-2-ol; (5R,6S)-5-(4-(2-(3-( (5R,6S)-5-(4-(2-(3-(difluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphth-2-ol; (5R,6R)-5-(2-fluoro-4-yl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphth-2-ol; (5R,6R)-5-(2-fluoro-4-yl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphth-2-ol; -(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6S)-5-(2-fluoro-4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (S)-1'-(4-(2-(3-) (fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3',4'-dihydro-rH-spiro[cyclopentane-1,2'-naphthalene]-6'-ol; (R)-1'-(4-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)phenyl)-3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-naphthalene]-6'-ol; (5R,6S)-5 -(4-((S)-2-((R)-3-(fluoromethyl)pyrrolidin-1-yl)propoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-((S)-2-((R)-3-(fluoromethyl)pyrrolidin-1-yl)propoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5R,6 (5S,6R)-5-(4-(((R)-1-((R)-3-(fluoromethyl)pyrrolidin-1-yl)prop-2-yl)oxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-(((R)-1-((R)-3-(fluoromethyl)pyrrolidin-1-yl)prop-2-yl)oxy)phenyl)-6-phenyl-5,6,7 ,8-Tetrahydronaphthyl-2-ol; (5S,6S)-5-(6-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)pyridin-3-yl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5R,6R)-5-(6-(2-(3-(fluoromethyl)azacyclobutane-1-yl)ethoxy)pyridin-3-yl)-6-phenyl-5,6,7 8-Tetrahydronaphthyl-2-ol; (5S,6R)-5-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; (5R,6S)-5-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)oxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol) ; (5S,6R)-5-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol; or (5R,6S)-5-(4-((1-(3-fluoropropyl)azacyclobutane-3-yl)amino)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthyl-2-ol, or pharmaceutical salts or combinations thereof.

B. Non-endocrine anticancer therapy

In some cases of any of the foregoing methods, anticancer therapies other than endocrine therapy may be administered to the individual. Exemplary anticancer therapies, in addition to endocrine therapy, include, but are not limited to, targets of mammalian rapamycin (mTOR) inhibitors such as sirolimus (also known as rapamycin), tamsurolimus (also known as CCI-779 or), everolimus (also known as RAD001 or), deforolimus (also known as AP-23573, MK-8669 or 42-(dimethylphosphono)rapamycin), OSI-027, AZD8055, and INK128; phosphatidylinositol 3-kinase (PI3K) inhibitors such as ederalipix (also known as GS-1101 or CAL-101), BKM120, and pelifosine (also known as KRX-0401); and dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitors such as XL76. 5. GDC-0980, BEZ235 (also known as NVP-BEZ235), BGT226, GSK2126458, PF-04691502 and PF-05212384 (also known as PKI-587); and cyclin-dependent protein kinase (CDK) 4/6 inhibitors such as pompicillin, palbociclib, ribociclib, trilacidine (G1T28); anthracyclines such as daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pentorubicin; taxanes, including paclitaxel and docetaxel; podophyllotoxin; gemcitabine; 5-fluorouracil (5-FU); cyclophosphamide; platinum analogs such as cisplatin and carboplatin; vinorelbine; capecitabine; ixaprone; elebulin; and their pharmaceutical salts, acids or derivatives thereof; and combinations thereof. In some cases, the anticancer agents described herein may be combined with the endocrine therapies described herein for use in the methods provided herein. For example, in one embodiment, a CDK4/6 inhibitor such as palbociclib may be administered in combination with an endocrine therapy described herein (e.g., SERD described herein). For example, in some cases, anticancer therapies other than endocrine therapy include chemotherapy agents and PI3K inhibitors.

Non-endocrine therapies may include administration of AKT inhibitors (e.g., Ipatasertib), angiogenesis agents (e.g., Avastin), BCL-2 inhibitors (e.g., Venetoclax), HDAC inhibitors, AURK inhibitors, or cancer immunotherapy agents (e.g., anti-PD1/PDL1 drugs, including, for example, atezolizumab, pembrolizumab, nivolumab, acitumab, durvalumab, and pildizumab).

C. Combination therapy

It should be understood that the methods described herein can be used with all the compounds described herein, whether as a monotherapy or in combination, including, for example, dual, triple, or quadruple therapies. In one case, the compounds described herein have been administered to the tested patient prior to surgery. In another case, the compounds described herein have been administered to the tested patient after surgery. In yet another case, the compounds described herein have been administered in 1L, 2L, 3L, or more therapies. In certain cases, the patients described herein may have received prior treatment with CDK4/6 inhibitors (such as, for example, palbociclib, ribociclib, or buprocillin) before, during, or after treatment with the compounds described herein.

In some cases of any of the foregoing methods, a combination therapy comprising endocrine therapy and one or more other anticancer agents may be administered to an individual. Such combination therapies encompass both combined administration (where two or more therapeutic agents are included in the same or separate formulation) and single administration. In the case of single administration, the administration of the endocrine therapy described herein may be performed before, simultaneously with, and/or after the administration of additional therapeutic agents or drugs.

V. Compositions and pharmaceutical preparations

Therapeutic formulations using the therapeutic agents described in the methods and compositions provided herein, including the anticancer agents or endocrine therapies described herein, are prepared by mixing a therapeutic agent of desired purity with an optional pharmaceutical carrier, excipient, or stabilizer in the form of a lyophilized formulation or aqueous solution. For general information on formulations, see, for example, Gilman et al. (eds.), The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 22nd ed., Mack Publishing Co., Pennsylvania, 2012; Avis et al. (eds.), Pharmaceutical Dosage Forms: Parenteral Medications Dekker, New York, 1993; Li eberman et al. (Eds.), Pharmaceutical DosageForms: Tablets Dekker, New York, 1990; Lieberman et al. (Eds.), Pharmaceutical DosageForms: Disperse Systems Dekker, New York, 1990; and Walters (eds) Dermatological and Transdermal Formulations (Drugs and the Pharmaceutical Sciences), Vol 119, Marcel Dekker, 2002.

Acceptable carriers, excipients, or stabilizers are non-toxic to the receptor at the dosage and concentration used, including buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethyl diammonium chloride; benzalkonium chloride; benzyl chloride; phenol, butanol, or benzyl alcohol; alkyl esters of p-hydroxybenzoate, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residuals). (Based on) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc protein complexes); and/or nonionic surfactants, such as TWEEN ^™ , PLURONICS ^™ , or polyethylene glycol (PEG).

The formulations described herein may also contain more than one active compound, preferably those with complementary activities that do not adversely affect each other. The type and effective amount of such drugs depend, for example, on the amount and type of the therapeutic agent described herein present in the formulation and on individual clinical parameters.

The active ingredient can be encapsulated in microcapsules (e.g., hydroxymethyl cellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared by, for example, cohesive drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or coarse drop emulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. ed. 1980.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include a semi-permeable matrix of a solid hydrophobic polymer containing a therapeutic agent, which is in the form of a molded article, such as a membrane or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(hydroxyethyl 2-methacrylate) or poly(vinyl alcohol)), polylactide (US Patent No. 3,773,919), copolymers of L-glutamic acid and γ-ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT ^™ (injectable microspheres composed of a lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.

Preparations intended for internal administration must be sterile. This can be easily achieved through filtration using sterile filter membranes.

VI. Products and Reagent Kits

On the other hand, this article provides a kit or article containing materials useful for the treatment, diagnosis and/or monitoring of an individual.

In some cases, such diagnostic kits include one or more reagents for identifying individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer) who may benefit from treatment including endocrine therapies as described herein, by determining an ER pathway activity score or E2 induction score, as described herein, from a sample (e.g., a tissue sample, such as a tumor tissue sample, such as an FFPE, FF, archived, fresh, or frozen tumor tissue sample). In some cases, the kit further includes one or more reagents for determining an ER pathway activity score or E2 induction score from a sample.

Optionally, the kit may further include instructions to select a therapy (such as endocrine therapy) for treating breast cancer provided herein if the ER pathway activity score or E2 induction score determined from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) is at or above a reference ER pathway activity score or reference E2 induction score. In another case, the instructions state that if the ER pathway activity score or E2 induction score determined from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) is below a reference ER pathway activity score or reference E2 induction score, the kit should be used to select an anticancer therapy other than endocrine therapy.

In other cases, the product or kit may include instructions for using the kit to monitor and/or assess the response of an individual with breast cancer to endocrine therapy as described herein.

On the one hand, a kit comprising multiple nucleic acids is provided. The multiple nucleic acids are at least 5 nucleotides in length and have at least 95%, 98%, 99%, or 100% identity with a 5-nucleotide continuous sequence within at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 4; or at least five genes listed in Table 3 and at least five genes listed in Table 6, or a sequence complementary to the 5-nucleotide continuous sequence has 95%, 98%, 99%, or 100% identity.

In one embodiment, the multiple nucleic acids are ligated to a solid support. In another embodiment, the multiple nucleic acids contain a detectable marker. In another embodiment, the multiple nucleic acids exhibit at least 95%, 98%, 99%, or 100% identity with five consecutive nucleotide sequences within at least five genes listed in Table 1, Table 2, or Table 3, which is greater than the standard control. In another embodiment, the multiple nucleic acids exhibit at least 95%, 98%, 99%, or 100% identity with five consecutive nucleotide sequences within at least five genes listed in Table 4, Table 5, or Table 6, which is less than the standard control. In yet another embodiment, the multiple nucleic acids exhibit at least 95%, 98%, 99%, or 100% identity with five consecutive nucleotide sequences within all genes listed in Table 1 and all genes listed in Table 4. In the embodiments, the multiple nucleic acids have at least 95%, 98%, 99%, or 100% identity with the five-nucleotide continuous sequences of all genes listed in Table 2 and all genes listed in Table 5. In the embodiments, the multiple nucleic acids have at least 95%, 98%, 99%, or 100% identity with the five-nucleotide continuous sequences of all genes listed in Table 3 and all genes listed in Table 6. In the embodiments, the multiple nucleic acids have at least 95%, 98%, 99%, or 100% identity with the five-nucleotide continuous sequences of all genes listed in Table 1 and all genes listed in Table 4, excluding other genes. In the embodiments, the multiple nucleic acids have at least 95%, 98%, 99%, or 100% identity with the five-nucleotide continuous sequences of all genes listed in Table 2 and all genes listed in Table 5, excluding other genes. In the embodiments, the multiple nucleic acids have at least 95%, 98%, 99%, or 100% identity with five consecutive nucleotide sequences of all genes listed in Table 3 and all genes listed in Table 6, excluding other genes of the subject.

In another embodiment, the plurality of nucleic acids have at least 95%, 98%, 99%, or 100% identity with a continuous nucleotide sequence comprising at least 10, 20, 25, 50, 75, 100, 150, or 200 nucleotides.

This article also provides an article comprising an endocrine therapy as described herein, packaged together in a pharmaceutical carrier, and a packaging insert indicating an endocrine therapy for treating an individual with breast cancer, as described herein, based on an ER pathway activity score or E2 induction score determined from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample).

The article may include, for example, a container and markings or packaging inserts on or associated with said container. Suitable containers include, for example, bottles, vials, syringes, etc. Containers may be formed from a variety of materials, such as glass or plastic. The container contains or contains a composition, which includes a cancer drug as an active agent, and may have a sterile inlet (e.g., the container may be an intravenous solution bag or a vial with a stopper that can be punctured by a hypodermic needle).

The article may further include a second container comprising pharmaceutical dilution buffers, such as bactericidal water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or glucose solution. The article may further include other materials required from a commercial and user perspective, including additional buffers, diluents, filters, needles, and syringes.

The kits or articles described herein may take many forms. In one case, the kit or article includes a container, a label on the container, and a composition contained within the container, wherein the composition comprises one or more polynucleotides that hybridize under stringent conditions to complementary sequences of genes listed herein (e.g., a group of genes listed in any of Tables 1-6), and the label on the container indicates that the composition can be used to assess the presence of a group of genes listed herein (e.g., a group of genes listed in any of Tables 1-6) in a sample, and wherein the kit includes instructions for using polynucleotides to assess the presence of RNA or DNA of genes in a particular sample type.

For oligonucleotide-based products or kits, the product or kit may include, for example: (1) an oligonucleotide, such as a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a protein, or (2) a pair of primers for amplifying the nucleic acid molecule. The product or kit may also include, for example, buffers, preservatives, or protein stabilizers. The product or kit may further include components required for detecting the detectable label (e.g., an enzyme or substrate). The product or kit may also contain a control sample or a series of control samples that can be measured and compared with the test sample. Each component of the product or kit may be packaged in a separate container, and all the various containers, along with instructions for interpreting the results of assays performed using the kit, may be packaged in a separate package.

The products described herein also include information, for example, in the form of a packaging insert, indicating that the composition is intended for the treatment of breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS, and/or metastatic or locally advanced breast cancer, as described herein, based on an ER pathway activity score or E2 induction score determined from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). The insert or label may be in any form, such as paper or on electronic media such as magnetic recording media (e.g., floppy disks), CD-ROMs, Universal Serial Bus (USB) flash drives. The label or insert may also include additional information regarding the pharmaceutical composition and dosage form found in the kit or product.

VII. Examples

The following are examples of the methods and compositions provided herein. It should be understood that various other embodiments may be practiced given the general description provided above.

Example 1. Identification of ER pathway activity characteristics

To assess the relationship between gene expression levels and estrogen receptor (ER) pathway activity in breast cancer cell lines and breast cancer xenograft mouse models in order to identify potential biomarkers for predictive purposes.

Characterization of ER pathway activity from in vitro sources. To obtain transcriptional characterization of ER pathway activity, RNA sequencing was performed on seven breast cancer cell lines after treatment with DMSO or 1 μM estradiol (E2) for 24 hours. Briefly, RNA libraries of the cell lines were constructed using RNA sample preparation kits according to the manufacturer's protocols. Each cell line in the library was sequenced in 1–4 lanes using HiSeq 2000. RNA sequencing (RNA-seq) data were analyzed in BioConductor (Huber et al., Nature Methods. 112:115-21, 2015) using HTSeqGenie (R package version 3.14.0), as follows: reads were trimmed to 75 base pairs (bp), quality screening and rRNA/adaptor contamination were performed, and alignment with the reference genome GRCh38 was performed using GSNAP (Wu et al., Bioinforma Octf Engl. 26:873-81, 2010). Gene expression was quantified as reads per kilobase per exon model per million mapped reads (nRPKM) normalized by a quantization factor, defined as the number of reads aligned to genes in the sample / (total number of uniquely mapped reads in the sample x gene length x quantization factor). Genes without gene symbols and genes with uncertain functions (LOC and Corf symbols) were excluded.

Compared to DMSO, E2 significantly induced 233 to 1,390 genes in a single cell line (fold change ≥2, p ≤0.05) (Figure 1A), while E2 significantly suppressed 365 to 1,251 genes in a single cell line (fold change ≤0.5, p ≤0.05) (Figure 1B). To capture the core set of ER-responsive genes that best reflect ER pathway activity across all heterogeneous tumors and are therefore broadly sensitive to ER perturbations, the selected genes were those that were significantly and consistently induced or suppressed by E2 in at least six of the seven cell lines. Furthermore, compared to 25 ER IHC- breast cell lines, higher expression of E2-induced genes was required in 12 ER IHC+ breast cell lines (one-sided t-test p <0.05). To compare genes across a wider range of ER+ and ER- mammary cell lines, RNA sequencing data from 37 mammary cell lines, as described by Klijn et al. in Nat Biotech 2015, were performed and deposited in the European Genome-Phenomenology Archive (http://www.ebi.ac.uk/ega/) with accession number EGAS00001000610. This data processing was identical to that used for RNA-seq data from seven mammary cell lines (previous section). This resulted in the identification of 28 E2-inducing genes and 19 E2-repressing genes.

To summarize the core set of E2-inducing and E2-repressing genes for patient data, RNA-seq data from 939 breast tumors from The Cancer Genome Atlas (TCGA) were examined, including 726 ER+ (via IHC) and 213 ER- breast tumors. In short, the RNA-seq data were downloaded from the National Cancer Institute Genome Data Sharing website (https://gdc.cancer.gov) and analyzed using HTSeqGenie in BioConductor as follows: First, reads with low nucleotide quality (70% of bases having a quality <23) or rRNA and adaptor contamination were removed. Then, the passed reads were aligned to the reference genome GRCh38 using GSNAP. Alignments reported as “uniquely mapped” by GSNAP were used for subsequent analyses. The raw counts were converted to counts per million (cpm), low-expression genes were screened for (e.g., cpm < 0.25 in over 90% of samples), normalized using TMM normalization in the edgeR package, and finally voom was transformed using the limma package in R. ER IHC was available for 84% of tumors, and PAM50 subtype markers derived from RNA-seq were assigned as previously described (Daemen et al., Breast Cancer Research. 20:8, 2018). Genes with low average expression in all 726 ER+ (via IHC) breast tumors were discarded (average expression in the 15th percentile).

Compared to ER- tumors, the expression of characteristic genes was required in ER+ TCGA tumors, and higher expression of E2-inducing genes was required in ER+ tumors (one-sided t-test p<0.05). This led to a further refinement of the signature into 41 gene signatures consisting of 23 E2-inducing genes and 18 E2-repressing genes, as shown in Table 7 below (see Figure 1C).

Table 7: ER repressor genes

To assess the ER activity profile of a large patient population, density curves for three scores were derived using TCGA RNA-seq data from 939 treatment-naïve primary breast tumors. The E2 induction score was defined as the mean z-score expression of 23 E2-inducible genes (Figure 1D); the E2 inhibition score was defined as the mean z-score expression of 18 E2-inhibiting genes (Figure 1E); and the ER pathway activity score was defined as the difference between the E2 induction and E2 inhibition scores (Figure 1F). Genes identified as ER-regulated and included in the characteristics, whether E2-inducible or E2-inhibited, were expressed at low levels in ER-/basal tumors; therefore, the expected expression of E2-inhibiting genes in ER- tumors is not necessarily higher than in ER+ tumors.

In vivo validation of ER pathway activity characteristics. The HCI-013PDX mammary model was treated with a mediator or different doses of compound A, a selective estrogen receptor degrader (SERD), (0.1 mg/kg, 1 mg/kg, or 10 mg/kg), in groups of four animals (Figure 2A). Samples were collected 8 hours after the last administration, and the expression of 23 E2-inducing genes, 18 E2-repressing genes, and housekeeping genes was measured. Data were processed using software. Expression data were normalized to housekeeping genes GUSB, PPIA, and UBC. Three genes (GRM-4, FMN1, and TP52INP2) that did not meet quality control criteria were excluded. In this study, two E2-inducing genes, AMZ1 and CT62, which were lowly expressed in multiple tumors (mean housekeeping normalized expression was in the 10th percentile of expressed genes) (Figure 2B), and two E2-repressing genes, EGLN3 and SEMA3A, were also excluded.

The effect of compound A treatment on ER pathway activity in the HCI-013PDX model was evaluated based on 20 E2-inducing genes and 14 E2-repressing genes. The fold change in expression of each gene after compound A exposure relative to the mean expression of that gene in four vector-treated animals was calculated. The E2 induction score was calculated as the mean log _10- fold change in expression of the 20 E2-inducing genes. The E2 inhibition score was calculated as the mean log _10- fold change in expression of the 14 E2-repressing genes. The overall score for ER pathway activity was calculated as the difference between the E2 induction and E2 inhibition scores (Figure 2C). These three scores show a dose-response effect, and the inhibitory effect on the ER pathway increases with increasing dose (0.1 mg/kg to 1 mg/kg to 10 mg/kg).

HCI-013 and HCI-011PDX mammary models were treated with various doses of endocrine agents (including compounds A, B, D, or F) (four animals per treatment group). Tumor samples were collected 8 hours after the last administration, and the expression of 23 E2-inducing genes, 18 E2-repressing genes, and housekeeping genes was measured using assays. Genes with low expression or that did not meet quality control criteria were removed from the analysis, as described above. For the data shown in Figures 2D-2F, expression data were normalized to housekeeping genes GUSB, SDHA, and UBC. One gene (FMN1) that did not meet quality control criteria was excluded. In this study, one E2-inducing gene, AMZ1, and four E2-repressing genes, EGLN3, GRM4, SEMA3A, and TP53INP2, which were lowly expressed in multiple tumors (mean housekeeping normalized expression was in the 10th percentile of expressed genes) (Figure 2E), were also excluded. For Figures 2G-2I, expression data were normalized to housekeeping genes GUSB, PPIA, and UBC. Two genes (CXCL12 and TP52INP2) that did not meet quality control criteria were excluded. In this study, two E2-inducing genes, FMN1 and CT62, which were lowly expressed in multiple tumors (mean housekeeping normalized expression was in the 10th percentile of expressed genes) (Fig. 2B), and three E2-repressing genes, GRM4, IL1R1, and SSPO, were also excluded. Gene expression analysis of HCI-013 and HCI-011 tumors revealed regulation of ER target gene expression: treatment with this compound steadily reduced the expression of 21 E2-inducing genes, while significantly upregulating 14 E2-repressing genes (Fig. 2E and 2H). The degree of ER pathway inhibition, as captured by the characteristics, was correlated with antitumor activity (Fig. 2F and 2I).

Example 2. ER pathway activity signatures capture the inhibition of ER pathway activity in patients’ responses to SERD treatment.

In clinical practice, RNA protocols are commonly used to generate transcript profiles from formalin-fixed and paraffin-embedded (FFPE) tissues.

To utilize ER pathway activity signatures as PD biomarkers for SERD activity or as predictive biomarkers for potential ER pathway associations in patients, a reference distribution of ER activity was obtained from RNA data. RNA data were generated from FFPE tissues in a derived collection of 139 HR+/HER2- breast tumors. Raw counts from the 139 breast tumors were converted to counts per million (cpm), low-expression genes (i.e., cpm < 0.25 in over 90% of samples) were screened, normalized using TMM normalization in the edgeR package, and voom was transformed using the limma package in R. ER pathway signature genes with mean voom-normalized expression in all 139 tumors were removed from downstream analysis, placing them in the 5th percentile from the bottom of all genes.

In this reference set, the two E2-inducing genes, SGK3 and CT62, were not expressed or expressed at low levels, and the E2-repressing gene, PSCA, was expressed at low levels. Next, the expression of characteristic genes other than these three was assessed (Figure 3A). Based on 21 E2-inducing genes and 17 E2-repressing genes, RNA reference densities for E2 induction score, E2 suppression score, and ER pathway activity were defined for use in collecting data from 139 HR+/HER2- breast tumors (Figures 3B-3D, 3H-3J).

Six patients with HR+/HER2- breast cancer were treated with SERD (compound B), and seven patients with HR+/HER2- breast cancer were treated with another SERD (compound A). RNA data (as described above) were generated from FFPE tissues collected during screening (pretreatment) and during the second or third cycle of SERD treatment (posttreatment). Genes were re-centered and rescaled using the mean and standard deviation of a reference set.

The pre- and post-treatment tumor characterization scores were calculated for six patients treated with compound B (Fig. 3B-3D) and seven patients treated with compound A (Fig. 3H-3J), and are shown at the top of the reference density. In the first batch of six patients treated with compound B, 4 out of 6 showed inhibition of ER pathway activity via SERD treatment. Two patients with low pre-treatment ER pathway activity (patients Pb and Pf) showed no change in ER pathway activity; therefore, ER pathway inhibition in response to SERD treatment was captured only in tumors that showed evidence of ER pathway activity pre-treatment (Fig. 3F). Two patients were considered PR+ (expression >4), and four were considered PR-. Pre-treatment ESR1 expression levels were also insufficient as a biomarker of ER pathway activity (Fig. 3E). These results were confirmed in the second batch of seven patients treated with compound A (Fig. 3H-M), with four PR+ patients and three PR- breast cancer patients, and ER pathway activity inhibition observed in 6 out of 7 patients via SERD treatment. Taken together, these results suggest that this characteristic can be used as a measure of pre-treatment ER pathway activity and a PD biomarker in PR+ and PR- breast tumors.

Example 3: Identification of core characteristic genes

To identify the core set of genes included in the ER pathway activity score, expression data were analyzed before and after treatment in four of six patients (excluding patients Pb and Pf) who received effective ER pathway inhibition with compound B. From these four patients, a subset of 41 in vitro-derived genes most significantly and consistently affected by endocrine therapy was selected to create a 19-gene signature with 11 E2-inducing genes and 8 E2-repressing genes (one-sided t-test, p < 0.1) and a 14-gene signature with 8 E2-inducing genes and 6 E2-repressing genes (one-sided t-test, p < 0.05). Both reduced gene sets performed well in the HCI-013PDX model treated with different doses of compound A compared to the 41-gene signature (Figures 4A-4C). In this in vivo model, the dose-dependent addition of E2-inducing and E2-repressing genes provided the largest dynamic range for ER pathway inhibition. Treatment of patients with Pa to Pf identified by 41 gene signatures using compound B resulted in a reduced gene set that also led to similar ER pathway inhibition (Figures 4D-4F). Similar results were also observed when changes in ER pathway activity were assessed based solely on E2-induced genes (Figures 4G-4I). Featured genes are provided in Tables 1-6.

Example 4. The activity signature levels of the ER pathway are independent of the sequencing platform and tissue preparation method used.

ER pathway activity scores were determined for 30 FFPE samples (including five breast tumor samples) and 30 FF (fresh-frozen) samples (including five breast tumor samples). All breast samples were primary ER+ breast tissue, stage II or III, ductal carcinoma. RNA sequencing data were generated for all samples using two different library kits: RNA and RIBO-. ER pathway activity levels obtained using either sequencing method were highly similar across these 60 tissue samples (Figure 5; Pearson correlation coefficient 0.97). Furthermore, ER pathway activity scores in breast FFPE samples (pink triangles) and breast FF samples (pink circles) were within the same range (Figure 5). These results suggest that features can be used in a platform-independent (RNA) and tissue preparation-independent (FFPE, FF) manner.

Example 5. ER repression and ER transcriptional activity

In a cohort of 14 ER+/HER2- breast cancer cell lines, the relationship between ER pathway activity and the antiproliferative effect of the ER antagonist fulvestrant was investigated. E2 induction scores were determined using RNA sequencing data, based on the expression of a set of E2-inducible genes (as described above) in a series of ER+/HER2- breast cancer cell lines grown under standard culture conditions in the presence of estrogen. The effect of 300 nM fulvestrant's inhibitory effect on ER on cell proliferation was determined using the GR (growth rate) method described by Hafner et al. (Nat Methods 13:6, 2016) in an 8-day in vitro viability assay. The E2 induction scores were then plotted against the effect of fulvestrant on cell growth rate.

ER+/HER2- breast cancer cell lines showed E2-inducible scores ranging from 1.73 to -0.57, with a median of 0.63 (Figure 6). Fulvestrant had little effect on the growth rate of cell lines with the lowest E2-inducible scores in the 25th percentile of 14 cell lines (ZR-75-1, MDA-MB-415, MDA-MB-175-VII, KPL-1), while having a greater effect on cell lines exhibiting higher E2-inducible scores (Figure 7). These in vitro data support the hypothesis that ER suppression may have the greatest impact when gene expression profiles reflect ER transcriptional activity.

VIII. Other Embodiments

Although the methods and compositions have been described in considerable detail above by way of illustration and examples for the purposes of clarity and understanding, such descriptions and examples should not be construed as limiting the scope of the methods and compositions provided herein. The entire contents of all patent and scientific literature disclosures cited herein are expressly incorporated by reference.

Example

Example 1. A method for identifying an individual with breast cancer who may benefit from treatment including endocrine therapy, the method comprising determining an estrogen receptor (ER) pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that meets or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including endocrine therapy.

Example 2. A method for selecting a therapy for an individual with breast cancer, the method comprising determining an ER pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

Example 3. The method according to Example 1 or 2, wherein the ER pathway activity score determined from the sample reaches or exceeds the reference ER pathway activity score, and the method further includes administering an effective amount of endocrine therapy to the individual.

Example 4. The method according to Example 1 or 2, wherein an ER pathway activity score from a sample lower than a reference ER pathway activity score identifies an individual as unlikely to benefit from treatment including endocrine therapy.

Example 5. The method according to Example 4, wherein the ER pathway activity score determined from the sample is lower than the reference ER pathway activity score, and the method further includes administering an effective amount of anticancer therapy to the individual in addition to endocrine therapy.

Example 6. A method for treating an individual with breast cancer, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified by the method of Example 1 as an individual more likely to benefit from treatment including endocrine therapy.

Example 7. A method for treating an individual with breast cancer, the individual being identified as having an ER pathway activity score that meets or exceeds a reference ER pathway activity score, the method comprising administering an effective amount of endocrine therapy to the individual.

Example 8. A method for treating an individual with breast cancer, the method comprising:

(a) Determining ER pathway activity scores from samples from individuals, wherein the ER pathway activity scores from the samples are determined to be at or above a reference ER pathway activity score; and

(b) Administer an effective dose of endocrine therapy to the individual.

Example 9. The method according to any one of Examples 1-8, wherein the reference ER pathway activity score is the ER pathway activity score in a reference population.

Example 10. The method according to any one of Examples 1-3 and 6-9, wherein the ER pathway activity score in the sample reaches or is greater than -1.0.

Example 11. The method according to Example 10, wherein the ER pathway activity score in the sample reaches or exceeds -0.2.

Example 12. The method according to Example 4 or 5, wherein the ER pathway activity score in the sample is less than -0.2.

Example 13. The method according to Example 4 or 5, wherein the ER pathway activity score in the sample is less than -1.0.

Example 14. The method according to any one of Examples 9-13, wherein the reference population is a group of individuals with hormone receptor-positive (HR+) breast cancer.

Example 15. A method for monitoring the response of an individual with breast cancer to endocrine therapy, the method comprising:

(a) Determine the first ER pathway activity score from samples from individuals at the first time point;

(b) Following step (a), at a second time point after administration of endocrine therapy, a second ER pathway activity score is determined from samples from the individual; and

(c) Compare the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score may predict individuals who respond to endocrine therapy.

Example 16. The method according to Example 15, wherein the second ER pathway activity score is reduced relative to the first ER pathway activity score, and the method further includes administering an additional dose of endocrine therapy to the individual.

Example 17. The method according to Example 15 or 16, wherein the reduction in the second ER pathway activity score relative to the first ER pathway activity score is at least 0.1.

Example 18. The method according to any one of Examples 15-17, wherein the activity score of the first ER pathway is:

(a) ER pathway activity scores determined from samples obtained from individuals prior to administration of the first dose of endocrine therapy;

(b) ER pathway activity scores determined from samples from individuals at a previous time point, wherein the previous time point is after administration of the first dose of endocrine therapy; or

(c) Pre-assigned ER pathway activity scores.

Example 19. A method for identifying an individual with breast cancer who may benefit from treatment including endocrine therapy, the method comprising determining an estradiol (E2) induction score from a sample from the individual, wherein an E2 induction score from the sample that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from treatment including endocrine therapy.

Example 20. A method for selecting a therapy for an individual with breast cancer, the method comprising determining an E2 induction score from a sample from the individual, wherein an E2 induction score from the sample that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

Example 21. The method according to Example 19 or 20, wherein the E2 induction score determined from the sample reaches or exceeds a reference E2 induction score, and the method further includes administering an effective amount of endocrine therapy to the individual.

Example 22. The method according to Example 19 or 20, wherein an E2-induced score below a reference E2-induced score from a sample identifies an individual as unlikely to benefit from treatment including endocrine therapy.

Example 23. The method according to Example 22, wherein the E2-induced score determined from the sample is lower than the reference E2-induced score, and the method further includes administering an effective amount of anticancer therapy to the individual in addition to endocrine therapy.

Example 24. A method for treating an individual with breast cancer, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified by the method of Example 19 as an individual more likely to benefit from treatment including endocrine therapy.

Example 25. A method for treating an individual with breast cancer, the individual being identified as having an E2 induction score that reaches or exceeds a reference E2 induction score, the method comprising administering an effective amount of endocrine therapy to the individual.

Example 26. A method for treating an individual with breast cancer, the method comprising:

(a) Determining E2-induced scores from samples from individuals, wherein the E2-induced scores from the samples are determined to be at or above a reference E2-induced score; and

(b) Administer an effective dose of endocrine therapy to the individual.

Example 27. The method according to any one of Examples 19-26, wherein the reference E2-induced score is the E2-induced score in the reference population.

Example 28. The method according to any one of Examples 19-21 and 24-27, wherein the E2 induction score in the sample reaches or is greater than -2.0.

Example 29. The method according to Example 28, wherein the E2 induction score in the sample reaches or is greater than -0.1.

Example 30. The method according to Example 22 or 23, wherein the E2 induction score in the sample is less than -0.1.

Example 31. The method according to Example 30, wherein the E2 induction score in the sample is less than -2.0.

Example 32. The method according to any one of Examples 27-31, wherein the reference population is a group of individuals with HR+ breast tumors.

Example 33. A method for monitoring the response of an individual with breast cancer to endocrine therapy, the method comprising:

(a) Determine the first E2-induced score from samples from individuals at the first time point;

(b) Following step (a), a second E2 induction score is determined from samples from the individual at a second time point after administration of endocrine therapy; and

(c) Compare the first E2-induced score with the second E2-induced score, wherein a decrease in the second E2-induced score relative to the first E2-induced score may predict individuals who respond to endocrine therapy.

Example 34. The method according to Example 33, wherein the second E2-induced score is reduced relative to the first E2-induced score, and the method further includes administering an additional dose of endocrine therapy to the individual.

Example 35. The method according to Example 33 or 34, wherein the reduction of the second E2 induced score relative to the first E2 induced score is at least 0.1.

Example 36. The method according to any one of Examples 33-35, wherein the first E2-induced score is:

(a) E2 induction score determined from a sample obtained from an individual prior to administration of the first dose of endocrine therapy;

(b) E2 induction score determined from samples from the individual at a previous time point, wherein the previous time point is after administration of the first dose of endocrine therapy; or

(c) Pre-assigned E2-induced scores.

Example 37. The method according to any one of Examples 1-6, 8-24 and 26-36, wherein the sample is a tissue sample.

Example 38. The method according to Example 37, wherein the tissue sample is a tumor tissue sample.

Example 39. The method according to Example 38, wherein the tumor tissue sample is a formalin-fixed and paraffin-embedded (FFPE) sample, a fresh-frozen (FF) sample, an archived sample, a fresh sample, or a frozen sample.

Example 40. The method according to Example 39, wherein the tumor tissue sample is an FFPE sample.

Example 41. The method according to Example 39, wherein the tumor tissue sample is an FF sample.

Example 42. The method according to any one of Examples 1-41, wherein the breast cancer is ER+ breast cancer.

Example 43. The method according to Example 42, wherein the ER+ breast cancer is luminal type A breast cancer.

Example 44. The method according to Example 42, wherein the ER+ breast cancer is luminal type B breast cancer.

Example 45. The method according to any one of Examples 1-44, wherein the breast cancer is advanced breast cancer or metastatic breast cancer.

Example 46. The method according to any one of Examples 3, 5-18, 21 and 23-45, wherein the endocrine therapy is administered orally, intravenously, intratumorally, intramuscularly, subcutaneously, locally or intranasally.

Example 47. The method according to Example 46, wherein the endocrine therapy is administered orally.

Example 48. The method according to Example 46, wherein the endocrine therapy is administered intramuscularly.

Example 49. A method for detecting estrogen receptor (ER) pathway activity in a subject with breast cancer, the method comprising detecting the expression levels of at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 5; or at least five genes listed in Table 3 and at least five genes listed in Table 6.

Example 50. The method according to Example 49, wherein the expression levels of the at least five genes listed in Table 1, the at least five genes listed in Table 2, or the at least five genes listed in Table 3 are all higher than the standard control.

Example 51. The method according to Example 49, wherein the expression levels of the at least five genes listed in Table 4, the at least five genes listed in Table 5, or the at least five genes listed in Table 6 are all lower than the standard control.

Example 52. The method according to one of Examples 49 to 51, wherein the subject has been treated with endocrine therapy prior to the test.

Example 53. The method according to one of Examples 49 to 52, wherein the subject is treated with endocrine therapy after the test.

Example 54. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4.

Example 55. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5.

Example 56. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6.

Example 57. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4, without detecting the expression levels of any other genes of the subject.

Example 58. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5, without detecting the expression levels of any other genes of the subject.

Example 59. The method according to one of Examples 49 to 53, comprising detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6, without detecting the expression levels of any other genes of the subject.

Example 60. The method according to one of Examples 49 to 59, wherein the subject is treated with an endocrine therapy comprising a selective estrogen receptor degrader.

Example 61. The method according to one of Examples 49 to 60, further comprising determining an estrogen receptor (ER) pathway activity score from a sample from a subject.

Example 62. The method according to Example 61, wherein an ER pathway activity score from a sample that reaches or exceeds a reference ER pathway activity score identifies an individual as an individual who may benefit from treatment including endocrine therapy.

Example 63. The method according to Example 61 further includes comparing ER pathway activity scores from samples that reach or exceed a reference ER pathway activity score to identify individuals who may benefit from treatment including endocrine therapy.

Example 64. A method comprising:

The first expression level of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 is detected by one or more processors;

The second expression level of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 is detected by one or more processors; and

The estrogen receptor (ER) pathway activity in subjects with cancer was detected based at least on the first expression level and/or the second expression level.

Example 65. The method according to Example 64, wherein the expression levels of the at least five genes listed in Table 1, the at least five genes listed in Table 2, or the at least five genes listed in Table 3 are all higher than the standard control.

Example 66. The method according to Example 64, wherein the expression levels of the at least five genes listed in Table 4, the at least five genes listed in Table 5, or the at least five genes listed in Table 6 are all lower than the standard control.

Example 67. The method according to any one of Examples 64 to 66, further comprising:

Prior to the test, the subject was treated with endocrine therapy.

Example 68. The method according to any one of Examples 64 to 67, further comprising:

Subjects were treated with endocrine therapy based at least on the estrogen receptor (ER) pathway activity detected in their bodies.

Example 69. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a selective estrogen receptor degrader (SERD), a selective estrogen receptor modulator (SERM), a selective estrogen receptor covalent antagonist (SERCA), a selective human estrogen receptor agonist (ShERPA), an aromatase inhibitor (AI), or a combination thereof.

Example 70. The method according to Example 69, wherein the SERD includes a brilanestrant (GDC-0810) having the following structure:

Or its medicinal salt.

Example 71. The method according to Example 69, wherein the SERD includes GDC-0927 (SRN-0927) having the following structure:

Or its medicinal salt.

Example 72. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 73. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Example 74. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 75. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 76. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 77. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 78. The method according to any one of Examples 1-68, wherein the endocrine therapy comprises a compound having the following formula:

Or its medicinal salt.

Example 79. The method according to Example 5 or 23, wherein the anticancer therapy other than endocrine therapy includes chemotherapy.

Example 80. The method according to Example 79, wherein the chemotherapy comprises anthracycline, taxane, 5-fluorouracil, cyclophosphamide, platinum, vinorelbine, capecitabine, gemcitabine, ixaprone, elebulin, or combinations thereof.

Example 81. The method according to Example 79, wherein the anticancer therapy other than endocrine therapy includes PI3K inhibitors, mTOR inhibitors, CDK4/6 inhibitors, or combinations thereof.

Example 82. The method according to any one of Examples 1-81, wherein the individual is a person.

Example 83. A kit containing multiple nucleic acids, wherein the multiple nucleic acids are at least 5 nucleotides in length and have at least 95% identity with a 5-nucleotide sequential sequence of at least five genes listed in Table 1 and at least five genes listed in Table 4, at least five genes listed in Table 2 and at least five genes listed in Table 4, or at least five genes listed in Table 3 and at least five genes listed in Table 6, or have 95% identity with a sequence complementary to the 5-nucleotide sequential sequence.

Example 84. The kit according to Example 83, wherein the plurality of nucleic acids are ligated to a solid support.

Example 85. The kit according to Example 84, wherein the plurality of nucleic acids include a detectable marker.

Example 86. The kit according to Example 83, wherein the plurality of nucleic acids have at least 95% identity with five consecutive nucleotide sequences within at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3, which is greater than the standard control.

Example 87. The kit according to Example 83, wherein the plurality of nucleic acids have at least 95% identity with five consecutive nucleotide sequences within at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6, which is less than the standard control.

Example 88. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with the five consecutive nucleotide sequences of all genes listed in Table 1 and all genes listed in Table 4.

Example 89. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with the five consecutive nucleotide sequences of all genes listed in Table 2 and all genes listed in Table 5.

Example 90. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with the five consecutive nucleotide sequences of all genes listed in Table 3 and all genes listed in Table 6.

Example 91. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with a 5-nucleotide consecutive sequence of all genes listed in Table 1 and all genes listed in Table 4, excluding other genes.

Example 92. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with a 5-nucleotide sequential sequence of all genes listed in Table 2 and all genes listed in Table 5, excluding other genes.

Example 93. A kit according to one of Examples 83-87, wherein the plurality of nucleic acids have at least 95% identity with five consecutive nucleotide sequences of all genes listed in Table 3 and all genes listed in Table 6, excluding other genes of the subject.

Example 94. A kit according to one of Examples 83-93, wherein the plurality of nucleic acids are identical to a five-nucleotide sequential sequence within the gene.

Example 95. A kit according to one of Examples 83-94, wherein the plurality of nucleic acids are identical to a continuous nucleotide sequence comprising at least 10, 20, 25, 50, 75, 100, 150 or 200 nucleotides.

sequence list

<110> F. Hoffmann-LaRoche AG

<120> Diagnostic and treatment methods for breast cancer

<130> 048893-517001WO

<150> US 62/719,545

<151> 2018-08-17

<160> 90

<170> PatentIn version 3.5

<210> 1

<211> 767

<212> DNA

<213> Homo sapiens

<400> 1

agaaacatcc agaatacatt tccaacaaga gcactggcca agtcagcttc ttctgagaga 60

gtctctagaa gacatgatgc tacactcagc tttgggtctc tgcctcttac tcgtcacagt 120

ttcttccaac cttgccattg caataaaaaa ggaaaagagg cctcctcaga cactctcaag 180

aggatgggga gatgacatca cttgggtaca aacttatgaa gaaggtctct tttatgctca 240

aaaaagtaag aagccattaa tggttatattca tcacctggag gattgtcaat actctcaagc 300

actaaagaaa gtatttgccc aaaatgaaga aatacaagaa atggctcaga ataagttcat 360

catgctaaac cttatgcatg aaaccactga taagaattta tcacctgatg ggcaatatgt 420

gcctagaatc atgtttgtag accttcttt aacagttaga gctgacatag ctggaagata 480

ctctaacaga ttgtacacat atgagcctcg ggatttaccc ctattgatag aaaacatgaa 540

gaaagcatta agacttattc agtcagagct ataagagatg atggaaaaaa gccttcactt 600

caaagaagtc aaatttcatg aagaaaacct ctggcacatt gacaaatact aaatgtgcaa 660

gtatatagat tttgtaatat tactatttag tttttttaat gtgtttgcaa tagtcttatt 720

aaaataaatg ttttttaaat ctgagactga aaaaaaaaaa aaaaaaa 767

<210> 2

<211> 166

<212> PRT

<213> Homo sapiens

<400> 2

Met Met Leu His Ser Ala Leu Gly Leu Cys Leu Leu Leu Val Thr Val

1 5 10 15

Ser Ser Asn Leu Ala Ile Ala Ile Lys Lys Glu Lys Arg Pro Pro Gln

20 25 30

Thr Leu Ser Arg Gly Trp Gly Asp Asp Ile Thr Trp Val Gln Thr Tyr

35 40 45

Glu Glu Gly Leu Phe Tyr Ala Gln Lys Ser Lys Lys Pro Leu Met Val

50 55 60

Ile His His Leu Glu Asp Cys Gln Tyr Ser Gln Ala Leu Lys Lys Val

65 70 75 80

Phe Ala Gln Asn Glu Glu Ile Gln Glu Met Ala Gln Asn Lys Phe Ile

85 90 95

Met Leu Asn Leu Met His Glu Thr Thr Asp Lys Asn Leu Ser Pro Asp

100 105 110

Gly Gln Tyr Val Pro Arg Ile Met Phe Val Asp Pro Ser Leu Thr Val

115 120 125

Arg Ala Asp Ile Ala Gly Arg Tyr Ser Asn Arg Leu Tyr Thr Tyr Tyr Glu

130 135 140

Pro Arg Asp Leu Pro Leu Leu Ile Glu Asn Met Lys Lys Ala Leu Arg

145 150 155 160

Leu Ile Gln Ser Glu Leu

165

<210> 3

<211> 5531

<212> DNA

<213> Homo sapiens

<400> 3

gattggtgct gtgacctgcg gcagcacagc cgcctgcgtt gagcgcccac ggtgggctgg 60

actttgcact aggtgctgac aggacggca gaggtggcca ctgccctcgt ccccagcctg 120

cactcctggg cgaaggctga cgctgaacag ggtgctgtgg gcccagaagc gcccatgcct 180

gagagcgtcc aggaccaggc agagctgggc cttaagggcc cttggaccag tgtctgtctg 240

cagggagccc ccggtagcca ctcggatcag cccgagggaa gattctggac gagaccgtgg 300

ccgtcccccg ggtggcccat ggacagcagc aggggctccc aggagtggcc aggccctgcc 360

cgcccaccat gctgcagtgt agacccgcac aggagttcag cttcgggccc cgggccttga 420

aggacgctct ggtctccact gacgcagccc tgcagcagct gtatgtgtcc gccttctccc 480

ctgccgagcg gctcttcctg gccgaggcct acaacccgca gaggacgctc ttctgcaccc 540

tgctcatccg cacgggcttc gactggctcc tgagccgacc cgaggctccc gaggacttcc 600

agaccttcca cgcctccctg cagcaccgga agccccgcct ggctcggaag cacatctacc 660

tacagccgat agacctgagc gaggagccgg tgggaagctc cctgctgcac cagctgtgca 720

gctgcacaga ggccttcttc ctgggcctgc gcgtcaagtg cctgccgtcg gtggcagccg 780

cgtccatccg ctgctcctcg cggcccagcc gggactctga caggctccag ctccacacag 840

acggcatcct gtccttcttg aagaacaaca agccagggga cgcgctgtgt gtgctgggcc 900

tcacactgtc tgacctgtac ccccatgagg cctggagctt caccttcagc aagttccttc 960

cagggcacga agtgggcgtc tgcagcttcg cccggttctc agggggaattc ccgaagtcgg 1020

ggcccagcgc ccctgatctg gccctggtag aggcagcagc agacggcccc gaggcccccc 1080

tgcaggacag gggctgggcc ctgtgcttca gtgccctggg gatggttcag tgctgcaagg 1140

tcacgtgcca cgagctctgc caccttctgg gcctggggaa ctgccgctgg ctccgctgcc 1200

tcatgcaggg tgcgctcagc ctggacgagg ccctgcggcg gcccctggac ctctgtccca 1260

tctgcctgag gaagctgcag catgtcctgg gtttcaggct catcgagagg taccagagac 1320

tctacacctg gactcaggcg gtggtgggga cgtggcccag ccaggaggcg ggggagccgt 1380

cagtgtggga ggacacccccg cctgccagcg ccgactcggg catgtgctgt gagagtgact 1440

cggagcccgg caccagtgtg tcggagcccc tcacccctga tgccgggagt cacaccttcg 1500

cctcggggcc agaggaaggg ctgagctacc tggcagcctc agaggctccg ctgccacctg 1560

ggggccctgc ggaggccatc aaggagcatg aacggtggct ggccatgtgc atccaggccc 1620

tgcagcggga agtggcagag gaggacctgg tgcaggtgga cagagccgtg gacgccctcg 1680

accgctggga gatgttcacg ggccagctcc cggccaccag gcaggaccca cccagcagca 1740

gggacagcgt ggggctgcgc aaggtgctgg gggacaagtt ctcctccctg aggaggaagc 1800

tgagtgcccg aaaactcgcc aggcagagt cggccccccg tccctgggat ggggaagaga 1860

gttagtacag caggggctgc cctacgtctc cttccctaag gatgctggcc agcactgtcc 1920

agtagctgag gccactactg acctgccagg gataaagagg aagggtctgc ctgggtggtg 1980

gctcaggcct gtcatcccat cactttgaga ggccaggagt ttgagaccag actgggcaac 2040

atggtgagac tctgcctcta caaaagaaaa attaaaaaat tagctggatg aagtggttca 2100

tgcctgtgtt cccagctatt caggaggctg aggtggggagg attgcttgag cctaggaggt 2160

cgaggctgca gtgggatgtg atcataccac tgtactgcag tctgggccac agaaagac 2220

tgtctccaga aaaaaaaaag ttctttggag aagccacaga ccacctgtct tcaggcgcct 2280

ccttcaactc ctgagtccca gccagccgct cccaggggcc tgcacacatg gagaggcctc 2340

cctgatcctg ggtgcttctc gtggagtaca agccggactg tgctgaggtt gggacagagc 2400

cccctcccct gcagaggcag aaggaagcag cgtgcgtcct gtctccttcc aggctgtggg 2460

cctgcccttc agttatttat agctggagct ggagaggctg gctcagatga ggagtgaccc 2520

cgggggcaca caggctccac actgccaccc agcttccaag gctgagtctc ctccctaacg 2580

gggaagtgac ggggttttgt ctctatcatc tcaggcgtca accacatgca cacacacact 2640

gtcacgttct gtggcgctaa cagcatcctg atcctgacgg acttcaccgg ggctctccag 2700

gcatctcttc tgacaaacac tgcaggaggt gaggtgtct gacgtgcact gaggcagag 2760

gcccccttat tcctgaggcg gctacagctc accgtgggga agatcaactg tggtgatgtt 2820

tttggggacag tttcttggca aaggtggccg cgctgtcagt accaagtagc tggaggtggt 2880

gatcagatga tctgtctttc cttttttttt cggtctagtt ctgtcagttg ctgagagagg 2940

ggtattattg ccatggctgg gcgtttgatc tgtctccctt tagttttgcc ggattttgct 3000

tcctgcactt tgaagctcct ttacgtccct gcacatttga ttgttgtgtc ttcctgagga 3060

attgaccctt ttattgtcac acgtaccccc tcagcctgtg gtggagggtc tctgggagag 3120

agacttccgg ttctgacagc ggaatccctt cggagtgacg agggcggggt cacagctcgc 3180

gcaccctcat ctggagagag gcaagaacag ggcagcttgg accttttgtg ggtgggtggc 3240

tcacacggtt atggagggct tctaagaaaa acaaaataca aaactaaaac tagaagggct 3300

atgcaggtga ggtgggctga ggcttccttg tgaatctgac attggtggag gccgactgaa 3360

ggctcccggt cctggtccca ctccgtgttg acttcagaga agcaaagatg cagctcagaa 3420

gtagcattag gatcttcgtc ccgttctctt ttgcgtagct tcaaaaaggc gtaacagtga 3480

cctgggaggg gagatgaaga gctaggcctt tcagaaagtg accaatggaa ggtgccggca 3540

gagcaccctg cagtaacaga aggtgaaagc cggagcctgg tggctgttgc tgcaaacaac 3600

cacccaaaac ttagtggctt aaaatcacca cagtctagct catgaatctg taacttgggc 3660

agagctcggt ggagacggtt tgcccctgtg gctcgactgg agtgttcgtt cacacggctg 3720

ccaagtggaa tttggctggg aatctcaggc cttggttcct gcccacgtga gactctccat 3780

ggaggagggg catcttctta ggaaggcagc tgccataccg tgaggaaacc cgacaaacag 3840

ggcagccaga gccagacagc aggctcctgg tcccagtccc ggaaaatgca aagggacaag 3900

tatgtgttga tttcagagaa gctcagatgt agcattagga ccttcatcca tacccttctc 3960

ttttgcatgg cttctaaagg gcatgacagt gacctggggag gtaactgtgc cagaataaag 4020

aggggagacg aaaaaaagag ggtcactttc agaaagggac ctgggcttcc tcacaatatg 4080

gcggttgccc tcctaaggtg gacatcggga gggtcagatg gaagctctgt ggcctttcct 4140

aactcggcct cacgtcacag agcgtcacct ttcctgcact ccacggcggc agtgacaagg 4200

accccacccc aggttcacgg ggaggggacg tggcagggaa tgtgagacaa cacaatattg 4260

ctgtggccat tcatgaacag tcagtcagcc ccactcggcg ttcactgtgg ggatttggct 4320

ggtgcacctg cgaggtggcc tgacctgttt tccgatttcc ttcatcttct gcaaaaggtt 4380

aaccgctgga gtgatgcgag attaaacaga ggtgataaaa atagaatgcc tggctcatgc 4440

tgagggtggg agcccactgg ggttatgacc aaagcctcgg cgctctctgt acccgtgtcc 4500

tttgaccctc agctgtgatg tgtgtcccaa aaaagcgttt tgaagtggga aggagcaaac 4560

cactaaaaaa aactcctttt atccgcagcg tttaccaact tgcagatgtc agtgaaattt 4620

tttaagacag ctgttagaag gactgttttg aaatgcaact ttgaggaaga gaaattggtt 4680

tccctcctct cccccgtgtt agccccaggt tctgtctgtg ctgtggtgaa gagtgacttg 4740

ggacagtcac caggaaagac gcaaggcaga ggagagagaa tgagggctgc cttctcgagg 4800

aaggtcacag ctcacgaatc tttctaaact taagtgctgc agaagttgaa ctgagattaa 4860

atttagagat gatggtttcc aagacacaca gggccacggt tctttcagtt tttaaacacg 4920

tgcaaagtcc actgaattgc tttctcgtct catctgtcag aagcccctgc attcacaagg 4980

atgggtcttc cagcttgacg atgacctctc ttcggagagc ctcacccatc ttggtaagcc 5040

aagtcagcgg ggcctcatgg agctaaaaat agtttcaggt catgacagat gttatctgta 5100

ttgctgtgtg tgcgatgagt ctggggaagc taacacatgc cttctgaagt ggctagaata 5160

cacactccca cgtcacagcc atgctatgat gaaggggtga gaagcagtgt cccctctgag 5220

gcaaatctct cttcaggcag ccccgcagtc ctcttccgaa atctcattct tttccctctc 5280

ttcctcccca aaaagcccaa actcattgtc agagtgggga gaggggagaa gcagcatcct 5340

gactcctgtc catggtgtga accctgaggg cacgggacag tgagtggagc tctgccacca 5400

cccgtttcca gagcatgggt gagagggag ggatgccgac ctgttaatat ttgcttcaga 5460

cctttccccg atgaacgaaa tctccaaaag ccttaaacat aaaatggctt agtcaaaaaa 5520

aaaaaaaaaa a 5531

<210> 4

<211> 498

<212> PRT

<213> Homo sapiens

<400> 4

Met Leu Gln Cys Arg Pro Ala Gln Glu Phe Ser Phe Gly Pro Arg Ala

1 5 10 15

Leu Lys Asp Ala Leu Val Ser Thr Asp Ala Ala Leu Gln Gln Leu Tyr

20 25 30

Val Ser Ala Phe Ser Pro Ala Glu Arg Leu Phe Leu Ala Glu Ala Tyr

35 40 45

Asn Pro Gln Arg Thr Leu Phe Cys Thr Leu Leu Ile Arg Thr Gly Phe

50 55 60

Asp Trp Leu Leu Ser Arg Pro Glu Ala Pro Glu Asp Phe Gln Thr Phe

65 70 75 80

His Ala Ser Leu Gln His Arg Lys Pro Arg Leu Ala Arg Lys His Ile

85 90 95

Tyr Leu Gln Pro Ile Asp Leu Ser Glu Glu Pro Val Gly Ser Ser Leu

100 105 110

Leu His Gln Leu Cys Ser Cys Thr Glu Ala Phe Phe Leu Gly Leu Arg

115 120 125

Val Lys Cys Leu Pro Ser Val Ala Ala Ala Ser Ile Arg Cys Ser Ser

130 135 140

Arg Pro Ser Arg Asp Ser Asp Arg Leu Gln Leu His Thr Asp Gly Ile

145 150 155 160

Leu Ser Phe Leu Lys Asn Asn Lys Pro Gly Asp Ala Leu Cys Val Leu

165 170 175

Gly Leu Thr Leu Ser Asp Leu Tyr Pro His Glu Ala Trp Ser Phe Thr

180 185 190

Phe Ser Lys Phe Leu Pro Gly His Glu Val Gly Val Cys Ser Phe Ala

195 200 205

Arg Phe Ser Gly Glu Phe Pro Lys Ser Gly Pro Ser Ala Pro Asp Leu

210 215 220

Ala Leu Val Glu Ala Ala Ala Asp Gly Pro Glu Ala Pro Leu Gln Asp

225 230 235 240

Arg Gly Trp Ala Leu Cys Phe Ser Ala Leu Gly Met Val Gln Cys Cys

245 250 255

Lys Val Thr Cys His Glu Leu Cys His Leu Leu Gly Leu Gly Asn Cys

260 265 270

Arg Trp Leu Arg Cys Leu Met Gln Gly Ala Leu Ser Leu Asp Glu Ala

275 280 285

Leu Arg Arg Pro Leu Asp Leu Cys Pro Ile Cys Leu Arg Lys Leu Gln

290 295 300

His Val Leu Gly Phe Arg Leu Ile Glu Arg Tyr Gln Arg Leu Tyr Thr

305 310 315 320

Trp Thr Gln Ala Val Val Gly Thr Trp Pro Ser Gln Glu Ala Gly Glu

325 330 335

Pro Ser Val Trp Glu Asp Thr Pro Pro Ala Ser Ala Asp Ser Gly Met

340 345 350

Cys Cys Glu Ser Asp Ser Glu Pro Gly Thr Ser Val Ser Glu Pro Leu

355 360 365

Thr Pro Asp Ala Gly Ser His Thr Phe Ala Ser Gly Pro Glu Glu Gly

370 375 380

Leu Ser Tyr Leu Ala Ala Ser Glu Ala Pro Leu Pro Pro Gly Gly Pro

385 390 395 400

Ala Glu Ala Ile Lys Glu His Glu Arg Trp Leu Ala Met Cys Ile Gln

405 410 415

Ala Leu Gln Arg Glu Val Ala Glu Glu Asp Leu Val Gln Val Asp Arg

420 425 430

Ala Val Asp Ala Leu Asp Arg Trp Glu Met Phe Thr Gly Gln Leu Pro

435 440 445

Ala Thr Arg Gln Asp Pro Pro Ser Ser Arg Asp Ser Val Gly Leu Arg

450 455 460

Lys Val Leu Gly Asp Lys Phe Ser Ser Leu Arg Arg Lys Leu Ser Ala

465 470 475 480

Arg Lys Leu Ala Arg Ala Glu Ser Ala Pro Arg Pro Trp Asp Gly Glu

485 490 495

Glu Ser

<210> 5

<211> 1290

<212> DNA

<213> Homo sapiens

<400> 5

ggctgagcct ataaagcggc aggtgcgcgc cgccctacag acgttcgcac acctgggtgc 60

cagcgcccca gaggtcccgg gacagcccga ggcgccgcgc ccgccgcccc gagctcccca 120

agccttcgag agcggcgcac actcccggtc tccactcgct cttccaacac ccgctcgttt 180

tggcggcagc tcgtgtccca gagaccgagt tgccccagag accgagacgc cgccgctgcg 240

aaggaccaat gagagccccg ctgctaccgc cggcgccggt ggtgctgtcg ctcttgatac 300

tcggctcagg ccattatgct gctggattgg acctcaatga cacctactct gggaagcgtg 360

aaccattttc tggggaccac agtgctgatg gatttgaggt tacctcaaga agtgagatgt 420

cttcaggggag tgagatttcc cctgtgagtg aaatgccttc tagtagtgaa ccgtcctcgg 480

gagccgacta tgactactca gaagagtatg ataacgaacc acaaatacct ggctatattg 540

tcgatgattc agtcagagtt gaacaggtag ttaagccccc ccaaaacaag acggaaagtg 600

aaaatacttc agataaaccc aaaagaaaga aaaagggagg caaaaatgga aaaaatagaa 660

gaaacagaaa gaagaaaaat ccatgtaatg cagaatttca aaatttctgc attcacggag 720

aatgcaaata tatagagcac ctggaagcag taacatgcaa atgtcagcaa gaatatttcg 780

gtgaacggtg tggggaaaag tccatgaaaa ctcacagcat gattgacagt agtttatcaa 840

aaattgcatt agcagccata gctgccttta tgtctgctgt gatcctcaca gctgttgctg 900

ttattacagt ccagcttaga agacaatacg tcaggaaata tgaaggagaa gctgaggaac 960

gaaagaaact tcgacaagag aatggaaatg tacatgctat agcataactg aagataaaat 1020

tacaggatat cacattggag tcactgccaa gtcatagcca taaatgatga gtcggtcctc 1080

tttccagtgg atcataagac aatggaccct ttttgttatg atggttttaa actttcaatt 1140

gtcacttttt atgctatttc tgtatataaa ggtgcacgaa ggtaaaaagt atttttcaa 1200

gttgtaaata atttatttaa tatttaatgg aagtgtattt attttacagc tcattaaact 1260

tttttaacca aacagaaaaa aaaaaaaaaa 1290

<210> 6

<211> 252

<212> PRT

<213> Homo sapiens

<400> 6

Met Arg Ala Pro Leu Leu Pro Pro Ala Pro Val Val Leu Ser Leu Leu

1 5 10 15

Ile Leu Gly Ser Gly His Tyr Ala Ala Gly Leu Asp Leu Asn Asp Thr

20 25 30

Tyr Ser Gly Lys Arg Glu Pro Phe Ser Gly Asp His Ser Ala Asp Gly

35 40 45

Phe Glu Val Thr Ser Arg Ser Glu Met Ser Ser Ser Gly Ser Glu Ile Ser

50 55 60

Pro Val Ser Glu Met Pro Ser Ser Ser Glu Pro Ser Ser Gly Ala Asp

65 70 75 80

Tyr Asp Tyr Ser Glu Glu Tyr Asp Asn Glu Pro Gln Ile Pro Gly Tyr

85 90 95

Ile Val Asp Asp Ser Val Arg Val Glu Gln Val Val Lys Pro Pro Gln

100 105 110

Asn Lys Thr Glu Ser Glu Asn Thr Ser Asp Lys Pro Lys Arg Lys Lys

115 120 125

Lys Gly Gly Lys Asn Gly Lys Asn Arg Arg Asn Arg Lys Lys Lys Asn

130 135 140

Pro Cys Asn Ala Glu Phe Gln Asn Phe Cys Ile His Gly Glu Cys Lys

145 150 155 160

Tyr Ile Glu His Leu Glu Ala Val Thr Cys Lys Cys Gln Gln Glu Tyr

165 170 175

Phe Gly Glu Arg Cys Gly Glu Lys Ser Met Lys Thr His Ser Met Ile

180 185 190

Asp Ser Ser Leu Ser Lys Ile Ala Leu Ala Ala Ile Ala Ala Phe Met

195 200 205

Ser Ala Val Ile Leu Thr Ala Val Ala Val Ile Thr Val Gln Leu Arg

210 215 220

Arg Gln Tyr Val Arg Lys Tyr Glu Gly Glu Ala Glu Glu Arg Lys Lys

225 230 235 240

Leu Arg Gln Glu Asn Gly Asn Val His Ala Ile Ala

245 250

<210> 7

<211> 1434

<212> DNA

<213> Homo sapiens

<400> 7

tataaagatt cactgggact ggtgaggtgg cagtgctcag cagcatccga caggagccct 60

ggcaaacagg acggatttcc aggactctac cagctgccag acacggcagg gagagacccc 120

agacctcctg ggtcctggct gtgggcccgg attgggctcc caagtggcgt ttgactcacg 180

tggggacact cttggaagag acgacaccag gagcctgaat gggaacgat tctgtcagct 240

acgagtatgg ggattacagc gacctctcgg accgccctgt ggactgcctg gatggcgcct 300

gcctggccat cgacccgctg cgcgtggccc cgctcccact gtatgccgcc atcttcctgg 360

tgggggtgcc gggcaatgcc atggtggcct gggtggctgg gaaggtggcc cgccggaggg 420

tgggtgccac ctggttgctc cacctggccg tggcggattt gctgtgctgt ttgtctctgc 480

ccatcctggc agtgcccatt gcccgtggag gccactggcc gtatggtgca gtgggctgtc 540

gggcgctgcc ctccatcatc ctgctgacca tgtatgccag cgtcctgctc ctggcagctc 600

tcagtgccga cctctgcttc ctggctctcg ggcctgcctg gtggtctacg gttcagcggg 660

cgtgcggggt gcaggtggcc tgtggggcag cctggacact ggccttgctg ctcaccgtgc 720

cctccgccat ctaccgccgg ctgcaccagg agcacttccc agcccggctg cagtgtgtgg 780

tggactacgg cggctcctcc agcaccgaga atgcggtgac tgccatccgg tttctttttg 840

gcttcctggg gcccctggtg gccgtggcca gctgccacag tgccctcctg tgctgggcag 900

cccgacgctg ccggccgctg ggcacagcca ttgtggtggg gttttttgtc tgctgggcac 960

cctaccacct gctggggctg gtgctcactg tggcggcccc gaactccgca ctcctggcca 1020

gggccctgcg ggctgaaccc ctcatcgtgg gccttgcct cgctcacagc tgcctcaatc 1080

ccatgctctt cctgtatttt gggagggctc aactccgccg gtcactgcca gctgcctgtc 1140

actgggccct gagggagtcc cagggccagg acgaaagtgt ggacagcaag aaatccacca 1200

gccatgacct ggtctcggag atggaggtgt aggctggaga gacattgtgg gtgtgtatct 1260

tcttatctca tttcacaaga ctggcttcag gcatagctgg atccaggagc tcaatgatgt 1320

cttcatttta ttccttcctt cattcaacag atatccatca tgcacttgct atgtgcaagg 1380

cctttttagg cactagagat atagcagtga ccaaaacaga cacaaatcct gccc 1434

<210> 8

<211> 337

<212> PRT

<213> Homo sapiens

<400> 8

Met Gly Asn Asp Ser Val Ser Tyr Glu Tyr Gly Asp Tyr Ser Asp Leu

1 5 10 15

Ser Asp Arg Pro Val Asp Cys Leu Asp Gly Ala Cys Leu Ala Ile Asp

20 25 30

Pro Leu Arg Val Ala Pro Leu Pro Leu Tyr Ala Ala Ile Phe Leu Val

35 40 45

Gly Val Pro Gly Asn Ala Met Val Ala Trp Val Ala Gly Lys Val Ala

50 55 60

Arg Arg Arg Val Gly Ala Thr Trp Leu Leu His Leu Ala Val Ala Asp

65 70 75 80

Leu Leu Cys Cys Leu Ser Leu Pro Ile Leu Ala Val Pro Ile Ala Arg

85 90 95

Gly Gly His Trp Pro Tyr Gly Ala Val Gly Cys Arg Ala Leu Pro Ser

100 105 110

Ile Ile Leu Leu Thr Met Tyr Ala Ser Val Leu Leu Leu Ala Ala Leu

115 120 125

Ser Ala Asp Leu Cys Phe Leu Ala Leu Gly Pro Ala Trp Trp Ser Thr

130 135 140

Val Gln Arg Ala Cys Gly Val Gln Val Ala Cys Gly Ala Ala Trp Thr

145 150 155 160

Leu Ala Leu Leu Leu Thr Val Pro Ser Ala Ile Tyr Arg Arg Leu His

165 170 175

Gln Glu His Phe Pro Ala Arg Leu Gln Cys Val Val Asp Tyr Gly Gly

180 185 190

Ser Ser Ser Thr Glu Asn Ala Val Thr Ala Ile Arg Phe Leu Phe Gly

195 200 205

Phe Leu Gly Pro Leu Val Ala Val Ala Ser Cys His Ser Ala Leu Leu

210 215 220

Cys Trp Ala Ala Arg Arg Cys Arg Pro Leu Gly Thr Ala Ile Val Val

225 230 235 240

Gly Phe Phe Val Cys Trp Ala Pro Tyr His Leu Leu Gly Leu Val Leu

245 250 255

Thr Val Ala Ala Pro Asn Ser Ala Leu Leu Ala Arg Ala Leu Arg Ala

260 265 270

Glu Pro Leu Ile Val Gly Leu Ala Leu Ala His Ser Cys Leu Asn Pro

275 280 285

Met Leu Phe Leu Tyr Phe Gly Arg Ala Gln Leu Arg Arg Ser Leu Pro

290 295 300

Ala Ala Cys His Trp Ala Leu Arg Glu Ser Gln Gly Gln Asp Glu Ser

305 310 315 320

Val Asp Ser Lys Lys Ser Thr Ser His Asp Leu Val Ser Glu Met Glu

325 330 335

Val

<210> 9

<211> 10540

<212> DNA

<213> Homo sapiens

<400> 9

aggagccgga ggaggagccg ccgccgccgt tgacccggcc gccggccggg agctgggaga 60

gatgcggagc ccggccaccg gcgtccccct cccaacgccg ccgccgccgc tgctgctgct 120

gttgctgctg ctgctgccgc cgccactatt gggagaccaa gtggggccct gtcgttcctt 180

ggggtccagg ggacgaggct cttcgggggc ctgcgccccc atgggctggc tctgtccatc 240

ctcagcgtcg aacctctggc tctacaccag ccgctgcagg gatgcgggca ctgagctgac 300

tggccacctg gtaccccacc acgatggcct gagggtttgg tgtccagaat ccgaggccca 360

tattccccta ccaccagctc ctgaaggctg cccctggagc tgtcgcctcc tgggcattgg 420

aggccacctt tccccacagg gcaagctcac actgcccgag gagcacccgt gcttaaaggc 480

tccacggctc agatgccagt cctgcaagct ggcacaggcc cccgggctca gggcagggga 540

aaggtcacca gaagagtccc tgggtgggcg tcggaaaagg aatgtaaata cagcccccca 600

gttccagccc cccagctacc aggccacagt gccggagaac cagccagcag gcacccctgt 660

tgcatccctg agggccatcg acccggacga gggtgaggca ggtcgactgg agtacaccat 720

ggatgccctc tttgatagcc gctccaacca gttcttctcc ctggacccag tcactggtgc 780

agtaaccaca gccgaggagc tggatcgtga gaccaagagc accacgtct tcagggtcac 840

ggcgcaggac cacggcatgc cccgacgaag tgccctggct acactcacca tcttggttac 900

tgacaccaat gaccatgacc ctgtgttcga gcagcaggag tacaaggaga gcctcaggga 960

gaacctggag gttggctatg aggtgctcac tgtcagggcc acggatggtg atgcccctcc 1020

caatgccaat attctgtacc gcctgctgga ggggtctggg ggcagcccct ctgaagtctt 1080

tgagatcgac cctcgctctg gggtgatccg aacccgtggc cctgtggatc gggaagaggt 1140

ggaatcctac cagctgacgg tagaggcaag tgaccagggt cgggacccgg gtcctcggag 1200

taccacagcc gctgttttcc tttctgtgga ggatgacaat gataatgccc cccagtttag 1260

tgagaagcgc tatgtggtcc aggtgaggga ggatgtgact ccaggggccc cagtactccg 1320

agtcacagcc tcggatcgag acaaggggag caatgccgtg gtgcactata gcatcatgag 1380

tggcaatgct cggggacagt tttatctgga tgcccagact ggagctctgg atgtggtgag 1440

ccctcttgac tatgagacga ccaaggagta caccctacgg gtgcgagcac aggatggtgg 1500

ccgtccccca ctctctaatg tctctggctt ggtgacagta caggtcctgg atatcaacga 1560

caatgccccc atcttcgtca gcaccccttt ccaggctact gtcctggaga gtgtcccctt 1620

aggctacctg gttctccatg tccaggctat cgacgctgat gctggtgaca atgcccgcct 1680

ggaataccgc cttgctgggg tgggacatga cttccccttc accatcaaca atggcacagg 1740

ctggatctct gtggctgctg aactggaccg ggaggaagtt gatttctaca gctttggggt 1800

agaagctcga gaccatggca ctccagcact cactgcctcg gccagtgtca gcgtgactgt 1860

cctggatgtc aacgacaaca atccaacctt tacccaacca gagtacacag tgcggctcaa 1920

tgaggatgca gctgtgggca ccagcgtggt gacggtgtca gctgtggacc gtgatgctca 1980

tagtgtcatc acctaccaga tcaccagtgg caatactcga aaccgcttct ccatcaccag 2040

ccaaagtggt ggtgggctgg tatcccttgc cctgccactg gactacaaac ttgagcggca 2100

gtatgtgttg gctgttaccg cctccgatgg cactcggcag gacacggcac agattgtggt 2160

gaatgtcacc gacgccaaca cccatcgtcc tgtctttcag agctcccact atacagtgaa 2220

tgttaatgag gaccggccgg caggcaccac ggtggtgctg atcagcgcca cggatgagga 2280

cacaggtgag aatgcccgca tcacctactt catggaggac agcatccccc agttccgcat 2340

cgatgcagac acgggggctg tcaccaccca ggctgagctg gactatgaag accaagtgtc 2400

ttacaccctg gccattactg ctcgggacaa tggcattccc cagaagtccg accaccaccta 2460

cctggagatc ctggtgaacg acgtgaatga caatgcccct cagttcctgc gagactccta 2520

ccagggcagt gtctatgagg atgtgccacc cttcactagc gtcctgcaga tctcagccac 2580

tgatcgtgat tctggactta atggcagggt cttctacacc ttccaaggag gcgacgatgg 2640

agacggtgac tttattgttg agtccacgtc aggcatcgtg cgaacgctac ggaggctgga 2700

tcgagagaac gtggcccagt atgtcttgcg ggcatatgca gtggacaagg ggatgccccc 2760

agcccgcaca cctatggaag tgacagtcac tgtgttggat gtgaatgaca atccccctgt 2820

ctttgagcag gatgagtttg atgtgtttgt ggaagagaac agccccattg ggctagccgt 2880

ggcccgggtc acagccactg accccgatga aggcaccaat gcccagatta tgtaccagat 2940

tgtggagggc aacatccctg aggtctttca gctggacatc ttctccgggg agctgacagc 3000

cctggtagac ttagactacg aggaccggcc tgagtacgtc ctggtcatcc aggccacgtc 3060

agctcctctg gtgagccggg ctacagtcca cgtccgcctc cttgaccgca atgacaaccc 3120

accagtgctg ggcaactttg agatcctttt caacaactat gtcaccaatc gctcaagcag 3180

cttccctggg ggtgccattg gccgagtacc tgcccatgac cctgatatct cagatagtct 3240

gacttacagc tttgagcggg gaaatgaact cagcctggtc ctgctcaatg cctccacggg 3300

tgagctgaag ctaagccgcg cactggacaa caaccggcct ctggaggcca tcatgagcgt 3360

gctggtgtca gacggcgtac acagcgtgac cgcccagtgc gcgctgcgtg tgaccatcat 3420

caccgatgag atgctcaccc acagcatcac gctgcgcctg gaggacatgt cacccgagcg 3480

cttcctgtca ccactgctag gcctcttcat ccaggcggtg gccgccacgc tggccacgcc 3540

accggaccac gtggtggtct tcaacgtaca gcgggacacc gacgcccccg ggggccacat 3600

cctcaacgtg agcctgtcgg tgggccagcc gccagggccc gggggcgggc cgcccttcct 3660

gccctctgag gacctgcagg agcgcctata cctcaaccgc agcctgctga cggccatctc 3720

ggcacagcgc gtgctgcct tcgacgacaa catctgcctg cgggagccct gcgagaacta 3780

catgcgctgc gtgtcggtgc tgcgcttcga ctcctccgcg cccttcatcg cctcctcctc 3840

cgtgctcttc cggcccatcc accccgtcgg aggggctgcgc tgccgctgcc cgcccggctt 3900

cacgggtgac tactgcgaga ccgaggtgga cctctgctac tcgcggccct gtggccccca 3960

cgggcgctgc cgcagccgcg agggcggcta cacctgcctc tgtcgtgatg gctacacggg 4020

tgagcactgt gaggtgagtg ctcgctcagg ccgttgcacc ccgggtgtct gcaagaatgg 4080

gggcacctgt gtcaacctgc tggtgggcgg tttcaagtgc gattgcccat ctggagactt 4140

cgagaagccc tactgccagg tgaccacgcg cagcttcccc gcccactcct tcatcacctt 4200

tcgcggcctg cgccagcgtt tccacttcac cctggccctc tcgtttgcca caaaggagcg 4260

cgacgggttg ctgttgtaca atgggcgttt caatgagaag catgactttg tggccctcga 4320

ggtgatccag gagcaggtcc agctcacctt ctctgcaggg gagtcaacca ccacggtgtc 4380

cccattcgtg cccggaggag tcagtgatgg ccagtggcat acggtgcagc tgaaatacta 4440

caataagcca ctgttgggtc agacagggct cccacagggc ccatcagagc agaaggtggc 4500

tgtggtgacc gtggatggct gtgacacagg agtggccttg cgcttcggat ctgtcctggg 4560

caactactcc tgtgctgccc agggcaccca gggtggcagc aagaagtctc tggatctgac 4620

ggggcccctg ctactaggcg gggtgcctga cctgcccgag agcttcccag tccgaatgcg 4680

gcagttcgtg ggctgcatgc ggaacctgca ggtggacagc cggcacatag acatggctga 4740

cttcattgcc aacaatggca ccgtgcctgg ctgccctgcc aagaagaacg tgtgtgacag 4800

caacacttgc cacaatgggg gcacttgcgt gaaccagtgg gacgcgttca gctgcgagtg 4860

ccccctgggc tttgggggca agagctgcgc ccaggaaatg gccaatccac agcacttcct 4920

gggcagcagc ctggtggcct ggcatggcct ctcgctgccc atctcccaac cctggtacct 4980

cagcctcatg ttccgcacgc gccaggccga cggtgtcctg ctgcaggcca tcaccagggg 5040

gcgcagcacc atcaccctac agctacgaga gggccacgtg atgctgagcg tggagggcac 5100

agggcttcag gcctcctctc tccgtctgga gccaggccgg gccaatgacg gtgactggca 5160

ccatgcacag ctggcactgg gagccagcgg ggggcccggc catgccattc tgtccttcga 5220

ttatgggcag cagagagcag agggcaacct gggcccccgg ctgcatggtc tgcacctgag 5280

caacataaca gtgggcggaa tacctgggcc agccggcggt gtggcccgtg gctttcgggg 5340

ctgtttgcag ggtgtgcggg tgagcgatac gccggagggg gttaacagcc tggatcccag 5400

ccatggggag agcatcaacg tggagcaagg ctgtagcctg cctgaccctt gtgactcaaa 5460

cccgtgtcct gctaacagct attgcagcaa cgactgggac agctattcct gcagctgtga 5520

tccaggttac tatggtgaca actgtactaa tgtgtgtgac ctgaacccgt gtgagcacca 5580

gtctgtgtgt acccgcaagc ccagtgcccc ccatggctat acctgcgagt gtcccccaaa 5640

ttaccttggg ccatactgtg agaccaggat tgaccagcct tgtccccgtg gctggtgggg 5700

acatcccaca tgtggcccat gcaactgtga tgtcagcaaa ggctttgacc cagactgcaa 5760

caagacaagc ggcgagtgcc actgcaagga gaaccactac cggcccccag gcagccccac 5820

ctgcctcttg tgtgactgct acccccacagg ctccttgtcc agagtctgtg accctgagga 5880

tggccagtgt ccatgcaagc caggtgtcat cgggcgtcag tgtgaccgct gtgacaaccc 5940

ttttgctgag gtcaccacca atggctgtga agtgaattat gacagctgcc cacgagcgat 6000

tgaggctggg atctggtggc cccgtacccg cttcgggctg cctgctgctg ctccctgtcc 6060

caaaggctcc tttgggactg ctgtgcgcca ctgtgatgag cacagggggt ggctcccccc 6120

aaacctcttc aactgcacgt ccatcacctt ctcagaactg aagggcttcg ctgagcggct 6180

acagcggaat gagtcaggcc tagactcagg gcgctcccag cagctagccc tgctcctgcg 6240

caacgccacg cagcacacag ctggctactt cggcagcgac gtcaaggtgg cctaccagct 6300

ggccacgcgg ctgctggccc acgagagcac ccagcggggc tttgggctgt ctgccacaca 6360

ggacgtgcac ttcactgaga atctgctgcg ggtgggcagc gccctcctgg acacagccaa 6420

caagcggcac tgggagctga tccagcagac agagggtggc accgcctggc tgctccagca 6480

ctatgaggcc tacgccagtg ccctggccca gaacatgcgg cacacctacc taagcccctt 6540

caccatcgtc acgcccaaca ttgtcatctc cgtagtgcgc ttggacaaag ggaactttgc 6600

tggggccaag ctgccccgct acgaggcct gcgtggggag cagcccccgg accttgagac 6660

aacagtcatt ctgcctgagt ctgtcttcag agagacgccc cccgtggtca ggcccgcagg 6720

ccccggagag gcccaggagc cagaggagct ggcacggcga cagcgacggc acccggagct 6780

gagccagggt gaggctgtgg ccagcgtcat catctaccgc accctggccg ggctactgcc 6840

tcataactat gaccctgaca agcgcagctt gagagtcccc aaacgcccga tcatcaacac 6900

acccgtggtg agcatcagcg tccatgatga tgaggagctt ctgccccggg ccctggacaa 6960

acccgtcacg gtgcagttcc gcctgctgga gacagaggag cggaccaagc ccatctgtgt 7020

cttctggaac cattcaatcc tggtcagtgg cacaggtggc tggtcggcca gaggctgtga 7080

agtcgtcttc cgcaatgaga gccacgtcag ctgccagtgc aaccacatga cgagcttcgc 7140

tgtgctcatg gacgtttctc ggcgggagaa tggggagatc ctgccactga agacactgac 7200

atacgtggct ctaggtgtca ccttggctgc ccttctgctc accttcttct tcctcactct 7260

cttgcgtatc ctgcgctcca accaacacgg catccgacgt aacctgacag ctgccctggg 7320

cctggctcag ctggtcttcc tcctgggaat caaccaggct gacctccctt ttgcctgcac 7380

agtcattgcc atcctgctgc acttcctgta cctctgcacc ttttcctggg ctctgctgga 7440

ggccttgcac ctgtaccggg cactcactga ggtgcgcgat gtcaacaccg gccccatgcg 7500

cttctactac atgctgggct ggggcgtgcc tgccttcatc acagggctag ccgtgggcct 7560

ggaccccgag ggctacggga accctgactt ctgctggctc tccatctatg acacgctcat 7620

ctggagtttt gctggcccgg tggcctttgc cgtctcgatg agtgtcttcc tgtacatcct 7680

ggcggcccgg gcctcctgtg ctgcccagcg gcagggcttt gagaagaaag gtcctgtctc 7740

gggcctgcag ccctccttcg ccgtcctcct gctgctgagc gccacgtggc tgctggcact 7800

gctctctgtc aacagcgaca ccctcctctt ccactacctc tttgctacct gcaattgcat 7860

ccagggcccc ttcatcttcc tctcctatgt ggtgcttagc aaggaggtcc ggaaagcact 7920

caagcttgcc tgcagccgca agcccagccc tgaccctgct ctgaccacca agtccaccct 7980

gacctcgtcc tacaactgcc ccagccccta cgcagatggg cggctgtacc agccctacgg 8040

agactcggcc ggctctctgc acagcaccag tcgctcgggc aagagtcagc ccagctacat 8100

ccccttcttg ctgagggagg agtccgcact gaaccctggc caagggcccc ctggcctggg 8160

ggatccaggc agcctgttcc tggaaggtca agaccagcag catgatcctg acacggactc 8220

cgacagtgac ctgtccttag aagacgacca gagtggctcc tatgcctcta cccactcatc 8280

agacagtgag gaggaagaag aggagggagga agaggaggcc gccttccctg gagagcaggg 8340

ctgggatagc ctgctggggc ctggagcaga gagactgccc ctgcacagta ctcccaagga 8400

tggggggccca gggcctggca aggccccctg gccaggagac tttgggacca cagcaaaaga 8460

gagtagtggc aacggggccc ctgaggagcg gctgcgggag aatggagatg ccctgtctcg 8520

agaggggtcc ctaggccccc ttccaggctc ttctgcccag cctcacaaag gcatccttaa 8580

gaagaagtgt ctgcccacca tcagcgagaa gagcagcctc ctgcggctcc ccctggagca 8640

atgcacaggg tcttcccggg gctcctccgc tagtgagggc agccggggag gcccccctcc 8700

ccgcccaccg ccccggcaga gcctccagga gcagctgaac ggggtcatgc ccatcgccat 8760

gagcatcaag gcaggcacgg tggatgagga ctcgtcaggc tccgaatttc tcttctttaa 8820

cttcctgcat taaccctggg ccgtggttcc tacgcccgag gctcccttcc cttccccagc 8880

cgcactcatg ccctgctcct gtcttgtgct ttatcctgcc ccgctcccca tcgcctgccc 8940

gcagcagcga cgaaacgtcc atctgaggag cctgggcctt gccgggaggg gtactcaccc 9000

cacctaaggc catctagtgc caactccccc cccaccattc ccctcactgc actttggacc 9060

cctggggcca acatctccaa gacaaagttt ttcagaaaag aggaaaaaaa gaatttaaaa 9120

aaggatctcc actcttcatg acttcaggga ttcatttttt ttatacgctg gaaattgact 9180

cccctttccc ttcccaaaga ggataggacc tcccaggatg cttcccagcc tctcctcagt 9240

ttcccatctg ctgtgcctct gggagaggagag ggactcctgg ggggcctgcc cctcatacgc 9300

catcaccaaa aggaaaggac aaagccacac gcagccaggg cttcacaccc ttcaggctgc 9360

acccgggcag gcctcagaac ggtgaggggc cagggcaaag ggtgtgcctc gtcctgcccg 9420

cactgcctct cccaggaact ggaaaagccc tgtccggtga gggggcagaa ggactcagcg 9480

cccctggacc cccaaatgct gcatgaacac atttcaggg gagcctgtgc ccccaggcgg 9540

gggtcgggca gccccagccc ctctcctttt cctggactct ggccgtgcgc ggcagcccag 9600

gtgtttgctc agttgctgac ccaaaagtgc ttcatttttc gtgcccgccc cgcgccccgg 9660

gcaggccagt catgtgttaa gttgcgcttc tttgctgtga tgtgggtggg ggaggaagag 9720

taaacacagt gctggctcgg ctgccctgag ggtgctcaat caagcacagg tttcaagtct 9780

gggttctggt gtccactcac ccaccccacc ccccaaaatc agacaaatgc tactttgtct 9840

aacctgctgt ggcctctgag acatgttcta tttttaaccc cttcttggaa ttggctctct 9900

tcttcaaagg accaggtcct gttcctcttt ctccccgact ccaccccagc tccctgtgaa 9960

gagagagtta atatatttgt tttatttatt tgctttttgt gttggggatgg gttcgtgtcc 10020

agtcccgggg gtctgatatg gccatcacag gctgggtgtt cccagcagcc ctggcttggg 10080

ggcttgacgc ccttcccctt gccccaggcc atcatctccc cacctctcct cccctctcct 10140

cagttttgcc gactgctttt catctgagtc accatttact ccaagcatgt attccagact 10200

tgtcactgac tttccttctg gagcaggtgg ctagaaaaag aggctgtggg caggaaagaa 10260

aggctcctgt ttctcatttg tgaggccagc ctctggcttt tctgccgtgg attctccccc 10320

gtcttctccc ctcagcaatt cctgcaaagg gttaaaaatt taactggttt ttaactactga 10380

tgacttgatt taaaaaaaat acaaagatgc tggatgctaa cttggtacta accatcagat 10440

tgtacagttt ggttgttgct gtaaataggg tagcgttttg ttgttgttgt tttttcatgc 10500

cccatactac tgaataaact agttctgtgc gggtacagca 10540

<210> 10

<211> 2923

<212> PRT

<213> Homo sapiens

<400> 10

Met Arg Ser Pro Ala Thr Gly Val Pro Leu Pro Thr Pro Pro Pro Pro

1 5 10 15

Leu Leu Leu Leu Leu Leu Leu Leu Leu Pro Pro Pro Leu Leu Gly Asp

20 25 30

Gln Val Gly Pro Cys Arg Ser Leu Gly Ser Arg Gly Arg Gly Ser Ser

35 40 45

Gly Ala Cys Ala Pro Met Gly Trp Leu Cys Pro Ser Ser Ala Ser Asn

50 55 60

Leu Trp Leu Tyr Thr Ser Arg Cys Arg Asp Ala Gly Thr Glu Leu Thr

65 70 75 80

Gly His Leu Val Pro His His Asp Gly Leu Arg Val Trp Cys Pro Glu

85 90 95

Ser Glu Ala His Ile Pro Leu Pro Pro Ala Pro Glu Gly Cys Pro Trp

100 105 110

Ser Cys Arg Leu Leu Gly Ile Gly Gly His Leu Ser Pro Gln Gly Lys

115 120 125

Leu Thr Leu Pro Glu Glu His Pro Cys Leu Lys Ala Pro Arg Leu Arg

130 135 140

Cys Gln Ser Cys Lys Leu Ala Gln Ala Pro Gly Leu Arg Ala Gly Glu

145 150 155 160

Arg Ser Pro Glu Glu Ser Leu Gly Gly Arg Arg Lys Arg Asn Val Asn

165 170 175

Thr Ala Pro Gln Phe Gln Pro Pro Ser Tyr Gln Ala Thr Val Pro Glu

180 185 190

Asn Gln Pro Ala Gly Thr Pro Val Ala Ser Leu Arg Ala Ile Asp Pro

195 200 205

Asp Glu Gly Glu Ala Gly Arg Leu Glu Tyr Thr Met Asp Ala Leu Phe

210 215 220

Asp Ser Arg Ser Asn Gln Phe Phe Ser Leu Asp Pro Val Thr Gly Ala

225 230 235 240

Val Thr Thr Ala Glu Glu Leu Asp Arg Glu Thr Lys Ser Thr His Val

245 250 255

Phe Arg Val Thr Ala Gln Asp His Gly Met Pro Arg Arg Ser Ala Leu

260 265 270

Ala Thr Leu Thr Ile Leu Val Thr Asp Thr Asn Asp His Asp Pro Val

275 280 285

Phe Glu Gln Gln Glu Tyr Lys Glu Ser Leu Arg Glu Asn Leu Glu Val

290 295 300

Gly Tyr Glu Val Leu Thr Val Arg Ala Thr Asp Gly Asp Ala Pro Pro

305 310 315 320

Asn Ala Asn Ile Leu Tyr Arg Leu Leu Glu Gly Ser Gly Gly Ser Pro

325 330 335

Ser Glu Val Phe Glu Ile Asp Pro Arg Ser Gly Val Ile Arg Thr Arg

340 345 350

Gly Pro Val Asp Arg Glu Val Glu Ser Tyr Gln Leu Thr Val Glu

355 360 365

Ala Ser Asp Gln Gly Arg Asp Pro Gly Pro Arg Ser Thr Thr Thr Ala Ala

370 375 380

Val Phe Leu Ser Val Glu Asp Asp Asn Asp Asn Ala Pro Gln Phe Ser

385 390 395 400

Glu Lys Arg Tyr Val Val Gln Val Arg Glu Asp Val Thr Pro Gly Ala

405 410 415

Pro Val Leu Arg Val Thr Ala Ser Asp Arg Asp Lys Gly Ser Asn Ala

420 425 430

Val Val His Tyr Ser Ile Met Ser Gly Asn Ala Arg Gly Gln Phe Tyr

435 440 445

Leu Asp Ala Gln Thr Gly Ala Leu Asp Val Val Ser Pro Leu Asp Tyr

450 455 460

Glu Thr Thr Lys Glu Tyr Thr Leu Arg Val Arg Ala Gln Asp Gly Gly

465 470 475 480

Arg Pro Pro Leu Ser Asn Val Ser Gly Leu Val Thr Val Gln Val Leu

485 490 495

Asp Ile Asn Asp Asn Ala Pro Ile Phe Val Ser Thr Pro Phe Gln Ala

500 505 510

Thr Val Leu Glu Ser Val Pro Leu Gly Tyr Leu Val Leu His Val Gln

515 520 525

Ala Ile Asp Ala Asp Ala Gly Asp Asn Ala Arg Leu Glu Tyr Arg Leu

530 535 540

Ala Gly Val Gly His Asp Phe Pro Phe Thr Ile Asn Asn Gly Thr Gly

545 550 555 560

Trp Ile Ser Val Ala Ala Glu Leu Asp Arg Glu Glu Val Asp Phe Tyr

565 570 575

Ser Phe Gly Val Glu Ala Arg Asp His Gly Thr Pro Ala Leu Thr Ala

580 585 590

Ser Ala Ser Val Ser Val Thr Val Leu Asp Val Asn Asp Asn Asn Pro

595 600 605

Thr Phe Thr Gln Pro Glu Tyr Thr Val Arg Leu Asn Glu Asp Ala Ala

610 615 620

Val Gly Thr Ser Val Val Thr Val Ser Ala Val Asp Arg Asp Ala His

625 630 635 640

Ser Val Ile Thr Tyr Gln Ile Thr Ser Gly Asn Thr Arg Asn Arg Phe

645 650 655

Ser Ile Thr Ser Gln Ser Gly Gly Gly Leu Val Ser Leu Ala Leu Pro

660 665 670

Leu Asp Tyr Lys Leu Glu Arg Gln Tyr Val Leu Ala Val Thr Ala Ser

675 680 685

Asp Gly Thr Arg Gln Asp Thr Ala Gln Ile Val Val Asn Val Thr Asp

690 695 700

Ala Asn Thr His Arg Pro Val Phe Gln Ser Ser His Tyr Thr Val Asn

705 710 715 720

Val Asn Glu Asp Arg Pro Ala Gly Thr Thr Val Val Leu Ile Ser Ala

725 730 735

Thr Asp Glu Asp Thr Gly Glu Asn Ala Arg Ile Thr Tyr Phe Met Glu

740 745 750

Asp Ser Ile Pro Gln Phe Arg Ile Asp Ala Asp Thr Gly Ala Val Thr

755 760 765

Thr Gln Ala Glu Leu Asp Tyr Glu Asp Gln Val Ser Tyr Thr Leu Ala

770 775 780

Ile Thr Ala Arg Asp Asn Gly Ile Pro Gln Lys Ser Asp Thr Thr Thr Tyr

785 790 795 800

Leu Glu Ile Leu Val Asn Asp Val Asn Asp Asn Ala Pro Gln Phe Leu

805 810 815

Arg Asp Ser Tyr Gln Gly Ser Val Tyr Glu Asp Val Pro Pro Phe Thr

820 825 830

Ser Val Leu Gln Ile Ser Ala Thr Asp Arg Asp Ser Gly Leu Asn Gly

835 840 845

Arg Val Phe Tyr Thr Phe Gln Gly Gly Asp Asp Gly Asp Gly Asp Phe

850 855 860

Ile Val Glu Ser Thr Ser Gly Ile Val Arg Thr Leu Arg Arg Leu Asp

865 870 875 880

Arg Glu Asn Val Ala Gln Tyr Val Leu Arg Ala Tyr Ala Val Asp Lys

885 890 895

Gly Met Pro Pro Ala Arg Thr Pro Met Glu Val Thr Val Thr Val Leu

900 905 910

Asp Val Asn Asp Asn Pro Pro Val Phe Glu Gln Asp Glu Phe Asp Val

915 920 925

Phe Val Glu Glu Asn Ser Pro Ile Gly Leu Ala Val Ala Arg Val Thr

930 935 940

Ala Thr Asp Pro Asp Glu Gly Thr Asn Ala Gln Ile Met Tyr Gln Ile

945 950 955 960

Val Glu Gly Asn Ile Pro Glu Val Phe Gln Leu Asp Ile Phe Ser Gly

965 970 975

Glu Leu Thr Ala Leu Val Asp Leu Asp Tyr Glu Asp Arg Pro Glu Tyr

980 985 990

Val Leu Val Ile Gln Ala Thr Ser Ala Pro Leu Val Ser Arg Ala Thr

995 1000 1005

Val His Val Arg Leu Leu Asp Arg Asn Asp Asn Pro Pro Val Leu

1010 1015 1020

Gly Asn Phe Glu Ile Leu Phe Asn Asn Tyr Val Thr Asn Arg Ser

1025 1030 1035

Ser Ser Phe Pro Gly Gly Ala Ile Gly Arg Val Pro Ala His Asp

1040 1045 1050

Pro Asp Ile Ser Asp Ser Leu Thr Tyr Tyr Ser Phe Glu Arg Gly Asn

1055 1060 1065

Glu Leu Ser Leu Val Leu Leu Asn Ala Ser Thr Gly Glu Leu Lys

1070 1075 1080

Leu Ser Arg Ala Leu Asp Asn Asn Arg Pro Leu Glu Ala Ile Met

1085 1090 1095

Ser Val Leu Val Ser Asp Gly Val His Ser Val Thr Ala Gln Cys

1100 1105 1110

Ala Leu Arg Val Thr Ile Ile Thr Asp Glu Met Leu Thr His Ser

1115 1120 1125

Ile Thr Leu Arg Leu Glu Asp Met Ser Pro Glu Arg Phe Leu Ser

1130 1135 1140

Pro Leu Leu Gly Leu Phe Ile Gln Ala Val Ala Ala Thr Leu Ala

1145 1150 1155

Thr Pro Pro Asp His Val Val Val Phe Asn Val Gln Arg Asp Thr

1160 1165 1170

Asp Ala Pro Gly Gly His Ile Leu Asn Val Ser Leu Ser Val Gly

1175 1180 1185

Gln Pro Pro Gly Pro Gly Gly Gly Pro Pro Phe Leu Pro Ser Glu

1190 1195 1200

Asp Leu Gln Glu Arg Leu Tyr Leu Asn Arg Ser Leu Leu Thr Ala

1205 1210 1215

Ile Ser Ala Gln Arg Val Leu Pro Phe Asp Asp Asn Ile Cys Leu

1220 1225 1230

Arg Glu Pro Cys Glu Asn Tyr Met Arg Cys Val Ser Val Leu Arg

1235 1240 1245

Phe Asp Ser Ser Ala Pro Phe Ile Ala Ser Ser Ser Val Leu Phe

1250 1255 1260

Arg Pro Ile His Pro Val Gly Gly Leu Arg Cys Arg Cys Pro Pro

1265 1270 1275

Gly Phe Thr Gly Asp Tyr Cys Glu Thr Glu Val Asp Leu Cys Tyr

1280 1285 1290

Ser Arg Pro Cys Gly Pro His Gly Arg Cys Arg Ser Arg Glu Gly

1295 1300 1305

Gly Tyr Thr Cys Leu Cys Arg Asp Gly Tyr Thr Gly Glu His Cys

1310 1315 1320

Glu Val Ser Ala Arg Ser Gly Arg Cys Thr Pro Gly Val Cys Lys

1325 1330 1335

Asn Gly Gly Thr Cys Val Asn Leu Leu Val Gly Gly Phe Lys Cys

1340 1345 1350

Asp Cys Pro Ser Gly Asp Phe Glu Lys Pro Tyr Cys Gln Val Thr

1355 1360 1365

Thr Arg Ser Phe Pro Ala His Ser Phe Ile Thr Phe Arg Gly Leu

1370 1375 1380

Arg Gln Arg Phe His Phe Thr Leu Ala Leu Ser Phe Ala Thr Lys

1385 1390 1395

Glu Arg Asp Gly Leu Leu Leu Tyr Asn Gly Arg Phe Asn Glu Lys

1400 1405 1410

His Asp Phe Val Ala Leu Glu Val Ile Gln Glu Gln Val Gln Leu

1415 1420 1425

Thr Phe Ser Ala Gly Glu Ser Thr Thr Thr Val Ser Pro Phe Val

1430 1435 1440

Pro Gly Gly Val Ser Asp Gly Gln Trp His Thr Val Gln Leu Lys

1445 1450 1455

Tyr Tyr Asn Lys Pro Leu Leu Gly Gln Thr Gly Leu Pro Gln Gly

1460 1465 1470

Pro Ser Glu Gln Lys Val Ala Val Val Thr Val Asp Gly Cys Asp

1475 1480 1485

Thr Gly Val Ala Leu Arg Phe Gly Ser Val Leu Gly Asn Tyr Ser

1490 1495 1500

Cys Ala Ala Gln Gly Thr Gln Gly Gly Ser Lys Lys Ser Leu Asp

1505 1510 1515

Leu Thr Gly Pro Leu Leu Leu Gly Gly Val Pro Asp Leu Pro Glu

1520 1525 1530

Ser Phe Pro Val Arg Met Arg Gln Phe Val Gly Cys Met Arg Asn

1535 1540 1545

Leu Gln Val Asp Ser Arg His Ile Asp Met Ala Asp Phe Ile Ala

1550 1555 1560

Asn Asn Gly Thr Val Pro Gly Cys Pro Ala Lys Lys Asn Val Cys

1565 1570 1575

Asp Ser Asn Thr Cys His Asn Gly Gly Thr Cys Val Asn Gln Trp

1580 1585 1590

Asp Ala Phe Ser Cys Glu Cys Pro Leu Gly Phe Gly Gly Lys Ser

1595 1600 1605

Cys Ala Gln Glu Met Ala Asn Pro Gln His Phe Leu Gly Ser Ser

1610 1615 1620

Leu Val Ala Trp His Gly Leu Ser Leu Pro Ile Ser Gln Pro Trp

1625 1630 1635

Tyr Leu Ser Leu Met Phe Arg Thr Arg Gln Ala Asp Gly Val Leu

1640 1645 1650

Leu Gln Ala Ile Thr Arg Gly Arg Ser Thr Ile Thr Leu Gln Leu

1655 1660 1665

Arg Glu Gly His Val Met Leu Ser Val Glu Gly Thr Gly Leu Gln

1670 1675 1680

Ala Ser Ser Leu Arg Leu Glu Pro Gly Arg Ala Asn Asp Gly Asp

1685 1690 1695

Trp His His Ala Gln Leu Ala Leu Gly Ala Ser Gly Gly Pro Gly

1700 1705 1710

His Ala Ile Leu Ser Phe Asp Tyr Gly Gln Gln Arg Ala Glu Gly

1715 1720 1725

Asn Leu Gly Pro Arg Leu His Gly Leu His Leu Ser Asn Ile Thr

1730 1735 1740

Val Gly Gly Ile Pro Gly Pro Ala Gly Gly Val Ala Arg Gly Phe

1745 1750 1755

Arg Gly Cys Leu Gln Gly Val Arg Val Ser Asp Thr Pro Glu Gly

1760 1765 1770

Val Asn Ser Leu Asp Pro Ser His Gly Glu Ser Ile Asn Val Glu

1775 1780 1785

Gln Gly Cys Ser Leu Pro Asp Pro Cys Asp Ser Asn Pro Cys Pro

1790 1795 1800

Ala Asn Ser Tyr Cys Ser Asn Asp Trp Asp Ser Tyr Ser Cys Ser

1805 1810 1815

Cys Asp Pro Gly Tyr Tyr Gly Asp Asn Cys Thr Asn Val Cys Asp

1820 1825 1830

Leu Asn Pro Cys Glu His Gln Ser Val Cys Thr Arg Lys Pro Ser

1835 1840 1845

Ala Pro His Gly Tyr Thr Cys Glu Cys Pro Pro Asn Tyr Leu Gly

1850 1855 1860

Pro Tyr Cys Glu Thr Arg Ile Asp Gln Pro Cys Pro Arg Gly Trp

1865 1870 1875

Trp Gly His Pro Thr Cys Gly Pro Cys Asn Cys Asp Val Ser Lys

1880 1885 1890

Gly Phe Asp Pro Asp Cys Asn Lys Thr Ser Gly Glu Cys His Cys

1895 1900 1905

Lys Glu Asn His Tyr Arg Pro Pro Gly Ser Pro Thr Cys Leu Leu

1910 1915 1920

Cys Asp Cys Tyr Pro Thr Gly Ser Leu Ser Arg Val Cys Asp Pro

1925 1930 1935

Glu Asp Gly Gln Cys Pro Cys Lys Pro Gly Val Ile Gly Arg Gln

1940 1945 1950

Cys Asp Arg Cys Asp Asn Pro Phe Ala Glu Val Thr Thr Asn Gly

1955 1960 1965

Cys Glu Val Asn Tyr Asp Ser Cys Pro Arg Ala Ile Glu Ala Gly

1970 1975 1980

Ile Trp Trp Pro Arg Thr Arg Phe Gly Leu Pro Ala Ala Ala Pro

1985 1990 1995

Cys Pro Lys Gly Ser Phe Gly Thr Ala Val Arg His Cys Asp Glu

2000 2005 2010

His Arg Gly Trp Leu Pro Pro Asn Leu Phe Asn Cys Thr Ser Ile

2015 2020 2025

Thr Phe Ser Glu Leu Lys Gly Phe Ala Glu Arg Leu Gln Arg Asn

2030 2035 2040

Glu Ser Gly Leu Asp Ser Gly Arg Ser Gln Gln Leu Ala Leu Leu

2045 2050 2055

Leu Arg Asn Ala Thr Gln His Thr Ala Gly Tyr Phe Gly Ser Asp

2060 2065 2070

Val Lys Val Ala Tyr Gln Leu Ala Thr Arg Leu Leu Ala His Glu

2075 2080 2085

Ser Thr Gln Arg Gly Phe Gly Leu Ser Ala Thr Gln Asp Val His

2090 2095 2100

Phe Thr Glu Asn Leu Leu Arg Val Gly Ser Ala Leu Leu Asp Thr

2105 2110 2115

Ala Asn Lys Arg His Trp Glu Leu Ile Gln Gln Thr Glu Gly Gly

2120 2125 2130

Thr Ala Trp Leu Leu Gln His Tyr Glu Ala Tyr Ala Ser Ala Leu

2135 2140 2145

Ala Gln Asn Met Arg His Thr Tyr Leu Ser Pro Phe Thr Ile Val

2150 2155 2160

Thr Pro Asn Ile Val Ile Ser Val Val Arg Leu Asp Lys Gly Asn

2165 2170 2175

Phe Ala Gly Ala Lys Leu Pro Arg Tyr Glu Ala Leu Arg Gly Glu

2180 2185 2190

Gln Pro Pro Asp Leu Glu Thr Thr Thr Val Ile Leu Pro Glu Ser Val

2195 2200 2205

Phe Arg Glu Thr Pro Pro Val Val Arg Pro Ala Gly Pro Gly Glu

2210 2215 2220

Ala Gln Glu Pro Glu Glu Leu Ala Arg Arg Gln Arg Arg His Pro

2225 2230 2235

Glu Leu Ser Gln Gly Glu Ala Val Ala Ser Val Ile Ile Tyr Arg

2240 2245 2250

Thr Leu Ala Gly Leu Leu Pro His Asn Tyr Asp Pro Asp Lys Arg

2255 2260 2265

Ser Leu Arg Val Pro Lys Arg Pro Ile Ile Asn Thr Pro Val Val

2270 2275 2280

Ser Ile Ser Val His Asp Asp Glu Glu Leu Leu Pro Arg Ala Leu

2285 2290 2295

Asp Lys Pro Val Thr Val Gln Phe Arg Leu Leu Glu Thr Glu

2300 2305 2310

Arg Thr Lys Pro Ile Cys Val Phe Trp Asn His Ser Ile Leu Val

2315 2320 2325

Ser Gly Thr Gly Gly Trp Ser Ala Arg Gly Cys Glu Val Val Phe

2330 2335 2340

Arg Asn Glu Ser His Val Ser Cys Gln Cys Asn His Met Thr Ser

2345 2350 2355

Phe Ala Val Leu Met Asp Val Ser Arg Arg Glu Asn Gly Glu Ile

2360 2365 2370

Leu Pro Leu Lys Thr Leu Thr Tyr Val Ala Leu Gly Val Thr Leu

2375 2380 2385

Ala Ala Leu Leu Leu Thr Phe Phe Phe Leu Thr Leu Leu Arg Ile

2390 2395 2400

Leu Arg Ser Asn Gln His Gly Ile Arg Arg Asn Leu Thr Ala Ala

2405 2410 2415

Leu Gly Leu Ala Gln Leu Val Phe Leu Leu Gly Ile Asn Gln Ala

2420 2425 2430

Asp Leu Pro Phe Ala Cys Thr Val Ile Ala Ile Leu Leu His Phe

2435 2440 2445

Leu Tyr Leu Cys Thr Phe Ser Trp Ala Leu Leu Glu Ala Leu His

2450 2455 2460

Leu Tyr Arg Ala Leu Thr Glu Val Arg Asp Val Asn Thr Gly Pro

2465 2470 2475

Met Arg Phe Tyr Tyr Met Leu Gly Trp Gly Val Pro Ala Phe Ile

2480 2485 2490

Thr Gly Leu Ala Val Gly Leu Asp Pro Glu Gly Tyr Gly Asn Pro

2495 2500 2505

Asp Phe Cys Trp Leu Ser Ile Tyr Asp Thr Leu Ile Trp Ser Phe

2510 2515 2520

Ala Gly Pro Val Ala Phe Ala Val Ser Met Ser Val Phe Leu Tyr

2525 2530 2535

Ile Leu Ala Ala Arg Ala Ser Cys Ala Ala Gln Arg Gln Gly Phe

2540 2545 2550

Glu Lys Lys Gly Pro Val Ser Gly Leu Gln Pro Ser Phe Ala Val

2555 2560 2565

Leu Leu Leu Leu Ser Ala Thr Trp Leu Leu Ala Leu Leu Ser Val

2570 2575 2580

Asn Ser Asp Thr Leu Leu Phe His Tyr Leu Phe Ala Thr Cys Asn

2585 2590 2595

Cys Ile Gln Gly Pro Phe Ile Phe Leu Ser Tyr Val Val Leu Ser

2600 2605 2610

Lys Glu Val Arg Lys Ala Leu Lys Leu Ala Cys Ser Arg Lys Pro

2615 2620 2625

Ser Pro Asp Pro Ala Leu Thr Thr Lys Ser Thr Leu Thr Ser Ser

2630 2635 2640

Tyr Asn Cys Pro Ser Pro Tyr Ala Asp Gly Arg Leu Tyr Gln Pro

2645 2650 2655

Tyr Gly Asp Ser Ala Gly Ser Leu His Ser Thr Ser Arg Ser Gly

2660 2665 2670

Lys Ser Gln Pro Ser Tyr Ile Pro Phe Leu Leu Arg Glu Glu Ser

2675 2680 2685

Ala Leu Asn Pro Gly Gln Gly Pro Pro Gly Leu Gly Asp Pro Gly

2690 2695 2700

Ser Leu Phe Leu Glu Gly Gln Asp Gln Gln His Asp Pro Asp Thr

2705 2710 2715

Asp Ser Asp Ser Asp Leu Ser Leu Glu Asp Asp Gln Ser Gly Ser

2720 2725 2730

Tyr Ala Ser Thr His Ser Ser Asp Ser Glu Glu Glu Glu Glu

2735 2740 2745

Glu Glu Glu Glu Ala Ala Phe Pro Gly Glu Gln Gly Trp Asp Ser

2750 2755 2760

Leu Leu Gly Pro Gly Ala Glu Arg Leu Pro Leu His Ser Thr Pro

2765 2770 2775

Lys Asp Gly Gly Pro Gly Pro Gly Lys Ala Pro Trp Pro Gly Asp

2780 2785 2790

Phe Gly Thr Thr Ala Lys Glu Ser Ser Gly Asn Gly Ala Pro Glu

2795 2800 2805

Glu Arg Leu Arg Glu Asn Gly Asp Ala Leu Ser Arg Glu Gly Ser

2810 2815 2820

Leu Gly Pro Leu Pro Gly Ser Ser Ala Gln Pro His Lys Gly Ile

2825 2830 2835

Leu Lys Lys Lys Cys Leu Pro Thr Ile Ser Glu Lys Ser Ser Leu

2840 2845 2850

Leu Arg Leu Pro Leu Glu Gln Cys Thr Gly Ser Ser Arg Gly Ser

2855 2860 2865

Ser Ala Ser Glu Gly Ser Arg Gly Gly Pro Pro Pro Arg Pro Pro

2870 2875 2880

Pro Arg Gln Ser Leu Gln Glu Gln Leu Asn Gly Val Met Pro Ile

2885 2890 2895

Ala Met Ser Ile Lys Ala Gly Thr Val Asp Glu Asp Ser Ser Gly

2900 2905 2910

Ser Glu Phe Leu Phe Phe Asn Phe Leu His

2915 2920

<210> 11

<211> 2091

<212> DNA

<213> Homo sapiens

<400> 11

cgctgtgccc cgattccgcg tcgggctgcg cgggcggcca gcggttcagg cgcgcgcgga 60

gagctctggc tcagagtttg cgatccgaga gcggggatccg cgctccctcg gtccttcctc 120

cctcccctct tgcggcctcc cgctgtcatc tggagccgct cctgccgccc cctggcggcg 180

accgcgggaa gggccggccc ccatccgcac ccctgacccc ggaggtcaac aacgggatgg 240

tccctgggtc ccaggggaag agacatcacc cagtaggagg gagtacggtc tagacagagg 300

ccacgagggc gggagggggc gagagtggag agtggcccag ctggccaggg tcgtctaagt 360

gagaggaaaa gggagagggc ggttgagacc aggccctgaa ttccgcgttc atcttatcct 420

gaggtctgtg gggacctgtt gaaggactgg ggcaggggac ggacgcgggc atccttccat 480

ttggaacagc cattccggca gcatcaggat ggggcggagg caaagcgggg agtgggcgag 540

gcaagtggtg ctgtaaacct gtgcgagaag ggggcggtga ctctaagggc aggaaggagc 600

cctggtcaca cacacactcc cacgcaaggt attcagtgcc gagtgtggcc ttggtgctag 660

gattcaaaga ggaaaggaag aaaactttcc attctaaaag aaactccacg tgaggcgaag 720

aagatgaaat atagtcagaa aaccatacca gtaggtggta gttaagttga taaatgatgc 780

atacgacatc ctatagaaga ctgtcaccac cccacctcac tgatcagccc tctgcctaca 840

gccacaccca cagaacattc agccatttct cctgtggttc ccagcctgca gcacagcgtc 900

tgcacgtgga actctggaat gctgacctac agtctgagtt cctgtgccct tgcctggggc 960

tgactctcta cttgacctgt aacccacaac tgggcaagag aaaattctgc agccacagct 1020

ctgaggacat gagcaaaatg gtttccagac ggaatgtcaa ggattcccat gaagtgtcag 1080

ggagtcttca ggccacactt caggttatct ccttctcttt cccttttctg cttcacactt 1140

gctctcatcc tctttctcac cccacatctg gtcagaggag ataggaaggt tcttgttacc 1200

tggtacaaga caacttttgg aatcccagat attcagatta tttccccttt tcctctttgc 1260

aaatgataat actcacagcc aagaggcatc acccggatcc gaggctgctt ctccttagga 1320

catgcagaca gaaggagaag gcggggctgg cagcctccag tccacagcct ccctttcttc 1380

ttccggcgat gattaactag gcctagacaa tggagatcta cggcatacgc ccagggcctc 1440

ctcttctcaa gcatggctga tcagtcactt tcccgtctat ccttcattta ttgaagccaa 1500

ctatgaacga ctaaaggaag gatgagaaaa gtcacccaaa gtcaaagggg acagcgtggg 1560

agactgttct agacagaagg aaacaccttt gcaaagaccc tgaggaaggc aggggactct 1620

ccaggagcag aagggctgtg tggcttcaga gtccacaaaa gagagcagat acaggacact 1680

ggctagagca ggccctggag cccgctgctg tcctggaggc cttggggagg cccagtgttc 1740

ccagggtgga agaagtaggg gacagcttga cgtagtggct gttgatcagc tgatatggaa 1800

gtatgtcatt ttattaacaa ttgagaaagg agtgctgtgc aattccattc aatgccagtg 1860

atgcttatgg ccgtttttat gagttctgtc attttcaaat gagcaagagg aagcctctaa 1920

gggggtttaa gcagggactg acgtaatcag atctgtgttt ttccaaaggg agagggagaa 1980

aaagaacatt tcttattttt caaaaaaggt aatgcaaaag catcattcca caattctctt 2040

gtaatgaaaa aaataaatgc aaacttaagc aaatccatca ttctgaaaga a 2091

<210> 12

<211> 136

<212> PRT

<213> Homo sapiens

<400> 12

Met Met His Thr Thr Ser Tyr Arg Arg Leu Ser Pro Pro His Leu Thr

1 5 10 15

Asp Gln Pro Ser Ala Tyr Ser His Thr His Arg Thr Phe Ser His Phe

20 25 30

Ser Cys Gly Ser Gln Pro Ala Ala Gln Arg Leu His Val Glu Leu Trp

35 40 45

Asn Ala Asp Leu Gln Ser Glu Phe Leu Cys Pro Cys Leu Gly Leu Thr

50 55 60

Leu Tyr Leu Thr Cys Asn Pro Gln Leu Gly Lys Arg Lys Phe Cys Ser

65 70 75 80

His Ser Ser Glu Asp Met Ser Lys Met Val Ser Arg Arg Asn Val Lys

85 90 95

Asp Ser His Glu Val Ser Gly Ser Leu Gln Ala Thr Leu Gln Val Ile

100 105 110

Ser Phe Ser Phe Pro Phe Leu Leu His Thr Cys Ser His Pro Leu Ser

115 120 125

His Pro Thr Ser Gly Gln Arg Arg

130 135

<210> 13

<211> 3715

<212> DNA

<213> Homo sapiens

<400> 13

cctaccccag ctctcgcgcc gcgtgcagag gtgctcaagc ctcctcgcgg tccgcagtca 60

gtgccgccgc gcccggcctc ccgcacgccc cgcaggtagc gcccccgccc gcggcccaga 120

gtgcgctcgc gccggcacca gctcccggat aaacggcgcg ccgcgcggag atgacagccg 180

aggagatgaa ggcgaccgag agcggggcgc agtcggcgcc gctgcccatg gagggagtgg 240

acatcagccc caaacaggac gaaggcgtgc tgaaggtcat caagagagag ggcacaggta 300

cagagatgcc catgattggg gaccgagtct ttgtccacta cactggctgg ctattagatg 360

gcacaaagtt tgactccagt ctggatcgca aggacaaatt ctcctttgac ctgggaaaag 420

gggaggtcat caaggcttgg gacattgcca tagccaccat gaaggtgggg gaggtgtgcc 480

acatcacctg caaaccagaa tatgcctacg gttcagcagg cagtcctcca aagattcccc 540

ccaatgccac gcttgtattt gagtggagt tgtttgagtt taagggagaa gatctgacgg 600

aagaggaaga tggcggaatc attcgcagaa tacagactcg cggtgaaggc tatgctaagc 660

ccaatgaggg tgctatcgtg gaggttgcac tggaagggta ctacaaggac aagctctttg 720

accagcggga gctccgcttt gagattggcg aggggggagaa cctggatctg ccttatggtc 780

tggagagggc cattcagcgc atggagaaag gagaacattc catcgtgtac ctcaagccca 840

gctatgcttt tggcagtgtt gggaaggaaa agttccaaat cccaccaaat gctgagctga 900

aatatgaatt acacctcaag agttttgaaa aggccaagga gtcttgggag atgaattcag 960

aagagaagct ggaacagagc accatagtga aagagcgggg cactgtgtac ttcaaggaag 1020

gtaaatacaa gcaagcttta ctacagtata agaagatcgt gtcttggctg gaatatgagt 1080

ctagtttttc caatgaggaa gcacagaaag cacaggccct tcgactggcc tctcacctca 1140

acctggccat gtgtcatctg aaactacagg ccttctctgc tgccattgaa agctgtaaca 1200

aggccctaga actggacagc aacaacgaga aggggcctctt ccgccgggga gaggcccacc 1260

tggccgtgaa tgactttgaa ctggcacggg ctgatttcca gaaggtcctg cagctctacc 1320

ccaacaacaa agccgccaag acccagctgg ctgtgtgcca gcagcggatc cgaaggcagc 1380

ttgcccggga gaagaagctc tatgccaata tgtttgagag gctggctgag gaggagaaca 1440

aggccaaggc aggggcttcc tcaggagacc atcccactga cacagagatg aaggaggagc 1500

agaagagcaa cacggcaggg agccagtctc aggtggagac agaagcatag cccctctcca 1560

ccagccctac tcctgcggct gcctgccccc cagtctcccc actccaccct gttagttttg 1620

taaaaactga agaattttga gtgaattaga cctttatatttt tctatctggt tggatggtgg 1680

ctttagggga agggggaaag gtgtaggctg ggggattgag gtggggaatc atttagctg 1740

gtgtcagccc ctcttccctt cctccattgc acatgaacat atgtccatcc atatatattc 1800

atcagaatgt taatttattt tgctccctct gttaggtcca ttttctaagg gtagaagagg 1860

caagtggtag ggatgaggtc tgataagaac ccagggtgga gagggagact cctgggcagc 1920

cgttttcctc atcctttccc tctcccagtc catttccaaa tgtggcctcc atgtgggtgc 1980

tagggacatg ggaaaaacca ctgctatgcc atttcttctc tctgttccct tcctcacccc 2040

cgacggtgtg gctgatgatg tcttctggtg tcatggtgac caccccctgt tccctgttct 2100

ggtatttccc ctgtcagttt cccctctcgg ccaggttgtg tcccaaaatc ccctcagcct 2160

cttctctgca cgttgctgaa ggtccaggct tgcctcaagt tccatgcttg agcaataaag 2220

tggaaacaat aaaacctggg tgtcagacaa ccctttctgt tcagccttgg agtggtgggt 2280

atgggtgggt acataatggg tagtagcaca atcaaggggt cacccactta gttccagttg 2340

agcttaaata agtgagcatc tcatgtagat gccatagttg ggcaggaagc agccccacca 2400

tgcatggctt cctgagcact gcacaggctg ccgctgggat ttgtgtctat ggcttcgccc 2460

aaggttccca gcactccctc cctccagcaa cctggcagtt ttagtgcctc tggttttctt 2520

ccctgacact taggaagacg aaagtataaa gatctagaag actgggacac catgcatgtt 2580

cattttgaag ttggaattgg tcttctgcct acctctgatc tggcagaggt atctgcattt 2640

tggtttgtta acaaggtaaa actcctggtg tcactgacct cctcctgtca gataacttac 2700

atgattaagg ttaagagtaa agcagagtgt tcacgtccag cttccttctc agccttaaca 2760

ggaaaaggct tgtgcttttt ttctaactat gctttgaccc ttaactccta tggcatgatg 2820

gggccctggg agaagccagg cagcacaagc cagtcatgct gagctgcctc cagataatcc 2880

tggctccagg ccagagcccg tgtctgcct catccctctc tcctactgtg agctctccag 2940

tcctttccca acagcgatgt ggttgtctgc ttagccacat gcctgtatag ttccttccag 3000

aagaaatgta taatggtgga agatgtattt ctgtgtgaaa attttcacca agtcatacaa 3060

cacagctgat gctggagcca ggattaaaat tggggtgtac aagtctccca gtgtgagtat 3120

cccttgagcc caagacacca aggatgcaga gaactgtgac tgtgccactg cacgccagcc 3180

tgggcaagag agtgagacca tctctttttt aaaaaagtcc ctgtgtaact gctttcttac 3240

tgggcttacc tcacatcaca gccctgtgtt tgtggtttgt gtctgggtcc tcttggtatt 3300

tcaaaagtag tagattctta cgcctgcagc caacaataat cactaactca agcatttatg 3360

gagtaagcct agcactgtac tgacagcatc acatgagtga aactgaatcc ttgcaaccat 3420

cctacaaaga aggtataact ttaataaccc tatttacaga taagaaaacc aagactcaga 3480

agttaaatgg aaaggtgagg tctctgaact aatccagact ctcccatgag gttcctttgg 3540

caagtcctgg gcttctgtcc tcatctgcaa aatcgaaagc attcctgagg tttcttccag 3600

ctctgcatcc tgtaggattc caagaatgta aaactgcatg taaccgtgga acatctagag 3660

ataagtctta gtttatgtaa cattaaaact gtctagtgag gatgttttgt taaaa 3715

<210> 14

<211> 459

<212> PRT

<213> Homo sapiens

<400> 14

Met Thr Ala Glu Glu Met Lys Ala Thr Glu Ser Gly Ala Gln Ser Ala

1 5 10 15

Pro Leu Pro Met Glu Gly Val Asp Ile Ser Pro Lys Gln Asp Glu Gly

20 25 30

Val Leu Lys Val Ile Lys Arg Glu Gly Thr Gly Thr Glu Met Pro Met

35 40 45

Ile Gly Asp Arg Val Phe Val His Tyr Thr Gly Trp Leu Leu Asp Gly

50 55 60

Thr Lys Phe Asp Ser Ser Leu Asp Arg Lys Asp Lys Phe Ser Phe Asp

65 70 75 80

Leu Gly Lys Gly Glu Val Ile Lys Ala Trp Asp Ile Ala Ile Ala Thr

85 90 95

Met Lys Val Gly Glu Val Cys His Ile Thr Cys Lys Pro Glu Tyr Ala

100 105 110

Tyr Gly Ser Ala Gly Ser Pro Pro Lys Ile Pro Pro Asn Ala Thr Leu

115 120 125

Val Phe Glu Val Glu Leu Phe Glu Phe Lys Gly Glu Asp Leu Thr Glu

130 135 140

Glu Glu Asp Gly Gly Ile Ile Arg Arg Ile Gln Thr Arg Gly Glu Gly

145 150 155 160

Tyr Ala Lys Pro Asn Glu Gly Ala Ile Val Glu Val Ala Leu Glu Gly

165 170 175

Tyr Tyr Lys Asp Lys Leu Phe Asp Gln Arg Glu Leu Arg Phe Glu Ile

180 185 190

Gly Glu Gly Glu Asn Leu Asp Leu Pro Tyr Gly Leu Glu Arg Ala Ile

195 200 205

Gln Arg Met Glu Lys Gly Glu His Ser Ile Val Tyr Leu Lys Pro Ser

210 215 220

Tyr Ala Phe Gly Ser Val Gly Lys Glu Lys Phe Gln Ile Pro Pro Asn

225 230 235 240

Ala Glu Leu Lys Tyr Glu Leu His Leu Lys Ser Phe Glu Lys Ala Lys

245 250 255

Glu Ser Trp Glu Met Asn Ser Glu Glu Lys Leu Glu Gln Ser Thr Ile

260 265 270

Val Lys Glu Arg Gly Thr Val Tyr Phe Lys Glu Gly Lys Tyr Lys Gln

275 280 285

Ala Leu Leu Gln Tyr Lys Lys Ile Val Ser Trp Leu Glu Tyr Glu Ser

290 295 300

Ser Phe Ser Asn Glu Glu Ala Gln Lys Ala Gln Ala Leu Arg Leu Ala

305 310 315 320

Ser His Leu Asn Leu Ala Met Cys His Leu Lys Leu Gln Ala Phe Ser

325 330 335

Ala Ala Ile Glu Ser Cys Asn Lys Ala Leu Glu Leu Asp Ser Asn Asn

340 345 350

Glu Lys Gly Leu Phe Arg Arg Gly Glu Ala His Leu Ala Val Asn Asp

355 360 365

Phe Glu Leu Ala Arg Ala Asp Phe Gln Lys Val Leu Gln Leu Tyr Pro

370 375 380

Asn Asn Lys Ala Ala Lys Thr Gln Leu Ala Val Cys Gln Gln Arg Ile

385 390 395 400

Arg Arg Gln Leu Ala Arg Glu Lys Lys Leu Tyr Ala Asn Met Phe Glu

405 410 415

Arg Leu Ala Glu Glu Glu Asn Lys Ala Lys Ala Glu Ala Ser Ser Gly

420 425 430

Asp His Pro Thr Asp Thr Glu Met Lys Glu Glu Gln Lys Ser Asn Thr

435 440 445

Ala Gly Ser Gln Ser Gln Val Glu Thr Glu Ala

450 455

<210> 15

<211> 13546

<212> DNA

<213> Homo sapiens

<400> 15

ggaggtcggc gcagctgccc ctttgggctt tggctctgga ctggagcgca gcatccttcg 60

aggctgcagc cgccacggct gttgccgtaa gcaatcctcc tgcctcagcc tcccgagtag 120

ctgggactcg ggaccagcct cccgagtatt ggtcagatga catttaccat caccgttttc 180

ttcttctttc atcatcatca tcatcaccat tgccactacc accacctcca aggccactac 240

caccacagca tctctgttcc tccatcagag ctcttcaagt tctgtaaagg cagattctct 300

aaaggcatgc ctggtggcat cacgtttttc acatctccgc atctggaccc tgcccaagcg 360

aaggctgatc taggcagtct cattgctgga gatgactgtc agctgctttc tctgcatagc 420

caccatcaca tgcctcacca ctggagcctg ggaagcctga ccacaaaccg gcatctccaa 480

ggcatgaata attaggtagg cataatggaa ggcactcatt gtaccctcca attgcataag 540

cccattacgg aactctgcta catcagcttc tgtcttccaa agggggaagt cagaggattt 600

tcatacaagg gcactgtaac tctagacaga tccaataaag gttttcataa ctgctaccaa 660

gtcagggagg agtcagacat catcagcctc agccaggagc cggacgaaca tccaggcgac 720

atatttttca agcagactcc cacgaaagac attctaactg agctgtacaa actcacaaca 780

gagagggaga gactgctaac caatctcctg agctcagacc acatcctggg gatcacgatg 840

gggaaccagg aggggaagct gcaagagctg tccgtgagcc tggcccccga ggatgactgt 900

ttccagagtg ctggtgactg gcagggag ctccccgtgg gccctctcaa taagaggagc 960

acccacggga acaaaaagcc tcggaggtct agtggaagga gagagagctt tggggccctt 1020

ccacagaaga ggaccaaaag aaaagggcgt ggaggccgag aatcagctcc tctgatgggc 1080

aaggacaaga tctgttccag ccactccctt cctctttcta gaacaaggcc taacctttgg 1140

gtactagagg agaaaggaaa tctgctcccg aatggggcac ttgcctgctc cctgcagagg 1200

agagagagct gccccccaga tattcccaag acgccagaca cagaccttgg ctttggggagc 1260

tttgagacgg ctttcaagga cactgggctt ggaagagaag tgctgccccc tgactgcagc 1320

tccacagagg caggagggga tggcattcgg aggccgccga gcgggctgga gcatcagcaa 1380

acaggtttgt ctgaaagtca ccaggaccct gagaagcatc cagaggcaga aaaggatgag 1440

atggagaagc cggctaagcg gacttgcaag cagaaacctg tctccaaagt ggtggccaaa 1500

gttcaggacc tgtcctccca ggtacaaaga gtagttaaaa cgcattctaa gggtaaggag 1560

acgattgcca ttcgcccagc agcccacgct gagtttgtac ccaaagccga cttgctcacc 1620

ctcccgggag ctgaggctgg ggctcatggc tccaggcggc agggcaagga gcggcaaggg 1680

gataggtcat cgcagtcgcc agccggggaa acagcctcca tttctagtgt gtcggccagt 1740

gccgaggggg ccgtgaacaa ggtccccctg aaggtgatag agtgagaa gttagatgaa 1800

gcccctgagg ggaaaagact gggcttccct gtccacacga gtgtccctca cactcgccca 1860

gaaacgagaa acaagaggag agccgggttg ccccttggtg gccacaagtc cttgtttctg 1920

gatctgcccc acaaagtagg tcctgactcc tcacaaccca gaggtgataa gaagaagcca 1980

tccccaccag caccggcagc tcttggcaag gtgtttaata attcagcctc gcagtccagc 2040

acacacaaac agacgtcacc tgttccctcg cctctgtctc caaggctccc cagccctcag 2100

cagcatcaca ggatcctccg gctccctgca ttgcctggtg agagggaagc tgctcttaat 2160

gactctcctt gtagaaagag ccgtgtcttc tctgggtgcg tctctgctga caccttggag 2220

ccaccatcct ctgcaaaggt cacggagacc aaaggagcca gcccggcctt cctcagagca 2280

ggccaacctc ggttggtgcc tggggaaact ttggaaaaga gcttggggcc agggaagacc 2340

acagctgagc cccagcacca gtcacctcca ggtatctcct ctgagggctt tccctgggac 2400

ggcttcaatg agcagacacc taaagacctt cccaacagag atggaggcgc gtgggttctg 2460

ggctacagag cgggaccagc ctgtccattt ttgcttcatg aggaaaggga gaagtcaaac 2520

aggagcgaat tgtacttgga tctccatcct gaccacagcc tgactgagca ggatgacagg 2580

actcctggca gacttcaagc tgtctggcca cccccaaaga caaaagacac agaagaaaaa 2640

gtgggactga agtacactga agcagaatac caagctgcta ttttacactt gaagaggggag 2700

cacaaagaag aaattgaaaa cctgcaggca cagtttgaac ttcgggcatt tcatatccgg 2760

ggcgagcatg caatgataac agcgagacta gaagaaacca ttgaaaatct gaaacacgag 2820

ctagaacaca gatggcgagg gggttgtgaa gagaggaaag atgtgtgcat ttccaccgat 2880

gatgactgcc ctccaaagac cttcagaaat gtgtgcgtcc agacagacag agagaccttc 2940

ctcaagccct gtgaaagtga aagcaagaca accagaagta atcaattagt acccaaaaag 3000

ctgaatatct cctctttaag ccagctctca cccccaaatg acccacaaaga catccatgca 3060

gcactccagc caatggaggg catggcatca aatcagcaga aggcattgcc tccgcctccc 3120

gcatccatcc ctccccctcc gcccctcccc tcaggacttg gatctttgtc tcccgcacct 3180

ccaatgccac ctgtgagtgc tgggccaccg ctaccacctc cgcctcctcc accgccacct 3240

ctacctccac cttcaagtgc tggacctcca ccacccccac ccccaccccc acttcctaac 3300

tcccctgccc cacccaaccc tggagggcct cctcctgctc caccaccccc aggacttgca 3360

cccccacctccccctggact cttctttgga cttggctctt cttccagtca atgtcctcga 3420

aaaccagcca tcgagcccag ttgtcccatg aagcctttat attggactag gatacaaata 3480

agtgatagga gccaaaatgc taccccaacc ttatgggact ccttagaaga acctgacatt 3540

cgggacccca gtgaatttga gtatttattc tccaaagaca caactcaaca gaagaaaaaa 3600

cctctgtcag agacttatga gaagaaaaac aaggtcaaaa agatcatcaa attgttggat 3660

ggaaaacgat ctcaaactgt gggaatcttg atatctagtt tacatttaga aatgaaggat 3720

atccaacagg ccattttcaa tgtggatgac tccgtggttg atctggagac cctggcagcc 3780

ttatatgaaa acaggccca agaggatgag ctggttaaaa taagaaagta ttacgagaca 3840

tccaaagaag aagaactgaa gctgctggat aaacctgagc aatttttaca tgagttagcc 3900

cagattccta attttgctga acgtgcccag tgcataatct tcagatctgt cttttctgag 3960

ggtatcacct ccttgcacag aaaggtagag atcatcacgc gagcttctaa ggacttgctg 4020

cacgtgaaga gcgtgaagga tattttagct ctcatcttgg cttttggaaa ttatatgaat 4080

ggaggaaata ggactcgggg acaagccgat ggatatagct tagaaattct gcccaaactc 4140

aaggatgtca aaagtcggga taatgggatt aatctggtgg actacgttgt taagtattac 4200

ctgcgttatact atgatcagga agctggaaca gaaaagagtg ttttcccctt gccggaacca 4260

caggatttct ttctggcctc ccaagtcaag tttgaagacc tcataaaaga tttgagaaaa 4320

ctgaagaggc aactagaagc aagtgagaaa cagatggtgg tggtgtgcaa ggagtcccca 4380

aaggagtatc tccagccttt caaggacaaa ctagaggagt tcttccaaaa agccaaaaaa 4440

gagcataaga tggaagaaag tcacttggag aatgcacaga aaagttttga aacaacagta 4500

cgatattttg ggatgaagcc aaagtctggt gagaaggaga tcacacccag ctacgtgttt 4560

atggtgtggt atgagttctg cagtgacttc aagacaattt ggaaacggga gagtaaaaac 4620

atatctaaag aaagattgaa aatggctcag gaatcagtca gcaagttgac ttcagagaag 4680

aaagtggaga caaagaaaat caatcccact gctagcctga aagaaagact gcgtcagaag 4740

gaagccagtg tgaccactaa ctaagatgaa gacacatgga aatgatggca ctggaggtgg 4800

aggaccttgc acgcatactc tttgtgacca cagggttgca ggacgttctt gaaagatgtg 4860

tcactaaatg tttgtttttg ctcatctctt tctgaggtca tctgcagaga gtgccccatg 4920

ccttctttaa gaagtccctc attaagccgc aggaacaatg gaaaactatt taagggaaca 4980

ttgcagaaat atttgatgac tgtttcttgt ggaagcccaa agtccactct aagagcagaa 5040

gaaataccaa aatgtttcca aaattttttt aaaagctgag atttccagct ttataaccaa 5100

agcttgatat atgtcacatt gtcacagaag agagaaaaga tcattgagga cagttgcctt 5160

gggagagttc aagtctttgt cgttacacac tgctgttttg attattggtc ttagttttga 5220

tcctgttgca gcaaaatcct gcagcatctt tctctccaat aatgttgcaa ctcaccaaaa 5280

ctattcttga agaggtccaa gaacatgtat tatccagact aaaaaaatga ttttttgttg 5340

ttatggttta cgtgatgaaa aggagaaaaa agagaatcat acctgggtgg agagaggggag 5400

acaaatagcc ataaacttca tcctggagaa caagttacca tgcaaggagt tgacatcagt 5460

tgttaagtga ggcccattct tgtttttaca tcggtccttt gtggtttttc tgggccagca 5520

gagattctgc acccccaactc ccaggagaaa atgtaatacc tgagcaagca cagccttggg 5580

tgtgcttgga caagagaccc agcggcagag caccttttac attttggacc gttcatgaat 5640

gggcaatgtt gtgttgatac gcagccgagt tctacgttat gtgctgtgac tgtgcagctg 5700

gacgaccccc atccccagga ggcagtttcc agacaggaga gcaaatgcaa ctcacagcac 5760

ctgctcatga ccttggctga taggcatgtg aagtaggatg aagcaggact ctttaatgtc 5820

aaaaaaactg aagggcagaa aaaaggttcc ttacatcaaa atgaaagtaa ttacattaat 5880

agaaaacttc caagtggaat attgttcaca ggcagctctt tctgaccctg gctcttgagt 5940

cacataagga aaccaccttt gacctctctg accacttttgt ctttaagcca cgtctctgaa 6000

atcttgtgag gggtgaagaa agaggactgg agatgaatgg acaatatgat caaagactca 6060

tttttaggcc ttgaagaggc cgagctttct ccccccaatt ggtggaggac agtccagaga 6120

tgagcagaaa tcttaaattc cttcctgatc cagcctccac atgtggcctg ccccttgccc 6180

cagcatcttt ccagaacccc tggacttgcc aggtgcctga gcatcttccc aggatatgcc 6240

tgccagccag cagcccctca ggaatgcttc tataatagat ccagtaatga aagcagcacc 6300

atatcctaat ctaatgtcag cttcgagaat gaagactgca gtcaggatca aatcaagtca 6360

cagaagccat attcatgcag gtgctaaccg ccttttctac tggtgcaact gaaaggaata 6420

tggtaacatg gttggatttt taaaattcac aatgaaggaa cgagacaagc aaaacagaaa 6480

agccgagaag gaacatgcat gactaaaaag gcttgaagtt gcttgtgagc aagaagcttt 6540

ttatgctgct ttcttacata gtttctcttc attttcactt aactctgaag acaaccaaaa 6600

gaacggatca attaaaaact gattccactt ataaccattg tatgctcctt ctagtgttat 6660

catgcacaag aaaagtgcca gttttaccca tgccatataa ttcagctctt ttgagttatg 6720

tggggccagc agaagtctca atccttatag gcttgatggt gagagcagcg ggaggtttga 6780

ggtgtactca ttgcagtcca ctttggtctg taagtaggat gcttacgaga aatcagtgaa 6840

ggtaagcagg gctgccactg tggccacgta acccttcagg aaccagtgct gaagaataat 6900

gagtgagaac acttaatttg agagttagac aaatacagcc cactttggat ttcatcctag 6960

tgaacagact aaaactttgc agtaaaatac ctatttctac aaagcaaggt ttgcctgcct 7020

cggttgggga aacctagtgg ttttgtcaca ctagtcgatg tatgatgtta gtgttgtaag 7080

acaccatggc agaatcttca ttatctcac ctattctgaa ccctgcatca tgtatctggg 7140

atgccccctc ccaagtccac caatgtacca cgttgctgac acagccttca tttttaactc 7200

aaattgatgc tcagtaaagg tcaatgacaa tttgttcaag gaagttcatc taaaataatc 7260

tggaggcctt gaaaatgatc cctctaaaat gctgttgagc ttgtgttcag tgtagcagga 7320

ggatctgaac ttttcctgga gaggaggtga tcggggatgcc atttggcagc ttaagcacat 7380

cctgccagca ggctttaagt ggctgttcta ggcatagccc tccctgaact agaaaggaga 7440

gtaaccagtt tgctatgctg catctaacca gacacacctg acttagtagt aactctaaga 7500

acccttaact tacaaacaac tttgtctcct cttagacaat attcattaaa tctgaggaca 7560

cagtttgaca gtagttcaga ttcttgcatg agcaattgac agcatcagag cacacaatat 7620

cataagttac ataaattaca caaagtacat cataaattac actacagaca cgttaggtaa 7680

aaagcatcag gcccgggccg ggcgtggtgg ctcatgccta taatcccagc actttggggag 7740

gccaagcggg ggcggatcac gagtcagga gattgagacc atcctggcta acacggtgaa 7800

accccatctc tactaaaaat acaaaaaatt agccgggcgt ggtggtgggc gcctgtagtc 7860

ccagctactc gggaggctga ggcaggagaa tggcgtgaac ccaggaggtg gagcttgcag 7920

ctagccgaga tagcaccact gcactccagc ctgggcgaca gtgagactcc gtttcaaaaa 7980

aaaaagcatc aggcccatga agtatcaaaa accaggttag gaggtgtgct gtatggcttt 8040

tatctcaata agtggcagct tactggggaa aaagaaataa gaaaaagtgt ggccaagcag 8100

aagtggatgt ttatgatgac ggtgggggcc cagaggtcat aggtgatggt cctactgccc 8160

aacagttgcc ttttgaatcc ttatgttgat gatggtgtct ttctacacac tcactgcaac 8220

tactcaggaa ttataaagat tttctgaaat ctgagaagtg gaataaggaa acccagtgga 8280

gctattacac ttttaaatgt tctagccaaa acaaattgcc agtatggttg aggaattgaa 8340

tatcagatgg catgcagtct cccctcccct cccctatcaa ggacagtaga agctgcaaac 8400

ctcttctcag cctccttcag gcacctcctg ttttcataag caccatgaag aatggtgttt 8460

cctaaatgaa aagttcagat actgctggta aagaaactgg aaaaactgaa ggaaggaata 8520

aaatatgttg gtggtattaa cacctccagt aagataagtc attggtacgg tttttctaag 8580

ggccgcagtg agatgtagca gaagaaatat gtttatattttg ggcaaagatt tgcttattgg 8640

cctgggattg cacattttct ctatgatgtt tgcaacagag aaattttcat tttaatgata 8700

ctcttccttt cttgaaagtt acatgtcctc attctgttt ctgcttctcc cttggccagt 8760

gtcattgatg cagatcattg catacaacag cacagcaaat tgcgccaagt cagtgtgtga 8820

atgggaatta gcaatgcacg cttgcaggct ctttttccag gaaccaggct gtaacattga 8880

ccggggaacc tcttcattcc ctgacatact aaattggtca attttgtagt actcatctcc 8940

atccacaaaa acaacaaaga taaaatcaat ttggagcttt atatgacaaa aaggaagaag 9000

tccaaaaata tatagccttc ccccctccca catatctgat ccaaatatta aatatctgat 9060

tttataaaac agtttaaatt gtctttttaa attgctaaca agcatcagtt atatttgagc 9120

ttcatttttc ttttatcctg tctgtcctaa taaaaacaaa aatggccaaa aagtggagag 9180

gaaagaaaaa gcttccactt tttaaaattt gttttgtatt agttatatttta cctttaggga 9240

ccctacaact gaagagagtg gagagaataa agaagtgaac tttcattcat gtctgctact 9300

ttgacctcat aaagaaatct gcaacacaga tgaaaccagt ctgtgtggcc aagctgatgg 9360

gatttgaaaa gagtggataa tttttagcct ttccaaaatg caaataactt ggatatattt 9420

ccattttcca gctatagaga gaaacaatcc agctgcctgg aaactgttat tagtatagaa 9480

gtggcttaaa gaaaagcatc ttcaaatact tgacttagca tatctttctt ctttagactt 9540

acataatgat attcatctct ccattagcaa ttgaatccag gcataaccgg gctcagttac 9600

acagcttgtc tgtgactggg aagcccattt tgtgtcattt ctgcacacct gtccgctgtt 9660

gacaccttat tagaggcact gcattttggt ttcacaattc ttcatctccc ttcccaagga 9720

atgggcaatc tactgaactt ccagatcaat gctttgttgg aaagtgatga atttaagaga 9780

gttttaacat gtcaaatttg aagccaattc agtatcctta tttgttccaa gactcttaac 9840

caatactgtg atataaagtt aggatttggg aaacgtgtag ttaacaactt ggaaacatga 9900

agatattaaa atggcagctg gctaactgtc tcttaagcca ctatgcaatt tctaccaatg 9960

gagagattag ggaagcaaat taagcctcat tcagtaggtc tgctgtctgg tggaacttac 10020

ggaactcatt tcctcctcta tccccagccc ttctcctaac tatggtgata accagggcca 10080

tagaagacct tttctctctt acctttctct gataggatcg tgtccttcag tcaagagctc 10140

atgtgaactc cagactttat attacatctc tgaagttctt gatgtgggga agattgactt 10200

ttattccatt tttatatgaa ggtgttagat atagccatca attattttt ctacatccc 10260

tctacgctta tgtaattttc tatttttaaa tcttctctta aatatactga gaatctctag 10320

tctccttttc taaaggctga tccaactaca cttgtgggct attttccaa gctttgtgtg 10380

aaacttgatg acattgggcc agcaaaatgc aaagaagact atagtttcag gcagaaaatc 10440

acgtccaaag aatttggcat ggattaaaca acctctacca cactatagct ctcacatagg 10500

ctgaacattt tcctaaattc tacctgtgca gacactgagg ggctctctac ctttgaaact 10560

atgagaacgt cttaaattaa tatgaatatt tctctccatg tatagtgtga gctgccaatg 10620

cattatctta atacatcaag aaggaaatca gatttcaggc acacattagc aattgtttgt 10680

taatgtcctt ggcaaacgtg tacctgcttt ccttcattgt tctcttcagg ggctttcttc 10740

cactttcctc ttatgaaacg aatgtgtttt tgactgttaa ctgggttcgc tttccagatc 10800

tgtctttccc aaatgaaagg ttagtcccat agaccactgg ctattcaggg aaattactct 10860

ctacctcccc atgacatgga tgataagtgt tgagggatga acactctgga aactcttagc 10920

atggattttg aattccagat ttctttatag gagatgtata aaaaggagtt tatagcatac 10980

aaaaattata ctgctcttcc cagtaaggga ctaaaaggac atttgaaatc tttacatttt 11040

agatgttttt gtgaattata aatatctcct ttttcctcgc ttcatgctaa cttgtctcta 11100

gataaaatct tatttcttca tacattggac cacaaggcat aaagaaggta gctcagcgcc 11160

actgagattg tgttctgcat aatatttgga aggcttccat ttccattgaa aacaaatcca 11220

tgagtgagag ggaaagtcta gtatcaattc ttctgtttgc tcgcaatgac acaaataggt 11280

tttggggatc tacctaaggg ataggtctac tccaaaatta ttaaatttat aattgtgcaa 11340

ttctgtaatt tcccaaggca taagtaatat gaccctactg tcagctagat gtcttatctt 11400

caaagagagt atgcattaat aaaaagaact tccctttaaa gaaccaatct aaaatactaa 11460

aaaggcagaa acttttaaaa ttagaaattg gataattttt aagaatcttt agagaaaaca 11520

ttggtttatc atagtctttt tctttcattg agttttcatt tagactagca tggcaagcag 11580

ggtggccttg gactttgatt taggggatcg tgctttggcc tggaaaataa gcactggcct 11640

gcatgcctag aacctgagtg aaggcagtca acatcctagt atgaatcaga cctagcagaa 11700

atgtaaatta tttcaagtac ttcagggttt agttttctta gtgacaccct ggaccctgga 11760

tgctgctttc taaagtgcac ctgatccatg cagttttatg tcttcatata actggtatct 11820

tgtgagtttg caagcaatgg gatgagcaag aaaaaaagga cgcatggagg agaaaaattt 11880

gaacgaggct agtgcaatgt tttgctgata gattacattg ttagggagct ggtgattttt 11940

tgccatggtc gtatcgtgga cagcttttcc gtggaaattc aaggcatctg tattaggcaa 12000

atgtgagtgc ccttgatctt gtattgatca gtgccaatgt actgggaaag caggtacccc 12060

agtgaaactg gtctgtgctt ggtttaacag ctccaacaat ttcagatcca tggggctgct 12120

tgaccataga ccctgtttac tccatgcctg ttcaaaagtc attttgactt ctagctttgt 12180

ttcactttct tctttcaata cttctgtttc ctcgtccttt tccttcatat tccatggcta 12240

tttctttcct actttacagt ttcccccaga cccagatttt ttcacacctc tgcatcatag 12300

acaactgagt agctcccttg gcccctcctc catcctctca caccctgtgc tccgttcctc 12360

agccgtttgg acaggagct ccgctgtcac caaggagccc atgtgagaca cactgctgtg 12420

actgcctctt gttaatgtca gcatcacctc atcacttaag caaaaaggaa aatccataaa 12480

agagatggaa aatacgtctc tttttatttt attttaagaa gattgggcgg ggtggggggg 12540

gggttcttat tctaggcctt ctcaatttct catagatttt accttaaact aattaaggcc 12600

attctcttga taaatttgta catcagaccg ggtcaccagc tatgatgcag aacgccagat 12660

ttttgaatct caagtaactt tctgtggtgc tggacaaatt gacttaattc tgtgcaggca 12720

aacactttga atcataagga tttttatattgc cgctccattc ttactactat tcatgattca 12780

aacatctacc cctgttctga atcaggatgt tgacacttct tggttatatttt cagatgaaca 12840

gtaactgcta cactcttgaa agcacttaaa agtgcaagca tgtcctaaat agccatttaa 12900

cctggtaaaa cataggcttt tctgtttaat taagtattag accagtctgt agatataatc 12960

tgaaaagatt gtaggcagta atgaagacag ttggggaaag gagaaggccc tttaaagaca 13020

tgaaacctta cacgctcttg ggatattttt aagcataata agctcattgg attcaggtat 13080

ttttcccttt gcatttttaa aaatacgtat ttctaatttg tttgcatatt taattttgtc 13140

aaagctgaga aatgctcatg agttgaattt ataaatgtca tttgcaacca aatgaagtat 13200

ttatttttaa aaagagagtg aaggaaccaa cactgatttg tacataataa aaatgtgtgt 13260

attatatata tatatttttt cctccttgac agtacttggt cacaatatca agtgtatttt 13320

tgtacataat atatattgat tagaaaaacg tcaattgtct attcaaaaaa ttctatctct 13380

gtgatagatt atattttatcc taatctgttg atacctctgt taatttgttt taagagaatt 13440

atattttttg gaatttacag agaattgcat tcatggcttt caattgtaaa tatgctaagg 13500

gtattttaat aaatcttggt ttcatgtcca aaaaaaaaaa aaaaaa 13546

<210> 16

<211> 1419

<212> PRT

<213> Homo sapiens

<400> 16

Met Glu Gly Thr His Cys Thr Leu Gln Leu His Lys Pro Ile Thr Glu

1 5 10 15

Leu Cys Tyr Ile Ser Phe Cys Leu Pro Lys Gly Glu Val Arg Gly Phe

20 25 30

Ser Tyr Lys Gly Thr Val Thr Leu Asp Arg Ser Asn Lys Gly Phe His

35 40 45

Asn Cys Tyr Gln Val Arg Glu Glu Ser Asp Ile Ile Ser Leu Ser Gln

50 55 60

Glu Pro Asp Glu His Pro Gly Asp Ile Phe Phe Lys Gln Thr Pro Thr

65 70 75 80

Lys Asp Ile Leu Thr Glu Leu Tyr Lys Leu Thr Thr Glu Arg Glu Arg

85 90 95

Leu Leu Thr Asn Leu Leu Ser Ser Asp His Ile Leu Gly Ile Thr Met

100 105 110

Gly Asn Gln Glu Gly Lys Leu Gln Glu Leu Ser Val Ser Leu Ala Pro

115 120 125

Glu Asp Asp Cys Phe Gln Ser Ala Gly Asp Trp Gln Gly Glu Leu Pro

130 135 140

Val Gly Pro Leu Asn Lys Arg Ser Thr His Gly Asn Lys Lys Pro Arg

145 150 155 160

Arg Ser Ser Gly Arg Arg Glu Ser Phe Gly Ala Leu Pro Gln Lys Arg

165 170 175

Thr Lys Arg Lys Gly Arg Gly Gly Arg Glu Ser Ala Pro Leu Met Gly

180 185 190

Lys Asp Lys Ile Cys Ser Ser His Ser Leu Pro Leu Ser Arg Thr Arg

195 200 205

Pro Asn Leu Trp Val Leu Glu Glu Lys Gly Asn Leu Leu Pro Asn Gly

210 215 220

Ala Leu Ala Cys Ser Leu Gln Arg Arg Glu Ser Cys Pro Pro Asp Ile

225 230 235 240

Pro Lys Thr Pro Asp Thr Asp Leu Gly Phe Gly Ser Phe Glu Thr Ala

245 250 255

Phe Lys Asp Thr Gly Leu Gly Arg Glu Val Leu Pro Pro Asp Cys Ser

260 265 270

Ser Thr Glu Ala Gly Gly Asp Gly Ile Arg Arg Pro Pro Ser Gly Leu

275 280 285

Glu His Gln Gln Thr Gly Leu Ser Glu Ser His Gln Asp Pro Glu Lys

290 295 300

His Pro Glu Ala Glu Lys Asp Glu Met Glu Lys Pro Ala Lys Arg Thr

305 310 315 320

Cys Lys Gln Lys Pro Val Ser Lys Val Val Ala Lys Val Gln Asp Leu

325 330 335

Ser Ser Gln Val Gln Arg Val Val Lys Thr His Ser Lys Gly Lys Glu

340 345 350

Thr Ile Ala Ile Arg Pro Ala Ala His Ala Glu Phe Val Pro Lys Ala

355 360 365

Asp Leu Leu Thr Leu Pro Gly Ala Glu Ala Gly Ala His Gly Ser Arg

370 375 380

Arg Gln Gly Lys Glu Arg Gln Gly Asp Arg Ser Ser Gln Ser Pro Ala

385 390 395 400

Gly Glu Thr Ala Ser Ile Ser Val Ser Ala Ser Ala Glu Gly Ala

405 410 415

Val Asn Lys Val Pro Leu Lys Val Ile Glu Ser Glu Lys Leu Asp Glu

420 425 430

Ala Pro Glu Gly Lys Arg Leu Gly Phe Pro Val His Thr Ser Val Pro

435 440 445

His Thr Arg Pro Glu Thr Arg Asn Lys Arg Arg Ala Gly Leu Pro Leu

450 455 460

Gly Gly His Lys Ser Leu Phe Leu Asp Leu Pro His Lys Val Gly Pro

465 470 475 480

Asp Ser Ser Gln Pro Arg Gly Asp Lys Lys Lys Pro Ser Pro Pro Ala

485 490 495

Pro Ala Ala Leu Gly Lys Val Phe Asn Asn Ser Ala Ser Gln Ser Ser

500 505 510

Thr His Lys Gln Thr Ser Pro Val Pro Ser Pro Leu Ser Pro Arg Leu

515 520 525

Pro Ser Pro Gln Gln His His Arg Ile Leu Arg Leu Pro Ala Leu Pro

530 535 540

Gly Glu Arg Glu Ala Ala Leu Asn Asp Ser Pro Cys Arg Lys Ser Arg

545 550 555 560

Val Phe Ser Gly Cys Val Ser Ala Asp Thr Leu Glu Pro Pro Ser Ser

565 570 575

Ala Lys Val Thr Glu Thr Lys Gly Ala Ser Pro Ala Phe Leu Arg Ala

580 585 590

Gly Gln Pro Arg Leu Val Pro Gly Glu Thr Leu Glu Lys Ser Leu Gly

595 600 605

Pro Gly Lys Thr Thr Ala Glu Pro Gln His Gln Ser Pro Pro Gly Ile

610 615 620

Ser Ser Glu Gly Phe Pro Trp Asp Gly Phe Asn Glu Gln Thr Pro Lys

625 630 635 640

Asp Leu Pro Asn Arg Asp Gly Gly Ala Trp Val Leu Gly Tyr Arg Ala

645 650 655

Gly Pro Ala Cys Pro Phe Leu Leu His Glu Glu Arg Glu Lys Ser Asn

660 665 670

Arg Ser Glu Leu Tyr Leu Asp Leu His Pro Asp His Ser Leu Thr Glu

675 680 685

Gln Asp Asp Arg Thr Pro Gly Arg Leu Gln Ala Val Trp Pro Pro Pro

690 695 700

Lys Thr Lys Asp Thr Glu Glu Lys Val Gly Leu Lys Tyr Thr Glu Ala

705 710 715 720

Glu Tyr Gln Ala Ala Ile Leu His Leu Lys Arg Glu His Lys Glu Glu

725 730 735

Ile Glu Asn Leu Gln Ala Gln Phe Glu Leu Arg Ala Phe His Ile Arg

740 745 750

Gly Glu His Ala Met Ile Thr Ala Arg Leu Glu Glu Thr Ile Glu Asn

755 760 765

Leu Lys His Glu Leu Glu His Arg Trp Arg Gly Gly Cys Glu Glu Arg

770 775 780

Lys Asp Val Cys Ile Ser Thr Asp Asp Asp Cys Pro Pro Lys Thr Phe

785 790 795 800

Arg Asn Val Cys Val Gln Thr Asp Arg Glu Thr Phe Leu Lys Pro Cys

805 810 815

Glu Ser Glu Ser Lys Thr Thr Arg Ser Asn Gln Leu Val Pro Lys Lys

820 825 830

Leu Asn Ile Ser Ser Leu Ser Gln Leu Ser Pro Pro Asn Asp His Lys

835 840 845

Asp Ile His Ala Ala Leu Gln Pro Met Glu Gly Met Ala Ser Asn Gln

850 855 860

Gln Lys Ala Leu Pro Pro Pro Pro Ala Ser Ile Pro Pro Pro Pro Pro

865 870 875 880

Leu Pro Ser Gly Leu Gly Ser Leu Ser Pro Ala Pro Pro Met Pro Pro

885 890 895

Val Ser Ala Gly Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Pro

900 905 910

Leu Pro Pro Pro Ser Ser Ala Gly Pro Pro Pro Pro Pro Pro Pro Pro

915 920 925

Pro Leu Pro Asn Ser Pro Ala Pro Pro Asn Pro Gly Gly Pro Pro Pro

930 935 940

Ala Pro Pro Pro Pro Gly Leu Ala Pro Pro Pro Pro Pro Gly Leu Phe

945 950 955 960

Phe Gly Leu Gly Ser Ser Ser Ser Gln Cys Pro Arg Lys Pro Ala Ile

965 970 975

Glu Pro Ser Cys Pro Met Lys Pro Leu Tyr Trp Thr Arg Ile Gln Ile

980 985 990

Ser Asp Arg Ser Gln Asn Ala Thr Pro Thr Leu Trp Asp Ser Leu Glu

995 1000 1005

Glu Pro Asp Ile Arg Asp Pro Ser Glu Phe Glu Tyr Leu Phe Ser

1010 1015 1020

Lys Asp Thr Thr Gln Gln Lys Lys Lys Pro Leu Ser Glu Thr Tyr

1025 1030 1035

Glu Lys Lys Asn Lys Val Lys Lys Ile Ile Lys Leu Leu Asp Gly

1040 1045 1050

Lys Arg Ser Gln Thr Val Gly Ile Leu Ile Ser Leu His Leu

1055 1060 1065

Glu Met Lys Asp Ile Gln Gln Ala Ile Phe Asn Val Asp Asp Ser

1070 1075 1080

Val Val Asp Leu Glu Thr Leu Ala Ala Leu Tyr Glu Asn Arg Ala

1085 1090 1095

Gln Glu Asp Glu Leu Val Lys Ile Arg Lys Tyr Tyr Glu Thr Ser

1100 1105 1110

Lys Glu Glu Glu Leu Lys Leu Leu Asp Lys Pro Glu Gln Phe Leu

1115 1120 1125

His Glu Leu Ala Gln Ile Pro Asn Phe Ala Glu Arg Ala Gln Cys

1130 1135 1140

Ile Ile Phe Arg Ser Val Phe Ser Glu Gly Ile Thr Ser Leu His

1145 1150 1155

Arg Lys Val Glu Ile Ile Thr Arg Ala Ser Lys Asp Leu Leu His

1160 1165 1170

Val Lys Ser Val Lys Asp Ile Leu Ala Leu Ile Leu Ala Phe Gly

1175 1180 1185

Asn Tyr Met Asn Gly Gly Asn Arg Thr Arg Gly Gln Ala Asp Gly

1190 1195 1200

Tyr Ser Leu Glu Ile Leu Pro Lys Leu Lys Asp Val Lys Ser Arg

1205 1210 1215

Asp Asn Gly Ile Asn Leu Val Asp Tyr Val Val Lys Tyr Tyr Leu

1220 1225 1230

Arg Tyr Tyr Asp Gln Glu Ala Gly Thr Glu Lys Ser Val Phe Pro

1235 1240 1245

Leu Pro Glu Pro Gln Asp Phe Phe Leu Ala Ser Gln Val Lys Phe

1250 1255 1260

Glu Asp Leu Ile Lys Asp Leu Arg Lys Leu Lys Arg Gln Leu Glu

1265 1270 1275

Ala Ser Glu Lys Gln Met Val Val Val Cys Lys Glu Ser Pro Lys

1280 1285 1290

Glu Tyr Leu Gln Pro Phe Lys Asp Lys Leu Glu Glu Phe Phe Gln

1295 1300 1305

Lys Ala Lys Lys Glu His Lys Met Glu Glu Ser His Leu Glu Asn

1310 1315 1320

Ala Gln Lys Ser Phe Glu Thr Thr Val Arg Tyr Phe Gly Met Lys

1325 1330 1335

Pro Lys Ser Gly Glu Lys Glu Ile Thr Pro Ser Tyr Val Phe Met

1340 1345 1350

Val Trp Tyr Glu Phe Cys Ser Asp Phe Lys Thr Ile Trp Lys Arg

1355 1360 1365

Glu Ser Lys Asn Ile Ser Lys Glu Arg Leu Lys Met Ala Gln Glu

1370 1375 1380

Ser Val Ser Lys Leu Thr Ser Glu Lys Lys Val Glu Thr Lys Lys

1385 1390 1395

Ile Asn Pro Thr Ala Ser Leu Lys Glu Arg Leu Arg Gln Lys Glu

1400 1405 1410

Ala Ser Val Thr Thr Asn

1415

<210> 17

<211> 8555

<212> DNA

<213> Homo sapiens

<400> 17

gctaaatggt taagagatac ataaatactg cagtagagat gggattttac ctcaaagtgc 60

aaaggtaaat gaaataaagt tttttcaatg gaaggcttgc agctcttgag gacctgccaa 120

atggaagaag gacagagacc tggagcccta tggaaagttc tgacaccatg tgtggaagga 180

catggctttt aacacgtgtg gtgactggag tagctgcagc tgaggacagc caccctttct 240

tcgtctctgc tgagcgaagg ctacacggcc cttcctcctt gcagctgttt caccttctac 300

cttgcgtgga gccaggcttt tgcaccgaat ctgagatgcc attttaaaca gaagactcca 360

tcctcttgaa gatgggaaat tcttacgctg gacagctgaa gacgacacgc tttgaagagg 420

tcttgcacaa ttccatcgag gcatccctgc ggtccaacaa cctggtgccc aggcccatct 480

tttcccagct gtacctggaa gctgagcagc agcttgccgc tctagaaggt ggtagccgag 540

tggacaatga ggaagaggaa gaagaggggag aaggagggct ggaaacaaat ggcccccccaa 600

accctttcca gctgcaccct ctgcctgaag gatgctgtac cacagacggg ttttgccagg 660

ccgggaagga cctgcgcctt gtctccattt ccaacgagcc catggatgtc cctgcgggct 720

ttctcctcgt gggggtcaag tcccccagcc tgccggacca tctcctggtg tgcgccgttg 780

acaagaggtt cttgccagat gacaatggcc acaatgctct tcttggtttc tctgggaatt 840

gtgttggctg tggaaagaaa ggcttctgtt acttcacgga attctccaat catataaatc 900

tgaaactgac cactcaaccc aagaagcaga aacacttgaa gtattacctg gtccgtaatg 960

cacaagggac tctaaccaaa ggacctttaa tctgttggaa aggctcagag tttagaagcc 1020

ggcagatccc cgccagtact tgttccagtt ccctcttccc agccctggag agcacggctg 1080

ccttccccag cgagcccgtt cctgggacga accccagcat cctgatggga gctcagcagg 1140

caggaccagc ttctgatcac ccctcactaa acgcagcaat gggtccggct gttttcaacg 1200

gcaaagattc cccgaagtgc caacaactgg caaagaataa cctgttggcc ctgccgcgac 1260

catcggcttt aggtatcttg tcaaactccg ggccccccaa aaaacgccac aaagggtggt 1320

ctccagaatc tccatcagct ccagatggtg gctgccccca aggtggtggg aacagagcta 1380

agtatgagag cgcaggcatg tcctgcgtgc cgcaggttgg cttggtggga ccagcttcag 1440

tcacctttcc agtggtggcc tctggagaac cagtgtctgt tcctgacaac ttgctgaaaa 1500

tatgcaaggc caagccagtg atatttaaag gccatgggaa cttcccttac ctctgtggga 1560

acctgaatga cgtcgtggtc agccccctct tgtacacgtg ctaccagaat tcccagtctg 1620

tctcacgggc atacgagcag tacggcgcct ctgccatcca gcccatctcc gaggagatgc 1680

agctcctgct taccgtctac tacctggtcc agctggccgc ggaccaggtg cccttgatgg 1740

aggacctgga gcagatcttc ctgcgctctt ggcgcgagtc gcacctgacc gagatccggc 1800

agtaccagca ggcgccgccg cagcccttcc cgcccgcgcc cagcgccgcg gcacccgtga 1860

cctccgcgca gctgccctgg ctggccagcc tggccgccag ctcctgcaac gacagcgtgc 1920

acgtcatcga gtgtgcttac tccctggccg aggggcctctc cgagatgttc cggctgttgg 1980

tcgagggcaa gcttgccaag accaactacg tggtcatcat ctgcgcctgc cgcagcgcgg 2040

ccatcgactc ctgcatcgcc gtcaccggaa aataccaagc ccggattctt tccgagagcc 2100

ttctcactcc tgcggagtac cagaaggaag tcaattacga gctggttacg gggaaggtag 2160

actcgctggg ggccttcttt agcaccctct gtccagaggg tgacattgac atttgctgg 2220

acaaatttca ccaggaaaat caaggccata tttcttcctc actcgctgcc tcttctgtca 2280

ctaaagcagc atccctggat gtcagtggga caccggtgtg cacaagttac aatctggagc 2340

cacacagcat ccggcccttc cagctggcag tagcgcagaa gctcctctcc catgtgtgtt 2400

ccattgcgga ttccagcacc caaaatctgg acctgggatc ctttgagaag gtggactttc 2460

tcatttgcat tcccccctca gaagtgacct accagcagac tctgctccat gtgtggcatt 2520

caggggtttt gctggagctt ggtctgaaga aagagcacat gacgaagcag agggtggaac 2580

agtatgttct gaagctagac acggaggcac agacaaaatt taaggctttt ctgcaaaact 2640

ccttccagaa cccgcataca ctttttgtcc taatccatga ccatgcgcac tgggatcttg 2700

tgagtagcac tgttcataac ctctattctc aaagtgaccc gtcggtggga ttggtggacc 2760

gattgctcaa ctgcagggag gtgaaggagg cccccaacat tgtgacactt cacgtgacct 2820

ccttcccgta tgcactgcag acacagcaca ccctcatcag cccctacaac gagatccact 2880

ggcctgcctc ctgcagtaat ggagtggact tatatcatga aaataagaag tacttcgggc 2940

tgtcggagtt tattgaatcc accctttcag gacacagcct ccccttgctc agatacgata 3000

gctcctttga ggccatggtc actgcattag gaaaaaggtt cccccgcctg cacagcgcgg 3060

tgatcaggac ctttgttctc gtgcagcact acgcggccgc cctgatggcc gtaagcggcc 3120

tcccgcagat gaagaactac acgtcggtgg agacgctgga gatcacgcag aacctcctca 3180

actccccgaa gcagtgcccc tgcggccacg ggctcatggt cctgctgcgg gtgccctgtt 3240

cgcccctggc ggtggtggcc tatgagcggc tggcccacgt gcgggcccgg ctggcgctgg 3300

aggagcactt tgagatcatc ctgggcagtc ccagctcagg cgtcaccgtg gggaagcact 3360

tcgtaaagca gctcaggatg tggcagaaaa ttgaggatgt ggagtggaga ccccagactt 3420

acttggagct ggagggtctg ccttgcatcc tgatcttcag tgggatggac ccgcatgggg 3480

agtccttgcc gaggtctttg aggtactgtg acctgcgatt gataaactcc tcctgcttgg 3540

tgagaacagc cttggagcag gagctgggcc tggctgccta ctttgtgagc aacgaggttc 3600

ccttggagaa gggggctagg aacgaggcct tggagagtga tgctgagaag ctgagcagca 3660

cagacaacga ggatgaggag ctggggacag aaggctctac ctcggagaag agaagcccca 3720

tgaaaaggga gaggtcccgc tcccacgact cagcatcctc atccctctcc tccaaggctt 3780

ccggttcagc gctcggtggc gagtcctcgg ctcagcccac agcactcccc cagggagc 3840

atgccaggtc gccccagccc cgtggccccg cagaggaggg cagagcccct ggtgagaaac 3900

agaggccccg ggcaagtcag gggccaccct cggccatcag caggcacagt cccgggccga 3960

cgccccagcc cgactgtagc ctcaggaccg gccagaggag cgtccaggtg tcggtcacct 4020

cgtcgtgctc ccagctgtcc tcctcctcgg gctcatcctc ctcatccgtg gcgcccgctg 4080

ccggcacgtg ggtcctgcag gcctcccagt gctccttgac caaggcctgc cgccagccac 4140

ccattgtctt cttgcccaag ctcgtgtacg acatggttgt gtccactgac agcagtggcc 4200

tgcccaaggc cgcctccctc ctgccctccc cctcggtcat gtgggccagc tctttccgcc 4260

ccctgctcag caagaccatg acatccaccg agcagtccct ctactaccgg cagtggacgg 4320

tgccccggcc cagccacatg gactacggca accgggccga gggccgcgtg gacggcttcc 4380

accccccgcag gctgctgctc agcggccccc ctcagatcgg gaagacaggt gcctacctgc 4440

agttcctcag tgtcctgtcc aggatgcttg ttcggctcac agaagtggat gtctatgacg 4500

aggaggagat caatatcaac ctcagagaag aatctgactg gcattatctc cagcttagcg 4560

acccctggcc agacctggag ctgttcaaga agttgccctt tgactacatc attcacgacc 4620

cgaagtatga agatgccagc ctgatttgtt cgcactatca gggtataaag agtgaagaca 4680

gagggatgtc ccggaagccg gaggacctt atgtgcggcg tcagacggca cggatgagac 4740

tgtccaagta cgcagcgtac aacacttacc accactgtga gcagtgccac cagtacatgg 4800

gcttccaccc ccgctaccag ctgtatgagt ccaccctgca cgcctttgcc ttctcttact 4860

ccatgctagg agaggagatc cagctgcact tcatcatccc caagtccaag gagcaccact 4920

ttgtcttcag ccaacctgga ggccagctgg agagcatgcg actacccctc gtgacagaca 4980

agagccatga atatataaaa agtccgacat tcactccaac caccggccgt cacgaacatg 5040

ggctctttaa tctgtaccac gcaatggacg gtgccagcca tttgcacgtg ctggttgtca 5100

aggaatacga gatggcaatt tataagaaat attggcccaa ccacatcatg ctggtgctcc 5160

ccagtatctt caacagtgct ggagttggtg ctgctcattt cctcatcaag gagctgtcct 5220

accataacct ggagctcgag cggaaccggc aggaggagct gggaatcaag ccgcaggaca 5280

tctggccttt cattgtgatc tctgatgact cctgcgtgat gtggaacgtg gtggatgtca 5340

actctgctgg ggagagaagc aggagttct cctggtcgga aaggaacgtg tctttgaagc 5400

acatcatgca gcacatcgag gcggcccccg acatcatgca ctacgccctg ctgggcctgc 5460

ggaagtggtc cagcaagacc cgggccagcg aggtgcaaga gcccttctcc cgctgccacg 5520

tgcacaactt catcatcctg aacgtggacc tgacccagaa cgtgcagtac aaccagaacc 5580

ggttcctgtg tgacgatgta gacttcaacc tgcgggtgca cagcgccggc ctcctgctct 5640

gccggttcaa ccgcttcagc gtgatgaaga agcagatcgt ggtgggcggc cacaggtcct 5700

tccacatcac atccaaggtg tctgataact ctgccgcggt cgtgccggcc cagtacatct 5760

gtgccccgga cagcaagcac acgttcctcg cagcgcccgc ccagctcctg ctggagaagt 5820

tcctgcagca ccacagccac ctcttcttcc cgctgtcct gaagaaccat gaccacccag 5880

tgctgtctgt cgactgttac ctgaacctgg gatctcagat ttctgtttgc tatgtgagct 5940

ccaggcccca ctctttaaac atcagctgct cggacttgct gttcagtggg ctgctgctgt 6000

acctctgtga ctcttttgtg ggagctagct ttttgaaaaa gtttcatttt ctgaaaggtg 6060

cgacgttgtg tgtcatctgt caggaccgga gctcactgcg ccagacggtc gtccgcctgg 6120

agctcgagga cgagtggcag ttccggctgc gcgatgagtt ccagaccgcc aatgccaggg 6180

aagaccggcc gctctttttt ctgacgggac gacacatctg aggaagacag cggcgagttt 6240

tctgaagaga tgagtgctca gagccctcat gctgttgagg ctaaagggag gcctggaacg 6300

gtggggcgtt tgactggaat ggaccccagg gactgtccag gtgcagcccc tcctagtaca 6360

catgggcccc cgaggccgtg gtcctgggag ccaggaagac tccgcagtgg gtgagaatga 6420

aaacttgaga ctcccaagtt ctgggccagc ccattgctct gggctgtttt aaagcccatt 6480

tcacgaggaa caaagattta cttcctgtcc tgccattcgt gtgcttccat ggacaaacct 6540

gatttttttc tcttagttct aaagaatctt gggttatatttt gtagcggtgc cagtatttca 6600

gtagatggga tttcagccaa gtaggttccc ctgtaacctc ctacaaagca atattccaaa 6660

ggaacatttt aactgtaaag gctggagaca agaaaaaata agtagatcgt tttaataaca 6720

attatttaat tgcctataag tttgctgttt cagaggctag cccaaaggca tcaaatttaa 6780

taaagttaaa caaattgatt tacttcagag caaatatgat cctattaaaa taatataggg 6840

taaataccct acctcttaga aagggcaaaa atgcaaagaa gctttcttta aaactaaaag 6900

ggttttttgg ggggggagtt ggcggggagg aaataaggct aacagaggtt gacctaaaat 6960

tagccttaca aaggagaaag gaccacatt cttacttgaa aacagacaatg aaaacaacca 7020

aagtgatata taaaatagtt gatgagaact agacttatga ctgtagttta ctagagttta 7080

gttttcagtt gctgaagtag ctcattttct cttactaatg tttggttcct cagggaagaa 7140

tctcacttga ctagagagga ggtgggaaca gaagagagaa ggaggcaggg agatgtattt 7200

cttagggctc accccttcac agactgacag aatggttttg ttttgttttg ttttgttttg 7260

ttttgttttt gagatggact ctagctctgt cacccaggct ggagtgcagt ggtgcgatct 7320

cggctcactg caagctccgc ctcccgggtt ctcaccattc tcctgcctca gcctcccgag 7380

tagctgggac tacaggcgcc caccacccacg cccggctaat tttttgtatt ttttagtaga 7440

gacggggttt caccatgtta gccaggatgg tctcgatctc ctgacctcgt gatccgcccg 7500

cctcggcctc ccaaagtgct gggattacag gcgtgagcca ccgtgcctgc cccagaatgg 7560

tttttaaagc cacagttgag aggccaccca ttgcccggcg cctggacagt gatcatcttg 7620

ttcatcttgt tcagtccttt cttgtgtgat tggaattatt catccccttt gaaagatgag 7680

aaggttgaga tgcaaagagt ctacctttcc aagttctcac tgctggaaag agctagaagc 7740

acagttcaaa gttctggctt ctggactctg cagtccaggt ctcccttctc ccacttgcct 7800

accctcaatg ccacactgtt tttgaagtgg cccataactt gaaggaaaag tttaaagaca 7860

gttcaattta atcatcagaa tgcattcttt tttttttcgg agacggagtt tcactcttgc 7920

tgcccaggct ggagtgcaat ggtgcaatga cctcggctca ctgcaacctc tgcctcctgg 7980

gttcaagtga ttctccagcc tcagcctccc gagtagctgg gattatgggc gcccaccacc 8040

atgcccagct aatttttgta tttttttttt ttagtagaga tggggtttcg ccaggttggc 8100

caggctggtc ttgtgaactc ctggcctcag gtgatctgcc cacctcatcc tccaaaagtg 8160

ctgggattac aggcatgagc cactgcgcct ggcctcagaa tgcattctta cacatctatc 8220

ctagacatt ataagcactc taatggataa caatccaaga ataaatgatt gtaaaagatg 8280

atgccgaaga gttgatgtca atcttttttt cctaagaaaa aaagtccgcg agtattaaat 8340

atttagatca atgtttataa aatgattact ttgtatatct cattattcct atttggaat 8400

aaaaactgac cttctttaat catatacttg tcttttgtaa atagcagctt ttgtgtcatt 8460

ctccccactt tattagttaa tttaaattgg aaaaaaccct caaactaata ttcttgtctg 8520

ttccagtctt ataaataaaa cttataatgc atgta 8555

<210> 18

<211> 1949

<212> PRT

<213> Homo sapiens

<400> 18

Met Gly Asn Ser Tyr Ala Gly Gln Leu Lys Thr Thr Arg Phe Glu Glu

1 5 10 15

Val Leu His Asn Ser Ile Glu Ala Ser Leu Arg Ser Asn Asn Leu Val

20 25 30

Pro Arg Pro Ile Phe Ser Gln Leu Tyr Leu Glu Ala Glu Gln Gln Leu

35 40 45

Ala Ala Leu Glu Gly Gly Ser Arg Val Asp Asn Glu Glu Glu Glu

50 55 60

Glu Gly Glu Gly Gly Leu Glu Thr Asn Gly Pro Pro Asn Pro Phe Gln

65 70 75 80

Leu His Pro Leu Pro Glu Gly Cys Cys Thr Thr Asp Gly Phe Cys Gln

85 90 95

Ala Gly Lys Asp Leu Arg Leu Val Ser Ile Ser Asn Glu Pro Met Asp

100 105 110

Val Pro Ala Gly Phe Leu Leu Val Gly Val Lys Ser Pro Ser Leu Pro

115 120 125

Asp His Leu Leu Val Cys Ala Val Asp Lys Arg Phe Leu Pro Asp Asp

130 135 140

Asn Gly His Asn Ala Leu Leu Gly Phe Ser Gly Asn Cys Val Gly Cys

145 150 155 160

Gly Lys Lys Gly Phe Cys Tyr Phe Thr Glu Phe Ser Asn His Ile Asn

165 170 175

Leu Lys Leu Thr Thr Gln Pro Lys Lys Gln Lys His Leu Lys Tyr Tyr

180 185 190

Leu Val Arg Asn Ala Gln Gly Thr Leu Thr Lys Gly Pro Leu Ile Cys

195 200 205

Trp Lys Gly Ser Glu Phe Arg Ser Arg Gln Ile Pro Ala Ser Thr Cys

210 215 220

Ser Ser Ser Leu Phe Pro Ala Leu Glu Ser Thr Ala Ala Phe Pro Ser

225 230 235 240

Glu Pro Val Pro Gly Thr Asn Pro Ser Ile Leu Met Gly Ala Gln Gln

245 250 255

Ala Gly Pro Ala Ser Asp His Pro Ser Leu Asn Ala Ala Met Gly Pro

260 265 270

Ala Val Phe Asn Gly Lys Asp Ser Pro Lys Cys Gln Gln Leu Ala Lys

275 280 285

Asn Asn Leu Leu Ala Leu Pro Arg Pro Ser Ala Leu Gly Ile Leu Ser

290 295 300

Asn Ser Gly Pro Pro Lys Lys Arg His Lys Gly Trp Ser Pro Glu Ser

305 310 315 320

Pro Ser Ala Pro Asp Gly Gly Cys Pro Gln Gly Gly Gly Asn Arg Ala

325 330 335

Lys Tyr Glu Ser Ala Gly Met Ser Cys Val Pro Gln Val Gly Leu Val

340 345 350

Gly Pro Ala Ser Val Thr Phe Pro Val Val Ala Ser Gly Glu Pro Val

355 360 365

Ser Val Pro Asp Asn Leu Leu Lys Ile Cys Lys Ala Lys Pro Val Ile

370 375 380

Phe Lys Gly His Gly Asn Phe Pro Tyr Leu Cys Gly Asn Leu Asn Asp

385 390 395 400

Val Val Val Ser Pro Leu Leu Tyr Thr Cys Tyr Gln Asn Ser Gln Ser

405 410 415

Val Ser Arg Ala Tyr Glu Gln Tyr Gly Ala Ser Ala Ile Gln Pro Ile

420 425 430

Ser Glu Glu Met Gln Leu Leu Leu Thr Val Tyr Tyr Leu Val Gln Leu

435 440 445

Ala Ala Asp Gln Val Pro Leu Met Glu Asp Leu Glu Gln Ile Phe Leu

450 455 460

Arg Ser Trp Arg Glu Ser His Leu Thr Glu Ile Arg Gln Tyr Gln Gln

465 470 475 480

Ala Pro Pro Gln Pro Phe Pro Pro Ala Pro Ser Ala Ala Ala Pro Val

485 490 495

Thr Ser Ala Gln Leu Pro Trp Leu Ala Ser Leu Ala Ala Ser Ser Cys

500 505 510

Asn Asp Ser Val His Val Ile Glu Cys Ala Tyr Ser Leu Ala Glu Gly

515 520 525

Leu Ser Glu Met Phe Arg Leu Leu Val Glu Gly Lys Leu Ala Lys Thr

530 535 540

Asn Tyr Val Val Ile Ile Cys Ala Cys Arg Ser Ala Ala Ile Asp Ser

545 550 555 560

Cys Ile Ala Val Thr Gly Lys Tyr Gln Ala Arg Ile Leu Ser Glu Ser

565 570 575

Leu Leu Thr Pro Ala Glu Tyr Gln Lys Glu Val Asn Tyr Glu Leu Val

580 585 590

Thr Gly Lys Val Asp Ser Leu Gly Ala Phe Phe Ser Thr Leu Cys Pro

595 600 605

Glu Gly Asp Ile Asp Ile Leu Leu Asp Lys Phe His Gln Glu Asn Gln

610 615 620

Gly His Ile Ser Ser Ser Leu Ala Ala Ser Ser Val Thr Lys Ala Ala

625 630 635 640

Ser Leu Asp Val Ser Gly Thr Pro Val Cys Thr Ser Tyr Asn Leu Glu

645 650 655

Pro His Ser Ile Arg Pro Phe Gln Leu Ala Val Ala Gln Lys Leu Leu

660 665 670

Ser His Val Cys Ser Ile Ala Asp Ser Ser Thr Gln Asn Leu Asp Leu

675 680 685

Gly Ser Phe Glu Lys Val Asp Phe Leu Ile Cys Ile Pro Pro Ser Glu

690 695 700

Val Thr Tyr Gln Gln Thr Leu Leu His Val Trp His Ser Gly Val Leu

705 710 715 720

Leu Glu Leu Gly Leu Lys Lys Glu His Met Thr Lys Gln Arg Val Glu

725 730 735

Gln Tyr Val Leu Lys Leu Asp Thr Glu Ala Gln Thr Lys Phe Lys Ala

740 745 750

Phe Leu Gln Asn Ser Phe Gln Asn Pro His Thr Leu Phe Val Leu Ile

755 760 765

His Asp His Ala His Trp Asp Leu Val Ser Ser Thr Val His Asn Leu

770 775 780

Tyr Ser Gln Ser Asp Pro Ser Val Gly Leu Val Asp Arg Leu Leu Asn

785 790 795 800

Cys Arg Glu Val Lys Glu Ala Pro Asn Ile Val Thr Leu His Val Thr

805 810 815

Ser Phe Pro Tyr Ala Leu Gln Thr Gln His Thr Leu Ile Ser Pro Tyr

820 825 830

Asn Glu Ile His Trp Pro Ala Ser Cys Ser Asn Gly Val Asp Leu Tyr

835 840 845

His Glu Asn Lys Lys Tyr Phe Gly Leu Ser Glu Phe Ile Glu Ser Thr

850 855 860

Leu Ser Gly His Ser Leu Pro Leu Leu Arg Tyr Asp Ser Ser Phe Glu

865 870 875 880

Ala Met Val Thr Ala Leu Gly Lys Arg Phe Pro Arg Leu His Ser Ala

885 890 895

Val Ile Arg Thr Phe Val Leu Val Gln His Tyr Ala Ala Ala Leu Met

900 905 910

Ala Val Ser Gly Leu Pro Gln Met Lys Asn Tyr Thr Ser Val Glu Thr

915 920 925

Leu Glu Ile Thr Gln Asn Leu Leu Asn Ser Pro Lys Gln Cys Pro Cys

930 935 940

Gly His Gly Leu Met Val Leu Leu Arg Val Pro Cys Ser Pro Leu Ala

945 950 955 960

Val Val Ala Tyr Glu Arg Leu Ala His Val Arg Ala Arg Leu Ala Leu

965 970 975

Glu Glu His Phe Glu Ile Ile Leu Gly Ser Pro Ser Ser Gly Val Thr

980 985 990

Val Gly Lys His Phe Val Lys Gln Leu Arg Met Trp Gln Lys Ile Glu

995 1000 1005

Asp Val Glu Trp Arg Pro Gln Thr Tyr Leu Glu Leu Glu Gly Leu

1010 1015 1020

Pro Cys Ile Leu Ile Phe Ser Gly Met Asp Pro His Gly Glu Ser

1025 1030 1035

Leu Pro Arg Ser Leu Arg Tyr Cys Asp Leu Arg Leu Ile Asn Ser

1040 1045 1050

Ser Cys Leu Val Arg Thr Ala Leu Glu Gln Glu Leu Gly Leu Ala

1055 1060 1065

Ala Tyr Phe Val Ser Asn Glu Val Pro Leu Glu Lys Gly Ala Arg

1070 1075 1080

Asn Glu Ala Leu Glu Ser Asp Ala Glu Lys Leu Ser Ser Thr Asp

1085 1090 1095

Asn Glu Asp Glu Glu Leu Gly Thr Glu Gly Ser Thr Ser Glu Lys

1100 1105 1110

Arg Ser Pro Met Lys Arg Glu Arg Ser Arg Ser His Asp Ser Ala

1115 1120 1125

Ser Ser Ser Leu Ser Ser Lys Ala Ser Gly Ser Ala Leu Gly Gly

1130 1135 1140

Glu Ser Ser Ala Gln Pro Thr Ala Leu Pro Gln Gly Glu His Ala

1145 1150 1155

Arg Ser Pro Gln Pro Arg Gly Pro Ala Glu Glu Gly Arg Ala Pro

1160 1165 1170

Gly Glu Lys Gln Arg Pro Arg Ala Ser Gln Gly Pro Pro Ser Ala

1175 1180 1185

Ile Ser Arg His Ser Pro Gly Pro Thr Pro Gln Pro Asp Cys Ser

1190 1195 1200

Leu Arg Thr Gly Gln Arg Ser Val Gln Val Ser Val Thr Ser

1205 1210 1215

Cys Ser Gln Leu Ser Ser Ser Ser Gly Ser Ser Ser Ser Val

1220 1225 1230

Ala Pro Ala Ala Gly Thr Trp Val Leu Gln Ala Ser Gln Cys Ser

1235 1240 1245

Leu Thr Lys Ala Cys Arg Gln Pro Pro Ile Val Phe Leu Pro Lys

1250 1255 1260

Leu Val Tyr Asp Met Val Val Ser Thr Asp Ser Ser Gly Leu Pro

1265 1270 1275

Lys Ala Ala Ser Leu Leu Pro Ser Pro Ser Val Met Trp Ala Ser

1280 1285 1290

Ser Phe Arg Pro Leu Leu Ser Lys Thr Met Thr Ser Thr Glu Gln

1295 1300 1305

Ser Leu Tyr Tyr Arg Gln Trp Thr Val Pro Arg Pro Ser His Met

1310 1315 1320

Asp Tyr Gly Asn Arg Ala Glu Gly Arg Val Asp Gly Phe His Pro

1325 1330 1335

Arg Arg Leu Leu Leu Ser Gly Pro Pro Gln Ile Gly Lys Thr Gly

1340 1345 1350

Ala Tyr Leu Gln Phe Leu Ser Val Leu Ser Arg Met Leu Val Arg

1355 1360 1365

Leu Thr Glu Val Asp Val Tyr Asp Glu Glu Glu Ile Asn Ile Asn

1370 1375 1380

Leu Arg Glu Glu Ser Asp Trp His Tyr Leu Gln Leu Ser Asp Pro

1385 1390 1395

Trp Pro Asp Leu Glu Leu Phe Lys Lys Leu Pro Phe Asp Tyr Ile

1400 1405 1410

Ile His Asp Pro Lys Tyr Glu Asp Ala Ser Leu Ile Cys Ser His

1415 1420 1425

Tyr Gln Gly Ile Lys Ser Glu Asp Arg Gly Met Ser Arg Lys Pro

1430 1435 1440

Glu Asp Leu Tyr Val Arg Arg Gln Thr Ala Arg Met Arg Leu Ser

1445 1450 1455

Lys Tyr Ala Ala Tyr Asn Thr Tyr Tyr His His Cys Glu Gln Cys His

1460 1465 1470

Gln Tyr Met Gly Phe His Pro Arg Tyr Gln Leu Tyr Glu Ser Thr

1475 1480 1485

Leu His Ala Phe Ala Phe Ser Tyr Ser Met Leu Gly Glu Glu Ile

1490 1495 1500

Gln Leu His Phe Ile Ile Pro Lys Ser Lys Glu His His Phe Val

1505 1510 1515

Phe Ser Gln Pro Gly Gly Gln Leu Glu Ser Met Arg Leu Pro Leu

1520 1525 1530

Val Thr Asp Lys Ser His Glu Tyr Ile Lys Ser Pro Thr Phe Thr

1535 1540 1545

Pro Thr Thr Gly Arg His Glu His Gly Leu Phe Asn Leu Tyr His

1550 1555 1560

Ala Met Asp Gly Ala Ser His Leu His Val Leu Val Val Lys Glu

1565 1570 1575

Tyr Glu Met Ala Ile Tyr Lys Lys Tyr Trp Pro Asn His Ile Met

1580 1585 1590

Leu Val Leu Pro Ser Ile Phe Asn Ser Ala Gly Val Gly Ala Ala

1595 1600 1605

His Phe Leu Ile Lys Glu Leu Ser Tyr His Asn Leu Glu Leu Glu

1610 1615 1620

Arg Asn Arg Gln Glu Glu Leu Gly Ile Lys Pro Gln Asp Ile Trp

1625 1630 1635

Pro Phe Ile Val Ile Ser Asp Asp Ser Cys Val Met Trp Asn Val

1640 1645 1650

Val Asp Val Asn Ser Ala Gly Glu Arg Ser Arg Glu Phe Ser Trp

1655 1660 1665

Ser Glu Arg Asn Val Ser Leu Lys His Ile Met Gln His Ile Glu

1670 1675 1680

Ala Ala Pro Asp Ile Met His Tyr Ala Leu Leu Gly Leu Arg Lys

1685 1690 1695

Trp Ser Ser Lys Thr Arg Ala Ser Glu Val Gln Glu Pro Phe Ser

1700 1705 1710

Arg Cys His Val His Asn Phe Ile Ile Leu Asn Val Asp Leu Thr

1715 1720 1725

Gln Asn Val Gln Tyr Asn Gln Asn Arg Phe Leu Cys Asp Asp Val

1730 1735 1740

Asp Phe Asn Leu Arg Val His Ser Ala Gly Leu Leu Leu Cys Arg

1745 1750 1755

Phe Asn Arg Phe Ser Val Met Lys Lys Gln Ile Val Val Gly Gly

1760 1765 1770

His Arg Ser Phe His Ile Thr Ser Ser Lys Val Ser Asp Asn Ser Ala

1775 1780 1785

Ala Val Val Pro Ala Gln Tyr Ile Cys Ala Pro Asp Ser Lys His

1790 1795 1800

Thr Phe Leu Ala Ala Pro Ala Gln Leu Leu Leu Glu Lys Phe Leu

1805 1810 1815

Gln His His Ser His Leu Phe Phe Pro Leu Ser Leu Lys Asn His

1820 1825 1830

Asp His Pro Val Leu Ser Val Asp Cys Tyr Leu Asn Leu Gly Ser

1835 1840 1845

Gln Ile Ser Val Cys Tyr Val Ser Ser Arg Pro His Ser Leu Asn

1850 1855 1860

Ile Ser Cys Ser Asp Leu Leu Phe Ser Gly Leu Leu Leu Tyr Leu

1865 1870 1875

Cys Asp Ser Phe Val Gly Ala Ser Phe Leu Lys Lys Phe His Phe

1880 1885 1890

Leu Lys Gly Ala Thr Leu Cys Val Ile Cys Gln Asp Arg Ser Ser

1895 1900 1905

Leu Arg Gln Thr Val Val Arg Leu Glu Leu Glu Asp Glu Trp Gln

1910 1915 1920

Phe Arg Leu Arg Asp Glu Phe Gln Thr Ala Asn Ala Arg Glu Asp

1925 1930 1935

Arg Pro Leu Phe Phe Leu Thr Gly Arg His Ile

1940 1945

<210> 19

<211> 2246

<212> DNA

<213> Homo sapiens

<400> 19

aaagtccggg ggagccggtc ccgggcagcc gctcagcccc ctgcccctcg ccgcccgccg 60

cctgcctggg ccgggccgag gatgcggcgc agcgcctcgg cggccaggct tgctcccctc 120

cggcacgcct gctaacttcc cccgctacgt ccccgttcgc ccgccgggcc gccccgtctc 180

cccgcgccct ccgggtcggg tcctccagga gcgccaggcg ctgccgccgt gtgccctccg 240

ccgctcgccc gcgcgcccgc gctccccgcc tgcgcccagc gccccgcgcc cgcgcccagt 300

cctcgggcgg tcatgctgcc cctctgcctc gtggccgccc tgctgctggc cgccgggccc 360

gggccgagcc tgggcgacga agccatccac tgcccgcct gctccgagga gaagctggcg 420

cgctgccgcc cccccgtggg ctgcgaggag ctggtgcgag agccgggctg cggctgttgc 480

gccacttgcg ccctgggctt ggggatgccc tgcggggtgt acaccccccg ttgcggctcg 540

ggcctgcgct gctacccgcc ccgaggggtg gagaagcccc tgcacacact gatgcacggg 600

caaggcgtgt gcatggagct ggcggagatc gaggccatcc aggaaagcct gcagccctct 660

gacaaggacg agggtgacca ccccaacaac agcttcagcc cctgtagcgc ccatgaccgc 720

aggtgcctgc agaagcactt cgccaaaatt cgagaccgga gcaccagtgg gggcaagatg 780

aaggtcaatg gggcgccccg ggaggatgcc cggcctgtgc cccagggctc ctgccagagc 840

gagctgcacc gggcgctgga gcggctggcc gcttcacaga gccgcaccca cgaggacctc 900

tacatcatcc ccatccccaa ctgcgaccgc aacggcaact tccaccccaa gcagtgtcac 960

ccagctctgg atgggcagcg tggcaagtgc tggtgtgtgg accggaagac gggggtgaag 1020

cttccggggg gcctggagcc aaagggggag ctggactgcc accagctggc tgacagcttt 1080

cgagagtgag gcctgccagc aggccaggga ctcagcgtcc cctgctactc ctgtgctctg 1140

gaggctgcag agctgaccca gagtggagtc tgagtctgag tcctgtctct gcctgcggcc 1200

cagaagtttc cctcaaatgc gcgtgtgcac gtgtgcgtgt gcgtgcgtgt gtgtgtgttt 1260

gtgagcatgg gtgtgccctt ggggtaagcc agagcctggg gtgttctctt tggtgttaca 1320

cagcccaaga ggactgagac tggcacttag cccaagaggt ctgagccctg gtgtgtttcc 1380

agatcgatcc tggattcact cactcactca ttccttcact catccagcca cctaaaaaca 1440

tttactgacc atgtactacg tgccagctct agttttcagc cttgggaggt tttattctga 1500

cttcctctga ttttggcatg tggagacact cctataagga gagttcaagc ctgtgggagt 1560

agaaaaatct cattcccaga gtcagaggag aagagacatg taccttgacc atcgtccttc 1620

ctctcaagct agccagaggg tgggagccta aggaagcgtg gggtagcaga tggagtaatg 1680

gtcacgaggt ccagacccac tcccaaagct cagacttgcc aggctccctt tctcttcttc 1740

cccaggtcct tcctttaggt ctggttgttg caccatctgc ttggttggct ggcagctgag 1800

agccctgctg tgggagagcg aagggggtca aaggaagact tgaagcacag agggctaggg 1860

aggtggggta catttctctg agcagtcagg gtgggaagaa agaatgcaag agtggactga 1920

atgtgcctaa tggagaagac ccacgtgcta ggggatgagg ggcttcctgg gtcctgttcc 1980

ctaccccatt tgtggtcaca gccatgaagt caccgggatg aacctatcct tccagtggct 2040

cgctccctgt agctctgcct ccctctccat atctccttcc cctacacctc cctccccaca 2100

cctccctact cccctgggca tcttctggct tgactggatg gaaggagact taggaaccta 2160

ccagttggcc atgatgtctt ttcttctttt tctttttttt aacaaaacag aacaaaacca 2220

aaaaatgtcc agatgaaaaa aaaaaa 2246

<210> 20

<211> 258

<212> PRT

<213> Homo sapiens

<400> 20

Met Leu Pro Leu Cys Leu Val Ala Ala Leu Leu Leu Ala Ala Gly Pro

1 5 10 15

Gly Pro Ser Leu Gly Asp Glu Ala Ile His Cys Pro Pro Cys Ser Glu

20 25 30

Glu Lys Leu Ala Arg Cys Arg Pro Pro Val Gly Cys Glu Glu Leu Val

35 40 45

Arg Glu Pro Gly Cys Gly Cys Cys Ala Thr Cys Ala Leu Gly Leu Gly

50 55 60

Met Pro Cys Gly Val Tyr Thr Pro Arg Cys Gly Ser Gly Leu Arg Cys

65 70 75 80

Tyr Pro Pro Arg Gly Val Glu Lys Pro Leu His Thr Leu Met His Gly

85 90 95

Gln Gly Val Cys Met Glu Leu Ala Glu Ile Glu Ala Ile Gln Glu Ser

100 105 110

Leu Gln Pro Ser Asp Lys Asp Glu Gly Asp His Pro Asn Asn Ser Phe

115 120 125

Ser Pro Cys Ser Ala His Asp Arg Arg Cys Leu Gln Lys His Phe Ala

130 135 140

Lys Ile Arg Asp Arg Ser Thr Ser Gly Gly Lys Met Lys Val Asn Gly

145 150 155 160

Ala Pro Arg Glu Asp Ala Arg Pro Val Pro Gln Gly Ser Cys Gln Ser

165 170 175

Glu Leu His Arg Ala Leu Glu Arg Leu Ala Ala Ser Gln Ser Arg Thr

180 185 190

His Glu Asp Leu Tyr Ile Ile Pro Ile Pro Asn Cys Asp Arg Asn Gly

195 200 205

Asn Phe His Pro Lys Gln Cys His Pro Ala Leu Asp Gly Gln Arg Gly

210 215 220

Lys Cys Trp Cys Val Asp Arg Lys Thr Gly Val Lys Leu Pro Gly Gly

225 230 235 240

Leu Glu Pro Lys Gly Glu Leu Asp Cys His Gln Leu Ala Asp Ser Phe

245 250 255

Arg Glu

<210> 21

<211> 5016

<212> DNA

<213> Homo sapiens

<400> 21

acaggaggag ccgctcgctg gcggctgatc cagcgtctcc gtgacaggca ccctgctccg 60

ccgccaccgc caccgccacc gccaccgtcg ccttttcttc ttcgtcccgg gcggtgcgtt 120

ccactgctct ggggccggcg ccgcgcccag tcccgcttcg ggccgcaagc cccaccgctc 180

ccctccccgg gcaggggcgc cgcgcagccc gctcccgccg ccacctcctc ccctgccgcc 240

ctcctagccg gcaggaattg cgcgaccaca gcgccgctcg cgtcgcccgc atcagctcag 300

cccgctgccg ctcggccctc ggcaccgctc cgggtccggc cgccgcgcgg ccagggctcc 360

ccctgcccag cgctcccagg ccccgccacg cgtcgccgcg cccagctcca gtctcccctc 420

cccggggtct cgccagcccc ttcctgcagc cgccgcctcc gaaggagcgg gtccgccgcg 480

ggtaaccatg cctagcaaaa ccaagtacaa ccttgtggac gatgggcacg acctgcggat 540

ccccttgcac aacgaggacg ccttccagca cggcatctgc tttgaggcca agtacgtagg 600

aagcctggac gtgccaaggc ccaacagcag ggtggagatc gtggctgcca tgcgccggat 660

acggtatgag tttaaagcca agaacatcaa gaagaagaaa gtgagcatta tggtttcagt 720

ggatggagtg aaagtgattc tgaagaagaa gaaaaagctt cttttatattgc agaaaaagga 780

atggacgtgg gatgagagca agatgctggt gatgcaggac cccatctaca ggatcttcta 840

tgtctctcat gattcccaag acttgaagat cttcagctat atcgctcgag atggtgccag 900

caatatcttc aggtgtaacg tctttaaatc caagaagaag agccaagcta tgagaatcgt 960

tcggacggtg gggcaggcct ttgaggtctg ccacaagctg agcctgcagc acacgcagca 1020

gaatgcagat ggccaggaag atggagagag cgagaggaac agcaacagct caggagaccc 1080

aggccgccag ctcactggag ccgagagggc ctccacggcc actgcagagg agactgacat 1140

cgatgcggtg gaggtcccac ttccagggaa tgatgtcctg gaattcagcc gaggtgtgac 1200

tgatctagat gctgtaggga aggaaggagg ctctcacaca ggctccaagg tttcgcaccc 1260

ccaggagccc atgctgacag cctcacccag gatgctgctc ccttcttctt cctcgaagcc 1320

tccaggcctg ggcacagaga caccgctgtc cactcaccac cagatgcagc tcctccagca 1380

gctcctccag cagcagcagc agcagacaca agtggctgtg gcccaggtac acttgctgaa 1440

ggaccagttg gctgctgagg ctgcggcgcg gctggaggcc caggctcgcg tgcatcagct 1500

tttgctgcag aacaaggaca tgctccagca catctccctg ctggtcaagc aggtgcaaga 1560

gctggaactg aagctgtcag gacagaacgc catgggctcc caggacagct tgctggagat 1620

caccttccgc tccggagccc tgcccgtgct ctgtgacccc acgaccccta agccagagga 1680

cctgcattcg ccgccgctgg gcgcgggctt ggctgacttt gcccaccctg cgggcagccc 1740

cttaggtagg cgcgactgct tggtgaagct ggagtgcttt cgctttcttc cgcccgagga 1800

caccccgccc ccagcgcagg gcgaggcgct cctgggcggt ctggagctca tcaagttccg 1860

agagtcaggc atcgcctcgg agtacgagtc caacacggac gagagcgagg agcgcgactc 1920

gtggtcccag gaggagctgc cgcgcctgct gaatgtcctg cagaggcagg aactgggcga 1980

cggcctggat gatgagatcg ccgtgtaggt gccgagggcg aggagatgga ggcggcggcg 2040

tggctggagg ggccgtgtct ggctgctgcc cgggtagggg atgcccagtg aatgtgcact 2100

gccgaggaga atgccagcca gggcccggga gagtgtgagg tttcaggaaa gtattgagat 2160

tctgctttgg agggtaaagt ggggaagaaa tcggattccc agaggtgaat cagctcctct 2220

cctacttgtg actagagggt ggtggaggta aggccttcca gagcccatgg cttcaggaga 2280

gggtctctct ccaggactgc caggctgctg gaggacctgc ccctacctgc tgcatcgtca 2340

ggctcccacg ctttgtccgt gatgcccccc taccccctca ctctccccgt ctccatggtc 2400

ccgaccagga agggaagcca tcggtacctt ctcaggtact ttgtttctgg atatcacgat 2460

gctgcgagtt gcctaaccct cccctacct ttatgagagg aattccttct ccaggccctt 2520

gctgagattg tagagattga gtgctctgga ccgcaaaagc caggctagtc cttgtagggt 2580

gagcatggaa ttggaatgtg tcacagtgga taagctttta gaggaactga atccaaacat 2640

tttctccagc cggacattga atgttgctac aaagggagcc ttgaagcttt aacatggttc 2700

aggcccttgg tgtgagagcc cagggggagg acagcttgtc tgctgctcca aatcacttag 2760

atctgattcc tgttttgaaa gtcctgccct gccttcctcc tgcctgtagc ccagcccatc 2820

taaatggaag ctgggaattg cccctcacct cccctgtgtc ctgtccagct gaagcttttg 2880

cagcacttta cctctctgaa agccccagag gaccagagcc cccagcctta cctctcaacc 2940

tgtcccctcc actgggcagt ggtggtcagt ttttactgca aaaaaaaaaa aagaaaaaag 3000

agaaagaaaa aaaagaatga atgcaagctg atagctgaga ctgtgagact gtttttgtcc 3060

actcttctga atcactgcca cttgggtcag ggaccacagc cattgccacc cttggcccat 3120

ctctctgcgt gcgtgccttg agcacacata taaaaagtgc catgtgcaat tgtctttct 3180

tttatgatct aggctttgcc tagggatcac tactccttaa cgggctggct ggggcaatga 3240

ggaaaagctc ctttgctcct gtaaggccat aagtggctgt taacagattt tcaaatgcct 3300

gaagagattg ctgagacctg ctagagtcat atgttcgggg aattaagtct ttatcctaga 3360

caacaaggta cagatgcaaa ctgcagtgtt attggagggt caatcggcaa ggatatgatt 3420

atcccaaaat ggagttcatc gaccctagct ttcctttaga ttatatataa ataaagtgc 3480

agtcctcttc taatggccac agttggtttt cttgtagccc agaaagtcca aattaaagga 3540

aataaattca gttttatgtt agccttcctt ggtgcatcag ggtgtcagtg gaaataggat 3600

caggtggtgt gtgtgtgtgt gttttgtgtg tgtgtgtaca catgtgttta tatatacatg 3660

tgtgagggaa agtgtgtaca tatatgtagg attgtaacca gacggaaaag aacgaggatc 3720

tccagggtgt ttgaatcagc aacagatttg tgttttctaa catgcattta gttggagagg 3780

catggttctg tttgttttgt tttgatctaa tttgccattg gaaataggta cagttacaca 3840

gagaaggaag aaccaggaaa gtgagatcca tgaaactaaa tgagcagctg tcagaatcca 3900

gtgtggctga gcctacctag cttatgaaat ctaacccagg gttccctgag tccaagacca 3960

cttagattat taagattttg aacgtccaga ggagtgaaaa gtctgttttc tgacgtaagc 4020

cggagctgag gataaagcca gaggccagtg gattaggtgt atggaatgtg gatggagagg 4080

gcttgtgtgg gatgtggcca gggagtgggt gaggaaggcc gcttctaaat ggcctgtaaa 4140

aacttgagat tggatagacg aaaggaaatg gagaaattaa agaattggag aaactagtta 4200

tctgtgttgc tgactttggg acccatccaa gactcctgcc cttggggtgt tccatggtgg 4260

tttcttcctg cctgggcgcc acctttccc cagttcaggc cctccctgga ggactagttt 4320

gtgtattggt atcctcccca gtggacccaa accagcgcat acttggtgtg tggagatggg 4380

agacaaagga cagatctagg agccttgaag gatcaccagc caccgaccct ccatcagggc 4440

caactgggca ggaaagggaa cattgcagac ctgatttccc gacgatgtca ccctgtcctc 4500

cctccttgct tcttgctctg ctaactcaac tctgccttcc tctttttcat tcttctactc 4560

tgccctatat ggaggacaaa tggacaccag gggtgctaac cttattggtg cctgccccag 4620

cctaccccag gtgccagcag actctcgtgc acaggaggct cccacagtta tggagccagg 4680

aaagaatttc tctgcactgg atggactgta tattgagatt aaaaattata ttccttatat 4740

tcctgcttat atcaatgctc tctctgtaaa acctcttcct agcctcattt ctctcaactg 4800

atcttgttta ggcgttgtat tccttttatt tactctttgc ttgactgctt cctcctaacc 4860

ctctacccac tagcactcta cttcctaaag ctgttgtgtc attaactctg ttggatcaac 4920

tctctgggaa aagattctgt taatgtaagt gcacttactc cctggatgtt gtcactagtc 4980

tagtggcttt tgctaaataa acctttctta tttcta 5016

<210> 22

<211> 506

<212> PRT

<213> Homo sapiens

<400> 22

Met Pro Ser Lys Thr Lys Tyr Asn Leu Val Asp Asp Gly His Asp Leu

1 5 10 15

Arg Ile Pro Leu His Asn Glu Asp Ala Phe Gln His Gly Ile Cys Phe

20 25 30

Glu Ala Lys Tyr Val Gly Ser Leu Asp Val Pro Arg Pro Asn Ser Arg

35 40 45

Val Glu Ile Val Ala Ala Met Arg Arg Ile Arg Tyr Glu Phe Lys Ala

50 55 60

Lys Asn Ile Lys Lys Lys Lys Val Ser Ile Met Val Ser Val Asp Gly

65 70 75 80

Val Lys Val Ile Leu Lys Lys Lys Lys Lys Leu Leu Leu Leu Gln Lys

85 90 95

Lys Glu Trp Thr Trp Asp Glu Ser Lys Met Leu Val Met Gln Asp Pro

100 105 110

Ile Tyr Arg Ile Phe Tyr Val Ser His Asp Ser Gln Asp Leu Lys Ile

115 120 125

Phe Ser Tyr Ile Ala Arg Asp Gly Ala Ser Asn Ile Phe Arg Cys Asn

130 135 140

Val Phe Lys Ser Lys Lys Lys Ser Gln Ala Met Arg Ile Val Arg Thr

145 150 155 160

Val Gly Gln Ala Phe Glu Val Cys His Lys Leu Ser Leu Gln His Thr

165 170 175

Gln Gln Asn Ala Asp Gly Gln Glu Asp Gly Glu Ser Glu Arg Asn Ser

180 185 190

Asn Ser Ser Gly Asp Pro Gly Arg Gln Leu Thr Gly Ala Glu Arg Ala

195 200 205

Ser Thr Ala Thr Ala Glu Glu Thr Asp Ile Asp Ala Val Glu Val Pro

210 215 220

Leu Pro Gly Asn Asp Val Leu Glu Phe Ser Arg Gly Val Thr Asp Leu

225 230 235 240

Asp Ala Val Gly Lys Glu Gly Gly Ser His Thr Gly Ser Lys Val Ser

245 250 255

His Pro Gln Glu Pro Met Leu Thr Ala Ser Pro Arg Met Leu Leu Pro

260 265 270

Ser Ser Ser Ser Lys Pro Pro Gly Leu Gly Thr Glu Thr Pro Leu Ser

275 280 285

Thr His His Gln Met Gln Leu Leu Gln Gln Leu Leu Gln Gln Gln Gln

290 295 300

Gln Gln Thr Gln Val Ala Val Ala Gln Val His Leu Leu Lys Asp Gln

305 310 315 320

Leu Ala Ala Glu Ala Ala Ala Ala Arg Leu Glu Ala Gln Ala Arg Val His

325 330 335

Gln Leu Leu Leu Gln Asn Lys Asp Met Leu Gln His Ile Ser Leu Leu

340 345 350

Val Lys Gln Val Gln Glu Leu Glu Leu Lys Leu Ser Gly Gln Asn Ala

355 360 365

Met Gly Ser Gln Asp Ser Leu Leu Glu Ile Thr Phe Arg Ser Gly Ala

370 375 380

Leu Pro Val Leu Cys Asp Pro Thr Thr Pro Lys Pro Glu Asp Leu His

385 390 395 400

Ser Pro Pro Leu Gly Ala Gly Leu Ala Asp Phe Ala His Pro Ala Gly

405 410 415

Ser Pro Leu Gly Arg Arg Asp Cys Leu Val Lys Leu Glu Cys Phe Arg

420 425 430

Phe Leu Pro Pro Glu Asp Thr Pro Pro Pro Ala Gln Gly Glu Ala Leu

435 440 445

Leu Gly Gly Leu Glu Leu Ile Lys Phe Arg Glu Ser Gly Ile Ala Ser

450 455 460

Glu Tyr Glu Ser Asn Thr Asp Glu Ser Glu Glu Arg Asp Ser Trp Ser

465 470 475 480

Gln Glu Glu Leu Pro Arg Leu Leu Asn Val Leu Gln Arg Gln Glu Leu

485 490 495

Gly Asp Gly Leu Asp Asp Glu Ile Ala Val

500 505

<210> 23

<211> 5618

<212> DNA

<213> Homo sapiens

<400> 23

agcacatctg ggcgagagcg gcgccgctgg agccgagggg ggcgccgagc gcagatctgg 60

agcagcagag ccacggcgca gctggggccc ttcgaggcgc tcggggcgca catctgggac 120

ctcgagcggg ggccgtgccg cgcgcagctg gaccagggga ggggggcggc ggctgcacag 180

ctggaccgaa gggggcgggg tcggccctgg gcgacccgct gaggggaggg ccgcgggccg 240

ccggggactg gagcatggga cggcgcgcct gaaggagcag gaaggggaag gaggcctggg 300

accccgaaaa gagaagggga gagcgagggg acgagagcgg aggaggaaga tgcaactgac 360

tcgctgctgc ttcgtgttcc tggtgcaggg tagcctctat ctggtcatct gtggccagga 420

tgatggtcct cccggctcag aggaccctga gcgtgatgac cacgagggcc agccccggcc 480

ccgggtgcct cggaagcggg gccacatctc acctaagtcc cgccccatgg ccaattccac 540

tctcctaggg ctgctggccc cgcctgggga ggcttggggc attcttgggc agccccccaa 600

ccgcccgaac cacagccccc caccctcagc caaggtgaag aaaatctttg gctggggcga 660

cttctactcc aacatcaaga cggtggccct gaacctgctc gtcacaggga agattgtgga 720

ccatggcaat gggaccttca gcgtccactt ccaacacaat gccacaggcc agggaaacat 780

ctccatcagc ctcgtgcccc ccagtaaagc tgtagagttc caccaggaac agcagatctt 840

catcgaagcc aaggcctcca aaatcttcaa ctgccggatg gagtgggaga aggtagaacg 900

gggccgccgg acctcgcttt gcacccacga cccagccaag atctgctccc gagaccacgc 960

tcagagctca gccacctgga gctgctccca gcccttcaaa gtcgtctgtg tctacatcgc 1020

cttctacagc acggactatc ggctggtcca gaaggtgtgc ccagattaca actaccatag 1080

tgataccccc tactacccat ctgggtgacc cggggcaggc cacagaggcc aggccagggc 1140

tggaaggaca ggcctgccca tgcaggagac catctggaca ccgggcaggg aaggggttgg 1200

gcctcaggca gggagggggg tggagacgag gagatgccaa gtggggccag ggccaagtct 1260

caagtggcag agaaagggtc ccaagtgctg gtcccaacct gaagctgtgg agtgactaga 1320

tcacaggagc actggaggag gagtgggctc tctgtgcagc ctcacagggc tttgccacgg 1380

agccacagag agatgctggg tccccgaggc ctgtgggcag gccgatcagt gtggccccag 1440

atcaagtcat gggaggaagc taagcccttg gttcttgcca tcctgaggaa agatagcaac 1500

agggaggggg agatttcatc agtgtggaca gcctgtcaac ttaggatgga tggctgagag 1560

ggcttcctag gagccagtca gcagggtggg gtggggccag aggagctctc cagccctgcc 1620

tagtgggcgc cctcagcccc ttgtcgtgtg ctgagcatgg catgaggctg aagtggcaac 1680

cctggggtct ttgatgtctt gacagattga ccatctgtct ccagccaggc cacccctttc 1740

caaaattccc tcttctgcca gtactccccc tgtaccaccc attgctgatg gcacacccat 1800

ccttaagcta agacaggacg attgtggtcc tcccacacta aggccacagc ccatccgcgt 1860

gctgtgtgtc cctcttccac cccaacccct gctggctcct ctggggagcat ccatgtcccg 1920

gagaggggtc cctcaacagt cagcctcacc tgtcagaccg gggttctccc ggatctggat 1980

ggcgccgccc tctcagcagc gggcacgggt ggggcggggc cgggccgcag agcatgtgct 2040

ggatctgttc tgtgtgtctg tctgtgggtg ggggagggg agggaagtct tgtgaaaccg 2100

ctgattgctg acttttgtgt gaagaatcgt gttcttggag caggaaataa agcttgcccc 2160

ggggcactgg agtcagagtt gtccaaggaa aggggcctcag gcatcccttg gtccaggaag 2220

aatttctctg atggccgcag gacatttgct tgagacccaa gtggcaggga tccaaccgcc 2280

cttggcgctg atgtttgctg aggggctcagg gcttccctct ccagccccgg ttccaagctg 2340

tctgatcccc cacgaggaaa cttgagcaaa caccctgggc tcggtgctgg aggagggcgt 2400

agcatcttca agaacagctc agggaggggag agctagcagg tagaatgggc caatgagggt 2460

gttccttggt gtcctccctg aactgccatc tgcagaccca gcagggtcct agccccgtca 2520

ttttgctgcg tggccttggc catgtccatt ctcctctctg gctttctttc tttgtttctt 2580

cctctatgac atgaagggct tgcccagacc aggggttctc aaacgcggat cacccagagg 2640

gtttgttaac acacagattt ctgggtccta cccacatttc taattcagca ggcctgggtg 2700

gggcctaaga attagaattt ctaacgagtg cccaggtcta tgctgatgct gctgctccag 2760

ggcccatgct gggagaccca ctcaaaggac cttgaagttc atctctggct atggctccgc 2820

aggaggggga gacacctcgg atgtgatttc ccagctgtaa tttccatctg cttctcctgg 2880

ggaaggggcc tttcagagaa tcggggctat tgtattggat tttcaatctg accacatgcc 2940

agtgaaggaa caggctggag tggggtgtgg acaagggcc tgcgtcagtc actcccctcc 3000

tgcagctagt aagaggcctc agaatggcca gctgccagtg gcaccttgtc tgggagttag 3060

ttgggccctt tgggactctg tgaagggaag acactaccaa ggtcacagtg ccttctggag 3120

gtcattctaa gtcggctctc ttgggagggc agcactcagg gccctttggg ccctcttgag 3180

gagaggagag tcctggcagt aaggtaagat gggcttgcca ccccccacct ttcgcccctg 3240

cccaccagcg ctccgcgcaa actggtcccc tcatactgca gcgcagagtt gggtggggct 3300

gagaagccat ctggttacag cccaccttgt aggaaatgac ccagcttgtt tcccccacat 3360

catgcttcca ggggccgtct ctcctgagtg gagatgtgag acacacaccc ctcctccaga 3420

ccaccctccg ctccccaccc tggaggcttg agactgctgg cactggagca gcccaccaat 3480

ggacacccac cgtgtgccgt tcagcctccc acagtgctgt ggagactgca ggaaggagga 3540

ggaagcaatg gggccagagg ccctgggcgc cctccccacc tcccctggct gaactctcag 3600

caggcactgg gggcactttg accccccctcc tgctcctctc ctcctgtgga gagccagatg 3660

ctggcgacag ctggagggcc cggccttcct ggcacacagt tctgcctgca ccagggatgg 3720

attcatttta ataacttcat ttcaccctca tgcacactgc cgcctcatcc ctcctttcca 3780

ccttccccag tagcctggct gctctcctca gctaggactt cgctaacaga tttcctccca 3840

aaccttaatt ctttggaata gccctctggt ccctactgtt cttgccagat acttctgtgc 3900

ccgcttggtc ctcacaaggg caaggggtcc atccaacttc ctctggctaa gaagacgtca 3960

cctctgcccc attggcgagc agtgtcccca tggtgatgcc cccccaccat cacgacgaag 4020

tgcgctggcc tcccactctt gccatgcaca cactcacagg agattcctct gaagaaacct 4080

gtccccactc tgcccagacc ccaaagggcc aggtcctact cacactccaa cccgttgacc 4140

ttccccatcc actgcccttc aaggcagtct gaaatgccct cagaccgttt agcggtcccg 4200

tggtcctcca ccctaacccc tcagcccagc tggggggctgc cgggggcctt gtctcctcca 4260

tcagtggagc ctctgggaca agtttaccag gctgggggtt ctttaaggac acagcttgga 4320

tctccccatc aggctgggga acacctaggg ccgggggcca tgcctccctc atcagactga 4380

ggacaccctg atgtcagggg ctggatggcc ccttagactg ggggtccctg agggcagaag 4440

ctatgcctcc cctcatcaga ctggagtctc cctgagggca agaactgtgc tatggatggg 4500

agggggacag cttgcctttt cctaggcatc aggcacctg gaggctgcct ctgcccttca 4560

gctttgctca aaggcgctgt ctgggtctca gcattccttt ctcaagtagg gtgaatctcc 4620

tagcactctg tgaagctaat aagggggatt acccgttagg tcaactggta gcaatgcccg 4680

agtctccttc tcgatgaagc ttaaggcaaa agcaaatgaa tatctaggtc ccttcccccc 4740

cttcccccct tccctttcct gggatgagca agcgggaact gagtcaccct gttccccatc 4800

cttggcagga atgctggtga ccttgcattg tggcagattc aggtggcgag gcccattgct 4860

cgagatgcac ctggtgggtg ggtggcaggg atcctggggg agtgtttatg gggacggagg 4920

cagctgaagg gcagggaggg gtgaccaggt gctgggatca tcgagtgagt atgtgcagga 4980

gggattgtag agacacaatg aaacagttgc tctgtgttgg gaagtgatcc agtgtcatcg 5040

ctgggagtgg gagacagaaa tgttatacttcc aaagattccg agtcctgtgg tactgccagg 5100

agaaccgggg gctggggtga tgggtaagga gaggcaccat tagccccgcc aggcagaggc 5160

aagatggggt gggggcggca cctgccaatt atgccaaagt cttggagtgg cagctggcac 5220

catcaccaag gcacaaatgc cagcagagac ctggcactca cctgggttgt gattccatag 5280

ggcccctgtc tcctgttggt ctcccaggct caaaggctga cctgataatt caagtgaagg 5340

atgcctagtt caaggcctcc cagttcctca tcccaggcca cctggtcagg tggtcccaag 5400

ggacaagcta ggtcctcctg aactgcagag gctgccaata aactggcaac acaggtgttg 5460

caggaagata tagctgggtc ctcatcctgg gtctgtaatt tattagacgt gtggctttgg 5520

acaaatgaca taatttccca gagcctcctt agataaaaaa ctagggcttt gcttaccttg 5580

gcgtattgtt aggaaaatta aatgagttgc tcaataaa 5618

<210> 24

<211> 252

<212> PRT

<213> Homo sapiens

<400> 24

Met Gln Leu Thr Arg Cys Cys Phe Val Phe Leu Val Gln Gly Ser Leu

1 5 10 15

Tyr Leu Val Ile Cys Gly Gln Asp Asp Gly Pro Pro Gly Ser Glu Asp

20 25 30

Pro Glu Arg Asp Asp His Glu Gly Gln Pro Arg Pro Arg Val Pro Arg

35 40 45

Lys Arg Gly His Ile Ser Pro Lys Ser Arg Pro Met Ala Asn Ser Thr

50 55 60

Leu Leu Gly Leu Leu Ala Pro Pro Gly Glu Ala Trp Gly Ile Leu Gly

65 70 75 80

Gln Pro Pro Asn Arg Pro Asn His Ser Pro Pro Pro Ser Ala Lys Val

85 90 95

Lys Lys Ile Phe Gly Trp Gly Asp Phe Tyr Ser Asn Ile Lys Thr Val

100 105 110

Ala Leu Asn Leu Leu Val Thr Gly Lys Ile Val Asp His Gly Asn Gly

115 120 125

Thr Phe Ser Val His Phe Gln His Asn Ala Thr Gly Gln Gly Asn Ile

130 135 140

Ser Ile Ser Leu Val Pro Pro Ser Lys Ala Val Glu Phe His Gln Glu

145 150 155 160

Gln Gln Ile Phe Ile Glu Ala Lys Ala Ser Lys Ile Phe Asn Cys Arg

165 170 175

Met Glu Trp Glu Lys Val Glu Arg Gly Arg Arg Thr Ser Leu Cys Thr

180 185 190

His Asp Pro Ala Lys Ile Cys Ser Arg Asp His Ala Gln Ser Ser Ala

195 200 205

Thr Trp Ser Cys Ser Gln Pro Phe Lys Val Val Cys Val Tyr Ile Ala

210 215 220

Phe Tyr Ser Thr Asp Tyr Arg Leu Val Gln Lys Val Cys Pro Asp Tyr

225 230 235 240

Asn Tyr His Ser Asp Thr Pro Tyr Tyr Pro Ser Gly

245 250

<210> 25

<211> 2608

<212> DNA

<213> Homo sapiens

<400> 25

agacgcgccg gaaccgggac gcgataaata tgcagagcgg aggcttcgcg cagcagagcc 60

cgcgcgccgc ccgctccggg tgctgaatcc aggcgtgggg acacgagcca ggcgccgccg 120

ccggagccag cggagccggg gccagagccg gagcgcgtcc gcgtccacgc agccgccggc 180

cggccagcac ccagggccct gcatgccagg tcgttggagg tggcagcgag acatgcaccc 240

ggcccggaag ctcctcagcc tcctcttcct catcctgatg ggcactgaac tcactcaagt 300

gctgcccacc aaccctgagg agctggca ggtgtacagc tctgcccagg acagcgaggg 360

caggtgtatc tgcacagtgg tcgctccaca gcagaccatg tgttcacggg atgcccgcac 420

aaaacagctg aggcagctac tggagaaggt gcagaacatg tctcaatcca tagaggtctt 480

ggacaggcgg acccagag acttgcagta cgtggagaag atggagaacc aaatgaaagg 540

actggagtcc aagttcaaac aggtggagga gagtcataag caacacctgg ccaggcagtt 600

taaggcgata aaagcgaaaa tggatgaact taggcctttg atacctgtgt tggaagagta 660

caaggccgat gccaaattgg tattgcagtt taaagaggag gtccagaatc tgacgtcagt 720

gcttaacgag ctgcaagagg aaattggcgc ctatgactac gatgaacttc agagcagagt 780

gtccaatctt gaagaaaggc tccgtgcatg catgcaaaaa ctagcttgcg ggaagttgac 840

gggcatcagt gaccccgtga ctgtcaagac ctccggctcg aggttcggat cctggatgac 900

agaccctctc gcccctgaag gcgataaccg ggtgtggtac atggacggct atcacaacaa 960

ccgcttcgta cgtgagtaca agtccatggt tgacttcatg aacacggaca atttcacctc 1020

ccaccgtctc ccccacccct ggtcgggcac ggggcaggtg gtctacaacg gttctatcta 1080

cttcaacaag ttccagagcc acatcatcat caggtttgac ctgaagacag agaccatcct 1140

caagacccgc agcctggact atgccggtta caacaacatg taccactacg cctggggtgg 1200

ccactcggac atcgacctca tggtggacga gagcgggctg tgggccgtgt acgccaccaa 1260

ccagaacgct ggcaacatcg tggtcagtag gctggacccc gtgtccctgc agaccctgca 1320

gacctggaac acgagctacc ccaagcgcag cgccggggag gccttcatca tctgcggcac 1380

gctgtacgtc accaacggct actcaggggg taccaaggtc cactatgcat accagaccaa 1440

tgcctccacc tatgaataca tcgacatccc attccagaac aaatactccc acatctccat 1500

gctggactac aaccccaagg accgggcct gtatgcctgg aacaacggcc accagatcct 1560

ctacaacgtg accctcttcc acgtcatccg ctccgacgag ttgtagctcc ctcctcctgg 1620

aagccaaggg cccacgtcct caccacaaag ggactcctgt gaaactgctg ccaaaaagat 1680

accaataaca ctaacaatac cgatcttgaa aaatcatcag cagtgcggat tctgacatcg 1740

agggatggca ttacctccgt gtttctccct ttcgagccgg cgggccacag acgtcggaag 1800

aaactcccgt atttgcagct ggaactgcag cccacggcgc cccggttttc ctccccgccc 1860

tgtccctctc tggtcaaaca acatactaaa gaggcgaggc aatgactgtt ggccagttct 1920

caccggggaa aaacccactg ttaggatggc atgaacattt ccttagatcg tggtcagctc 1980

cgaggaatgt ggcgtccagg ctctttgaga gccatgggct gcacccggcc gtaggctagt 2040

gtaactcgca tcccattgca gtgccgtttc ttgactgtgt tgctgtctct tagattaacc 2100

gtgctgaggc tccacatagc tcctggacct gtgtctagta catactgaag cgatggtcag 2160

agtgtgtaga gtgaagttgc tgtgcccaca ttgtttgaac tcgcgtaccc cgtagataca 2220

ttgtgcaacg ttcttctgtt attcccttga ggtggtaact tcgtatgttc agtttatgcg 2280

atgattgttg taaatgcaat gccgtagttt ggattaataa gtggatggtt tttgtttcta 2340

aaaagaaaaa aaaaatcagt gttcaccctt atagagacat agtcaagttc atgttgataa 2400

taatcaaagg aattactctc ttcttgttaa attagctaaa tcatgtaacc gcagatagga 2460

agggctcgcc tggggaaact ctggtttccg atgggacagg aaagtcatac gggcaacagt 2520

atgcggaaag tacgtttttt aagtaaaaaa caaaggcaaa ctttgtacta tccagttatc 2580

taaggaacaa taaaaacatt aggagatc 2608

<210> 26

<211> 485

<212> PRT

<213> Homo sapiens

<400> 26

Met Ser Val Pro Leu Leu Lys Ile Gly Val Val Leu Ser Thr Met Ala

1 5 10 15

Met Ile Thr Asn Trp Met Ser Gln Thr Leu Pro Ser Leu Val Gly Leu

20 25 30

Asn Thr Thr Lys Leu Ser Ala Ala Gly Gly Gly Thr Leu Asp Arg Ser

35 40 45

Thr Gly Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr Ser

50 55 60

Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val Ala Pro

65 70 75 80

Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln Leu Arg Gln

85 90 95

Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile Glu Val Leu Asp

100 105 110

Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu Lys Met Glu Asn Gln

115 120 125

Met Lys Gly Leu Glu Ser Lys Phe Lys Gln Val Glu Ser His Lys

130 135 140

Gln His Leu Ala Arg Gln Phe Lys Ala Ile Lys Ala Lys Met Asp Glu

145 150 155 160

Leu Arg Pro Leu Ile Pro Val Leu Glu Glu Tyr Lys Ala Asp Ala Lys

165 170 175

Leu Val Leu Gln Phe Lys Glu Glu Val Gln Asn Leu Thr Ser Val Leu

180 185 190

Asn Glu Leu Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln

195 200 205

Ser Arg Val Ser Asn Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys

210 215 220

Leu Ala Cys Gly Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys

225 230 235 240

Thr Ser Gly Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro

245 250 255

Glu Gly Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg

260 265 270

Phe Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn

275 280 285

Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln Val

290 295 300

Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His Ile Ile

305 310 315 320

Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr Arg Ser Leu

325 330 335

Asp Tyr Ala Gly Tyr Asn Asn Met Tyr His Tyr Ala Trp Gly Gly His

340 345 350

Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly Leu Trp Ala Val Tyr

355 360 365

Ala Thr Asn Gln Asn Ala Gly Asn Ile Val Val Ser Arg Leu Asp Pro

370 375 380

Val Ser Leu Gln Thr Leu Gln Thr Trp Asn Thr Ser Tyr Pro Lys Arg

385 390 395 400

Ser Ala Gly Glu Ala Phe Ile Ile Cys Gly Thr Leu Tyr Val Thr Asn

405 410 415

Gly Tyr Ser Gly Gly Thr Lys Val His Tyr Ala Tyr Gln Thr Asn Ala

420 425 430

Ser Thr Tyr Glu Tyr Tyr Ile Asp Ile Pro Phe Gln Asn Lys Tyr Ser His

435 440 445

Ile Ser Met Leu Asp Tyr Asn Pro Lys Asp Arg Ala Leu Tyr Ala Trp

450 455 460

Asn Asn Gly His Gln Ile Leu Tyr Asn Val Thr Leu Phe His Val Ile

465 470 475 480

Arg Ser Asp Glu Leu

485

<210> 27

<211> 13037

<212> DNA

<213> Homo sapiens

<400> 27

agtccacagc tgtcactaat cggggtaagc cttgttgtat ttgtgcgtgt gggtggcatt 60

ctcaatgaga actagcttca cttgtcattt gagtgaaatc tacaacccga ggcggctagt 120

gctcccgcac tactggggatc tgagatcttc ggagatgact gtcgcccgca gtacggagcc 180

agcagaagtc cgacccttcc tgggaatggg ctgtaccgag aggtccgact agccccaggg 240

ttttagtgag ggggcagtgg aactcagcga gggactgaga gcttcacagc atgcacgagt 300

ttgatgccag agaaaaagtc gggagataaa ggagccgcgt gtcactaaat tgccgtcgca 360

gccgcagcca ctcaagtgcc ggacttgtga gtactctgcg tctccagtcc tcggacagaa 420

gttggagaac tctcttggag aactccccga gttaggagac gagatctcct aacaattact 480

actttttctt gcgctcccca cttgccgctc gctgggacaa acgacagcca cagttcccct 540

gacgacagga tggaggccaa gggcaggagc tgaccagcgc cgccctcccc cgcccccgac 600

ccaggaggtg gagatccctc cggtccagcc acattcaaca cccactttct cctccctctg 660

cccctatatt cccgaaaccc cctcctcctt cccttttccc tcctcctgga gacggggggag 720

gagaaaaggg gagtccagtc gtcatgactg agctgaaggc aaagggtccc cgggctcccc 780

acgtggcggg cggcccgccc tcccccgagg tcggatcccc actgctgtgt cgcccagccg 840

caggtccgtt cccggggagc cagacctcgg acaccttgcc tgaagtttcg gccataccta 900

tctccctgga cgggctactc ttccctcggc cctgccaggg acaggaccc tccgacgaaa 960

agacgcagga ccagcagtcg ctgtcggacg tggagggcgc atattccaga gctgaagcta 1020

caaggggtgc tggaggcagc agttctagtc ccccagaaaa ggacagcgga ctgctggaca 1080

gtgtcttgga cactctgttg gcgccctcag gtcccgggca gagccaaccc agccctcccg 1140

cctgcgaggt caccagctct tggtgcctgt ttggccccga acttcccgaa gatccaccgg 1200

ctgcccccgc cacccagcgg gtgttgtccc cgctcatgag ccggtccggg tgcaaggttg 1260

gagacagctc cgggacggca gctgcccata aagtgctgcc ccggggcctg tcaccagccc 1320

ggcagctgct gctcccggcc tctgagagcc ctcactggtc cggggcccca gtgaagccgt 1380

ctccgcaggc cgctgcggtg gaggttgagg aggaggatgg ctctgagtcc gaggagtctg 1440

cgggtccgct tctgaagggc aaacctcggg ctctgggtgg cgcggcggct ggaggaggag 1500

ccgcggctgt cccgccgggg gcggcagcag gaggcgtcgc cctggtcccc aaggaagatt 1560

cccgcttctc agcgcccagg gtcgccctgg tggagcagga cgcgccgatg gcgcccgggc 1620

gctccccgct ggccaccacg gtgatggatt tcatccacgt gcctatcctg cctctcaatc 1680

acgccttatt ggcagcccgc actcggcagc tgctggaaga cgaaagttac gacggcgggg 1740

ccggggctgc cagcgccttt gccccgccgc ggagttcacc ctgtgcctcg tccaccccgg 1800

tcgctgtagg cgacttcccc gactgcgcgt acccgcccga cgccgagccc aaggacgacg 1860

cgtaccctct ctatagcgac ttccagccgc ccgctctaaa gataaaggag gaggaggaag 1920

gcgcggaggc ctccgcgcgc tccccgcgtt cctaccttgt ggccggtgcc aaccccgcag 1980

ccttccccgga tttcccgttg gggccaccgc ccccgctgcc gccgcgagcg acccatcca 2040

gacccgggga agcggcggtg acggccgcac ccgccagtgc ctcagtctcg tctgcgtcct 2100

cctcggggtc gaccctggag tgcatcctgt acaaagcgga gggcgcgccg ccccagcagg 2160

gcccgttcgc gccgccgccc tgcaaggcgc cgggcgcgag cggctgcctg ctcccgcggg 2220

acggcctgcc ctccacctcc gcctctgccg ccgccgccgg ggcggcccccc gcgctctacc 2280

ctgcactcgg cctcaacggg ctcccgcagc tcggctacca ggccgccgtg ctcaaggagg 2340

gcctgccgca ggtctacccg ccctatctca actacctgag gccggattca gaagccagcc 2400

agagcccaca atacagcttc gagtcattac ctcagaagat ttgtttaatc tgtggggatg 2460

aagcatcagg ctgtcattat ggtgtcctta cctgtgggag ctgtaaggtc ttctttaaga 2520

gggcaatgga aggcagcac aactacttat gtgctggaag aaatgactgc atcgttgata 2580

aaatccgcag aaaaaactgc ccagcatgtc gccttagaaa gtgctgtcag gctggcatgg 2640

tccttggagg tcgaaaattt aaaaagttca ataaagtcag agttgtgaga gcactggatg 2700

ctgttgctct cccacagcca gtgggcgttc caaatgaaag ccaagcccta agccagagat 2760

tcactttttc accaggtcaa gacatacagt tgattccacc actgatcaac ctgttaatga 2820

gcattgaacc agatgtgatc tatgcaggac atgacaacac aaaacctgac acctccagtt 2880

ctttgctgac aagtcttaat caactaggcg agaggcaact tctttcagta gtcaagtggt 2940

ctaaatcatt gccaggtttt cgaaacttac atattgatga ccagataact ctcattcagt 3000

attcttggat gagcttaatg gtgtttggtc taggatggag atcctacaaa cacgtcagtg 3060

ggcagatgct gtattttgca cctgatctaa tactaaatga acagcggatg aaagaatcat 3120

cattctattc atttgcctt accatgtggc agatcccaca ggagtttgtc aagcttcaag 3180

ttagccaaga agttcctc tgtatgaaag tattgttatact tcttaataca attcctttgg 3240

aagggctacg aagtcaaacc cagtttgagg agatgaggtc aagctacatt agagagctca 3300

tcaaggcaat tggtttgagg caaaaaggag ttgtgtcgag ctcacagcgt ttctatcaac 3360

ttacaaaact tcttgataac ttgcatgatc ttgtcaaaca acttcatctg tactgcttga 3420

atacatttat ccagtcccgg gcactgagtg ttgaatttcc agaaatgatg tctgaagtta 3480

ttgctgcaca attcccaag atattggcag ggatggtgaa accccttctc tttcataaaa 3540

agtgaatgtc atctttttct tttaaagaat taaattttgt ggtatgtctt tttgttttgg 3600

tcaggattat gaggtcttga gtttttataa tgttcttctg aaagccttac atttataaca 3660

tcatagtgtg taaatttaaa agaaaaattg tgaggttcta attattttct tttataaagt 3720

ataattagaa tgtttaactg ttttgtttac ccatattttc ttgaagaatt tacaagattg 3780

aaaaagtact aaaattgtta aagtaaacta tcttatccat attatttcat accatgtagg 3840

tgaggatttt taacttttgc atctaacaaa tcatcgactt aagagaaaaa atcttacatg 3900

taataacaca aagctattat atgttatatttc taggtaactc cctttgtgtc aattatattt 3960

ccaaaaatga acctttaaaa tggtatgcaa aattttgtct atatatattt gtgtgaggag 4020

gaaattcata actttcctca gattttcaaa agtattttta atgcaaaaaa tgtagaaaga 4080

gtttaaaacc actaaaatag attgatgttc ttcaaactag gcaaaacaac tcatatgtta 4140

agaccatttt ccagatgga aacacaaatc tcttaggaag ttaataagta gattcatatc 4200

attatgcaaa tagtattgtg ggttttgtag gtttttaaaa taaccttttt tggggagaga 4260

attgtcctct aatgaggtat tgcgagtgga cataagaaat cagaagatta tggcctaact 4320

gtactcctta ccaactgtgg catgctgaaa gttagtcact cttactgatt ctcaattctc 4380

tcacctttga aagtagtaaa atatctttcc tgccaattgc tcctttgggt cagagcttat 4440

taacatcttt tcaaatcaaa ggaaagaaga aagggagagg aggaggaggg aggtatcaat 4500

tcacatacct ttctcctctt tatcctccac tatcatgaat tcatattatg tttcagccat 4560

gcaaatcttt ttaccatgaa atttcttcca gaattttccc cctttgacac aaattccatg 4620

catgtttcaa ccttcgagac tcagccaaat gtcatttctg taaaatcttc cctgagtctt 4680

ccaagcagta atttgccttc tcctagagtt tacctgccat tttgtgcaca tttgagttac 4740

agtagcatgt tattttacaa ttgtgactct cctggggagtc tgggagccat ataaagtggt 4800

caatagtgtt tgctgactga gagttgaatg acatttctc tctgtcttgg tattactgta 4860

gatttcgatc attctttggt tacatttctg catatttctg tacccatgac tttatcactt 4920

tcttctccca tgctttatct ccatcaatta tcttcattac ttttaaattt tccacctttg 4980

cttcctactt tgtgagatct ctccctttac tgactataac atagaagaat agaagtgtat 5040

tttatgtgtc ttaaggacaa tactttagat tccttgttct aagtttttaa actgaatgaa 5100

tggaatatta tttctctccc taagcaaaat tccacaaaac aattatttct tatgtttatg 5160

tagccttaaa ttgttttgta ctgtaaacct cagcataaaa actttcttca tttctaattt 5220

cattcaacaa atattgattg aatacctggt attagcacaa gaaaaatgtg ctaataagcc 5280

ttatgagaat ttggagctga agaaagacat ataactcagg aaagttacag tccagtagta 5340

ggtataaatt acagtgcctg ataaataggc attttaatat ttgtacactc aacgtatact 5400

aggtaggtgc aaaacattta catataattt tactgatacc catgcagcac aaaggtacta 5460

actttaaata ttaaataaca cctttatgtg tcagtaattc atttgcatta aatcttattg 5520

aaaaggcttt caatatattt tccccacaaa tgtcatccca agaaaaaagt atttttaaca 5580

tctcccaaat ataatagtta caggaaatct acctctgtga gagtgacacc tctcagaatg 5640

aactgtgtga cacaagaaaa tgaatgtagg tctatccaaa aaaaacccca agaaacaaaa 5700

acaatattat tagcccttta tgcttaagtg atggactcag ggaacagttg atgttgtgat 5760

cattttatta tctgattctt gttatactttga attaaaccaa tattttgatg atataaatca 5820

tttccaccag catatattta attccataa taactttaaa attttctaat ttcactcaac 5880

tatgagggaa tagaatgtgg tggccacagg tttggctttt gttaaaatgt ttgatatctt 5940

cgatgttgat ctctgtctgc aatgtagatg tctaaacact aggatttaat atttaaggct 6000

aagctttaaa aataaagtac ctttttaaaa agaatatggc ttcaccaaat ggaaaatacc 6060

taatttctaa atctttttct ctacaaagtc ctatctacta atgtctccat tactatttag 6120

tcatcataac cattatcttc attttacatg tcgtgttctt tctggtagct ctaaaatgac 6180

actaaatcat aagaagacag gttacatatc aggaaatact tgaaggttac tgaaatagat 6240

tcttgagtta atgaaaatat tttctgtaaa aaggtttgaa aagccatttg agtctaaagc 6300

attatacctc cattatcagt agttatgtga caattgtgtg tgtgtttaat gtttaaagat 6360

gtggcacttt ttaataaggc aatgctatgc tattttttcc catttaacat taagataatt 6420

tattgctata cagatgatat ggaaatatga tgaacaatat tttttttgcc aaaactatgc 6480

cttgtaagta gccatggaat gtcaacctgt aacttaaatt atccacagat agtcatgtgt 6540

ttgatgatgg gcactgtgga gataactgac ataggactgt gccccccttc tctgccactt 6600

actagctgga tgagattaag caagtcattt aactgctctg attaaacctg cctttcccaa 6660

gtgctttgta atgaatagaa atggaaacca aaaaaaacgt atacaggcct tcagaaatag 6720

taattgctac tattttgttt tcattaagcc atagttctgg ctataatttt atcaaactca 6780

ccagctatat tctacagtga aagcaggatt ctagaaagtc tcactgtttt atttatgtca 6840

ccatgtgcta tgatatattt ggttgaattc atttgaaatt aggggctggaa gtattcaagt 6900

aatttcttct gctgaaaaaa tacagtgttt tgagtttagg gcctgtttta tcaaagttct 6960

aaagagccta tcactcttcc attgtagaca ttttaaaata atgacactga ttttaacatt 7020

tttaagtgtc tttttagaac agagagcctg actagaacac agcccctcca aaaacccatg 7080

ctcaaattat ttttatactatg gcagcaattc cacaaaaggg aacaatgggt ttagaaatta 7140

caatgaagtc atcaacccaa aaaacatccc tatccctaag aaggttatga tataaaatgc 7200

ccacaagaaa tctatgtctg ctttaatctg tcttttatattg ctttggaagg atggctatta 7260

catttttagt ttttgctgtg aatacctgag cagtttctct catccatact tatccttcac 7320

acatcagaag tcaggataga atatgaatca ttttaaaaac ttttacaact ccagagccat 7380

gtgcataaga agcattcaaa acttgccaaa acatacattt tttttcaaat ttaaagatac 7440

tctatttttg tattcaatag ctcaacaact gtggtcccca ctgataaagt gaagtggaca 7500

aggagacaag taatggcata agtttgtttt tcccaaagta tgcctgttca atagccattg 7560

gatgtgggaa atttctacat ctcttaaaat tttacagaaa atacatagcc agatagtcta 7620

gcaaaagttc accaagtcct aaattgctta tccttatacttc actaagtcat gaaatcattt 7680

taatgaaaag aacatcacct aggttttgtg gtttcttttt ttcttattca tggctgagtg 7740

aaaacaacaa tctctgtttc tccctagcat ctgtggacta tttaatgtac cattattcca 7800

cactctatgg tccttactaa atacaaatt gaacaaaaag cagtaaaaca actgactctt 7860

cacccatatt ataaaata atccaagcca gattagtcaa catccataag atgaatccaa 7920

gctgaactgg gcctagatta ttgagttcag gttggatcac atccctattt attaataaac 7980

ttaggaaaga aggccttaca gaccatcagt tagctggagc taatagaacc tacacttcta 8040

aagttcggcc tagaatcaat gtggccttaa aagctgaaaa gaagcaggaa agaacagttt 8100

tcttcaataa tttgtccacc ctgtcactgg agaaaattta agaatttggg ggtgttggta 8160

gtaagttaaa cacagcagct gttcatggca gaaattattc aatacatacc ttctctgaat 8220

atcctataac caaagcaaag aaaaacacca aggggtttgt tctcctcctt ggagttgacc 8280

tcattccaag gcagagctca ggtcacaggc acaggggctg cgcccaagct tgtccgcagc 8340

cttatgcagc tgtggagtct ggaagactgt tgcaggactg ctggcctagt cccagaatgt 8400

cagcctcatt ttcgatttac tggctcttgt tgctgtatgt catgctgacc ttattgttaa 8460

acacaggttt gtttgctttt tttccactca tggagacatg ggagaggcat tatttttaag 8520

ctggttgaaa gctttaaccg ataaagcatt tttagagaaa tgtgaatcag gcagctaaga 8580

aagcatactc tgtccattac ggtaaagaaa atgcacagat tattaactct gcagtgtggc 8640

attagtgtcc tggtcaatat tcggatagat atgaataaaa tatttaaatg gtattgtaaa 8700

tagttttcag gacatatgct atagcttatt tttattatct tttgaaattg ctcttaatac 8760

atcaaatcct gatgtattca atttatcaga tataaattat tctaaatgaa gcccagttaa 8820

atgtttttgt cttgtcagtt atatgttaag tttctgatct ctttgtctat gacgtttact 8880

aatctgcatt tttactgtta tgaattattt tagacagcag tggtttcaag ctttttgcca 8940

ctaaaaatac cttttatttt ctcctccccc agaaaagtct ataccttgaa gtatctatcc 9000

accaaactgt acttctatta agaaatagtt attgtgtttt cttaatgttt tgttattcaa 9060

agacatatca atgaaagctg ctgagcagca tgaataacaa ttatatccac acagatttga 9120

tatattttgt gcagccttaa cttgatagta taaaatgtca ttgcttttta aataatagtt 9180

agtcaatgga cttctatcat agctttccta aactaggtta agatccagag ctttggggtc 9240

ataatatatt acatacaatt aagttatctt tttctaaggg ctttaaaatt catgagaata 9300

accaaaaaag gtatgtggag agttaataca aacataccat attcttgttg aaacagagat 9360

gtggctctgc ttgttctcca taaggtagaa atactttcca gaatttgcct aaactagtaa 9420

gccctgaatt tgctatgatt agggatagga aggattttc acatggcaga ctttagaatt 9480

cttcacttta gccagtaaag tatctccttt tgatcttagt attctgtgta ttttaacttt 9540

tctgagttgt gcatgtttat aagaaaaatc agcacaaagg gtttaagtta aagccttttt 9600

actgaaattt gaaagaaaca gaagaaaata tcaaagttct ttgtattttg agaggattaa 9660

atatgattta caaaagttac atggagggct ctctaaaaca ttaaattaat tattttttgt 9720

tgaaaagtct tactttaggc atcattttat tcctcagcaa ctagctgtga agcctttat 9780

gtgctgtatg ccagtcactc tgctagattg tggagattac cagtgttccc gtcttctccg 9840

agcttagagt tggatgggga ataaagacag gtaaacagat agctacaata ttgtactgtg 9900

aatgctttatg ctggaggaag tacagggaac tattggagca cctaagagga gcacctacct 9960

tgaatttagg ggttagcaga ggcatcctga aaaaagtcaa agctaagcca caatctataa 10020

gcagtttagg aattagcaga acgtgcgtgg tgaggagatg ccaaaggcaa gaagagaaga 10080

gtattccaaa caggagggat tccaaagaga gaagagtatc ccaaacaaca tttgcacaaa 10140

cctgatgggg agagaaatg tggggtgggg atggatgatg agactgaaga agaaagccag 10200

gtctagataa tcagtggcct tgtacaccat gttaaagagt gtagacttga ttctgttgta 10260

aacaggaaag cagcacaatt catatgaata ttttagaaga ctcccactgg aatatggaga 10320

ataaagttgg agatgactaa tcctggaagc agggaagaaca tttttgagga agttgcacta 10380

ttttggtgaa aatgatgatc ataaacatga agaattgtag gtgatcatga cctcctctct 10440

aattttccag aagggttttg gaagatataa cataggaaca ttgacaggac tgacgaaagg 10500

agatgaaata caccatataa attgtcaaac acaaggccag atgtctaatt atttgctta 10560

tgtgttgaaa ttacaaattt ttcatcagga aaccaaaaac tacaaaactt agttttccca 10620

agtcccagaa ttctatctgt ccaaacaatc tgtaccactc cacctatatc cctacctttg 10680

catgtctgtc caacctcaaa gtccaggtct atacacacgg gtaagactag agcagttcaa 10740

gtttcagaaa atgagaaaga ggaactgagt tgtgctgaac ccatacaaaa taaacacatt 10800

ctttgtatag attcttggaa cctcgagagg aattcaccta actcataggt atttgatggt 10860

atgaatccat ggctgggctc ggcttttaaa aagccttatc tgggattcct tctatggaac 10920

caagttccat caaagcccat ttaaaagcct acattaaaaa caaaattctt gctgcattgt 10980

atacaaataa tgatgtcatg atcaaataat cagatgccat tatcaagtgg aattacaaaa 11040

tggtataccc actccaaaaa aaaaaaaaaa gctaaattct cagtagaaca ttgtgacttc 11100

atgagccctc cacagccttg gagctgagga gggagcactg gtgagcagta ggttgaagag 11160

aaaacttggc gcttaataat ctatccatgt tttttcatct aaaagagcct tctttttgga 11220

ttaccttatt caatttccat caaggaaatt gttagttcca ctaaccagac agcagctggg 11280

aaggcagaag cttactgtat gtacatggta gctgtgggaa ggaggtttct ttctccaggt 11340

cctcactggc catacaccag tcccttgtta gttatgcctg gtcatagacc cccgttgcta 11400

tcatctcata tttaagtctt tggcttgtga atttatctat tctttcagct tcagcactgc 11460

agagtgctgg gactttgcta acttccattt cttgctggct tagcacattc ctcataggcc 11520

cagctctttt ctcatctggc cctgctgtgg agtcaccttg ccccttcagg agccatgg 11580

cttaccactg cctgctaagc ctccactcag ctgccaccac actaaatcca agcttctcta 11640

agatgttgca gactttacag gcaagcataa aaggcttgat cttcctggac ttccctttac 11700

ttgtctgaat ctcacctcct tcaactttca gtctcagaat gtaggcattt gtcctctttg 11760

ccctacatct tccttcttct gaatcatgaa agcctctcac ttcctcttgc tatgtgctgg 11820

aggcttctgt caggttttag aatgagttct catctagtcc tagtagcttt tgatgcttaa 11880

gtccaccttt taaggatacc tttgagattt agaccatgtt tttcgcttga gaaagcccta 11940

atctccagac ttgcctttct gtggatttca aagaccaact gaggaagtca aaagctgaat 12000

gttgactttc tttgaacatt tccgctataa caattccaat tctcctcaga gcaatatgcc 12060

tgcctccaac tgaccaggag aaaggtccag tgccaaagag aaaaacacaa agattaatta 12120

tttcagttga gcacatactt tcaaagtggt ttgggtattc atatgaggtt ttctgtcaag 12180

agggtgagac tcttcatcta tccatgtgtg cctgacagtt ctcctggcac tggctggtaa 12240

cagatgcaaa actgtaaaaa ttaagtgatc atgtatttta acgatatcat cacatactta 12300

ttttctatgt aatgttttaa attccccta acatactttg actgttttgc acatggtaga 12360

tattcacatt tttttgtgtt gaagttgatg caatcttcaa agttatctac cccgttgctt 12420

attagtaaaa ctagtgttaa tacttggcaa gagatgcagg gaatctttct catgactcac 12480

gccctattta gttattaatg ctactaccct attttgagta agtagtaggt ccctaagtac 12540

attgtccaga gttatacttt taaagatatt tagccccata tacttcttga atctaaagtc 12600

atacaccttg ctcctcattt ctgagtggga aagacatttg agagtatgtt gacaattgtt 12660

ctgaaggttt ttgccaagaa ggtgaaactg tcctttcatc tgtgtatgcc tggggctggg 12720

tccctggcag tgatggggtg acaatgcaaa gctgtaaaaa ctaggtgcta gtgggcacct 12780

aatatcatca tcatatactt attttcaagc taatatgcaa aatcccatct ctgtttttaa 12840

actaagtgta gatttcagag aaaatatttt gtggttcaca taagaaaaca gtctactcag 12900

cttgacaagt gttttatgtt aaattggctg gtggtttgaa atgaatcatc ttcacataat 12960

gttttcttta aaaatattgt gaatttaact ctaattcttg ttatctgtg tgataataaa 13020

gaataaacta attcta 13037

<210> 28

<211> 933

<212> PRT

<213> Homo sapiens

<400> 28

Met Thr Glu Leu Lys Ala Lys Gly Pro Arg Ala Pro His Val Ala Gly

1 5 10 15

Gly Pro Pro Ser Pro Glu Val Gly Ser Pro Leu Leu Cys Arg Pro Ala

20 25 30

Ala Gly Pro Phe Pro Gly Ser Gln Thr Ser Asp Thr Leu Pro Glu Val

35 40 45

Ser Ala Ile Pro Ile Ser Leu Asp Gly Leu Leu Phe Pro Arg Pro Cys

50 55 60

Gln Gly Gln Asp Pro Ser Asp Glu Lys Thr Gln Asp Gln Gln Ser Leu

65 70 75 80

Ser Asp Val Glu Gly Ala Tyr Ser Arg Ala Glu Ala Thr Arg Gly Ala

85 90 95

Gly Gly Ser Ser Ser Ser Pro Pro Glu Lys Asp Ser Gly Leu Leu Asp

100 105 110

Ser Val Leu Asp Thr Leu Leu Ala Pro Ser Gly Pro Gly Gln Ser Gln

115 120 125

Pro Ser Pro Pro Ala Cys Glu Val Thr Ser Ser Trp Cys Leu Phe Gly

130 135 140

Pro Glu Leu Pro Glu Asp Pro Pro Ala Ala Pro Ala Thr Gln Arg Val

145 150 155 160

Leu Ser Pro Leu Met Ser Arg Ser Gly Cys Lys Val Gly Asp Ser Ser

165 170 175

Gly Thr Ala Ala Ala His Lys Val Leu Pro Arg Gly Leu Ser Pro Ala

180 185 190

Arg Gln Leu Leu Leu Pro Ala Ser Glu Ser Pro His Trp Ser Gly Ala

195 200 205

Pro Val Lys Pro Ser Pro Gln Ala Ala Ala Val Glu Val Glu Glu Glu

210 215 220

Asp Gly Ser Glu Ser Glu Glu Ser Ala Gly Pro Leu Leu Lys Gly Lys

225 230 235 240

Pro Arg Ala Leu Gly Gly Ala Ala Ala Ala Gly Gly Gly Ala Ala Ala Ala Val

245 250 255

Pro Pro Gly Ala Ala Ala Gly Gly Val Ala Leu Val Pro Lys Glu Asp

260 265 270

Ser Arg Phe Ser Ala Pro Arg Val Ala Leu Val Glu Gln Asp Ala Pro

275 280 285

Met Ala Pro Gly Arg Ser Pro Leu Ala Thr Thr Val Met Asp Phe Ile

290 295 300

His Val Pro Ile Leu Pro Leu Asn His Ala Leu Leu Ala Ala Arg Thr

305 310 315 320

Arg Gln Leu Leu Glu Asp Glu Ser Tyr Asp Gly Gly Ala Gly Ala Ala

325 330 335

Ser Ala Phe Ala Pro Pro Arg Ser Ser Pro Cys Ala Ser Ser Thr Pro

340 345 350

Val Ala Val Gly Asp Phe Pro Asp Cys Ala Tyr Pro Pro Asp Ala Glu

355 360 365

Pro Lys Asp Asp Ala Tyr Pro Leu Tyr Ser Asp Phe Gln Pro Pro Ala

370 375 380

Leu Lys Ile Lys Glu Glu Glu Glu Gly Ala Glu Ala Ser Ala Arg Ser

385 390 395 400

Pro Arg Ser Tyr Leu Val Ala Gly Ala Asn Pro Ala Ala Phe Pro Asp

405 410 415

Phe Pro Leu Gly Pro Pro Pro Pro Pro Leu Pro Pro Arg Ala Thr Pro Ser

420 425 430

Arg Pro Gly Glu Ala Ala Val Thr Ala Ala Pro Ala Ser Ala Ser Val

435 440 445

Ser Ser Ala Ser Ser Ser Gly Ser Thr Leu Glu Cys Ile Leu Tyr Lys

450 455 460

Ala Glu Gly Ala Pro Pro Gln Gln Gly Pro Phe Ala Pro Pro Pro Cys

465 470 475 480

Lys Ala Pro Gly Ala Ser Gly Cys Leu Leu Pro Arg Asp Gly Leu Pro

485 490 495

Ser Thr Ser Ala Ser Ala Ala Ala Ala Gly Ala Ala Pro Ala Leu Tyr

500 505 510

Pro Ala Leu Gly Leu Asn Gly Leu Pro Gln Leu Gly Tyr Gln Ala Ala

515 520 525

Val Leu Lys Glu Gly Leu Pro Gln Val Tyr Pro Pro Tyr Leu Asn Tyr

530 535 540

Leu Arg Pro Asp Ser Glu Ala Ser Gln Ser Pro Gln Tyr Ser Phe Glu

545 550 555 560

Ser Leu Pro Gln Lys Ile Cys Leu Ile Cys Gly Asp Glu Ala Ser Gly

565 570 575

Cys His Tyr Gly Val Leu Thr Cys Gly Ser Cys Lys Val Phe Phe Lys

580 585 590

Arg Ala Met Glu Gly Gln His Asn Tyr Leu Cys Ala Gly Arg Asn Asp

595 600 605

Cys Ile Val Asp Lys Ile Arg Arg Lys Asn Cys Pro Ala Cys Arg Leu

610 615 620

Arg Lys Cys Cys Gln Ala Gly Met Val Leu Gly Gly Arg Lys Phe Lys

625 630 635 640

Lys Phe Asn Lys Val Arg Val Val Arg Ala Leu Asp Ala Val Ala Leu

645 650 655

Pro Gln Pro Val Gly Val Pro Asn Glu Ser Gln Ala Leu Ser Gln Arg

660 665 670

Phe Thr Phe Ser Pro Gly Gln Asp Ile Gln Leu Ile Pro Pro Leu Ile

675 680 685

Asn Leu Leu Met Ser Ile Glu Pro Asp Val Ile Tyr Ala Gly His Asp

690 695 700

Asn Thr Lys Pro Asp Thr Ser Ser Ser Leu Leu Thr Ser Ser Leu Asn Gln

705 710 715 720

Leu Gly Glu Arg Gln Leu Leu Ser Val Val Lys Trp Ser Lys Ser Leu

725 730 735

Pro Gly Phe Arg Asn Leu His Ile Asp Asp Gln Ile Thr Leu Ile Gln

740 745 750

Tyr Ser Trp Met Ser Leu Met Val Phe Gly Leu Gly Trp Arg Ser Tyr

755 760 765

Lys His Val Ser Gly Gln Met Leu Tyr Phe Ala Pro Asp Leu Ile Leu

770 775 780

Asn Glu Gln Arg Met Lys Glu Ser Ser Phe Tyr Ser Leu Cys Leu Thr

785 790 795 800

Met Trp Gln Ile Pro Gln Glu Phe Val Lys Leu Gln Val Ser Gln Glu

805 810 815

Glu Phe Leu Cys Met Lys Val Leu Leu Leu Leu Asn Thr Ile Pro Leu

820 825 830

Glu Gly Leu Arg Ser Gln Thr Gln Phe Glu Glu Met Arg Ser Ser Tyr

835 840 845

Ile Arg Glu Leu Ile Lys Ala Ile Gly Leu Arg Gln Lys Gly Val Val

850 855 860

Ser Ser Ser Gln Arg Phe Tyr Gln Leu Thr Lys Leu Leu Asp Asn Leu

865 870 875 880

His Asp Leu Val Lys Gln Leu His Leu Tyr Cys Leu Asn Thr Phe Ile

885 890 895

Gln Ser Arg Ala Leu Ser Val Glu Phe Pro Glu Met Met Ser Glu Val

900 905 910

Ile Ala Ala Gln Leu Pro Lys Ile Leu Ala Gly Met Val Lys Pro Leu

915 920 925

Leu Phe His Lys Lys

930

<210> 29

<211> 1762

<212> DNA

<213> Homo sapiens

<400> 29

cggccgaggg cggggcaggg aggcagcatg ctaaaccggg tgcgctcggc cgtggcgcac 60

ctggtgagct ccgggggcgc tccgcctccg cgccccaaat ccccggacct gcccaacgcc 120

gcctcggcgc cgcccgccgc cgctccagaa gcgcccagga gccctcccgc gaaggctggg 180

agcggggagcg cgacgcccgc gaaggctgtt gaggctcgag cgagcttctc cagaccgacc 240

tttctgcagc tgagccccgg ggggctgcga cgcgccgatg accacgcggg ccgggctgtg 300

caaagccccc cggacacggg ccgccgcctg ccctggagca caggctacgc cgaggtcatc 360

aatgctggca agagtcggca caatgaggac caggcttgct gtgaagtggt gtatgtggaa 420

ggtcggagga gtgttacagg agtacctagg gagcctagcc gaggccaggg actctgcttc 480

tactactggg gcctatttga tgggcatgca gggggcggag ctgctgaaat ggcctcacgg 540

ctcctgcatc gccatatccg agagcagcta aaggacctgg tagagatact tcaggaccct 600

tcgccaccac ccctctgcct cccaaccact ccggggaccc cagattcctc cgatccctct 660

cacttgcttg gccctcagtc ctgctggtct tcacagaagg aagtgagcca cgagagcctg 720

gtagtggggg ccgttgagaa tgccttccag ctcatggatg agcagatggc ccgggagcgg 780

cgtggccacc aagtggaggg gggctgctgt gcactggttg tgatctacct gctaggcaag 840

gtgtacgtgg ccaatgcagg cgatagcagg gccatcattg tccggaatgg tgaaatcatt 900

ccaatgtccc gggagtttac cccggagact gagcgccagc gtcttcagct gcttggcttc 960

ctgaaaccag agctgctagg cagtgaattc acccaccttg agttcccccg cagagttctg 1020

cccaaggagc tggggcagag gatgttgtac cgggaccaga acatgaccgg ctgggcctac 1080

aaaaagatcg agctggagga tctcaggttt cctctggtct gtggggaggg caaaaaggct 1140

cgggtgatgg ccaccattgg ggtgacccga ggcttgggag accacagcct taaggtctgc 1200

agttccaccc tgcccatcaa gccctttctc tcctgcttcc ctgaggtacg agtgtatgac 1260

ctgacacaat atgagcactg cccagatgat gtgctagtcc tgggaacaga tggcctgtgg 1320

gatgtcacta ctgactgtga ggtagctgcc actgtggaca gggtgctgtc ggcctatgag 1380

cctaatgacc acagcaggta tacagctctg gcccaagctc tggtcctggg ggcccggggt 1440

accccccgag accgtggctg gcgtctcccc aacaacaagc tgggttccgg ggatgacatc 1500

tctgtcttcg tcatccccct gggagggcca ggcagttat cctgaggggc tgaacaccat 1560

ccctcccact agcctctcca tacttactcc tctcacagcc caaattctga agttgtctcc 1620

ctgacccttc tttagtggca acttaactga agaagggatg tccgctatat ccaaaattac 1680

agctattggc aaataaacga gatggataaa ggtgaaaaaa aaaaaaaaaa aaaaaaaaaa 1740

aaaaaaaaaa aaaaaaaaaa aa 1762

<210> 30

<211> 505

<212> PRT

<213> Homo sapiens

<400> 30

Met Leu Asn Arg Val Arg Ser Ala Val Ala His Leu Val Ser Ser Gly

1 5 10 15

Gly Ala Pro Pro Pro Arg Pro Lys Ser Pro Asp Leu Pro Asn Ala Ala

20 25 30

Ser Ala Pro Pro Ala Ala Ala Pro Glu Ala Pro Arg Ser Pro Pro Ala

35 40 45

Lys Ala Gly Ser Gly Ser Ala Thr Pro Ala Lys Ala Val Glu Ala Arg

50 55 60

Ala Ser Phe Ser Arg Pro Thr Phe Leu Gln Leu Ser Pro Gly Gly Leu

65 70 75 80

Arg Arg Ala Asp Asp His Ala Gly Arg Ala Val Gln Ser Pro Pro Asp

85 90 95

Thr Gly Arg Arg Leu Pro Trp Ser Thr Gly Tyr Ala Glu Val Ile Asn

100 105 110

Ala Gly Lys Ser Arg His Asn Glu Asp Gln Ala Cys Cys Glu Val Val

115 120 125

Tyr Val Glu Gly Arg Arg Ser Val Thr Gly Val Pro Arg Glu Pro Ser

130 135 140

Arg Gly Gln Gly Leu Cys Phe Tyr Tyr Trp Gly Leu Phe Asp Gly His

145 150 155 160

Ala Gly Gly Gly Ala Ala Glu Met Ala Ser Arg Leu Leu His Arg His

165 170 175

Ile Arg Glu Gln Leu Lys Asp Leu Val Glu Ile Leu Gln Asp Pro Ser

180 185 190

Pro Pro Pro Leu Cys Leu Pro Thr Thr Pro Gly Thr Pro Asp Ser Ser

195 200 205

Asp Pro Ser His Leu Leu Gly Pro Gln Ser Cys Trp Ser Ser Gln Lys

210 215 220

Glu Val Ser His Glu Ser Leu Val Val Gly Ala Val Glu Asn Ala Phe

225 230 235 240

Gln Leu Met Asp Glu Gln Met Ala Arg Glu Arg Arg Gly His Gln Val

245 250 255

Glu Gly Gly Cys Cys Ala Leu Val Val Ile Tyr Leu Leu Gly Lys Val

260 265 270

Tyr Val Ala Asn Ala Gly Asp Ser Arg Ala Ile Ile Val Arg Asn Gly

275 280 285

Glu Ile Ile Pro Met Ser Arg Glu Phe Thr Pro Glu Thr Glu Arg Gln

290 295 300

Arg Leu Gln Leu Leu Gly Phe Leu Lys Pro Glu Leu Leu Gly Ser Glu

305 310 315 320

Phe Thr His Leu Glu Phe Pro Arg Arg Val Leu Pro Lys Glu Leu Gly

325 330 335

Gln Arg Met Leu Tyr Arg Asp Gln Asn Met Thr Gly Trp Ala Tyr Lys

340 345 350

Lys Ile Glu Leu Glu Asp Leu Arg Phe Pro Leu Val Cys Gly Glu Gly

355 360 365

Lys Lys Ala Arg Val Met Ala Thr Ile Gly Val Thr Arg Gly Leu Gly

370 375 380

Asp His Ser Leu Lys Val Cys Ser Ser Thr Leu Pro Ile Lys Pro Phe

385 390 395 400

Leu Ser Cys Phe Pro Glu Val Arg Val Tyr Asp Leu Thr Gln Tyr Glu

405 410 415

His Cys Pro Asp Asp Val Leu Val Leu Gly Thr Asp Gly Leu Trp Asp

420 425 430

Val Thr Thr Asp Cys Glu Val Ala Ala Thr Val Asp Arg Val Leu Ser

435 440 445

Ala Tyr Glu Pro Asn Asp His Ser Arg Tyr Thr Ala Leu Ala Gln Ala

450 455 460

Leu Val Leu Gly Ala Arg Gly Thr Pro Arg Asp Arg Gly Trp Arg Leu

465 470 475 480

Pro Asn Asn Lys Leu Gly Ser Gly Asp Asp Ile Ser Val Phe Val Ile

485 490 495

Pro Leu Gly Gly Pro Gly Ser Tyr Ser

500 505

<210> 31

<211> 3468

<212> DNA

<213> Homo sapiens

<400> 31

attgtgccct accagagagg agatgggc accgcctcca gtggcaatgc taattcaccc 60

aagaggcctt cccagctctt ctcacagaag gaagataaac tccacatatt tctatatcct 120

gctggatgac attgtcctta cccattctct cttcctcccg acggagaaat ttctgcagga 180

gctacaccag tactttgttc gggcaggagg catggagggc cctgaagggc tgggccggaa 240

gcaagcctgt ctagccatgc ttctccattt cttggacacc taccaggggc tgcttcaaga 300

ggaagagggg gccggccaca tcatcaagga tctatacctg ctaattatga aggacgagtc 360

cctttaccag ggcctccgag aggacactct gaggctgcac cagctggtgg agacggtgga 420

actaaagatt ccagaggaga accagccacc cagcaagcag gtgaagccac tcttccgcca 480

cttccgccgg atagactcct gtctgcagac ccgggtggcc ttccggggct ctgatgagat 540

cttctgccgt gtatacatgc ctgaccactc ttatgtgacc atacgcagcc gcctttcagc 600

atctgtgcag gacattctgg gctctgtgac ggagaaactt caatattcag aggagcccgc 660

ggggcgtgag gattccctca tcctggtagc tgtgtcctcc tctggagaga aggtccttct 720

ccagcccact gaggactgtg ttttcaccgc actgggcatc aacagccacc tgtttgcctg 780

tactcgggac agctatgagg ctctggtgcc cctccccgag gagatccagg tctcccctgg 840

agacacag atccaccgag tggagcctga ggacgttgcc aaccacctaa ctgccttcca 900

ctgggagctg ttccgatgtg tgcatgagct ggagttcgtg gactacgtgt tccacgggga 960

gcgcggccgc cgggagacgg ccaacttgga gctgctgctg cagcgctgca gcgaggtcac 1020

gcactgggtg gccaccgaag tgctgctctg cgaggccccg ggcaagcgcg cgcagctgct 1080

caagaagttc atcaagatcg cggccctctg caagcagaac caggacctgc tgtctttcta 1140

cgccgtggtc atggggctgg acaacgccgc tgtcagccgc cttcgactca cctgggagaa 1200

gctgccaggg aaattcaaga acttgtttcg caaatttgag aacctgacgg accctgcag 1260

gaaccacaaa agctaccgag aagtgatctc caaaatgaag ccccctgtga ttcccttcgt 1320

gcctctgatc ctcaaagacc tgactttcct gcacgaaggg agtaagaccc ttgtagatgg 1380

tttggtgaac atcgagaagc tgcattcagt ggccgaaaaa gtgaggacaa tccgcaaata 1440

ccggagccgg cccctttgcc tggacatgga ggcatccccc aatcacctgc agaccaaggc 1500

ctatgtgcgc cagtttcagg tcatcgacaa ccagaacctc ctcttcgagc tctcctacaa 1560

gctggaggca aacagtcagt gagagtggag gctccagtca gacccgccag atccttgggc 1620

acctggcact caagcacttt gcacgatgtc tcaaccaaca tctgacatct ttcccgtgga 1680

gcaacttcct gctccacggg aaagaggtcg atggatttac ccctggaccc ataagtctgt 1740

tcatcctgct gaagtcccct ccccattgct ccttcaagcc aaaactacac tttgctggtt 1800

cctgtcccct ctgagaaagg ggatagaaag ctccttcctc tatgtcctcc catcgagatc 1860

tgttctgggg atggagcttc caacttcctc ttgcagcagg aaagaatgct gctcaccctt 1920

ctgtcttgca gagtgggatt gtgggaggga ttggcagcct tcttctccac cacctgtcca 1980

gcttcttcct ggtcagggct gggaccccca ggaatattat gttgccgtgt gtgtgtgtgt 2040

gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtcttctt ttagggagca 2100

ggagtgcatc tggtaattga gggtggatgt tgtgtgtgct gggaggggt ccttctgttt 2160

ggtgctaccc ttgtctactc tgcccctgga tggtgcgggg tgctttctcc accccacac 2220

tccctgctca gctcctcgtg ctgccctgca tgcccaggct tgtgagccaa gctgcttttt 2280

ggggcaggga gtagcagcag gtgggagggg ttacccatca gcccttgcaa gtcccccact 2340

caggcctctg gaaggtccag ggatgggctc tgatgagagg gtaaaagatg ctcagggaaa 2400

cacaggcctc agctgcctag aggaccctcc ccctgccttg cagtgggctc gggtagagca 2460

gtatcaggag ctagggttgt ctgctgccca cactcctgct ttttgggata tctaactgct 2520

aaggagggag ttgacatccc ccttctggct catgtgtctg aaccaacaa catggtctct 2580

gtccctctct ctttgactct ccctttgtcc tccccataga gctggggtgg ggtggatccc 2640

tatacctggg gcaggcagcc ccaaagtggg ggagggggat ggcagagact gtaaaggcgc 2700

cactggactc tggcaaggcc tttattacct ttactcccct ccctctccca tcaccagcct 2760

caaggcctga ggggtgcagg ggctcctggc agctactggg tgaggtttcc tggcacagac 2820

tcacccttct ttctggcacc acctctttcc cttttgaaga gacagcaaca gccgtagcaa 2880

aagcagctgc tgctcctgct atgagggtgt atatattttt tacccaaagc tctggaattg 2940

tacatttatt ttttaaaact caaagaggga aagagccttg tatcatatgt gaacattgta 3000

tcataggtaa tgttgtacag acccttttat acagtgatct gtcttgttcc tgcagcaaaa 3060

atcctctatg gacataggag gtgctgtgtc ccatgccctc ttgccctgac agtgtcccat 3120

gggccccctt ctgctccctg ccccctcct gctactgctg atgcactctc ctctccctgc 3180

agcccctggc ttcccagcct tcctcctgac cccttccaac agccttggaa ctccagctgc 3240

caccaccctc tgggtcggac actgggaccc actggcccag tcttggctgc tgcttacccc 3300

tagccttgat gcctgcccag ggacccccag ccccctcccg ttgccctgca gctttaacag 3360

agtgaaccat gtgtattgta caggcgcggt tgtcattgca gaaaccgctg ggtggagaag 3420

aagccgataa agtctatgaa tcaacctgcc aaaaaaaaaa aaaaaaaa 3468

<210> 32

<211> 662

<212> PRT

<213> Homo sapiens

<400> 32

Met Lys Pro Leu Glu Lys Phe Leu Lys Lys Gln Thr Ser Gln Leu Ala

1 5 10 15

Gly Arg Thr Val Ala Gly Gly Pro Gly Gly Gly Leu Gly Ser Cys Gly

20 25 30

Gly Pro Gly Gly Gly Gly Gly Pro Gly Gly Gly Gly Gly Pro Ala Gly

35 40 45

Gly Gln Arg Ser Leu Gln Arg Arg Gln Ser Val Ser Arg Leu Leu Leu

50 55 60

Pro Ala Phe Leu Arg Glu Pro Pro Ala Glu Pro Gly Leu Glu Pro Pro

65 70 75 80

Val Pro Glu Glu Gly Gly Glu Pro Ala Gly Val Ala Glu Glu Pro Gly

85 90 95

Ser Gly Gly Pro Cys Trp Leu Gln Leu Glu Glu Val Pro Gly Pro Gly

100 105 110

Pro Leu Gly Gly Gly Gly Pro Leu Arg Ser Pro Ser Ser Tyr Ser Ser

115 120 125

Asp Glu Leu Ser Pro Gly Glu Pro Leu Thr Ser Pro Pro Trp Ala Pro

130 135 140

Leu Gly Ala Pro Glu Arg Pro Glu His Leu Leu Asn Arg Val Leu Glu

145 150 155 160

Arg Leu Ala Gly Gly Ala Thr Arg Asp Ser Ala Ala Ser Asp Ile Leu

165 170 175

Leu Asp Asp Ile Val Leu Thr His Ser Leu Phe Leu Pro Thr Glu Lys

180 185 190

Phe Leu Gln Glu Leu His Gln Tyr Phe Val Arg Ala Gly Gly Met Glu

195 200 205

Gly Pro Glu Gly Leu Gly Arg Lys Gln Ala Cys Leu Ala Met Leu Leu

210 215 220

His Phe Leu Asp Thr Tyr Gln Gly Leu Leu Gln Glu Glu Glu Gly Ala

225 230 235 240

Gly His Ile Ile Lys Asp Leu Tyr Leu Leu Ile Met Lys Asp Glu Ser

245 250 255

Leu Tyr Gln Gly Leu Arg Glu Asp Thr Leu Arg Leu His Gln Leu Val

260 265 270

Glu Thr Val Glu Leu Lys Ile Pro Glu Glu Asn Gln Pro Pro Ser Lys

275 280 285

Gln Val Lys Pro Leu Phe Arg His Phe Arg Arg Ile Asp Ser Cys Leu

290 295 300

Gln Thr Arg Val Ala Phe Arg Gly Ser Asp Glu Ile Phe Cys Arg Val

305 310 315 320

Tyr Met Pro Asp His Ser Tyr Val Thr Ile Arg Ser Arg Leu Ser Ala

325 330 335

Ser Val Gln Asp Ile Leu Gly Ser Val Thr Glu Lys Leu Gln Tyr Ser

340 345 350

Glu Glu Pro Ala Gly Arg Glu Asp Ser Leu Ile Leu Val Ala Val Ser

355 360 365

Ser Ser Gly Glu Lys Val Leu Leu Gln Pro Thr Glu Asp Cys Val Phe

370 375 380

Thr Ala Leu Gly Ile Asn Ser His Leu Phe Ala Cys Thr Arg Asp Ser

385 390 395 400

Tyr Glu Ala Leu Val Pro Leu Pro Glu Glu Ile Gln Val Ser Pro Gly

405 410 415

Asp Thr Glu Ile His Arg Val Glu Pro Glu Asp Val Ala Asn His Leu

420 425 430

Thr Ala Phe His Trp Glu Leu Phe Arg Cys Val His Glu Leu Glu Phe

435 440 445

Val Asp Tyr Val Phe His Gly Glu Arg Gly Arg Arg Glu Thr Ala Asn

450 455 460

Leu Glu Leu Leu Leu Gln Arg Cys Ser Glu Val Thr His Trp Val Ala

465 470 475 480

Thr Glu Val Leu Leu Cys Glu Ala Pro Gly Lys Arg Ala Gln Leu Leu

485 490 495

Lys Lys Phe Ile Lys Ile Ala Ala Leu Cys Lys Gln Asn Gln Asp Leu

500 505 510

Leu Ser Phe Tyr Ala Val Val Met Gly Leu Asp Asn Ala Ala Val Ser

515 520 525

Arg Leu Arg Leu Thr Trp Glu Lys Leu Pro Gly Lys Phe Lys Asn Leu

530 535 540

Phe Arg Lys Phe Glu Asn Leu Thr Asp Pro Cys Arg Asn His Lys Ser

545 550 555 560

Tyr Arg Glu Val Ile Ser Lys Met Lys Pro Pro Val Ile Pro Phe Val

565 570 575

Pro Leu Ile Leu Lys Asp Leu Thr Phe Leu His Glu Gly Ser Lys Thr

580 585 590

Leu Val Asp Gly Leu Val Asn Ile Glu Lys Leu His Ser Val Ala Glu

595 600 605

Lys Val Arg Thr Ile Arg Lys Tyr Arg Ser Arg Pro Leu Cys Leu Asp

610 615 620

Met Glu Ala Ser Pro Asn His Leu Gln Thr Lys Ala Tyr Val Arg Gln

625 630 635 640

Phe Gln Val Ile Asp Asn Gln Asn Leu Leu Phe Glu Leu Ser Tyr Lys

645 650 655

Leu Glu Ala Asn Ser Gln

660

<210> 33

<211> 2467

<212> DNA

<213> Homo sapiens

<400> 33

gaagatgcac acgacccaga aggacacgac gtacaccaag atcttcgtcg gggggctgcc 60

ctaccacacc accgacgcca gcctgcgcaa gtacttcgag gtcttcggcg agatcgagga 120

ggcggtggtc atcaccgacc ggcagacggg caagtcccgg ggctatggat ttgtcaccat 180

ggctgaccgg gctgctgccg aaagggcctg caaggatccc aatcccatca ttgatggcag 240

aaaggccaac gtgaacctgg catacttagg agcaaaacca aggatcatgc aaccaggttt 300

tgcctttggt gttcaacaac ttcatccagc ccttatacaa agacctttcg ggatacctgc 360

ccactatgtc tatccgcagg cttttgtgca gccgggagtg gtcattccac acgtccagcc 420

gacagcagct gccgcctcca ccacccctta cattgattac actggagctg catacgcaca 480

atactcagca gctgctgctg ctgccgccgc cgctgctgcc tatgaccagt acccctatgc 540

agcctctcca gctgctgcag gatatgttac tgctgggggc tatggctacg cagtccagca 600

gccaatcacc gcagcggcac ctgggacagc tgccgccgcc gctgcagcag ctgctgccgc 660

tgcagcattt ggccagtacc agcctcagca gctgcagaca gaccgaatgc aatagaccag 720

ccatctgatc aaagttgaat tgttttctct ttccctccca attttccaat ttttagtagc 780

taataagaga gttaacattg acttaacagc tttaaaaaaa aaaacagcca tgctattgtg 840

aagcagagtt attatttttt ttatactcca ggtagtgttc tagatgagaa agaggtaaga 900

atgaggggaa tgggcacaat tttggaaatc aatcccaaag agcctgagta aatgaaaggc 960

cactacgaaa tgacgccagg agtaacaacg gaacttcact tttgtaacgg gatttttatt 1020

tttgctcttt ttatagtatc agggaagcaa actgcctttt acaagttaga aaatgctgtt 1080

tgaatctagt tgaaccaggg aatacagagc gagcaatatg tagcttgaat tacatttaaa 1140

agcagatttt ttacaaacaa aatggcgaaa gcactgattg tcatttttag cagtcactta 1200

aggcctatag aacttttttc aagtcggaag gtcctgttct tactatctca aaaatgggca 1260

tcgaacaatc aatctaggag cgtggcagtg ggtaaaatgg tggacaggca ccaaagctat 1320

tttctcatct gtcctgtgga tgagtggaac tgtggaacaa gtgatgtgga attaatgggt 1380

gcaacagctg tacagacaat caataacaca cacagttctg gaaagaacac atcacttgtg 1440

cttgtttgat gagcttgtca cattctaatc cctctcccca tcctgtttca atttgggaa 1500

acttgtatct gctggtgtca gcaattctga ttctgaaata ggatcaggct tttactacaa 1560

cagccttctc tttctattta ttgtgtcgac tcgtggctta tgaataaagg caggcaaagt 1620

ttgcagaact gtcttaagga catttatttt ttttcccttt ttaagtaatt ttacacttta 1680

gtatctattt cagagtcata tttaaaacta tttattagtg actacagtac atgagacaac 1740

aaggttactg agattacaat tcttcaaagg ttaatgataa tgtggtttat actgtgcctt 1800

aatagtaatg ctatttaaga tatttatttt taagttttac tatgctgcac tctaaagaaa 1860

ggaactttag atgtgacact gtaaaattat gtattcatct catggcataa attatttagt 1920

aagtctagat gtagcgtatt aaatattaac ctattcaact aaagatgttg acttggattt 1980

atttaaattc atatgtgcac tgtataagag agtactctta cattaacaca ttttagttta 2040

gtttttagat ttttttttaa acgatatatt gctagtttca tgcttcctcc tctgattttg 2100

cctgtgtaga tttcatttat tggtaattca ttagtttaac actattatgt agtttttaaa 2160

tgctgcttta catttttctt ctgaaactgc aatacttgca atttttattc ttaaactaaa 2220

ttgaatacta ttttacactg tattggattt ttatacttga acaatttcat acaagggaag 2280

acaggttagc atttttatgg actttctcca ttatcactgg atttacttta agtattccca 2340

tactagacag tgttatgtaa tgtagacatg actctcctgt gcaaattatt tattcgttgt 2400

gtatattgct ttataacatt tcagatcttc taatctattc acttgtatta aatataattt 2460

ttaaaaa 2467

<210> 34

<211> 236

<212> PRT

<213> Homo sapiens

<400> 34

Met His Thr Thr Gln Lys Asp Thr Thr Tyr Tyr Thr Lys Ile Phe Val Gly

1 5 10 15

Gly Leu Pro Tyr His Thr Thr Asp Ala Ser Leu Arg Lys Tyr Phe Glu

20 25 30

Val Phe Gly Glu Ile Glu Glu Ala Val Val Ile Thr Asp Arg Gln Thr

35 40 45

Gly Lys Ser Arg Gly Tyr Gly Phe Val Thr Met Ala Asp Arg Ala Ala

50 55 60

Ala Glu Arg Ala Cys Lys Asp Pro Asn Pro Ile Ile Asp Gly Arg Lys

65 70 75 80

Ala Asn Val Asn Leu Ala Tyr Leu Gly Ala Lys Pro Arg Ile Met Gln

85 90 95

Pro Gly Phe Ala Phe Gly Val Gln Gln Leu His Pro Ala Leu Ile Gln

100 105 110

Arg Pro Phe Gly Ile Pro Ala His Tyr Val Tyr Pro Gln Ala Phe Val

115 120 125

Gln Pro Gly Val Val Ile Pro His Val Gln Pro Thr Ala Ala Ala Ala Ala

130 135 140

Ser Thr Thr Pro Tyr Ile Asp Tyr Thr Gly Ala Ala Tyr Ala Gln Tyr

145 150 155 160

Ser Ala Ala Ala Ala Ala Ala Ala Ala Ala Tyr Asp Gln Tyr

165 170 175

Pro Tyr Ala Ala Ser Pro Ala Ala Ala Gly Tyr Val Thr Ala Gly Gly

180 185 190

Tyr Gly Tyr Ala Val Gln Gln Pro Ile Thr Ala Ala Ala Pro Gly Thr

195 200 205

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Phe Gly Gln

210 215 220

Tyr Gln Pro Gln Gln Leu Gln Thr Asp Arg Met Gln

225                 230                 235

<210> 35

<211> 2264

<212> DNA

<213> Homo sapiens

<400> 35

gcagtccctc cgccgctagt cggagcgagc gcgagtgagg agacccccgc cgggccactg 60

gcacttgctt ctgcggcgag tcccaccac gaccgcagcc cagcaactcg caaacgcaac 120

ctgaagcctg ggctgcgcag tgtgggaggg cttcgcgatc ttgggggacc cattccgaac 180

ttgcagagga ccgtagctct cctggcctgg agagtgtgaa caggattgtg gactcttcca 240

agattcacaa tgatatggtg aatccaaaga ctggaaccaa aaagatttac tcagtgcttt 300

agttttaaca acagtaaatt gtctaccaac acccatcatg gctaaaagtg cggaggtcaa 360

actggcaata tttgggagag caggcgtggg caagtcagct cttgtagtga gatttctgac 420

caaacggttc atctgggaat atgatcccac cctcgaatca acctaccgac accaagcaac 480

catcgatgat gaagttgttt ccatggagat actagacact gctggtcagg aagataccat 540

tcagagggag gggcacatgc gatgggggga aggctttgtg ctggtctacg acattactga 600

ccgaggaagt tttgaggaag tgctgccact taagaacatc ctagatgaga tcaaaaagcc 660

caagaatgtg actctcatct tggttggaaa caaagctgac ttggaccact ccaggcaggt 720

tagcacagaa gaaggagaga agctggccac agaattggct tgtgcttttt acgagtgctc 780

tgcctgcact ggagaaggga acatcacaga gatattctat gaattgtgtc gagaggtgcg 840

tcgccggagg atggtgcagg gcaagacgag gcgacgcagc tccaccacgc atgtcaagca 900

agccattaac aagatgctca ccaaaatcag tagttaggca gcccagctga ggtggaccaa 960

ctaattggaa acactcttcc ccttctgttc ccctttcaaa aataaaacaa aatattgcat 1020

tctttgtttg gattctgaga aatgtctggg cttcccattg tttctggcct ctaataggtt 1080

gggaagtttt agcgtgtttt atgcaatttc agtgctaaca attcttcct ttcctgcttg 1140

aataagatac actctaatgg catttgaaca tgtaatcacc agagattctg aaatgactgg 1200

tttatgttaa gctattttta ggcatcttca ccttgcttta agtaggttga agtttttgca 1260

aaggcattta aaaattcaat ttcttgtcag atactacaaa taattttctt aaaagtctaa 1320

gatagcagaa aatacagtaa aaacacagga gaagaagctg agctattgga acaggaaata 1380

gaaggaactc tagtttctgt ttgaagtgag gattttctga attatctaat atcatctagg 1440

ttttctttaa aattttattt tgttcttcag ttcaagcatc ttctcactaa tgtttttcac 1500

tataacagag aattcatttc aatttgagtt ggttctctca atgatctatt gatcattaca 1560

ccctaactct ccttccttgg ctcaaacaat attttcccta taacaaaggc aataggacac 1620

aaaattcaca tcctgctggg ccttttttca tcaagtcagg gtgatataaa aacattggaa 1680

gtcttttcac caaaccctga ctttattgaa tgctagtaga agatgtagaa ttagagacat 1740

ctgatttgtt tatcacctta gcagaaaaac cacagtccaa aagacaagca aattaagaat 1800

ggagcttaac catgcctcca ttgggaagtc tagactttga gccaggtaca gtaagaaaaa 1860

ttagcctctg attcattaag tttgccacat gacttatttt gatattttgg atacattaac 1920

tcacttagga gaattcagaa aagaatgggt gattaaagtt cattacagct gaataaatgt 1980

gtctaaaaca gactcttgta ttctgaaagt acagtctaca actgataaaa ccttatgatt 2040

cttttctccc ccattatgcc cctatatata tcaagatttg ggtactttat tttagtagaa 2100

aatatatatc ttttacatat gtatgtattt ataaatgcat agatatatgt ataaaaattt 2160

gtaagcgtta gcggcattaa ttcaccaatg catttggaca acttgatgta actgacttta 2220

ttttatgtga ctataataaa aagcataatt ttctcattct gtca 2264

<210> 36

<211> 199

<212> PRT

<213> Homo sapiens

<400> 36

Met Ala Lys Ser Ala Glu Val Lys Leu Ala Ile Phe Gly Arg Ala Gly

1 5 10 15

Val Gly Lys Ser Ala Leu Val Val Arg Phe Leu Thr Lys Arg Phe Ile

20 25 30

Trp Glu Tyr Asp Pro Thr Leu Glu Ser Thr Tyr Arg His Gln Ala Thr

35 40 45

Ile Asp Asp Glu Val Val Ser Met Glu Ile Leu Asp Thr Ala Gly Gln

50 55 60

Glu Asp Thr Ile Gln Arg Glu Gly His Met Arg Trp Gly Glu Gly Phe

65 70 75 80

Val Leu Val Tyr Asp Ile Thr Asp Arg Gly Ser Phe Glu Glu Val Leu

85 90 95

Pro Leu Lys Asn Ile Leu Asp Glu Ile Lys Lys Pro Lys Asn Val Thr

100 105 110

Leu Ile Leu Val Gly Asn Lys Ala Asp Leu Asp His Ser Arg Gln Val

115 120 125

Ser Thr Glu Glu Gly Glu Lys Leu Ala Thr Glu Leu Ala Cys Ala Phe

130 135 140

Tyr Glu Cys Ser Ala Cys Thr Gly Glu Gly Asn Ile Thr Glu Ile Phe

145 150 155 160

Tyr Glu Leu Cys Arg Glu Val Arg Arg Arg Arg Met Val Gln Gly Lys

165 170 175

Thr Arg Arg Arg Ser Ser Thr Thr His Val Lys Gln Ala Ile Asn Lys

180 185 190

Met Leu Thr Lys Ile Ser Ser

195

<210> 37

<211> 5617

<212> DNA

<213> Homo sapiens

<400> 37

agtcccgcga ccgaagcagg gcgcgcagca gcgctgagtg ccccggaacg tgcgtcgcgc 60

ccccagtgtc cgtcgcgtcc gccgcgcccc gggcggggat ggggcggcca gactgagcgc 120

cgcacccgcc atccagaccc gccggcccta gccgcagtcc ctccagccgt ggccccagcg 180

cgcacgggcg atggcgaagg cgacgtccgg tgccgcgggg ctgcgtctgc tgttgctgct 240

gctgctgccg ctgctaggca aagtggcatt gggcctctac ttctcgaggg atgcttactg 300

ggagaagctg tatgtggacc aggcagccgg cacgcccttg ctgtacgtcc atgccctgcg 360

ggacgcccct gaggaggtgc ccagcttccg cctgggccag catctctacg gcacgtaccg 420

cacacggctg catgagaaca actggatctg catccaggag gacaccggcc tcctctacct 480

taaccggagc ctggaccata gctcctggga gaagctcagt gtccgcaacc gcggctttcc 540

cctgctcacc gtctacctca aggtcttcct gtcacccaca tcccttcgtg agggcgagtg 600

ccagtggcca ggctgtgccc gcgtatactt ctccttcttc aacacctcct ttccagcctg 660

cagctccctc aagccccggg agctctgctt cccagagaca aggccctcct tccgcattcg 720

ggagaaccga cccccaggca ccttccacca gttccgcctg ctgcctgtgc agttcttgtg 780

ccccaacatc agcgtggcct acaggctcct ggagggtgag ggtctgcct tccgctgcgc 840

cccggacagc ctggaggtga gcacgcgctg ggccctggac cgcgagcagc gggagaagta 900

cgagctggtg gccgtgtgca ccgtgcacgc cggcgcgcgc gaggaggtgg tgatggtgcc 960

cttcccggtg accgtgtacg acgaggacga ctcggcgccc accttccccg cgggcgtcga 1020

caccgccagc gccgtggtgg agttcaagcg gaaggaggac accgtggtgg ccacgctgcg 1080

tgtcttcgat gcagacgtgg tacctgcatc aggggagctg gtgaggcggt acacaagcac 1140

gctgctcccc ggggacacct gggcccagca gaccttccgg gtggaacact ggcccaacga 1200

gacctcggtc caggccaacg gcagcttcgt gcgggcgacc gtacatgact ataggctggt 1260

tctcaaccgg aacctctcca tctcggagaa ccgcaccatg cagctggcgg tgctggtcaa 1320

tgactcagac ttccagggcc caggagcggg cgtcctcttg ctccacttca acgtgtcggt 1380

gctgccggtc agcctgcacc tgcccagtac ctactccctc tccgtgagca ggagggctcg 1440

ccgatttgcc cagatcggga aagtctgtgt ggaaaactgc caggcattca gtggcatcaa 1500

cgtccagtac aagctgcatt cctctggtgc caactgcagc acgctagggg tggtcacctc 1560

agccgaggac acctcgggga tcctgtttgt gaatgacacc aaggccctgc ggcggcccaa 1620

gtgtgccgaa cttcactaca tggtggtggc caccgaccag cagacctcta ggcaggccca 1680

ggcccagctg cttgtaacag tggaggggtc atatgtggcc gaggaggcgg gctgccccct 1740

gtcctgtgca gtcagcaaga gacggctgga gtgtgaggag tgtggcggcc tgggctcccc 1800

aacaggcagg tgtgagtgga ggcaaggaga tggcaaaggg atcaccagga acttctccac 1860

ctgctctccc agcaccaaga cctgccccga cggccactgc gatgttgtgg agacccaaga 1920

catcaacatt tgccctcagg actgcctccg gggcagcatt gttgggggac acgagcctgg 1980

ggagccccgg gggattaaag ctggctatgg cacctgcaac tgcttccctg aggaggagaa 2040

gtgcttctgc gagcccgaag acatccagga tccactgtgc gacgagctgt gccgcacggt 2100

gatcgcagcc gctgtcctct tctccttcat cgtctcggtg ctgctgtctg ccttctgcat 2160

ccactgctac cacaagtttg cccacaagcc acccatctcc tcagctgaga tgaccttccg 2220

gaggcccgcc caggccttcc cggtcagcta ctcctcttcc ggtgcccgcc ggccctcgct 2280

ggactccatg gagaaccagg tctccgtgga tgccttcaag atcctggagg atccaaagtg 2340

ggaattccct cggaagaact tggttcttgg aaaaactcta ggagaaggcg aatttggaaa 2400

agtggtcaag gcaacggcct tccatctgaa aggcagagca gggtacacca cggtggccgt 2460

gaagatgctg aaagagaacg cctccccgag tgagctgcga gacctgctgt cagagttcaa 2520

cgtcctgaag caggtcaacc acccacatgt catcaaattg tatggggcct gcagccagga 2580

tggcccgctc ctcctcatcg tggagtacgc caaatacggc tccctgcggg gcttcctccg 2640

cgagagccgc aaagtggggc ctggctacct gggcagtgga ggcagccgca actccagctc 2700

cctggaccac ccggatgagc gggccctcac catgggcgac ctcatctcat ttgcctggca 2760

gatctcacag gggatgcagt atctggccga gatgaagctc gttcatcggg acttggcagc 2820

cagaaacatc ctggtagctg aggggcggaa gatgaagatt tcggatttcg gcttgtcccg 2880

agatgtttat gaagaggatt cctacgtgaa gaggagccag ggtcggattc cagttaaatg 2940

gatggcaatt gaatcccttt ttgatcatat ctacaccacg caaagtgatg tatggtcttt 3000

tggtgtcctg ctgtgggaga tcgtgaccct agggggaaac ccctatcctg ggattcctcc 3060

tgagcggctc ttcaaccttc tgaagaccgg ccaccggatg gagaggccag acaactgcag 3120

cgaggagatg taccgcctga tgctgcaatg ctggaagcag gagccggaca aaaggccggt 3180

gtttgcggac atcagcaaag acctggagaa gatgatggtt aagaggagag actacttgga 3240

ccttgcggcg tccactccat ctgactccct gattttatgac gacggcctct cagaggagga 3300

gacaccgctg gtggactgta ataatgcccc cctccctcga gccctccctt ccacatggat 3360

tgaaaacaaa ctctatggca tgtcagaccc gaactggcct ggagagagtc ctgtaccact 3420

cacgagagct gatggcacta acactgggtt tccaagatat ccaaatgata gtgtatatgc 3480

taactggatg ctttcaccct cagcggcaaa attaatggac acgtttgata gttaacattt 3540

ctttgtgaaa ggtaatggac tcacaagggg aagaaacatg ctgagaatgg aaagtctacc 3600

ggccctttct ttgtgaacgt cacattggcc gagccgtgtt cagttcccag gtggcagact 3660

cgtttttggt agtttgtttt aacttccaag gtggttttac ttctgatagc cggtgatttt 3720

ccctcctagc agacatgcca caccgggtaa gagctctgag tcttagtggt taagcattcc 3780

tttctcttca gtgcccagca gcacccagtg ttggtctgtg tccatcagtg accaccaaca 3840

ttctgtgttc acatgtgtgg gtccaacact tactacctgg tgtatgaaat tggacctgaa 3900

ctgttggatt tttctagttg ccgccaaaca aggcaaaaaa atttaaacat gaagcacaca 3960

cacaaaaaag gcagtaggaa aaatgctggc cctgatgacc tgtccttat cagaatgaga 4020

gactgcgggg ggggcctggg ggtagtgtca atgcccctcc aggggctggag gggaagaggg 4080

gccccgagga tgggcctggg ctcagcattc gagatcttga gaatgatttt ttttaaatca 4140

tgcaaccttt ccttaggaag acattggtt ttcatcatga ttaagatgat tcctagattt 4200

agcacaatgg aggattcca tgccatcttt actatgtgga tggtggtatc agggaagagg 4260

gctcacaaga cacatttgtc ccccgggccc accacatcat cctcacgtgt tcggtactga 4320

gcagccacta cccctgatga gaacagtatg aagaaagggg gctgttggag tcccagaatt 4380

gctgacagca gaggctttgc tgctgtgaat cccacctgcc accagcctgc agcacacccc 4440

acagccaagt agaggcgaaa gcagtggctc atcctacctg ttaggagcag gtagggcttg 4500

tactcacttt aatttgaatc ttatcaactt actcataaag ggacaggcta gctagctgtg 4560

ttagaagtag caatgacaat gaccaaggac tgctacacct ctgattacaa ttctgatgtg 4620

aaaaagatgg tgtttggctc ttatagagcc tgtgtgaaag gcccatggat cagctcttcc 4680

tgtgtttgta atttaatgct gctacaagat gtttctgttt cttagattct gaccatgact 4740

cataagcttc ttgtcattct tcattgcttg tttgtggtca cagatgcaca acactcctcc 4800

agtcttgtgg gggcagcttt tgggaagtct cagcagctct tctggctgtg ttgtcagcac 4860

tgtaacttcg cagaaaagag tcggattacc aaaacactgc ctgctcttca gacttaaagc 4920

actgatagga cttaaaatag tctcattcaa atactgtatt ttatataggc atttcacaaa 4980

aacagcaaaa ttgtggcatt ttgtgaggcc aaggcttgga tgcgtgtgta atagagcctt 5040

gtggtgtgtg cgcacacacc cagagggaga gtttgaaaaa tgcttattgg acacgtaacc 5100

tggctctaat ttgggctgtt tttcagatac actgtgataa gttcttttac aaatatctat 5160

agacatggta aacttttggt tttcagatat gcttaatgat agtcttacta aatgcagaaa 5220

taagaataaa ctttctcaaa ttattaaaaa tgcctacaca gtaagtgtga attgctgcaa 5280

caggtttgtt ctcaggaggg taagaactcc aggtctaaac agctgaccca gtgatgggga 5340

atttatcctt gaccaattta tccttgacca ataacctaat tgtctattcc tgagttataa 5400

aagtccccat ccttattagc tctactggaa ttttcataca cgtaaatgca gaagttacta 5460

agtattaagt attactgagt attaagtagt aatctgtcag ttattaaaat ttgtaaaatc 5520

tatttatgaa aggtcattaa accagatcat gttccttttt ttgtaatcaa ggtgactaag 5580

aaaatcagtt gtgtaaataa aatcatgtat cataaaa 5617

<210> 38

<211> 1114

<212> PRT

<213> Homo sapiens

<400> 38

Met Ala Lys Ala Thr Ser Gly Ala Ala Gly Leu Arg Leu Leu Leu Leu

1 5 10 15

Leu Leu Leu Pro Leu Leu Gly Lys Val Ala Leu Gly Leu Tyr Phe Ser

20 25 30

Arg Asp Ala Tyr Trp Glu Lys Leu Tyr Val Asp Gln Ala Ala Gly Thr

35 40 45

Pro Leu Leu Tyr Val His Ala Leu Arg Asp Ala Pro Glu Glu Val Pro

50 55 60

Ser Phe Arg Leu Gly Gln His Leu Tyr Gly Thr Tyr Arg Thr Arg Leu

65 70 75 80

His Glu Asn Asn Trp Ile Cys Ile Gln Glu Asp Thr Gly Leu Leu Tyr

85 90 95

Leu Asn Arg Ser Leu Asp His Ser Trp Glu Lys Leu Ser Val Arg

100 105 110

Asn Arg Gly Phe Pro Leu Leu Thr Val Tyr Leu Lys Val Phe Leu Ser

115 120 125

Pro Thr Ser Leu Arg Glu Gly Glu Cys Gln Trp Pro Gly Cys Ala Arg

130 135 140

Val Tyr Phe Ser Phe Phe Asn Thr Ser Phe Pro Ala Cys Ser Ser Leu

145 150 155 160

Lys Pro Arg Glu Leu Cys Phe Pro Glu Thr Arg Pro Ser Phe Arg Ile

165 170 175

Arg Glu Asn Arg Pro Pro Gly Thr Phe His Gln Phe Arg Leu Leu Pro

180 185 190

Val Gln Phe Leu Cys Pro Asn Ile Ser Val Ala Tyr Arg Leu Leu Glu

195 200 205

Gly Glu Gly Leu Pro Phe Arg Cys Ala Pro Asp Ser Leu Glu Val Ser

210 215 220

Thr Arg Trp Ala Leu Asp Arg Glu Gln Arg Glu Lys Tyr Glu Leu Val

225 230 235 240

Ala Val Cys Thr Val His Ala Gly Ala Arg Glu Glu Val Val Met Val

245 250 255

Pro Phe Pro Val Thr Val Tyr Asp Glu Asp Asp Ser Ala Pro Thr Phe

260 265 270

Pro Ala Gly Val Asp Thr Ala Ser Ala Val Val Glu Phe Lys Arg Lys

275 280 285

Glu Asp Thr Val Val Ala Thr Leu Arg Val Phe Asp Ala Asp Val Val

290 295 300

Pro Ala Ser Gly Glu Leu Val Arg Arg Tyr Thr Ser Thr Leu Leu Pro

305 310 315 320

Gly Asp Thr Trp Ala Gln Gln Thr Phe Arg Val Glu His Trp Pro Asn

325 330 335

Glu Thr Ser Val Gln Ala Asn Gly Ser Phe Val Arg Ala Thr Val His

340 345 350

Asp Tyr Arg Leu Val Leu Asn Arg Asn Leu Ser Ile Ser Glu Asn Arg

355 360 365

Thr Met Gln Leu Ala Val Leu Val Asn Asp Ser Asp Phe Gln Gly Pro

370 375 380

Gly Ala Gly Val Leu Leu Leu His Phe Asn Val Ser Val Leu Pro Val

385 390 395 400

Ser Leu His Leu Pro Ser Thr Tyr Ser Leu Ser Val Ser Arg Arg Ala

405 410 415

Arg Arg Phe Ala Gln Ile Gly Lys Val Cys Val Glu Asn Cys Gln Ala

420 425 430

Phe Ser Gly Ile Asn Val Gln Tyr Lys Leu His Ser Ser Gly Ala Asn

435 440 445

Cys Ser Thr Leu Gly Val Val Thr Ser Ala Glu Asp Thr Ser Gly Ile

450 455 460

Leu Phe Val Asn Asp Thr Lys Ala Leu Arg Arg Pro Lys Cys Ala Glu

465 470 475 480

Leu His Tyr Met Val Val Ala Thr Asp Gln Gln Thr Ser Arg Gln Ala

485 490 495

Gln Ala Gln Leu Leu Val Thr Val Glu Gly Ser Tyr Val Ala Glu Glu

500 505 510

Ala Gly Cys Pro Leu Ser Cys Ala Val Ser Lys Arg Arg Leu Glu Cys

515 520 525

Glu Glu Cys Gly Gly Leu Gly Ser Pro Thr Gly Arg Cys Glu Trp Arg

530 535 540

Gln Gly Asp Gly Lys Gly Ile Thr Arg Asn Phe Ser Thr Cys Ser Pro

545 550 555 560

Ser Thr Lys Thr Cys Pro Asp Gly His Cys Asp Val Val Glu Thr Gln

565 570 575

Asp Ile Asn Ile Cys Pro Gln Asp Cys Leu Arg Gly Ser Ile Val Gly

580 585 590

Gly His Glu Pro Gly Glu Pro Arg Gly Ile Lys Ala Gly Tyr Gly Thr

595 600 605

Cys Asn Cys Phe Pro Glu Glu Glu Lys Cys Phe Cys Glu Pro Glu Asp

610 615 620

Ile Gln Asp Pro Leu Cys Asp Glu Leu Cys Arg Thr Val Ile Ala Ala

625 630 635 640

Ala Val Leu Phe Ser Phe Ile Val Ser Val Leu Leu Ser Ala Phe Cys

645 650 655

Ile His Cys Tyr His Lys Phe Ala His Lys Pro Pro Ile Ser Ser Ala

660 665 670

Glu Met Thr Phe Arg Arg Pro Ala Gln Ala Phe Pro Val Ser Tyr Ser

675 680 685

Ser Ser Gly Ala Arg Arg Pro Ser Leu Asp Ser Met Glu Asn Gln Val

690 695 700

Ser Val Asp Ala Phe Lys Ile Leu Glu Asp Pro Lys Trp Glu Phe Pro

705 710 715 720

Arg Lys Asn Leu Val Leu Gly Lys Thr Leu Gly Glu Gly Glu Phe Gly

725 730 735

Lys Val Val Lys Ala Thr Ala Phe His Leu Lys Gly Arg Ala Gly Tyr

740 745 750

Thr Thr Val Ala Val Lys Met Leu Lys Glu Asn Ala Ser Pro Ser Glu

755 760 765

Leu Arg Asp Leu Leu Ser Glu Phe Asn Val Leu Lys Gln Val Asn His

770 775 780

Pro His Val Ile Lys Leu Tyr Gly Ala Cys Ser Gln Asp Gly Pro Leu

785 790 795 800

Leu Leu Ile Val Glu Tyr Ala Lys Tyr Gly Ser Leu Arg Gly Phe Leu

805 810 815

Arg Glu Ser Arg Lys Val Gly Pro Gly Tyr Leu Gly Ser Gly Gly Ser

820 825 830

Arg Asn Ser Ser Ser Leu Asp His Pro Asp Glu Arg Ala Leu Thr Met

835 840 845

Gly Asp Leu Ile Ser Phe Ala Trp Gln Ile Ser Gln Gly Met Gln Tyr

850 855 860

Leu Ala Glu Met Lys Leu Val His Arg Asp Leu Ala Ala Arg Asn Ile

865 870 875 880

Leu Val Ala Glu Gly Arg Lys Met Lys Ile Ser Asp Phe Gly Leu Ser

885 890 895

Arg Asp Val Tyr Glu Glu Asp Ser Tyr Val Lys Arg Ser Gln Gly Arg

900 905 910

Ile Pro Val Lys Trp Met Ala Ile Glu Ser Leu Phe Asp His Ile Tyr

915 920 925

Thr Thr Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile

930 935 940

Val Thr Leu Gly Gly Asn Pro Tyr Pro Gly Ile Pro Pro Glu Arg Leu

945 950 955 960

Phe Asn Leu Leu Lys Thr Gly His Arg Met Glu Arg Pro Asp Asn Cys

965 970 975

Ser Glu Glu Met Tyr Arg Leu Met Leu Gln Cys Trp Lys Gln Glu Pro

980 985 990

Asp Lys Arg Pro Val Phe Ala Asp Ile Ser Lys Asp Leu Glu Lys Met

995 1000 1005

Met Val Lys Arg Arg Asp Tyr Leu Asp Leu Ala Ala Ser Thr Pro

1010 1015 1020

Ser Asp Ser Leu Ile Tyr Asp Asp Gly Leu Ser Glu Glu Glu Thr

1025 1030 1035

Pro Leu Val Asp Cys Asn Asn Ala Pro Leu Pro Arg Ala Leu Pro

1040 1045 1050

Ser Thr Trp Ile Glu Asn Lys Leu Tyr Gly Met Ser Asp Pro Asn

1055 1060 1065

Trp Pro Gly Glu Ser Pro Val Pro Leu Thr Arg Ala Asp Gly Thr

1070 1075 1080

Asn Thr Gly Phe Pro Arg Tyr Pro Asn Asp Ser Val Tyr Ala Asn

1085 1090 1095

Trp Met Leu Ser Pro Ser Ala Ala Lys Leu Met Asp Thr Phe Asp

1100 1105 1110

Ser

<210> 39

<211> 4483

<212> DNA

<213> Homo sapiens

<400> 39

actgcgggcg gagcagaggg aaacaccaga gtctgtgact ccagacagga cccactgtgt 60

cctcttgaac tttgcacagc gcgtgacggg ggcagacggt gcaccgtggc ccggcctttc 120

gcgggggtcc tcggggaaga gagagagcg cgggtttcct cggaggcctg agcgggacgc 180

agcctgcagc ccctccccgc acgggctgcc cccggcccgc cgctcgcgcc gctctgctgg 240

gatccggcgc cttccccggc tgtcctcggc ctcccgcgcg ctccgcggga ggagccgcca 300

gcggccgtga cgcgtcaagg aggaaacgcc ggcgcccggc ggccctgccg ggaaggagga 360

agcgcagtgc gttcggctcc gcgcccgccg cgccgggagc agcaccgcgg ggccaggttg 420

catgatggaa tttgaacatt acttcaagag gttttgtatt ttggattagt taattgggtt 480

tgtcctctgc tgactgtttc ttcggatgca ttttttggtg tgctcttgag ggattaaatg 540

caaagagatc acaccatgga ctacaaggaa agctgcccaa gtgtaagcat tcccagctcc 600

gatgaacaca gagagaaaaa gaagaggttt actgtttata aagttctggt ttcagtggga 660

agaagtgaat ggtttgtctt caggagatat gcagagtttg ataaacttta taacacttta 720

aaaaaacagt ttcctgctat ggccctgaag attcctgcca agagaatatt tggtgataat 780

tttgatccag atttattaa acaaagacga gcaggactaa acgaattcat tcagaaccta 840

gttaggtatc cagaacttta taaccatcca gatgtcagag cattccttca aatggacagt 900

ccaaaacacc agtcagatcc atctgaagat gaggatgaaa gaagttctca gaagctacac 960

tctacctcac agaacatcaa cctgggaccg tctggaaatc ctcatgccaa accaactgac 1020

tttgatttct taaaagttat tggaaaaggc agctttggca aggttcttct tgcaaaacgg 1080

aaactggatg gaaaatttta tgctgtcaaa gtgttacaga aaaaaatagt tctcaacaga 1140

aaagagcaaa aacatattat ggctgaacgt aatgtgctct tgaaaaatgt gaaacatccg 1200

tttttggttg gattgcatta ttccttccaa acaactgaaa agctttattt tgttctggat 1260

tttgttaatg gaggggagct ttttttccac ttacaaagag aacggtcctt tcctgagcac 1320

agagctaggt tttacgctgc tgaaattgct agtgcattgg gttacttaca ttccatcaaa 1380

atagtataca gagacttgaa accagaaaat attcttttgg attcagtagg acatgttgtc 1440

ttaacagatt ttgggctttg taaagaagga attgctattt ctgacaccac taccacattt 1500

tgtgggacac cagagtatct tgcacctgaa gtaattagaa aacagcccta tgacaatact 1560

gtagattggt ggtgccttgg ggctgttctg tatgaaatgc tgtatggatt gcctcctttt 1620

tattgccgag atgttgctga aatgtatgac aatatccttc acaaacccct aagtttgagg 1680

ccaggagtga gtcttacagc ctggtccatt ctggaagaac tcctagaaaa agacaggcaa 1740

aatcgacttg gtgccaagga agactttctt gaaattcaga atcatccttt ttttgaatca 1800

ctcagctggg ctgaccttgt acaaaagaag attccaccac catttaatcc taatgtggct 1860

ggaccagatg atatcagaaa ctttgacaca gcatttacag aagaaacagt tccatattct 1920

gtgtgtgtat cttctgacta ttctatagtg aatgccagtg tattggaggc agatgatgca 1980

ttcgttggtt tctcttatgc acctccttca gaagacttat ttttgtgagc agtttgccat 2040

tcagaaacca ttgagcaaaa taagtctata gatgggactg aaacttctat ttgtgtgaat 2100

atattcaaat atgtataact agtgcctcat ttttatatgt aatgatgaaa actatgaaaa 2160

aatgtatttt cttctatgtg caagaaaaat agggcatttc aaagagctgt tttgattaaa 2220

atttatattc ttgtttaata agcttatttt taaacaattt aaaagctatt attcttagca 2280

ttaacctatt tttaaagaaa ccttttttgc tattgactgt tttttccctc taagtttaca 2340

ctaacatcta cccaagatag actgtttttt aacagtcaat ttcagttcag ctaacatata 2400

ttaatacctt tgtaactctt tgctatggct tttgttatca caccaaaact atgcaattgg 2460

tacatggttg tttaagaaga aaccgtattt ttccatgata aatcactgtt tgaaatattt 2520

ggttcatggt atgatcgaaa tgtaaaagca taattaacac attggctgct agttaacaat 2580

tggaataact ttatctctgca gatcatttaa gaagtaacag gccgggcgcg gtggctcacg 2640

cctgtaatcc cagcactttg ggaggctgag gcgggcagat cacctgaggt caggagttgg 2700

agaccagcct gaccaacatg gacaaacccc gtctctacta aaaatacaaa attggcaggg 2760

tgtggtggca catgcctata atcccagcta cttgggaggc taaggcagga gaatcgcttg 2820

aacccgggag gcggaggttg cagtgagccg agatcgcacc attgcactcc tgcctgggca 2880

acaagagtga aactccatct ccaaaaaaaa aaagaaaaag taacaaaagg aaattatttg 2940

tttttgaaat accagttcaa ctttgtggat tatttttcct ctgaaggaaa agaaaaggct 3000

taatggttag gatttttaag tattcccaaa gatctgaagg gtaataaaat gtactggatt 3060

ttttaaggtg gtaccaaaaa tgaatgtctg tcatatattt atattacaaa tacattatat 3120

ttatgttcta ttcatctttt gaatgtttag tatgctatta agtcattctg aatctttgta 3180

tttgcttttg caaataggta tttcaaagct cttttcctaa ctggttaagt aaaataaaaa 3240

attgagcttt ctagaatatt tgcctaattg ggaattaaaa agtaaaataa taggccaggc 3300

atggtggctc atgcctataa gcaccctggg aggccgaggc aggcagatta tttgagctca 3360

ggagtttgag accatcctgg gcaacatggc gaaaccctat ctctacaaaa aatacaaaaa 3420

ttagccagac atggtggcac atgcctttag tcccagctac tctggaggct gaagttggag 3480

gatggcttga gcccacgaga tggaagttgc agtgaactga aattgtgcca ctgcactttt 3540

cagcctgggt gccacagcga gaccctagtt aagagaaaaa aaaagtaaaa acaaattgtg 3600

ggtcaaagta aatgtataca gttttattac aatgtaacaa aagttgaaaa tcaggcagat 3660

gtgtattcag tatccaattc aatatatctt agaaaaagca caggaaacag accttaaaat 3720

tgtaacctac caactaactt acatgcttat aaaagtaaag gagaataact ggccgggcac 3780

ggtggctcat gcctataaaa ttccagcact ttgggaggcc aaggcaggag gatcacttga 3840

gcctatgagt tcaagaccag cctaggcaat gtagtgacac ctcatttcta tttatattttaa 3900

aaaaaagaga gagtaactac agaagaactt taaaaaataa aaaataagct taccttggat 3960

tcttggctta gagtagaggt tttttttaag ttatggagga aacatttttg taaaagttta 4020

atgacccact ttagatgctc caagaacaag catcccttcc atgtatgtct tgagaaagaa 4080

atcacagaag catttctcac caatactctt tggcttaaaa tgttcagcag aattgggcag 4140

tgggggtgac ttttcttata ttaataatat ttacatccaa tacactgaat cttcctttag 4200

aggtaagact ttaatatcta tactgtaaat atttggttta tttggcacta ctgtaagttt 4260

tgtttttcac aaagctctta ttatgaagca aaataaaaat tctagtttct tgtatgattt 4320

tttgtactca ttcattcctg ttaagctgcc aaaaattaaa gtgcaatatt gtatattttt 4380

aagaacaaat ttaaaataga attttgatgt ttctcagatc acaagaaata caaatctata 4440

tagtataata aaatcagcaa aaagatcaaa aaaaaaaaaa aaa 4483

<210> 40

<211> 496

<212> PRT

<213> Homo sapiens

<400> 40

Met Gln Arg Asp His Thr Met Asp Tyr Lys Glu Ser Cys Pro Ser Val

1 5 10 15

Ser Ile Pro Ser Ser Asp Glu His Arg Glu Lys Lys Lys Arg Phe Thr

20 25 30

Val Tyr Lys Val Leu Val Ser Val Gly Arg Ser Glu Trp Phe Val Phe

35 40 45

Arg Arg Tyr Ala Glu Phe Asp Lys Leu Tyr Asn Thr Leu Lys Lys Gln

50 55 60

Phe Pro Ala Met Ala Leu Lys Ile Pro Ala Lys Arg Ile Phe Gly Asp

65 70 75 80

Asn Phe Asp Pro Asp Phe Ile Lys Gln Arg Arg Ala Gly Leu Asn Glu

85 90 95

Phe Ile Gln Asn Leu Val Arg Tyr Pro Glu Leu Tyr Asn His Pro Asp

100 105 110

Val Arg Ala Phe Leu Gln Met Asp Ser Pro Lys His Gln Ser Asp Pro

115 120 125

Ser Glu Asp Glu Asp Glu Arg Ser Ser Gln Lys Leu His Ser Thr Ser

130 135 140

Gln Asn Ile Asn Leu Gly Pro Ser Gly Asn Pro His Ala Lys Pro Thr

145 150 155 160

Asp Phe Asp Phe Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val

165 170 175

Leu Leu Ala Lys Arg Lys Leu Asp Gly Lys Phe Tyr Ala Val Lys Val

180 185 190

Leu Gln Lys Lys Ile Val Leu Asn Arg Lys Glu Gln Lys His Ile Met

195 200 205

Ala Glu Arg Asn Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val

210 215 220

Gly Leu His Tyr Ser Phe Gln Thr Thr Glu Lys Leu Tyr Phe Val Leu

225 230 235 240

Asp Phe Val Asn Gly Gly Glu Leu Phe Phe His Leu Gln Arg Glu Arg

245 250 255

Ser Phe Pro Glu His Arg Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser

260 265 270

Ala Leu Gly Tyr Leu His Ser Ile Lys Ile Val Tyr Arg Asp Leu Lys

275 280 285

Pro Glu Asn Ile Leu Leu Asp Ser Val Gly His Val Val Leu Thr Asp

290 295 300

Phe Gly Leu Cys Lys Glu Gly Ile Ala Ile Ser Asp Thr Thr Thr Thr

305 310 315 320

Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Ile Arg Lys Gln

325 330 335

Pro Tyr Asp Asn Thr Val Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr

340 345 350

Glu Met Leu Tyr Gly Leu Pro Pro Phe Tyr Cys Arg Asp Val Ala Glu

355 360 365

Met Tyr Asp Asn Ile Leu His Lys Pro Leu Ser Leu Arg Pro Gly Val

370 375 380

Ser Leu Thr Ala Trp Ser Ile Leu Glu Glu Leu Leu Glu Lys Asp Arg

385 390 395 400

Gln Asn Arg Leu Gly Ala Lys Glu Asp Phe Leu Glu Ile Gln Asn His

405 410 415

Pro Phe Phe Glu Ser Leu Ser Trp Ala Asp Leu Val Gln Lys Lys Ile

420 425 430

Pro Pro Pro Phe Asn Pro Asn Val Ala Gly Pro Asp Asp Ile Arg Asn

435 440 445

Phe Asp Thr Ala Phe Thr Glu Glu Thr Val Pro Tyr Ser Val Cys Val

450 455 460

Ser Ser Asp Tyr Ser Ile Val Asn Ala Ser Val Leu Glu Ala Asp Asp

465 470 475 480

Ala Phe Val Gly Phe Ser Tyr Ala Pro Pro Ser Glu Asp Leu Phe Leu

485 490 495

<210> 41

<211> 2032

<212> DNA

<213> Homo sapiens

<400> 41

ggactctggg acgctcagac gccgcgcggg gcggggattg gtctgtggtc ctctctcggc 60

tcctcgcggc tcgcggcggc cgacggttcc tgggacacct gcttgcttgg cccgtccggc 120

ggctcagggc ttctctgctg cgctcccggt tcgctggacg ggaagaaggg ctgggccgtc 180

ccgtcccgtc cccatcggaa ccccaagtcg cgccgctgac ccgtcgcagg gcgagatgag 240

cgcggacgca gcggccgggg cgcccctgcc ccggctctgc tgcctggaga agggtccgaa 300

cggctacggc ttccacctgc acggggagaa gggcaagttg ggccagtaca tccggctggt 360

ggagcccggc tcgccggccg agaaggcggg gctgctggcg ggggaccggc tggtggaggt 420

gaacggcgaa aacgtggaga aggagaccca ccagcaggtg gtgagccgca tccgcgccgc 480

actcaacgcc gtgcgcctgc tggtggtcga ccccgagacg gacgagcagc tgcagaagct 540

cggcgtccag gtccgagagg agctgctgcg cgcccaggaa gcgccggggc aggccgagcc 600

gccggccgcc gccgaggtgc aggggctgg caacgaaaat gagcctcgcg aggccgacaa 660

gagccacccg gagcagcgcg agcttcggcc tcggctctgt accatgaaga aggggccccag 720

tggctatggc ttcaacctgc acagcgacaa gtccaagcca ggccagttca tccggtcagt 780

ggacccagac tccccggctg aggcttcagg gctccgggcc caggatcgca ttgtggaggt 840

gaacggggtc tgcatggagg ggaagcagca tggggacgtg gtgtccgcca tcagggctgg 900

cggggacgag accaagctgc tggtggtgga cagggaaact gacgagttct tcaagaaatg 960

cagagtgatc ccatctcagg agcacctgaa tggtcccctg cctgtgccct tcaccaatgg 1020

ggagatacag aaggagaaca gtcgtgaagc cctggcagag gcagccttgg aggccccag 1080

gccagccctg gtgagatccg cctccagtga caccagcgag gagctgaatt cccaagacag 1140

ccccccaaaa caggactcca cagcgccctc gtctacctcc tcctccgacc ccatcctaga 1200

cttcaacatc tccctggcca tggccaaaga gagggcccac cagaaacgca gcagcaaacg 1260

ggccccgcag atggactgga gcaagaaaaa cgaactcttc agcaacctct gagcgccctg 1320

ctgccaccca gtgactggca gggccgagcc agcattccac cccacctttt tccttctccc 1380

caattactcc cctgaatcaa tgtacaaatc agcacccaca tcccctttct tgacaaatga 1440

tttttctaga gaactatgtt cttccctgac tttagggaag gtgaatgtgt tcccgtcctc 1500

ccgcagtcag aaaggagact ctgcctccct cctcctcact gagtgcctca tcctaccggg 1560

tgtccctttg ccaccctgcc tgggacatcg ctggaacctg caccatgcca ggatcatggg 1620

accaggcgag agggcacct cccttcctcc cccatgtgat aaatgggtcc aggggctgatc 1680

aaagaactct gactgcagaa ctgccgctct cagtggacag ggcatctgtt accctgagac 1740

ctgtggcaga cacgtcttgt tttcatttga tttttgttaa gagtgcagta ttgcagagtc 1800

tagaggaatt tttgtttcct tgattaacat gattttcctg gttgttacat ccagggcatg 1860

gcagtggcct cagccttaaa cttttgttcc tactcccacc ctcagcgaac tgggcagcac 1920

ggggagggtt tggctacccc tgcccatccc tgagccaggt accaccattg taaggaaaca 1980

ctttcagaaa ttcagctggt tcctccaaac ccttcaaaaa aaaaaaaaaa aa 2032

<210> 42

<211> 358

<212> PRT

<213> Homo sapiens

<400> 42

Met Ser Ala Asp Ala Ala Ala Gly Ala Pro Leu Pro Arg Leu Cys Cys

1 5 10 15

Leu Glu Lys Gly Pro Asn Gly Tyr Gly Phe His Leu His Gly Glu Lys

20 25 30

Gly Lys Leu Gly Gln Tyr Ile Arg Leu Val Glu Pro Gly Ser Pro Ala

35 40 45

Glu Lys Ala Gly Leu Leu Ala Gly Asp Arg Leu Val Glu Val Asn Gly

50 55 60

Glu Asn Val Glu Lys Glu Thr His Gln Gln Val Val Ser Arg Ile Arg

65 70 75 80

Ala Ala Leu Asn Ala Val Arg Leu Leu Val Val Asp Pro Glu Thr Asp

85 90 95

Glu Gln Leu Gln Lys Leu Gly Val Gln Val Arg Glu Glu Leu Leu Arg

100 105 110

Ala Gln Glu Ala Pro Gly Gln Ala Glu Pro Pro Ala Ala Ala Glu Val

115 120 125

Gln Gly Ala Gly Asn Glu Asn Glu Pro Arg Glu Ala Asp Lys Ser His

130 135 140

Pro Glu Gln Arg Glu Leu Arg Pro Arg Leu Cys Thr Met Lys Lys Gly

145 150 155 160

Pro Ser Gly Tyr Gly Phe Asn Leu His Ser Asp Lys Ser Lys Pro Gly

165 170 175

Gln Phe Ile Arg Ser Val Asp Pro Asp Ser Pro Ala Glu Ala Ser Gly

180 185 190

Leu Arg Ala Gln Asp Arg Ile Val Glu Val Asn Gly Val Cys Met Glu

195 200 205

Gly Lys Gln His Gly Asp Val Val Ser Ala Ile Arg Ala Gly Gly Asp

210 215 220

Glu Thr Lys Leu Leu Val Val Asp Arg Glu Thr Asp Glu Phe Phe Lys

225 230 235 240

Lys Cys Arg Val Ile Pro Ser Gln Glu His Leu Asn Gly Pro Leu Pro

245 250 255

Val Pro Phe Thr Asn Gly Glu Ile Gln Lys Glu Asn Ser Arg Glu Ala

260 265 270

Leu Ala Glu Ala Ala Leu Glu Ser Pro Arg Pro Ala Leu Val Arg Ser

275 280 285

Ala Ser Ser Asp Thr Ser Glu Glu Leu Asn Ser Gln Asp Ser Pro Pro

290 295 300

Lys Gln Asp Ser Thr Ala Pro Ser Ser Thr Ser Ser Ser Asp Pro Ile

305 310 315 320

Leu Asp Phe Asn Ile Ser Leu Ala Met Ala Lys Glu Arg Ala His Gln

325 330 335

Lys Arg Ser Ser Lys Arg Ala Pro Gln Met Asp Trp Ser Lys Lys Asn

340 345 350

Glu Leu Phe Ser Asn Leu

355

<210> 43

<211> 492

<212> DNA

<213> Homo sapiens

<400> 43

atccctgact cggggtcgcc tttggagcag agaggaggca atggccacca tggagaacaa 60

ggtgatctgc gccctggtcc tggtgtccat gctggccctc ggcaccctgg ccgaggccca 120

gacagagacg tgtacagtgg ccccccgtga aagacagaat tgtggttttc ctggtgtcac 180

gccctcccag tgtgcaaata aggggctgctg tttcgacgac accgttcgtg gggtcccctg 240

gtgcttctat cctaatacca tcgacgtccc tccagaagag gagtgtgaat tttagacact 300

tctgcaggga tctgcctgca tcctgacgcg gtgccgtccc cagcacggtg attagtccca 360

gagctcggct gccacctcca ccggacacct cagacacgct tctgcagctg tgcctcggct 420

cacaacacag attgactgct ctgactttga ctactcaaaa ttggcctaaa aattaaaaga 480

gatcgatatt aa 492

<210> 44

<211> 84

<212> PRT

<213> Homo sapiens

<400> 44

Met Ala Thr Met Glu Asn Lys Val Ile Cys Ala Leu Val Leu Val Ser

1 5 10 15

Met Leu Ala Leu Gly Thr Leu Ala Glu Ala Gln Thr Glu Thr Cys Thr

20 25 30

Val Ala Pro Arg Glu Arg Gln Asn Cys Gly Phe Pro Gly Val Thr Pro

35 40 45

Ser Gln Cys Ala Asn Lys Gly Cys Cys Phe Asp Asp Thr Val Arg Gly

50 55 60

Val Pro Trp Cys Phe Tyr Pro Asn Thr Ile Asp Val Pro Pro Glu Glu

65 70 75 80

Glu Cys Glu Phe

<210> 45

<211> 3316

<212> DNA

<213> Homo sapiens

<400> 45

ggtttttgtg ttgctagccg gggccagcgg cggtggcggc ggcggcggag gcgtcggtgg 60

aggagggggag gcggcgagga ggcgcagctc ccgctgcacc gcgatcgacg ctgcggagcg 120

agcccacccg ccccgggagc tcgcctcccc ggtgctcccc cgccctcccc gcccccccag 180

cggcgctgcc tcctccaaat gagcgattcg cccgctggat ctaacccaag gacacccgaa 240

agcagcggca gcggcagcgg cggcggcggg aagaggccgg cggtgccggc agcggtgtcc 300

ctcttgccac cggcggaccc cctgcgccag gcgaaccggc tcccgatcag ggtcctgaag 360

atgctgagcg ctcacaccgg tcacctcctg cacccggagt acctgcagcc gctgtcctcc 420

actcccgtca gccccattga gctggacgcc aagaagagcc ccttggcgct gctggctcag 480

acctgctcgc agatcggcaa gccggacccg ccgccctcct ccaaactcaa ctcggtggcg 540

gcggcggcca acgggctggg agcggagaag gaccccggcc gctcagcccc gggcgccgcc 600

tccgcagccg cggccctgaa gcagctgggg gactcaccgg ccgaggacaa gtccagcttc 660

aagccctact ccaagggctc cggcggcggc gactcccgca aagacagcgg ctcctcctcg 720

gtgtcttcca cctcctcctc gtcctcctcg tccccgggag acaaggcggg cttcagggtc 780

cccagcgccg cctgcccgcc ctttcccccg catggagcgc cggtctccgc atcctcgtcc 840

tcgtcgtcgc ccggcggctc ccgcggcggc tccccgcacc actctgactg caagaacggc 900

ggcggggttg gcggcgggga gctggacaag aaagaccagg agcccaagcc cagcccggag 960

ccggcagccg tgagccgcgg cggcggtggg gagcccgggg cgcacggtgg cgccgagtcc 1020

ggggcctccg ggcgcaagtc cgagccgccc tcggcgctgg tgggggccgg ccacgtggcg 1080

ccggtgtctc cctacaagcc gggccactcg gtgttcccgc tgccgccctc cagcattggc 1140

taccacggct ccatcgtggg cgcctacgcc ggctacccgt ctcagttcgt gcctggcctg 1200

gatcctagca agtccggcct cgtgggaggc cagctgtctg ggggcctggg cctgccgccg 1260

ggcaagcccc ccagctccag cccgctcacc ggggcctccc cgccctcctt cctgcaggga 1320

ttatgccgcg acccctattg cttggggaggt taccacggcg cctcgcacct cggcggctcc 1380

agctgctcca cctgcagcgc gcacgacct gccgggccca gcctgaaggc ggggggctac 1440

ccgctggtgt accccgggca cccgctgcag cccgccgcgc tctcgtccag cgccgcccag 1500

gccgcgctcc ccggccaccc gctctacacc tacggcttca tgctgcagaa cgaaccgctg 1560

ccgcacagct gcaactgggt ggcagccagt gggccgtgcg acaagcgctt cgccacctcg 1620

gaggagctgc tcagccacct acggacccac acggccctgc cgggagccga gaaacttctg 1680

gccgcctacc ccggggcctc gggcctgggc agcgccgccg ccgccgccgc cgccgccgcc 1740

tcctgccatc tgcacctccc cccgcccgcc gcccccggca gccccgggtc gctgtccttg 1800

cggaatccac acactttggg cctaagccgg taccacccct atggcaagag ccacttatcc 1860

acagcggggg gcctggccgt gccgtccctc cccacagccg gaccctacta ttcgccatac 1920

gcgctgtatg gacagagact agcttcagcc tcggcgctgg gataccagta actacagctc 1980

ttcctccacc ccagccccct caccctcctc cctctccctc ctcctccctc cccacctgcc 2040

gtcgccgctg caacctccac tactgcttga ccctgccggg attccccacc cagcccttcc 2100

ccaccggact gtgtattttat ttactataat gttagcttac aagctgggaa tataagtgca 2160

ttaacggccc acatgagtca atggtatgca aaaagtctgt gttctcccaa atataatat 2220

taatcccaca aataacgaca tgatccccgc ccctgttcct ttctgttatttttcttaga 2280

tataagtttt acatttttta ttccttttcc tctttttttg gttttgattg gtttggtttg 2340

agggagtt ggggtctttg ggttcttcta gacgttttgt tttcccttcc tggggagttt 2400

cttgcatgag tcttaactta aaactacgtt tccgccttct ctttttccct cttccccctt 2460

cattccctct tgtttccttc catttgcggt tctgtttttg ttttttgttt tgttttgttt 2520

tgttttttcc tttgttgtac aagtaacaga gaggaggttt tttttgtaac tcattttggg 2580

ggtggagggg gccacctggg tggcaggggc cctggagctc tattgacctg gtacactgct 2640

ccgggactcc tcccccgcca ccctccgcgc atagggtcct tggtctggac cctgcccccc 2700

aaaagtaggg ccttgctcct ctaccttgct ctgagcacgg agagccctga ccccaccagt 2760

aggctcgccc ccagaagggc ccaagtggcc gtctaccgtc accttccaga ctcccgcccc 2820

taacacccag tggctacagt gcgcctgtcg gggcacctgg agcgctcacc tggttgaatt 2880

caaagtccca gaaggccccg ctggcgtgaa gccggcccct tacattttgc gaagtgcatt 2940

atagtccttg tttttctctc cctcgtgggg gcaacgaccc ctcccctggc agtaggggtg 3000

gggtaggtga ctctcgctag atccctccaa agcagaccgg tggcgatgtc agcggatgtc 3060

acgagctcgt tagctgcgtt cggggaaggt tggggcgtca gggagctctc ggatcacagc 3120

agcccccgcc ctctcctagg cctggcccgg cagagccccc agagtggacc ccccagcgac 3180

tggggtcttc tccccactcc tccctccttc tggtctgatg cggcagcgcg ggggctgcgg 3240

ggcctgtttg ggacgaacag agctctccct tggtaagact tattttgtta ataaatggaa 3300

tacttggcta tattca 3316

<210> 46

<211> 590

<212> PRT

<213> Homo sapiens

<400> 46

Met Ser Asp Ser Pro Ala Gly Ser Asn Pro Arg Thr Pro Glu Ser Ser

1 5 10 15

Gly Ser Gly Ser Gly Gly Gly Gly Lys Arg Pro Ala Val Pro Ala Ala

20 25 30

Val Ser Leu Leu Pro Pro Ala Asp Pro Leu Arg Gln Ala Asn Arg Leu

35 40 45

Pro Ile Arg Val Leu Lys Met Leu Ser Ala His Thr Gly His Leu Leu

50 55 60

His Pro Glu Tyr Leu Gln Pro Leu Ser Ser Thr Pro Val Ser Pro Ile

65 70 75 80

Glu Leu Asp Ala Lys Lys Ser Pro Leu Ala Leu Leu Ala Gln Thr Cys

85 90 95

Ser Gln Ile Gly Lys Pro Asp Pro Pro Pro Pro Ser Ser Lys Leu Asn Ser

100 105 110

Val Ala Ala Ala Ala Asn Gly Leu Gly Ala Glu Lys Asp Pro Gly Arg

115 120 125

Ser Ala Pro Gly Ala Ala Ser Ala Ala Ala Ala Leu Lys Gln Leu Gly

130 135 140

Asp Ser Pro Ala Glu Asp Lys Ser Ser Phe Lys Pro Tyr Ser Lys Gly

145 150 155 160

Ser Gly Gly Gly Asp Ser Arg Lys Asp Ser Gly Ser Ser Ser Ser Val Ser

165 170 175

Ser Thr Ser Ser Ser Ser Ser Ser Ser Ser Pro Gly Asp Lys Ala Gly Phe

180 185 190

Arg Val Pro Ser Ala Ala Cys Pro Pro Phe Pro Pro His Gly Ala Pro

195 200 205

Val Ser Ala Ser Ser Ser Ser Ser Ser Pro Gly Gly Ser Arg Gly Gly

210 215 220

Ser Pro His His Ser Asp Cys Lys Asn Gly Gly Gly Val Gly Gly Gly

225 230 235 240

Glu Leu Asp Lys Lys Asp Gln Glu Pro Lys Pro Ser Pro Glu Pro Ala

245 250 255

Ala Val Ser Arg Gly Gly Gly Gly Glu Pro Gly Ala His Gly Gly Ala

260 265 270

Glu Ser Gly Ala Ser Gly Arg Lys Ser Glu Pro Pro Ser Ala Leu Val

275 280 285

Gly Ala Gly His Val Ala Pro Val Ser Pro Tyr Lys Pro Gly His Ser

290 295 300

Val Phe Pro Leu Pro Pro Ser Ser Ile Gly Tyr His Gly Ser Ile Val

305 310 315 320

Gly Ala Tyr Ala Gly Tyr Pro Ser Gln Phe Val Pro Gly Leu Asp Pro

325 330 335

Ser Lys Ser Gly Leu Val Gly Gly Gln Leu Ser Gly Gly Leu Gly Leu

340 345 350

Pro Pro Gly Lys Pro Pro Ser Ser Ser Pro Leu Thr Gly Ala Ser Pro

355 360 365

Pro Ser Phe Leu Gln Gly Leu Cys Arg Asp Pro Tyr Cys Leu Gly Gly

370 375 380

Tyr His Gly Ala Ser His Leu Gly Gly Ser Ser Ser Cys Ser Thr Cys Ser

385 390 395 400

Ala His Asp Pro Ala Gly Pro Ser Leu Lys Ala Gly Gly Tyr Pro Leu

405 410 415

Val Tyr Pro Gly His Pro Leu Gln Pro Ala Ala Leu Ser Ser Ser Ala

420 425 430

Ala Gln Ala Ala Leu Pro Gly His Pro Leu Tyr Thr Tyr Tyr Gly Phe Met

435 440 445

Leu Gln Asn Glu Pro Leu Pro His Ser Cys Asn Trp Val Ala Ala Ser

450 455 460

Gly Pro Cys Asp Lys Arg Phe Ala Thr Ser Glu Glu Leu Leu Ser His

465 470 475 480

Leu Arg Thr His Thr Ala Leu Pro Gly Ala Glu Lys Leu Leu Ala Ala

485 490 495

Tyr Pro Gly Ala Ser Gly Leu Gly Ser Ala Ala Ala Ala Ala

500 505 510

Ala Ala Ser Cys His Leu His Leu Pro Pro Pro Ala Ala Pro Gly Ser

515 520 525

Pro Gly Ser Leu Ser Leu Arg Asn Pro His Thr Leu Gly Leu Ser Arg

530 535 540

Tyr His Pro Tyr Gly Lys Ser His Leu Ser Thr Ala Gly Gly Leu Ala

545 550 555 560

Val Pro Ser Leu Pro Thr Ala Gly Pro Tyr Tyr Ser Pro Tyr Ala Leu

565 570 575

Tyr Gly Gln Arg Leu Ala Ser Ala Ser Ala Leu Gly Tyr Gln

580 585 590

<210> 47

<211> 1691

<212> DNA

<213> Homo sapiens

<400> 47

gggctggcgc gggcgggagc tgcggcggat acccttgcgt gctgtggaga ccctactctc 60

ttcgctgaga acggccgcta gcggggactg aaggccggga gcccactccc gacccggggc 120

tagcgtgcgt ccctagagtc gagcggggca agggagccag tggccgccga cgggggaccg 180

ggaaactttt ctgggctcct gggcgcgccc tgtagccgcg ctccatgctc cggcagcggc 240

ccgaaaccca gccccgccgc tgacggcgcc cgccgctccg ggcagggccc atgccctgcg 300

cgctccgggg gtcgtaggct gccgccgagc cggggctccg gaagccggcg ggggcgccgc 360

ggccgtgcgg ggcgtcaatg gatcgccact ccagctacat cttcatctgg ctgcagctgg 420

agctctgcgc catggccgtg ctgctcacca aaggtgaaat tcgatgctac tgtgatgctg 480

cccactgtgt agccactggt tatatgtgta aatctgagct cagcgcctgc ttctctagac 540

ttcttgatcc tcagaactca aattccccac tcacccatgg ctgcctggac tctcttgcaa 600

gcacgacaga catctgccaa gccaaacagg cccgaaacca ctctggcacc accataccca 660

cattggaatg ctgtcatgaa gacatgtgca attacagagg gctgcacgat gttctctctc 720

ctcccagggg tgaggcctca ggacaaggaa acaggtatca gcatgatggt agcagaaacc 780

ttatcaccaa ggtgcaggag ctgacttctt ccaaagagtt gtggttccgg gcagcggtca 840

ttgccgtgcc cattgctgga gggctgattt tagtgttgct tattatgttg gccctgagga 900

tgcttcgaag tgaaaataag aggctgcagg atcagcggca acagatgctc tcccgtttgc 960

actacagctt tcacggacac cattccaaaa aggggcaggt tgcaaagtta gacttggaat 1020

gcatggtgcc ggtcagtggg cacgagaact gctgtctgac ctgtgataaa atgagacaag 1080

cagacctcag caacgataag atcctctcgc ttgttcactg gggcatgtac agtgggcacg 1140

ggaagctgga attcgtatga cggagtctta tctgaactac acttactgaa cagcttgaag 1200

gccttttgag ttctgctgga caggagcact ttatctgaag acaaactcat ttaatcatct 1260

ttgagagaca aaatgacctc tgcaaacaga atcttggata tttcttctga aggattattt 1320

gcacagactt aaatacagtt aaatgtgtta tttgctttta aaattataaa aagcaaagag 1380

aagactttgt accacactgtc accagggtta tttgcatcca agggagctgg aattgagtac 1440

ctaaataaac aaaaatgtgc cctatgtaag cttctacatc ttgatttatt gtaaagattt 1500

aaaagaaata tatatatttt gtctgaaatt taatagtgtc tttcataaat ttaactggga 1560

aacgtgagac agtacatgtt aattatacaa atggccattt gctgttaata attgttctc 1620

aactctagga tgtggcttgg tttttttttt tctcttttct tttttaaaca agaccaagat 1680

cttgcttatt c 1691

<210> 48

<211> 260

<212> PRT

<213> Homo sapiens

<400> 48

Met Asp Arg His Ser Ser Tyr Ile Phe Ile Trp Leu Gln Leu Glu Leu

1 5 10 15

Cys Ala Met Ala Val Leu Leu Thr Lys Gly Glu Ile Arg Cys Tyr Cys

20 25 30

Asp Ala Ala His Cys Val Ala Thr Gly Tyr Met Cys Lys Ser Glu Leu

35 40 45

Ser Ala Cys Phe Ser Arg Leu Leu Asp Pro Gln Asn Ser Asn Ser Pro

50 55 60

Leu Thr His Gly Cys Leu Asp Ser Leu Ala Ser Thr Thr Asp Ile Cys

65 70 75 80

Gln Ala Lys Gln Ala Arg Asn His Ser Gly Thr Thr Ile Pro Thr Leu

85 90 95

Glu Cys Cys His Glu Asp Met Cys Asn Tyr Arg Gly Leu His Asp Val

100 105 110

Leu Ser Pro Pro Arg Gly Glu Ala Ser Gly Gln Gly Asn Arg Tyr Gln

115 120 125

His Asp Gly Ser Arg Asn Leu Ile Thr Lys Val Gln Glu Leu Thr Ser

130 135 140

Ser Lys Glu Leu Trp Phe Arg Ala Ala Val Ile Ala Val Pro Ile Ala

145 150 155 160

Gly Gly Leu Ile Leu Val Leu Leu Ile Met Leu Ala Leu Arg Met Leu

165 170 175

Arg Ser Glu Asn Lys Arg Leu Gln Asp Gln Arg Gln Gln Met Leu Ser

180 185 190

Arg Leu His Tyr Ser Phe His Gly His His Ser Lys Lys Gly Gln Val

195 200 205

Ala Lys Leu Asp Leu Glu Cys Met Val Pro Val Ser Gly His Glu Asn

210 215 220

Cys Cys Leu Thr Cys Asp Lys Met Arg Gln Ala Asp Leu Ser Asn Asp

225 230 235 240

Lys Ile Leu Ser Leu Val His Trp Gly Met Tyr Ser Gly His Gly Lys

245 250 255

Leu Glu Phe Val

260

<210> 49

<211> 3490

<212> DNA

<213> Homo sapiens

<400> 49

actgggtaga atacttgggg tgccagggag gcattaatgc gagaggagtc aggtgctcag 60

tttttattgg agttggggagg gcagccccac atcaggaaga gaacctgttt ctgcaggatg 120

gtccggggag aagggaggac tccacccagg cttgtgtttg ccctgctctg tgtattcagc 180

cagcaggctc tgcacaagga agcaaagtgc agggagccag gctccaccga cagccaggca 240

ctgggcagca cgcactggag acccaggacc ctgtgcagga gcagctccgg gtgacacgag 300

gggactgaag atactcccac aggggctcag caggagcaat gggtaaccaa atgagtgttc 360

cccaaagagt tgaagaccaa gagaatgaac cagaagcaga gacttaccag gacaacgcgt 420

ctgctctgaa cggggttcca gtggtggtgt cgacccaac agttcagcac ttagaggaag 480

tcgacttggg aataagtgtc aagacggata atgtggccac ttcttccccc gagacaacgg 540

agataagtgc tgttgcggat gccaacggaa agaatcttgg gaaagaggcc aaacccgagg 600

caccagctgc taaatctcgt tttttcttga tgctctctcg gcctgtacca ggacgtaccg 660

gagaccaagc cgcagattca tcccttggat cagtgaagct tgatgtcagc tccaataaag 720

ctccagcgaa caaagaccca agtgagagct ggacacttcc ggtggcagct ggaccggggc 780

aggacacaga taaaacccca gggcacgccc cggcccaaga caaggtcctc tctgccgcca 840

gggatcccac gcttctccca cctgagacag ggggagcagg aggagaagct ccctccaagc 900

ccaaggactc cagctttttt gacaaattct tcaagctgga caagggacag gaaaaggtgc 960

caggtgacag ccaacaggaa gccaagaggg cagagcatca agacaaggtg gatgaggttc 1020

ctggcttatc agggcagtcc gatgatgtcc ctgcagggaa ggacatagtt gacggcaagg 1080

aaaaagaagg acaagaactt ggaactgcgg attgctctgt ccctggggac ccagaaggac 1140

tggagactgc aaaggacgat tcccaggcag cagctatagc agagaataat aattccatca 1200

tgagtttctt taaaactctg gtttcaccta acaaagctga aacaaaaaag gacccagaag 1260

acacgggtgc tgaaaagtca cccaccactt cagctgacct taagtcagac aaagccaact 1320

ttacatccca ggagacccaa ggggctggca agaattccaa aggatgcaac ccatcggggc 1380

acacacagtc cgtgacaacc cctgaacctg cgaaggaagg caccaaggag aaatcaggac 1440

ccacctctct gcctctgggc aaactgtttt ggaaaaagtc agttaaagag gactcagtcc 1500

ccacaggtgc ggaggagaat gtggtgtgtg agtcaccagt agagattata aagtccaagg 1560

aagtagaatc agccttacaa acagtggacc tcaacgaagg agatgctgca cctgaaccca 1620

cagaagcgaa actcaaaaga gaagaaagca aaccaagaac ctctctgatg gcgtttctca 1680

gacaaatgtc agtgaaaggg gatggaggga tcacccactc agaagaaata aatgggaaag 1740

actccagctg ccaaacatca gactccacag aaaagactat cacaccgcca gagcctgaac 1800

caacaggagc accacagaag ggtaaagagg gctcctcgaa ggacaagaag tcagcagccg 1860

agatgaacaa gcagaagagc aacaagcagg aagccaaaga accagcccag tgcacagagc 1920

aggccacggt ggacacgaac tcactgcaga atggggacaa gctccaaaag agacctgaga 1980

agcggcagca gtcccttggg ggcttcttta aaggcctggg accaaagcgg atgttggatg 2040

ctcaagtgca aacagaccca gtatccatcg gaccagttgg caaatccaag taaacaaatc 2100

agcacggttc ccaccaggtt ctcctgccac caagatgtgt tctccttat ccatctcctc 2160

cccaaacacg ctccatgtat atattcttct gatggccagc aaatgaaatt ctgcctagaa 2220

attaagcccg agctgttgta tattgaggtg tattatttac gtctctggtc cagtcttttc 2280

tggcaaataa cagtaaagat ggtttagcag gtcacctagt tgggtcagaa gagtcgatga 2340

tcaccaagca ggaaagggag ggaatagagg aatgtgttcg ggttaagtga tgaaaatggc 2400

agtggtggcc gggcgtggtg gctctcgcct gtaatctcag cactttggga ggccgaggca 2460

ggtggatcac ctgaggtcag gagttcaaga ctagcctggc caacatcatg aaaccccgtc 2520

tctactaaaa atacaaaaat tagccaggca tggtggcaca cacctgtagt cccagctact 2580

cgggagccca acgcacgaga accgcttgta cccaggaggt ggaggttgca gtgagccgaa 2640

gttgcaccat tgcactccac cctgggcgac agagcaagat tctatcaaaa aaaaaaaaag 2700

gcagtggcaa gtaagttata gaagagaaat gctgctagaa ggaattaagc gttgtagtaa 2760

atgcgtgctt atcctctaag cttgaagaag ggagacgaaa atccatttgt ttaaattcac 2820

atctcaagga gggagaaccc gggctgtgtt gggtggttgc caatttccta gaacggaatg 2880

tgtggggtat agaaaaagga atgaataagc gttgtttttc aaatagggtc cttgtaagtt 2940

attgatgaga gggaaaagat tgactgggga gggcttaaaa tgatttggga aaacaattgc 3000

ttttgaggct cagtgacaac ggcaaagatt acaacttaaa aaaaaaaaat aaataaaaaa 3060

taaaggaagt tgcacggtta ttttgcaaca caagggggcg gcaaggtccc catttttatc 3120

ctgtaatact gtatccctaa caaagatttg gtctctgcta tcttacatta ttaatgtttc 3180

tcagatggct gaggggctcg cttcatctgt tccgtctgac acttatctca agtgtgtctg 3240

tcattcctaa tgttctcagg atgtgctctg ataaaccct ccccataacc tcagttaata 3300

aaaatttaca gaagacttct caaatacctg agttgttttt aatacctgta caaaggagta 3360

aataggaccc tgagtctatt aaaatgtaat tcaaagtagc atatgattga ctgacagtca 3420

tgtaaactgt atctttcttt ttctgattta ataaaaata catttacttc taaagtaaaa 3480

aaaaaaaaaa 3490

<210> 50

<211> 584

<212> PRT

<213> Homo sapiens

<400> 50

Met Gly Asn Gln Met Ser Val Pro Gln Arg Val Glu Asp Gln Glu Asn

1 5 10 15

Glu Pro Glu Ala Glu Thr Tyr Gln Asp Asn Ala Ser Ala Leu Asn Gly

20 25 30

Val Pro Val Val Val Ser Thr His Thr Val Gln His Leu Glu Glu Val

35 40 45

Asp Leu Gly Ile Ser Val Lys Thr Asp Asn Val Ala Thr Ser Ser Pro

50 55 60

Glu Thr Thr Glu Ile Ser Ala Val Ala Asp Ala Asn Gly Lys Asn Leu

65 70 75 80

Gly Lys Glu Ala Lys Pro Glu Ala Pro Ala Ala Lys Ser Arg Phe Phe

85 90 95

Leu Met Leu Ser Arg Pro Val Pro Gly Arg Thr Gly Asp Gln Ala Ala

100 105 110

Asp Ser Ser Leu Gly Ser Val Lys Leu Asp Val Ser Ser Asn Lys Ala

115 120 125

Pro Ala Asn Lys Asp Pro Ser Glu Ser Trp Thr Leu Pro Val Ala Ala

130 135 140

Gly Pro Gly Gln Asp Thr Asp Lys Thr Pro Gly His Ala Pro Ala Gln

145 150 155 160

Asp Lys Val Leu Ser Ala Ala Arg Asp Pro Thr Leu Leu Pro Pro Glu

165 170 175

Thr Gly Gly Ala Gly Gly Glu Ala Pro Ser Lys Pro Lys Asp Ser Ser

180 185 190

Phe Phe Asp Lys Phe Phe Lys Leu Asp Lys Gly Gln Glu Lys Val Pro

195 200 205

Gly Asp Ser Gln Gln Glu Ala Lys Arg Ala Glu His Gln Asp Lys Val

210 215 220

Asp Glu Val Pro Gly Leu Ser Gly Gln Ser Asp Asp Val Pro Ala Gly

225 230 235 240

Lys Asp Ile Val Asp Gly Lys Glu Lys Glu Gly Gln Glu Leu Gly Thr

245 250 255

Ala Asp Cys Ser Val Pro Gly Asp Pro Glu Gly Leu Glu Thr Ala Lys

260 265 270

Asp Asp Ser Gln Ala Ala Ala Ala Ile Ala Glu Asn Asn Asn Ser Ile Met

275 280 285

Ser Phe Phe Lys Thr Leu Val Ser Pro Asn Lys Ala Glu Thr Lys Lys

290 295 300

Asp Pro Glu Asp Thr Gly Ala Glu Lys Ser Pro Thr Thr Ser Ala Asp

305 310 315 320

Leu Lys Ser Asp Lys Ala Asn Phe Thr Ser Gln Glu Thr Gln Gly Ala

325 330 335

Gly Lys Asn Ser Lys Gly Cys Asn Pro Ser Gly His Thr Gln Ser Val

340 345 350

Thr Thr Pro Glu Pro Ala Lys Glu Gly Thr Lys Glu Lys Ser Gly Pro

355 360 365

Thr Ser Leu Pro Leu Gly Lys Leu Phe Trp Lys Lys Ser Val Lys Glu

370 375 380

Asp Ser Val Pro Thr Gly Ala Glu Glu Asn Val Val Cys Glu Ser Pro

385 390 395 400

Val Glu Ile Ile Lys Ser Lys Glu Val Glu Ser Ala Leu Gln Thr Val

405 410 415

Asp Leu Asn Glu Gly Asp Ala Ala Pro Glu Pro Thr Glu Ala Lys Leu

420 425 430

Lys Arg Glu Glu Ser Lys Pro Arg Thr Ser Leu Met Ala Phe Leu Arg

435 440 445

Gln Met Ser Val Lys Gly Asp Gly Gly Ile Thr His Ser Glu Glu Ile

450 455 460

Asn Gly Lys Asp Ser Ser Cys Gln Thr Ser Asp Ser Thr Glu Lys Thr

465 470 475 480

Ile Thr Pro Pro Glu Pro Glu Pro Thr Gly Ala Pro Gln Lys Gly Lys

485 490 495

Glu Gly Ser Ser Lys Asp Lys Lys Ser Ala Ala Glu Met Asn Lys Gln

500 505 510

Lys Ser Asn Lys Gln Glu Ala Lys Glu Pro Ala Gln Cys Thr Glu Gln

515 520 525

Ala Thr Val Asp Thr Asn Ser Leu Gln Asn Gly Asp Lys Leu Gln Lys

530 535 540

Arg Pro Glu Lys Arg Gln Gln Ser Leu Gly Gly Phe Phe Lys Gly Leu

545 550 555 560

Gly Pro Lys Arg Met Leu Asp Ala Gln Val Gln Thr Asp Pro Val Ser

565 570 575

Ile Gly Pro Val Gly Lys Ser Lys

580

<210> 51

<211> 2767

<212> DNA

<213> Homo sapiens

<400> 51

cgccgtgggt ttctttgttc gtggtgggga ctgtgggctt tgaggaggtt ggtaccatgc 60

gagtgcctcg gtgctgcctg ctcctcatcc gctggagcga ccagggtgct gccctcagcc 120

ccagccccgg ggggagctgg cgcccgcgat ggacagatag atgctcgtgg ggtggaagga 180

ggttgcgact aggttaaggg cagtctccgc ctcggtgccc cccgcccccg ctcgtgttgt 240

cacggggact tgctggcgtg gtgcttctcg aattgacagc cccggggctc tgcagagttg 300

tggggccccg gcatcagtgg gtggacgggt gttgtcccta cgggcgcggg gcgggcgggc 360

tggactggac ttctctcccc ggaccgtagc cgggtgtgcc gcgccacccc aggggctcctg 420

ggacgggggt atccgcctct cggatgaagg attgggggc agagcacttg gcaggtcatg 480

aaggggtcca acttctcggg ttgttgaacg tctacctgga acaagaagag agattccaac 540

ctcgagaaaa aggggctgagt ttgattgagg ctaccccgga gaatgataac actttgtgtc 600

caggattgag aaatgccaaa gttgaagatt taaggagttt agccaacttt tttggatctt 660

gcactgaaac ttttgtcctg gctgtcaata ttttggacag gttcttggct cttatgaagg 720

tgaaacctaa acattgtct tgcattggag tctgttcttt tttgctggct gctagaatag 780

ttgaagaaga ctgcaatatt ccatccactc atgatgtgat ccggattagt cagtgtaaat 840

gtactgcttc tgacataaaa cggatggaaa aaataatttc agaaaaattg cactatgaat 900

tggaagctac tactgcctta aactttttgc acttatacca tactattata ctttgtcata 960

cttcagaaag gaaagaaata ctgagccttg ataaactaga agctcagctg aaagcttgca 1020

actgccgact catcttttca aaagcaaaac catctgtatt agccttgtgc cttctcaatt 1080

tggaagtgga aactttgaaa tctgttgaat tactggaaat tctcttgcta gttaaaaaac 1140

attccaagat taatgacact gagttcttct actggagaga gttggtttct aaatgcctag 1200

ccgagtattc ttctcctgaa tgttgcaaac cagatcttaa gaagttggtt tggatcgttt 1260

caaggcgcac agcccagaac ctccacaaca gctactatag tgttcctgag ctgccaacga 1320

tacctgaggg gggttgtttt gatgaaagtg aaagtgagga ctcttgtgaa gatatgagtt 1380

gtggagagga gagtctcagc agctctcctc ccagtgatca agagtgcacc ttctttttca 1440

acttcaaagt ggcacaaaca ctgtgctttc catcttagaa atctgattgt tctgtcagaa 1500

tttatattta caggtttcaa agcaataaat gggggaatag gtagtttcct ggtttagccc 1560

ccatctagtc aggaattaat atactggaat acctaccttc tatttgttat tcagatcaga 1620

tctggcctat tttcatattt atcctaagcc atcaaatggg gtagtgcctc ttaaaccatt 1680

aacagtactt tagacattgg cactttatattt ttctcgtaga tctttagcta ctttggggag 1740

gagggaaggt gctgatacct tcaatttgtt acttttcaag atttttaaaa ataactagtg 1800

tagctttatct taaacatttt ataaaacctt cagatgtctt taagcagatt ggaagtatgc 1860

aagtgcttcc ttagcaggga cagtggataa tccttaatgg tttatcatag atttcaccct 1920

ccccccttct cagaagagtg agtatgctct taaatgtcaa acacatttt gttgttttgt 1980

tttttaaatg atcagtgtct atttgatgtg atgcagatct tataaatttg ggaattataa 2040

tattgacatt tctgtgattt ttatatatgt aatgtcttaa ttgagatttc tgttaaggca 2100

gaaataatta ggctagggct cttagttttc attcctattg cccaagtatt gtcaaactat 2160

ggtattattt taatgttat ttaaaaatcc ataatctgct agttttgcat gtacttatat 2220

gaaaacagtg cagtaagttg aaaactcagt atctatggaa ttgataaatg ttgatctggt 2280

gtagtatatt ttatcgcatt ttctttatatt aaaaaatgtc tgcatgatta cattttattt 2340

cctttgtaat ttacatttca gaatagtgta ttgctatatg ggtgccaaga ttgaatatga 2400

agaacccgag tgtttgtagt attatagttt taagcaaatc tgtgtggtga tacagccata 2460

agaatggggc ttatataaac tctgtacatg taagattttg tacagagaat ttttaacttt 2520

ataaattgta tatgaacatg taaatctttt aaaatgtaca taaaatactg tattttttta 2580

ccttgtgtgt gatagtctag tcattgcatg taaataat ttattatgta ttctgtagta 2640

taaatcatac attgatgact tacattttta ctggtaagtc aacatccgtt ggatgttttc 2700

tgaagtggct ctttttgaag tgataataga ttgtaattca aaataaaatt attaatgaat 2760

tctcctt 2767

<210> 52

<211> 344

<212> PRT

<213> Homo sapiens

<400> 52

Met Lys Asp Leu Gly Ala Glu His Leu Ala Gly His Glu Gly Val Gln

1 5 10 15

Leu Leu Gly Leu Leu Asn Val Tyr Leu Glu Gln Glu Glu Arg Phe Gln

20 25 30

Pro Arg Glu Lys Gly Leu Ser Leu Ile Glu Ala Thr Pro Glu Asn Asp

35 40 45

Asn Thr Leu Cys Pro Gly Leu Arg Asn Ala Lys Val Glu Asp Leu Arg

50 55 60

Ser Leu Ala Asn Phe Phe Gly Ser Cys Thr Glu Thr Phe Val Leu Ala

65 70 75 80

Val Asn Ile Leu Asp Arg Phe Leu Ala Leu Met Lys Val Lys Pro Lys

85 90 95

His Leu Ser Cys Ile Gly Val Cys Ser Phe Leu Leu Ala Ala Arg Ile

100 105 110

Val Glu Glu Asp Cys Asn Ile Pro Ser Thr His Asp Val Ile Arg Ile

115 120 125

Ser Gln Cys Lys Cys Thr Ala Ser Asp Ile Lys Arg Met Glu Lys Ile

130 135 140

Ile Ser Glu Lys Leu His Tyr Glu Leu Glu Ala Thr Thr Ala Leu Asn

145 150 155 160

Phe Leu His Leu Tyr His Thr Ile Ile Leu Cys His Thr Ser Glu Arg

165 170 175

Lys Glu Ile Leu Ser Leu Asp Lys Leu Glu Ala Gln Leu Lys Ala Cys

180 185 190

Asn Cys Arg Leu Ile Phe Ser Lys Ala Lys Pro Ser Val Leu Ala Leu

195 200 205

Cys Leu Leu Asn Leu Glu Val Glu Thr Leu Lys Ser Val Glu Leu Leu

210 215 220

Glu Ile Leu Leu Leu Val Lys Lys His Ser Lys Ile Asn Asp Thr Glu

225 230 235 240

Phe Phe Tyr Trp Arg Glu Leu Val Ser Lys Cys Leu Ala Glu Tyr Ser

245 250 255

Ser Pro Glu Cys Cys Lys Pro Asp Leu Lys Lys Leu Val Trp Ile Val

260 265 270

Ser Arg Arg Thr Ala Gln Asn Leu His Asn Ser Tyr Tyr Ser Val Pro

275 280 285

Glu Leu Pro Thr Ile Pro Glu Gly Gly Cys Phe Asp Glu Ser Glu Ser

290 295 300

Glu Asp Ser Cys Glu Asp Met Ser Cys Gly Glu Glu Ser Leu Ser Ser

305 310 315 320

Ser Pro Pro Ser Asp Gln Glu Cys Thr Phe Phe Phe Asn Phe Lys Val

325 330 335

Ala Gln Thr Leu Cys Phe Pro Ser

340

<210> 53

<211> 1744

<212> DNA

<213> Homo sapiens

<400> 53

gcagcaggcc aagggggagg tgcgagcgtg gacctgggac gggtctgggc ggctctcggt 60

ggttggcacg ggttcgcaca cccattcaag cggcaggacg cacttgtctt agcagttctc 120

gctgaccgcg ctagctgcgg cttctacgct ccggcactct gagttcatca gcaaacgccc 180

tggcgtctgt cctcaccatg cctagccttt gggacgctt ctcgtcgtcg tccacctcct 240

cttcgccctc gtccttgccc cgaactccca ccccagatcg gccgccgcgc tcagcctggg 300

ggtcggcgac ccgggaggag gggtttgacc gctccacgag cctggagagc tcggactgcg 360

agtccctgga cagcagcaac agtggcttcg ggccggagga agacacggct tacctggatg 420

gggtgtcgtt gcccgacttc gagctgctca gtgaccctga ggatgaacac ttgtgtgcca 480

acctgatgca gctgctgcag gagagcctgg cccaggcgcg gctgggctct cgacgccctg 540

cgcgcctgct gatgcctagc cagttggtaa gccaggtggg caaagaacta ctgcgcctgg 600

cctacagcga gccgtgcggc ctgcgggggg cgctgctgga cgtctgcgtg gagcagggca 660

agagctgcca cagcgtgggc cagctggcac tcgaccccag cctggtgccc accttccagc 720

tgaccctcgt gctgcgcctg gactcacgac tctggcccaa gatccagggg ctgtttagct 780

ccgccaactc tcccttcctc cctggcttca gccagtccct gacgctgagc actggcttcc 840

gagtcatcaa gaagaagctg tacagctcgg aacagctgct cattgaggag tgttgaactt 900

caacctgagg gggccgacag tgccctccaa gacagagacg actgaacttt tggggtggag 960

actagaggca ggagctgagg gactgattcc tgtggttgga aaactgaggc agccacctaa 1020

ggtggaggtg ggggaatagt gtttcccagg aagctcattg agttgtgtgc gggtggctgt 1080

gcattgggga cacatacccc tcagtactgt agcatgaaac aaaggcttag gggccaacaa 1140

ggcttccagc tggatgtgtg tgtagcatgt acctattat ttttgttat gacagttaac 1200

agtggtgtga catccagaga gcagctgggc tgctcccgcc ccagcccggc ccagggtgaa 1260

ggaagaggca cgtgctcctc agagcagccg gagggagggg ggaggtcgga ggtcgtggag 1320

gtggtttgtg tatcttactg gtctgaaggg accaagtgtg tttgttgttt gttttgtatc 1380

ttgtttttct gatcggagca tcactactga cctgttgtag gcagctatct tacagacgca 1440

tgaatgtaag agtaggaagg ggtgggtgtc agggatcact tgggatcttt gacacttgaa 1500

aaattacacc tggcagctgc gtttaagcct tcccccatcg tgtactgcag agttgagctg 1560

gcaggggagg ggctgagagg gtgggggctg gaacccctcc ccgggaggag tgccatctgg 1620

gtcttccatc tagaactgtt tacatgaaga taagatactc actgttcatg aatacacttg 1680

atgttcaagt attaagacct atgcaatatt ttttactttt ctaataaaca tgtttgttaa 1740

aaca 1744

<210> 54

<211> 232

<212> PRT

<213> Homo sapiens

<400> 54

Met Pro Ser Leu Trp Asp Arg Phe Ser Ser Ser Ser Thr Ser Ser Ser

1 5 10 15

Pro Ser Ser Leu Pro Arg Thr Pro Thr Pro Asp Arg Pro Pro Arg Ser

20 25 30

Ala Trp Gly Ser Ala Thr Arg Glu Glu Gly Phe Asp Arg Ser Thr Ser

35 40 45

Leu Glu Ser Ser Asp Cys Glu Ser Leu Asp Ser Ser Asn Ser Gly Phe

50 55 60

Gly Pro Glu Glu Asp Thr Ala Tyr Leu Asp Gly Val Ser Leu Pro Asp

65 70 75 80

Phe Glu Leu Leu Ser Asp Pro Glu Asp Glu His Leu Cys Ala Asn Leu

85 90 95

Met Gln Leu Leu Gln Glu Ser Leu Ala Gln Ala Arg Leu Gly Ser Arg

100 105 110

Arg Pro Ala Arg Leu Leu Met Pro Ser Gln Leu Val Ser Gln Val Gly

115 120 125

Lys Glu Leu Leu Arg Leu Ala Tyr Ser Glu Pro Cys Gly Leu Arg Gly

130 135 140

Ala Leu Leu Asp Val Cys Val Glu Gln Gly Lys Ser Cys His Ser Val

145 150 155 160

Gly Gln Leu Ala Leu Asp Pro Ser Leu Val Pro Thr Phe Gln Leu Thr

165 170 175

Leu Val Leu Arg Leu Asp Ser Arg Leu Trp Pro Lys Ile Gln Gly Leu

180 185 190

Phe Ser Ser Ala Asn Ser Pro Phe Leu Pro Gly Phe Ser Gln Ser Leu

195 200 205

Thr Leu Ser Thr Gly Phe Arg Val Ile Lys Lys Lys Leu Tyr Ser Ser

210 215 220

Glu Gln Leu Leu Ile Glu Glu Cys

225 230

<210> 55

<211> 2722

<212> DNA

<213> Homo sapiens

<400> 55

gagtctggcc gcagtcgcgg cagtggtggc ttcccatccc caaaaggcgc cctccgactc 60

cttgcgccgc actgctcgcc gggccagtcc ggaaacgggt cgtggagctc cgcaccactc 120

ccgctggttc ccgaaggcag atcccttctc ccgagagttg cgagaaactt tcccttgtcc 180

ccgacgctgc agcggctcgg gtaccgtggc agccgcaggt ttctgaaccc cgggccacgc 240

tccccgcgcc tcggcttcgc gctcgtgtag atcgttccct ctctggttgc acgctgggga 300

tcccggacct cgattctgcg ggcgagatgc ccctgggaca catcatgagg ctggacctgg 360

agaaaattgc cctggagtac atcgtgccct gtctgcacga ggtgggcttc tgctacctgg 420

acaacttcct gggcgaggtg gtgggcgact gcgtcctgga gcgcgtcaag cagctgcact 480

gcaccggggc cctgcgggac ggccagctgg cggggccgcg cgccggcgtc tccaagcgac 540

acctgcgggg cgaccagatc acgtggatcg ggggcaacga ggagggctgc gaggccatca 600

gcttcctcct gtccctcatc gacaggctgg tcctctactg cggggagccgg ctgggcaaat 660

actacgtcaa ggagaggtct aaggcaatgg tggcttgcta tccgggaaat ggaacaggtt 720

atgttcgcca cgtggacaac cccaacggtg atggtcgctg catcacctgc atctactatc 780

tgaacaagaa ttggggatgcc aagctacatg gtgggatcct gcggatattt ccagagggga 840

aatcattcat agcagatgtg gagcccattt ttgacagact cctgttcttc tggtcagatc 900

gtaggaaccc acacgaagtg cagccctctt acgcaaccag atatgctatg actgtctggt 960

actttgatgc tgaagaaagg gcagaagcca aaaagaaatt caggaattta actaggaaaa 1020

ctgaatctgc cctcactgaa gactgaccgt gctctgaaat ctgctggcct tgttcatttt 1080

agtaacggtt cctgaattct cttaaattct ttgagatcca aagatggcct cttcagtgac 1140

aacaatctcc ctgctacttc ttgcatcctt cacatccctg tcttgtgtgt ggtacttcat 1200

gttttcttgc caagactgtg ttgatcttca gatactctct ttgccagatg aagttatacttg 1260

ctaactccag aaattcctgc agacatccta ctcggccagc ggtttacctg atagattcgg 1320

taatactatc aagagaagag cctaggagca cagcgaggga atgaacctta cttgcacttt 1380

atgtatactt cctgatttga aaggaggagg tttgaaaaga aaaaaatgga ggtggtagat 1440

gccacagaga ggcatcacgg aagccttaac agcaggaaac agagaaattt gtgtcatctg 1500

aacaatttcc agatgttctt aatccagggc tgttggggtt tctggagaat tatcacaacc 1560

taatgacatt aatacctcta gaaagggctg ctgtcatagt gaacaattta taagtgtccc 1620

atggggcaga cactcctttt ttcccagtcc tgcaacctgg atttctgcc tcagccccat 1680

tttgctgaaa ataatgactt tctgaataaa gatggcaaca caattttttc tccattttca 1740

gttcttacct gggaacctaa ttccccagaa gctaaaaaac tagacattag ttgttttggt 1800

tgctttgttg gaatggaatt taaatttaaa tgaaaggaaa aatatatccc tggtagtttt 1860

gtgttaacca ctgataactg tggaaagagc taggtctact gatatacaat aaacatgtgt 1920

gcatcttgaa caatttgaga ggggaggtgg agttggaaat gtgggtgttc ctgttttttt 1980

tttttttttt tttttagttt tcctttttaa tgagctcacc ctttaacaca aaaaaagcaa 2040

ggtgatgtat tttaaaaaag gaagtggaaa taaaaaaatc tcaaagctat ttgagttctc 2100

gtctgtcct agcagtcttt cttcagctca cttggctctc tagatccact gtggttggca 2160

gtatgaccag aatcatggaa tttgctagaa ctgtggaagc ttctactcct gcagtaagca 2220

cagatcgcac tgcctcaata acttggtatt gagcacgtat tttgcaaaag ctacttttcc 2280

tagttttcag tattactttc atgttttaaa aatcccttta attctttgct tgaaaatccc 2340

atgaacatta aagagccaga aatattttcc tttgttatgt acggatat atatatatag 2400

tcttccaaga tagaagttta ctttttcctc ttctggtttt ggaaaatttc cagataagac 2460

atgtcaccat taattctcaa cgactgctct atttgttgt acggtaatag ttatcacctt 2520

ctaaattact atgtaattta ttcacttatt atgtttattg tcttgtatcc tttctctgga 2580

gtgtaagcac aatgaagaca ggaattttgt atatttttaa ccaatgcaac atactctcag 2640

cacctaaaat agtgccggga acatagtaag ggctcagtaa atacttgttg aataaactca 2700

gtctcctaca ttagcattct aa 2722

<210> 56

<211> 239

<212> PRT

<213> Homo sapiens

<400> 56

Met Pro Leu Gly His Ile Met Arg Leu Asp Leu Glu Lys Ile Ala Leu

1 5 10 15

Glu Tyr Ile Val Pro Cys Leu His Glu Val Gly Phe Cys Tyr Leu Asp

20 25 30

Asn Phe Leu Gly Glu Val Val Gly Asp Cys Val Leu Glu Arg Val Lys

35 40 45

Gln Leu His Cys Thr Gly Ala Leu Arg Asp Gly Gln Leu Ala Gly Pro

50 55 60

Arg Ala Gly Val Ser Lys Arg His Leu Arg Gly Asp Gln Ile Thr Trp

65 70 75 80

Ile Gly Gly Asn Glu Glu Gly Cys Glu Ala Ile Ser Phe Leu Leu Ser

85 90 95

Leu Ile Asp Arg Leu Val Leu Tyr Cys Gly Ser Arg Leu Gly Lys Tyr

100 105 110

Tyr Val Lys Glu Arg Ser Lys Ala Met Val Ala Cys Tyr Pro Gly Asn

115 120 125

Gly Thr Gly Tyr Val Arg His Val Asp Asn Pro Asn Gly Asp Gly Arg

130 135 140

Cys Ile Thr Cys Ile Tyr Tyr Leu Asn Lys Asn Trp Asp Ala Lys Leu

145 150 155 160

His Gly Gly Ile Leu Arg Ile Phe Pro Glu Gly Lys Ser Phe Ile Ala

165 170 175

Asp Val Glu Pro Ile Phe Asp Arg Leu Leu Phe Phe Trp Ser Asp Arg

180 185 190

Arg Asn Pro His Glu Val Gln Pro Ser Tyr Ala Thr Arg Tyr Ala Met

195 200 205

Thr Val Trp Tyr Phe Asp Ala Glu Glu Arg Ala Glu Ala Lys Lys Lys

210 215 220

Phe Arg Asn Leu Thr Arg Lys Thr Glu Ser Ala Leu Thr Glu Asp

225                 230                 235

<210> 57

<211> 5731

<212> DNA

<213> Homo sapiens

<400> 57

gcagattgcg cgaggggggag cgagcgagcg ggcgctgcca ggagcccgca gccctggcgc 60

ccgccgccgc ccggagcccc gcaatatgcc gccgcggccc tctggctcta ggccatggcg 120

aggctctgcc ggcgtgtccc ctgcaccctg cttctcggcc tggccgtggt gctgctgaaa 180

gcgcggctgg tccccgcggc cgccagagcg gaactcagcc gctccgacct cagcctcatc 240

caacagcagc agcagcagca gcaacaacaa caacaacagc aaaagcagct ggaggaggct 300

gaggaggaga ggacagaggt gcctggggca acctccacct tgacggttcc agtgtctgta 360

tttatgttga aagtccaggt gaatgacatc atcagtcgtc agtacctgag ccaagcagtt 420

gtagaagtgt ttgtaaacta cacgaagaca aattccacag taactaaaag caatggagca 480

gtgctgataa aagtacccta caaattagga cttagtttaa ctattattgc ttacaaagat 540

ggctacgtgt tgacccctct gccttggaaa accagaagaa tgccaatata ttcatcagtt 600

acactttcac tgttcccgca aagccaagca aatatatggc tatttgaaga cactgtttta 660

attactggaa aattagctga tgccaagtct caaccaagtg ttcagttttc aaaagcctta 720

attaaacttc ctgacaacca tcatattagc aacgttatactg gctatcttac agttctacaa 780

cagtttttga aagtggacaa ttttctgcat acaactggaa ttactctcaa taaaccaggt 840

tttgaaaaca ttgaattgac tcctcttgct gcaatatgtg tgaaaatata ttctggagga 900

aaagaactaa aggtcaatgg ctctattcaa gtttctcttc ctcttctacg tctgaatgat 960

ataagtgcag gggatcgcat acctgcttgg acatttgata tgaacacagg tgcttgggta 1020

aatcatggtc ggggaatggt caaggaacat aacaatcatt taatctggac atatgatgca 1080

ccaatttgg ggtactggat agcagctcca cttccaggaa ctagaggttc aggtataaat 1140

gaagattcca aggacataac tgcctaccac acagtgtttc ttacagccat attaggagga 1200

acaatagtca ttgtcattgg attttttgct gtactacttt gttattgcag ggacaagtgt 1260

ggtactccac agaaaagaga aagaaatatc actaaacttg aggtcctcaa gagagaccag 1320

acaacttcaa caacacacat aaatcatatc agtacagtta aagttgcatt aaaagctgag 1380

gacaagtcgc agttatattcaa tgccaaaaac tcctcatata gtcctcagaa aaaggaacca 1440

tcaaaggcag aaacagaaga aagagtttcc atggtaaaaa ctcgggacga ttttaaaatc 1500

tacaatgaag atgtttcatt tctatcagtc aatcaaaata attactcaag aaacccaaca 1560

cagtctttgg agcccaatgt agggtccaaa caacctaaac atattaacaa caatctatct 1620

tcatctctag gtgatgctca agatgaaaag aggtatctca caggtaatga ggaggcgtat 1680

gggcgttccc atattcctga acagcttatg catatttaca gccaacccat tgccatcctt 1740

caaacatctg accttttctc cacaccggaa caattacata ctgctaagtc agctactttg 1800

ccaagaaagg gacagttagt ctatggccaa ttgatggaac cagtaaatcg agagaacttt 1860

acgcagacct tgcccaaaat gccaattcat tctcatgcac agccccccaga tgccagggaa 1920

gaggatatca tacttgaagg tcaacagagc ctgccatccc aggcttcaga ttggagccga 1980

tactcaagca gcttactgga atccgtctct gttcctggaa cactaaatga ggctgttgta 2040

atgactccat tttcatcgga acttcaagga atttcagaac agaccctcct ggagctgtcc 2100

aaaggaaagc cctccccgca tcccagcc tggtttgtgt ctcttgatgg aaagccagtt 2160

gcacaagtga ggcactcctt tatagacctg aaaaagggca agagaaccca gagcaatgac 2220

accagtctgg actctggggt ggacatgaat gagcttcact caagtagaaa gctcgagagg 2280

gagaaaacat tcatcaaaag catgcatcag cccaagatcc tttaacttaga agatttagac 2340

ctaagcagca gtgagagtgg aaccaccgtc tgttcccctg aggacccagc tttaaggcac 2400

atcctagatg gagggagtgg agtgatcatg gagcaccctg gagaagagtc gccaggaagg 2460

aaaagcactg ttgaagattt tgaagctaat acatccccca ctaaaagaag gggcagacca 2520

ccactagcca aaagagatag caagactaac atctggaaga agcgagagga acgcccactg 2580

attcccataa attaactcca atggggattg tgtgtctgct gtctcgtgct gtttattctt 2640

gcttcttgtt gtaaattgca gtacgaactt aagaaaatga gactgagcaa tctcatggtt 2700

cttggacatg tctcaagcag agtaaatggt aattcagtaa tcagagagaa agataccaag 2760

gaatgctttt tctggcctat tcatttattt ttgggtgatg aatttacagt atctaagttt 2820

tcaaaatgta aaatagcttc aagatgttag ttatctgaaa atgttgctca gccagccagt 2880

ttggccttga ctctcttaag aataacagtg aaatatatac tcctcaagtt gcctccaaaa 2940

atgttgcctc taccatggtg actaccccat ggaacattta gaaacaaaac tgacttcagg 3000

catcatatta ttttaaatgt tactattacg tcttcttctg cctatactta aaaataactt 3060

gataaatgac ttggactgat gttatctctgg agttatcaca aagaaaatgt tgtttggtct 3120

ttaaagagca tgtgtattgt atcatcccaa acgtaaatcc tacatttata taagatgggc 3180

aagaagctac ttggtcatta gagagggaga caccagctct ttggttgttt ttggatataa 3240

ctttacaaaa taagtaagat gttaatttag aaatttgaga aattaatgct ctaatactga 3300

gtttttattt aaaaattatt ttttcttccc ctcaacaatg aagcaagctt agctgtcaag 3360

ggaaactttt tacaaatctg aaaaaaacaa tctatgactt tggtttaagg ctcactgata 3420

cttttaggct aaattggttt taatatattt cttctattct aaaaacctga actcagtcac 3480

ttaaaggcta tgaaatttaa aaaaaaagtc gatgtgaaag tttcttttga accactaaaat 3540

aaaatatgtg cagataaaat atatacattgat ttgtttttct taaatgttga tgagaagaaa 3600

aagagatgcc attttcctga ggctcaaaaa taccttcagg atagttgtat atccagttat 3660

tgattttctt aaaagatgtg taaggaaaac agtttcaatt tcaggggaaa agtaaaagtt 3720

tttccctaag tcacttaaag cctttgcaac ttcttttttc agttttgtaa gtaatatatc 3780

tatgttcttt tcattatagc aagcattcaa tgtgaacaac tttttaatta actctgaatt 3840

accattcata catcctaaaa ataaaagctc gttattcatt aaaatcaact gatcccattt 3900

ttcttaaaat ttccctgaag gcaaatgtct gaagcacctt tcccttgtgg gggtaaaaat 3960

cctaaattgc tttatttttc attccctcct attcaacatg ggagcagcat agagacccaa 4020

accatgtaaa caagttcagt gaaccaaaac agccacatta gcttcagtaa aattatagct 4080

agatgtgcaa ttttttcctc caacttctaa cgtgtcaaat aaccttccta ctgttctgtg 4140

ttaactgaaa gaacataaag accctaggca aatatttgct atatattacc ccaatccata 4200

gaagaaataa tgttttgggt aatacctagg cttccttttt tttttttttt tttttttttt 4260

agtgataagg ctcataacaa ttaattagag aaggcttctt attggtctta cacagaaaga 4320

tacatcaaaa gcagcatgac tcaaaatgat ttggaaaagg ttaaagttag tgctctgctg 4380

aagtgccttt gatatagact tgcattatta gaaggatata acatcttttt taagtgtgca 4440

ttttctttca gttaaccaaa ttaaacagat gtgcagtttt attaaaaata tagacctagt 4500

gtttcatgtt ggaacaataa atattgcatg tgagtagtat ttcttgtttt ttgaatacag 4560

tatatattga taaattgttt atgttggaat gaagttagaa actatatagc aaaacattat 4620

attttaagtg tttatttttc ccacctttaa ataaaatgt ttcatctcag cttggtaatg 4680

aaatacacat attggtataa gggtatacca ttcaggtatg ccacttattt tattcatttt 4740

tgtgtaaggg aaatgagatg atgtatccca aggggcttttc tagaactact tgtttgcttt 4800

cagaataaaa ccttattattttttacactg cacatgctgt tctcaattgg taattatagg 4860

caatttatct tttctaatga tcaaaagagt gtgacttctc atttgtgagt agttcacaaa 4920

tttcctgtta aaaagctgaa accatctact ttttcttaac ccaagtgata ataaacaata 4980

ttcacaactt tcttaaattt ttaaattgaa aaccaaggtt ttttcaaata taaacctaga 5040

tgattttggt cacaaattgt taacatttgt cgatcctttg tatatacttt ggatatatat 5100

taaaggcaaa actatctctt gactaactga tggattcatt tactaaagca cagctgtatg 5160

tatttttgaa tacatattat gatcttgaga ctttataaat caatttttat gactttatgc 5220

agttgtatag ggattatgcc ctttcagttc tatagggatt atgccctttt atatacata 5280

atataccaca gagattacaa atgttgagga atgaaagcac ttctttgctt tggcaatcat 5340

tttcagacca ctatgtgttt gaatcctctg gtatcaatac gtattatagg gttttagaga 5400

tctgtgggtc aaatgatgtc cctcaaaact tcctaaaaag gtgaagctca aagtcacaca 5460

ttcttataag gcgcatgagt ttctcatttt cccatgtacg agcattgtaa aggaattcag 5520

ctgtattaat ttctatttca gatctagaat tgacattttg ccttcttgtt tccaggtgtt 5580

tctatttttt gtattctttc agagaaatct catatttcgg tgtatttatt gctgttacta 5640

ctatatttac tgctgaaaac tgtaacaacc tgaagatttg taaaatgtta aacatagttc 5700

attaaaaata ataaataaa tctaaaatgt a 5731

<210> 58

<211> 826

<212> PRT

<213> Homo sapiens

<400> 58

Met Ala Arg Leu Cys Arg Arg Val Pro Cys Thr Leu Leu Leu Gly Leu

1 5 10 15

Ala Val Val Leu Leu Lys Ala Arg Leu Val Pro Ala Ala Ala Ala Arg Ala

20 25 30

Glu Leu Ser Arg Ser Asp Leu Ser Leu Ile Gln Gln Gln Gln Gln Gln

35 40 45

Gln Gln Gln Gln Gln Gln Gln Gln Lys Gln Leu Glu Glu Ala Glu Glu

50 55 60

Glu Arg Thr Glu Val Pro Gly Ala Thr Ser Thr Leu Thr Val Pro Val

65 70 75 80

Ser Val Phe Met Leu Lys Val Gln Val Asn Asp Ile Ile Ser Arg Gln

85 90 95

Tyr Leu Ser Gln Ala Val Val Glu Val Phe Val Asn Tyr Thr Lys Thr

100 105 110

Asn Ser Thr Val Thr Lys Ser Asn Gly Ala Val Leu Ile Lys Val Pro

115 120 125

Tyr Lys Leu Gly Leu Ser Leu Thr Ile Ile Ala Tyr Lys Asp Gly Tyr

130 135 140

Val Leu Thr Pro Leu Pro Trp Lys Thr Arg Arg Met Pro Ile Tyr Ser

145 150 155 160

Ser Val Thr Leu Ser Leu Phe Pro Gln Ser Gln Ala Asn Ile Trp Leu

165 170 175

Phe Glu Asp Thr Val Leu Ile Thr Gly Lys Leu Ala Asp Ala Lys Ser

180 185 190

Gln Pro Ser Val Gln Phe Ser Lys Ala Leu Ile Lys Leu Pro Asp Asn

195 200 205

His His Ile Ser Asn Val Thr Gly Tyr Leu Thr Val Leu Gln Gln Phe

210 215 220

Leu Lys Val Asp Asn Phe Leu His Thr Thr Thr Gly Ile Thr Leu Asn Lys

225 230 235 240

Pro Gly Phe Glu Asn Ile Glu Leu Thr Pro Leu Ala Ala Ile Cys Val

245 250 255

Lys Ile Tyr Ser Gly Gly Lys Glu Leu Lys Val Asn Gly Ser Ile Gln

260 265 270

Val Ser Leu Pro Leu Leu Arg Leu Asn Asp Ile Ser Ala Gly Asp Arg

275 280 285

Ile Pro Ala Trp Thr Phe Asp Met Asn Thr Gly Ala Trp Val Asn His

290 295 300

Gly Arg Gly Met Val Lys Glu His Asn Asn His Leu Ile Trp Thr Tyr

305 310 315 320

Asp Ala Pro His Leu Gly Tyr Tyr Trp Ile Ala Ala Pro Leu Pro Gly Thr

325 330 335

Arg Gly Ser Gly Ile Asn Glu Asp Ser Lys Asp Ile Thr Ala Tyr His

340 345 350

Thr Val Phe Leu Thr Ala Ile Leu Gly Gly Thr Ile Val Ile Val Ile

355 360 365

Gly Phe Phe Ala Val Leu Leu Cys Tyr Cys Arg Asp Lys Cys Gly Thr

370 375 380

Pro Gln Lys Arg Glu Arg Asn Ile Thr Lys Leu Glu Val Leu Lys Arg

385 390 395 400

Asp Gln Thr Thr Thr Ser Thr Thr Thr His Ile Asn His Ile Ser Thr Val Lys

405 410 415

Val Ala Leu Lys Ala Glu Asp Lys Ser Gln Leu Phe Asn Ala Lys Asn

420 425 430

Ser Ser Tyr Ser Pro Gln Lys Lys Glu Pro Ser Lys Ala Glu Thr Glu

435 440 445

Glu Arg Val Ser Met Val Lys Thr Arg Asp Asp Phe Lys Ile Tyr Asn

450 455 460

Glu Asp Val Ser Phe Leu Ser Val Asn Gln Asn Asn Tyr Ser Arg Asn

465 470 475 480

Pro Thr Gln Ser Leu Glu Pro Asn Val Gly Ser Lys Gln Pro Lys His

485 490 495

Ile Asn Asn Asn Leu Ser Ser Ser Leu Gly Asp Ala Gln Asp Glu Lys

500 505 510

Arg Tyr Leu Thr Gly Asn Glu Glu Ala Tyr Gly Arg Ser His Ile Pro

515 520 525

Glu Gln Leu Met His Ile Tyr Ser Gln Pro Ile Ala Ile Leu Gln Thr

530 535 540

Ser Asp Leu Phe Ser Thr Pro Glu Gln Leu His Thr Ala Lys Ser Ala

545 550 555 560

Thr Leu Pro Arg Lys Gly Gln Leu Val Tyr Gly Gln Leu Met Glu Pro

565 570 575

Val Asn Arg Glu Asn Phe Thr Gln Thr Leu Pro Lys Met Pro Ile His

580 585 590

Ser His Ala Gln Pro Pro Asp Ala Arg Glu Asp Ile Ile Leu Glu

595 600 605

Gly Gln Gln Ser Leu Pro Ser Gln Ala Ser Asp Trp Ser Arg Tyr Ser

610 615 620

Ser Ser Leu Leu Glu Ser Val Ser Val Pro Gly Thr Leu Asn Glu Ala

625 630 635 640

Val Val Met Thr Pro Phe Ser Ser Glu Leu Gln Gly Ile Ser Glu Gln

645 650 655

Thr Leu Leu Glu Leu Ser Lys Gly Lys Pro Ser Pro His Pro Arg Ala

660 665 670

Trp Phe Val Ser Leu Asp Gly Lys Pro Val Ala Gln Val Arg His Ser

675 680 685

Phe Ile Asp Leu Lys Lys Gly Lys Arg Thr Gln Ser Asn Asp Thr Ser

690 695 700

Leu Asp Ser Gly Val Asp Met Asn Glu Leu His Ser Arg Lys Leu

705 710 715 720

Glu Arg Glu Lys Thr Phe Ile Lys Ser Met His Gln Pro Lys Ile Leu

725 730 735

Tyr Leu Glu Asp Leu Asp Leu Ser Ser Ser Glu Ser Gly Thr Thr Thr Val

740 745 750

Cys Ser Pro Glu Asp Pro Ala Leu Arg His Ile Leu Asp Gly Gly Ser

755 760 765

Gly Val Ile Met Glu His Pro Gly Glu Glu Ser Pro Gly Arg Lys Ser

770 775 780

Thr Val Glu Asp Phe Glu Ala Asn Thr Ser Pro Thr Lys Arg Arg Gly

785 790 795 800

Arg Pro Pro Leu Ala Lys Arg Asp Ser Lys Thr Asn Ile Trp Lys Lys

805 810 815

Arg Glu Glu Arg Pro Leu Ile Pro Ile Asn

820 825

<210> 59

<211> 7368

<212> DNA

<213> Homo sapiens

<400> 59

gctgtacttt tctgggtgtg tgttagggag gctatgttcc tgaccctccc cctctggggt 60

gagaaggggt ccccgccatg tcctcggggt tggtaggagg agaggattgg agctgttttc 120

tccttgatgc caagatacgc caagctagga gcattctgcc ctttccacag tcatccaccg 180

agaacaggcc tgcaggacgg gacaaggatc agagccttcc tgcaaccccg gccactgcct 240

gctgtctgtg ggcctggact gtgcgggcaa ctgtgcttgg cccgagtgac aaggaggtgg 300

gagagggtag cagcatgggc tacgcggttg gctgccctca gtccccctgc tgctgaagct 360

gccctgccca tgcccaccca ggccgtgggg ccaggggcct gccagggcta ggagtgggcc 420

tgccgttcat gggtctctag ggatttccga gatgcctggg aagagaggct tgggctggtg 480

gtgggcccgg ctgccccttt gcctgctcct cagcctttac ggcccctgga tgccttcctc 540

cctgggaaag cccaaaggcc accctcacat gaattccatc cgcatagatg gggacatcac 600

actgggaggc ctgttcccgg tgcatggccg gggctcagag ggcaagccct gtggagaact 660

taagaaggaa aagggcatcc accggctgga ggccatgctg ttcgccctgg atcgcatcaa 720

caacgacccg gacctgctgc ctaacatcac gctgggcgcc cgcattctgg acacctgctc 780

cagggacacc catgccctcg agcagtcgct gacctttgtg caggcgctca tcgagaagga 840

tggcacagag gtccgctgtg gcagtggcgg cccacccatc atcaccaagc ctgaacgtgt 900

ggtgggtgtc atcggtgctt cagggagctc ggtctccatc atggtggcca acatccttcg 960

cctcttcaag ataccccaga tcagctacgc ctccacagcg ccagacctga gtgacaacag 1020

ccgctacgac ttcttctccc gcgtggtgcc ctcggacacg taccaggccc aggccatggt 1080

ggacatcgtc cgtgccctca agtggaacta tgtgtccaca gtggcctcgg agggcagcta 1140

tggtgagagc ggtgtggagg ccttcatcca gaagtcccgt gaggacgggg gcgtgtgcat 1200

cgcccagtcg gtgaagatac cacggggagcc caaggcaggc gagttcgaca agatcatccg 1260

ccgcctcctg gagacttcga acgccagggc agtcatcatc tttgccaacg aggatgacat 1320

caggcgtgtg ctggaggcag cacgaagggc caaccagaca ggccatttct tctggatggg 1380

ctctgacagc tggggctcca agattgcacc tgtgctgcac ctggaggagg tggctgaggg 1440

tgctgtcacg atcctcccca agaggatgtc cgtacgaggc ttcgaccgct acttctccag 1500

ccgcacgctg gacaacaacc ggcgcaacat ctggtttgcc gagttctggg aggacaactt 1560

ccactgcaag ctgagccgcc acgccctcaa gaagggcagc cacgtcaaga agtgcaccaa 1620

ccgtgagcga attgggcagg attcagctta tgagcaggag gggaaggtgc agtttgtgat 1680

cgatgccgtg tacgccatgg gccacgcgct gcacgccatg caccgtgacc tgtgtcccgg 1740

ccgcgtgggg ctctgcccgc gcatggaccc tgtagatggc acccagctgc ttaagtacat 1800

ccgaaacgtc aacttctcag gcatcgcagg gaaccctgtg accttcaatg agaatggaga 1860

tgcgcctggg cgctatgaca tctaccaata ccagctgcgc aacgattctg ccgagtacaa 1920

ggtcattggc tcctggactg accacctgca ccttagaata gagcggatgc actggccggg 1980

gagcgggcag cagctgcccc gctccatctg cagcctgccc tgccaaccgg gtgagcggaa 2040

gaagacagtg aagggcatgc cttgctgctg gcactgcgag ccttgcacag ggtaccagta 2100

ccaggtggac cgctacacct gtaagacgtg tccctatgac atgcggccca cagagaaccg 2160

cacgggctgc cggcccatcc ccatcatcaa gcttgagtgg ggctcgccct gggccgtgct 2220

gcccctcttc ctggccgtgg tgggcatcgc tgccacgttg ttcgtggtga tcacctttgt 2280

gcgctacaac gacacgccca tcgtcaaggc ctcgggccgt gaactgagct acgtgctgct 2340

ggcaggcatc ttcctgtgct atgccaccac cttcctcatg atcgctgagc ccgaccttgg 2400

cacctgctcg ctgcgccgaa tcttcctggg actagggatg agcatcagct atgcagccct 2460

gctcaccaag accaaccgca tctaccgcat cttcgagcag ggcaagcgct cggtcagtgc 2520

cccacgcttc atcagccccg cctcacagct ggccatcacc ttcagcctca tctcgctgca 2580

gctgctgggc atctgtgtgt ggtttgtggt ggacccctcc cactcggtgg tggacttcca 2640

ggaccagcgg acactcgacc cccgcttcgc caggggtgtg ctcaagtgtg acatctcgga 2700

cctgtcgctc atctgcctgc tgggctacag catgctgctc atggtcacgt gcaccgtgta 2760

tgccatcaag acacgcggcg tgcccgagac cttcaatgag gccaagccca ttggcttcac 2820

catgtacacc acttgcatcg tctggctggc cttcatcccc atcttctttg gcacctcgca 2880

gtcggccgac aagctgtaca tccagacgac gacgctgacg gtctcggtga gtctgagcgc 2940

ctcggtgtcc ctgggaatgc tctacatgcc caaagtctac atcatcctct tccacccgga 3000

gcagaacgtg cccaagcgca agcgcagcct caaagccgtc gttacggcgg ccaccatgtc 3060

caacaagttc acgcagaagg gcaacttccg gcccaacgga gaggccaagt ctgagctctg 3120

cgagaacctt gaggccccag cgctggccac caaacagact tacgtcactt acaccaacca 3180

tgcaatctag cgagtccatg gagctgagca gcaggaggag gagccgtgac cctgtggaag 3240

gtgcgtcggg ccagggccac acccaagggc ccagctgtct tgcctgcccg tgggcaccca 3300

cggacgtggc ttggtgctga ggatagcaga gcccccagcc atcactgctg gcagcctggg 3360

caaaccgggt gagcaacagg aggacgaggg gccggggcgg tgccaggcta ccacaagaac 3420

ctgcgtcttg gaccatgcc cctcccggcc ccaaaccaca ggggctcagg tcgtgtgggc 3480

cccagtgcta gatctctccc tcccttcgtc tctgtctgtg ctgttggcga cccctctgtc 3540

tgtctccagc cctgtctttc tgttctctta tctctttgtt tcaccttttc cctctctggc 3600

gtccccggct gcttgtactc ttggcctttt ctgtgtctcc tttctggctc ttgcctccgc 3660

ctctctctct catcctcttt gtcctcagct cctcctgctt tcttgggtcc caccagtgtc 3720

acttttctgc cgttttcttt cctgttctcc tctgcttcat tctcgtccag ccattgctcc 3780

cctctccctg ccacccttcc ccagttcacc aaaccttaca tgttgcaaaa gagaaaaaag 3840

gaaaaaaaat caaaacacaa aaaagccaaa acgaaaacaa atctcgagtg tgttgccaag 3900

tgctgcgtcc tcctggtggc ctctgtgtgt gtccctgtgg cccgcagcct gcccgcctgc 3960

cccgcccatc tgccgtgtgt cttgcccgcc tgccccgccc gtctgccgtc tgtcttgccc 4020

gcctgcccgc ctgcccctcc tgccgaccac acggagttca gtgcctgggt gtttggtgat 4080

ggttattgac gacaatgtgt agcgcatgat tgtttttata ccaagaacat ttctaataaa 4140

aataaacaca tggttttgca cccgggctcc acatccactg agggtcctgc catgggacca 4200

caggctcagc ctgcagctgg aggggcttaga cctagaggga agcgggaact gggctctgga 4260

gacccagggc ttgggggctg tggagactgc tccctaggct gggatctagt gtggtgtggt 4320

gaggccttgg gcatggaggg gccagattcc caggtaaggg gcagggacat tgcaggaaat 4380

tccaggaatc agcacctagt agtcccctaa ttagggggta tgctctgtcc cctgccctgc 4440

agccctggga gggtaacatt tctgccttgc ctgtcctctg tctcacaccc ctcacacctg 4500

ggactgccct tccacccctg cccccataac ctgtgcctct ctccttccag ccaggaagtc 4560

ctcttcttga gaagttagct tcccgggctg ccagcactca tagccgtccc ctcctgcttg 4620

tgttggctcc aggctcgggt gctaagaaga tgtgtgtctg tcctggagat cagtgtgttg 4680

ttatgtgtcc acgtgggccc acaagtgcac ggcacaggca tggccgtgtg gctgtgttgg 4740

ctgtgttggc tgtgtgtctg tgtgcacgtc cagcgcctcc atgcgcatgc gtgcctgtct 4800

tgtttgcgtg tctgatcatc tgtttgggcc ccggtggctc atgcagatgc ctgtctcagg 4860

cccatggcga gtgttcacct cagctggctt ccctggcagg ttgggaggtg ggaaacagga 4920

gcgcttaggg gctgggctct ggctggggta aattatagag ccagaaacac aatgaggcca 4980

taggcagcag ctggagcctg ggctgcctgt gccgtcccct cctgccctgc ccctgggtcc 5040

tgcaccccct cccacctcca ggctagctga cagcgctatg gagcacagtg gaagggactg 5100

gaggaaccct aggcaggggg ccacgcaggg acaggtatg agagtgtgtg tataactgag 5160

gctgggacat tgaatcatgc caggtatgtc ttctccatca gcccactctt actcctggcc 5220

tgggcatctc acacatctgt gcataggaaa tctcttcttc cctggggtct gtgtgcagca 5280

cctagtagat gctcaataaa tgtttgtgtg agggaaggag acaggaaagg aagtgtctcg 5340

ctgatcatct tgcggaatgg ttcctaagac ctctgcccag gaaagattcc accagtgct 5400

ccagcccggt caggcagaac taggttgcca gatcaagggt atctcccaaa agcttccagg 5460

gcagttgggg gtgggggggt ggggggtagg gatggggaat gcagaagcgg gtgcagccag 5520

ctctccccca gggtgactct ggcagcaccc ccatcctggg caccctgcct gctctgtggc 5580

tcacgcccct cctgaagtga ctgatgctct gaggcccaag gctaggtcca gggcagggcc 5640

tgcaggggtt tcatgctcag tccaggactt gcctaggtcc ccctacatct gtggggcccc 5700

catctaggtt ctaacaggag aatcacctct ccaaggggga tgctgcccct cggctcccct 5760

tggctctcag gaggggccct cagggactac cagtcccctg ccagtgggaa gaaatagccc 5820

tgccctcagg gagcttccag tgtgatgggg gagatacagc agactgtgtc ccaaagtaaa 5880

atgactgtta gaatgaggtg ggtggaggag ggaagccttg ggtgggtgtg actttgggca 5940

tctgagcctg gggtgcagag gtgggctctg tgggcctgag gtggacagga gggaaccagg 6000

ccctagcaag acttttgcca gctagacctg ctgcagcagt tgggagggtg ggtgctgctg 6060

gagtcctggg tccatcacct agaaggctca ggccagtgca gccagggctg gggcccacag 6120

ctggcctggg tgggacctgc cctgatgccc atggcaggag ggacgcctgg cccttcacaa 6180

ttggcttggc tgctcacctt tgctctcatc ctcaattatt aatgactgga gaaagctgct 6240

aagtatcttc agaatgttag atttcaacaa gatggggggt tcagggtccc tggcaccctg 6300

gatagggagc cagcggcccc tagagacctt tgctgtgtgc aggggggtatg tgctcacccc 6360

cgtggcctca gcctcctcaa tgtctgaatg aaggattggg ctagcagaca tcccacccca 6420

cagcacactt tctaaccagc agggggaactt ctagacaata gagacgctgg gctccctcca 6480

gaacactgga cctgaacttc tggggggagg gctgggcacg ggcatatttt aaaagctccc 6540

cagcagatgg gccgtgcagt caagtgggcc aagagtggca ccagactttg gggcttgtga 6600

agtcaggagg gagcaacagt gcccactcga gcttgcctgg ggctcaagcc caaggctggg 6660

ctgctgccag cctgagcaga cacccaggag cttccaggcc agctggatgc acaggcacc 6720

tttgtggaac tcctaggacc ctggggagac ccacctcagg agcagagtct caggtccctt 6780

ccggctctga ggggctgttc tgagctctaa tgtctttatgg tctgcccctc ccatccttac 6840

ttctcaggcc ctggaggcag aggcatagag ccaggcagga cagaggtctc agtgggccac 6900

atgccagctg cccccacact gcctcagcct ccaggcctcc aaggggtcct ggggagcccc 6960

tgagaagatg ctgagcctgc ataaggctgg gcgcccctct ttctgacacc ctcactggct 7020

ccacggctcc cccttcccat cccaggtttc catctgccca ctgaacaggg agggggaaact 7080

gaggcactcc cctggcactg agggctcctt ctgtcatcct gcctgccctg gatggtcctg 7140

gctgcccctc aggggcttggc cctggcactg tgagcctcac aggggctcaga cccccacccc 7200

caacccagca ctaaatggca ctcggcacca gaatctcact tcagttggca aaagcagcaa 7260

ttagcatgta atgaggcttc ttgctttatttttaggtaac ctccaaggcc ctgcctgtgt 7320

aattcagccc gccattgctc ggtggataat taaagcatgt caccataa 7368

<210> 60

<211> 912

<212> PRT

<213> Homo sapiens

<400> 60

Met Pro Gly Lys Arg Gly Leu Gly Trp Trp Trp Ala Arg Leu Pro Leu

1 5 10 15

Cys Leu Leu Leu Ser Leu Tyr Gly Pro Trp Met Pro Ser Ser Leu Gly

20 25 30

Lys Pro Lys Gly His Pro His Met Asn Ser Ile Arg Ile Asp Gly Asp

35 40 45

Ile Thr Leu Gly Gly Leu Phe Pro Val His Gly Arg Gly Ser Glu Gly

50 55 60

Lys Pro Cys Gly Glu Leu Lys Lys Glu Lys Gly Ile His Arg Leu Glu

65 70 75 80

Ala Met Leu Phe Ala Leu Asp Arg Ile Asn Asn Asp Pro Asp Leu Leu

85 90 95

Pro Asn Ile Thr Leu Gly Ala Arg Ile Leu Asp Thr Cys Ser Arg Asp

100 105 110

Thr His Ala Leu Glu Gln Ser Leu Thr Phe Val Gln Ala Leu Ile Glu

115 120 125

Lys Asp Gly Thr Glu Val Arg Cys Gly Ser Gly Gly Pro Pro Ile Ile

130 135 140

Thr Lys Pro Glu Arg Val Val Gly Val Ile Gly Ala Ser Gly Ser Ser

145 150 155 160

Val Ser Ile Met Val Ala Asn Ile Leu Arg Leu Phe Lys Ile Pro Gln

165 170 175

Ile Ser Tyr Ala Ser Thr Ala Pro Asp Leu Ser Asp Asn Ser Arg Tyr

180 185 190

Asp Phe Phe Ser Arg Val Val Pro Ser Asp Thr Tyr Gln Ala Gln Ala

195 200 205

Met Val Asp Ile Val Arg Ala Leu Lys Trp Asn Tyr Val Ser Thr Val

210 215 220

Ala Ser Glu Gly Ser Tyr Gly Glu Ser Gly Val Glu Ala Phe Ile Gln

225 230 235 240

Lys Ser Arg Glu Asp Gly Gly Val Cys Ile Ala Gln Ser Val Lys Ile

245 250 255

Pro Arg Glu Pro Lys Ala Gly Glu Phe Asp Lys Ile Ile Arg Arg Leu

260 265 270

Leu Glu Thr Ser Asn Ala Arg Ala Val Ile Ile Phe Ala Asn Glu Asp

275 280 285

Asp Ile Arg Arg Val Leu Glu Ala Ala Arg Arg Ala Asn Gln Thr Gly

290 295 300

His Phe Phe Trp Met Gly Ser Asp Ser Trp Gly Ser Lys Ile Ala Pro

305 310 315 320

Val Leu His Leu Glu Glu Val Ala Glu Gly Ala Val Thr Ile Leu Pro

325 330 335

Lys Arg Met Ser Val Arg Gly Phe Asp Arg Tyr Phe Ser Ser Arg Thr

340 345 350

Leu Asp Asn Asn Arg Arg Asn Ile Trp Phe Ala Glu Phe Trp Glu Asp

355 360 365

Asn Phe His Cys Lys Leu Ser Arg His Ala Leu Lys Lys Gly Ser His

370 375 380

Val Lys Lys Cys Thr Asn Arg Glu Arg Ile Gly Gln Asp Ser Ala Tyr

385 390 395 400

Glu Gln Glu Gly Lys Val Gln Phe Val Ile Asp Ala Val Tyr Ala Met

405 410 415

Gly His Ala Leu His Ala Met His Arg Asp Leu Cys Pro Gly Arg Val

420 425 430

Gly Leu Cys Pro Arg Met Asp Pro Val Asp Gly Thr Gln Leu Leu Lys

435 440 445

Tyr Ile Arg Asn Val Asn Phe Ser Gly Ile Ala Gly Asn Pro Val Thr

450 455 460

Phe Asn Glu Asn Gly Asp Ala Pro Gly Arg Tyr Asp Ile Tyr Gln Tyr

465 470 475 480

Gln Leu Arg Asn Asp Ser Ala Glu Tyr Lys Val Ile Gly Ser Trp Thr

485 490 495

Asp His Leu His Leu Arg Ile Glu Arg Met His Trp Pro Gly Ser Gly

500 505 510

Gln Gln Leu Pro Arg Ser Ile Cys Ser Leu Pro Cys Gln Pro Gly Glu

515 520 525

Arg Lys Lys Thr Val Lys Gly Met Pro Cys Cys Trp His Cys Glu Pro

530 535 540

Cys Thr Gly Tyr Gln Tyr Gln Val Asp Arg Tyr Thr Cys Lys Thr Cys

545 550 555 560

Pro Tyr Asp Met Arg Pro Thr Glu Asn Arg Thr Gly Cys Arg Pro Ile

565 570 575

Pro Ile Ile Lys Leu Glu Trp Gly Ser Pro Trp Ala Val Leu Pro Leu

580 585 590

Phe Leu Ala Val Val Gly Ile Ala Ala Thr Leu Phe Val Val Ile Thr

595 600 605

Phe Val Arg Tyr Asn Asp Thr Pro Ile Val Lys Ala Ser Gly Arg Glu

610 615 620

Leu Ser Tyr Val Leu Leu Ala Gly Ile Phe Leu Cys Tyr Ala Thr Thr

625 630 635 640

Phe Leu Met Ile Ala Glu Pro Asp Leu Gly Thr Cys Ser Leu Arg Arg

645 650 655

Ile Phe Leu Gly Leu Gly Met Ser Ile Ser Tyr Ala Ala Leu Leu Thr

660 665 670

Lys Thr Asn Arg Ile Tyr Arg Ile Phe Glu Gln Gly Lys Arg Ser Val

675 680 685

Ser Ala Pro Arg Phe Ile Ser Pro Ala Ser Gln Leu Ala Ile Thr Phe

690 695 700

Ser Leu Ile Ser Leu Gln Leu Leu Gly Ile Cys Val Trp Phe Val Val

705 710 715 720

Asp Pro Ser His Ser Val Val Asp Phe Gln Asp Gln Arg Thr Leu Asp

725 730 735

Pro Arg Phe Ala Arg Gly Val Leu Lys Cys Asp Ile Ser Asp Leu Ser

740 745 750

Leu Ile Cys Leu Leu Gly Tyr Ser Met Leu Leu Met Val Thr Cys Thr

755 760 765

Val Tyr Ala Ile Lys Thr Arg Gly Val Pro Glu Thr Phe Asn Glu Ala

770 775 780

Lys Pro Ile Gly Phe Thr Met Tyr Thr Thr Cys Ile Val Trp Leu Ala

785 790 795 800

Phe Ile Pro Ile Phe Phe Gly Thr Ser Gln Ser Ala Asp Lys Leu Tyr

805 810 815

Ile Gln Thr Thr Thr Leu Thr Val Ser Val Ser Leu Ser Ala Ser Val

820 825 830

Ser Leu Gly Met Leu Tyr Met Pro Lys Val Tyr Ile Ile Leu Phe His

835 840 845

Pro Glu Gln Asn Val Pro Lys Arg Lys Arg Ser Leu Lys Ala Val Val

850 855 860

Thr Ala Ala Thr Met Ser Asn Lys Phe Thr Gln Lys Gly Asn Phe Arg

865 870 875 880

Pro Asn Gly Glu Ala Lys Ser Glu Leu Cys Glu Asn Leu Glu Ala Pro

885 890 895

Ala Leu Ala Thr Lys Gln Thr Tyr Val Thr Tyr Thr Asn His Ala Ile

900 905 910

<210> 61

<211> 4959

<212> DNA

<213> Homo sapiens

<400> 61

acttgtatct tttcatatca aaaatgggag gtgacaccca gtttaaggaa aattccaagg 60

catttgtctc gactaatgtg aaagatgatt acagtggcca gaggactgcc aaggctcctt 120

ctcaagctgc ttgagtcaat gaggtagac gcaccctctg aagatggtga ctccctcctg 180

agaagctgga ccccttggta aaagacaagg ccttctccaa gaagaatatg aaagtgttac 240

tcagacttat ttgtttcata gctctactga tttcttctct ggaggctgat aaatgcaagg 300

aacgtgaaga aaaaataatt ttagtgtcat ctgcaaatga aattgatgtt cgtccctgtc 360

ctcttaaccc aaatgaacac aaaggcacta taacttggta taaagatgac agcaagacac 420

ctgtatctac agaacaagcc tccaggattc atcaacacaa agagaaactt tggtttgttc 480

ctgctaaggt ggaggattca ggacattact attgcgtggt aagaaattca tcttactgcc 540

tcagaattaa aataagtgca aaatttgtgg agaatgagcc taacttatgt tataatgcac 600

aagccatatt taagcagaaa ctacccgttg caggagacgg aggacttgtg tgcccttata 660

tggagttttt taaaaatgaa aataatgagt tacctaaatt acagtggtat aaggattgca 720

aacctctact tcttgacaat atacacttta gtggagtcaa agataggctc atcgtgatga 780

atgtggctga aaagcataga gggaactata cttgtcatgc atcctacaca tacttgggca 840

agcaatatcc tattacccgg gtaatagaat ttattactct agaggaaaac aaacccacaa 900

ggcctgtgat tgtgagccca gctaatgaga caatggaagt agacttggga tcccagatac 960

aattgatctg taatgtcacc ggccagttga gtgacattgc ttactggaag tggaatgggt 1020

cagtaattga tgaagatgac ccagtgctag gggaagacta ttacagtgtg gaaaatcctg 1080

caaacaaaag aaggagtacc ctcatcacag tgcttaatat atcggaaatt gaaagtagat 1140

tttataaaca tccatttacc tgttttgcca agaatacaca tggtatagat gcagcatata 1200

tccagttaat atatccagtc actaatttcc agaagcacat gattggtata tgtgtcacgt 1260

tgacagtcat aattgtgtgt tctgttttca tctataaaat cttcaagatt gacattgtgc 1320

tttggtacag ggattcctgc tatgattttc tcccaataaa agtcttgcct gaggtcttgg 1380

aaaaacagtg tggatataag ctgttcattt atggaaggga tgactacgtt ggggaagaca 1440

ttgttgaggt cattaatgaa aacgtaaaga aaagcagaag actgattatc atttagtca 1500

gagaaacatc aggcttcagc tggctgggtg gttcatctga agagcaaata gccatgtata 1560

atgctcttgt tcaggatgga attaaagttg tcctgcttga gctggagaaa atccaagact 1620

atgagaaaat gccagaatcg attaaattca ttaagcagaa acatggggct atccgctggt 1680

caggggactt tacacaggga ccacagtctg caaagacaag gttctggaag aatgtcaggt 1740

accacatgcc agtccagcga cggtcacctt catctaaaca ccagttatactg tcaccagcca 1800

ctaaggagaa actgcaaaga gaggctcacg tgcctctcgg gtagcatgga gaagttgcca 1860

agagttcttt aggtgcctcc tgtcttatgg cgttgcaggc caggttatgc ctcatgctga 1920

cttgcagagt tcatggaatg taactatatc atcctttatc cctgaggtca cctggaatca 1980

gattattaag ggaataagcc atgacgtcaa tagcagccca gggcacttca gagtagaggg 2040

cttgggaaga tcttttaaaa aggcagtagg cccggtgtgg tggctcacgc ctataatccc 2100

agcactttgg gaggctgaag tgggtggatc accagaggtc aggagttcga gaccagccca 2160

gccaacatgg caaaacccca tctctactaa aaatacaaaa atgagctagg catggtggca 2220

cacgcctgta atcccagcta cacctgaggc tgaggcagga gaattgcttg aaccggggag 2280

acggaggttg cagtgagccg agtttgggcc actgcactct agcctggcaa cagagcaaga 2340

ctccgtctca aaaaaagggc aataaatgcc ctctctgaat gtttgaactg ccaagaaaag 2400

gcatggagac agcgaactag aagaaagggc aagaaggaaa tagccaccgt ctacagatgg 2460

cttagttaag tcatccacag cccaagggcg gggctatgcc ttgtctgggg accctgtaga 2520

gtcactgacc ctggagcggc tctcctgaga ggtgctgcag gcaaagtgag actgacacct 2580

cactgaggaa gggagacata ttcttggaga actttccatc tgcttgtatt ttccatacac 2640

atccccagcc agaagttagt gtccgaagac cgaattttat tttacagagc ttgaaaactc 2700

acttcaatga acaaagggat tctccaggat tccaaagttt tgaagtcatc ttagctttcc 2760

acaggaggga gagaacttaa aaaagcaaca gtagcaggga attgatccac ttcttaatgc 2820

tttcctccct ggcatgacca tcctgtcctt tgttattatc ctgcatttta cgtctttgga 2880

ggaacagctc cctagtggct tcctccgtct gcaatgtccc ttgcacagcc cacacatgaa 2940

ccatccttcc catgatgccg ctcttctgtc atcccgctcc tgctgaaaca cctcccaggg 3000

gctccacctg ttcaggagct gaagcccatg ctttcccacc agcatgtcac tcccagacca 3060

cctccctgcc ctgtcctcca gcttcccctc gctgtcctgc tgtgtgaatt cccaggttgg 3120

cctggtggcc atgtcgcctg cccccagcac tcctctgtct ctgctcttgc ctgcaccctt 3180

cctcctcctt tgcctaggag gccttctcgc atttctcta gctgatcaga attttaccaa 3240

aattcagaac atcctccaat tccacagtct ctggggagact ttccctaaga ggcgacttcc 3300

tctccagcct tctctctctg gtcaggccca ctgcagagat ggtggtgagc acatctggga 3360

ggctggtctc cctccagctg gaattgctgc tctctgaggg agaggctgtg gtggctgtct 3420

ctgtccctca ctgccttcca ggagcaattt gcacatgtaa catagattta tgtaatgctt 3480

tatgtttaaa aacattcccc aattatctta tttaattttt gcaattattc taattttata 3540

tatagagaaa gtgacctatt ttttaaaaaa atcacactct aagttctatt gaacctagga 3600

cttgagcctc catttctggc ttctagtctg gtgttctgag tacttgattt caggtcaata 3660

acggtccccc ctcactccac actggcacgt ttgtgagaag aaatgacatt ttgctaggaa 3720

gtgaccgagt ctaggaatgc ttttatattcaa gacaccaaat tccaaacttc taaatgttgg 3780

aattttcaaa aattgtgttt agattttatg aaaaactctt ctactttcat ctattctttc 3840

cctagaggca aacatttctt aaaatgtttc attttcatta aaaatgaaag ccaaatttat 3900

atgccaccga ttgcaggaca caagcacagt tttaagagtt gtatgaacat ggagaggact 3960

tttggttttt atatttctcg tatttaatat gggtgaacac caacttttat ttggaataat 4020

aattttcctc ctaaacaaaa acacattgag tttaagtctc tgactcttgc ctttccacct 4080

gctttctcct gggcccgctt tgcctgcttg aaggaacagt gctgttctgg agctgctgtt 4140

ccaacagaca gggcctagct ttcatttgac acaacagacta cagccagaag cccatggagc 4200

agggatgtca cgtcttgaaa agcctattag atgttttaca aatttaattt tgcagattat 4260

tttagtctgt catccagaaa atgtgtcagc atgcatagtg ctaagaaagc aagccaattt 4320

ggaaacttag gttagtgaca aaattggcca gagagtgggg gtgatgatga ccaagaatta 4380

caagtagaat ggcagctgga atttaaggag ggacaagaat caatggataa gcgtgggtgg 4440

aggaagatcc aaacagaaaa gtgcaaagtt attccccatc ttccaagggt tgaattctgg 4500

aggaagaaga cacattccta gttccccgtg aacttccttt gacttattgt ccccactaaa 4560

acaaaacaaa aaacttttaa tgccttccac attataga ttttcttgca gtttttttat 4620

ggcatttttt taaagatgcc ctaagtgttg aagaagagtt tgcaaatgca acaaaatatt 4680

taattaccgg ttgttaaaac tggtttagca caatttatat tttccctctc ttgcctttct 4740

tatttgcaat aaaaggtatt gagccatttt ttaaatgaca tttttgataa attgtttg 4800

tactagttga tgaaggagtt ttttttaacc tgtttatata atttgcagc agaagccaaa 4860

ttttttgtat attaaagcac caaattcatg tacagcatgc atcacggatc aatagactgt 4920

acttattttc caataaaatt ttcaaacttt gtactgtta 4959

<210> 62

<211> 569

<212> PRT

<213> Homo sapiens

<400> 62

Met Lys Val Leu Leu Arg Leu Ile Cys Phe Ile Ala Leu Leu Ile Ser

1 5 10 15

Ser Leu Glu Ala Asp Lys Cys Lys Glu Arg Glu Glu Lys Ile Ile Leu

20 25 30

Val Ser Ser Ala Asn Glu Ile Asp Val Arg Pro Cys Pro Leu Asn Pro

35 40 45

Asn Glu His Lys Gly Thr Ile Thr Trp Tyr Lys Asp Asp Ser Lys Thr

50 55 60

Pro Val Ser Thr Glu Gln Ala Ser Arg Ile His Gln His Lys Glu Lys

65 70 75 80

Leu Trp Phe Val Pro Ala Lys Val Glu Asp Ser Gly His Tyr Tyr Cys

85 90 95

Val Val Arg Asn Ser Ser Tyr Cys Leu Arg Ile Lys Ile Ser Ala Lys

100 105 110

Phe Val Glu Asn Glu Pro Asn Leu Cys Tyr Asn Ala Gln Ala Ile Phe

115 120 125

Lys Gln Lys Leu Pro Val Ala Gly Asp Gly Gly Leu Val Cys Pro Tyr

130 135 140

Met Glu Phe Phe Lys Asn Glu Asn Asn Glu Leu Pro Lys Leu Gln Trp

145 150 155 160

Tyr Lys Asp Cys Lys Pro Leu Leu Leu Asp Asn Ile His Phe Ser Gly

165 170 175

Val Lys Asp Arg Leu Ile Val Met Asn Val Ala Glu Lys His Arg Gly

180 185 190

Asn Tyr Thr Cys His Ala Ser Tyr Thr Tyr Leu Gly Lys Gln Tyr Pro

195 200 205

Ile Thr Arg Val Ile Glu Phe Ile Thr Leu Glu Glu Asn Lys Pro Thr

210 215 220

Arg Pro Val Ile Val Ser Pro Ala Asn Glu Thr Met Glu Val Asp Leu

225 230 235 240

Gly Ser Gln Ile Gln Leu Ile Cys Asn Val Thr Gly Gln Leu Ser Asp

245 250 255

Ile Ala Tyr Trp Lys Trp Asn Gly Ser Val Ile Asp Glu Asp Asp Pro

260 265 270

Val Leu Gly Glu Asp Tyr Tyr Ser Val Glu Asn Pro Ala Asn Lys Arg

275 280 285

Arg Ser Thr Leu Ile Thr Val Leu Asn Ile Ser Glu Ile Glu Ser Arg

290 295 300

Phe Tyr Lys His Pro Phe Thr Cys Phe Ala Lys Asn Thr His Gly Ile

305 310 315 320

Asp Ala Ala Tyr Ile Gln Leu Ile Tyr Pro Val Thr Asn Phe Gln Lys

325 330 335

His Met Ile Gly Ile Cys Val Thr Leu Thr Val Ile Ile Val Cys Ser

340 345 350

Val Phe Ile Tyr Lys Ile Phe Lys Ile Asp Ile Val Leu Trp Tyr Arg

355 360 365

Asp Ser Cys Tyr Asp Phe Leu Pro Ile Lys Ala Ser Asp Gly Lys Thr

370 375 380

Tyr Asp Ala Tyr Ile Leu Tyr Pro Lys Thr Val Gly Glu Gly Ser Thr

385 390 395 400

Ser Asp Cys Asp Ile Phe Val Phe Lys Val Leu Pro Glu Val Leu Glu

405 410 415

Lys Gln Cys Gly Tyr Lys Leu Phe Ile Tyr Gly Arg Asp Asp Tyr Val

420 425 430

Gly Glu Asp Ile Val Glu Val Ile Asn Glu Asn Val Lys Lys Ser Arg

435 440 445

Arg Leu Ile Ile Ile Leu Val Arg Glu Thr Ser Gly Phe Ser Trp Leu

450 455 460

Gly Gly Ser Ser Glu Glu Gln Ile Ala Met Tyr Asn Ala Leu Val Gln

465 470 475 480

Asp Gly Ile Lys Val Val Leu Leu Glu Leu Glu Lys Ile Gln Asp Tyr

485 490 495

Glu Lys Met Pro Glu Ser Ile Lys Phe Ile Lys Gln Lys His Gly Ala

500 505 510

Ile Arg Trp Ser Gly Asp Phe Thr Gln Gly Pro Gln Ser Ala Lys Thr

515 520 525

Arg Phe Trp Lys Asn Val Arg Tyr His Met Pro Val Gln Arg Arg Ser

530 535 540

Pro Ser Ser Lys His Gln Leu Leu Ser Pro Ala Thr Lys Glu Lys Leu

545 550 555 560

Gln Arg Glu Ala His Val Pro Leu Gly

565

<210> 63

<211> 3142

<212> DNA

<213> Homo sapiens

<400> 63

aacttcctgt tgtcaccaca cctctgagtc gtctgagctc actgtgagca aaatcccaca 60

gtggaaactc ttaagcctct gcgaagtaaa tcattcttgt gaatgtgaca cacgatctct 120

ccagtttcca tatgttgaga ttctacttat tcatcagttt gttgtgcttg tcaagatcag 180

acgcagaaga aacatgtcct tcattcacca ggctgagctt tcacagtgca gtggttggta 240

cgggactaaa tgtgaggctg atgctctaca caaggaaaaa cctgacctgc gcacaaacca 300

tcaactcctc agcttttggg aacttgaatg tgaccaagaa aaccaccttc attgtccatg 360

gattcaggcc aacaggctcc cctcctgttt ggatggatga cttagtaaag ggtttgctct 420

ctgttgaaga catgaacgta gttgttgttg attggaatcg aggagctaca actttaatat 480

atacccatgc ctctagtaag accagaaaag tagccatggt cttgaaggaa tttattgacc 540

agatgttggc agaaggagct tctcttgatg acatttacat gatcggagta agtctaggag 600

cccacatatc tgggtttgtt ggagagatgt acgatggatg gctggggaga attacaggcc 660

tcgaccctgc aggcccttta ttcaacggga aacctcacca agacagatta gatcccagtg 720

atgcgcagtt tgttgatgtc atccattccg acactgatgg atttcagtat tttaaatgtg 780

accaccagag gtctgtatac ctgtacctgt cttccctgag agagagctgc accatcactg 840

cgtatccctg tgactcctac caggattata ggaatggcaa gtgtgtcagc tgcggcacgt 900

cacaaaaaga gtcctgtccc cttctgggct attgctga taattggaaa gaccatctaa 960

gggggaaaga tcctccaatg acgaaggcat tctttgacac agctgaggag agcccattct 1020

gcatgtatca ttactttgtg gatattataa catggaacaa gaatgtaaga agaggggaca 1080

ttaccatcaa attgagagac aaagctggaa acaccacaga atccaaaatc aatcatgaac 1140

ccaccacatt tcagaaatat caccaagtga gtctacttgc aagatttaat caagatctgg 1200

ataaagtggc tgcaatttcc ttgatgttct ctacaggatc tctaataggc ccaaggtaca 1260

agctcaggat tctccgaatg aagttaaggt cccttgccca tccggagagg cctcagctgt 1320

gtcggtatga tcttgtcctg atggaaaacg ttgaaacagt cttccaacct attctttgcc 1380

cagagttgca gttgtaactg ttgccaggac acatggccat aaataataga aagaaagcta 1440

caaccacagg ctgtttgaaa gcttcacctc acctttctgc aaggcagaaa aagtatgaaa 1500

aaaaccaagg cttttttcag tagcgtccta tggatgtcac attgtacatc aaacaacctt 1560

gtgattataa aacgatcctg ggaaggagcc cctaactagg gcaagtcaga aatagccagg 1620

ctcgcagcag cgcagcgctg tgtctgctgt gtcctggggc ctcccttgtt ccgacctgtc 1680

aattctgctg cctgtcacgc gggtggttct gcccatcgcg gctgcgggtc aagcatcttc 1740

aagggaagga cggactggag gcctcaccgt ggactcaact ctgcattctc cgtgccacat 1800

tcctccagtt cccacacgta gaagggaacg aaactgacgt ctacctcatg gggctgctgt 1860

gtgggtttgg gaggcaaaaa tctatgaagg gttttttgaa atcccatagg tgccacatct 1920

atgagatgtt tgataaatgt gaatatgctt ttacatttgg gcttatctaa tttgcaataa 1980

gagagcctct ctctatcaac accagcttct ctctcgggct gtttgctcag ggaaggcaag 2040

aaagccacgt gctggccctc tgccttctct aaagtgctgt tggagcatgg aggagctgga 2100

ggagatgggg atggactgac agctaagagg gcggctgctg ggactagata gtggatgaag 2160

aaagaaggac gaggaagccg tggggcagcc tcttcacatg gggacagggg atggagcatg 2220

aggcaaggga agggaaaagca gagcttattt ttcacctaag gtggagaagg atcactttac 2280

aggcaacgct cattttaagc aacccttaag aaatgtttat gtttctttat taccaatgta 2340

atctatgatt attgaaggaa atttagaaaa tgcgtagata caaaattaaa aaaaaatact 2400

gtccacgatc ctattagagg taattaatgt tagccttttg gaacaaggct gtcacctatt 2460

ttgccaacac gtgaattcaa aacatgaacc ggtttgcttt tggagaatct gaagactcca 2520

gtttgaggaa tcctttgctt ccctggaggt agatgctgtc tgcaaatcta gaatgacagc 2580

aggagtccag tcaagaggtc ctgtcaggcc aaggccagaa agaagggagg acaatccctg 2640

gggccagatg cccagtgtga ggggaggcat gatctgtccc atggctgtgg ccactgcagg 2700

aaggtctgtg aaaaggaggt gacaggccca gtcacctcct cttcacccaa gtgattgctc 2760

cttcaactgc tatctgtgaa aatagccttt gttatgaaga aattgactct ctctctcttt 2820

tttttttttt ggagttgcct aggctggagt gcaatggtac gatctcagct cactgcaacc 2880

tccacctccc aggttcaatt gattctcctg cctcagcctc ctgagtagct gggattacag 2940

gcatgtgcca ccacacccgg ctaatttttg tatttttatt agagacaggg tttcaccacg 3000

ttagccaggc tcgtctcgaa ctcctgtcct caggtgacta cccgtctcgg cctcccaaag 3060

tgctgggatt acaggcatga gccaccacac ccggccaaaa atggattctc tatgtcataa 3120

attaaagaaa tctataaatg ta 3142

<210> 64

<211> 451

<212> PRT

<213> Homo sapiens

<400> 64

Met Leu Arg Phe Tyr Leu Phe Ile Ser Leu Leu Cys Leu Ser Arg Ser

1 5 10 15

Asp Ala Glu Glu Thr Cys Pro Ser Phe Thr Arg Leu Ser Phe His Ser

20 25 30

Ala Val Val Gly Thr Gly Leu Asn Val Arg Leu Met Leu Tyr Thr Arg

35 40 45

Lys Asn Leu Thr Cys Ala Gln Thr Ile Asn Ser Ser Ala Phe Gly Asn

50 55 60

Leu Asn Val Thr Lys Lys Thr Thr Phe Ile Val His Gly Phe Arg Pro

65 70 75 80

Thr Gly Ser Pro Pro Val Trp Met Asp Asp Leu Val Lys Gly Leu Leu

85 90 95

Ser Val Glu Asp Met Asn Val Val Val Val Asp Trp Asn Arg Gly Ala

100 105 110

Thr Thr Leu Ile Tyr Thr His Ala Ser Ser Lys Thr Arg Lys Val Ala

115 120 125

Met Val Leu Lys Glu Phe Ile Asp Gln Met Leu Ala Glu Gly Ala Ser

130 135 140

Leu Asp Asp Ile Tyr Met Ile Gly Val Ser Leu Gly Ala His Ile Ser

145 150 155 160

Gly Phe Val Gly Glu Met Tyr Asp Gly Trp Leu Gly Arg Ile Thr Gly

165 170 175

Leu Asp Pro Ala Gly Pro Leu Phe Asn Gly Lys Pro His Gln Asp Arg

180 185 190

Leu Asp Pro Ser Asp Ala Gln Phe Val Asp Val Ile His Ser Asp Thr

195 200 205

Asp Ala Leu Gly Tyr Lys Glu Pro Leu Gly Asn Ile Asp Phe Tyr Pro

210 215 220

Asn Gly Gly Leu Asp Gln Pro Gly Cys Pro Lys Thr Ile Leu Gly Gly

225 230 235 240

Phe Gln Tyr Phe Lys Cys Asp His Gln Arg Ser Val Tyr Leu Tyr Leu

245 250 255

Ser Ser Leu Arg Glu Ser Cys Thr Ile Thr Ala Tyr Pro Cys Asp Ser

260 265 270

Tyr Gln Asp Tyr Arg Asn Gly Lys Cys Val Ser Cys Gly Thr Ser Gln

275 280 285

Lys Glu Ser Cys Pro Leu Leu Gly Tyr Tyr Ala Asp Asn Trp Lys Asp

290 295 300

His Leu Arg Gly Lys Asp Pro Pro Met Thr Lys Ala Phe Phe Asp Thr

305 310 315 320

Ala Glu Glu Ser Pro Phe Cys Met Tyr His Tyr Phe Val Asp Ile

325 330 335

Thr Trp Asn Lys Asn Val Arg Arg Gly Asp Ile Thr Ile Lys Leu Arg

340 345 350

Asp Lys Ala Gly Asn Thr Thr Thr Glu Ser Lys Ile Asn His Glu Pro Thr

355 360 365

Thr Phe Gln Lys Tyr His Gln Val Ser Leu Leu Ala Arg Phe Asn Gln

370 375 380

Asp Leu Asp Lys Val Ala Ala Ile Ser Leu Met Phe Ser Thr Gly Ser

385 390 395 400

Leu Ile Gly Pro Arg Tyr Lys Leu Arg Ile Leu Arg Met Lys Leu Arg

405 410 415

Ser Leu Ala His Pro Glu Arg Pro Gln Leu Cys Arg Tyr Asp Leu Val

420 425 430

Leu Met Glu Asn Val Glu Thr Val Phe Gln Pro Ile Leu Cys Pro Glu

435 440 445

Leu Gln Leu

450

<210> 65

<211> 11140

<212> DNA

<213> Homo sapiens

<400> 65

aggcaggggg cggcaacatg gcggagtgag cggcggcgtc ggggcttcac aacaacagtg 60

gtggccgtag cagcggcggc agcagcgtca atagcatcgg ccacagcctg agcttcagca 120

ccggccagcg tcgtggccag ctgctcgcgt cctcgggctt ctcggagcgg ctgcagcatc 180

tccgcggggg gcgggccggg ccggacagac cgggagaggg agagagcaga ggcagcggcg 240

gcggcagcgg cagcggcagc ggcacacctg ctgggcgggc acagccgctt gcccggcagc 300

ggttagcggt accgccaccg ccgagaataa gcctgcggat cccccgccgc ctccgcgggg 360

gagagcgccg gagcgggccg ggctgaggcg caggcgggga gcgggcccgg cgccgcggcg 420

ctggtggatg ctggggctcc gaggcgacgg ccggggggcg ggggccgagg caggtataac 480

ggtaccggcg gcggcagcgc cgctgctctt cccttctcct caggaggggg gccaatggct 540

agcgagaagc cgggcccggg cccggggctc gagcctcagc ccgtggggct cattgccgtc 600

ggggccgctg gcggaggcgg cgggggcagc ggtggtggcg gcaccggggg cagcggggatg 660

gggagctaa gggggcgtc cggctccggc tcggtgatgc tccccgcggg gatgattaac 720

ccttcggtgc cgatccgcaa catccggatg aaattcgcag tgttgattgg actcatacag 780

gtcggagagg tcagcaacag ggacatcgtg gagacggtgc tcaacctgct ggttggtgga 840

gaatttgact tggagatgaa ctttattatc caggatgctg agagtataac atgtatgaca 900

gagcttttgg agcactgtga tgtaacatgt caagcagaaa tatggagcat gtttacagcc 960

attctacgaa aaagtgttcg gaatttacag actagcacag aagttgggct aattgaacaa 1020

gtattgctga aaatgagtgc tgtagatgac atgatagcag atcttctagt tgatatgttg 1080

ggggttcttg ccagctacag catcactgtc aaggagttga agcttttgtt cagcatgctt 1140

cgaggagaaa gtggaatctg gccaagacat gcagtaaaat tattatcagt tcttaatcag 1200

atgccacaga gacacggtcc tgatactttt ttcaatttcc ctggttgtag cgctgcggca 1260

attgccttgc ctcctattgc aaagtggcct tatcagaatg gcttcacctt aaacacttgg 1320

tttcgtatgg atccattaaa taatattaat gttgataagg ataaacctta tctttatattgt 1380

tttcgtacta gcaaaggagt tggttatactct gctcattttg ttggcaactg tttaatagtc 1440

acatcattga agtccaaagg aaaaggtttt cagcattgtg tgaaatatga ttttcaacca 1500

cgcaagtggt acatgatcag cattgtccac atttacaatc gatggaggaa cagtgaaatt 1560

cggtgttatg ttaatggaca actggtatct tatggtgata tggcttggca tgttaacaca 1620

aatgatagct atgacaagtg ctttcttgga tcatcagaaa ctgctgatgc aaatagggta 1680

ttctgtggtc aacttggtgc cgtgtatgtg ttcagtgaag cactcaaccc agcacagata 1740

tttgcaattc atcagttagg acctggatat aagagtacct tcaagtttaa atctgagagt 1800

gatattcatt tggcagaaca tcataaacag gtgttatatg atgggaaact tgcaagtagc 1860

attgccttta catataatgc taaggccact gatgctcagc tctgcctgga atcatcacca 1920

aaagagaatg catcaatttt tgtgcattcc ccacatgctc taatgcttca ggatgtgaaa 1980

gcgatagtaa cacattcaat tcatagtgca attcattcaa ttggagggat tcaagtgctt 2040

tttccacttt ttgcccaatt ggataatagg cagctcaatg acagtcaagt ggaaacaact 2100

gtctgtgcta ctctgttggc attcctggtt gaactactta aaagttcagt agccatgcaa 2160

gaacagatgc tgggtggaaa aggcttttta gtcattggct acttacttga aaagtcatca 2220

agagttcata taactagagc tgtcctggag caatttttat cttttgcaaa atacttgat 2280

ggtttatctc atggagcacc tttgctgaag cagctttgtg atcacatttt atttaaccca 2340

gccatctgga tacatacacc tgcaaaggtt cagctttccc tatacacata tttgtctgct 2400

gaatttattg gaactgctac catctacacc accatacgca gagtaggaac agtattacag 2460

ctaatgcaca ccttaaaata ttaactactgg gttattaatc ctgctgacag tagtggcatt 2520

acacctaaag gattagatgg tccccggcca tcacaaaaag aaattatatc actgagggca 2580

tttatgctac tttttctgaa acagctgata ctaaaggatc gaggggtcaa ggaagatgaa 2640

cttcagagta tattaaatta cctacttacg atgcatgagg atgaaaatat tcatgatgtg 2700

ctacagttac tggtggcttt aatgtcggaa cacccagcct caatgatacc agcatttgat 2760

caaagaaatg gaataagggt gatctacaaa ttatggctt ctaaaagtga aagtatttgg 2820

gttcaagctt tgaaggttct gggatacttt ctgaagcatt taggtcacaa gagaaaagtt 2880

gaaattatgc acacccatag tcttttcact cttcttggag aaaggctgat gttgcataca 2940

aacactgtga ctgtcaccac atacaacaca ctttatgaga tcttgacaga acaagtatgt 3000

actcaggtcg tacacaaacc acatccagag ccagattcta cagtgaaaat tcagaatcca 3060

atgattctta aagtggtggc aactttgtta aaaaactcta caccaagtgc agagctgatg 3120

gaagttcgtc gtttatattttt atctgatatg ataaacttt tcagtaacag ccgtgaaaat 3180

agaagatgct tattgcagtg ttcagtgtgg caggattgga tgttttctct tggctatatc 3240

aatcctaaaa attctgagga agaagatt accgaaatgg tctacaatat cttccggatt 3300

cttttgtatc atgcaataaa atatgaatgg ggaggctgga gagtctgggt ggataccctc 3360

tcaatagccc attccaaggt cacttatgaa gctcataagg aatacctagc caaaatgtat 3420

gaggaatatc aaagacaaga ggaggaaaac attaaaaagg gaaagaaagg gaatgtgagc 3480

accatctctg gtctttcatc acagacaaca ggagcaaaag gtggaatgga aattcgagag 3540

atagaagatc tttcacaaag ccagagccca gaaagtgaga ccgattaccc tgtcagcaca 3600

gatactcgag acttactcat gtcaacaaaa gtgtcagatg atattcttgg aaattcagat 3660

agaccaggaa gtggtgtaca tgtggaagta catgatcttt tagtagatat aaaagcagag 3720

aaagtggaag caacagaagt aaagctcgat gatatggatt tatcaccgga gactttagta 3780

ggtggagaga atggtgccct tgtggaggtt gaatctctgt tggataatgt atatatagtgct 3840

gctgttgaga aactccagaa caatgtacat ggaagtgttg gtatcattaa aaaaaatgaa 3900

gaaaaggata atggtccatt gataacatta gcagatgaga aagaagacct tcccaatagt 3960

agtacatcat ttctctttga taaaataccc aaacaggagg aaaaactact tcctgaactt 4020

tctagcaatc acatattcc aaatattcag gacacacaag tacatcttgg tgttagtgat 4080

gatcttggat tgcttgctca catgaccggt agcgtagact taacttgtac atccagtata 4140

atagaagaaa aagaattcaa aatccataca acttcagatg gaatgagcag tatttctgaa 4200

agagacttag cgtcatcaac taaggggctg gagtatgctg aaatgactgc tacaactctg 4260

gaaactgagt cttctagtag caaaattgta ccaaatattg atgcaggaag tataatttca 4320

gatactgaaa ggtctgacga tggcaaagaa tcaggaaaag aaatccgaaa aatccaaaca 4380

actactacga cacaagctgt gcagggtcgg tctatcaccc aacaagaccg agatctccga 4440

gttgatttag gatttcgagg aatgccaatg actgaggaac agcgacgcca gtttagccca 4500

ggtccacgga ctacaatgtt tcgtattcct gagtttaaat ggtctccaat gcaccagcgg 4560

cttctcactg atttactatt tgcattagaa actgatgtac atgtttggag gagccattct 4620

acaaagtctg taatggattt tgtcaatagc aatgaaaata ttattttgt acataacaca 4680

attcacctca tttcccaaat ggtagacaac atcatcattg cttgtggagg aattttacct 4740

ttgctctctg ctgctacatc accaactggt tctaagacgg aattggaaaa tattgaagtg 4800

acacaaggca tgtcagctga gacagcagta actttcctca gccggctgat ggctatggtt 4860

gatgtacttg tgtttgcaag ctctctaaat tttagtgaga ttgaagctga gaaaaacatg 4920

tcttctggag gtttaatgcg acagtgccta agattagttt gttgtgttgc tgtgagaaac 4980

tgtttagaat gtcggcaaag acagagagac agggggaaata aatcttccca tggaagcagt 5040

aaacctcagg aagttcctca aagtgtgact gctacagcag cttcgaagac tccattggaa 5100

aatgttccag gtaacctttc tcctattaag gatccggata gacttcttca ggatgttgat 5160

atcaatcgcc ttcgtgctgt tgtctttcgg gatgtggatg atagcaaaca agcacagttc 5220

ttagctctgg ctgttgttta cttcatttcg gttctgatgg tttccaagta tcgtgacata 5280

ttagaacccc agagagagac tacaagaact ggaagccaac caggtagaaa catcaggcaa 5340

gaaataaatt caccaacaag tacagttgtg gtcataccat ctatccctca tccaagtttg 5400

aaccatggat tccttgccaa gttaattcct gagcagagct ttggccactc attttacaaa 5460

gaaacacctg ctgcatttcc agacaccata aaagaaaaag aaacaccaac tcctggtgaa 5520

gatattcagg tagaaagttc aattccccat acagattcag gaattggaga ggagcaagtg 5580

gctagcatcc tgaatggggc agaattagaa acaagtacag gccctgatgc catgagtgaa 5640

ctcttatcca ctttgtcatc cgaagtgaag aaatcacaag aggcttaac tgaaaatcct 5700

agtgaaacgt tgaagcctgc aacatccata tctagcatta gtcaaaccaa aggcatcaat 5760

gtgaaggaaa tactgaaaag tcttgtggct gctccagttg aaatagcaga atgtggccct 5820

gaacctatcc catacccaga tccagcattg aagagagaaa cacaagctat tcttcctatg 5880

cagtttcatt cctttgacag gagtgttgtg gtgcctgtaa agaaaccacc tccaggtagt 5940

ttagctgtaa ccactgtggg agccactact gctggaagtg ggctgccaac aggcagtacc 6000

tctaatatat ttgctgctac tggagctaca ccaaaaagta tgattaatac aacaggtgcc 6060

gtggattcag ggtcctcctc ctcttcctcc tcttctagtt ttgtgaatgg tgctactagc 6120

aaaaaccttc cagctgtaca aactgttgct ccaatgccag aagattcagc tgaaaatatg 6180

agcatcactg caaaacttga aagagcgtta gaaaaagttg ctcctcttct tcgtgaaatt 6240

tttgtagact ttgccccatt cctatctcgt acacttcttg gcagtcatgg acaagagcta 6300

ttgatagaag gccttgtttg tatgaagtcc agcacatctg tggttgagct tgttatgctg 6360

ctttgttctc aggaatggca aaactctatt cagaagaatg caggacttgc atttattgag 6420

ctcatcaatg aaggaagatt actgtgccat gctatgaagg accatatagt ccgtgttgca 6480

aatgaagctg agtttatttt gaacagacaa agagccgagg atgtacataa acatgcagag 6540

tttgagtcac agtgtgccca atatgctgct gatagaagag aggaagaaaa gatgtgtgac 6600

catctttatca gtgctgctaa acatcgagat catgtaacag caaatcagct gaaacagaag 6660

attctcaata ttctcacaaa taaacatggt gcttggggag cagtttctca tagccaattg 6720

catgatttct ggcgtttgga ttatgggaa gatgatcttc gtcgaaggag acgatttgtt 6780

cgcaatgcat ttggctccac tcatgctgaa gcattgctga aagctgcaat agaatatggc 6840

acggaagaag atgtagtaaa gtcaaagaaa acattcagaa gtcaagcaat agtgaaccaa 6900

aatgcagaga cagaacttat gctggaagga gacgatgatg cagtcagtct gctacaggag 6960

aaagaaattg acaaccttgc aggcccagtg gttctcagca cccctgccca gctcatcgct 7020

cccgtggtgg tggccaaggg gactctctcc atcaccacga cagaaatcta cttcgaggta 7080

gatgaggatg attctgcctt caagaagatc gacacgaaag ttcttgcata cactgaggga 7140

cttcacggaa aatggatgtt cagcgagata cgagctgtat tttcaagacg ttaccttcta 7200

caaaacactg ctttggaagt atttatggca aaccgaacct cagttatgtt taatttccct 7260

gatcaagcaa cagtaaaaaa agttgtctat agcttgcctc gggttggagt agggaccagc 7320

tatggtctgc cacaagccag gaggatatca ttggccactc ctcgacagct ttataaatct 7380

tccaatatga ctcagcgctg gcaaagaagg gaaatttcaa acttcgaata tttgatgttc 7440

cttaatacta ttgcaggacg gacatataat gatctgaacc aatatccagt gtttccgtgg 7500

gtgttaacca actatgaatc agaagagttg gacctgactc ttccaggaaa cttcagggat 7560

ctatcaaagc caattggtgc tttgaaccc aagagagctg tgttttatgc agagcgttat 7620

gagacatggg aagatgatca aagcccaccc taccatta atacccatta ttcaacagca 7680

acatctactt tatcctggct tgttcgaatt gaacctttca caaccttctt cctcaatgca 7740

aatgatggaa aatttgatca tccagatcga accttctcat ccgttgcaag gtcttggaga 7800

actagtcaga gagatacttc tgatgtaaag gaactaattc cagagttcta ctacctacca 7860

gagatgtttg tcaacagtaa tggatataat cttggagtca gagaagatga agtagtggta 7920

aatgatgttg atcttccccc ttgggcaaaa aaacctgaag actttgtgcg gatcaacagg 7980

atggccctag aaagtgaatt tgtttcttgc caacttcatc agtggatcga ccttatattt 8040

ggctataagc agcgaggacc agaagcagtt cgtgctctga atgtttttca ctacttgact 8100

tatgaaggct ctgtgaacct ggatagtatc actgatcctg tgctcaggga ggccatggag 8160

gcacagatac agaactttgg acagacgcca tctcagttgc ttattgagcc acatccgcct 8220

cggagctctg ccatgcacct gtgtttcctt ccacagagtc cgctcatgtt taaagatcag 8280

atgcaacagg atgtgataat ggtgctgaag tttccttcaa attctccagt aacccatgtg 8340

gcagccaaca ctctgcccca cttgaccatc cccgcagtgg tgacagtgac ttgcagccga 8400

ctctttgcag tgaatagatg gcacaacaca gtaggcctca gaggagctcc aggatactcc 8460

ttggatcaag cccaccatct tcccattgaa atggatccat taatagccaa taattcaggt 8520

gtaaacaaac ggcagatcac agacctcgtt gaccagagta tacaaatcaa tgcacattgt 8580

tttgtggtaa cagcagataa tcgctatatt cttatctgtg gattctggga taagagcttc 8640

agagtttatt ctacagaaac agggaaattg actcagattg tatttggcca ttggggatgtg 8700

gtcacttgct tggccaggtc cgagtcatac attggtgggg actgctacat cgtgtccgga 8760

tctcgagatg ccaccctgct gctctggtac tggagtgggc ggcaccatat cataggagac 8820

aaccctaaca gcagtgacta tccggcacca agagccgtcc tcacaggcca tgaccatgaa 8880

gttgtctgtg tttctgtctg tgcagaactt gggcttgtta tcagtggtgc taaagagggc 8940

ccttgccttg tccacaccat cactggagat ttgctgagag cccttgaagg accagaaaac 9000

tgcttattcc cacgcttgat atctgtctcc agcgaaggcc actgtatcat atactatgaa 9060

cgagggcgat tcagtaattt cagcattaat gggaaacttt tggctcaaat ggagatcaat 9120

gattcaacac gggccattct cctgagcagt gacggccaga acctggtcac cggaggggac 9180

aatggggtag tagaggtctg gcaggcctgt gacttcaagc aactgtacat ttaccctgga 9240

tgtgatgctg gcattagagc aatggacttg tcccatgacc agaggactct gatcactggc 9300

atggcttctg gtagcattgt agcttttaat atagattta atcggtggca ttatgagcat 9360

cagaacagat actgaagata aaggaagaac caaaagccaa gttaaagctg agagcacaag 9420

tgctgcatgg aaaggcaata tctctggtgg aaaaaactcg tctacatcga cctccgtttg 9480

tacattccat cacacccagc aatagctgta cattgtagtc agcaaccatt ttactttgtg 9540

tgttttttca cgactgaaca ccagctgcta tcaagcaagc ttatatcatg taaattatat 9600

gaattaggag atgttttggt aattatttca tatattgttg tttattgaga aaaggttgta 9660

ggatgtgtca caagagactt ttgacaattc tgaggaacct tgtgtccagt tgttacaaag 9720

tttaagcttt gaacctaacc tgcatcccat ttccagcctc ttttcaagct gagaaaaaaa 9780

aaaaaaaaca cgtttgatac tttgtacatc agatgcatct tatttaaaag ggatactttt 9840

gtaaaagtaa aaccttgtat aaagaacaaa atgtttctta atttattgt ggagttacaa 9900

cttgcatgtt ccttactcct gttggcttga tggaacaggt gcattcacac tatgaaacag 9960

aaagatctgt ccaaggacac agcttgtatg aaagggttga atttgggctc catcagtaat 10020

ttttgacatt ttcaccaaaa tatagtttgc actttttaat ctaaagtcat cccttctgag 10080

tgaaatttgc tcataaagca tttggatact aagccattat ttgccatttt gggtacttta 10140

tacaaagaaa attcagccct accctgcata atttgaagac acagcagaaa gggggcttag 10200

ggatgaggtc ctggtttttc ttgtataaat aggagtcatg ggcgttagtt ctgtagtaat 10260

aacttcccag cacctggaca tctcttccag agttatccca ctggcttggt gtgtatacat 10320

taggggagga taatctgatg ctaacttttt ttttctcttt ggttcttgaa tagcttagtt 10380

tctttaataa caagtcaaac tttattacaa caataactga agttatattctt ttaggttctc 10440

gtgaaattct cactgaaagc cacattctta gcctaaggca tttcatcttt tatgatataa 10500

aatgatggct atcaaatgat tttccataca ttgtactgat caagttatac acccaggggt 10560

atatacactt tcttcatgtt tcttctttgt atatttggtg actgtatcgt catagatgta 10620

catattgtgt cggtagggct atgaggcatg ttacaggaat gtaattttct cagaatttac 10680

actcactcgc agtcatttat ttaaaaagat aaaacaagat aatgggttct ttgtattggc 10740

actttgcacc agaaacatat cattatttat tgatgtgatt acttatttgt tatccacctt 10800

gtactagtaa gttttagcac tgaattcctt cttcactgtt gtttgtattt atgaaattct 10860

gaaattatgg ggaatcagcg taatgattaa gttattcatc accaggctgt aagcaatatc 10920

ttgagtttgt agcttagaat tgggaggata cttaacatct ggaagacaag ttcatttcat 10980

cttgagatca tggtgaaata ttttggatat ataaattcct taagctattg taaccatgtt 11040

ttattgcaaa gatgtaaaat atgccagatg tgtgtgagtt ggaaatcaaa aaaagaaaaa 11100

taaaatatgc aaagaattca aaaaaaaaaa aaaaaaaaaa 11140

<210> 66

<211> 2946

<212> PRT

<213> Homo sapiens

<400> 66

Met Ala Ser Glu Lys Pro Gly Pro Gly Pro Gly Leu Glu Pro Gln Pro

1 5 10 15

Val Gly Leu Ile Ala Val Gly Ala Ala Gly Gly Gly Gly Gly Gly Gly Ser

20 25 30

Gly Gly Gly Gly Thr Gly Gly Ser Gly Met Gly Glu Leu Arg Gly Ala

35 40 45

Ser Gly Ser Gly Ser Val Met Leu Pro Ala Gly Met Ile Asn Pro Ser

50 55 60

Val Pro Ile Arg Asn Ile Arg Met Lys Phe Ala Val Leu Ile Gly Leu

65 70 75 80

Ile Gln Val Gly Glu Val Ser Asn Arg Asp Ile Val Glu Thr Val Leu

85 90 95

Asn Leu Leu Val Gly Gly Glu Phe Asp Leu Glu Met Asn Phe Ile Ile

100 105 110

Gln Asp Ala Glu Ser Ile Thr Cys Met Thr Glu Leu Leu Glu His Cys

115 120 125

Asp Val Thr Cys Gln Ala Glu Ile Trp Ser Met Phe Thr Ala Ile Leu

130 135 140

Arg Lys Ser Val Arg Asn Leu Gln Thr Ser Thr Glu Val Gly Leu Ile

145 150 155 160

Glu Gln Val Leu Leu Lys Met Ser Ala Val Asp Asp Met Ile Ala Asp

165 170 175

Leu Leu Val Asp Met Leu Gly Val Leu Ala Ser Tyr Ser Ile Thr Val

180 185 190

Lys Glu Leu Lys Leu Leu Phe Ser Met Leu Arg Gly Glu Ser Gly Ile

195 200 205

Trp Pro Arg His Ala Val Lys Leu Leu Ser Val Leu Asn Gln Met Pro

210 215 220

Gln Arg His Gly Pro Asp Thr Phe Phe Asn Phe Pro Gly Cys Ser Ala

225 230 235 240

Ala Ala Ile Ala Leu Pro Pro Ile Ala Lys Trp Pro Tyr Gln Asn Gly

245 250 255

Phe Thr Leu Asn Thr Trp Phe Arg Met Asp Pro Leu Asn Asn Ile Asn

260 265 270

Val Asp Lys Asp Lys Pro Tyr Leu Tyr Cys Phe Arg Thr Ser Lys Gly

275 280 285

Val Gly Tyr Ser Ala His Phe Val Gly Asn Cys Leu Ile Val Thr Ser

290 295 300

Leu Lys Ser Lys Gly Lys Gly Phe Gln His Cys Val Lys Tyr Asp Phe

305 310 315 320

Gln Pro Arg Lys Trp Tyr Met Ile Ser Ile Val His Ile Tyr Asn Arg

325 330 335

Trp Arg Asn Ser Glu Ile Arg Cys Tyr Val Asn Gly Gln Leu Val Ser

340 345 350

Tyr Gly Asp Met Ala Trp His Val Asn Thr Asn Asp Ser Tyr Asp Lys

355 360 365

Cys Phe Leu Gly Ser Ser Glu Thr Ala Asp Ala Asn Arg Val Phe Cys

370 375 380

Gly Gln Leu Gly Ala Val Tyr Val Phe Ser Glu Ala Leu Asn Pro Ala

385 390 395 400

Gln Ile Phe Ala Ile His Gln Leu Gly Pro Gly Tyr Lys Ser Thr Phe

405 410 415

Lys Phe Lys Ser Glu Ser Asp Ile His Leu Ala Glu His His Lys Gln

420 425 430

Val Leu Tyr Asp Gly Lys Leu Ala Ser Ser Ile Ala Phe Thr Tyr Asn

435 440 445

Ala Lys Ala Thr Asp Ala Gln Leu Cys Leu Glu Ser Ser Pro Lys Glu

450 455 460

Asn Ala Ser Ile Phe Val His Ser Pro His Ala Leu Met Leu Gln Asp

465 470 475 480

Val Lys Ala Ile Val Thr His Ser Ile His Ser Ala Ile His Ser Ile

485 490 495

Gly Gly Ile Gln Val Leu Phe Pro Leu Phe Ala Gln Leu Asp Asn Arg

500 505 510

Gln Leu Asn Asp Ser Gln Val Glu Thr Thr Thr Val Cys Ala Thr Leu Leu

515 520 525

Ala Phe Leu Val Glu Leu Leu Lys Ser Ser Val Ala Met Gln Glu Gln

530 535 540

Met Leu Gly Gly Lys Gly Phe Leu Val Ile Gly Tyr Leu Leu Glu Lys

545 550 555 560

Ser Ser Arg Val His Ile Thr Arg Ala Val Leu Glu Gln Phe Leu Ser

565 570 575

Phe Ala Lys Tyr Leu Asp Gly Leu Ser His Gly Ala Pro Leu Leu Lys

580 585 590

Gln Leu Cys Asp His Ile Leu Phe Asn Pro Ala Ile Trp Ile His Thr

595 600 605

Pro Ala Lys Val Gln Leu Ser Leu Tyr Thr Tyr Leu Ser Ala Glu Phe

610 615 620

Ile Gly Thr Ala Thr Ile Tyr Thr Thr Ile Arg Arg Val Gly Thr Val

625 630 635 640

Leu Gln Leu Met His Thr Leu Lys Tyr Tyr Tyr Tyr Trp Val Ile Asn Pro

645 650 655

Ala Asp Ser Ser Gly Ile Thr Pro Lys Gly Leu Asp Gly Pro Arg Pro

660 665 670

Ser Gln Lys Glu Ile Ile Ser Leu Arg Ala Phe Met Leu Leu Phe Leu

675 680 685

Lys Gln Leu Ile Leu Lys Asp Arg Gly Val Lys Glu Asp Glu Leu Gln

690 695 700

Ser Ile Leu Asn Tyr Leu Leu Thr Met His Glu Asp Glu Asn Ile His

705 710 715 720

Asp Val Leu Gln Leu Leu Val Ala Leu Met Ser Glu His Pro Ala Ser

725 730 735

Met Ile Pro Ala Phe Asp Gln Arg Asn Gly Ile Arg Val Ile Tyr Lys

740 745 750

Leu Leu Ala Ser Lys Ser Glu Ser Ile Trp Val Gln Ala Leu Lys Val

755 760 765

Leu Gly Tyr Phe Leu Lys His Leu Gly His Lys Arg Lys Val Glu Ile

770 775 780

Met His Thr His Ser Leu Phe Thr Leu Leu Gly Glu Arg Leu Met Leu

785 790 795 800

His Thr Asn Thr Val Thr Val Thr Thr Tyr Tyr Asn Thr Leu Tyr Glu Ile

805 810 815

Leu Thr Glu Gln Val Cys Thr Gln Val Val His Lys Pro His Pro Glu

820 825 830

Pro Asp Ser Thr Val Lys Ile Gln Asn Pro Met Ile Leu Lys Val Val

835 840 845

Ala Thr Leu Leu Lys Asn Ser Thr Pro Ser Ala Glu Leu Met Glu Val

850 855 860

Arg Arg Leu Phe Leu Ser Asp Met Ile Lys Leu Phe Ser Asn Ser Arg

865 870 875 880

Glu Asn Arg Arg Cys Leu Leu Gln Cys Ser Val Trp Gln Asp Trp Met

885 890 895

Phe Ser Leu Gly Tyr Ile Asn Pro Lys Asn Ser Glu Glu Gln Lys Ile

900 905 910

Thr Glu Met Val Tyr Asn Ile Phe Arg Ile Leu Leu Tyr His Ala Ile

915 920 925

Lys Tyr Glu Trp Gly Gly Trp Arg Val Trp Val Asp Thr Leu Ser Ile

930 935 940

Ala His Ser Lys Val Thr Tyr Tyr Glu Ala His Lys Glu Tyr Leu Ala Lys

945 950 955 960

Met Tyr Glu Glu Tyr Gln Arg Gln Glu Glu Glu Asn Ile Lys Lys Gly

965 970 975

Lys Lys Gly Asn Val Ser Thr Ile Ser Gly Leu Ser Gln Thr Thr

980 985 990

Gly Ala Lys Gly Gly Met Glu Ile Arg Glu Ile Glu Asp Leu Ser Gln

995 1000 1005

Ser Gln Ser Pro Glu Ser Glu Thr Asp Tyr Pro Val Ser Thr Asp

1010 1015 1020

Thr Arg Asp Leu Leu Met Ser Thr Lys Val Ser Asp Asp Ile Leu

1025 1030 1035

Gly Asn Ser Asp Arg Pro Gly Ser Gly Val His Val Glu Val His

1040 1045 1050

Asp Leu Leu Val Asp Ile Lys Ala Glu Lys Val Glu Ala Thr Glu

1055 1060 1065

Val Lys Leu Asp Asp Met Asp Leu Ser Pro Glu Thr Leu Val Gly

1070 1075 1080

Gly Glu Asn Gly Ala Leu Val Glu Val Glu Ser Leu Leu Asp Asn

1085 1090 1095

Val Tyr Ser Ala Ala Val Glu Lys Leu Gln Asn Asn Val His Gly

1100 1105 1110

Ser Val Gly Ile Ile Lys Lys Asn Glu Glu Lys Asp Asn Gly Pro

1115 1120 1125

Leu Ile Thr Leu Ala Asp Glu Lys Glu Asp Leu Pro Asn Ser Ser

1130 1135 1140

Thr Ser Phe Leu Phe Asp Lys Ile Pro Lys Gln Glu Glu Lys Leu

1145 1150 1155

Leu Pro Glu Leu Ser Ser Asn His Ile Ile Pro Asn Ile Gln Asp

1160 1165 1170

Thr Gln Val His Leu Gly Val Ser Asp Asp Leu Gly Leu Leu Ala

1175 1180 1185

His Met Thr Gly Ser Val Asp Leu Thr Cys Thr Ser Ser Ser Ile

1190 1195 1200

Glu Glu Lys Glu Phe Lys Ile His Thr Thr Ser Asp Gly Met Ser

1205 1210 1215

Ser Ile Ser Glu Arg Asp Leu Ala Ser Ser Thr Lys Gly Leu Glu

1220 1225 1230

Tyr Ala Glu Met Thr Ala Thr Thr Leu Glu Thr Glu Ser Ser Ser

1235 1240 1245

Ser Lys Ile Val Pro Asn Ile Asp Ala Gly Ser Ile Ile Ser Asp

1250 1255 1260

Thr Glu Arg Ser Asp Asp Gly Lys Glu Ser Gly Lys Glu Ile Arg

1265 1270 1275

Lys Ile Gln Thr Thr Thr Thr Thr Thr Gln Ala Val Gln Gly Arg Ser

1280 1285 1290

Ile Thr Gln Gln Asp Arg Asp Leu Arg Val Asp Leu Gly Phe Arg

1295 1300 1305

Gly Met Pro Met Thr Glu Glu Gln Arg Arg Gln Phe Ser Pro Gly

1310 1315 1320

Pro Arg Thr Thr Met Phe Arg Ile Pro Glu Phe Lys Trp Ser Pro

1325 1330 1335

Met His Gln Arg Leu Leu Thr Asp Leu Leu Phe Ala Leu Glu Thr

1340 1345 1350

Asp Val His Val Trp Arg Ser His Ser Thr Lys Ser Val Met Asp

1355 1360 1365

Phe Val Asn Ser Asn Glu Asn Ile Ile Phe Val His Asn Thr Ile

1370 1375 1380

His Leu Ile Ser Gln Met Val Asp Asn Ile Ile Ile Ala Cys Gly

1385 1390 1395

Gly Ile Leu Pro Leu Leu Ser Ala Ala Thr Ser Pro Thr Gly Ser

1400 1405 1410

Lys Thr Glu Leu Glu Asn Ile Glu Val Thr Gln Gly Met Ser Ala

1415 1420 1425

Glu Thr Ala Val Thr Phe Leu Ser Arg Leu Met Ala Met Val Asp

1430 1435 1440

Val Leu Val Phe Ala Ser Ser Leu Asn Phe Ser Glu Ile Glu Ala

1445 1450 1455

Glu Lys Asn Met Ser Ser Gly Gly Leu Met Arg Gln Cys Leu Arg

1460 1465 1470

Leu Val Cys Cys Val Ala Val Arg Asn Cys Leu Glu Cys Arg Gln

1475 1480 1485

Arg Gln Arg Asp Arg Gly Asn Lys Ser Ser His Gly Ser Ser Lys

1490 1495 1500

Pro Gln Glu Val Pro Gln Ser Val Thr Ala Thr Ala Ala Ser Lys

1505 1510 1515

Thr Pro Leu Glu Asn Val Pro Gly Asn Leu Ser Pro Ile Lys Asp

1520 1525 1530

Pro Asp Arg Leu Leu Gln Asp Val Asp Ile Asn Arg Leu Arg Ala

1535 1540 1545

Val Val Phe Arg Asp Val Asp Asp Ser Lys Gln Ala Gln Phe Leu

1550 1555 1560

Ala Leu Ala Val Val Tyr Phe Ile Ser Val Leu Met Val Ser Lys

1565 1570 1575

Tyr Arg Asp Ile Leu Glu Pro Gln Arg Glu Thr Thr Arg Thr Gly

1580 1585 1590

Ser Gln Pro Gly Arg Asn Ile Arg Gln Glu Ile Asn Ser Pro Thr

1595 1600 1605

Ser Thr Val Val Val Ile Pro Ser Ile Pro His Pro Ser Leu Asn

1610 1615 1620

His Gly Phe Leu Ala Lys Leu Ile Pro Glu Gln Ser Phe Gly His

1625 1630 1635

Ser Phe Tyr Lys Glu Thr Pro Ala Ala Phe Pro Asp Thr Ile Lys

1640 1645 1650

Glu Lys Glu Thr Pro Thr Pro Gly Glu Asp Ile Gln Val Glu Ser

1655 1660 1665

Ser Ile Pro His Thr Asp Ser Gly Ile Gly Glu Glu Gln Val Ala

1670 1675 1680

Ser Ile Leu Asn Gly Ala Glu Leu Glu Thr Ser Thr Gly Pro Asp

1685 1690 1695

Ala Met Ser Glu Leu Leu Ser Thr Leu Ser Ser Glu Val Lys Lys

1700 1705 1710

Ser Gln Glu Ser Leu Thr Glu Asn Pro Ser Glu Thr Leu Lys Pro

1715 1720 1725

Ala Thr Ser Ile Ser Ser Ser Ile Ser Gln Thr Lys Gly Ile Asn Val

1730 1735 1740

Lys Glu Ile Leu Lys Ser Leu Val Ala Ala Pro Val Glu Ile Ala

1745 1750 1755

Glu Cys Gly Pro Glu Pro Ile Pro Tyr Pro Asp Pro Ala Leu Lys

1760 1765 1770

Arg Glu Thr Gln Ala Ile Leu Pro Met Gln Phe His Ser Phe Asp

1775 1780 1785

Arg Ser Val Val Val Pro Val Lys Lys Pro Pro Pro Gly Ser Leu

1790 1795 1800

Ala Val Thr Thr Val Gly Ala Thr Thr Ala Gly Ser Gly Leu Pro

1805 1810 1815

Thr Gly Ser Thr Ser Asn Ile Phe Ala Ala Thr Gly Ala Thr Pro

1820 1825 1830

Lys Ser Met Ile Asn Thr Thr Thr Gly Ala Val Asp Ser Gly Ser Ser

1835 1840 1845

Ser Ser Ser Ser Ser Phe Val Asn Gly Ala Thr Ser Lys

1850 1855 1860

Asn Leu Pro Ala Val Gln Thr Val Ala Pro Met Pro Glu Asp Ser

1865 1870 1875

Ala Glu Asn Met Ser Ile Thr Ala Lys Leu Glu Arg Ala Leu Glu

1880 1885 1890

Lys Val Ala Pro Leu Leu Arg Glu Ile Phe Val Asp Phe Ala Pro

1895 1900 1905

Phe Leu Ser Arg Thr Leu Leu Gly Ser His Gly Gln Glu Leu Leu

1910 1915 1920

Ile Glu Gly Leu Val Cys Met Lys Ser Ser Thr Ser Val Val Glu

1925 1930 1935

Leu Val Met Leu Leu Cys Ser Gln Glu Trp Gln Asn Ser Ile Gln

1940 1945 1950

Lys Asn Ala Gly Leu Ala Phe Ile Glu Leu Ile Asn Glu Gly Arg

1955 1960 1965

Leu Leu Cys His Ala Met Lys Asp His Ile Val Arg Val Ala Asn

1970 1975 1980

Glu Ala Glu Phe Ile Leu Asn Arg Gln Arg Ala Glu Asp Val His

1985 1990 1995

Lys His Ala Glu Phe Glu Ser Gln Cys Ala Gln Tyr Ala Ala Asp

2000 2005 2010

Arg Arg Glu Glu Lys Met Cys Asp His Leu Ile Ser Ala Ala

2015 2020 2025

Lys His Arg Asp His Val Thr Ala Asn Gln Leu Lys Gln Lys Ile

2030 2035 2040

Leu Asn Ile Leu Thr Asn Lys His Gly Ala Trp Gly Ala Val Ser

2045 2050 2055

His Ser Gln Leu His Asp Phe Trp Arg Leu Asp Tyr Trp Glu Asp

2060 2065 2070

Asp Leu Arg Arg Arg Arg Arg Phe Val Arg Asn Ala Phe Gly Ser

2075 2080 2085

Thr His Ala Glu Ala Leu Leu Lys Ala Ala Ile Glu Tyr Gly Thr

2090 2095 2100

Glu Glu Asp Val Val Lys Ser Lys Lys Thr Phe Arg Ser Gln Ala

2105 2110 2115

Ile Val Asn Gln Asn Ala Glu Thr Glu Leu Met Leu Glu Gly Asp

2120 2125 2130

Asp Asp Ala Val Ser Leu Leu Gln Glu Lys Glu Ile Asp Asn Leu

2135 2140 2145

Ala Gly Pro Val Val Leu Ser Thr Pro Ala Gln Leu Ile Ala Pro

2150 2155 2160

Val Val Val Ala Lys Gly Thr Leu Ser Ile Thr Thr Thr Thr Glu Ile

2165 2170 2175

Tyr Phe Glu Val Asp Glu Asp Asp Ser Ala Phe Lys Lys Ile Asp

2180 2185 2190

Thr Lys Val Leu Ala Tyr Thr Glu Gly Leu His Gly Lys Trp Met

2195 2200 2205

Phe Ser Glu Ile Arg Ala Val Phe Ser Arg Arg Tyr Leu Leu Gln

2210 2215 2220

Asn Thr Ala Leu Glu Val Phe Met Ala Asn Arg Thr Ser Val Met

2225 2230 2235

Phe Asn Phe Pro Asp Gln Ala Thr Val Lys Lys Val Val Tyr Ser

2240 2245 2250

Leu Pro Arg Val Gly Val Gly Thr Ser Tyr Gly Leu Pro Gln Ala

2255 2260 2265

Arg Arg Ile Ser Leu Ala Thr Pro Arg Gln Leu Tyr Lys Ser Ser

2270 2275 2280

Asn Met Thr Gln Arg Trp Gln Arg Arg Glu Ile Ser Asn Phe Glu

2285 2290 2295

Tyr Leu Met Phe Leu Asn Thr Ile Ala Gly Arg Thr Tyr Asn Asp

2300 2305 2310

Leu Asn Gln Tyr Pro Val Phe Pro Trp Val Leu Thr Asn Tyr Glu

2315 2320 2325

Ser Glu Glu Leu Asp Leu Thr Leu Pro Gly Asn Phe Arg Asp Leu

2330 2335 2340

Ser Lys Pro Ile Gly Ala Leu Asn Pro Lys Arg Ala Val Phe Tyr

2345 2350 2355

Ala Glu Arg Tyr Glu Thr Trp Glu Asp Asp Gln Ser Pro Pro Tyr

2360 2365 2370

His Tyr Asn Thr His Tyr Ser Thr Ala Thr Ser Thr Leu Ser Trp

2375 2380 2385

Leu Val Arg Ile Glu Pro Phe Thr Thr Phe Phe Leu Asn Ala Asn

2390 2395 2400

Asp Gly Lys Phe Asp His Pro Asp Arg Thr Phe Ser Ser Val Ala

2405 2410 2415

Arg Ser Trp Arg Thr Ser Gln Arg Asp Thr Ser Asp Val Lys Glu

2420 2425 2430

Leu Ile Pro Glu Phe Tyr Tyr Leu Pro Glu Met Phe Val Asn Ser

2435 2440 2445

Asn Gly Tyr Asn Leu Gly Val Arg Glu Asp Glu Val Val Val Asn

2450 2455 2460

Asp Val Asp Leu Pro Pro Trp Ala Lys Lys Pro Glu Asp Phe Val

2465 2470 2475

Arg Ile Asn Arg Met Ala Leu Glu Ser Glu Phe Val Ser Cys Gln

2480 2485 2490

Leu His Gln Trp Ile Asp Leu Ile Phe Gly Tyr Lys Gln Arg Gly

2495 2500 2505

Pro Glu Ala Val Arg Ala Leu Asn Val Phe His Tyr Leu Thr Tyr

2510 2515 2520

Glu Gly Ser Val Asn Leu Asp Ser Ile Thr Asp Pro Val Leu Arg

2525 2530 2535

Glu Ala Met Glu Ala Gln Ile Gln Asn Phe Gly Gln Thr Pro Ser

2540 2545 2550

Gln Leu Leu Ile Glu Pro His Pro Pro Arg Ser Ser Ala Met His

2555 2560 2565

Leu Cys Phe Leu Pro Gln Ser Pro Leu Met Phe Lys Asp Gln Met

2570 2575 2580

Gln Gln Asp Val Ile Met Val Leu Lys Phe Pro Ser Asn Ser Pro

2585 2590 2595

Val Thr His Val Ala Ala Asn Thr Leu Pro His Leu Thr Ile Pro

2600 2605 2610

Ala Val Val Thr Val Thr Cys Ser Arg Leu Phe Ala Val Asn Arg

2615 2620 2625

Trp His Asn Thr Val Gly Leu Arg Gly Ala Pro Gly Tyr Ser Leu

2630 2635 2640

Asp Gln Ala His His Leu Pro Ile Glu Met Asp Pro Leu Ile Ala

2645 2650 2655

Asn Asn Ser Gly Val Asn Lys Arg Gln Ile Thr Asp Leu Val Asp

2660 2665 2670

Gln Ser Ile Gln Ile Asn Ala His Cys Phe Val Val Thr Ala Asp

2675 2680 2685

Asn Arg Tyr Ile Leu Ile Cys Gly Phe Trp Asp Lys Ser Phe Arg

2690 2695 2700

Val Tyr Ser Thr Glu Thr Gly Lys Leu Thr Gln Ile Val Phe Gly

2705 2710 2715

His Trp Asp Val Val Thr Cys Leu Ala Arg Ser Glu Ser Tyr Ile

2720 2725 2730

Gly Gly Asp Cys Tyr Ile Val Ser Gly Ser Arg Asp Ala Thr Leu

2735 2740 2745

Leu Leu Trp Tyr Trp Ser Gly Arg His His Ile Ile Gly Asp Asn

2750 2755 2760

Pro Asn Ser Ser Asp Tyr Pro Ala Pro Arg Ala Val Leu Thr Gly

2765 2770 2775

His Asp His Glu Val Val Cys Val Ser Val Cys Ala Glu Leu Gly

2780 2785 2790

Leu Val Ile Ser Gly Ala Lys Glu Gly Pro Cys Leu Val His Thr

2795 2800 2805

Ile Thr Gly Asp Leu Leu Arg Ala Leu Glu Gly Pro Glu Asn Cys

2810 2815 2820

Leu Phe Pro Arg Leu Ile Ser Val Ser Ser Glu Gly His Cys Ile

2825 2830 2835

Ile Tyr Tyr Glu Arg Gly Arg Phe Ser Asn Phe Ser Ile Asn Gly

2840 2845 2850

Lys Leu Leu Ala Gln Met Glu Ile Asn Asp Ser Thr Arg Ala Ile

2855 2860 2865

Leu Leu Ser Ser Asp Gly Gln Asn Leu Val Thr Gly Gly Asp Asn

2870 2875 2880

Gly Val Val Glu Val Trp Gln Ala Cys Asp Phe Lys Gln Leu Tyr

2885 2890 2895

Ile Tyr Pro Gly Cys Asp Ala Gly Ile Arg Ala Met Asp Leu Ser

2900 2905 2910

His Asp Gln Arg Thr Leu Ile Thr Gly Met Ala Ser Gly Ser Ile

2915 2920 2925

Val Ala Phe Asn Ile Asp Phe Asn Arg Trp His Tyr Glu His Gln

2930 2935 2940

Asn Arg Tyr

2945

<210> 67

<211> 4675

<212> DNA

<213> Homo sapiens

<400> 67

agatgacaga cacttctcaa aagacagctt ttcttcctgg agaacagact ttttcagcag 60

gattttcctt tcagtgaaac atatttgac ttgaaaggaa cccagggaaa agtgtccagg 120

tgtgagcatg agcgggtaga ggtgtgccct tgtttgcttc aggctgtctg cttttcgccc 180

ctgactgttt tttctgtttc tggccatgga ggaagagaaa gatgacagcc cacaggctga 240

cttctgcctg ggcaccgccc tgcactcttg gggactgtgg ttcacggagg aaggttcacc 300

gtccaccatg ctgacgggga ttgcagttgg agccctcctg gccctggcct tggttggtgt 360

cctcatcctt ttcatgttca gaaggcttag acaatttcga caagcacagc ccactcctca 420

gtaccggttc cggaagagag acaaagtgat gttttacggc cggaagatca tgaggaaggt 480

gaccacactc cccaacaccc ttgtggagaa cactgccctg ccccggcagc gggccaggaa 540

gaggaccaag gtgctgtctt tggccaagag gattctgcgt ttcaagaagg aatacccggc 600

cctgcagccc aaggagcccc cgccctccct gctggaggcc gacctcacgg agtttgacgt 660

gaagaattct cacctgccat cggaagttct gtacatgctg aaaaacgttc gggtcctggg 720

ccactttgag aagccgctgt tcctggagct ttgcaaacac atcgtctttg tgcagctgca 780

ggaaggggag cacgtcttcc agcccaggga gccggacccc agcatctgtg tggtgcagga 840

cgggcggctg gaggtctgca tccaggacac tgacggcacc gaggtggtgg tgaaagaggt 900

tctggcggga gacagcgtcc acagcctgct cagcatcctg gacatcatca ccggccatgc 960

tgcaccttac aaaacggtct ccgtccgcgc ggccatcccg tccaccatcc tccggcttcc 1020

agctgcggct tttcatggag tttttgagaa atatccggaa actctggtga gggtggtgca 1080

gatcatcatg gtgcggctgc agagggtgac ctttctggct ctgcacaact acctcggcct 1140

gaccacagag ctcttcaacg ctgagagcca ggccatccct ctcgtgtctg tagccagtgt 1200

ggctgccggg aaggccaaga agcaggtgtt ctatggcgaa gaagagcggc ttaaaaagcc 1260

accgcggctc caggagtcct gtgactcaga tcacgggggc ggccgcccgg cagctgctgg 1320

gcccctgctg aagaggagcc actccgtccc cgcgccttcc attcgcaaac agatcttgga 1380

ggagctggag aagcccgggg caggtgaccc tgacccttcg gccccacaag ggggcccagg 1440

cagtgccact tctgatctgg ggatggcatg tgaccgtgcc agggtcttcc tgcactcgga 1500

cgagcacccc gggagctccg tggccagcaa gtccaggaaa agcgtgatgg ttgcagagat 1560

accctccacg gtctcccagc actcagagag tcacacggat gagaccctgg ccagcaggaa 1620

gtcggatgcc atcttcagag ctgccaagaa ggacctgctc accctgatga agctggaaga 1680

ctcatctctg ttggatggcc gggtggcgct tctgcacgtt cctgcaggca cggtggtgtc 1740

aaggcaggga gaccaggacg ccagcatcct gttcgtggtc tcggggctgc tgcacgtgta 1800

ccagcggaag atcggcagcc aggaggacac ctgcttgttc ctcacgcgcc ccggggagat 1860

ggtgggccag ctggccgtgc tcaccgggga gcctctcatc ttcaccgtca aggccaacag 1920

ggactgcagc ttcctgtcca tctccaaggc ccacttctat gaaatcatgc ggaagcagcc 1980

gaccgtcgtc ctgggtgtgg cgcacactgt ggtgaagagg atgtcgtcct tcgtgcggca 2040

aatcgacttt gccctggact gggtggaggt ggaggccggg cgagcaatat acaggcaggg 2100

ggacaagtcc gactgcacgt acatcatgct cagcggccgg ctgcgctctg tgatccggaa 2160

ggatgatggg aagaagcgcc tggccgggga gtacggccga ggagacctcg tcggcgtggt 2220

ggagacactg acccaccagg cccgggcgac cacggtgcat gccgttcggg actcagaatt 2280

ggccaagctg ccggcaggag ccctcacgtc catcaagcgc aggtacccac aggtggtgac 2340

tcggctgatt catctcttgg gtgagaagat cctgggcagc ctccagcagg gacctgtgac 2400

aggccaccag cttgggctcc ccacggaggg cagcaagtgg gacttgggga acccggctgt 2460

caacctgtcc acggtggcag tgatgcccgt gtcagaggaa gtgcccctca ccgccttcgc 2520

cctggagctg gagcatgccc tcagcgccat cggcccgacc ctgctgctga ctagtgacaa 2580

cataaaacgg cgccttggct ccgctgccct ggacagtgtt cacgagtacc ggctgtccag 2640

ctggctgggg cagcaggagg acacccag gatcgtgctc taccaggcag atggcacgct 2700

cacaccctgg accagcgct gcgtgcgcca ggccgactgc atcctcatcg tgggcctggg 2760

tgaccaggag cccacagtgg gcgagctgga gcggatgctg gagagcacag ctgtgcgtgc 2820

ccagaagcag ctgatcctgc tgcacaggga ggagggcccg gcgccagcgc gcaccgtgga 2880

gtggctcaac atgcggagct ggtgctccgg ccacctgcac ctctgctgcc cgcgccgcgt 2940

cttctccagg aggagcctgc ccaagctggt ggagatgtac aagcatgtct tccagcggcc 3000

cccggaccga cactcagact tctcccgcct ggcgagggtg ctgacgggca acgccattgc 3060

cctggtgctt gggggagggg gagcaagagg ctgtgcccag gtgggcgttc tcaaggcctt 3120

ggcggagtgc ggcatccctg tggacatggt gggaggcacg tccatcgggg ccttcgtggg 3180

tgccctgtac tctgaggagc ggaactacag ccagatgcgg atccgggcca agcagtgggc 3240

cgagggcatg acgtccttga tgaaggccgc gctggacctc acctacccca tcacgtccat 3300

gttctccgga gccggcttca acagcagcat cttcagcgtc ttcaaggacc agcagatcga 3360

ggacctgtgg attccttatttcgccatcac caccgacatc acagcctcgg ccatgcgggt 3420

ccacaccgac ggctccctgt ggtggtacgt gcgtgccagc atgtccctgt ccggttacat 3480

gccccctctc tgtgacccga aggacggaca cctgctgatg gacgggggct acatcaacaa 3540

cctcccagcg gatgtggccc ggtccatggg ggcaaaagtg gtgatcgcca ttgacgtggg 3600

cagccgagat gagacggacc tcaccaacta tggggatgcg ctgtctgggt ggtggctgct 3660

gtggaaacgc tggaacccct tggccacgaa agtcaaggtg ttgaacatgg cagagattca 3720

gacgcgcctg gcctacgtgt gttgcgtgcg gcagctggag gtggtgaaga gcagtgacta 3780

ctgcgagtac ctgcgccccc ccatcgacag ctacagcacc ctggacttcg gcaagttcaa 3840

cgagatctgc gaagtgggct accagcacgg gcgcacggtg tttgacatct ggggccgcag 3900

cggcgtgctg gagaagatgc tccgcgacca gcaggggccg agcaagaagc ccgcgagtgc 3960

ggtcctcacc tgtcccaacg cctccttcac ggaccttgcc gaaattgtgt ctcgcattga 4020

gcccgccaag cccgccatgg tggatgacga atctgactac cagacggagt acgaggagga 4080

gctgctggac gtccccaggg atgcatacgc agacttccag agcacctcag cccagcaggg 4140

ctcagacttg gaggacgagt cctcactgcg gcatcgacac cccagtctgg ctttcccaaa 4200

actgtctgag ggctcctctg accaggacgg gtagaggcct ctgctaaaga gcccggatgc 4260

agcgtcttcc gtgggactgt ccccaaggct gaggctcctg ccaagtccta ggggcctctg 4320

tacctgccct gctggaagcc ctgacttccc cggggcccca ggctgtgtta gggttctctg 4380

ggcctcttct ttgtaccagc agccctgcat acagggccct gtgagccccc ctgcagtcct 4440

gtgaggcccc tgaagctctg tgaggcccct gaagctctgt gaaccccctg cagccctgtg 4500

aggccccccg aagccctgtg aggccccccg aagccctgtg aaccacctgc tgccctgtga 4560

ggcccccaaa gccctgtgaa ctgcctgctg tcctgtgaac tgcctgctgc cctgtgaggt 4620

gtggggagccc tgatgctgcc gtgtgatgtt tcaataaagg tggatctcac tgttg 4675

<210> 68

<211> 1317

<212> PRT

<213> Homo sapiens

<400> 68

Met Glu Glu Glu Lys Asp Asp Ser Pro Gln Leu Thr Gly Ile Ala Val

1 5 10 15

Gly Ala Leu Leu Ala Leu Ala Leu Val Gly Val Leu Ile Leu Phe Met

20 25 30

Phe Arg Arg Leu Arg Gln Phe Arg Gln Ala Gln Pro Thr Pro Gln Tyr

35 40 45

Arg Phe Arg Lys Arg Asp Lys Val Met Phe Tyr Gly Arg Lys Ile Met

50 55 60

Arg Lys Val Thr Thr Leu Pro Asn Thr Leu Val Glu Asn Thr Ala Leu

65 70 75 80

Pro Arg Gln Arg Ala Arg Lys Arg Thr Lys Val Leu Ser Leu Ala Lys

85 90 95

Arg Ile Leu Arg Phe Lys Lys Glu Tyr Pro Ala Leu Gln Pro Lys Glu

100 105 110

Pro Pro Pro Ser Leu Leu Glu Ala Asp Leu Thr Glu Phe Asp Val Lys

115 120 125

Asn Ser His Leu Pro Ser Glu Val Leu Tyr Met Leu Lys Asn Val Arg

130 135 140

Val Leu Gly His Phe Glu Lys Pro Leu Phe Leu Glu Leu Cys Lys His

145 150 155 160

Ile Val Phe Val Gln Leu Gln Glu Gly Glu His Val Phe Gln Pro Arg

165 170 175

Glu Pro Asp Pro Ser Ile Cys Val Val Gln Asp Gly Arg Leu Glu Val

180 185 190

Cys Ile Gln Asp Thr Asp Gly Thr Glu Val Val Val Lys Glu Val Leu

195 200 205

Ala Gly Asp Ser Val His Ser Leu Leu Ser Ile Leu Asp Ile Ile Thr

210 215 220

Gly His Ala Ala Pro Tyr Lys Thr Val Ser Val Arg Ala Ala Ile Pro

225 230 235 240

Ser Thr Ile Leu Arg Leu Pro Ala Ala Ala Phe His Gly Val Phe Glu

245 250 255

Lys Tyr Pro Glu Thr Leu Val Arg Val Val Gln Ile Ile Met Val Arg

260 265 270

Leu Gln Arg Val Thr Phe Leu Ala Leu His Asn Tyr Leu Gly Leu Thr

275 280 285

Thr Glu Leu Phe Asn Ala Glu Ser Gln Ala Ile Pro Leu Val Ser Val

290 295 300

Ala Ser Val Ala Ala Gly Lys Ala Lys Lys Gln Val Phe Tyr Gly Glu

305 310 315 320

Glu Glu Arg Leu Lys Lys Pro Pro Arg Leu Gln Glu Ser Cys Asp Ser

325 330 335

Asp His Gly Gly Gly Arg Pro Ala Ala Ala Gly Pro Leu Leu Lys Arg

340 345 350

Ser His Ser Val Pro Ala Pro Ser Ile Arg Lys Gln Ile Leu Glu Glu

355 360 365

Leu Glu Lys Pro Gly Ala Gly Asp Pro Asp Pro Ser Ala Pro Gln Gly

370 375 380

Gly Pro Gly Ser Ala Thr Ser Asp Leu Gly Met Ala Cys Asp Arg Ala

385 390 395 400

Arg Val Phe Leu His Ser Asp Glu His Pro Gly Ser Ser Val Ala Ser

405 410 415

Lys Ser Arg Lys Ser Val Met Val Ala Glu Ile Pro Ser Thr Val Ser

420 425 430

Gln His Ser Glu Ser His Thr Asp Glu Thr Leu Ala Ser Arg Lys Ser

435 440 445

Asp Ala Ile Phe Arg Ala Ala Lys Lys Asp Leu Leu Thr Leu Met Lys

450 455 460

Leu Glu Asp Ser Ser Leu Leu Asp Gly Arg Val Ala Leu Leu His Val

465 470 475 480

Pro Ala Gly Thr Val Val Ser Arg Gln Gly Asp Gln Asp Ala Ser Ile

485 490 495

Leu Phe Val Val Ser Gly Leu Leu His Val Tyr Gln Arg Lys Ile Gly

500 505 510

Ser Gln Glu Asp Thr Cys Leu Phe Leu Thr Arg Pro Gly Glu Met Val

515 520 525

Gly Gln Leu Ala Val Leu Thr Gly Glu Pro Leu Ile Phe Thr Val Lys

530 535 540

Ala Asn Arg Asp Cys Ser Phe Leu Ser Ile Ser Lys Ala His Phe Tyr

545 550 555 560

Glu Ile Met Arg Lys Gln Pro Thr Val Val Leu Gly Val Ala His Thr

565 570 575

Val Val Lys Arg Met Ser Ser Phe Val Arg Gln Ile Asp Phe Ala Leu

580 585 590

Asp Trp Val Glu Val Glu Ala Gly Arg Ala Ile Tyr Arg Gln Gly Asp

595 600 605

Lys Ser Asp Cys Thr Tyr Tyr Ile Met Leu Ser Gly Arg Leu Arg Ser Val

610 615 620

Ile Arg Lys Asp Asp Gly Lys Lys Arg Leu Ala Gly Glu Tyr Gly Arg

625 630 635 640

Gly Asp Leu Val Gly Val Val Glu Thr Leu Thr His Gln Ala Arg Ala

645 650 655

Thr Thr Val His Ala Val Arg Asp Ser Glu Leu Ala Lys Leu Pro Ala

660 665 670

Gly Ala Leu Thr Ser Ile Lys Arg Arg Tyr Pro Gln Val Val Thr Arg

675 680 685

Leu Ile His Leu Leu Gly Glu Lys Ile Leu Gly Ser Leu Gln Gln Gly

690 695 700

Pro Val Thr Gly His Gln Leu Gly Leu Pro Thr Glu Gly Ser Lys Trp

705 710 715 720

Asp Leu Gly Asn Pro Ala Val Asn Leu Ser Thr Val Ala Val Met Pro

725 730 735

Val Ser Glu Glu Val Pro Leu Thr Ala Phe Ala Leu Glu Leu Glu His

740 745 750

Ala Leu Ser Ala Ile Gly Pro Thr Leu Leu Leu Thr Ser Asp Asn Ile

755 760 765

Lys Arg Arg Leu Gly Ser Ala Ala Leu Asp Ser Val His Glu Tyr Arg

770 775 780

Leu Ser Ser Trp Leu Gly Gln Gln Glu Asp Thr His Arg Ile Val Leu

785 790 795 800

Tyr Gln Ala Asp Gly Thr Leu Thr Pro Trp Thr Gln Arg Cys Val Arg

805 810 815

Gln Ala Asp Cys Ile Leu Ile Val Gly Leu Gly Asp Gln Glu Pro Thr

820 825 830

Val Gly Glu Leu Glu Arg Met Leu Glu Ser Thr Ala Val Arg Ala Gln

835 840 845

Lys Gln Leu Ile Leu Leu His Arg Glu Glu Gly Pro Ala Pro Ala Arg

850 855 860

Thr Val Glu Trp Leu Asn Met Arg Ser Trp Cys Ser Gly His Leu His

865 870 875 880

Leu Cys Cys Pro Arg Arg Val Phe Ser Arg Arg Ser Leu Pro Lys Leu

885 890 895

Val Glu Met Tyr Lys His Val Phe Gln Arg Pro Pro Asp Arg His Ser

900 905 910

Asp Phe Ser Arg Leu Ala Arg Val Leu Thr Gly Asn Ala Ile Ala Leu

915 920 925

Val Leu Gly Gly Gly Gly Ala Arg Gly Cys Ala Gln Val Gly Val Leu

930 935 940

Lys Ala Leu Ala Glu Cys Gly Ile Pro Val Asp Met Val Gly Gly Thr

945 950 955 960

Ser Ile Gly Ala Phe Val Gly Ala Leu Tyr Ser Glu Glu Arg Asn Tyr

965 970 975

Ser Gln Met Arg Ile Arg Ala Lys Gln Trp Ala Glu Gly Met Thr Ser

980 985 990

Leu Met Lys Ala Ala Leu Asp Leu Thr Tyr Pro Ile Thr Ser Met Phe

995 1000 1005

Ser Gly Ala Gly Phe Asn Ser Ser Ile Phe Ser Val Phe Lys Asp

1010 1015 1020

Gln Gln Ile Glu Asp Leu Trp Ile Pro Tyr Phe Ala Ile Thr Thr

1025 1030 1035

Asp Ile Thr Ala Ser Ala Met Arg Val His Thr Asp Gly Ser Leu

1040 1045 1050

Trp Trp Tyr Val Arg Ala Ser Met Ser Leu Ser Gly Tyr Met Pro

1055 1060 1065

Pro Leu Cys Asp Pro Lys Asp Gly His Leu Leu Met Asp Gly Gly

1070 1075 1080

Tyr Ile Asn Asn Leu Pro Ala Asp Val Ala Arg Ser Met Gly Ala

1085 1090 1095

Lys Val Val Ile Ala Ile Asp Val Gly Ser Arg Asp Glu Thr Asp

1100 1105 1110

Leu Thr Asn Tyr Gly Asp Ala Leu Ser Gly Trp Trp Leu Leu Trp

1115 1120 1125

Lys Arg Trp Asn Pro Leu Ala Thr Lys Val Lys Val Leu Asn Met

1130 1135 1140

Ala Glu Ile Gln Thr Arg Leu Ala Tyr Val Cys Cys Val Arg Gln

1145 1150 1155

Leu Glu Val Val Lys Ser Ser Asp Tyr Cys Glu Tyr Leu Arg Pro

1160 1165 1170

Pro Ile Asp Ser Tyr Ser Thr Leu Asp Phe Gly Lys Phe Asn Glu

1175 1180 1185

Ile Cys Glu Val Gly Tyr Gln His Gly Arg Thr Val Phe Asp Ile

1190 1195 1200

Trp Gly Arg Ser Gly Val Leu Glu Lys Met Leu Arg Asp Gln Gln

1205 1210 1215

Gly Pro Ser Lys Lys Pro Ala Ser Ala Val Leu Thr Cys Pro Asn

1220 1225 1230

Ala Ser Phe Thr Asp Leu Ala Glu Ile Val Ser Arg Ile Glu Pro

1235 1240 1245

Ala Lys Pro Ala Met Val Asp Asp Glu Ser Asp Tyr Gln Thr Glu

1250 1255 1260

Tyr Glu Glu Glu Leu Leu Asp Val Pro Arg Asp Ala Tyr Ala Asp

1265 1270 1275

Phe Gln Ser Thr Ser Ala Gln Gln Gly Ser Asp Leu Glu Asp Glu

1280 1285 1290

Ser Ser Leu Arg His Arg His Pro Ser Leu Ala Phe Pro Lys Leu

1295 1300 1305

Ser Glu Gly Ser Ser Asp Gln Asp Gly

1310 1315

<210> 69

<211> 982

<212> DNA

<213> Homo sapiens

<400> 69

acagcccacc agtgaccacg aaggctgtgc tgcttgccct gttgatggca ggcttggccc 60

tgcagccagg cactgccctg ctgtgctact cctgcaaagc ccaggtgagc aacgaggact 120

gcctgcaggt ggagaactgc accagctgg gggagcagtg ctggaccgcg cgcatccgcg 180

cagttggcct cctgaccgtc atcagcaaag gctgcagctt gaactgcgtg gatgactcac 240

aggactacta cgtgggcaag aagaacatca cgtgctgtga caccgacttg tgcaacgcca 300

gcggggccca tgccctgcag ccggctgctg ccatccttgc gctgctccct gcactcggcc 360

tgctgctctg gggacccggc cagctctagg ctctgggggg ccccgctgca gcccacactg 420

ggtgtggtgc cccaggcctc tgtgccactc ctcacacacc cggcccagtg ggagcctgtc 480

ctggttcctg aggcacatcc taacgcaagt ctgaccatgt atgtctgcgc ccctgtcccc 540

caccctgacc ctcccatggc cctctccagg actcccaccc ggcagatcgg ctctattgac 600

acagatccgc ctgcagatgg cctccaac cctctctgct gctgtttcca tggcccagca 660

ttctccaccc ttaaccctgt gctcaggcac ctcttccccc aggaagcctt ccctgcccac 720

cccatctatg acttgagcca ggtctggtcc gtggtgtccc ccgcacccag caggggacag 780

gcactcagga gggcccggta aaggctgaga tgaagtggac tgagtagaac tggaggacag 840

gagtcgacgt gagttcctgg gagtctccag agatggggcc tggaggcctg gaggaagggg 900

ccaggcctca cattcgtggg gctccctgaa tggcagcctc agcacagcgt aggcccttaa 960

taaacacctg ttggataagc ca 982

<210> 70

<211> 114

<212> PRT

<213> Homo sapiens

<400> 70

Met Ala Gly Leu Ala Leu Gln Pro Gly Thr Ala Leu Leu Cys Tyr Ser

1 5 10 15

Cys Lys Ala Gln Val Ser Asn Glu Asp Cys Leu Gln Val Glu Asn Cys

20 25 30

Thr Gln Leu Gly Glu Gln Cys Trp Thr Ala Arg Ile Arg Ala Val Gly

35 40 45

Leu Leu Thr Val Ile Ser Lys Gly Cys Ser Leu Asn Cys Val Asp Asp

50 55 60

Ser Gln Asp Tyr Tyr Val Gly Lys Lys Asn Ile Thr Cys Cys Asp Thr

65 70 75 80

Asp Leu Cys Asn Ala Ser Gly Ala His Ala Leu Gln Pro Ala Ala Ala

85 90 95

Ile Leu Ala Leu Leu Pro Ala Leu Gly Leu Leu Leu Trp Gly Pro Gly

100 105 110

Gln Leu

<210> 71

<211> 7273

<212> DNA

<213> Homo sapiens

<400> 71

aaccctgcct gaactttcct gtaaacagcc actgacagac tgcatccctg ctgggtggat 60

cctgcgactc ctagagggaa tggcacttct tgtttttaat tagcaaggtg aaaggtgaat 120

taaaactagc agtttggcaa gtcagtgcaa gaggctgact tctgagaggc ttccaggagc 180

ccgaagagag gacctccacg ggagaaggga gtgcgtgtgc tcggttttgt ttttttctct 240

cttttttttt tttttttctg aatgaacagc tttgcccaag tgactgaaaa atacagcttc 300

ttcctgaatc taccggcgta gttgctgaag agcgctctag acaggacatg gctctgaaga 360

ctcactcttt ggaatgtcct cttgctcccg gcttataaac aactgtcccg aggaaagaaa 420

ggttttacat agccaaatac agcctgacaa atggcacttc ggaactgtgc tttctgatga 480

caacgcgttc gatttctgac aaagcctctc gcacgctgcc cctggaggga agtcctaagt 540

aaaactcaga ccctccttaa agtgaggagc gagggcttgg acggtgaaca cggcagcatg 600

gcatccgcgg ggcacattat caccttgctc ctgtggggtt acttactgga gctttggaca 660

ggaggtcata cagctgatac tacccacccc cggttacgcc tgtcacataa agagctcttg 720

aatctgaaca gaacatcaat atttcatagc ccttttggat ttcttgatct ccatacaatg 780

ctgctggatg aatatcaaga gaggctcttc gtgggaggca gggaccttgt atattccctc 840

agcttggaga gaatcagtga cggctataaa gagatacact ggccgagtac agctctaaaa 900

atggaagaat gcataatgaa gggaaaagat gcgggtgaat gtgcaaatta tgttcgggtt 960

ttgcatcact ataacaggac acccttctg acctgtggta ctggagcttt tgatccagtt 1020

tgtgccttca tcagagttgg atatcatttg gaggatcctc tgtttcacct ggaatcaccc 1080

agatctgaga gaggaagggg cagatgtcct tttgacccca gctcctcctt catctccact 1140

ttaattggta gtgaattgtt tgctggactc tacagtgact actggagcag agacgctgcg 1200

atcttccgca gcatggggcg actggcccat atccgcactg agcatgacga tgagcgtctg 1260

ttgaaagaac caaaatttgt aggttcatac atgattcctg acaatgaaga cagagatgac 1320

aacaaagtat atttcttttt tactgagaag gcactggagg cagaaaacaa tgctcacgca 1380

atttacacca gggtcgggcg actctgtgtg aatgatgtag gaggcagag aatactggtg 1440

aataagtgga gcactttcct aaaagcgaga ctcgtttgct cagtaccagg aatgaatgga 1500

attgacacat attttgatga attagaggac gtttttttgc tacctaccag agatcataag 1560

aatccagtga tatttggact ctttaacact accagtaata tttttcgagg gcatgctata 1620

tgtgtctatc acatgtctag cattcgggca gccttcaacg gaccatatgc acataaggaa 1680

ggacctgaat accactggtc agtctatgaa ggaaaagtcc cttatccaag gcctggttct 1740

tgtgccagca aagtaaatgg agggatac ggaaccacca aggactatcc tgatgatgcc 1800

atccgatttg caagaagtca tccactaatg taccaggcca taaaacctgc ccataaaaaa 1860

ccaatattgg taaaaacaga tggaaaatat aacctgaaac aaatagcagt agatcgagtg 1920

gaagctgagg atggccaata tgacgtcttg tttattggga cagataatgg aattgtgctg 1980

aaagtaatca caatttacaa ccaagaaatg gaatcaatgg aagaagtaat tctagaagaa 2040

cttcagatat tcaaggatcc agttcctatt attctatgg agatttcttc aaagcggcaa 2100

cagctgtata ttggatctgc ttctgctgtg gctcaagtca gattccatca ctgtgacatg 2160

tatggaagtg cttgtgctga ctgctgcctg gctcgagacc cttactgtgc ctgggatggc 2220

atatcctgct cccggtatta cccaacaggc acacatgcaa aaaggcgttt ccggagacaa 2280

gatgttcgac atggaaatgc agctcagcag tgctttggac aacagtttgt tggggatgct 2340

ttggataaga ctgaagaaca tctggcttat ggcatagaga acaacagtac tttgctggaa 2400

tgtaccccac gatctttaca agcgaaagtt atctggtttg tacagaaagg acgtgagaca 2460

agaaaagagg aggtgaagac agatgacaga gtggttaaga tggaccttgg tttactcttc 2520

ctaaggttac acaaatcaga tgctgggacc tatttttgcc agacagtaga gcatagcttt 2580

gtccatacgg tccgtaaaat caccttggag gtagtggaag aggagaaagt cgaggatatg 2640

tttaacaagg acgatgagga ggacaggcat cacaggatgc cttgtcctgc tcagagtagc 2700

atctcgcagg gagcaaaacc atggtacaag gaattcttgc agctgatcgg ttatagcaac 2760

ttccagagag tggaagaata ctgcgagaaa gtatggtgca cagatagaaa gaggaaaaag 2820

cttaaaatgt caccctccaa gtggaagtat gccaaccctc aggaaaagaa gctccgttcc 2880

aaacctgagc attaccgcct gcccaggcac acgctggact cctgatgggg tgagactatc 2940

tactgtcttt tgaagaattt atatttggaa agtaaaaaag taaaaaaata aatcatccaa 3000

cttctttgca ttacttaaaa gagatttctg taatacagga atgactatga aggtgttata 3060

ataaattatt ctacatactc atttgactgg ataaacttta cataaaatta actaattttt 3120

taaataaatg cattgcttaa tggtttctca ttatgtttat caaaaaacaa ctgtagctgt 3180

tattttcagt acttggctgc ttttctgtga aaattattat tttacttttg gaagacaaga 3240

ttattagaat attgaagaaa aattggagac ttataatcat ggtaaatata aaactaaata 3300

tgttttaata tttctgaatt tttcttttcc atcacaatgt aagatatgca gaatacaaga 3360

tactttggca ttctcatgtg aactttctgt actctttaag gattatttta ttagtgttgt 3420

ttaagccatg agtgttaagt agcaggtgtg ttgtgagtgc tgtaacccat gaaaggaaaa 3480

atgtcattct gaggcttgtg cccttcgtaa aatattcatt aaagtacatt cacactattt 3540

ttgctttata acacagtctt taattttcac tcactgtgga aataaaaact aaggtaactt 3600

ctcagaaaga tatcaaatct cagaaagaat gtcaaatcag atgaagttat agttaggatt 3660

ctaactactg taaaagattt ttgcttccct cttgtggtaa aaaaaattat attctcacac 3720

atttcttttt tctctacaga cggatatctg tttaggaaag atttgaaagc agattatcag 3780

taggtacatg gatacatcaa gttcatttgc agaaacaaat aactgaaata aaaaacatgt 3840

taatccttgt atcatacttt aatatgaaag tattgtttat agataattta tctcacaagt 3900

caaaaatgaa gattttgcag cactgaaaat ctattaaagc tccaaatttt aagtttctaa 3960

ataatcttcg ctgaaatcta aaatatacta taacaaccgt gttttatttg tgaaaaaaat 4020

attaaagtga tttgctctca aatatcaaat tttcttctct cttttatatt aagagacaga 4080

aaattgtttc atgagttcac ttaactactg agatattcag agcattttta cctctctctt 4140

aaatgttata aaaaacaatt gtatttttaa gaatgtttat ttatcaaagt ctttccttct 4200

tctattaaat atttagcaat tacctttcta aaatatgaaa ttttgtaaga tgttttcacc 4260

taaataaaaa ttgaaagcaa gtggattaca caggagaacc attatgaaca tttatttaga 4320

tattaatctt aaacagtgtt tatttcagtt ttcaaagtta gcttataggt tatacattta 4380

agttaaagtg ctcataatca cttgcaattt cattgtaaaa tgaacaaata cataaatatt 4440

ttaagaaaaa tttaagttta ttcagataag tcaccatgct tcaaaagatc taagaaatgc 4500

aaatatactg aaaattgaca tcctctgaaa attccacttg ctatttaccc aagaatccac 4560

tggaggtcat tactgccatt aaataataac tgaaaagact atgtagtgaa atgtattttt 4620

aaaaactata ttcagtaaaa gcctgctcaa tttggagaaa tagaaccaca aacacagatc 4680

acaggggcct tacaaagttt atgtctgaac aaataagtca attaagtaca ctttattgaa 4740

aattgccttc cattaacaca caagaaagaa agcaggattt tctcctgtat ctgaatttta 4800

aaattaaaaa ggcagataag acataaatag ttatcatttt aattgcaata acacagacaa 4860

gtagttaatg atgataacaa tggtgtaact tgtaaactaa atatttggta actgaagcaa 4920

taggcagagg aaaatagctt ttctatgaca caagtcataa gaagtccata tactgaagag 4980

cgtttgatta aaataaagtg actattaacc agaaaagaaa cattttacat aaaatgctaa 5040

aatttattat aggaaaataa atcaaaccca aagaaagttt attcaatgct aatttgaaag 5100

aaaattgata agaaaacttt gagggcccaa gtccacaatt tggtgagacc actaaatttt 5160

acatataatt atacacacac atatgtacat atatatgtat atataatcttgc ttcccgcctg 5220

tttatggcag tactgaagag aaatgggaaa gaagagggag ggagagagaa agacgaaggg 5280

agagagaaag cagtttccaa ggatatgttt catgtcccac cattttctca gtttctccct 5340

ctctctccca acacacacacacacacaccc ctcacatact ataaataaa tcttcactgc 5400

cctatcaaaa tacaaataaa tcaatctatg ctgttctgtc cttcttgaga atctaaaaca 5460

taccacaaaa atacatcccc agtcttttgt tctgtctgag gttagaatta attcaaattc 5520

agaatctgtt gtgagaaatg cccaggcttt aaaaattaaa aatggatgga tcttctctga 5580

actcaggggag ggcacatact tagataccta caagacttgg aggaattaag agttcaccct 5640

tcatctcacc aaattttccc catttttctc tttcttgtag aaggagagaa accatgctct 5700

ctagcaacat tgagcaaaaa tcataaccac tcatctaatt tctaagaggc acctccatcg 5760

agggccggtc tcctgcttct ttagacctct tctatctttg ttacaggaga ggacctgtgg 5820

atagacttag ttttgacata aaacaatgcc cattcacctc ctccttcagc acaacgtcac 5880

ccattgggca agagatccag atttgttaac aaaaaagatt ttacttcgtg attccacgtc 5940

tataattcta tattgctaat tttttctttt gtgtgaatta ctgaatattt cagagcaaag 6000

ctatcaactt ggagaaacag ggattaaaaa taaggataaa cactaataag agctctagaa 6060

aaaagggaac agaaagtctg cctgtttagt aagtggcaat tccatacata ttttagagtt 6120

ttttctatct aaaattagtt aaatacttag aatgtttgta atgagtgttc gatatttgct 6180

ataggtttta gggttttgta aatcttcata gtaattataa acattgtaa aatttgtaaa 6240

atactataag tcattttgag tgttggtgtt aagcatgaaa caaacagcag ctgttgtcct 6300

taaaaatgaa ttgacctggc cgggcgcggt ggctcacgcc tgtaatccca gcactttggg 6360

aggccgaggc gggtggatca tgaggtcagg agatcgagac catcctggct aacaaggtga 6420

aaccccgtct ctactaaaaa tacaaaaaat tagccgggcg cggtggcggg cgcctgtagt 6480

cccagctact tgggaggctg aggcaggaga atggcgtgaa cccgggaagc ggagcttgca 6540

gtgagccgag attgcgccac tgcagtccgc agtccggcct gggcgacaga gcgagactcc 6600

gtctcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa tgaattgacc 6660

tgtgacacct gtagcctaat aaacatatta agaaaagtac ttagtattgt atagatattt 6720

ggattccaag agaaaatgca acatttataa taagaagtcc atactctttt tcttacagca 6780

gagcgtcaca ctgagttcca ttttaaaaaa ggactcattt ttcaggccaa caactgttgc 6840

atttgaatca gatataaata atagattttc cacaaacact cagctgattg tagcagtgtt 6900

atttaagctg gtatgtttat tttttttttc ttggaaggat agctttatat tttggctttc 6960

attataaatt gtgttctgct tgtgtttaaa tggcttactt ataagctaga gcactatatg 7020

ggagtgttct tctctgtatg gtatcctttt atttgcttgg ctgggttcat aacagtgtgt 7080

gccatattct ttcttttcac tgattctaag ccatgagact tattagcatc tggtggcaag 7140

ctgcagggac cattaacagt gtgtctcttt gactacaacg tggatctgcc actacgcgct 7200

atgtaccatt atgtacaatc tctatttggc tcaacttcga tgaaaaagaa ataaatattt 7260

gctaaactct caa 7273

<210> 72

<211> 775

<212> PRT

<213> Homo sapiens

<400> 72

Met Ala Ser Ala Gly His Ile Ile Thr Leu Leu Leu Trp Gly Tyr Leu

1 5 10 15

Leu Glu Leu Trp Thr Gly Gly His Thr Ala Asp Thr Thr Thr His Pro Arg

20 25 30

Leu Arg Leu Ser His Lys Glu Leu Leu Asn Leu Asn Arg Thr Ser Ile

35 40 45

Phe His Ser Pro Phe Gly Phe Leu Asp Leu His Thr Met Leu Leu Asp

50 55 60

Glu Tyr Gln Glu Arg Leu Phe Val Gly Gly Arg Asp Leu Val Tyr Ser

65 70 75 80

Leu Ser Leu Glu Arg Ile Ser Asp Gly Tyr Lys Glu Ile His Trp Pro

85 90 95

Ser Thr Ala Leu Lys Met Glu Glu Cys Ile Met Lys Gly Lys Asp Ala

100 105 110

Gly Glu Cys Ala Asn Tyr Val Arg Val Leu His His Tyr Asn Arg Thr

115 120 125

His Leu Leu Thr Cys Gly Thr Gly Ala Phe Asp Pro Val Cys Ala Phe

130 135 140

Ile Arg Val Gly Tyr His Leu Glu Asp Pro Leu Phe His Leu Glu Ser

145 150 155 160

Pro Arg Ser Glu Arg Gly Arg Gly Arg Cys Pro Phe Asp Pro Ser Ser

165 170 175

Ser Phe Ile Ser Thr Leu Ile Gly Ser Glu Leu Phe Ala Gly Leu Tyr

180 185 190

Ser Asp Tyr Trp Ser Arg Asp Ala Ala Ile Phe Arg Ser Met Gly Arg

195 200 205

Leu Ala His Ile Arg Thr Glu His Asp Asp Glu Arg Leu Leu Lys Glu

210 215 220

Pro Lys Phe Val Gly Ser Tyr Met Ile Pro Asp Asn Glu Asp Arg Asp

225 230 235 240

Asp Asn Lys Val Tyr Phe Phe Phe Thr Glu Lys Ala Leu Glu Ala Glu

245 250 255

Asn Asn Ala His Ala Ile Tyr Thr Arg Val Gly Arg Leu Cys Val Asn

260 265 270

Asp Val Gly Gly Gln Arg Ile Leu Val Asn Lys Trp Ser Thr Phe Leu

275 280 285

Lys Ala Arg Leu Val Cys Ser Val Pro Gly Met Asn Gly Ile Asp Thr

290 295 300

Tyr Phe Asp Glu Leu Glu Asp Val Phe Leu Leu Pro Thr Arg Asp His

305 310 315 320

Lys Asn Pro Val Ile Phe Gly Leu Phe Asn Thr Thr Ser Asn Ile Phe

325 330 335

Arg Gly His Ala Ile Cys Val Tyr His Met Ser Ser Ile Arg Ala Ala

340 345 350

Phe Asn Gly Pro Tyr Ala His Lys Glu Gly Pro Glu Tyr His Trp Ser

355 360 365

Val Tyr Glu Gly Lys Val Pro Tyr Pro Arg Pro Gly Ser Cys Ala Ser

370 375 380

Lys Val Asn Gly Gly Arg Tyr Gly Thr Thr Thr Lys Asp Tyr Pro Asp Asp

385 390 395 400

Ala Ile Arg Phe Ala Arg Ser His Pro Leu Met Tyr Gln Ala Ile Lys

405 410 415

Pro Ala His Lys Lys Pro Ile Leu Val Lys Thr Asp Gly Lys Tyr Asn

420 425 430

Leu Lys Gln Ile Ala Val Asp Arg Val Glu Ala Glu Asp Gly Gln Tyr

435 440 445

Asp Val Leu Phe Ile Gly Thr Asp Asn Gly Ile Val Leu Lys Val Ile

450 455 460

Thr Ile Tyr Asn Gln Glu Met Glu Ser Met Glu Glu Val Ile Leu Glu

465 470 475 480

Glu Leu Gln Ile Phe Lys Asp Pro Val Pro Ile Ile Ser Met Glu Ile

485 490 495

Ser Ser Lys Arg Gln Gln Leu Tyr Ile Gly Ser Ala Ser Ala Val Ala

500 505 510

Gln Val Arg Phe His His Cys Asp Met Tyr Gly Ser Ala Cys Ala Asp

515 520 525

Cys Cys Leu Ala Arg Asp Pro Tyr Cys Ala Trp Asp Gly Ile Ser Cys

530 535 540

Ser Arg Tyr Tyr Pro Thr Gly Thr His Ala Lys Arg Arg Phe Arg Arg

545 550 555 560

Gln Asp Val Arg His Gly Asn Ala Ala Gln Gln Cys Phe Gly Gln Gln

565 570 575

Phe Val Gly Asp Ala Leu Asp Lys Thr Glu Glu His Leu Ala Tyr Gly

580 585 590

Ile Glu Asn Asn Ser Thr Leu Leu Glu Cys Thr Pro Arg Ser Leu Gln

595 600 605

Ala Lys Val Ile Trp Phe Val Gln Lys Gly Arg Glu Thr Arg Lys Glu

610 615 620

Glu Val Lys Thr Asp Asp Arg Val Val Lys Met Asp Leu Gly Leu Leu

625 630 635 640

Phe Leu Arg Leu His Lys Ser Asp Ala Gly Thr Tyr Phe Cys Gln Thr

645 650 655

Val Glu His Ser Phe Val His Thr Val Arg Lys Ile Thr Leu Glu Val

660 665 670

Val Glu Glu Glu Lys Val Glu Asp Met Phe Asn Lys Asp Asp Glu Glu

675 680 685

Asp Arg His His Arg Met Pro Cys Pro Ala Gln Ser Ser Ile Ser Gln

690 695 700

Gly Ala Lys Pro Trp Tyr Lys Glu Phe Leu Gln Leu Ile Gly Tyr Ser

705 710 715 720

Asn Phe Gln Arg Val Glu Glu Tyr Cys Glu Lys Val Trp Cys Thr Asp

725 730 735

Arg Lys Arg Lys Lys Leu Lys Met Ser Pro Ser Lys Trp Lys Tyr Ala

740 745 750

Asn Pro Gln Glu Lys Lys Leu Arg Ser Lys Pro Glu His Tyr Arg Leu

755 760 765

Pro Arg His Thr Leu Asp Ser

770 775

<210> 73

<211> 15580

<212> DNA

<213> Homo sapiens

<400> 73

atgctactcc ctgccctcct ctttgggatg gcgtgggccc tggctgacgg gcggtggtgt 60

gagtggacag agaccatccg tgtggaggag gaagtggcac cccgtcagga ggacctggta 120

ccctgtgcca gcctcgacca ttacagccgc ctgggctggc ggctggacct gccctggagt 180

ggccgctcgg ggcttacccg gtccccagcg cctgggctct gtcctatcta caaacctcca 240

gaaacccggc ctgccaagtg gaaccggaca gtgaggactt gttgcccagg ctgggggggc 300

gcccactgca ctgaggccct tgccaaagcc agtcctgaag gccactgctt tgccatgtgg 360

cagtgccagc tacaggcagg ctcagctaat gcctcagcag gaagcctgga ggagtgctgc 420

gcccggccct ggggacaaag ctggtggggat ggcagctccc aggcctgccg cagctgctcc 480

agccgacacc tgccaggcag tgcctcttct ccagccctcc tgcagcccct ggcaggggct 540

gtgggccagc tctggagcca gcaccagcgt ccctcggcca cctgtgcctc ctggtcgggc 600

ttccactacc gcacctttga tggccgccac tatcacttcc tgggccgctg cacctacctg 660

ctggcgggtg ctgcggactc cacctgggct gtccacctaa cacccgggga ccgctgcccc 720

cagcctggac actgtcagcg ggtgactatg ggacccgagg aggtgctgat ccaggctgga 780

aatgtgtctg tgaaggggca gctggtacct gaagggcagt cttggctgct ccacgggctg 840

agcctgcaat ggctggggga ctggctggtg ctgtcaggag gcctgggggt cgtggtgcgg 900

ctggacagga ctggctccat ctccatctct gtggaccacg agctctgggg acagacacaa 960

ggcctctgtg ggctctacaa tggctggcca gaggatgact tcatggagcc aggcggaggg 1020

ctggccatgt tagcagccac ctttggaaat tcctggaggc tccctggctc ggagtctggg 1080

tgtctggatg cagtggaggt ggcccagggc tgtgaccccc tggggctcat agacgcagat 1140

gtagaacctg gccacctgcg ggctgaagcc caggacgtgt gccatcagct gctggaaggt 1200

ccattcgggc agtgccatgc ccaggtttcc cctgctgagt accacgaggc ctgtctcttt 1260

gcctactgcg caggggccat ggcaggcagt gggcaagagg ggcggcagca ggctgtttgt 1320

gccacctttg ccagctatgt ccaggcctgt gccaggcggc acatccacat tcgctggagg 1380

aagcctggct tctgcgagcg cctgtgcccc gggggccagc tctactccga ctgcgtctcc 1440

ctctgcccac ccagctgcga ggcggtgggt cagggagagg aggagtcctg cagggaagag 1500

tgtgtgagtg gctgtgagtg cccgcgaggc ctcttctgga atggcaccct ctgtgtgcct 1560

gctgcccact gcccctgcta ctactgccgc cagcgctatg tacccggtga caccgtgcgc 1620

cagctgtgta acccctgcgt gtgcagggat ggccgctggc actgtgccca ggcactgtgc 1680

cccgccgagt gtgcagtggg tggggacggg cactacctca ccttcgatgg gcggagctac 1740

tccttctggg gtggtcaagg ttgccgctac agcctggtgc aggactatgt gaagggacag 1800

ctactgatcc tactggagca tggggcctgc gacgctggga gctgcctgca cgccatctcc 1860

gtctccctgg aggacacca catccagctc agggactcag gagctgtgct ggtcaatggg 1920

caggatgtgg gcttgccctg gattggcgct gaggcctca gtgtgcgccg agcttcctct 1980

gcctttctgc tgctgcgctg gcctggggcc caggtgctct ggggactgtc tgaccctgta 2040

gcctacatca ccctggaccc ccgccatgcc caccaggtgc agggtctgtg tggcaccttc 2100

acccagaacc agcaggacga cttcctgaca ccagccggag atgtggaaac tagcattgct 2160

gcctttgcta gcaagttcca ggtggccggc aagggaagat gcccctctga ggacagtgcc 2220

ctgctgtctc cctgcaccac ccactcccag cgccacgcct tcgcagaggc ggcctgtgcc 2280

atcctgcaca gctctgtctt ccaggaatgc cacaggctgg tggacaaaga gccattctat 2340

ctgcgctgcc tggcagccgt gtgtggctgt gatcccggca gtgactgcct gtgcccggtg 2400

ctgtctgcct atgcgcgtcg ctgtgcccag gaaggtgcct cacctccctg gaggaaccag 2460

accctctgcc ctgttatgtg tcctggtggc caggagtacc gagagtgtgc cccagcatgc 2520

ggtcaacact gcgggaaacc agaggactgt ggagagctgg gcagctgtgt ggctggttgt 2580

aactgtcctc tggggctgct gtgggacct gagggccagt gtgtgccccc cagcttgtgc 2640

ccctgccagc tcggagcccg tcgctatgcc cctggcagtg ccaccatgaa ggagtgcaac 2700

cgctgcatct gccaggaaag gggcctctgg aattgcacgg ctcgccactg cccttcacag 2760

gcattctgcc ccagggagct tgtctatgcc cctggtgcct gtctcctcac ctgtgacagc 2820

cccagcgcca atcactcctg ccctgcaggc agtactgatg gctgtgtctg tccaccaggc 2880

acggtgctgc tggacgagcg ctgtgtgcct cctgacctct gtccctgccg tcacagtggg 2940

cagtggtacc tgcccaacgc caccatccag gaagactgca acgtttgcgt gtgccggggc 3000

cggcagtggc actgcacagg ccagcggcgc agtgggcggt gccaggcatc aggcgccccc 3060

cactatgtga catttgacgg actggccttc acctatcctg gggcctgcga gtatctgctg 3120

gtgcgagagg ccagtggcct attcacagtc tctgcccaga acctgccctg tggggccagc 3180

ggtctcacct gcaccaaagc gctggccgtg cgtctggagg gcactgttgt gcacatgctc 3240

agaggccggg cagtgacggt gaatggggtg agcgtgacgc cccccaaggt ctacacaggc 3300

cctgggctga gcctgcgtcg tgctggcctc ttcctgctgc tctcgaccca cctgggcctc 3360

accctgctct gggatggagg gactcgggtc ctggtgcaac tgtcccctca gttccgtggt 3420

cgcgtggctg ggctgtgtgg tgactttgat ggagatgcca gtaatgatct gcggagccgc 3480

cagggcgtcc tggagcccac agctgaactg gctgcccact cctggcgcct cagccccctc 3540

tgccctgagc caggagacct gccacacccc tgcacgatga acacacaccg ggctggttgg 3600

gctcgggccc gctgtggggc gctgctgcag ccgctcttca cattatgcca cgcggaggtc 3660

cccccgcagc agcactatga gtggtgcctg tatgacgcct gcggctgcga ctcggggggt 3720

gactgtgagt gcctctgctc ggccattgcc acctatgcag atgagtgtgc ccggcatggg 3780

caccacgtgc gctggcgtag ccaggagctc tgctccctgc agtgtgaagg gggacaggta 3840

tatgaggcct gtggccccac gtgtcccccc acctgccatg agcagcatcc tgagcccggg 3900

tggcactgcc aggtggtggc ctgtgtggag ggctgcttct gccccgaggg gactctgctg 3960

cacggaggag cctgcttgga gccagcttcc tgcccctgtg agtggggccg caactccttc 4020

ccgccggggt ctgtgctgca aaaggactgc gggactgca cgtgccagga aggtcaatgg 4080

cattgtgggg gtgacggtgg ccactgtgag gagcttgtgc ctgcctgtgc agagggag 4140

gccctgtgcc aagagaatgg gcactgtgtg ccccatgggt ggctttgtga caaccaggac 4200

gactgtggcg atggctctga tgaggagggt tgtgccgccc caggctgtgg ggaggggcag 4260

atgacttgca gctccggcca ctgcctgccc ctggccctgc tctgtgaccg ccaggatgac 4320

tgtggagatg gcacggatga gccgagctat ccgtgccccc aggggcttgct ggcctgtgcc 4380

gatggacgct gcctgccgcc ggccctgctc tgcgatgggc atcctgactg tctggatgcc 4440

gccgacgagg agtcctgtct ggggcaggtg acctgcgtcc ccggggaggt gtcctgtgtt 4500

gatggcacct gcctgggggc catccagctg tgtgacggag tctgggactg cccagatgga 4560

gccgatgagg ggccgggaca ctgcccccta ccttctctgc ccacacctcc tgccagcacc 4620

ttgcctggcc cctccccagg ctccctggac actgcgtcaa gtcccctggc cagcgccagc 4680

cctgcgccac cctgcggccc cttcgagttt cggtgcggca gcggcgagtg caccccgcgg 4740

ggctggcgct gcgaccagga ggaagactgc gccgacggca gcgacgagcg cggctgcgga 4800

gggccctgcg cgccgcacca cgcgccctgc gcccgcggcc ctcactgcgt gtcccccgag 4860

cagctgtgcg acggcgtgcg gcagtgtccc gacggctcgg acgagggccc cgacgcctgc 4920

gggggctgc cagccctggg aggccccaac aggacagggc ttccctgccc agaatacacc 4980

tgccccaatg gcacctgcat aggcttccag ctggtgtgtg atgggcagcc tgactgtgga 5040

aggccagggc aggtgggccc ctccccagaa gagcagggtt gtggggcctg gggcccctgg 5100

agcccatggg ggccctgcag ccggacgtgt gggccctggg gccagggccg gagccgccgc 5160

tgctccccac tcggcctcct ggtgctacag aactgcccag ggcctgagca ccagtctcag 5220

gcctgcttca cggcagcctg cccagtggac ggtgaatgga gcacctggtc ccctggtct 5280

gtgtgctctg agccgtgcag gggcaccatg acgcggcaac ggcagtgcca ctcaccccag 5340

aatgggggcc gcacctgtgc tgcactgccc ggaggcctgc acagcacccg ccagaccaag 5400

ccttgccctc aggacggctg ccccaatgcc acttgctctg gggagctgat gttccagccc 5460

tgtgccccct gcccactgac ctgtgatgac atctctggcc aggtcacgtg cccacctgat 5520

tggccctgcg gcagcccggg ctgctggtgc ccagaagggc aggtgctggg cagcgagggg 5580

tggtgtgtgt ggccccggca gtgcccctgc ctggtggacg gtgcccgcta ctggcctggg 5640

caacgcatca aggccgactg ccagctctgc atctgccaag acggacggcc ccgacgctgc 5700

cgactcaacc cggactgcgc tgtggactgt ggctggtcct cctggtcacc ctgggccaag 5760

tgcctgggcc cctgtggaag ccagagcatc cagtggtcct tccggagctc caacaacccc 5820

cgcccctccg gccgaggtcg ccagtgccgt ggcatccacc gcaaggcacg caggtgccag 5880

acggagccct gtgaggggtg tgagcatcag ggccaggtcc accgtgtcgg ggaacgctgg 5940

catgggggcc cctgcagggt gtgccagtgt ctgcacaacc tcaccgcaca ctgctcaccc 6000

tactgcccgc tcggcagctg cccccagggc tgggtcttgg tggaggggac gggagaatca 6060

tgctgccact gtgccctacc tggagagaac cagacggtcc agcccatggc cactcctgcc 6120

gcagctccgg ctcccagtcc ccagatcaga ttccctttgg ccacttacat tctgcctccg 6180

tcaggagacc cctgctattc tcccctgggg ctggccggac tggctgaggg gagtctgcat 6240

gcatcgtccc agcagctgga accaccccacc caggctgccc tcctgggggc tcccacccag 6300

gggcccagcc ctcagggatg gcacgctgga ggggatgctt atgccaagtg gcacactcgg 6360

ccccattacc tgcagctgga cctgcttcag cctcggaacc tcactggcat cctagtgccg 6420

gagactggct cctccaacgc atatgccagc agcttctcac tccagttcag cagcaatggt 6480

ctacactggc atgactatcg tgacctcctg cctggcatct tgcccctgcc caagcttttc 6540

cccagaaact gggatgacct ggaccctgcc gtatggactt tcggccgcat ggtgcaggcg 6600

aggtttgtca gggtgtggcc ccacgatgtc caccacagcg atgtccccct gcaggtggag 6660

ctgctgggct gcgagccagg gtccccaccg gcacctctgt gcccaggggt tggactccgc 6720

tgtgccagtg gtgagtgtgt cctgagaggg ggcccttgtg acggtgttct ggactgcgag 6780

gatggctcgg atgaggaggg ctgtgtgttg ctgcctgagg gcactggcag attccattcc 6840

acagccaaga ccctggccct ctcctctgcc cagccggggc agctgctgca ctggcccagg 6900

gagggcctgg cagagactga gcactggccc cctgggcagg aatcccccac gtccccgaca 6960

gagacaaggc ccgtgagtcc tggcccagcc tccggggtgc ctcaccatgg ggaatctgtg 7020

cagatggtga ccaccacccc cataccccag atggaggcca ggaccctgcc accaggtatg 7080

gcagctgtga cggtggtgcc cccacaccct gtgactccag cgacccctgc tggccagagc 7140

gtcgccccag gacccttccc acctgtgcag tgtggccccg gccagacgcc ctgtgaggtg 7200

ctgggctgcg tggaacaggc gcaggtgtgt gatggcaggg aggattgcct cgacggctcc 7260

gacgagaggc actgcgccag gaatctactt atgtggctcc cttctctccc tgccttgtgg 7320

gcagcgagca ctgtgccctt catgatgcct accatggccc tgcctgggct tccagcctca 7380

agggccctct gttccccgag ccagctgagc tgtggcagcg gggagtgtct gtctgctgag 7440

cggcgctgtg acctgcggcc tgactgccag gatggctcgg acgaggatgg ctgtgtggac 7500

tgcgtgctgg ccccctggtc tgtctggagc agctgcagcc gcagctgtgg cctgggcctc 7560

accttccagc gccaggagct gctgcggcct cctctgccag ggggcagctg cccgcgtgac 7620

cggttccgaa gccagtcctg ctttgtgcag gcctgcccag tggctggggc atgggccatg 7680

tgggaggcct ggggaccctg cagcgtctcc tgcgggggtg gccatcagag tcgccagaga 7740

agctgtgtgg acccccccacc caagaatggc ggtgccccct gccccggggc ctcccaagag 7800

agggcaccct gcggcttgca gccctgctca ggtggcacag actgcgagct gggccgtgtg 7860

tatgtgagtg ccgatctgtg ccagaagggg ctggtgcccc catgcccacc ctcctgcctg 7920

gatcccaagg ccaacagaag ctgcagtggg cattgtgtgg aaggatgccg ctgtcccccg 7980

gggctccttc tgcatgacac tcgctgcctg cccctctctg agtgcccctg cctggtgggc 8040

gaagagctga agtggccagg ggtgtccttc ctcctgggca actgcagcca atgcgtgtgt 8100

gagaaggggg agttgctgtg ccaaccaggg ggctgccccc tgccctgcgg ctggtcagcc 8160

tggtcctcct gggctccctg cgaccgctcc tgtggctctg gagtgagggc caggttcagg 8220

tctccctcca accctccggc agcctggggg ggtgccccgt gtgaaggtga ccggcaggaa 8280

ctgcagggct gccacacagt gtgtgggaca gaggtgttcg gctggacgcc ctggacttcc 8340

tggtcctcct gctcccaaag ctgccttgcc ccgggagggg gccctggctg gcgcagtcgt 8400

tcccgactct gccccagccc tggggattca tcctgcccag gagatgccac ccaggaggag 8460

ccctgcagcc cccctgtatg cccagtgcca agcatctggg gtctgtgggc tccctggtcc 8520

acttgctcag ccccctgtga tggaggcatc cagacacgtg ggcgcagctg ctccagcttg 8580

gctccagggg acaccacgtg cccaggaccc cacagtcaga ccagggactg caacacgcag 8640

ccctgcacag cccagtgccc agagaacatg ttgttccgct cagcagagca gtgtcaccag 8700

gaggggggtc cttgccctcg gctatgcctg acgcagggcc ccgggataga gtgtacgggc 8760

ttctgcgccc ccggctgcac ctgcccccct ggtcttttcc tgcacaatgc tagctgcctg 8820

ccccgcagcc agtgcccctg ccagctgcac gggcagctct atgcatcagg agcaatggct 8880

cgcctggact cctgcaacaa ctgcacctgt gtctctggta agatggcatg cacctcggag 8940

cgctgcccag tggcctgtgg ctggagtccc tggaccctgt ggagtctctg tagctgcagc 9000

tgcaacgtgg gcattcggcg ccgcttccgg gcaggcactg cacccccagc tgcctttggg 9060

ggtgctgagt gccaaggccc caccatggag gctgaattct gcagcctgcg gccatgtcca 9120

ggtcctggtg gggagtgggg cccttggtct ccgtgctccg tgccctgtgg tggtggctac 9180

aggaaccgca cccgaggcag cagccgcagc ctcatggagt tttccacctg tggcctgcag 9240

ccctgcgcag ggccagtgcc tggcatgtgt cccagggaca agcagtggct ggactgtgcc 9300

cagggccctg cctcttgtgc agagctcagc gccccaagag ggactaacca gacctgccac 9360

cctggctgcc actgcccctc tgggatgctt ctgctgaaca acgtgtgtgt gcccacccag 9420

gactgcccct gtgcccacga ggggcacctc taccccccgg gcagcactgt ggttcgtcca 9480

tgtgaaaact gctcctgtgt ctccgggctc atcgccaact gcagctcctg gccttgtgcg 9540

gagggtgagc ccacgtggtc accctggacc ccttggagcc agtgttcagc ctcctgtggc 9600

cctgcccggt gccatcggca ccggttctgt gccaggtccc ccagtgcagt gccatccacc 9660

gtggctccgc tgcccctgcc agccaccccc acaccctctct gctcaggccc cgaggctgaa 9720

gaggagccat gtctcctgca ggggtgtgat cgagctgggg gatggggtcc atgggggccc 9780

tggtcccact gtagccggag ctgtggggga ggcctgcgga gccggacccg ggcctgtgac 9840

cagcccccac cccagggcct gggggattac tgcgaggggc cacgggcaca gggggaggtc 9900

tgccaggctc tgccctgccc agtgaccaac tgcactgcca ttgaaggggc cgagtatagc 9960

ccctgtggcc ctccgtgccc tcgctcctgt gatgacctag tgcactgcgt gtggcgctgc 10020

cagcctggct gctactgccc accaggccag gtactgagtt ccaacggggc catctgcgtg 10080

cagccgggtc actgcagctg cctggacctg ctgaccgggc agcggcacca tccgggtgct 10140

cggctggcaa ggcctgacgg ctgcaaccac tgcacctgcc tggaggggag gctgaactgc 10200

acagacctgc cctgcccagt gcccggaggc tggtgcccgt ggtcggagtg gacaatgtgc 10260

tcccagccct gcaggggcca gaccaggagc cgctccaggg cctgtgcctg ccccactcct 10320

cagcacggtg gtgccccgtg cactggagag gctggggagg caggggccca gcatcagagg 10380

gaggcctgcc ccagctacgc cacgtgccca gtggacggag cctggggccc atgggggcca 10440

tggtctccct gcgacatgtg cttggggcag tcccaccgga gccgggcgtg cagccggccc 10500

cccacccctg agggaggggag gccctgcct gggaaccaca cgcagagtcg cccttgccag 10560

gaaaattcca cccagtgcac agactgcggg ggtggccaga gtctgcatcc ctgtgggcag 10620

ccctgccccc gctcctgcca ggacctgtcc cctgggagtg tgtgccagcc aggctctgtg 10680

ggctgccagc ccacttgtgg gtgccccctg ggccagctct cccaggacgg gctgtgcgtg 10740

cccccagccc actgccgctg ccagtaccag cctggagcca tggggatccc tgagaaccag 10800

agccgctcag cagggtctag gtttagctcc tggggagagcc tggaacccgg agaggtggtc 10860

actgggccat gtgacaactg cacctgtgtg gcaggcattc tgcaatgcca ggaggtgcct 10920

gactgcccgg accctggggt gtggagctct tggggccctt gggaagactg cagtgtttcg 10980

tgtgggggcg gggagcagct gcgctcccgg cgctgtgctc gtcctccctg cccagggcct 11040

gcccgccaga gccgcacatg cagcacacag gtctgcagag aggcaggctg cccggctggc 11100

cgcctgtacc gtgaatgcca gcccggcgag ggatgcccct tctcctgcgc ccacgtcacg 11160

cagcaggtgg gctgcttctc tgagggctgc gaggagggct gccactgccc cgagggcacc 11220

ttccagcacc gcctggcctg tgtgcaggag tgcccttgtg tgctgacagc ctggctgctg 11280

caggagctgg gagccaccat aggtgaccct ggtcagcccc tcgggcctgg agatgagctg 11340

gactcaggcc agacacttcg tacaagctgt ggcaactgct cgtgtgcaca cgggaagctg 11400

tcttgctccc tggacgactg cttcgaggcc gatggtggtt tcggtccctg gagcccgtgg 11460

ggcccgtgct cccgctcctg tggagggctg ggcacccgta cccgcagccg ccagtgtgtg 11520

ctcaccatgc ccaccctcag tggtcagggc tgccgtgggc cccgccagga cctcgagtgc 11580

cccagcccag actgccctgg ggctgaaggg tccacggtgg agccagtaac aggccttcca 11640

ggtggctggg gcccatggtc ctcctggtcc ccctgctcca gaagctgcac ggaccccgct 11700

cgccctgcat ggcgcagccg cacccgcctc tgcctggcta actgcaccat gggggaccca 11760

ttacaggagc gcccctgcaa cctgccctca tgcacagagc tgcccgtgtg ccctggccct 11820

ggctgtgggg ctgggaactg ttcctggacc tcctgggccc cgtggggaacc ttgctcccgc 11880

agctgcggag tgggccagca gcgccgcctg cgggcatacc gtccccctgg gcccggcggg 11940

cactggtgcc ccaacatcct tactgcctac caagagcgcc gcttctgcaa cctgcgagcc 12000

tgcccagtgc ccgggggctg gtcacgctgg agtccctggt cctggtgtga ccgcagctgt 12060

gggggaggcc aatccctgag aagccgcagc tgctcaagcc ccccatccaa gaacggggga 12120

gccccctgtg ctggggagcg gcaccaggcc cgcctctgca atcccatgcc ttgtgaggcc 12180

ggctgcccag caggcatgga ggtggtcacc tgtgccaacc gctgcccccg ccgctgctca 12240

gacctccagg agggaattgt gtgtcaggac gaccaggtct gccagaaggg ctgccgctgc 12300

ccaaaggggt ccctggagca ggatggtggc tgcgtgccaa ttgggcactg tgactgcacc 12360

gatgcccagg gccacagctg ggccccgggg agccagcacc aggatgcctg caacaactgc 12420

tcatgccaag ctgggcagct ctcctgcacg gctcagccct gcccgcctcc cacccactgt 12480

gcctggagcc actggtcggc ctggagtccc tgcagccact catgcgggcc cagagggcag 12540

cagagccgct tccggtcctc cacgtcgggc tcgtgggccc cagagtgtcg ggaggagcag 12600

tcccagcc agccctgccc tcagccctcg tgcccacccc tgtgcctgca gggcactcgc 12660

tcccgcaccc tgggggacag ctggctgcag ggggagtgcc agcggtgctc ctgcaccccg 12720

gagggtgtga tctgcgaaga tacggagtgt gcagtgcctg aggcttggac gctgtggtcc 12780

tcctggtccg actgccctgt ctcctgtgga ggtggaaacc aggtccgaac ccgggcctgc 12840

agggccgcag cccctcacca caggagccca ccctgcctgg gccctgacac ccagaccagg 12900

cagcagcctt gcccagggct gctggaggcc tgctcctggg gcccgtgggg gccctgttcc 12960

cgcagctgcg gcccgggcct ggcctctcgc tctgggtcct gcccctgcct gatggccaag 13020

gccgacccca cctgcaacag caccttcctc cacctggaca cccagggctg ctactcaggg 13080

ccctgcccag aggagtgtgt gtggagcagc tggagcagct ggacgcgctg ctcttgccgg 13140

gtgctggtgc agcagcgcta ccgacaccag ggcccggcgt cccgaggggc cagggcaggc 13200

gccccctgca cgcggctgga tggccacttc cggccttgcc ttatcagcaa ctgctctgag 13260

gacagctgca cgcctccctt tgagttccat gcctgcggct ccccctgtgc tgggctctgt 13320

gccacacacc tgagccatca gctctgccag gacctgccac cctgccagcc gggctgctac 13380

tgccccaagg ggctgctgga gcaggctggg ggctgcattc ccccagagga gtgtaactgc 13440

tggcatacct cagcagcagg agccgggatg accctggccc ctggggaccg cctgcagctg 13500

ggctgtaagg agtgtgaatg ccggcgtggg gagctgcact gcaccagcca gggctgtcaa 13560

ggtcttctgc ctctgagtga gtggtccgag tggtcgccct gtgggccctg cctgccgccc 13620

agcgccctgg cccctgcctc caggactgcc ctagaggagc actggctccg agacccaact 13680

ggcctctccc ccaccttggc cccgctgctg gcttcagagc agcaccgcca ccggctctgt 13740

ctggatcctg cgacaggggag gccctggact ggagcccctc acctctgcac cgcacccctc 13800

agccagcagc gcctctgccc tgaccctgga gcctgccctg actcatgcca gtggagtctg 13860

tgggggccat ggagcccctg ccaggtgccc tgcagtgggg ggttcaggct acgctggaga 13920

gaggcagagg ccctctgtgg aggaggctgc cgggagccat gggctcaaga aagctgcaac 13980

ggagggccct gcccagagtg cgaggcccaa gacactgtat tcaccctgga ctgtgccaac 14040

cagtgcccac acagctgtgc cgacctctgg gaccgcgttc agtgtctgca gggaccctgc 14100

cgcccaggct gccgctgtcc ccctggccag ctggtccagg atgggcgctg tgtgccgatc 14160

tcctcttgcc gctgtggcct ccccagtgcc aatgcctctt gggagctggc cccggcccag 14220

gcggtgcagc tggactgcca aaactgcacc tgtgtcaacg agtccctggt gtgcccacac 14280

caggagtgtc cagtccttgg gccttggtca gcctggagca gttgctcggc cccctgtggt 14340

gggggcacta tggagcgaca tcggacttgt gaggggggtc ctggggtggc accatgccag 14400

gcccaggaca cagagcaacg gcaggagtgt aacctgcagc cctgccctga gtgcccccct 14460

ggccaggtgc ttagtgcctg tgccacctca tgcccgtgcc tctgctggca tctgcagcct 14520

ggtgccatct gtgtgcagga gccctgccag cctggctgtg gctgccctgg agggcagctg 14580

ctgcacaatg gcacgtgtgt gcctcccact gcctgcccct gcacccagca ttctctgccc 14640

tggggcctca ccctgaccct ggaagagcag gcccaggagc tgcccccagg gactgtgctc 14700

acccggaact gcacccgctg tgtctgccac ggtggagcct tcagctgctc cctcgttgac 14760

tgtcaggtgc cccctgggga aacgtggcag caggtggccc cgggggagct ggggctctgc 14820

gagcagacgt gcctggagat gaacgccaca aagacccaga gtaactgcag ttcagctcga 14880

gcctcgggct gcgtgtgcca gcccgggcac ttccgcagcc aggcaggccc ctgcgtcccc 14940

gaagaccact gcgagtgctg gcaccttggg cgtccccacc tgcctggatc tgaatggcag 15000

gaggcctgtg agagctgcct ctgcctcagt gggaggcctg tctgcaccca gcactgctcc 15060

ccactcacct gtgctcaggg cgaggagatg gtgctggagc cagggagctg ctgtccctct 15120

tgccgcaggg aggctccgga ggagcagtcg ccctcctgcc agctcctcac ggagcttcga 15180

aacttcacca aagggacctg ttacctggac caggtagaag tgagctactg cagtgggtac 15240

tgcccatcca gcacccatgt catgccagag gagccatacc tgcagagcca gtgtgactgc 15300

tgcagctacc gtctagaccc ggagagccct gtgcggatcc tgaacctgcg ctgtctgggt 15360

ggccacacag agcccgtggt gctgccggtc atccacagct gccagtgcag ctcctgccag 15420

ggtggggact tctcaaagcg ctaacaggct ccgctgggtg agtccacagc tgtccctctt 15480

gtgatcatgg gactcagcag cactgaccac gtccttccac gctctctcac ctgcccccaa 15540

ctgggggccc atgacttggc attagcatgt tccaaataaa 15580

<210> 74

<211> 5150

<212> PRT

<213> Homo sapiens

<400> 74

Met Leu Leu Pro Ala Leu Leu Phe Gly Met Ala Trp Ala Leu Ala Asp

1 5 10 15

Gly Arg Trp Cys Glu Trp Thr Glu Thr Ile Arg Val Glu Glu Glu Val

20 25 30

Ala Pro Arg Gln Glu Asp Leu Val Pro Cys Ala Ser Leu Asp His Tyr

35 40 45

Ser Arg Leu Gly Trp Arg Leu Asp Leu Pro Trp Ser Gly Arg Ser Gly

50 55 60

Leu Thr Arg Ser Pro Ala Pro Gly Leu Cys Pro Ile Tyr Lys Pro Pro

65 70 75 80

Glu Thr Arg Pro Ala Lys Trp Asn Arg Thr Val Arg Thr Cys Cys Pro

85 90 95

Gly Trp Gly Gly Ala His Cys Thr Glu Ala Leu Ala Lys Ala Ser Pro

100 105 110

Glu Gly His Cys Phe Ala Met Trp Gln Cys Gln Leu Gln Ala Gly Ser

115 120 125

Ala Asn Ala Ser Ala Gly Ser Leu Glu Glu Cys Cys Ala Arg Pro Trp

130 135 140

Gly Gln Ser Trp Trp Asp Gly Ser Ser Gln Ala Cys Arg Ser Cys Ser

145 150 155 160

Ser Arg His Leu Pro Gly Ser Ala Ser Ser Pro Ala Leu Leu Gln Pro

165 170 175

Leu Ala Gly Ala Val Gly Gln Leu Trp Ser Gln His Gln Arg Pro Ser

180 185 190

Ala Thr Cys Ala Ser Trp Ser Gly Phe His Tyr Arg Thr Phe Asp Gly

195 200 205

Arg His Tyr His Phe Leu Gly Arg Cys Thr Tyr Leu Leu Ala Gly Ala

210 215 220

Ala Asp Ser Thr Trp Ala Val His Leu Thr Pro Gly Asp Arg Cys Pro

225 230 235 240

Gln Pro Gly His Cys Gln Arg Val Thr Met Gly Pro Glu Glu Val Leu

245 250 255

Ile Gln Ala Gly Asn Val Ser Val Lys Gly Gln Leu Val Pro Glu Gly

260 265 270

Gln Ser Trp Leu Leu His Gly Leu Ser Leu Gln Trp Leu Gly Asp Trp

275 280 285

Leu Val Leu Ser Gly Gly Leu Gly Val Val Val Arg Leu Asp Arg Thr

290 295 300

Gly Ser Ile Ser Ile Ser Val Asp His Glu Leu Trp Gly Gln Thr Gln

305 310 315 320

Gly Leu Cys Gly Leu Tyr Asn Gly Trp Pro Glu Asp Asp Phe Met Glu

325 330 335

Pro Gly Gly Gly Leu Ala Met Leu Ala Ala Thr Phe Gly Asn Ser Trp

340 345 350

Arg Leu Pro Gly Ser Glu Ser Gly Cys Leu Asp Ala Val Glu Val Ala

355 360 365

Gln Gly Cys Asp Ser Pro Leu Gly Leu Ile Asp Ala Asp Val Glu Pro

370 375 380

Gly His Leu Arg Ala Glu Ala Gln Asp Val Cys His Gln Leu Leu Glu

385 390 395 400

Gly Pro Phe Gly Gln Cys His Ala Gln Val Ser Pro Ala Glu Tyr His

405 410 415

Glu Ala Cys Leu Phe Ala Tyr Cys Ala Gly Ala Met Ala Gly Ser Gly

420 425 430

Gln Glu Gly Arg Gln Gln Ala Val Cys Ala Thr Phe Ala Ser Tyr Val

435 440 445

Gln Ala Cys Ala Arg Arg His Ile His Ile Arg Trp Arg Lys Pro Gly

450 455 460

Phe Cys Glu Arg Leu Cys Pro Gly Gly Gln Leu Tyr Ser Asp Cys Val

465 470 475 480

Ser Leu Cys Pro Pro Ser Cys Glu Ala Val Gly Gln Gly Glu Glu Glu

485 490 495

Ser Cys Arg Glu Glu Cys Val Ser Gly Cys Glu Cys Pro Arg Gly Leu

500 505 510

Phe Trp Asn Gly Thr Leu Cys Val Pro Ala Ala His Cys Pro Cys Tyr

515 520 525

Tyr Cys Arg Gln Arg Tyr Val Pro Gly Asp Thr Val Arg Gln Leu Cys

530 535 540

Asn Pro Cys Val Cys Arg Asp Gly Arg Trp His Cys Ala Gln Ala Leu

545 550 555 560

Cys Pro Ala Glu Cys Ala Val Gly Gly Asp Gly His Tyr Leu Thr Phe

565 570 575

Asp Gly Arg Ser Tyr Ser Phe Trp Gly Gly Gln Gly Cys Arg Tyr Ser

580 585 590

Leu Val Gln Asp Tyr Val Lys Gly Gln Leu Leu Ile Leu Leu Glu His

595 600 605

Gly Ala Cys Asp Ala Gly Ser Cys Leu His Ala Ile Ser Val Ser Leu

610 615 620

Glu Asp Thr His Ile Gln Leu Arg Asp Ser Gly Ala Val Leu Val Asn

625 630 635 640

Gly Gln Asp Val Gly Leu Pro Trp Ile Gly Ala Glu Gly Leu Ser Val

645 650 655

Arg Arg Ala Ser Ser Ala Phe Leu Leu Leu Arg Trp Pro Gly Ala Gln

660 665 670

Val Leu Trp Gly Leu Ser Asp Pro Val Ala Tyr Ile Thr Leu Asp Pro

675 680 685

Arg His Ala His Gln Val Gln Gly Leu Cys Gly Thr Phe Thr Gln Asn

690 695 700

Gln Gln Asp Asp Phe Leu Thr Pro Ala Gly Asp Val Glu Thr Ser Ile

705 710 715 720

Ala Ala Phe Ala Ser Lys Phe Gln Val Ala Gly Lys Gly Arg Cys Pro

725 730 735

Ser Glu Asp Ser Ala Leu Leu Ser Pro Cys Thr Thr Thr His Ser Gln Arg

740 745 750

His Ala Phe Ala Glu Ala Ala Cys Ala Ile Leu His Ser Ser Val Phe

755 760 765

Gln Glu Cys His Arg Leu Val Asp Lys Glu Pro Phe Tyr Leu Arg Cys

770 775 780

Leu Ala Ala Val Cys Gly Cys Asp Pro Gly Ser Asp Cys Leu Cys Pro

785 790 795 800

Val Leu Ser Ala Tyr Ala Arg Arg Cys Ala Gln Glu Gly Ala Ser Pro

805 810 815

Pro Trp Arg Asn Gln Thr Leu Cys Pro Val Met Cys Pro Gly Gly Gln

820 825 830

Glu Tyr Arg Glu Cys Ala Pro Ala Cys Gly Gln His Cys Gly Lys Pro

835 840 845

Glu Asp Cys Gly Glu Leu Gly Ser Cys Val Ala Gly Cys Asn Cys Pro

850 855 860

Leu Gly Leu Leu Trp Asp Pro Glu Gly Gln Cys Val Pro Pro Ser Leu

865 870 875 880

Cys Pro Cys Gln Leu Gly Ala Arg Arg Tyr Ala Pro Gly Ser Ala Thr

885 890 895

Met Lys Glu Cys Asn Arg Cys Ile Cys Gln Glu Arg Gly Leu Trp Asn

900 905 910

Cys Thr Ala Arg His Cys Pro Ser Gln Ala Phe Cys Pro Arg Glu Leu

915 920 925

Val Tyr Ala Pro Gly Ala Cys Leu Leu Thr Cys Asp Ser Pro Ser Ala

930 935 940

Asn His Ser Cys Pro Ala Gly Ser Thr Asp Gly Cys Val Cys Pro Pro

945 950 955 960

Gly Thr Val Leu Leu Asp Glu Arg Cys Val Pro Pro Asp Leu Cys Pro

965 970 975

Cys Arg His Ser Gly Gln Trp Tyr Leu Pro Asn Ala Thr Ile Gln Glu

980 985 990

Asp Cys Asn Val Cys Val Cys Arg Gly Arg Gln Trp His Cys Thr Gly

995 1000 1005

Gln Arg Arg Ser Gly Arg Cys Gln Ala Ser Gly Ala Pro His Tyr

1010 1015 1020

Val Thr Phe Asp Gly Leu Ala Phe Thr Tyr Pro Gly Ala Cys Glu

1025 1030 1035

Tyr Leu Leu Val Arg Glu Ala Ser Gly Leu Phe Thr Val Ser Ala

1040 1045 1050

Gln Asn Leu Pro Cys Gly Ala Ser Gly Leu Thr Cys Thr Lys Ala

1055 1060 1065

Leu Ala Val Arg Leu Glu Gly Thr Val Val His Met Leu Arg Gly

1070 1075 1080

Arg Ala Val Thr Val Asn Gly Val Ser Val Thr Pro Pro Lys Val

1085 1090 1095

Tyr Thr Gly Pro Gly Leu Ser Leu Arg Arg Ala Gly Leu Phe Leu

1100 1105 1110

Leu Leu Ser Thr His Leu Gly Leu Thr Leu Leu Trp Asp Gly Gly

1115 1120 1125

Thr Arg Val Leu Val Gln Leu Ser Pro Gln Phe Arg Gly Arg Val

1130 1135 1140

Ala Gly Leu Cys Gly Asp Phe Asp Gly Asp Ala Ser Asn Asp Leu

1145 1150 1155

Arg Ser Arg Gln Gly Val Leu Glu Pro Thr Ala Glu Leu Ala Ala

1160 1165 1170

His Ser Trp Arg Leu Ser Pro Leu Cys Pro Glu Pro Gly Asp Leu

1175 1180 1185

Pro His Pro Cys Thr Met Asn Thr His Arg Ala Gly Trp Ala Arg

1190 1195 1200

Ala Arg Cys Gly Ala Leu Leu Gln Pro Leu Phe Thr Leu Cys His

1205 1210 1215

Ala Glu Val Pro Pro Gln Gln His Tyr Glu Trp Cys Leu Tyr Asp

1220 1225 1230

Ala Cys Gly Cys Asp Ser Gly Gly Asp Cys Glu Cys Leu Cys Ser

1235 1240 1245

Ala Ile Ala Thr Tyr Ala Asp Glu Cys Ala Arg His Gly His

1250 1255 1260

Val Arg Trp Arg Ser Gln Glu Leu Cys Ser Leu Gln Cys Glu Gly

1265 1270 1275

Gly Gln Val Tyr Glu Ala Cys Gly Pro Thr Cys Pro Pro Thr Cys

1280 1285 1290

His Glu Gln His Pro Glu Pro Gly Trp His Cys Gln Val Val Ala

1295 1300 1305

Cys Val Glu Gly Cys Phe Cys Pro Glu Gly Thr Leu Leu His Gly

1310 1315 1320

Gly Ala Cys Leu Glu Pro Ala Ser Cys Pro Cys Glu Trp Gly Arg

1325 1330 1335

Asn Ser Phe Pro Pro Gly Ser Val Leu Gln Lys Asp Cys Gly Asn

1340 1345 1350

Cys Thr Cys Gln Glu Gly Gln Trp His Cys Gly Gly Asp Gly Gly

1355 1360 1365

His Cys Glu Glu Leu Val Pro Ala Cys Ala Glu Gly Glu Ala Leu

1370 1375 1380

Cys Gln Glu Asn Gly His Cys Val Pro His Gly Trp Leu Cys Asp

1385 1390 1395

Asn Gln Asp Asp Cys Gly Asp Gly Ser Asp Glu Glu Gly Cys Ala

1400 1405 1410

Ala Pro Gly Cys Gly Glu Gly Gln Met Thr Cys Ser Ser Gly His

1415 1420 1425

Cys Leu Pro Leu Ala Leu Leu Cys Asp Arg Gln Asp Asp Cys Gly

1430 1435 1440

Asp Gly Thr Asp Glu Pro Ser Tyr Pro Cys Pro Gln Gly Leu Leu

1445 1450 1455

Ala Cys Ala Asp Gly Arg Cys Leu Pro Pro Ala Leu Leu Cys Asp

1460 1465 1470

Gly His Pro Asp Cys Leu Asp Ala Ala Asp Glu Glu Ser Cys Leu

1475 1480 1485

Gly Gln Val Thr Cys Val Pro Gly Glu Val Ser Cys Val Asp Gly

1490 1495 1500

Thr Cys Leu Gly Ala Ile Gln Leu Cys Asp Gly Val Trp Asp Cys

1505 1510 1515

Pro Asp Gly Ala Asp Glu Gly Pro Gly His Cys Pro Leu Pro Ser

1520 1525 1530

Leu Pro Thr Pro Pro Ala Ser Thr Leu Pro Gly Pro Ser Pro Gly

1535 1540 1545

Ser Leu Asp Thr Ala Ser Ser Pro Leu Ala Ser Ala Ser Pro Ala

1550 1555 1560

Pro Pro Cys Gly Pro Phe Glu Phe Arg Cys Gly Ser Gly Glu Cys

1565 1570 1575

Thr Pro Arg Gly Trp Arg Cys Asp Gln Glu Glu Asp Cys Ala Asp

1580 1585 1590

Gly Ser Asp Glu Arg Gly Cys Gly Gly Pro Cys Ala Pro His His

1595 1600 1605

Ala Pro Cys Ala Arg Gly Pro His Cys Val Ser Pro Glu Gln Leu

1610 1615 1620

Cys Asp Gly Val Arg Gln Cys Pro Asp Gly Ser Asp Glu Gly Pro

1625 1630 1635

Asp Ala Cys Gly Gly Leu Pro Ala Leu Gly Gly Pro Asn Arg Thr

1640 1645 1650

Gly Leu Pro Cys Pro Glu Tyr Thr Cys Pro Asn Gly Thr Cys Ile

1655 1660 1665

Gly Phe Gln Leu Val Cys Asp Gly Gln Pro Asp Cys Gly Arg Pro

1670 1675 1680

Gly Gln Val Gly Pro Ser Pro Glu Glu Gln Gly Cys Gly Ala Trp

1685 1690 1695

Gly Pro Trp Ser Pro Trp Gly Pro Cys Ser Arg Thr Cys Gly Pro

1700 1705 1710

Trp Gly Gln Gly Arg Ser Arg Arg Cys Ser Pro Leu Gly Leu Leu

1715 1720 1725

Val Leu Gln Asn Cys Pro Gly Pro Glu His Gln Ser Gln Ala Cys

1730 1735 1740

Phe Thr Ala Ala Cys Pro Val Asp Gly Glu Trp Ser Thr Trp Ser

1745 1750 1755

Pro Trp Ser Val Cys Ser Glu Pro Cys Arg Gly Thr Met Thr Arg

1760 1765 1770

Gln Arg Gln Cys His Ser Pro Gln Asn Gly Gly Arg Thr Cys Ala

1775 1780 1785

Ala Leu Pro Gly Gly Leu His Ser Thr Arg Gln Thr Lys Pro Cys

1790 1795 1800

Pro Gln Asp Gly Cys Pro Asn Ala Thr Cys Ser Gly Glu Leu Met

1805 1810 1815

Phe Gln Pro Cys Ala Pro Cys Pro Leu Thr Cys Asp Asp Ile Ser

1820 1825 1830

Gly Gln Val Thr Cys Pro Pro Asp Trp Pro Cys Gly Ser Pro Gly

1835 1840 1845

Cys Trp Cys Pro Glu Gly Gln Val Leu Gly Ser Glu Gly Trp Cys

1850 1855 1860

Val Trp Pro Arg Gln Cys Pro Cys Leu Val Asp Gly Ala Arg Tyr

1865 1870 1875

Trp Pro Gly Gln Arg Ile Lys Ala Asp Cys Gln Leu Cys Ile Cys

1880 1885 1890

Gln Asp Gly Arg Pro Arg Arg Cys Arg Leu Asn Pro Asp Cys Ala

1895 1900 1905

Val Asp Cys Gly Trp Ser Ser Trp Ser Pro Trp Ala Lys Cys Leu

1910 1915 1920

Gly Pro Cys Gly Ser Gln Ser Ile Gln Trp Ser Phe Arg Ser Ser

1925 1930 1935

Asn Asn Pro Arg Pro Ser Gly Arg Gly Arg Gln Cys Arg Gly Ile

1940 1945 1950

His Arg Lys Ala Arg Arg Cys Gln Thr Glu Pro Cys Glu Gly Cys

1955 1960 1965

Glu His Gln Gly Gln Val His Arg Val Gly Glu Arg Trp His Gly

1970 1975 1980

Gly Pro Cys Arg Val Cys Gln Cys Leu His Asn Leu Thr Ala His

1985 1990 1995

Cys Ser Pro Tyr Cys Pro Leu Gly Ser Cys Pro Gln Gly Trp Val

2000 2005 2010

Leu Val Glu Gly Thr Gly Glu Ser Cys Cys His Cys Ala Leu Pro

2015 2020 2025

Gly Glu Asn Gln Thr Val Gln Pro Met Ala Thr Pro Ala Ala Ala

2030 2035 2040

Pro Ala Pro Ser Pro Gln Ile Arg Phe Pro Leu Ala Thr Tyr Ile

2045 2050 2055

Leu Pro Pro Ser Gly Asp Pro Cys Tyr Ser Pro Leu Gly Leu Ala

2060 2065 2070

Gly Leu Ala Glu Gly Ser Leu His Ala Ser Ser Gln Gln Leu Glu

2075 2080 2085

His Pro Thr Gln Ala Ala Leu Leu Gly Ala Pro Thr Gln Gly Pro

2090 2095 2100

Ser Pro Gln Gly Trp His Ala Gly Gly Asp Ala Tyr Ala Lys Trp

2105 2110 2115

His Thr Arg Pro His Tyr Leu Gln Leu Asp Leu Leu Gln Pro Arg

2120 2125 2130

Asn Leu Thr Gly Ile Leu Val Pro Glu Thr Gly Ser Ser Asn Ala

2135 2140 2145

Tyr Ala Ser Ser Phe Ser Leu Gln Phe Ser Ser Asn Gly Leu His

2150 2155 2160

Trp His Asp Tyr Arg Asp Leu Leu Pro Gly Ile Leu Pro Leu Pro

2165 2170 2175

Lys Leu Phe Pro Arg Asn Trp Asp Asp Leu Asp Pro Ala Val Trp

2180 2185 2190

Thr Phe Gly Arg Met Val Gln Ala Arg Phe Val Arg Val Trp Pro

2195 2200 2205

His Asp Val His His Ser Asp Val Pro Leu Gln Val Glu Leu Leu

2210 2215 2220

Gly Cys Glu Pro Gly Ser Pro Pro Ala Pro Leu Cys Pro Gly Val

2225 2230 2235

Gly Leu Arg Cys Ala Ser Gly Glu Cys Val Leu Arg Gly Gly Pro

2240 2245 2250

Cys Asp Gly Val Leu Asp Cys Glu Asp Gly Ser Asp Glu Glu Gly

2255 2260 2265

Cys Val Leu Leu Pro Glu Gly Thr Gly Arg Phe His Ser Thr Ala

2270 2275 2280

Lys Thr Leu Ala Leu Ser Ser Ala Gln Pro Gly Gln Leu Leu His

2285 2290 2295

Trp Pro Arg Glu Gly Leu Ala Glu Thr Glu His Trp Pro Pro Gly

2300 2305 2310

Gln Glu Ser Pro Thr Ser Pro Thr Glu Thr Arg Pro Val Ser Pro

2315 2320 2325

Gly Pro Ala Ser Gly Val Pro His His Gly Glu Ser Val Gln Met

2330 2335 2340

Val Thr Thr Thr Pro Ile Pro Gln Met Glu Ala Arg Thr Leu Pro

2345 2350 2355

Pro Gly Met Ala Ala Val Thr Val Val Pro Pro His Pro Val Thr

2360 2365 2370

Pro Ala Thr Pro Ala Gly Gln Ser Val Ala Pro Gly Pro Phe Pro

2375 2380 2385

Pro Val Gln Cys Gly Pro Gly Gln Thr Pro Cys Glu Val Leu Gly

2390 2395 2400

Cys Val Glu Gln Ala Gln Val Cys Asp Gly Arg Glu Asp Cys Leu

2405 2410 2415

Asp Gly Ser Asp Glu Arg His Cys Ala Arg Asn Leu Leu Met Trp

2420 2425 2430

Leu Pro Ser Leu Pro Ala Leu Trp Ala Ala Ser Thr Val Pro Phe

2435 2440 2445

Met Met Pro Thr Met Ala Leu Pro Gly Leu Pro Ala Ser Arg Ala

2450 2455 2460

Leu Cys Ser Pro Ser Gln Leu Ser Cys Gly Ser Gly Glu Cys Leu

2465 2470 2475

Ser Ala Glu Arg Arg Cys Asp Leu Arg Pro Asp Cys Gln Asp Gly

2480 2485 2490

Ser Asp Glu Asp Gly Cys Val Asp Cys Val Leu Ala Pro Trp Ser

2495 2500 2505

Val Trp Ser Ser Cys Ser Arg Ser Cys Gly Leu Gly Leu Thr Phe

2510 2515 2520

Gln Arg Gln Glu Leu Leu Arg Pro Pro Leu Pro Gly Gly Ser Cys

2525 2530 2535

Pro Arg Asp Arg Phe Arg Ser Gln Ser Cys Phe Val Gln Ala Cys

2540 2545 2550

Pro Val Ala Gly Ala Trp Ala Met Trp Glu Ala Trp Gly Pro Cys

2555 2560 2565

Ser Val Ser Cys Gly Gly Gly His Gln Ser Arg Gln Arg Ser Cys

2570 2575 2580

Val Asp Pro Pro Pro Lys Asn Gly Gly Ala Pro Cys Pro Gly Ala

2585 2590 2595

Ser Gln Glu Arg Ala Pro Cys Gly Leu Gln Pro Cys Ser Gly Gly

2600 2605 2610

Thr Asp Cys Glu Leu Gly Arg Val Tyr Val Ser Ala Asp Leu Cys

2615 2620 2625

Gln Lys Gly Leu Val Pro Pro Cys Pro Pro Ser Cys Leu Asp Pro

2630 2635 2640

Lys Ala Asn Arg Ser Cys Ser Gly His Cys Val Glu Gly Cys Arg

2645 2650 2655

Cys Pro Pro Gly Leu Leu Leu His Asp Thr Arg Cys Leu Pro Leu

2660 2665 2670

Ser Glu Cys Pro Cys Leu Val Gly Glu Glu Leu Lys Trp Pro Gly

2675 2680 2685

Val Ser Phe Leu Leu Gly Asn Cys Ser Gln Cys Val Cys Glu Lys

2690 2695 2700

Gly Glu Leu Leu Cys Gln Pro Gly Gly Cys Pro Leu Pro Cys Gly

2705 2710 2715

Trp Ser Ala Trp Ser Ser Trp Ala Pro Cys Asp Arg Ser Cys Gly

2720 2725 2730

Ser Gly Val Arg Ala Arg Phe Arg Ser Pro Ser Asn Pro Pro Ala

2735 2740 2745

Ala Trp Gly Gly Ala Pro Cys Glu Gly Asp Arg Gln Glu Leu Gln

2750 2755 2760

Gly Cys His Thr Val Cys Gly Thr Glu Val Phe Gly Trp Thr Pro

2765 2770 2775

Trp Thr Ser Trp Ser Ser Cys Ser Gln Ser Cys Leu Ala Pro Gly

2780 2785 2790

Gly Gly Pro Gly Trp Arg Ser Arg Ser Arg Leu Cys Pro Ser Pro

2795 2800 2805

Gly Asp Ser Ser Cys Pro Gly Asp Ala Thr Gln Glu Glu Pro Cys

2810 2815 2820

Ser Pro Pro Val Cys Pro Val Pro Ser Ile Trp Gly Leu Trp Ala

2825 2830 2835

Pro Trp Ser Thr Cys Ser Ala Pro Cys Asp Gly Gly Ile Gln Thr

2840 2845 2850

Arg Gly Arg Ser Cys Ser Ser Leu Ala Pro Gly Asp Thr Thr Cys

2855 2860 2865

Pro Gly Pro His Ser Gln Thr Arg Asp Cys Asn Thr Gln Pro Cys

2870 2875 2880

Thr Ala Gln Cys Pro Glu Asn Met Leu Phe Arg Ser Ala Glu Gln

2885 2890 2895

Cys His Gln Glu Gly Gly Pro Cys Pro Arg Leu Cys Leu Thr Gln

2900 2905 2910

Gly Pro Gly Ile Glu Cys Thr Gly Phe Cys Ala Pro Gly Cys Thr

2915 2920 2925

Cys Pro Pro Gly Leu Phe Leu His Asn Ala Ser Cys Leu Pro Arg

2930 2935 2940

Ser Gln Cys Pro Cys Gln Leu His Gly Gln Leu Tyr Ala Ser Gly

2945 2950 2955

Ala Met Ala Arg Leu Asp Ser Cys Asn Asn Cys Thr Cys Val Ser

2960 2965 2970

Gly Lys Met Ala Cys Thr Ser Glu Arg Cys Pro Val Ala Cys Gly

2975 2980 2985

Trp Ser Pro Trp Thr Leu Trp Ser Leu Cys Ser Cys Ser Cys Asn

2990 2995 3000

Val Gly Ile Arg Arg Arg Phe Arg Ala Gly Thr Ala Pro Pro Ala

3005 3010 3015

Ala Phe Gly Gly Ala Glu Cys Gln Gly Pro Thr Met Glu Ala Glu

3020 3025 3030

Phe Cys Ser Leu Arg Pro Cys Pro Gly Pro Gly Gly Glu Trp Gly

3035 3040 3045

Pro Trp Ser Pro Cys Ser Val Pro Cys Gly Gly Gly Tyr Arg Asn

3050 3055 3060

Arg Thr Arg Gly Ser Ser Arg Ser Leu Met Glu Phe Ser Thr Cys

3065 3070 3075

Gly Leu Gln Pro Cys Ala Gly Pro Val Pro Gly Met Cys Pro Arg

3080 3085 3090

Asp Lys Gln Trp Leu Asp Cys Ala Gln Gly Pro Ala Ser Cys Ala

3095 3100 3105

Glu Leu Ser Ala Pro Arg Gly Thr Asn Gln Thr Cys His Pro Gly

3110 3115 3120

Cys His Cys Pro Ser Gly Met Leu Leu Leu Asn Asn Val Cys Val

3125 3130 3135

Pro Thr Gln Asp Cys Pro Cys Ala His Glu Gly His Leu Tyr Pro

3140 3145 3150

Pro Gly Ser Thr Val Val Arg Pro Cys Glu Asn Cys Ser Cys Val

3155 3160 3165

Ser Gly Leu Ile Ala Asn Cys Ser Ser Ser Trp Pro Cys Ala Glu Gly

3170 3175 3180

Glu Pro Thr Trp Ser Pro Trp Thr Pro Trp Ser Gln Cys Ser Ala

3185 3190 3195

Ser Cys Gly Pro Ala Arg Cys His Arg His Arg Phe Cys Ala Arg

3200 3205 3210

Ser Pro Ser Ala Val Pro Ser Thr Val Ala Pro Leu Pro Leu Pro

3215 3220 3225

Ala Thr Pro Thr Pro Leu Cys Ser Gly Pro Glu Ala Glu Glu Glu

3230 3235 3240

Pro Cys Leu Leu Gln Gly Cys Asp Arg Ala Gly Gly Trp Gly Pro

3245 3250 3255

Trp Gly Pro Trp Ser His Cys Ser Arg Ser Cys Gly Gly Gly Leu

3260 3265 3270

Arg Ser Arg Thr Arg Ala Cys Asp Gln Pro Pro Pro Gln Gly Leu

3275 3280 3285

Gly Asp Tyr Cys Glu Gly Pro Arg Ala Gln Gly Glu Val Cys Gln

3290 3295 3300

Ala Leu Pro Cys Pro Val Thr Asn Cys Thr Ala Ile Glu Gly Ala

3305 3310 3315

Glu Tyr Ser Pro Cys Gly Pro Pro Cys Pro Arg Ser Cys Asp Asp

3320 3325 3330

Leu Val His Cys Val Trp Arg Cys Gln Pro Gly Cys Tyr Cys Pro

3335 3340 3345

Pro Gly Gln Val Leu Ser Ser Asn Gly Ala Ile Cys Val Gln Pro

3350 3355 3360

Gly His Cys Ser Cys Leu Asp Leu Leu Thr Gly Gln Arg His His

3365 3370 3375

Pro Gly Ala Arg Leu Ala Arg Pro Asp Gly Cys Asn His Cys Thr

3380 3385 3390

Cys Leu Glu Gly Arg Leu Asn Cys Thr Asp Leu Pro Cys Pro Val

3395 3400 3405

Pro Gly Gly Trp Cys Pro Trp Ser Glu Trp Thr Met Cys Ser Gln

3410 3415 3420

Pro Cys Arg Gly Gln Thr Arg Ser Arg Ser Arg Ala Cys Ala Cys

3425 3430 3435

Pro Thr Pro Gln His Gly Gly Ala Pro Cys Thr Gly Glu Ala Gly

3440 3445 3450

Glu Ala Gly Ala Gln His Gln Arg Glu Ala Cys Pro Ser Tyr Ala

3455 3460 3465

Thr Cys Pro Val Asp Gly Ala Trp Gly Pro Trp Gly Pro Trp Ser

3470 3475 3480

Pro Cys Asp Met Cys Leu Gly Gln Ser His Arg Ser Arg Ala Cys

3485 3490 3495

Ser Arg Pro Pro Thr Pro Glu Gly Gly Arg Pro Cys Pro Gly Asn

3500 3505 3510

His Thr Gln Ser Arg Pro Cys Gln Glu Asn Ser Thr Gln Cys Thr

3515 3520 3525

Asp Cys Gly Gly Gly Gln Ser Leu His Pro Cys Gly Gln Pro Cys

3530 3535 3540

Pro Arg Ser Cys Gln Asp Leu Ser Pro Gly Ser Val Cys Gln Pro

3545 3550 3555

Gly Ser Val Gly Cys Gln Pro Thr Cys Gly Cys Pro Leu Gly Gln

3560 3565 3570

Leu Ser Gln Asp Gly Leu Cys Val Pro Pro Ala His Cys Arg Cys

3575 3580 3585

Gln Tyr Gln Pro Gly Ala Met Gly Ile Pro Glu Asn Gln Ser Arg

3590 3595 3600

Ser Ala Gly Ser Arg Phe Ser Ser Trp Glu Ser Leu Glu Pro Gly

3605 3610 3615

Glu Val Val Thr Gly Pro Cys Asp Asn Cys Thr Cys Val Ala Gly

3620 3625 3630

Ile Leu Gln Cys Gln Glu Val Pro Asp Cys Pro Asp Pro Gly Val

3635 3640 3645

Trp Ser Ser Trp Gly Pro Trp Glu Asp Cys Ser Val Ser Cys Gly

3650 3655 3660

Gly Gly Glu Gln Leu Arg Ser Arg Arg Cys Ala Arg Pro Pro Cys

3665 3670 3675

Pro Gly Pro Ala Arg Gln Ser Arg Thr Cys Ser Thr Gln Val Cys

3680 3685 3690

Arg Glu Ala Gly Cys Pro Ala Gly Arg Leu Tyr Arg Glu Cys Gln

3695 3700 3705

Pro Gly Glu Gly Cys Pro Phe Ser Cys Ala His Val Thr Gln Gln

3710 3715 3720

Val Gly Cys Phe Ser Glu Gly Cys Glu Glu Gly Cys His Cys Pro

3725 3730 3735

Glu Gly Thr Phe Gln His Arg Leu Ala Cys Val Gln Glu Cys Pro

3740 3745 3750

Cys Val Leu Thr Ala Trp Leu Leu Gln Glu Leu Gly Ala Thr Ile

3755 3760 3765

Gly Asp Pro Gly Gln Pro Leu Gly Pro Gly Asp Glu Leu Asp Ser

3770 3775 3780

Gly Gln Thr Leu Arg Thr Ser Cys Gly Asn Cys Ser Cys Ala His

3785 3790 3795

Gly Lys Leu Ser Cys Ser Leu Asp Asp Cys Phe Glu Ala Asp Gly

3800 3805 3810

Gly Phe Gly Pro Trp Ser Pro Trp Gly Pro Cys Ser Arg Ser Cys

3815 3820 3825

Gly Gly Leu Gly Thr Arg Thr Arg Ser Arg Gln Cys Val Leu Thr

3830 3835 3840

Met Pro Thr Leu Ser Gly Gln Gly Cys Arg Gly Pro Arg Gln Asp

3845 3850 3855

Leu Glu Tyr Cys Pro Ser Pro Asp Cys Pro Gly Ala Glu Gly Ser

3860 3865 3870

Thr Val Glu Pro Val Thr Gly Leu Pro Gly Gly Trp Gly Pro Trp

3875 3880 3885

Ser Ser Trp Ser Pro Cys Ser Arg Ser Cys Thr Asp Pro Ala Arg

3890 3895 3900

Pro Ala Trp Arg Ser Arg Thr Arg Leu Cys Leu Ala Asn Cys Thr

3905 3910 3915

Met Gly Asp Pro Leu Gln Glu Arg Pro Cys Asn Leu Pro Ser Cys

3920 3925 3930

Thr Glu Leu Pro Val Cys Pro Gly Pro Gly Cys Gly Ala Gly Asn

3935 3940 3945

Cys Ser Trp Thr Ser Ser Trp Ala Pro Trp Glu Pro Cys Ser Arg Ser

3950 3955 3960

Cys Gly Val Gly Gln Gln Arg Arg Leu Arg Ala Tyr Arg Pro Pro

3965 3970 3975

Gly Pro Gly Gly His Trp Cys Pro Asn Ile Leu Thr Ala Tyr Gln

3980 3985 3990

Glu Arg Arg Phe Cys Asn Leu Arg Ala Cys Pro Val Pro Gly Gly

3995 4000 4005

Trp Ser Arg Trp Ser Pro Trp Ser Trp Cys Asp Arg Ser Cys Gly

4010 4015 4020

Gly Gly Gln Ser Leu Arg Ser Arg Ser Cys Ser Ser Pro Pro Ser

4025 4030 4035

Lys Asn Gly Gly Ala Pro Cys Ala Gly Glu Arg His Gln Ala Arg

4040 4045 4050

Leu Cys Asn Pro Met Pro Cys Glu Ala Gly Cys Pro Ala Gly Met

4055 4060 4065

Glu Val Val Thr Cys Ala Asn Arg Cys Pro Arg Arg Cys Ser Asp

4070 4075 4080

Leu Gln Glu Gly Ile Val Cys Gln Asp Asp Gln Val Cys Gln Lys

4085 4090 4095

Gly Cys Arg Cys Pro Lys Gly Ser Leu Glu Gln Asp Gly Gly Cys

4100 4105 4110

Val Pro Ile Gly His Cys Asp Cys Thr Asp Ala Gln Gly His Ser

4115 4120 4125

Trp Ala Pro Gly Ser Gln His Gln Asp Ala Cys Asn Asn Cys Ser

4130 4135 4140

Cys Gln Ala Gly Gln Leu Ser Cys Thr Ala Gln Pro Cys Pro Pro

4145 4150 4155

Pro Thr His Cys Ala Trp Ser His Trp Ser Ala Trp Ser Pro Cys

4160 4165 4170

Ser His Ser Cys Gly Pro Arg Gly Gln Gln Ser Arg Phe Arg Ser

4175 4180 4185

Ser Thr Ser Gly Ser Trp Ala Pro Glu Cys Arg Glu Glu Gln Ser

4190 4195 4200

Gln Ser Gln Pro Cys Pro Gln Pro Ser Cys Pro Pro Leu Cys Leu

4205 4210 4215

Gln Gly Thr Arg Ser Arg Thr Leu Gly Asp Ser Trp Leu Gln Gly

4220 4225 4230

Glu Cys Gln Arg Cys Ser Cys Thr Pro Glu Gly Val Ile Cys Glu

4235 4240 4245

Asp Thr Glu Cys Ala Val Pro Glu Ala Trp Thr Leu Trp Ser Ser

4250 4255 4260

Trp Ser Asp Cys Pro Val Ser Cys Gly Gly Gly Asn Gln Val Arg

4265 4270 4275

Thr Arg Ala Cys Arg Ala Ala Ala Pro His His Arg Ser Pro Pro

4280 4285 4290

Cys Leu Gly Pro Asp Thr Gln Thr Arg Gln Gln Pro Cys Pro Gly

4295 4300 4305

Leu Leu Glu Ala Cys Ser Trp Gly Pro Trp Gly Pro Cys Ser Arg

4310 4315 4320

Ser Cys Gly Pro Gly Leu Ala Ser Arg Ser Gly Ser Cys Pro Cys

4325 4330 4335

Leu Met Ala Lys Ala Asp Pro Thr Cys Asn Ser Thr Phe Leu His

4340 4345 4350

Leu Asp Thr Gln Gly Cys Tyr Ser Gly Pro Cys Pro Glu Glu Cys

4355 4360 4365

Val Trp Ser Ser Trp Ser Ser Trp Thr Arg Cys Ser Cys Arg Val

4370 4375 4380

Leu Val Gln Gln Arg Tyr Arg His Gln Gly Pro Ala Ser Arg Gly

4385 4390 4395

Ala Arg Ala Gly Ala Pro Cys Thr Arg Leu Asp Gly His Phe Arg

4400 4405 4410

Pro Cys Leu Ile Ser Asn Cys Ser Glu Asp Ser Cys Thr Pro Pro

4415 4420 4425

Phe Glu Phe His Ala Cys Gly Ser Pro Cys Ala Gly Leu Cys Ala

4430 4435 4440

Thr His Leu Ser His Gln Leu Cys Gln Asp Leu Pro Pro Cys Gln

4445 4450 4455

Pro Gly Cys Tyr Cys Pro Lys Gly Leu Leu Glu Gln Ala Gly Gly

4460 4465 4470

Cys Ile Pro Pro Glu Glu Cys Asn Cys Trp His Thr Ser Ala Ala

4475 4480 4485

Gly Ala Gly Met Thr Leu Ala Pro Gly Asp Arg Leu Gln Leu Gly

4490 4495 4500

Cys Lys Glu Cys Glu Cys Arg Arg Gly Glu Leu His Cys Thr Ser

4505 4510 4515

Gln Gly Cys Gln Gly Leu Leu Pro Leu Ser Glu Trp Ser Glu Trp

4520 4525 4530

Ser Pro Cys Gly Pro Cys Leu Pro Pro Ser Ala Leu Ala Pro Ala

4535 4540 4545

Ser Arg Thr Ala Leu Glu Glu His Trp Leu Arg Asp Pro Thr Gly

4550 4555 4560

Leu Ser Pro Thr Leu Ala Pro Leu Leu Ala Ser Glu Gln His Arg

4565 4570 4575

His Arg Leu Cys Leu Asp Pro Ala Thr Gly Arg Pro Trp Thr Gly

4580 4585 4590

Ala Pro His Leu Cys Thr Ala Pro Leu Ser Gln Gln Arg Leu Cys

4595 4600 4605

Pro Asp Pro Gly Ala Cys Pro Asp Ser Cys Gln Trp Ser Leu Trp

4610 4615 4620

Gly Pro Trp Ser Pro Cys Gln Val Pro Cys Ser Gly Gly Phe Arg

4625 4630 4635

Leu Arg Trp Arg Glu Ala Glu Ala Leu Cys Gly Gly Gly Cys Arg

4640 4645 4650

Glu Pro Trp Ala Gln Glu Ser Cys Asn Gly Gly Pro Cys Pro Glu

4655 4660 4665

Ser Cys Glu Ala Gln Asp Thr Val Phe Thr Leu Asp Cys Ala Asn

4670 4675 4680

Gln Cys Pro His Ser Cys Ala Asp Leu Trp Asp Arg Val Gln Cys

4685 4690 4695

Leu Gln Gly Pro Cys Arg Pro Gly Cys Arg Cys Pro Pro Gly Gln

4700 4705 4710

Leu Val Gln Asp Gly Arg Cys Val Pro Ile Ser Ser Cys Arg Cys

4715 4720 4725

Gly Leu Pro Ser Ala Asn Ala Ser Trp Glu Leu Ala Pro Ala Gln

4730 4735 4740

Ala Val Gln Leu Asp Cys Gln Asn Cys Thr Cys Val Asn Glu Ser

4745 4750 4755

Leu Val Cys Pro His Gln Glu Cys Pro Val Leu Gly Pro Trp Ser

4760 4765 4770

Ala Trp Ser Ser Cys Ser Ala Pro Cys Gly Gly Gly Thr Met Glu

4775 4780 4785

Arg His Arg Thr Cys Glu Gly Gly Pro Gly Val Ala Pro Cys Gln

4790 4795 4800

Ala Gln Asp Thr Glu Gln Arg Gln Glu Cys Asn Leu Gln Pro Cys

4805 4810 4815

Pro Glu Cys Pro Pro Gly Gln Val Leu Ser Ala Cys Ala Thr Ser

4820 4825 4830

Cys Pro Cys Leu Cys Trp His Leu Gln Pro Gly Ala Ile Cys Val

4835 4840 4845

Gln Glu Pro Cys Gln Pro Gly Cys Gly Cys Pro Gly Gly Gln Leu

4850 4855 4860

Leu His Asn Gly Thr Cys Val Pro Pro Thr Ala Cys Pro Cys Thr

4865 4870 4875

Gln His Ser Leu Pro Trp Gly Leu Thr Leu Thr Leu Glu Glu Gln

4880 4885 4890

Ala Gln Glu Leu Pro Pro Gly Thr Val Leu Thr Arg Asn Cys Thr

4895 4900 4905

Arg Cys Val Cys His Gly Gly Ala Phe Ser Cys Ser Leu Val Asp

4910 4915 4920

Cys Gln Val Pro Pro Gly Glu Thr Trp Gln Gln Val Ala Pro Gly

4925 4930 4935

Glu Leu Gly Leu Cys Glu Gln Thr Cys Leu Glu Met Asn Ala Thr

4940 4945 4950

Lys Thr Gln Ser Asn Cys Ser Ser Ala Arg Ala Ser Gly Cys Val

4955 4960 4965

Cys Gln Pro Gly His Phe Arg Ser Gln Ala Gly Pro Cys Val Pro

4970 4975 4980

Glu Asp His Cys Glu Cys Trp His Leu Gly Arg Pro His Leu Pro

4985 4990 4995

Gly Ser Glu Trp Gln Glu Ala Cys Glu Ser Cys Leu Cys Leu Ser

5000 5005 5010

Gly Arg Pro Val Cys Thr Gln His Cys Ser Pro Leu Thr Cys Ala

5015 5020 5025

Gln Gly Glu Glu Met Val Leu Glu Pro Gly Ser Cys Cys Pro Ser

5030 5035 5040

Cys Arg Arg Glu Ala Pro Glu Glu Gln Ser Pro Ser Cys Gln Leu

5045 5050 5055

Leu Thr Glu Leu Arg Asn Phe Thr Lys Gly Thr Cys Tyr Leu Asp

5060 5065 5070

Gln Val Glu Val Ser Tyr Cys Ser Gly Tyr Cys Pro Ser Ser Thr

5075 5080 5085

His Val Met Pro Glu Glu Pro Tyr Leu Gln Ser Gln Cys Asp Cys

5090 5095 5100

Cys Ser Tyr Arg Leu Asp Pro Glu Ser Pro Val Arg Ile Leu Asn

5105 5110 5115

Leu Arg Cys Leu Gly Gly His Thr Glu Pro Val Val Leu Pro Val

5120 5125 5130

Ile His Ser Cys Gln Cys Ser Ser Cys Gln Gly Gly Asp Phe Ser

5135 5140 5145

Lys Arg

5150

<210> 75

<211> 5651

<212> DNA

<213> Homo sapiens

<400> 75

ctggtgtggc tggctgcggc cagaatcgga gccccaaccg cgctgccgct cggaccttag 60

cctgtgcctg cagcccggag tcccctcctg ccctggaagg caaggagcca ggccacgggg 120

ccacagccgc gggggccacc acactggccc aaatatttcc tgcagagtca acctatttga 180

tttcttgaca agaccacaat ctgatcccaa agatgtgctc cacaaatcca ggcaaatggg 240

tcacctttga tgatgatcct gctgttcaat cttctcaaaa gtcaaagaat tttcctctgg 300

agaatcaagg tgtctgtaga ccaaatggac tgaagctgaa ccttcctggc ctcagggaat 360

ttcccagtgg atcttcctcc accagcagca ctcctctctc ctcccccatt gtagattttt 420

atttcagtcc aggacctcca agtaactctc ctctttctac acctaccaaa gacttcccag 480

gttttcctgg catccccaaa gcagggactc atgtgcttta tcctattcca gaatcatctt 540

cagacagccc actcgcaata tcaggaggag aatcttcctt actgcctacc agaccaacat 600

gtttatccca tgccttgtta cccagtgacc actcatgtac acatccaact cccaaagtag 660

gtcttccaga tgaagttaat cctcaacagg ctgaaagcct aggattccaa agtgatgatc 720

tcccccagtt tcagtatttt cgagaggact gtgctttttc aagtccattt tggaaagatg 780

aaggcagtga ttcccatttc acccttgacc caccaggaag caaaaagatg ttctcatcaa 840

gaaacaagga gatgcctatt gaccaaaaaa gcctaaataa gtgttcactc aactatatct 900

gtgagaagct tgaacatctc cagtcagctg agaaccaaga ctcacttaga agtttgtcta 960

tgcactgtct atgtgctgaa gaaaatgcct cttcctttgt cccccacaca ctcttcagga 1020

gtcagccaaa atccggatgg tctttcatgc tgagaattcc tgagaagaag aatatgatgt 1080

cttcccggca atggggacca attttctga aagttttgcc tggaggaatt ttgcagatgt 1140

attatgaaca gggattagaa aaaccattta aagagataca gcttgatcca tattgtaggc 1200

tttctgaacc caaggttgag aacttcagtg tagcaggaaa aatccacact gtgaagattg 1260

aacatgtgtc ttacacagaa aaaaggaaat accattctaa gacagaagta gttcatgaac 1320

ctgacataga gcagatgctg aagttggggt ccacatcgta ccatgacttc cttgactttc 1380

tgactactgt ggaggaggag ctgatgaagt tgccagctgt ttcaaaacca aaaaagaact 1440

acgaggagca agaaatttcc ttggaaattg tggacaactt ttggggtaaa gtcacaaaag 1500

aaggaaaatt tgttgaaagt gctgtgataa ctcaaattta ttgcctctgc tttgtgaatg 1560

ggaacctgga atgcttttta accttgaatg accttgagtt gccgaagcga gatgaatcct 1620

attatgagaa ggactcagaa aaaaagggga ttgatattct tgactaccat tttcataagt 1680

gtgtgaatgt acaagaattt gagcaatcaa gaatcattaa gtttgtacct ctggatgcct 1740

gccggtttga gctgatgcgt ttcaagactt tgtataatgg ggataatctt cccttttcct 1800

tgaagtctgt agtggttgtc cagggagcat acgtggaact tcaggctttt gtcaacatgg 1860

cctcattggc gcagaggtca tcctatgctg gttccttaag gtcctgtgac aatataagga 1920

tacactttcc tgtcccatcg cagtggatca aggccctttg gaccatgaac ctccagaggc 1980

agaagtctct gaaagctaaa atgaaccgcc gagcatgtct ggggagttta caggaacttg 2040

aatctgaacc tgtcattcaa gtcactgtgg ggtcagcaaa atatgagagt gcctaccagg 2100

cagtggtatg gaagatagat cggcttccag acaaaaattc aagtctagat catccccatt 2160

gtctgtcata caaattagag cttggatcag accaagaaat tccctctgat tggtatccat 2220

ttgctactgt tcagttttcc gtgcctgaca cctgtgcctc aaggacagag gtcaggtctc 2280

tgggagtgga gagtgatgtc cagccacaga aacatgttca gcagcgagct tgctacaaca 2340

tccaggttga aatagaaaag aagtggatta aaatcgatgg agaagaccca gataaaattg 2400

gtgactgcat aactcagtag gagtagcaag agtttatgat gacagcccac ttgtcaaata 2460

tgtaattcac cgaaaccaca ccaagtcctg ctactgtaga gtggaaatga cttctgaata 2520

gcggttttag gacaggtctg atggctgtgt ttagagaagt ttagacctaa aaccgaacaa 2580

tctgtatttt ttgcttttca tgtgtttttg tcctaggggt tcgatctaaa atgtttctat 2640

aattcgtgtg atgttttgct tcctattgaa actcaaaggc actgttactc gttgtgtgac 2700

cccgcagcca gtatgatttt tgattactca gtggctgact gttttgctct ctggattact 2760

gaggtgccgt cttcatttct tcccatctct tcttgctgct tagtgtctgt actagagggt 2820

aagggaatca aaggagacat aaaccaaaat agttaatttt ccctctttct tgcctctgaa 2880

atgtggctag gtgtagaatg atgttgaaac cacaggctaa aatgtagatc tggaagtatc 2940

tgtgcttttg aattacttat ttacctgtcc tcttaccgtt ggtaaataat aattggctat 3000

atttggtacc tgtctctctc ctactgtatt gtcattttca aaatgtgttt gttttctggc 3060

gcgtgctgca aagaagctat ttctgttgtc ctacatattt tagtataaat cactaagaca 3120

tatttccttt cacttggcag gattcctttc aaaatggaat ctgagtatta gacactagtt 3180

aacatatttg tgtatattaa atatgaattt ttaaaattta taaatactat tttccaaaag 3240

tacagactct aaggacatat tttgataaag tattatttgt aatgaacaca agcctctctt 3300

gagtagaagt ctaaatcaca ttatgattat tttatactag ttctgctatc atgctgtttt 3360

atgctaattc tgcttatttt agagtatttt tcattaaaag gtgagcaaag tgaaagatac 3420

ttggtatttt acccagattt ctaagtggca acatttttat tcttcagagt caggtaaatg 3480

actataatag tttggtttct aatgaaaagt caatagcatt agcagttata attctgttta 3540

taatttcctt tcagcattta cagtgaaaag tgagaatttt aaaatttatg aaatctatat 3600

tccaggtatt gtttttagtc tgaaaaacaa actcccccat gtggtattaa tataccttca 3660

atttatgttg agtcttaaac atattagga gatatttttc tctatttgct agatttgttt 3720

tgagtcaaaa ctgatttagt gttcttccaa acaacattta tgtgttggcc tacagagttt 3780

atttcatgtg ttttttttaa tatttaatat tatattacat tcattgaaat ctgttcaaaa 3840

acagattaag acaaacattt atgatggtct gtatcaatca gcagatttta ttgcttttca 3900

ttattttact gtaaaggcaa agaatgcaat aggtgatggt tggttgaaag gaattgttat 3960

tgctgttttt attttttact ttttttgaga cagagtctca ctctgttgcc cagcctggag 4020

tgcagtgtgt catcttggct cactgcaacc tccgcctcct gggttcaagg gattctcctg 4080

cctcagcctc caactagctg ggattacagg cacaagccac catgcctggc taaaattctt 4140

ttgtattttt actacagacg gagtttcccc atgttggccg ggctagtctc gaactcctga 4200

cctcaggtga tccaccagcc tcggcctccc aaagttctgg gattaaatgc gtgagccacc 4260

atgcccggcc gctattgctc tttttaactt catttgatgc cttgcttata atatcatatg 4320

cttgaggctc actgttgatg tagagtaggg caaatctgtg tgtgtatgtc attaaaaaaa 4380

ttctaccatc tttctttatc atctggtgtg ggcgcactct acagtgactt cagtctgctc 4440

agaacgaatg tggaggccgg ccgaaactga tgctgcccac agtcccagtg aagttaggtg 4500

ggttaattac tgccattcct ttctaagtgt gttttatggc atcctgccca caaagaactc 4560

acagtctgat taggatgaac ttaatgacta tttacacctc aaaatatatt cagcaaaggg 4620

ttcacttagt tgcccctcat gcttcacagg ttgactagta tctgtgggta cctccctgcc 4680

caggttattc actcacaagc caccgggcct tcaggacatc tcaagattca gtcttgacaa 4740

tataatagca aaagctggac taaagcccaa atggattgtc tgtggcaatg cagaagctga 4800

tagcattaac agcagggtgt tacagcataa ttgttaattc gcacatctat taggatcctt 4860

aaatattcat tacttaatgt taaattaaca ttctgtgtag ggaggggagg cttattcaat 4920

tcttctgacc tcagaactgg cagaaggtca gatgtgacta cagaactcta ggtgaaaaat 4980

caggtagggt tcaaattaag tagaactgcc cttgccggaa tagtgatctt caaaaaaccc 5040

ttgcttttag gggagggaag cggggaagga aaggaatgag ggaggaaata ttcctttcta 5100

gcattcattt tgcttagatc actccattgt gagtttgacc atttggagt caaatgagca 5160

gacttccaag gagttgacca gtttgtgact agtctggtca cctttccagt tacaggatca 5220

tattaactgt gtaaatgaat tcatgggtag atgatttgtg cagatctgaa tttaagaaca 5280

tttccttttt ctgtgggaat cacaagagtt tatccactaa aaaaagatat gtaaaaaaga 5340

tactttccag cacataaata aaggctggaa ttttacaacc tgatgtatat attagacagt 5400

tctaggatgt tagttccctt cattccagag ctatgcttgt gatacagccc cttttctttat 5460

aaagtcagtt agaaggactt ccttaacaat gactattata atgtcttact taaaatacag 5520

ttttgtattc tgtcaatgca aatataagac aggttgagcc ttaatcatgt aacaaaatat 5580

tttgtagatt acatattgat ttttcaaaaa ttaaaaatgt atttcaaact attaaaaaaa 5640

aaaaaaaaaa a 5651

<210> 76

<211> 735

<212> PRT

<213> Homo sapiens

<400> 76

Met Cys Ser Thr Asn Pro Gly Lys Trp Val Thr Phe Asp Asp Asp Pro

1 5 10 15

Ala Val Gln Ser Ser Gln Lys Ser Lys Asn Phe Pro Leu Glu Asn Gln

20 25 30

Gly Val Cys Arg Pro Asn Gly Leu Lys Leu Asn Leu Pro Gly Leu Arg

35 40 45

Glu Phe Pro Ser Gly Ser Ser Ser Thr Ser Ser Thr Pro Leu Ser Ser

50 55 60

Pro Ile Val Asp Phe Tyr Phe Ser Pro Gly Pro Pro Ser Asn Ser Pro

65 70 75 80

Leu Ser Thr Pro Thr Lys Asp Phe Pro Gly Phe Pro Gly Ile Pro Lys

85 90 95

Ala Gly Thr His Val Leu Tyr Pro Ile Pro Glu Ser Ser Ser Asp Ser

100 105 110

Pro Leu Ala Ile Ser Gly Gly Glu Ser Ser Leu Leu Pro Thr Arg Pro

115 120 125

Thr Cys Leu Ser His Ala Leu Leu Pro Ser Asp His Ser Cys Thr His

130 135 140

Pro Thr Pro Lys Val Gly Leu Pro Asp Glu Val Asn Pro Gln Gln Ala

145 150 155 160

Glu Ser Leu Gly Phe Gln Ser Asp Asp Leu Pro Gln Phe Gln Tyr Phe

165 170 175

Arg Glu Asp Cys Ala Phe Ser Ser Pro Phe Trp Lys Asp Glu Gly Ser

180 185 190

Asp Ser His Phe Thr Leu Asp Pro Pro Gly Ser Lys Lys Met Phe Ser

195 200 205

Ser Arg Asn Lys Glu Met Pro Ile Asp Gln Lys Ser Leu Asn Lys Cys

210 215 220

Ser Leu Asn Tyr Ile Cys Glu Lys Leu Glu His Leu Gln Ser Ala Glu

225 230 235 240

Asn Gln Asp Ser Leu Arg Ser Leu Ser Met His Cys Leu Cys Ala Glu

245 250 255

Glu Asn Ala Ser Ser Phe Val Pro His Thr Leu Phe Arg Ser Gln Pro

260 265 270

Lys Ser Gly Trp Ser Phe Met Leu Arg Ile Pro Glu Lys Lys Asn Met

275 280 285

Met Ser Ser Arg Gln Trp Gly Pro Ile Phe Leu Lys Val Leu Pro Gly

290 295 300

Gly Ile Leu Gln Met Tyr Tyr Glu Gln Gly Leu Glu Lys Pro Phe Lys

305 310 315 320

Glu Ile Gln Leu Asp Pro Tyr Cys Arg Leu Ser Glu Pro Lys Val Glu

325 330 335

Asn Phe Ser Val Ala Gly Lys Ile His Thr Val Lys Ile Glu His Val

340 345 350

Ser Tyr Thr Glu Lys Arg Lys Tyr His Ser Lys Thr Glu Val Val His

355 360 365

Glu Pro Asp Ile Glu Gln Met Leu Lys Leu Gly Ser Thr Ser Tyr His

370 375 380

Asp Phe Leu Asp Phe Leu Thr Thr Val Glu Glu Glu Leu Met Lys Leu

385 390 395 400

Pro Ala Val Ser Lys Pro Lys Lys Asn Tyr Glu Glu Gln Glu Ile Ser

405 410 415

Leu Glu Ile Val Asp Asn Phe Trp Gly Lys Val Thr Lys Glu Gly Lys

420 425 430

Phe Val Glu Ser Ala Val Ile Thr Gln Ile Tyr Cys Leu Cys Phe Val

435 440 445

Asn Gly Asn Leu Glu Cys Phe Leu Thr Leu Asn Asp Leu Glu Leu Pro

450 455 460

Lys Arg Asp Glu Ser Tyr Tyr Glu Lys Asp Ser Glu Lys Lys Gly Ile

465 470 475 480

Asp Ile Leu Asp Tyr His Phe His Lys Cys Val Asn Val Gln Glu Phe

485 490 495

Glu Gln Ser Arg Ile Ile Lys Phe Val Pro Leu Asp Ala Cys Arg Phe

500 505 510

Glu Leu Met Arg Phe Lys Thr Leu Tyr Asn Gly Asp Asn Leu Pro Phe

515 520 525

Ser Leu Lys Ser Val Val Val Val Gln Gly Ala Tyr Val Glu Leu Gln

530 535 540

Ala Phe Val Asn Met Ala Ser Leu Ala Gln Arg Ser Ser Tyr Ala Gly

545 550 555 560

Ser Leu Arg Ser Cys Asp Asn Ile Arg Ile His Phe Pro Val Pro Ser

565 570 575

Gln Trp Ile Lys Ala Leu Trp Thr Met Asn Leu Gln Arg Gln Lys Ser

580 585 590

Leu Lys Ala Lys Met Asn Arg Arg Ala Cys Leu Gly Ser Leu Gln Glu

595 600 605

Leu Glu Ser Glu Pro Val Ile Gln Val Thr Val Gly Ser Ala Lys Tyr

610 615 620

Glu Ser Ala Tyr Gln Ala Val Val Trp Lys Ile Asp Arg Leu Pro Asp

625 630 635 640

Lys Asn Ser Ser Leu Asp His Pro His Cys Leu Ser Tyr Lys Leu Glu

645 650 655

Leu Gly Ser Asp Gln Glu Ile Pro Ser Asp Trp Tyr Pro Phe Ala Thr

660 665 670

Val Gln Phe Ser Val Pro Asp Thr Cys Ala Ser Arg Thr Glu Val Arg

675 680 685

Ser Leu Gly Val Glu Ser Asp Val Gln Pro Gln Lys His Val Gln Gln

690 695 700

Arg Ala Cys Tyr Asn Ile Gln Val Glu Ile Glu Lys Lys Trp Ile Lys

705 710 715 720

Ile Asp Gly Glu Asp Pro Asp Lys Ile Gly Asp Cys Ile Thr Gln

725 730 735

<210> 77

<211> 3510

<212> DNA

<213> Homo sapiens

<400> 77

aaaatttcag cagagagaaa tagagaaagc agtgtgtgtg catgtgtgtg tgtgtgagag 60

agagagggga aggagcgaga gggagaggga gagggagaga gagaaggga gggaagcaga 120

gagtcaagtc caagggaatg agcgagagag gcagagacag gggaagaggc gtgcgagaga 180

aggaataaca gctttccgga gcaggcgtgc cgtgaactgg cttctatttt atttattttt 240

tttctccttt ttatttttta aagagaagca ggggacagaa gcaatggccg aggcagaaga 300

caagccgagg tgctggtgac cctgggcgtc tgagtggatg attggggctg ctgcgctcag 360

aggcctgcct ccctgccttc caatgcatat aaccccacac cccagccaat gaagacgaga 420

ggcagcgtga acaaagtcat ttagaaagcc cccgaggaag tgtaaacaaa agagaaagca 480

tgaatggagt gcctgagaga caagtgtgtc ctgtactgcc cccaccttta gctgggccag 540

caactgcccg gccctgcttc tccccaccta ctcactggtg atcttttttt ttttactttt 600

ttttcccttt tcttttccat tctcttttct tattttcttt caaggcaagg caaggatttt 660

gattttggga cccagccatg gtccttctgc ttcttcttta aaataccccac tttctcccca 720

tcgccaagcg gcgtttggca atatcagata tccactctat ttattttac ctaaggaaaa 780

actccagctc ccttcccact cccagctgcc ttgccacccc tcccagccct ctgcttgccc 840

tccacctggc ctgctgggag tcagagccca gcaaaacctg tttagacaca tggacaagaa 900

tcccagcgct acaaggcaca cagtccgctt cttcgtcctc agggttgcca gcgcttcctg 960

gaagtcctga agctctcgca gtgcagtgag ttcatgcacc ttcttgccaa gcctcagtct 1020

ttggggatctg gggggccgc ctggttttcc tccctccttc tgcacgtctg ctggggtctc 1080

ttcctctcca ggccttgccg tccccctggc ctctcttccc agctcacaca tgaagatgca 1140

cttgcaaagg gctctggtgg tcctggccct gctgaacttt gccacggtca gcctctctct 1200

gtccacttgc accaccttgg acttcggcca catcaagaag aagagggtgg aagccattag 1260

gggacagatc ttgagcaagc tcaggctcac cagcccccct gagccaacgg tgatgaccca 1320

cgtcccctat caggtcctgg ccctttacaa cagcacccgg gagctgctgg aggagatgca 1380

tggggagagg gaggaaggct gcacccagga aaacaccgag tcggaatact atgccaaaga 1440

aatccataaa ttcgacatga tccaggggct ggcggagcac aacgaactgg ctgtctgccc 1500

taaaggaatt acctccaagg ttttccgctt caatgtgtcc tcagtggaga aaaatagaac 1560

caacctattc cgagcagaat tccgggtctt gcgggtgccc aaccccagct ctaagcggaa 1620

tgagcagagg atcgagctct tccagatcct tcggccagat gagcacattg ccaaacagcg 1680

ctatatcggt ggcaagaatc tgcccacacg gggcactgcc gagtggctgt cctttgatgt 1740

cactgacact gtgcgtgagt ggctgttgag aagagagtcc aacttaggtc tagaaatcag 1800

cattcactgt ccatgtcaca cctttcagcc caatggagat atcctggaaa acattcacga 1860

ggtgatggaa atcaaattca aaggcgtgga caatgaggat gaccatggcc gtggagatct 1920

gggcgcctc aagaagcaga aggatcacca caaccctcat ctaatcctca tgatgattcc 1980

cccacaccgg ctcgacaacc cgggccaggg gggtcagagg aagaagcggg ctttggacac 2040

caattactgc ttccgcaact tggaggagaa ctgctgtgtg cgccccctct acattgactt 2100

ccgacaggat ctgggctgga agtgggtcca tgaacctaag ggctactatg ccaacttctg 2160

ctcaggccct tgcccatacc tccgcagtgc agacacaacc cacagcacgg tgctgggact 2220

gtacaacact ctgaaccctg aagcatctgc ctcgccttgc tgcgtgcccc aggacctgga 2280

gcccctgacc atcctgtact atgttgggag gacccccaaa gtggagcagc tctccaacat 2340

ggtggtgaag tcttgtaaat gtagctgaga ccccacgtgc gacagagaga ggggagagag 2400

aaccaccact gcctgactgc ccgctcctcg ggaaacacac aagcaacaaa cctcactgag 2460

aggcctggag cccacaacct tcggctccgg gcaaatggct gagatggagg tttccttttg 2520

gaacatttct ttcttgctgg ctctgagaat cacggtggta aagaaagtgt gggtttggtt 2580

agaggaaggc tgaactcttc agaacacaca gactttctgt gacgcagaca gaggggatgg 2640

ggatagagga aagggatggt aagttgagat gttgtgtggc aatgggattt gggctaccct 2700

aaagggagaa ggaagggcag agaatggctg ggtcagggcc agactggaag acacttcaga 2760

tctgaggttg gatttgctca ttgctgtacc acatctgctc tagggaatct ggattatgtt 2820

atacaaggca agcatttttt tttttttttt aaagacaggt tacgaagaca aagtcccaga 2880

attgtatctc atactgtctg ggattaaggg caaatctatt acttttgcaa actgtcctct 2940

acatcaatta acatcgtggg tcactacagg gagaaaatcc aggtcatgca gttcctggcc 3000

catcaactgt attgggcctt ttggatatgc tgaacgcaga agaaagggtg gaaatcaacc 3060

ctctcctgtc tgccctctgg gtccctcctc tcacctctcc ctcgatcata tttccccttg 3120

gacacttggt tagacgcctt ccaggtcagg atgcacattt ctggattgtg gttccatgca 3180

gccttggggc atttgggtt cttcccccac ttcccctcca agaccctgtg ttcatttggt 3240

gttcctggaa gcaggtgcta caacatgtga ggcattcggg gaagctgcac atgtgccaca 3300

cagtgacttg gccccagacg catagactga ggtataaaga caagtatgaa tattactctc 3360

aaaatctttg tataaataaa tatttttggg gcatcctgga tgatttcatc ttctggaata 3420

ttgtttctag aacagtaaaa gccttatattct aaggtgtatg tctgactcga taaatatcct 3480

tcaattaccc ttaaaaaaaa aaaaaaaaaa 3510

<210> 78

<211> 412

<212> PRT

<213> Homo sapiens

<400> 78

Met Lys Met His Leu Gln Arg Ala Leu Val Val Leu Ala Leu Leu Asn

1 5 10 15

Phe Ala Thr Val Ser Leu Ser Leu Ser Thr Cys Thr Thr Leu Asp Phe

20 25 30

Gly His Ile Lys Lys Lys Arg Val Glu Ala Ile Arg Gly Gln Ile Leu

35 40 45

Ser Lys Leu Arg Leu Thr Ser Pro Pro Pro Glu Pro Thr Val Met Thr His

50 55 60

Val Pro Tyr Gln Val Leu Ala Leu Tyr Asn Ser Thr Arg Glu Leu Leu

65 70 75 80

Glu Glu Met His Gly Glu Arg Glu Glu Gly Cys Thr Gln Glu Asn Thr

85 90 95

Glu Ser Glu Tyr Tyr Ala Lys Glu Ile His Lys Phe Asp Met Ile Gln

100 105 110

Gly Leu Ala Glu His Asn Glu Leu Ala Val Cys Pro Lys Gly Ile Thr

115 120 125

Ser Lys Val Phe Arg Phe Asn Val Ser Ser Val Glu Lys Asn Arg Thr

130 135 140

Asn Leu Phe Arg Ala Glu Phe Arg Val Leu Arg Val Pro Asn Pro Ser

145 150 155 160

Ser Lys Arg Asn Glu Gln Arg Ile Glu Leu Phe Gln Ile Leu Arg Pro

165 170 175

Asp Glu His Ile Ala Lys Gln Arg Tyr Ile Gly Gly Lys Asn Leu Pro

180 185 190

Thr Arg Gly Thr Ala Glu Trp Leu Ser Phe Asp Val Thr Asp Thr Val

195 200 205

Arg Glu Trp Leu Leu Arg Arg Glu Ser Asn Leu Gly Leu Glu Ile Ser

210 215 220

Ile His Cys Pro Cys His Thr Phe Gln Pro Asn Gly Asp Ile Leu Glu

225 230 235 240

Asn Ile His Glu Val Met Glu Ile Lys Phe Lys Gly Val Asp Asn Glu

245 250 255

Asp Asp His Gly Arg Gly Asp Leu Gly Arg Leu Lys Lys Gln Lys Asp

260 265 270

His His Asn Pro His Leu Ile Leu Met Met Ile Pro Pro His Arg Leu

275 280 285

Asp Asn Pro Gly Gln Gly Gly Gln Arg Lys Lys Arg Ala Leu Asp Thr

290 295 300

Asn Tyr Cys Phe Arg Asn Leu Glu Glu Asn Cys Cys Val Arg Pro Leu

305 310 315 320

Tyr Ile Asp Phe Arg Gln Asp Leu Gly Trp Lys Trp Val His Glu Pro

325 330 335

Lys Gly Tyr Tyr Ala Asn Phe Cys Ser Gly Pro Cys Pro Tyr Leu Arg

340 345 350

Ser Ala Asp Thr Thr His Ser Thr Val Leu Gly Leu Tyr Asn Thr Leu

355 360 365

Asn Pro Glu Ala Ser Ala Ser Pro Cys Cys Val Pro Gln Asp Leu Glu

370 375 380

Pro Leu Thr Ile Leu Tyr Tyr Val Gly Arg Thr Pro Lys Val Glu Gln

385 390 395 400

Leu Ser Asn Met Val Val Lys Ser Cys Lys Cys Ser

405 410

<210> 79

<211> 5605

<212> DNA

<213> Homo sapiens

<400> 79

gttgcgagcg ctgcacaaca acaaaaggac ttggactggc cggcctgggc gcagcgaccc 60

gagggctgga gccggccccg cgcctgccgt ctgggtacct gaacgaggtg cagcgcagcc 120

cggccccacc gcagctacct cagcagtccc gccccgcccg cgtccttccc cgccgagccg 180

gcggccgctc ccttccccgc gcagccccgc acggcccggg cccacgtaca atgactcttc 240

ttgcttttca cctaagttga ataagcaccc tgtgcacttt aatctcctgt cggtaccatt 300

gggccaacta aagacaaggt tttgaaatct cagctataaa agacatccag ccaaactctc 360

agtcttgcct taacaatgtt ccagaggctg aataaaatgt ttgtgggtga agtcagttct 420

tcctccaacc aagaaccaga attcaatgag aaagaagatg atgaatggat tcttgttgac 480

ttcatagata cttgcactgg tttctcagca gaagaagaag aagaagagga ggacatcagt 540

gaagagtcac ctactgagca cccttcagtc ttttcctgtt taccggcatc tcttgagtgc 600

ttggctgata caagtgattc ctgctttctc cagtttgagt catgtccaat ggaggagagc 660

tggtttatca ccccaccccc atgttttat gcaggtggat taaccactat caaggtggaa 720

acaagtccta tggaaaacct tctcattgaa catcccagca tgtctgtcta tgctgtgcat 780

aactcctgcc ctggtctcag tgaggccacc cgtgggactg atgaattaca tagcccaagt 840

agtcccagag tggaagctca aaatgaaatg gggcagcata ttcattgtta tgttgcagct 900

cttgctgctc atacaacttt tctggaacaa cccaagagct ttcgcccttc ccagtggata 960

aaagaacaca gtgaaagaca gcctcttaac agaaatagcc ttcgtcgcca aaatcttacc 1020

agggattgcc accctcggca agtcaagcac aatggctggg ttgttcatca gccctgcccg 1080

cgtcagtaca attachaata gtttcaagtt ttgttggttg gtttctcttg gtttgtgctt 1140

acatgtatgg atgtgtgtat atgtacagtg aaaatgttgt ctctttacaa ccaattgata 1200

accaatcaca tagttttatc agtgtattta gacactatct tgaaaatcag atttatatgc 1260

tgtgtatcac ataatgcctt gcctttaaca tttacttttt ttgtacactt tttcagatta 1320

tttctggaaa catatcaata taattacagt gtttgggggt gtctttaaat atattaggtt 1380

atacattagt cagcatttta aagacatttc ttcccaagta cgagaatagg catctttcat 1440

tttcatttta ttttgtatta cttaatcttt taagcaagca aaaatttatt ctcagggtca 1500

gctgtacact ttattgacca gtacttgata atctctctgt atatgatgaa tacattttta 1560

cacactaaca ttagcattaa caggtgatag ttgccatgga tataatggaa ttatggctgg 1620

actttctttt gaaagaaaac ttgatgtatt ctgtgtgtat ggtttttccc cagattagtc 1680

atacagttca tttggaattc aggtacatta agctttagtg aagagtgcat gcagtaattc 1740

caatgtgact gcatgacgtg gtacagacat tacaggtgtt gtagacagag gcacttgtct 1800

cgtgcagagg gattaaatta gacctgtgag attatttg gaaaaattca tgtctgtaac 1860

taacccatta gtgcagtatt taatttgtta ctattccttc ccgccaattc tgtccactcc 1920

tcacctcgca tcagctataa atttggaagt acttgtccag gcactcaagt gacttcatat 1980

ttctctctgc ccatgggaaa agagataggc tttatatttc cacagagtga aaaatcctct 2040

gtcatggagc ctgtcctgcc aagtggcaag agtgtgggga ctgtctggtg atgatgtctt 2100

tcatggcatc tgagtgaaga gtgacaggtt ggctcaactt ttttcttttt ttttttttaa 2160

ttgccttgta ttgtaagtat tcttccctgc agtccaagtg acttttcatt ttttgtttta 2220

acttcaggca aaatctttaa ccactctggc ctctgtttcc cccaccaacg gggagcagtg 2280

acatttacct ccctcacaga gtcactgtga ggattctata ctgatttgaa gtggagctgt 2340

tcagaactga accttgtagg aaattccaag ggcctttcta ctgaatctgg tgatggggtg 2400

gggccgtggc actttctctg ccacagctgt tcttcacagt gttggtgcta atgaggccag 2460

ggtgcagggt tcgattcaca cgtaggccag ttaacttaga gaaaatctat ttccttacct 2520

ctagccagtc acttcctttt tccgcagttg tgatgggttt tgctgagcca tccactctga 2580

ctgatttcct ctgaagtaaa catattttaca atccaaagca attctactga cagaagtgtt 2640

gccttcataa tcaaacagct tgtttttcca tctcctctgc aaccctaatt aaatgagtac 2700

aggtctacaa aatgttttca aggagaaaag cagcatatcc ttaagtgaag tattatattt 2760

ttcaataacc ctgtagtggc ttgatgcagg gaaccctggg ggactttcag cgaagagctg 2820

tgctcttttc tgactagatt agagcgtttg gagtggaaga cgtcaaatgt gtagtgagat 2880

ggaggtttta cattgttctt ctactggctg tgatgaagtg ccagaatgtc tctttagaac 2940

aagagttaga ttcccccttt ctccttatattg ccccttccgt tttgacttcc cctttattta 3000

tttgttgtct aattaggggc caagtctgta aagttttgtc aaagtgagtt agaagttgtt 3060

ttctcttact atttgtgttt accagagttg ggagataaga tagtttccat gaaggtgtgt 3120

atgttttata cgatgtttgt tatagggcca tgcattggta acttgaaaat agaccagctt 3180

aatgtcttca ggatgtaaaa ctctgaatac acggcgtctc tttttcatac attgcatgta 3240

agttgttagt acctcacaag ctacagaagt tcagccatga gattttgttt ggcaacatga 3300

acagatttgt gtataactgc aatggccttt ttttccagat ttccttattg actttttgtt 3360

tgccttacct ggggctagtt ttttatgctt tgtacctaga aaacaaaaaa ttacattcgt 3420

tgggcttttt ttcaaggttg ggattaccac accacctgga atatcatact gtggtttctg 3480

cctaaaattg gcacatgtaa gtattgaaga aaatggttat ataattcagt tgaaactctt 3540

ggttattaga tgttaggcat ctcctgtatg taagacacaa ggccaaccac aacacagaac 3600

gatgttgacc tgttaagtat tctctgaaac atggccaaaa tgcattttat gagctttttt 3660

ttttgctatt gtaaatatta gtggtttaca atgcgcttta gacatatttc tttaaaatgc 3720

aagcagtgag aaataagacc tctctgaatt agtagctcta aactgttaac atagaatgtt 3780

acttggaaaa agtctggaat atgtggtgta cacaagcagt gcttcgtgaa tgagtttctt 3840

agcttttata gtgcgccatg tttctcaaag tttgtttttg ttgacaaaac attttataat 3900

atatatctta tgtttatttt ttttctcaac taattgtgta ctgcactgta aggtgaaaat 3960

tagccatcca ttatttatct tctgtggcaa tgcatttata tggttgattg ggtggggaat 4020

tttttgcaga aagatgcaaa gtgattgggt tttcgacttc ctatcgcagg gagcttttaa 4080

gaaatattaa tttcctatac atttttccaa tccccatgca aactgttcct gtttacatac 4140

cttctctgtt gtatcagtac tttgagtgag aagacagttt atttaaaact tgagcaggct 4200

gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 4260

ttcattgaaa tccttgctac ttctcttcct cctcaatgaa atatacattata tattatcttt 4320

atgtactctt aagaaaaacg agcaaggaag agtatcttca ttatctctcat tttctctgag 4380

ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 4440

agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 4500

tccttgtact gggagacact agtagtatat gtttgtaatg ttatctttaaa attctttt 4560

tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 4620

atggtttcac tgccatcagc catgctgata tattagaaat ggcatcccta tctacttact 4680

ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtggtg 4740

tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 4800

agggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 4860

atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 4920

tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 4980

tttgctctgt tttgcctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 5040

accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 5100

tgtattttcc tccagagatt ttgaacttta atatgcgt gtgttttttt tttttttaag 5160

tggctttgtt tttttttctc aagtaaaatt gtgaacatat ttcctttata ggggcagggc 5220

atgagttagg gagactgaag agtattgtag actgtacatg tgccttctta atgtgtttct 5280

cgacacattttttttcagta acttgaaaat tcaaaaggga catttggtta ggttatactgta 5340

catcaatcta tgcataaatg gcagcttgtt ttcttgagcc acggtctaaa ttttgttttt 5400

atagaaattt tttatactga ttggttcata gatggtcagt tttgtacaca gactgaacaa 5460

tacagcactt tgccaaaaat gagtgtagca ttgtttaaac attgtgtgtt aacacctgtt 5520

ctttgtaatt gggttgtggt gcattttgca ctacctggag ttacagtttt caatctgtca 5580

gtaaataaag tgtcctttaa cttca 5605

<210> 80

<211> 240

<212> PRT

<213> Homo sapiens

<400> 80

Met Phe Gln Arg Leu Asn Lys Met Phe Val Gly Glu Val Ser Ser Ser

1 5 10 15

Ser Asn Gln Glu Pro Glu Phe Asn Glu Lys Glu Asp Asp Glu Trp Ile

20 25 30

Leu Val Asp Phe Ile Asp Thr Cys Thr Gly Phe Ser Ala Glu Glu Glu

35 40 45

Glu Glu Glu Glu Asp Ile Ser Glu Glu Ser Pro Thr Glu His Pro Ser

50 55 60

Val Phe Ser Cys Leu Pro Ala Ser Leu Glu Cys Leu Ala Asp Thr Ser

65 70 75 80

Asp Ser Cys Phe Leu Gln Phe Glu Ser Cys Pro Met Glu Glu Ser Trp

85 90 95

Phe Ile Thr Pro Pro Pro Pro Cys Phe Thr Ala Gly Gly Leu Thr Thr Ile

100 105 110

Lys Val Glu Thr Ser Pro Met Glu Asn Leu Leu Ile Glu His Pro Ser

115 120 125

Met Ser Val Tyr Ala Val His Asn Ser Cys Pro Gly Leu Ser Glu Ala

130 135 140

Thr Arg Gly Thr Asp Glu Leu His Ser Pro Ser Ser Pro Arg Val Glu

145 150 155 160

Ala Gln Asn Glu Met Gly Gln His Ile His Cys Tyr Val Ala Ala Leu

165 170 175

Ala Ala His Thr Thr Phe Leu Glu Gln Pro Lys Ser Phe Arg Pro Ser

180 185 190

Gln Trp Ile Lys Glu His Ser Glu Arg Gln Pro Leu Asn Arg Asn Ser

195 200 205

Leu Arg Arg Gln Asn Leu Thr Arg Asp Cys His Pro Arg Gln Val Lys

210 215 220

His Asn Gly Trp Val Val His Gln Pro Cys Pro Arg Gln Tyr Asn Tyr

225 230 235 240

<210> 81

<211> 4127

<212> DNA

<213> Homo sapiens

<400> 81

gcacagactc aaagccccgc gggcgagctc agcagcccgg agcgaccgcg gccccgccgc 60

ctcccccgcg agtcccggcg atgcggcccg gcctgtgagc ggccggcgac cctgggacgc 120

cccgccgcac aactacctca acgccgtgcc gcccccctcc cgcccccagg gaatctctgg 180

agattggttc accttttgtg gtcctgaccc cttctgtcct cactgtacct tgaagtccta 240

gagtccaata aaatcgctgc ctcccagctg tttggatcac agagaggttt ttgcactgcc 300

atagggcgcc cccgtgaggc gcttcgcccc ccaccatgtt ccagcgcctc tccagcctct 360

tcttcagcac cccctcgccc cccgaagacc ccgactgccc ccgcgccttc gtgtcggagg 420

aggatgaagt ggacggctgg ctcatcattg acctgccgga cagctacgcg gctccaccca 480

gccccggggc cgcccctgcc cccgcgggcc gccctccgcc cgcgccctcc ttgatggacg 540

agagctggtt tgttacccct cccgcctgtt ttacggcaga ggggcctgga ctcggtcccg 600

cccgcctcca gagcagtccc ctggaggacc tcctcatcga gcaccccagc atgtccgttt 660

acgtcaccgg cagcaccata gtgctagagc ccgggtcccc ttccccgctc ccggacgcgg 720

ccctgcctga cggcgacctc agcgaagggg aattgacgcc cgcccgccgc gagccgcggg 780

ccgcgcgcca cgccgctcct ctcccagcgc gggcggcgct gctggagaag gcgggccagg 840

tgcggcggct gcagcgggcc cggcagcggg cagagcgcca cgcgctgagc gccaaggcgg 900

tgcagcggca gaaccgagcc cgcgagagcc gtccgcgccg gtccaagaac cagagcagct 960

tcatctacca gccgtgccag cgccagttca actactgagc gtccaccggc cgcgccacga 1020

accccttgcc gatcccgatc cctgtcgggc tcctccgact cctcgggctg gacaccgaaa 1080

cctcccttct taaagcgtgt gaggttgggt gatagccgtt ccttccccga caccctcaat 1140

ttccccatct ctgatcctct aatctgcctc tgaacccatt cacccttcac cctcactcct 1200

ggtccccata cccagcatct aatcatccat gccccctact cctggcccct ccatcctttc 1260

ttctctggtc cccatccctg tctctccctt tcacccttgc cctccagtcc tctacctctg 1320

gcctgcccct atttctgaaa gcttcttcca gtccctgatc tggctcattc cccaccttca 1380

actcccacct tacatgtctc acactatccc atggttggca ttacactcac tcctgttccc 1440

ttattcttca ttcccagtaa ttccctacca aatggtgggg accctgagcc cagctctgac 1500

caggtagagc ctgtgcagcc tgggctgctg tcattgccct ccagtaaggg ctcagggttt 1560

tgcttttagt ctccccttcc ttctgccttg ggggcggtac tctgtggagc tgcttaggcc 1620

tggaaaggta cagtatgtag aagaggactg tgagacgtga gttagaggga gaagatggag 1680

ggaatctagg gaacgaggca gcctattgga gatgcggaca ggacagacac gttgagaagc 1740

tgcagggagc agggcaccaa gggagtgtgc actgtgcttg ctcagagagg ccaaaccctg 1800

ctcccaggct gaagcctgga gtctgccccc acttcccttt tctataatcc acccttctgc 1860

aggccctgaa atctgaaggg cttagttagt accttgccac tctaccccca acacgtcacc 1920

cgagtagaag ctgggcaagg ccctaccatc ctggccgtct gttcacaagc ccaaggtgct 1980

agaactagct taggagacat gcaggccaca gggcttctag gcagggaaag ggcacacacc 2040

ctaggtcagc gtgcagagca gtgatgctgg aggacacac atggggtgaa gccatcccaa 2100

ggctgacagc tcagtcttca ccttgcctct ggccttgtat ttcacaccct gctcagtatg 2160

gctagccagc agtcctgagt aggagtccag gactcccact gtctcaatct gcaaattgtt 2220

cctatccagg ttcagggcct tcagggggcc tcttttcatt ttctcccaca ggcctctctt 2280

tctttctagg ttgctgggga gaaatgggta ccctatgatc cccctcccct tctcctccag 2340

taaatacctg gaagagggaa cctgaatccc tgggggagac agaaggggca ggggccacca 2400

gcctcccctt cttgtggtga gactgaattt tgggctcaga caccagcaac agcctcttgg 2460

gatgccctga gttgcttccc attcctctt tctagccgtc cttttctagt gtgtgctcac 2520

tcttcctagg aacttttaag acttcttggt acctatgaac ataggtcctc ccctcacccc 2580

aactctaggt ttccaggcct cacagccaag ctgaagcttg gagaaaactc tgcattccca 2640

tgagggcaaa ggcagctgcc ctccctgacc ctatagcccc aggcctcatg gggggtatgt 2700

ggggaaggga tggggtatcc ccatggatgc tgggatgagg acagaggaag acctgatggg 2760

gtctcctatt ccagggaata agccaaatta accactaaaaa cggatcaaag ctcccacgcc 2820

agtccactag ggccccagta gttgacagcc ttgctcctct cccaagttct ccttcagaac 2880

ctagttgctt ttatctcttcc agctaccact tgggcacttc acagccagcc tagggtcttc 2940

ggcacctcca agagctgaat ctccctccaa cccttcttgc ctactcctca ctgccagctg 3000

ggacctaggc tcagtcctgt gtggtgccca tgatccttct ggtgggggaa gagtttaagt 3060

tatagggcat ttggctcaaa ttttaaaagg ccttttgttt acctatattt ctggaggctc 3120

ctgtattcta gaacccaatc tctcacctgc ttggttgcaa ggctcatatt tttttgtacc 3180

tttcctatag attctgtagc atttgagtgt ggcaatattt taattgtgta tagatttcta 3240

agaaccaaca ctactcagtc tcctgctagt ctgactcctg aagcatcagc ccttgtcata 3300

ctgtattgac tgtgtacgtg cctttcacct tgagcatgct tcaggatttt tttttaaacc 3360

acagaacttg aatacatgag ggaaccagag ttcaaagtcc tatgcaacct taggaggggg 3420

ttagagagtc tgttttgatt gatgttttct gaggccctag aggagtttgt atcaatttgt 3480

gagtattaat gtcagtacta ccagcacttt gccaaaactg tcagagggac ccgtttctag 3540

agtgagtccc agttacatca aacagtgact tccagttatt ccccagtaag tctgagtggt 3600

tccttcaagc tgggtgtctt tccagccttt gccagtctag ccccagcagg gcaccgtgta 3660

tgaatgcagt ttggtgctgt tttagagtat gcctgctccc cagccccctg cctggaaccc 3720

tctgagcaac ttgctctgac ctataatgtc ttaggtgcaa cacggacccc accagagctc 3780

ttggataccc ccctagatcc atgtggcttt atgtgagggg actgaatgca gacacaccat 3840

agcccccttc tactactttc cctctcgccc tgccacctag ttccacatgg aaccaacaag 3900

ttgagtgcat ccctgttggg tgttttgtgt tgagactggc tgaaatgagg agactttgac 3960

catgtgacgt gtcaacagac tcaaggagac aaccacctca actgggtcat gtggcatgcc 4020

tgtgtatgtg tgtaacagaa ttctgattgt tagactgtaa tgctattcct ctatgggaga 4080

aaaaaattaa tataaagaaa aacaaataaa aatatattta aagcaca 4127

<210> 82

<211> 220

<212> PRT

<213> Homo sapiens

<400> 82

Met Phe Gln Arg Leu Ser Ser Leu Phe Phe Ser Thr Pro Ser Pro Pro

1 5 10 15

Glu Asp Pro Asp Cys Pro Arg Ala Phe Val Ser Glu Glu Asp Glu Val

20 25 30

Asp Gly Trp Leu Ile Ile Asp Leu Pro Asp Ser Tyr Ala Ala Pro Pro

35 40 45

Ser Pro Gly Ala Ala Pro Ala Pro Ala Gly Arg Pro Pro Pro Ala Pro

50 55 60

Ser Leu Met Asp Glu Ser Trp Phe Val Thr Pro Pro Ala Cys Phe Thr

65 70 75 80

Ala Glu Gly Pro Gly Leu Gly Pro Ala Arg Leu Gln Ser Ser Pro Leu

85 90 95

Glu Asp Leu Leu Ile Glu His Pro Ser Met Ser Val Tyr Val Thr Gly

100 105 110

Ser Thr Ile Val Leu Glu Pro Gly Ser Pro Ser Pro Leu Pro Asp Ala

115 120 125

Ala Leu Pro Asp Gly Asp Leu Ser Glu Gly Glu Leu Thr Pro Ala Arg

130 135 140

Arg Glu Pro Arg Ala Ala Arg His Ala Ala Pro Leu Pro Ala Arg Ala

145 150 155 160

Ala Leu Leu Glu Lys Ala Gly Gln Val Arg Arg Leu Gln Arg Ala Arg

165 170 175

Gln Arg Ala Glu Arg His Ala Leu Ser Ala Lys Ala Val Gln Arg Gln

180 185 190

Asn Arg Ala Arg Glu Ser Arg Pro Arg Arg Ser Lys Asn Gln Ser Ser

195 200 205

Phe Ile Tyr Gln Pro Cys Gln Arg Gln Phe Asn Tyr

210 215 220

<210> 83

<211> 2199

<212> DNA

<213> Homo sapiens

<400> 83

agacggtggc cgagcggggg accgggaagc atggcccggg ggtcggcggt tgcctgggcg 60

gcgctcgggc cgttgttgtg gggctgcgcg ctggggctgc agggcgggat gctgtacccc 120

caggagagcc cgtcgcggga gtgcaaggag ctggacggcc tctggagctt ccgcgccgac 180

ttctctgaca accgacgccg gggcttcgag gagcagtggt accggcggcc gctgtgggag 240

tcaggcccca ccgtggacat gccagttccc tccagcttca atgacatcag ccaggactgg 300

cgtctgcggc attttgtcgg ctgggtgtgg tacgaacggg aggtgatcct gccggagcga 360

tggacccagg acctgcgcac aagagtggtg ctgaggattg gcagtgccca ttcctatgcc 420

atcgtgtggg tgaatggggt cgacacgcta gagcatgagg ggggctacct ccccttcgag 480

gccgacatca gcaacctggt ccaggtgggg cccctgccct cccggctccg aatcactatc 540

gccatcaaca acacactcac ccccaccacc ctgccaccag ggaccatcca atacctgact 600

gacacctcca agtatcccaa gggttatacttt gtccagaaca catattttga ctttttcaac 660

tacgctggac tgcagcggtc tgtacttctg tacacgacac ccaccaccta catcgatgac 720

atcaccgtca ccaccagcgt ggagcaagac agtgggctgg tgaattacca gatctctgtc 780

aagggcagta acctgttcaa gttggaagtg cgtcttttgg atgcagaaaa caaagtcgtg 840

gcgaatggga ctgggaccca gggccaactt aaggtgccag gtgtcagcct ctggtggccg 900

tacctgatgc acgaacgccc tgcctatctg tattcattgg aggtgcagct gactgcacag 960

acgtcactgg ggcctgtgtc tgacttctac acactccctg tggggatccg cactgtggct 1020

gtcaccaaga gccagttcct catcaatggg aaacctttct atttccacgg tgtcaacaag 1080

catgaggatg cggacatccg agggaagggc ttcgactggc cgctgctggt gaaggacttc 1140

aacctgcttc gctggcttgg tgccaacgct ttccgtacca gccactaccc ctatgcagag 1200

gaagtgatgc agatgtgtga ccgctatggg attgtggtca tcgatgagtg tcccggcgtg 1260

ggcctggcgc tgccgcagtt cttcaacaac gtttctctgc atcaccacat gcaggtgatg 1320

gaagaagtgg tgcgtaggga caagaaccac cccgcggtcg tgatgtggtc tgtggccaac 1380

gagcctgcgt cccacctaga atctgctggc tactacttga agatggtgat cgctcacacc 1440

aaatccttgg acccctcccg gcctgtgacc tttgtgagca actctaacta tgcagcagac 1500

aagggggctc cgtatgtgga tgtgatctgt ttgaacagct actactcttg gtatcacgac 1560

tacgggcacc tggagttgat tcagctgcag ctggccaccc agtttgagaa ctggtataag 1620

aagtatcaga agcccattat tcagagcgag tatggagcag aaacgattgc aggggtttcac 1680

caggatccac ctctgatgtt cactgaagag taccagaaaa gtctgctaga gcagtaccat 1740

ctgggtctgg atcaaaaacg cagaaaatac gtggttggag agctcatttg gaattttgcc 1800

gatttcatga ctgaacagtc accgacgaga gtgctgggga ataaaaggg gatcttcact 1860

cggcagagac aaccaaaaag tgcagcgttc cttttgcgag agagatactg gaagattgcc 1920

aatgaaacca ggtatcccca ctcagtagcc aagtcacaat gtttggaaaa cagcctgttt 1980

acttgagcaa gactgatacc acctgcgtgt cccttcctcc ccgagtcagg gcgacttcca 2040

cagcagcaga acaagtgcct cctggactgt tcacggcaga ccagaacgtt tctggcctgg 2100

gttttgtggt catctattct agcagggaac actaaaggtg gaaataaaag attttctatt 2160

atggaaataa agagttggca tgaaagtggc tactgaaaa 2199

<210> 84

<211> 651

<212> PRT

<213> Homo sapiens

<400> 84

Met Ala Arg Gly Ser Ala Val Ala Trp Ala Ala Leu Gly Pro Leu Leu

1 5 10 15

Trp Gly Cys Ala Leu Gly Leu Gln Gly Gly Met Leu Tyr Pro Gln Glu

20 25 30

Ser Pro Ser Arg Glu Cys Lys Glu Leu Asp Gly Leu Trp Ser Phe Arg

35 40 45

Ala Asp Phe Ser Asp Asn Arg Arg Arg Gly Phe Glu Glu Gln Trp Tyr

50 55 60

Arg Arg Pro Leu Trp Glu Ser Gly Pro Thr Val Asp Met Pro Val Pro

65 70 75 80

Ser Ser Phe Asn Asp Ile Ser Gln Asp Trp Arg Leu Arg His Phe Val

85 90 95

Gly Trp Val Trp Tyr Glu Arg Glu Val Ile Leu Pro Glu Arg Trp Thr

100 105 110

Gln Asp Leu Arg Thr Arg Val Val Leu Arg Ile Gly Ser Ala His Ser

115 120 125

Tyr Ala Ile Val Trp Val Asn Gly Val Asp Thr Leu Glu His Glu Gly

130 135 140

Gly Tyr Leu Pro Phe Glu Ala Asp Ile Ser Asn Leu Val Gln Val Gly

145 150 155 160

Pro Leu Pro Ser Arg Leu Arg Ile Thr Ile Ala Ile Asn Asn Thr Leu

165 170 175

Thr Pro Thr Thr Leu Pro Pro Gly Thr Ile Gln Tyr Leu Thr Asp Thr

180 185 190

Ser Lys Tyr Pro Lys Gly Tyr Phe Val Gln Asn Thr Tyr Phe Asp Phe

195 200 205

Phe Asn Tyr Ala Gly Leu Gln Arg Ser Val Leu Leu Tyr Thr Thr Pro

210 215 220

Thr Thr Tyr Tyr Ile Asp Asp Ile Thr Val Thr Thr Thr Ser Val Glu Gln Asp

225 230 235 240

Ser Gly Leu Val Asn Tyr Gln Ile Ser Val Lys Gly Ser Asn Leu Phe

245 250 255

Lys Leu Glu Val Arg Leu Leu Asp Ala Glu Asn Lys Val Val Ala Asn

260 265 270

Gly Thr Gly Thr Gln Gly Gln Leu Lys Val Pro Gly Val Ser Leu Trp

275 280 285

Trp Pro Tyr Leu Met His Glu Arg Pro Ala Tyr Leu Tyr Ser Leu Glu

290 295 300

Val Gln Leu Thr Ala Gln Thr Ser Leu Gly Pro Val Ser Asp Phe Tyr

305 310 315 320

Thr Leu Pro Val Gly Ile Arg Thr Val Ala Val Thr Lys Ser Gln Phe

325 330 335

Leu Ile Asn Gly Lys Pro Phe Tyr Phe His Gly Val Asn Lys His Glu

340 345 350

Asp Ala Asp Ile Arg Gly Lys Gly Phe Asp Trp Pro Leu Leu Val Lys

355 360 365

Asp Phe Asn Leu Leu Arg Trp Leu Gly Ala Asn Ala Phe Arg Thr Ser

370 375 380

His Tyr Pro Tyr Ala Glu Glu Val Met Gln Met Cys Asp Arg Tyr Gly

385 390 395 400

Ile Val Val Ile Asp Glu Cys Pro Gly Val Gly Leu Ala Leu Pro Gln

405 410 415

Phe Phe Asn Asn Val Ser Leu His His His Met Gln Val Met Glu Glu

420 425 430

Val Val Arg Arg Asp Lys Asn His Pro Ala Val Val Met Trp Ser Val

435 440 445

Ala Asn Glu Pro Ala Ser His Leu Glu Ser Ala Gly Tyr Tyr Leu Lys

450 455 460

Met Val Ile Ala His Thr Lys Ser Leu Asp Pro Ser Arg Pro Val Thr

465 470 475 480

Phe Val Ser Asn Ser Asn Tyr Ala Ala Asp Lys Gly Ala Pro Tyr Val

485 490 495

Asp Val Ile Cys Leu Asn Ser Tyr Tyr Ser Trp Tyr His Asp Tyr Gly

500 505 510

His Leu Glu Leu Ile Gln Leu Gln Leu Ala Thr Gln Phe Glu Asn Trp

515 520 525

Tyr Lys Lys Tyr Gln Lys Pro Ile Ile Gln Ser Glu Tyr Gly Ala Glu

530 535 540

Thr Ile Ala Gly Phe His Gln Asp Pro Pro Leu Met Phe Thr Glu Glu

545 550 555 560

Tyr Gln Lys Ser Leu Leu Glu Gln Tyr His Leu Gly Leu Asp Gln Lys

565 570 575

Arg Arg Lys Tyr Val Val Gly Glu Leu Ile Trp Asn Phe Ala Asp Phe

580 585 590

Met Thr Glu Gln Ser Pro Thr Arg Val Leu Gly Asn Lys Lys Gly Ile

595 600 605

Phe Thr Arg Gln Arg Gln Pro Lys Ser Ala Ala Phe Leu Leu Arg Glu

610 615 620

Arg Tyr Trp Lys Ile Ala Asn Glu Thr Arg Tyr Pro His Ser Val Ala

625 630 635 640

Lys Ser Gln Cys Leu Glu Asn Ser Leu Phe Thr

645 650

<210> 85

<211> 2237

<212> DNA

<213> Homo sapiens

<400> 85

gttttgcaga cgccaccgcc gaggaaaacc gtgtactatt agccatggtc aaccccaccg 60

tgttcttcga cattgccgtc gacggcgagc ccttgggccg cgtctccttt gagctgtttg 120

cagacaaggt cccaaagaca gcagaaaatt ttcgtgctct gagcactgga gagaaggat 180

ttggttataa gggttcctgc tttcacagaa ttatccagg gtttatgtgt cagggtggtg 240

acttcacacg ccataatggc actggtggca agtccatcta tggggagaaa tttgaagatg 300

agaacttcat cctaaagcat acgggtcctg gcatcttgtc catggcaaat gctggaccca 360

acacaaatgg ttcccagttt ttcatctgca ctgccaagac tgagtggttg gatggcaagc 420

atgtggtgtt tggcaaagtg aaagaaggca tgaatattgt ggaggccatg gagcgctttg 480

ggtccaggaa tggcaagacc agcaagaaga tcaccattgc tgactgtgga caactcgaat 540

aagtttgact tgtgttttat cttaaccacc agatcattcc ttctgtagct caggagagca 600

cccctccacc ccatttgctc gcagtatcct agaatctttg tgctctcgct gcagttccct 660

ttgggttcca tgttttcctt gttccctccc atgcctagct ggattgcaga gttaagttta 720

tgattatgaa ataaaaacta aataacaatt gtcctcgttt gagttaagag tgttgatgta 780

ggctttattt taagcagtaa tgggttatactt ctgaaacatc acttgtttgc ttaattctac 840

acagtactta gatttttttt actttccagt cccaggaagt gtcaatgttt gttgagtgga 900

atattgaaaa tgtaggcagc aactgggcat ggtggctcac tgtctgtaat gtattacctg 960

aggcagaaga ccacctgagg gtaggagtca agatcagcct gggcaacata gtgagacgct 1020

gtctctacaa aaaataatta gcctggcctg gtggtgcatg cctagtccta gctgatctgg 1080

aggctgacgt gggaggattg cttgagccta gagtgagcta ttatcatgcc actgtacagc 1140

ctgggtgttc acagatcttg tgtctcaaag gtaggcagag gcaggaaaag caaggagcca 1200

gaattaagag gttgggtcag tctgcagtga gttcatgcat ttagaggtgt tcttcaagat 1260

gactaatgtc aaaaattgag acatctgttg cggttttttt tttttttttt tcccctggaa 1320

tgcagtggcg tgatctcagc tcactgcagc ctccgcctcc tgggttcaag tgattctagt 1380

gcctcagcct cctgagtagc tgggataatg ggcgtgtgcc accatgccca gctaattttt 1440

gtatttttag tatagatggg gtttcatcat tttgaccagg ctggtctcaa actcttgacc 1500

tcagctgatg cgcctgcctt ggcctcccaa actgctgaga ttacagatgt gagccaccgc 1560

accctacctc attttctgta acaaagctaa gcttgaacac tgttgatgtt cttgagggaa 1620

gcatattggg ctttaggctg taggtcaagt ttatacatct taattatggt ggaattccta 1680

tgtagagtct aaaaagccag gtacttggtg ctacagtcag tctccctgca gaggttaag 1740

gcgcagacta cctgcagtga ggaggtactg cttgtagcat atagagcctc tccctagctt 1800

tggttatgga ggctttgagg ttttgcaaac ctgaccaatt taagccataa gatctggtca 1860

aagggatacc cttcccacta aggacttggt ttctcaggaa attatatgta cagtgcttgc 1920

tggcagttag atgtcaggac aatctaagct gagaaaaccc cttctctgcc caccttaaca 1980

gacctctagg gttcttaacc cagcaatcaa gtttgcctat cctagaggtg gcggatttga 2040

tcatttggtg tgttgggcaa tttttgtttt actgtctggt tccttctgcg tgaattacca 2100

ccaccaccac ttgtgcatct cagtcttgtg tgttgtctgg ttacgtattc cctgggtgat 2160

accattcaat gtcttaatgt acttgtggct cagacctgag tgcaaggtgg aaataaacat 2220

caaacatctt ttcatta 2237

<210> 86

<211> 165

<212> PRT

<213> Homo sapiens

<400> 86

Met Val Asn Pro Thr Val Phe Phe Asp Ile Ala Val Asp Gly Glu Pro

1 5 10 15

Leu Gly Arg Val Ser Phe Glu Leu Phe Ala Asp Lys Val Pro Lys Thr

20 25 30

Ala Glu Asn Phe Arg Ala Leu Ser Thr Gly Glu Lys Gly Phe Gly Tyr

35 40 45

Lys Gly Ser Cys Phe His Arg Ile Ile Pro Gly Phe Met Cys Gln Gly

50 55 60

Gly Asp Phe Thr Arg His Asn Gly Thr Gly Gly Lys Ser Ile Tyr Gly

65 70 75 80

Glu Lys Phe Glu Asp Glu Asn Phe Ile Leu Lys His Thr Gly Pro Gly

85 90 95

Ile Leu Ser Met Ala Asn Ala Gly Pro Asn Thr Asn Gly Ser Gln Phe

100 105 110

Phe Ile Cys Thr Ala Lys Thr Glu Trp Leu Asp Gly Lys His Val Val

115 120 125

Phe Gly Lys Val Lys Glu Gly Met Asn Ile Val Glu Ala Met Glu Arg

130 135 140

Phe Gly Ser Arg Asn Gly Lys Thr Ser Lys Lys Ile Thr Ile Ala Asp

145 150 155 160

Cys Gly Gln Leu Glu

165

<210> 87

<211> 2193

<212> DNA

<213> Homo sapiens

<400> 87

agttccgtcg cagccgggat ttgggtcgca gttcttgttt gtggatcgct gtgatcgtca 60

cttgacaatg cagatcttcg tgaagactct gactggtaag accatcaccc tcgaggttga 120

gcccagtgac accatcgaga atgtcaaggc aaagatccaa gataaggaag gcatccctcc 180

tgaccagcag aggctgatct ttgctggaaa acagctggaa gatgggcgca ccctgtctga 240

ctacaacatc cagaaagagt ccaccctgca cctggtgctc cgtctcagag gtgggatgca 300

aatcttcgtg aagacactca ctggcaagac catcaccctt gagtcgagc ccagtgacac 360

catcgagaac gtcaaagcaa agatccagga caaggaaggc attcctcctg accagcagag 420

gttgatcttt gccggaaagc agctggaaga tgggcgcacc ctgtctgact acaacatcca 480

gaaagagtct accctgcacc tggtgctccg tctcagaggt gggatgcaga tcttcgtgaa 540

gaccctgact ggtaagacca tcaccctcga ggtggagccc agtgacacca tcgagaatgt 600

caaggcaaag atccaagata aggaaggcat tcctcctgat cagcagaggt tgatctttgc 660

cggaaaacag ctggaagatg gtcgtaccct gtctgactac aacatccaga aagagtccac 720

cttgcacctg gtactccgtc tcagaggtgg gatgcaaatc ttcgtgaaga cactcactgg 780

caagaccatc acccttgagg tcgagcccag tgacactatc gagaacgtca aagcaaagat 840

ccaagacaag gaaggcattc ctcctgacca gcagaggttg atctttgccg gaaagcagct 900

ggaagatggg cgcaccctgt ctgactacaa catccagaaa gagtctaccc tgcacctggt 960

gctccgtctc agaggtggga tgcagatctt cgtgaagacc ctgactggta agaccatcac 1020

tctcgaagtg gagccgagtg acaccattga gaatgtcaag gcaaagatcc aagacaagga 1080

aggcatccct cctgaccagc agaggttgat ctttgccgga aaacagctgg aagatggtcg 1140

taccctgtct gactacaaca tccagaaaga gtccaccttg cacctggtgc tccgtctcag 1200

aggtggggatg cagatcttcg tgaagaccct gactggtaag accatcactc tcgaggtgga 1260

gccgagtgac accattgaga atgtcaaggc aaagatccaa gacaaggaag gcatccctcc 1320

tgaccagcag aggttgatct ttgctgggaa acagctggaa gatggacgca ccctgtctga 1380

ctacaacatc cagaaagagt ccaccctgca cctggtgctc cgtcttagag gtgggatgca 1440

gatcttcgtg aagaccctga ctggtaagac catcactctc gaagtggagc cgagtgacac 1500

cattgagaat gtcaaggcaa agatccaaga caaggaaggc atccctcctg accagcagag 1560

gttgatcttt gctgggaaac agctggaaga tggacgcacc ctgtctgact acaacatcca 1620

gaaagagtcc accctgcacc tggtgctccg tcttagaggt gggatgcaga tcttcgtgaa 1680

gaccctgact ggtaagacca tcactctcga agtggagccg agtgacacca ttgagaatgt 1740

caaggcaaag atccaagaca aggaaggcat ccctcctgac cagcagaggt tgatctttgc 1800

tgggaaacag ctggaagatg gacgcaccct gtctgactac aacatccaga aagagtccac 1860

cctgcacctg gtgctccgtc tcagaggtgg gatgcaaatc ttcgtgaaga ccctgactgg 1920

taagaccatc accctcgagg tggagcccag tgacaccatc gagaatgtca aggcaaagat 1980

ccaagataag gaaggcatcc ctcctgatca gcagaggttg atctttgctg ggaaacagct 2040

ggaagatgga cgcaccctgt ctgactacaa catccagaaa gagtccactc tgcacttggt 2100

cctgcgcttg aggggggggtg tctaagtttc cccttttaag gtttcaacaa atttcattgc 2160

actttccttt caataaagtt gttgcattcc caa 2193

<210> 88

<211> 685

<212> PRT

<213> Homo sapiens

<400> 88

Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu

1 5 10 15

Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp

20 25 30

Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys

35 40 45

Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu

50 55 60

Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe

65 70 75 80

Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser

85 90 95

Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile

100 105 110

Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp

115 120 125

Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His

130 135 140

Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu

145 150 155 160

Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu

165 170 175

Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln

180 185 190

Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu

195 200 205

Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg

210 215 220

Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr

225 230 235 240

Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala

245 250 255

Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile

260 265 270

Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn

275 280 285

Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly

290 295 300

Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu

305 310 315 320

Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp

325 330 335

Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys

340 345 350

Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu

355 360 365

Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe

370 375 380

Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser

385 390 395 400

Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile

405 410 415

Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp

420 425 430

Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His

435 440 445

Leu Val Leu Arg Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu

450 455 460

Thr Gly Lys Thr Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu

465 470 475 480

Asn Val Lys Ala Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln

485 490 495

Gln Arg Leu Ile Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu

500 505 510

Ser Asp Tyr Asn Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg

515 520 525

Leu Arg Gly Gly Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr

530 535 540

Ile Thr Leu Glu Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala

545 550 555 560

Lys Ile Gln Asp Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile

565 570 575

Phe Ala Gly Lys Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn

580 585 590

Ile Gln Lys Glu Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly

595 600 605

Met Gln Ile Phe Val Lys Thr Leu Thr Gly Lys Thr Ile Thr Leu Glu

610 615 620

Val Glu Pro Ser Asp Thr Ile Glu Asn Val Lys Ala Lys Ile Gln Asp

625 630 635 640

Lys Glu Gly Ile Pro Pro Asp Gln Gln Arg Leu Ile Phe Ala Gly Lys

645 650 655

Gln Leu Glu Asp Gly Arg Thr Leu Ser Asp Tyr Asn Ile Gln Lys Glu

660 665 670

Ser Thr Leu His Leu Val Leu Arg Leu Arg Gly Gly Val

675 680 685

<210> 89

<211> 2547

<212> DNA

<213> Homo sapiens

<400> 89

actgcagccc cgctcgactc cggcgtggtg cgcaggcgcg gtatcccccc tcccccgcca 60

gctcgacccc ggtgtggtgc gcaggcgcag tctgcgcagg gactggcggg actgcgcggc 120

ggcaacagca gacatgtcgg gggtccgggg cctgtcgcgg ctgctgagcg ctcggcgcct 180

ggcgctggcc aaggcgtggc caacagtgtt gcaaacagga acccgaggtt ttcacttcac 240

tgttgatggg aacaagaggg catctgctaa agtttcagat tccatttctg ctcagtatcc 300

agtagtggat catgaatttg atgcagtggt ggtaggcgct ggaggggcag gcttgcgagc 360

tgcatttggc ctttctgagg cagggtttaa tacagcatgt gttaccaagc tgtttcctac 420

caggtcacac actgttgcag cacagggagg aatcaatgct gctctgggga acatggagga 480

ggacaactgg aggtggcatt tctacgacac cgtgaagggc tccgactggc tgggggacca 540

ggatgccatc cactacatga cggagcaggc ccccgccgcc gtggtcgagc tagaaatta 600

tggcatgccg tttagcagaa ctgaagatgg gaagatttat cagcgtgcat ttggtggaca 660

gagcctcaag tttggaaagg gcgggcaggc ccatcggtgc tgctgtgtgg ctgatcggac 720

tggccactcg ctattgcaca ccttatatgg aaggtctctg cgatatgata ccagctattt 780

tgtggagtat tttgccttgg atctcctgat ggagaatggg gagtgccgtg gtgtcatcgc 840

actgtgcata gaggacgggt ccatccatcg cataagagca aagaacactg ttgttgccac 900

aggaggctac gggcgcacct acttcagctg cacgtctgcc cacaccagca ctggcgacgg 960

cacggccatg atcaccaggg caggccttcc ttgccaggac ctagagtttg ttcagttcca 1020

ccctacaggc atatatggtg ctggttgtct cattacggaa ggatgtcgtg gagagggagg 1080

cattctcatt aacagtcaag gcgaaaggtt tatggagcga tacgcccctg tcgcgaagga 1140

cctggcgtct agagatgtgg tgtctcggtc catgactctg gagatccgag aaggaagagg 1200

ctgtggccct gagaaagatc acgtctacct gcagctgcac cacctacctc cagagcagct 1260

ggccacgcgc ctgcctggca tttcagagac agccatgatc ttcgctggcg tggacgtcac 1320

gaaggagccg atccctgtcc tccccaccgt gcattataac atgggcggca ttcccaccaa 1380

ctacaagggg caggtcctga ggcacgtgaa tggccaggat cagattgtgc ccggcctgta 1440

cgcctgtggg gaggccgcct gtgcctcggt acatggtgcc aaccgcctcg gggcaaactc 1500

gctcttggac ctggttgtct ttggtcgggc atgtgccctg agcatcgaag agtcatgcag 1560

gcctggagat aaagtccctc caattaaacc aaacgctggg gaagaatctg tcatgaatct 1620

tgacaaattg agatttgctg atggaagcat aagaacatcg gaactgcgac tcagcatgca 1680

gaaggtgcgg attgatgagt acgattactc caagcccatc caggggcaac agaagaagcc 1740

ctttgaggag cactggagga agcacaccct gtcctatgtg gacgttggca ctgggaaggt 1800

cactctggaa tatagacccg tgatcgacaa aactttgaac gaggctgact gtgccaccgt 1860

cccgccagcc attcgctcct actgatgaga caagatgtgg tgatgacaga atcagctttt 1920

gtaattatgt ataatagctc atgcatgtgt ccatgtcata actgtcttca tacgcttctg 1980

cactctgggg aagaaggagt acatgaagg gagattggca cctagtggct gggagcttgc 2040

caggaaccca gtggccaggg agcgtggcac ttacctttgt cccttgcttc attcttgtga 2100

gatgataaaa ctgggcacag ctcttaaata aaataaaat gaacaaactt tcttttatattt 2160

ccaaatccat ttgaaatatt ttactgttgt gactttagtc atatttgttg acctaaaaat 2220

caaatgtaat ctttgtattg tgttacatca aaatccagat attttgtata gtttcttttt 2280

tctttttctt ttcttttttt tttttgagac aggatcggtg cagtagtaca atcacagctc 2340

actgcagcct caaactcctg ggcagctcag gtgatcttcc tgactcagcc ttctgagtag 2400

ttggggctac aggtgtgcac caccatgccc agctcattta ttttgtaatt gtagggacag 2460

ggtctcactg tgttgcctag gctggtctca agtgatcctc cctccttggc ctcccaaggt 2520

gctggaatta taggtgtgaa caaacca 2547

<210> 90

<211> 664

<212> PRT

<213> Homo sapiens

<400> 90

Met Ser Gly Val Arg Gly Leu Ser Arg Leu Leu Ser Ala Arg Arg Leu

1 5 10 15

Ala Leu Ala Lys Ala Trp Pro Thr Val Leu Gln Thr Gly Thr Arg Gly

20 25 30

Phe His Phe Thr Val Asp Gly Asn Lys Arg Ala Ser Ala Lys Val Ser

35 40 45

Asp Ser Ile Ser Ala Gln Tyr Pro Val Val Asp His Glu Phe Asp Ala

50 55 60

Val Val Val Gly Ala Gly Gly Ala Gly Leu Arg Ala Ala Phe Gly Leu

65 70 75 80

Ser Glu Ala Gly Phe Asn Thr Ala Cys Val Thr Lys Leu Phe Pro Thr

85 90 95

Arg Ser His Thr Val Ala Ala Gln Gly Gly Ile Asn Ala Ala Leu Gly

100 105 110

Asn Met Glu Glu Asp Asn Trp Arg Trp His Phe Tyr Asp Thr Val Lys

115 120 125

Gly Ser Asp Trp Leu Gly Asp Gln Asp Ala Ile His Tyr Met Thr Glu

130 135 140

Gln Ala Pro Ala Ala Val Val Glu Leu Glu Asn Tyr Gly Met Pro Phe

145 150 155 160

Ser Arg Thr Glu Asp Gly Lys Ile Tyr Gln Arg Ala Phe Gly Gly Gln

165 170 175

Ser Leu Lys Phe Gly Lys Gly Gly Gln Ala His Arg Cys Cys Cys Val

180 185 190

Ala Asp Arg Thr Gly His Ser Leu Leu His Thr Leu Tyr Gly Arg Ser

195 200 205

Leu Arg Tyr Asp Thr Ser Tyr Phe Val Glu Tyr Phe Ala Leu Asp Leu

210 215 220

Leu Met Glu Asn Gly Glu Cys Arg Gly Val Ile Ala Leu Cys Ile Glu

225 230 235 240

Asp Gly Ser Ile His Arg Ile Arg Ala Lys Asn Thr Val Val Ala Thr

245 250 255

Gly Gly Tyr Gly Arg Thr Tyr Phe Ser Cys Thr Ser Ala His Thr Ser

260 265 270

Thr Gly Asp Gly Thr Ala Met Ile Thr Arg Ala Gly Leu Pro Cys Gln

275 280 285

Asp Leu Glu Phe Val Gln Phe His Pro Thr Gly Ile Tyr Gly Ala Gly

290 295 300

Cys Leu Ile Thr Glu Gly Cys Arg Gly Glu Gly Gly Ile Leu Ile Asn

305 310 315 320

Ser Gln Gly Glu Arg Phe Met Glu Arg Tyr Ala Pro Val Ala Lys Asp

325 330 335

Leu Ala Ser Arg Asp Val Val Ser Arg Ser Met Thr Leu Glu Ile Arg

340 345 350

Glu Gly Arg Gly Cys Gly Pro Glu Lys Asp His Val Tyr Leu Gln Leu

355 360 365

His His Leu Pro Pro Glu Gln Leu Ala Thr Arg Leu Pro Gly Ile Ser

370 375 380

Glu Thr Ala Met Ile Phe Ala Gly Val Asp Val Thr Lys Glu Pro Ile

385 390 395 400

Pro Val Leu Pro Thr Val His Tyr Asn Met Gly Gly Ile Pro Thr Asn

405 410 415

Tyr Lys Gly Gln Val Leu Arg His Val Asn Gly Gln Asp Gln Ile Val

420 425 430

Pro Gly Leu Tyr Ala Cys Gly Glu Ala Ala Cys Ala Ser Val His Gly

435 440 445

Ala Asn Arg Leu Gly Ala Asn Ser Leu Leu Asp Leu Val Val Phe Gly

450 455 460

Arg Ala Cys Ala Leu Ser Ile Glu Glu Ser Cys Arg Pro Gly Asp Lys

465 470 475 480

Val Pro Pro Ile Lys Pro Asn Ala Gly Glu Glu Ser Val Met Asn Leu

485 490 495

Asp Lys Leu Arg Phe Ala Asp Gly Ser Ile Arg Thr Ser Glu Leu Arg

500 505 510

Leu Ser Met Gln Lys Ser Met Gln Asn His Ala Ala Val Phe Arg Val

515 520 525

Gly Ser Val Leu Gln Glu Gly Cys Gly Lys Ile Ser Lys Leu Tyr Gly

530 535 540

Asp Leu Lys His Leu Lys Thr Phe Asp Arg Gly Met Val Trp Asn Thr

545 550 555 560

Asp Leu Val Glu Thr Leu Glu Leu Gln Asn Leu Met Leu Cys Ala Leu

565 570 575

Gln Thr Ile Tyr Gly Ala Glu Ala Arg Lys Glu Ser Arg Gly Ala His

580 585 590

Ala Arg Glu Asp Tyr Lys Val Arg Ile Asp Glu Tyr Asp Tyr Ser Lys

595 600 605

Pro Ile Gln Gly Gln Gln Lys Lys Pro Phe Glu Glu His Trp Arg Lys

610 615 620

His Thr Leu Ser Tyr Val Asp Val Gly Thr Gly Lys Val Thr Leu Glu

625 630 635 640

Tyr Arg Pro Val Ile Asp Lys Thr Leu Asn Glu Ala Asp Cys Ala Thr

645 650 655

Val Pro Pro Ala Ile Arg Ser Tyr

660

Claims (29)

1. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of a kit for identifying individuals with breast cancer who may benefit from treatment including an endocrine therapy agent, wherein the endocrine therapy agent is selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof, the method comprising determining an estrogen receptor pathway activity score from a sample from the individual, wherein an estrogen receptor pathway activity score from the sample that reaches or exceeds a reference estrogen receptor pathway activity score identifies the individual as potentially benefiting from treatment including an endocrine therapy agent, wherein the estrogen receptor pathway activity score is determined by subtracting from an estradiol-inducible score determined by the average z-score expression of at least 8 estradiol-inducible genes the estrogen receptor pathway activity score determined by at least 6 estradiol-inducible genes. The estradiol suppression score is calculated based on the average z-score expression of the estradiol-inducing genes, wherein the at least eight estradiol-inducing genes are selected from the group consisting of: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, and wherein the at least six estradiol-suppressing genes are selected from the group consisting of: BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2. 2. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of a kit for selecting endocrine therapy agents for individuals with breast cancer by means of a method selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof, the method comprising determining an estrogen receptor pathway activity score from a sample from the individual, wherein the estrogen receptor pathway activity score is calculated by subtracting an estradiol inhibition score determined by the average z-score expression of at least six estradiol inhibition genes from an estradiol induction score determined by the average z-score expression of at least eight estradiol induction genes, wherein the at least eight estradiol induction genes are selected from the group consisting of: AGR3, AMZ1, AREG, C5AR2, CELS. R2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, wherein at least six of the estradiol-inhibiting genes are selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2, wherein an estrogen receptor pathway activity score from the sample that reaches or exceeds a reference estrogen receptor pathway activity score identifies the individual as potentially eligible for treatment including endocrine therapy. 3. Use of an endocrine therapeutic agent in the preparation of a medicament for treating an individual with breast cancer, wherein the endocrine therapeutic agent is selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof, wherein the individual has been identified as an individual more likely to benefit from treatment including the endocrine therapeutic agent by calculating an estrogen receptor pathway activity score determined from samples from said individual, said estrogen receptor pathway activity score being calculated by subtracting an estradiol inhibition score determined by the average z-score expression of at least six estradiol inhibitory genes from an estradiol induction score determined by the average z-score expression of at least eight estradiol induction genes, wherein said at least eight estradiol induction genes Because it is selected from the following groups: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703, and wherein at least 6 of the estradiol-suppressing genes are selected from the following groups: BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1 and TP53INP2; Individuals whose estrogen receptor pathway activity scores from the samples reach or exceed a reference estrogen receptor pathway activity score are identified as potentially eligible for treatment, including endocrine therapy agents; and The reference estrogen receptor pathway activity score is any one of the following: (a) Estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of the first dose of endocrine therapy; (b) Estrogen receptor pathway activity scores determined from samples from said individual at a previous time point, wherein said previous time point is after administration of the first dose of endocrine therapy agent; (c) Pre-assigned estrogen receptor pathway activity score; or (d) Reference group. 4. The use according to any one of claims 1-3, wherein the reference estrogen receptor pathway activity score is the estrogen receptor pathway activity score in a reference population. 5. The use according to claim 4, wherein the reference population is a group of individuals with hormone receptor-positive breast cancer. 6. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of kits for monitoring the response of individuals with breast cancer to treatment with endocrine therapy agents, wherein the endocrine therapy agent is selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof. The method includes: (a) A first estrogen receptor pathway activity score is determined from a sample from said individual at a first time point, said estrogen receptor pathway activity score being calculated by subtracting an estradiol suppression score determined by the average z-score expression of at least 6 estradiol suppression genes from an estradiol induction score determined by the average z-score expression of at least 8 estradiol induction genes, wherein said at least 8 estradiol induction genes are selected from the group consisting of: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, wherein at least six of the estradiol-suppressing genes are selected from the group consisting of: BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2; (b) Following step (a), at a second time point after administration of the endocrine therapy agent, a second estrogen receptor pathway activity score is determined from samples from said individual; and (c) Compare the first estrogen receptor pathway activity score with the second estrogen receptor pathway activity score, wherein a decrease in the second estrogen receptor pathway activity score relative to the first estrogen receptor pathway activity score is likely to predict individuals who respond to endocrine therapy. 7. The use according to claim 6, wherein the first estrogen receptor pathway activity score is: (a) Estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of the first dose of endocrine therapy; (b) an estrogen receptor pathway activity score determined from a sample from said individual at a previous time point, wherein said previous time point was after administration of the first dose of endocrine therapy; or (c) Pre-assigned estrogen receptor pathway activity score. 8. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of kits for identifying individuals with breast cancer who may benefit from treatment including endocrine therapy agents, wherein the endocrine therapy agents are selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, or aromatase inhibitors, or combinations of two or more thereof, wherein the method comprises determining an estradiol induction score from a sample from said individual by the average z-score expression of at least 23 estradiol-inducible genes. The 23 estradiol-inducing genes were selected from the following group: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; wherein an estradiol-inducing score from the sample that reaches or exceeds a reference estradiol-inducing score identifies the individual as potentially eligible for treatment including endocrine therapy. 9. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of a kit for selecting endocrine therapy agents for individuals with breast cancer by means of a method selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof, the method comprising determining an estradiol induction score from a sample from the individual by the mean z-score expression of 23 estradiol-inducible genes, the 23 estradiol-inducible genes... Estradiol-inducing genes were selected from the following group: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; wherein an estradiol-inducing score from said sample that reaches or exceeds a reference estradiol-inducing score identifies said individual as an individual who may benefit from treatment including endocrine therapy agents. 10. Use of an endocrine therapeutic agent in the preparation of a medicament for treating an individual with breast cancer, wherein the endocrine therapeutic agent is selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof, wherein the individual has been identified as more likely to benefit from treatment including an endocrine therapeutic agent by an estradiol induction score determined from the expression of the average z-score of 23 estradiol induction genes, the 23 estradiol induction genes being selected from the group consisting of: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; Individuals whose estrogen receptor pathway activity scores reach or exceed the reference estrogen receptor pathway activity score are identified as potentially beneficial to treatment, including endocrine therapy agents; and The reference estrogen receptor pathway activity score is any one of the following: (a) Estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of the first dose of endocrine therapy; (b) Estrogen receptor pathway activity scores determined from samples from said individual at a previous time point, wherein said previous time point is after administration of the first dose of endocrine therapy agent; (c) Pre-assigned estrogen receptor pathway activity score; or (d) Reference group. 11. The use according to claim 10, wherein the reference population is a group of individuals with hormone receptor-positive breast tumors. 12. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of kits for monitoring the response of individuals with breast cancer to treatment with endocrine therapy agents, wherein the endocrine therapy agent is selected from the group consisting of: selective estrogen receptor degraders, selective estrogen receptor modulators, selective estrogen receptor covalent antagonists, selective human estrogen receptor agonists, aromatase inhibitors, or combinations of two or more thereof. The method includes: (a) A first estradiol induction score was determined from samples from said individuals at a first time point by the average z-score expression of 23 estradiol induction genes selected from the group consisting of: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; (b) Following step (a), a second estradiol-induced score is determined from samples from said individual at a second time point after administration of the endocrine therapy agent; and (c) Compare the first estradiol-induced score with the second estradiol-induced score, wherein a decrease in the second estradiol-induced score relative to the first estradiol-induced score is likely to predict an individual who responds to treatment with an endocrine therapy agent. 13. The use according to claim 12, wherein the first estradiol induction score is: (a) Estradiol-induced score determined from a sample obtained from the individual prior to administration of the first dose of endocrine therapy; (b) an estradiol-induced score determined from a sample from said individual at a previous time point, wherein said previous time point is after administration of the first dose of endocrine therapy; or (c) Pre-assigned estradiol induction score. 14. The use according to any one of claims 1-3, 6, 8-10 and 12, wherein the breast cancer is estrogen receptor-positive breast cancer. 15. The use according to claim 14, wherein the estrogen receptor-positive breast cancer is luminal type A breast cancer. 16. The use according to claim 14, wherein the estrogen receptor-positive breast cancer is luminal type B breast cancer. 17. The use according to claim 16, wherein the breast cancer is advanced or metastatic breast cancer. 18. Use of reagents for detecting estrogen receptor pathway activity in individuals with breast cancer in the preparation of kits for identifying said individuals as potentially benefiting from treatment including endocrine therapy agents by means of: Step 1: Detect the expression levels of the following genes: (a) All estradiol-suppressing genes selected from BCAS1, CCNG2, IL1R1, PNPLA7, SEMA3E, and STON1, and all estradiol-inducing genes selected from AMZ1, C5AR2, CELSR2, FKBP4, GREB1, OLFM1, SLC9A3R1, and TFF1; or (b) All estradiol-suppressing genes selected from BCAS1, CCNG2, IL1R1, NBEA, PNPLA7, SEMA3E, STON1, and TP53INP1, and all estradiol-inducing genes selected from AMZ1, AREG, C5AR2, CELSR2, FKBP4, FMN1, GREB1, OLFM1, RBM24, SLC9A3R1, and TFF1; or (c) All estradiol-suppressing genes selected from BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1 and TP53INP2, and all estradiol-inducing genes selected from AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703; Step 2: Determine the estrogen receptor pathway activity score. The estrogen receptor pathway activity score is calculated by subtracting the estradiol inhibition score, determined by the average z-score expression of all estradiol-inducing genes in steps 1(a), (b), or (c), from the estradiol induction score determined by the average z-score expression of all estradiol-inhibiting genes in steps 1(a), (b), or (c), in the sample from the individual. An estradiol-inducing score from the sample that reaches or exceeds a reference estradiol-inducing score identifies the individual as potentially eligible for treatment, including endocrine therapy agents. 19. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a selective estrogen receptor degrader. 20. The use according to any one of claims 1-3, 6, 8-10, 12, and 18, wherein the selective estrogen receptor degrader is a brilanestrant having the following structure: Or its medicinal salt. 21. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the selective estrogen receptor degrader is GDC-0927 having the following structure: Or its medicinal salt. 22. The use according to any one of claims 1-3, 6, 8-10, 12, and 18, wherein the endocrine therapeutic agent is selected from compounds having the following formula: Or its medicinal salt. 23. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula: 24. The use according to any one of claims 1-3, 6, 8-10, 12, and 18, wherein the endocrine therapeutic agent is a compound having the following formula: Or its medicinal salt. 25. The use according to any one of claims 1-3, 6, 8-10, 12, and 18, wherein the endocrine therapeutic agent is a compound having the following formula: Or its medicinal salt. 26. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula: Or its medicinal salt. 27. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is selected from compounds having the following formula: Or its medicinal salt. 28. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein The endocrine therapeutic agent is a compound having the following formula: Or its medicinal salt. 29. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein The individual in question is a person.